(lp0
(dp1
S'line'
p2
S'This is the first evidence of increased GLP2R expression in chief cells of patients with severe obesity regardless of diabetes status.\n'
p3
sS'genes'
p4
(lp5
(dp6
S'index'
p7
I40
sS'uniprot'
p8
S''
p9
sS'lengthInChars'
p10
I5
sS'name'
p11
VGLP2R
p12
sS'lengthInWords'
p13
I1
sasS'diseases'
p14
(lp15
(dp16
g7
I118
sS'cui'
p17
VC0011849
p18
sg10
I8
sg11
Vdiabetes
p19
sg13
I1
sa(dp20
g7
I89
sg17
VC0028756
p21
sg10
I14
sg11
Vsevere obesity
p22
sg13
I2
sasa(dp23
g2
S'We examined the importance of GLP-2 receptor (GLP-2R) signaling for glucose homeostasis in multiple models of metabolic stress, diabetes, and obesity.\n'
p24
sg4
(lp25
(dp26
g7
I30
sg8
g9
sg10
I14
sg11
VGLP-2 receptor
p27
sg13
I2
sa(dp28
g7
I46
sg8
g9
sg10
I6
sg11
VGLP-2R
p29
sg13
I1
sasg14
(lp30
(dp31
g7
I128
sg17
VC0011849
p32
sg10
I8
sg11
Vdiabetes
p33
sg13
I1
sa(dp34
g7
I142
sg17
VC0028754
p35
sg10
I7
sg11
Vobesity
p36
sg13
I1
sasa(dp37
g2
S'Moreover, glucose homeostasis was comparable in Glp2r(-/-) and Glp2r(+/+) mice fed a high-fat diet for 5 months or after induction of streptozotocin-induced diabetes.\n'
p38
sg4
(lp39
(dp40
g7
I48
sg8
g9
sg10
I5
sg11
VGlp2r
p41
sg13
I1
sa(dp42
g7
I48
sg8
g9
sg10
I5
sg11
VGlp2r
p43
sg13
I1
sasg14
(lp44
(dp45
g7
I157
sg17
VC0011849
p46
sg10
I8
sg11
Vdiabetes
p47
sg13
I1
sasa(dp48
g2
S'In a model of tubulointerstitial fibrosis induced by unilateral ureteral obstruction in mice, increased collagen I protein content and an almost complete disappearance of erythropoietin mRNA expression were observed in the ureteral ligated kidney with respect to the contralateral control.\n'
p49
sg4
(lp50
(dp51
g7
I171
sg8
VP01588
p52
sg10
I19
sg11
Verythropoietin mRNA
p53
sg13
I2
sa(dp54
g7
I104
sg8
VP42768
p55
sg10
I18
sg11
Vcollagen I protein
p56
sg13
I3
sasg14
(lp57
(dp58
g7
I33
sg17
VC0016059
p59
sg10
I8
sg11
Vfibrosis
p60
sg13
I1
sa(dp61
g7
I64
sg17
VC0041956
p62
sg10
I20
sg11
Vureteral obstruction
p63
sg13
I2
sasa(dp64
g2
S'In the present study, employing a mouse model of renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction (UUO), we demonstrated that EPO markedly reduced the disruption of the tubular basement membrane (TBM) through attenuating the activation of tissue plasminogen activator (tPA) and matrix metalloproteinase 9 (MMP9), the major matrix proteolytic network in the obstructed kidney.\n'
p65
sg4
(lp66
(dp67
g7
I297
sg8
VP00747
p68
sg10
I3
sg11
VtPA
p69
sg13
I1
sa(dp70
g7
I306
sg8
VP14780
p71
sg10
I26
sg11
Vmatrix metalloproteinase 9
p72
sg13
I3
sa(dp73
g7
I154
sg8
VP01588
p74
sg10
I3
sg11
VEPO
p75
sg13
I1
sa(dp76
g7
I267
sg8
VP00747
p77
sg10
I28
sg11
Vtissue plasminogen activator
p78
sg13
I3
sa(dp79
g7
I334
sg8
VP14780
p80
sg10
I4
sg11
VMMP9
p81
sg13
I1
sasg14
(lp82
(dp83
g7
I127
sg17
VC0041956
p84
sg10
I3
sg11
VUUO
p85
sg13
I1
sa(dp86
g7
I74
sg17
VC0016059
p87
sg10
I8
sg11
Vfibrosis
p88
sg13
I1
sa(dp89
g7
I105
sg17
VC0041956
p90
sg10
I20
sg11
Vureteral obstruction
p91
sg13
I2
sasa(dp92
g2
S'The MVs derived from untreated MSCs (MSC-MVs) or from MSCs incubated in different concentrations of EPO (1, 10, 100, and 500 IU/ml EPO-MVs) were used to treat renal injury of unilateral ureteral obstruction (UUO) in vivo, and transforming growth factor-Beta1 (TGF-Beta1)-induced fibrosis in a human renal proximal tubular epithelial (HK2) cell line in vitro.\n'
p93
sg4
(lp94
(dp95
g7
I100
sg8
VP01588
p96
sg10
I3
sg11
VEPO
p97
sg13
I1
sa(dp98
g7
I226
sg8
VP01137
p99
sg10
I32
sg11
Vtransforming growth factor-Beta1
p100
sg13
I3
sa(dp101
g7
I260
sg8
VP01137
p102
sg10
I9
sg11
VTGF-Beta1
p103
sg13
I1
sasg14
(lp104
(dp105
g7
I208
sg17
VC0041956
p106
sg10
I3
sg11
VUUO
p107
sg13
I1
sa(dp108
g7
I186
sg17
VC0041956
p109
sg10
I20
sg11
Vureteral obstruction
p110
sg13
I2
sa(dp111
g7
I279
sg17
VC0016059
p112
sg10
I8
sg11
Vfibrosis
p113
sg13
I1
sasa(dp114
g2
S'Twenty-four male C57BL6 mice were randomly divided into four groups, each comprising six mice: (i) control group (Sh); (ii) unilateral ureteral obstruction (UUO) plus vehicle group (U+V); (#) UUO plus 300 U/kg body weight recombinant human (rh)EPO (U+E1) and (#) UUO plus 1,000 U/kg body weight rhEPO (U+E2).\n'
p115
sg4
(lp116
(dp117
g7
I244
sg8
VP01588
p118
sg10
I3
sg11
VEPO
p119
sg13
I1
sasg14
(lp120
(dp121
g7
I157
sg17
VC0041956
p122
sg10
I3
sg11
VUUO
p123
sg13
I1
sa(dp124
g7
I135
sg17
VC0041956
p125
sg10
I20
sg11
Vureteral obstruction
p126
sg13
I2
sa(dp127
g7
I157
sg17
VC0041956
p128
sg10
I3
sg11
VUUO
p129
sg13
I1
sa(dp130
g7
I157
sg17
VC0041956
p131
sg10
I3
sg11
VUUO
p132
sg13
I1
sasa(dp133
g2
S'The aim of this study is to show and compare the actions of Simvastatin (Simv) and Erythropoietin (Epo) in renal expression of nuclear factor kappa B (NFKB), transforming growth factor-Beta (TGF-Beta), basic fibroblast growth factor (bFGF), platelet-derived growth factor B (PDGF-B), fibronectin and development of interstitial fibrosis in rats with unilateral ureteral obstruction (UUO).\n'
p134
sg4
(lp135
(dp136
g7
I151
sg8
g9
sg10
I4
sg11
VNFKB
p137
sg13
I1
sa(dp138
g7
I99
sg8
VP01588
p139
sg10
I3
sg11
VEpo
p140
sg13
I1
sa(dp141
g7
I158
sg8
VP18075
p142
sg10
I31
sg11
Vtransforming growth factor-Beta
p143
sg13
I3
sa(dp144
g7
I191
sg8
VP18075
p145
sg10
I8
sg11
VTGF-Beta
p146
sg13
I1
sa(dp147
g7
I275
sg8
VP01127
p148
sg10
I6
sg11
VPDGF-B
p149
sg13
I1
sa(dp150
g7
I83
sg8
VP01588
p151
sg10
I14
sg11
VErythropoietin
p152
sg13
I1
sa(dp153
g7
I234
sg8
VP53370
p154
sg10
I4
sg11
VbFGF
p155
sg13
I1
sa(dp156
g7
I127
sg8
VP01160
p157
sg10
I22
sg11
Vnuclear factor kappa B
p158
sg13
I4
sa(dp159
g7
I241
sg8
VP01127
p160
sg10
I32
sg11
Vplatelet-derived growth factor B
p161
sg13
I4
sa(dp162
g7
I202
sg8
VP53370
p163
sg10
I30
sg11
Vbasic fibroblast growth factor
p164
sg13
I4
sasg14
(lp165
(dp166
g7
I383
sg17
VC0041956
p167
sg10
I3
sg11
VUUO
p168
sg13
I1
sa(dp169
g7
I315
sg17
VC0240035
p170
sg10
I21
sg11
Vinterstitial fibrosis
p171
sg13
I2
sa(dp172
g7
I361
sg17
VC0041956
p173
sg10
I20
sg11
Vureteral obstruction
p174
sg13
I2
sasa(dp175
g2
S'In a novel mouse model, unilateral ureteral obstruction-induced inflammatory milieu activated NFKB and Smad signaling pathways in REPs, rapidly repressed the Epo-producing potential of REPs, and led to myofibroblast transformation of these cells.\n'
p176
sg4
(lp177
(dp178
g7
I94
sg8
g9
sg10
I4
sg11
VNFKB
p179
sg13
I1
sa(dp180
g7
I158
sg8
VP01588
p181
sg10
I3
sg11
VEpo
p182
sg13
I1
sasg14
(lp183
(dp184
g7
I35
sg17
VC0041956
p185
sg10
I20
sg11
Vureteral obstruction
p186
sg13
I2
sa(dp187
g7
I216
sg17
VC1510411
p188
sg10
I14
sg11
Vtransformation
p189
sg13
I1
sasa(dp190
g2
S'Reversing the unilateral ureteral obstruction-induced inflammatory microenvironment restored the Epo-producing potential and the physiologic phenotype of REPs.\n'
p191
sg4
(lp192
(dp193
g7
I97
sg8
VP01588
p194
sg10
I3
sg11
VEpo
p195
sg13
I1
sasg14
(lp196
(dp197
g7
I25
sg17
VC0041956
p198
sg10
I20
sg11
Vureteral obstruction
p199
sg13
I2
sasa(dp200
g2
S'Secondary polycythemia with increased production of erythropoietin (EPO) is known to occur in kidney diseases such as hydronephrosis and cystic disease, but the mechanism remains unclear.\n'
p201
sg4
(lp202
(dp203
g7
I52
sg8
VP01588
p204
sg10
I14
sg11
Verythropoietin
p205
sg13
I1
sa(dp206
g7
I68
sg8
VP01588
p207
sg10
I3
sg11
VEPO
p208
sg13
I1
sasg14
(lp209
(dp210
g7
I118
sg17
VC0020295
p211
sg10
I14
sg11
Vhydronephrosis
p212
sg13
I1
sa(dp213
g7
I0
sg17
VC1318533
p214
sg10
I22
sg11
VSecondary polycythemia
p215
sg13
I2
sa(dp216
g7
I137
sg17
VC0334054
p217
sg10
I14
sg11
Vcystic disease
p218
sg13
I2
sa(dp219
g7
I94
sg17
VC0022658
p220
sg10
I15
sg11
Vkidney diseases
p221
sg13
I2
sasa(dp222
g2
S'Decompartmentalized hemoglobin, arginase 1, asymmetric dimethylarginine, and adenine nucleotides are all products of hemolysis that promote vasomotor dysfunction, proliferative vasculopathy, and a multitude of clinical complications of pulmonary and systemic vasculopathy, including pulmonary hypertension, leg ulcers, priapism, chronic kidney disease, and large-artery ischemic stroke.\n'
p223
sg4
(lp224
(dp225
g7
I20
sg8
g9
sg10
I10
sg11
Vhemoglobin
p226
sg13
I1
sa(dp227
g7
I32
sg8
VP05089
p228
sg10
I10
sg11
Varginase 1
p229
sg13
I2
sasg14
(lp230
(dp231
g7
I307
sg17
VC0023223
p232
sg10
I10
sg11
Vleg ulcers
p233
sg13
I2
sa(dp234
g7
I329
sg17
VC1561643
p235
sg10
I22
sg11
Vchronic kidney disease
p236
sg13
I3
sa(dp237
g7
I163
sg17
VC0334094
p238
sg10
I13
sg11
Vproliferative
p239
sg13
I1
sa(dp240
g7
I283
sg17
VC0020542
p241
sg10
I22
sg11
Vpulmonary hypertension
p242
sg13
I2
sa(dp243
g7
I370
sg17
VC3272363
p244
sg10
I15
sg11
Vischemic stroke
p245
sg13
I2
sa(dp246
g7
I117
sg17
VC0019054
p247
sg10
I9
sg11
Vhemolysis
p248
sg13
I1
sa(dp249
g7
I319
sg17
VC0033117
p250
sg10
I8
sg11
Vpriapism
p251
sg13
I1
sasa(dp252
g2
S'We report a patient with bilateral incyclotorsion, asymmetric facial palsy, monocular depression deficiency, and unilateral Type 3 Duane syndrome, along with contralateral anotia and a midline cleft palate.\n'
p253
sg4
(lp254
sg14
(lp255
(dp256
g7
I172
sg17
VC0702139
p257
sg10
I6
sg11
Vanotia
p258
sg13
I1
sa(dp259
g7
I86
sg17
VC0011581
p260
sg10
I10
sg11
Vdepression
p261
sg13
I1
sa(dp262
g7
I193
sg17
VC0008925
p263
sg10
I12
sg11
Vcleft palate
p264
sg13
I2
sa(dp265
g7
I131
sg17
VC0013261
p266
sg10
I14
sg11
VDuane syndrome
p267
sg13
I2
sa(dp268
g7
I62
sg17
VC0015469
p269
sg10
I12
sg11
Vfacial palsy
p270
sg13
I2
sasa(dp271
g2
S'The authors report a child with features of Cardiofacial syndrome with anotia and facial paralysis.\n'
p272
sg4
(lp273
sg14
(lp274
(dp275
g7
I82
sg17
VC0015469
p276
sg10
I16
sg11
Vfacial paralysis
p277
sg13
I2
sa(dp278
g7
I44
sg17
VC0431406
p279
sg10
I21
sg11
VCardiofacial syndrome
p280
sg13
I2
sa(dp281
g7
I71
sg17
VC0702139
p282
sg10
I6
sg11
Vanotia
p283
sg13
I1
sasa(dp284
g2
S'Thirty-three cases had microtia or anotia, and all instances of facial palsy were associated with auricular malformation.\n'
p285
sg4
(lp286
sg14
(lp287
(dp288
g7
I64
sg17
VC0015469
p289
sg10
I12
sg11
Vfacial palsy
p290
sg13
I2
sa(dp291
g7
I23
sg17
VC0152423
p292
sg10
I8
sg11
Vmicrotia
p293
sg13
I1
sa(dp294
g7
I108
sg17
VC0000768
p295
sg10
I12
sg11
Vmalformation
p296
sg13
I1
sa(dp297
g7
I35
sg17
VC0702139
p298
sg10
I6
sg11
Vanotia
p299
sg13
I1
sasa(dp300
g2
S'A girl was born with anotia, facial palsy and cardiac malformations.\n'
p301
sg4
(lp302
sg14
(lp303
(dp304
g7
I21
sg17
VC0702139
p305
sg10
I6
sg11
Vanotia
p306
sg13
I1
sa(dp307
g7
I29
sg17
VC0015469
p308
sg10
I12
sg11
Vfacial palsy
p309
sg13
I2
sa(dp310
g7
I54
sg17
VC0000768
p311
sg10
I13
sg11
Vmalformations
p312
sg13
I1
sasa(dp313
g2
S'Freshly isolated LSECs, Kupffer cells (KCs), and stabilin-1- and stabilin-2-transfected human embryonic kidney cells were incubated with fluorescently labeled or radiolabeled oxLDLs [oxidized for 3 h (oxLDL(3)), 6 h, or 24 h (oxLDL(24))] to measure endocytosis.\n'
p314
sg4
(lp315
(dp316
g7
I49
sg8
g9
sg10
I26
sg11
Vstabilin-1- and stabilin-2
p317
sg13
I3
sasg14
(lp318
(dp319
g7
I39
sg17
VC0022575
p320
sg10
I3
sg11
VKCs
p321
sg13
I1
sa(dp322
g7
I24
sg17
VC0022575
p323
sg10
I13
sg11
VKupffer cells
p324
sg13
I2
sasa(dp325
g2
S'Furthermore, pleiotrophin (PTN), an endogenous ligand of Ptprz, also induced gastritis specifically in Ptprz+/+ mice when administered orally.\n'
p326
sg4
(lp327
(dp328
g7
I27
sg8
VP21246
p329
sg10
I3
sg11
VPTN
p330
sg13
I1
sa(dp331
g7
I13
sg8
VP21246
p332
sg10
I12
sg11
Vpleiotrophin
p333
sg13
I1
sasg14
(lp334
(dp335
g7
I77
sg17
VC0017152
p336
sg10
I9
sg11
Vgastritis
p337
sg13
I1
sasa(dp338
g2
S'We aimed to determine whether serum levels of Krebs von den Lungen-6 (KL-6) and surfactant protein-D (SP-D) correlate with SSc/MCTD-associated ILD activity.\n'
p339
sg4
(lp340
(dp341
g7
I102
sg8
VP35247
p342
sg10
I4
sg11
VSP-D
p343
sg13
I1
sa(dp344
g7
I80
sg8
VP35453
p345
sg10
I20
sg11
Vsurfactant protein-D
p346
sg13
I2
sasg14
(lp347
(dp348
g7
I127
sg17
VC0026272
p349
sg10
I4
sg11
VMCTD
p350
sg13
I1
sasa(dp351
g2
S'Serum KL-6 correlated positively with diffusing capacity of the lung for carbon monoxide (DLCO) (% predicted) and disease extent on HRCT, and the changes in serum levels of KL-6 were significantly related to the changes in forced vital capacity (FVC) in SSc/MCTD-associated ILD.\n'
p352
sg4
(lp353
(dp354
g7
I0
sg8
g9
sg10
I10
sg11
VSerum KL-6
p355
sg13
I2
sasg14
(lp356
(dp357
g7
I258
sg17
VC0026272
p358
sg10
I4
sg11
VMCTD
p359
sg13
I1
sasa(dp360
g2
S'Our study suggests that serum KL-6 can be a useful monitoring tool of SSc/MCTD-associated ILD activity.\n'
p361
sg4
(lp362
(dp363
g7
I24
sg8
g9
sg10
I10
sg11
Vserum KL-6
p364
sg13
I2
sasg14
(lp365
(dp366
g7
I74
sg17
VC0026272
p367
sg10
I4
sg11
VMCTD
p368
sg13
I1
sasa(dp369
g2
S"The KL-6 levels did not differ significantly according to the connective tissue diseases in the diagnostic groups (systemic lupus erythematosus, Sjoegren's syndrome, rheumatoid arthritis, mixed connective tissue disease, scleroderma, polymyositis/ dermatomyositis).\n"
p370
sg4
(lp371
sg14
(lp372
(dp373
g7
I221
sg17
VC0011644
p374
sg10
I11
sg11
Vscleroderma
p375
sg13
I1
sa(dp376
g7
I234
sg17
VC0085655
p377
sg10
I12
sg11
Vpolymyositis
p378
sg13
I1
sa(dp379
g7
I166
sg17
VC0003873
p380
sg10
I20
sg11
Vrheumatoid arthritis
p381
sg13
I2
sa(dp382
g7
I145
sg17
VC1527336
p383
sg10
I19
sg11
VSjoegren's syndrome
p384
sg13
I2
sa(dp385
g7
I115
sg17
VC0024141
p386
sg10
I28
sg11
Vsystemic lupus erythematosus
p387
sg13
I3
sa(dp388
g7
I62
sg17
VC0009782
p389
sg10
I26
sg11
Vconnective tissue diseases
p390
sg13
I3
sa(dp391
g7
I188
sg17
VC0026272
p392
sg10
I31
sg11
Vmixed connective tissue disease
p393
sg13
I4
sa(dp394
g7
I248
sg17
VC0221056
p395
sg10
I15
sg11
Vdermatomyositis
p396
sg13
I1
sasa(dp397
g2
S"To quantify and compare human mucin 1 (MUC1) protein and mRNA expression in tears and conjunctival epithelial cells collected from Sjogren's syndrome (SS), non-Sjogren's keratoconjunctivitus sicca (KCS) and non-dry eyed (NDE) control subjects.\n"
p398
sg4
(lp399
(dp400
g7
I24
sg8
g9
sg10
I13
sg11
Vhuman mucin 1
p401
sg13
I3
sasg14
(lp402
(dp403
g7
I131
sg17
VC1527336
p404
sg10
I18
sg11
VSjogren's syndrome
p405
sg13
I2
sa(dp406
g7
I131
sg17
VC1527336
p407
sg10
I9
sg11
VSjogren's
p408
sg13
I1
sa(dp409
g7
I198
sg17
VC0022575
p410
sg10
I3
sg11
VKCS
p411
sg13
I1
sa(dp412
g7
I170
sg17
VC0022575
p413
sg10
I26
sg11
Vkeratoconjunctivitus sicca
p414
sg13
I2
sa(dp415
g7
I151
sg17
VC1527336
p416
sg10
I2
sg11
VSS
p417
sg13
I1
sasa(dp418
g2
S'We studied 21 patients referred for idiopathic short stature, 5 with clinically suspected hypochondroplasia and 4 with achondroplasia.\n'
p419
sg4
(lp420
sg14
(lp421
(dp422
g7
I90
sg17
VC0410529
p423
sg10
I17
sg11
Vhypochondroplasia
p424
sg13
I1
sa(dp425
g7
I119
sg17
VC0001080
p426
sg10
I14
sg11
Vachondroplasia
p427
sg13
I1
sa(dp428
g7
I36
sg17
VC1740819
p429
sg10
I24
sg11
Vidiopathic short stature
p430
sg13
I3
sasa(dp431
g2
S'A series of 140 patients with short stature operated on for limb lengthening (80 had achondroplasia, 20 had hypochondroplasia, 20 had Turner syndrome, 10 had idiopathic short stature due to an undemonstrated cause, 5 regarded their stature as too short, and 5 had a psychopathic personality due to dysmorphophobia that had developed because of their short stature) was reviewed.\n'
p432
sg4
(lp433
sg14
(lp434
(dp435
g7
I30
sg17
VC0013336
p436
sg10
I13
sg11
Vshort stature
p437
sg13
I2
sa(dp438
g7
I108
sg17
VC0410529
p439
sg10
I17
sg11
Vhypochondroplasia
p440
sg13
I1
sa(dp441
g7
I30
sg17
VC0013336
p442
sg10
I13
sg11
Vshort stature
p443
sg13
I2
sa(dp444
g7
I298
sg17
VC0005887
p445
sg10
I15
sg11
Vdysmorphophobia
p446
sg13
I1
sa(dp447
g7
I85
sg17
VC0001080
p448
sg10
I14
sg11
Vachondroplasia
p449
sg13
I1
sa(dp450
g7
I266
sg17
VC0003431
p451
sg10
I24
sg11
Vpsychopathic personality
p452
sg13
I2
sa(dp453
g7
I134
sg17
VC0041408
p454
sg10
I15
sg11
VTurner syndrome
p455
sg13
I2
sa(dp456
g7
I158
sg17
VC1740819
p457
sg10
I24
sg11
Vidiopathic short stature
p458
sg13
I3
sasa(dp459
g2
S'In the present study, we investigated whether the impairment of IRS-1-mediated insulin signaling contributes to neurite outgrowth and neuronal loss, both in mice fed a high-fat diet and in mouse neuroblastoma (Neuro2A) cells.\n'
p460
sg4
(lp461
(dp462
g7
I64
sg8
VP35568
p463
sg10
I5
sg11
VIRS-1
p464
sg13
I1
sa(dp465
g7
I79
sg8
VP01308
p466
sg10
I7
sg11
Vinsulin
p467
sg13
I1
sasg14
(lp468
(dp469
g7
I50
sg17
VC0684336
p470
sg10
I10
sg11
Vimpairment
p471
sg13
I1
sa(dp472
g7
I189
sg17
VC1524043
p473
sg10
I19
sg11
Vmouse neuroblastoma
p474
sg13
I2
sasa(dp475
g2
S'To investigate the changes caused by the inhibition of IRS-1-mediated insulin signaling in neuroblastoma cells, we performed Western blot analysis, reverse transcription-PCR, and immunochemical analysis.\n'
p476
sg4
(lp477
(dp478
g7
I55
sg8
VP35568
p479
sg10
I5
sg11
VIRS-1
p480
sg13
I1
sa(dp481
g7
I70
sg8
VP01308
p482
sg10
I7
sg11
Vinsulin
p483
sg13
I1
sasg14
(lp484
(dp485
g7
I91
sg17
VC0027819
p486
sg10
I13
sg11
Vneuroblastoma
p487
sg13
I1
sasa(dp488
g2
S'miR-145 might act as a tumor suppressor in uveal melanoma, and downregulation of the target IRS-1 might be a potential mechanism.\n'
p489
sg4
(lp490
(dp491
g7
I0
sg8
g9
sg10
I7
sg11
VmiR-145
p492
sg13
I1
sa(dp493
g7
I85
sg8
VP35568
p494
sg10
I12
sg11
Vtarget IRS-1
p495
sg13
I2
sasg14
(lp496
(dp497
g7
I23
sg17
VC0027651
p498
sg10
I5
sg11
Vtumor
p499
sg13
I1
sa(dp500
g7
I43
sg17
VC0220633
p501
sg10
I14
sg11
Vuveal melanoma
p502
sg13
I2
sasa(dp503
g2
S'Almost a decade ago, we reported the presence of nuclear IRS-1 in medulloblastoma clinical samples, which express viral oncoprotein, large T-antigen of human polyomavirus JC (JCV T-antigen).\n'
p504
sg4
(lp505
(dp506
g7
I133
sg8
VP14209
p507
sg10
I15
sg11
Vlarge T-antigen
p508
sg13
I2
sa(dp509
g7
I175
sg8
VP14209
p510
sg10
I13
sg11
VJCV T-antigen
p511
sg13
I2
sasg14
(lp512
(dp513
g7
I66
sg17
VC0025149
p514
sg10
I15
sg11
Vmedulloblastoma
p515
sg13
I1
sasa(dp516
g2
S'More recently, nuclear IRS-1 was detected in breast cancer cells in association with estrogen receptor alpha (ERAlfa), and in JC virus negative medulloblastoma cells expressing estrogen receptor beta (ERBeta), further implicating nuclear IRS-1 in cellular transformation.\n'
p517
sg4
(lp518
(dp519
g7
I85
sg8
VP03372
p520
sg10
I23
sg11
Vestrogen receptor alpha
p521
sg13
I3
sa(dp522
g7
I177
sg8
VP03372
p523
sg10
I22
sg11
Vestrogen receptor beta
p524
sg13
I3
sa(dp525
g7
I15
sg8
VP35568
p526
sg10
I13
sg11
Vnuclear IRS-1
p527
sg13
I2
sa(dp528
g7
I201
sg8
VP03372
p529
sg10
I6
sg11
VERBeta
p530
sg13
I1
sasg14
(lp531
(dp532
g7
I247
sg17
VC1510411
p533
sg10
I23
sg11
Vcellular transformation
p534
sg13
I2
sa(dp535
g7
I45
sg17
VC0678222
p536
sg10
I13
sg11
Vbreast cancer
p537
sg13
I2
sa(dp538
g7
I144
sg17
VC0025149
p539
sg10
I15
sg11
Vmedulloblastoma
p540
sg13
I1
sasa(dp541
g2
S'We have previously reported that ERBeta, which is highly expressed in medulloblastomas, translocates insulin receptor substrate 1 (IRS-1) to the nucleus, and that nuclear IRS-1 binds to Rad51 and attenuates homologous recombination directed DNA repair (HRR).\n'
p542
sg4
(lp543
(dp544
g7
I186
sg8
g9
sg10
I5
sg11
VRad51
p545
sg13
I1
sa(dp546
g7
I101
sg8
VP35568
p547
sg10
I28
sg11
Vinsulin receptor substrate 1
p548
sg13
I4
sa(dp549
g7
I163
sg8
VP35568
p550
sg10
I13
sg11
Vnuclear IRS-1
p551
sg13
I2
sa(dp552
g7
I131
sg8
VP35568
p553
sg10
I5
sg11
VIRS-1
p554
sg13
I1
sasg14
(lp555
(dp556
g7
I70
sg17
VC0025149
p557
sg10
I16
sg11
Vmedulloblastomas
p558
sg13
I1
sasa(dp559
g2
S'Jacobsen syndrome (JBS) is a contiguous gene deletion syndrome involving terminal chromosome 11q.\n'
p560
sg4
(lp561
sg14
(lp562
(dp563
g7
I0
sg17
VC0795841
p564
sg10
I17
sg11
VJacobsen syndrome
p565
sg13
I2
sa(dp566
g7
I40
sg17
VC1442161
p567
sg10
I13
sg11
Vgene deletion
p568
sg13
I2
sa(dp569
g7
I9
sg17
VC0039082
p570
sg10
I8
sg11
Vsyndrome
p571
sg13
I1
sa(dp572
g7
I19
sg17
VC0795841
p573
sg10
I3
sg11
VJBS
p574
sg13
I1
sasa(dp575
g2
S'We investigated a boy with features of JBS using classic cytogenetic methods, FISH and high-resolution array CGH.\n'
p576
sg4
(lp577
sg14
(lp578
(dp579
g7
I109
sg17
VC1855900
p580
sg10
I3
sg11
VCGH
p581
sg13
I1
sa(dp582
g7
I39
sg17
VC0795841
p583
sg10
I3
sg11
VJBS
p584
sg13
I1
sasa(dp585
g2
S'The patient had a hemizygous deletion in the FLI1 gene region without apparent thrombocytopenia, and he developed diabetes mellitus type I, which has not previously been described in the spectrum of disorders associated with JBS.\n'
p586
sg4
(lp587
(dp588
g7
I45
sg8
g9
sg10
I9
sg11
VFLI1 gene
p589
sg13
I2
sasg14
(lp590
(dp591
g7
I225
sg17
VC0795841
p592
sg10
I3
sg11
VJBS
p593
sg13
I1
sa(dp594
g7
I114
sg17
VC0011854
p595
sg10
I24
sg11
Vdiabetes mellitus type I
p596
sg13
I4
sasa(dp597
g2
S'The relationship of some of the genes within the context of the phenotype caused by a partial deletion of 11q has provided insights concerning the developmental anomalies presented in this patient with atypical features of JBS.\n'
p598
sg4
(lp599
sg14
(lp600
(dp601
g7
I223
sg17
VC0795841
p602
sg10
I3
sg11
VJBS
p603
sg13
I1
sasa(dp604
g2
S'All local patients were clustered "high-risk" for future CV events based on the Framingham score (mean 21.8%, 95% CI 20.0-23.6), JBS-2 (16.3%, 14.7-17.9) and ASSIGN (25.2%, 22.7-27.7).\n'
p605
sg4
(lp606
(dp607
g7
I129
sg8
g9
sg10
I5
sg11
VJBS-2
p608
sg13
I1
sasg14
(lp609
(dp610
g7
I129
sg17
VC0795841
p611
sg10
I3
sg11
VJBS
p612
sg13
I1
sasa(dp613
g2
S'Loss-of-function mutations in the UBR1 gene cause Johanson-Blizzard syndrome, which involves pancreatic exocrine insufficiency.\n'
p614
sg4
(lp615
(dp616
g7
I34
sg8
g9
sg10
I9
sg11
VUBR1 gene
p617
sg13
I2
sasg14
(lp618
(dp619
g7
I50
sg17
VC0175692
p620
sg10
I26
sg11
VJohanson-Blizzard syndrome
p621
sg13
I2
sasa(dp622
g2
S'No previous studies have examined an association of UBR1 variants with pancreatitis, in part due to the large size of the gene.\n'
p623
sg4
(lp624
(dp625
g7
I52
sg8
g9
sg10
I13
sg11
VUBR1 variants
p626
sg13
I2
sasg14
(lp627
(dp628
g7
I71
sg17
VC0030305
p629
sg10
I12
sg11
Vpancreatitis
p630
sg13
I1
sasa(dp631
g2
S'This study aimed to clarify whether UBR1 variants are associated with chronic pancreatitis (CP) by the application of targeted next generation sequencing.\n'
p632
sg4
(lp633
(dp634
g7
I36
sg8
g9
sg10
I13
sg11
VUBR1 variants
p635
sg13
I2
sasg14
(lp636
(dp637
g7
I70
sg17
VC0149521
p638
sg10
I20
sg11
Vchronic pancreatitis
p639
sg13
I2
sa(dp640
g7
I92
sg17
VC0149521
p641
sg10
I2
sg11
VCP
p642
sg13
I1
sasa(dp643
g2
S'Jacobsen syndrome (JBS) is a contiguous gene deletion syndrome involving 11q terminal deletion.\n'
p644
sg4
(lp645
sg14
(lp646
(dp647
g7
I0
sg17
VC0795841
p648
sg10
I17
sg11
VJacobsen syndrome
p649
sg13
I2
sa(dp650
g7
I40
sg17
VC1442161
p651
sg10
I13
sg11
Vgene deletion
p652
sg13
I2
sa(dp653
g7
I9
sg17
VC0039082
p654
sg10
I8
sg11
Vsyndrome
p655
sg13
I1
sa(dp656
g7
I19
sg17
VC0795841
p657
sg10
I3
sg11
VJBS
p658
sg13
I1
sasa(dp659
g2
S'Interstitial deletions at distal 11q are rare and their contributions to the clinical phenotype of JBS are unknown.\n'
p660
sg4
(lp661
sg14
(lp662
(dp663
g7
I99
sg17
VC0795841
p664
sg10
I3
sg11
VJBS
p665
sg13
I1
sasa(dp666
g2
S'Our finds support the notion that more than one critical region at 11q23.3-qter are responsible for the variable clinical presentation of JBS, thus JBS is a true contiguous gene deletion syndrome where multiple loci contributed to the clinical characteristics of JBS.\n'
p667
sg4
(lp668
(dp669
g7
I138
sg8
g9
sg10
I3
sg11
VJBS
p670
sg13
I1
sasg14
(lp671
(dp672
g7
I138
sg17
VC0795841
p673
sg10
I3
sg11
VJBS
p674
sg13
I1
sa(dp675
g7
I138
sg17
VC0795841
p676
sg10
I3
sg11
VJBS
p677
sg13
I1
sa(dp678
g7
I138
sg17
VC0795841
p679
sg10
I3
sg11
VJBS
p680
sg13
I1
sa(dp681
g7
I187
sg17
VC0039082
p682
sg10
I8
sg11
Vsyndrome
p683
sg13
I1
sa(dp684
g7
I173
sg17
VC1442161
p685
sg10
I13
sg11
Vgene deletion
p686
sg13
I2
sasa(dp687
g2
S'Jacobsen syndrome (JBS) is an uncommon contiguous gene syndrome.\n'
p688
sg4
(lp689
sg14
(lp690
(dp691
g7
I0
sg17
VC0795841
p692
sg10
I17
sg11
VJacobsen syndrome
p693
sg13
I2
sa(dp694
g7
I9
sg17
VC0039082
p695
sg10
I8
sg11
Vsyndrome
p696
sg13
I1
sa(dp697
g7
I19
sg17
VC0795841
p698
sg10
I3
sg11
VJBS
p699
sg13
I1
sasa(dp700
g2
S'The typical clinical features in JBS include intellectual disability, growth retardation, craniofacial dysmorphism as well as craniosynostosis, congenital heart disease, and platelet abnormalities.\n'
p701
sg4
(lp702
sg14
(lp703
(dp704
g7
I126
sg17
VC0010278
p705
sg10
I16
sg11
Vcraniosynostosis
p706
sg13
I1
sa(dp707
g7
I144
sg17
VC0152021
p708
sg10
I24
sg11
Vcongenital heart disease
p709
sg13
I3
sa(dp710
g7
I45
sg17
VC0025362
p711
sg10
I23
sg11
Vintellectual disability
p712
sg13
I2
sa(dp713
g7
I33
sg17
VC0795841
p714
sg10
I3
sg11
VJBS
p715
sg13
I1
sa(dp716
g7
I70
sg17
VC0151686
p717
sg10
I18
sg11
Vgrowth retardation
p718
sg13
I2
sa(dp719
g7
I103
sg17
VC1737329
p720
sg10
I11
sg11
Vdysmorphism
p721
sg13
I1
sasa(dp722
g2
S'We report a novel deletion in JBS that increases the knowledge of the variability in the mutation sites in this region and expands the spectrum of molecular and clinical defects in this syndrome.\n'
p723
sg4
(lp724
sg14
(lp725
(dp726
g7
I186
sg17
VC0039082
p727
sg10
I8
sg11
Vsyndrome
p728
sg13
I1
sa(dp729
g7
I30
sg17
VC0795841
p730
sg10
I3
sg11
VJBS
p731
sg13
I1
sasa(dp732
g2
S'Johanson-Blizzard syndrome (JBS) is considered as an infrequent, but clinically easily recognizable autosomal recessive entity by the pathognomonic combination of congenital exocrine pancreatic insufficiency and hypoplastic alae nasi, in addition to other distinctive findings such as scalp defects, hypothyroidism, and rectourogenital malformations.\n'
p733
sg4
(lp734
sg14
(lp735
(dp736
g7
I336
sg17
VC0000768
p737
sg10
I13
sg11
Vmalformations
p738
sg13
I1
sa(dp739
g7
I0
sg17
VC0175692
p740
sg10
I26
sg11
VJohanson-Blizzard syndrome
p741
sg13
I2
sa(dp742
g7
I300
sg17
VC0020676
p743
sg10
I14
sg11
Vhypothyroidism
p744
sg13
I1
sa(dp745
g7
I28
sg17
VC0175692
p746
sg10
I3
sg11
VJBS
p747
sg13
I1
sa(dp748
g7
I174
sg17
VC0267963
p749
sg10
I33
sg11
Vexocrine pancreatic insufficiency
p750
sg13
I3
sasa(dp751
g2
S"There are few reports of patients with JBS in association with facial clefting, referring all to types 2 to 6 of Tessier's classification that can be characterized properly as oblique facial clefts (OFCs).\n"
p752
sg4
(lp753
sg14
(lp754
(dp755
g7
I199
sg17
VC1838348
p756
sg10
I4
sg11
VOFCs
p757
sg13
I1
sa(dp758
g7
I176
sg17
VC1838348
p759
sg10
I21
sg11
Voblique facial clefts
p760
sg13
I3
sa(dp761
g7
I39
sg17
VC0795841
p762
sg10
I3
sg11
VJBS
p763
sg13
I1
sasa(dp764
g2
S'We describe the clinical aspects in four patients with JBS and extensive OFCs.\n'
p765
sg4
(lp766
sg14
(lp767
(dp768
g7
I55
sg17
VC0795841
p769
sg10
I3
sg11
VJBS
p770
sg13
I1
sasa(dp771
g2
S'In all of them, the diagnosis of JBS was confirmed by the demonstration of homozygous or compound-heterozygous mutations in the UBR1 gene.\n'
p772
sg4
(lp773
(dp774
g7
I128
sg8
g9
sg10
I9
sg11
VUBR1 gene
p775
sg13
I2
sasg14
(lp776
(dp777
g7
I33
sg17
VC0795841
p778
sg10
I3
sg11
VJBS
p779
sg13
I1
sasa(dp780
g2
S'Additionally, we review three previously reported cases of JBS with OFCs.\n'
p781
sg4
(lp782
sg14
(lp783
(dp784
g7
I59
sg17
VC0795841
p785
sg10
I3
sg11
VJBS
p786
sg13
I1
sasa(dp787
g2
S'Taking into account a number of approximately 100 individuals affected by JBS that have been published in the literature we estimate that the frequency of OFCs in JBS is between 5% and 10%.\n'
p788
sg4
(lp789
sg14
(lp790
(dp791
g7
I74
sg17
VC0795841
p792
sg10
I3
sg11
VJBS
p793
sg13
I1
sa(dp794
g7
I74
sg17
VC0795841
p795
sg10
I3
sg11
VJBS
p796
sg13
I1
sasa(dp797
g2
S'This report emphasizes that extensive OFCs may be the severe end of the spectrum of facial malformations occurring in JBS.\n'
p798
sg4
(lp799
sg14
(lp800
(dp801
g7
I84
sg17
VC0266617
p802
sg10
I20
sg11
Vfacial malformations
p803
sg13
I2
sa(dp804
g7
I118
sg17
VC0795841
p805
sg10
I3
sg11
VJBS
p806
sg13
I1
sasa(dp807
g2
S'Jacobsen syndrome (JBS) is a rare congenital disorder caused by a terminal deletion of the long arm of chromosome 11.\n'
p808
sg4
(lp809
sg14
(lp810
(dp811
g7
I0
sg17
VC0795841
p812
sg10
I17
sg11
VJacobsen syndrome
p813
sg13
I2
sa(dp814
g7
I34
sg17
VC0242354
p815
sg10
I19
sg11
Vcongenital disorder
p816
sg13
I2
sa(dp817
g7
I19
sg17
VC0795841
p818
sg10
I3
sg11
VJBS
p819
sg13
I1
sasa(dp820
g2
S'PX-RICS is located in the chromosomal region commonly deleted in JBS patients with autistic-like behaviour.\n'
p821
sg4
(lp822
(dp823
g7
I0
sg8
g9
sg10
I7
sg11
VPX-RICS
p824
sg13
I1
sasg14
(lp825
(dp826
g7
I65
sg17
VC0795841
p827
sg10
I3
sg11
VJBS
p828
sg13
I1
sa(dp829
g7
I83
sg17
VC0004352
p830
sg10
I8
sg11
Vautistic
p831
sg13
I1
sasa(dp832
g2
S'Our findings demonstrate a critical role of PX-RICS in cognition and suggest a causal link between PX-RICS deletion and ASD-like behaviour in JBS patients.\n'
p833
sg4
(lp834
(dp835
g7
I44
sg8
g9
sg10
I7
sg11
VPX-RICS
p836
sg13
I1
sasg14
(lp837
(dp838
g7
I142
sg17
VC0795841
p839
sg10
I3
sg11
VJBS
p840
sg13
I1
sa(dp841
g7
I120
sg17
VC1510586
p842
sg10
I3
sg11
VASD
p843
sg13
I1
sasa(dp844
g2
S'Johanson-Blizzard Syndrome (JBS) (MIM #243800) is a rare autosomal recessive genetic disorder characterized by exocrine pancreatic insufficiency, abnormal facial appearance and varying degrees of mental retardation.\n'
p845
sg4
(lp846
sg14
(lp847
(dp848
g7
I0
sg17
VC0175692
p849
sg10
I26
sg11
VJohanson-Blizzard Syndrome
p850
sg13
I2
sa(dp851
g7
I77
sg17
VC0019247
p852
sg10
I16
sg11
Vgenetic disorder
p853
sg13
I2
sa(dp854
g7
I28
sg17
VC0175692
p855
sg10
I3
sg11
VJBS
p856
sg13
I1
sa(dp857
g7
I196
sg17
VC0025362
p858
sg10
I18
sg11
Vmental retardation
p859
sg13
I2
sa(dp860
g7
I111
sg17
VC0267963
p861
sg10
I33
sg11
Vexocrine pancreatic insufficiency
p862
sg13
I3
sasa(dp863
g2
S'Here, we report a 3 year-old mentally normal JBS girl.\n'
p864
sg4
(lp865
sg14
(lp866
(dp867
g7
I45
sg17
VC0795841
p868
sg10
I3
sg11
VJBS
p869
sg13
I1
sasa(dp870
g2
S'With these findings, JBS diagnosis was established clinically.\n'
p871
sg4
(lp872
sg14
(lp873
(dp874
g7
I21
sg17
VC0795841
p875
sg10
I3
sg11
VJBS
p876
sg13
I1
sasa(dp877
g2
S'Joubert syndrome (JBS) is a rare neurodevelopmental disorder belonging to the group of ciliary diseases.\n'
p878
sg4
(lp879
sg14
(lp880
(dp881
g7
I18
sg17
VC0795841
p882
sg10
I3
sg11
VJBS
p883
sg13
I1
sa(dp884
g7
I0
sg17
VC0431399
p885
sg10
I16
sg11
VJoubert syndrome
p886
sg13
I2
sa(dp887
g7
I33
sg17
VC1535926
p888
sg10
I27
sg11
Vneurodevelopmental disorder
p889
sg13
I2
sasa(dp890
g2
S'JBS is genetically heterogeneous, with &gt;20 causative genes identified to date.\n'
p891
sg4
(lp892
sg14
(lp893
(dp894
g7
I0
sg17
VC0795841
p895
sg10
I3
sg11
VJBS
p896
sg13
I1
sasa(dp897
g2
S'A molecular diagnosis of JBS is essential for prediction of disease progression and genetic counseling.\n'
p898
sg4
(lp899
sg14
(lp900
(dp901
g7
I25
sg17
VC0795841
p902
sg10
I3
sg11
VJBS
p903
sg13
I1
sa(dp904
g7
I60
sg17
VC0242656
p905
sg10
I19
sg11
Vdisease progression
p906
sg13
I2
sasa(dp907
g2
S'We developed a targeted next-generation sequencing (NGS) approach for parallel sequencing of 22 known JBS genes plus 599 additional ciliary genes.\n'
p908
sg4
(lp909
sg14
(lp910
(dp911
g7
I102
sg17
VC0795841
p912
sg10
I3
sg11
VJBS
p913
sg13
I1
sasa(dp914
g2
S'This method was used to genotype a cohort of 51 well-phenotyped Northern European JBS cases (in some of the cases, Sanger sequencing of individual JBS genes had been performed previously).\n'
p915
sg4
(lp916
sg14
(lp917
(dp918
g7
I82
sg17
VC0795841
p919
sg10
I3
sg11
VJBS
p920
sg13
I1
sa(dp921
g7
I82
sg17
VC0795841
p922
sg10
I3
sg11
VJBS
p923
sg13
I1
sasa(dp924
g2
S'Altogether, 21 of the 51 cases (41%) harbored biallelic pathogenic mutations in known JBS genes, including 14 mutations not previously described.\n'
p925
sg4
(lp926
sg14
(lp927
(dp928
g7
I86
sg17
VC0795841
p929
sg10
I3
sg11
VJBS
p930
sg13
I1
sasa(dp931
g2
S'Our study represents a population-based cohort of JBS patients not enriched for consanguinity, providing insight into the relative importance of the different JBS genes in a Northern European population.\n'
p932
sg4
(lp933
(dp934
g7
I159
sg8
g9
sg10
I9
sg11
VJBS genes
p935
sg13
I2
sasg14
(lp936
(dp937
g7
I50
sg17
VC0795841
p938
sg10
I3
sg11
VJBS
p939
sg13
I1
sa(dp940
g7
I50
sg17
VC0795841
p941
sg10
I3
sg11
VJBS
p942
sg13
I1
sasa(dp943
g2
S'Furthermore, we report a case with heterozygous mutations in CC2D2A and B9D1, a gene associated with the more severe Meckel-Gruber syndrome that was recently published as a potential new JBS gene, and discuss the significance of this finding.\n'
p944
sg4
(lp945
(dp946
g7
I187
sg8
g9
sg10
I8
sg11
VJBS gene
p947
sg13
I2
sa(dp948
g7
I72
sg8
g9
sg10
I4
sg11
VB9D1
p949
sg13
I1
sa(dp950
g7
I61
sg8
g9
sg10
I6
sg11
VCC2D2A
p951
sg13
I1
sasg14
(lp952
(dp953
g7
I187
sg17
VC0795841
p954
sg10
I3
sg11
VJBS
p955
sg13
I1
sa(dp956
g7
I117
sg17
VC0265215
p957
sg10
I22
sg11
VMeckel-Gruber syndrome
p958
sg13
I2
sasa(dp959
g2
S'ZIC2 and OVOL1 may function in nasopharyngeal carcinoma through targeting significantly up-regulated genes (such as PTGS2, FN1, CXCL9 and CXCL10) in the Transcription factor-differentially expressed gene regulatory network (e.g., ZIC2-&gt;PTGS2 and OVOL1-&gt;CXCL10).\n'
p960
sg4
(lp961
(dp962
g7
I116
sg8
VP35354
p963
sg10
I5
sg11
VPTGS2
p964
sg13
I1
sa(dp965
g7
I128
sg8
g9
sg10
I5
sg11
VCXCL9
p966
sg13
I1
sa(dp967
g7
I116
sg8
VP35354
p968
sg10
I5
sg11
VPTGS2
p969
sg13
I1
sa(dp970
g7
I0
sg8
g9
sg10
I4
sg11
VZIC2
p971
sg13
I1
sa(dp972
g7
I9
sg8
g9
sg10
I5
sg11
VOVOL1
p973
sg13
I1
sa(dp974
g7
I0
sg8
g9
sg10
I4
sg11
VZIC2
p975
sg13
I1
sa(dp976
g7
I-1
sg8
g9
sg10
I13
sg11
VOVOL1->CXCL10
p977
sg13
I1
sa(dp978
g7
I138
sg8
VP02778
p979
sg10
I6
sg11
VCXCL10
p980
sg13
I1
sasg14
(lp981
(dp982
g7
I31
sg17
VC2931822
p983
sg10
I24
sg11
Vnasopharyngeal carcinoma
p984
sg13
I2
sasa(dp985
g2
S'PTGS2, FN1, CXCL9, CXCL10, ZIC2 and OVOL1 might play roles in nasopharyngeal carcinoma.\n'
p986
sg4
(lp987
(dp988
g7
I12
sg8
g9
sg10
I5
sg11
VCXCL9
p989
sg13
I1
sa(dp990
g7
I36
sg8
g9
sg10
I5
sg11
VOVOL1
p991
sg13
I1
sa(dp992
g7
I27
sg8
g9
sg10
I4
sg11
VZIC2
p993
sg13
I1
sa(dp994
g7
I19
sg8
VP02778
p995
sg10
I6
sg11
VCXCL10
p996
sg13
I1
sa(dp997
g7
I0
sg8
VP35354
p998
sg10
I5
sg11
VPTGS2
p999
sg13
I1
sasg14
(lp1000
(dp1001
g7
I48
sg17
VC0699820
p1002
sg10
I10
sg11
Vplay roles
p1003
sg13
I2
sa(dp1004
g7
I62
sg17
VC2931822
p1005
sg10
I24
sg11
Vnasopharyngeal carcinoma
p1006
sg13
I2
sasa(dp1007
g2
S"Literature data indicate that hyperprolactinemia (HPRL) is one of the important factors in the pathogenesis and course of autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis and Sjogren's syndrome.\n"
p1008
sg4
(lp1009
(dp1010
g7
I50
sg8
VP01236
p1011
sg10
I4
sg11
VHPRL
p1012
sg13
I1
sa(dp1013
g7
I30
sg8
VP01236
p1014
sg10
I18
sg11
Vhyperprolactinemia
p1015
sg13
I1
sasg14
(lp1016
(dp1017
g7
I225
sg17
VC1527336
p1018
sg10
I18
sg11
VSjogren's syndrome
p1019
sg13
I2
sa(dp1020
g7
I180
sg17
VC0003873
p1021
sg10
I20
sg11
Vrheumatoid arthritis
p1022
sg13
I2
sa(dp1023
g7
I202
sg17
VC0036421
p1024
sg10
I18
sg11
Vsystemic sclerosis
p1025
sg13
I2
sa(dp1026
g7
I30
sg17
VC0020514
p1027
sg10
I18
sg11
Vhyperprolactinemia
p1028
sg13
I1
sa(dp1029
g7
I122
sg17
VC0004364
p1030
sg10
I19
sg11
Vautoimmune diseases
p1031
sg13
I2
sa(dp1032
g7
I50
sg17
VC0020514
p1033
sg10
I4
sg11
VHPRL
p1034
sg13
I1
sa(dp1035
g7
I95
sg17
VC0699748
p1036
sg10
I12
sg11
Vpathogenesis
p1037
sg13
I1
sa(dp1038
g7
I150
sg17
VC0024141
p1039
sg10
I28
sg11
Vsystemic lupus erythematosus
p1040
sg13
I3
sasa(dp1041
g2
S"Furthermore in the last 2 decades multi-organ and organ specific autoimmune diseases like systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjogren's syndrome (SS), Hashimoto's thyroiditis (HT), multiple sclerosis (MS), psoriasis, hepatitis C patients, Behcet's disease, peripartum cardiomyopathy (PPCM) and active celiac disease were discussed to be associated with HPRL.\n"
p1042
sg4
(lp1043
(dp1044
g7
I380
sg8
VP01236
p1045
sg10
I4
sg11
VHPRL
p1046
sg13
I1
sasg14
(lp1047
(dp1048
g7
I148
sg17
VC0003873
p1049
sg10
I2
sg11
VRA
p1050
sg13
I1
sa(dp1051
g7
I120
sg17
VC0024141
p1052
sg10
I3
sg11
VSLE
p1053
sg13
I1
sa(dp1054
g7
I173
sg17
VC1527336
p1055
sg10
I2
sg11
VSS
p1056
sg13
I1
sa(dp1057
g7
I244
sg17
VC0019196
p1058
sg10
I11
sg11
Vhepatitis C
p1059
sg13
I2
sa(dp1060
g7
I90
sg17
VC0024141
p1061
sg10
I28
sg11
Vsystemic lupus erythematosus
p1062
sg13
I3
sa(dp1063
g7
I233
sg17
VC0033860
p1064
sg10
I9
sg11
Vpsoriasis
p1065
sg13
I1
sa(dp1066
g7
I208
sg17
VC0026769
p1067
sg10
I18
sg11
Vmultiple sclerosis
p1068
sg13
I2
sa(dp1069
g7
I153
sg17
VC1527336
p1070
sg10
I18
sg11
VSjogren's syndrome
p1071
sg13
I2
sa(dp1072
g7
I284
sg17
VC0877208
p1073
sg10
I25
sg11
Vperipartum cardiomyopathy
p1074
sg13
I2
sa(dp1075
g7
I203
sg17
VC0920350
p1076
sg10
I2
sg11
VHT
p1077
sg13
I1
sa(dp1078
g7
I65
sg17
VC0004364
p1079
sg10
I19
sg11
Vautoimmune diseases
p1080
sg13
I2
sa(dp1081
g7
I266
sg17
VC0004943
p1082
sg10
I16
sg11
VBehcet's disease
p1083
sg13
I2
sa(dp1084
g7
I228
sg17
VC0026769
p1085
sg10
I2
sg11
VMS
p1086
sg13
I1
sa(dp1087
g7
I126
sg17
VC0003873
p1088
sg10
I20
sg11
Vrheumatoid arthritis
p1089
sg13
I2
sa(dp1090
g7
I328
sg17
VC0007570
p1091
sg10
I14
sg11
Vceliac disease
p1092
sg13
I2
sa(dp1093
g7
I311
sg17
VC0877208
p1094
sg10
I4
sg11
VPPCM
p1095
sg13
I1
sa(dp1096
g7
I178
sg17
VC0920350
p1097
sg10
I23
sg11
VHashimoto's thyroiditis
p1098
sg13
I2
sasa(dp1099
g2
S"Hyperprolactinemia (HPRL) is observed in multi-organ and organ specific autoimmune diseases like systemic lupus erythematosus (SLE) rheumatoid arthritis (RA), Sjogren's syndrome (SS), Hashimoto's thyroiditis (HT) and multiple sclerosis (MS).\n"
p1100
sg4
(lp1101
(dp1102
g7
I20
sg8
VP01236
p1103
sg10
I4
sg11
VHPRL
p1104
sg13
I1
sa(dp1105
g7
I0
sg8
VP01236
p1106
sg10
I18
sg11
VHyperprolactinemia
p1107
sg13
I1
sasg14
(lp1108
(dp1109
g7
I97
sg17
VC0024141
p1110
sg10
I28
sg11
Vsystemic lupus erythematosus
p1111
sg13
I3
sa(dp1112
g7
I154
sg17
VC0003873
p1113
sg10
I2
sg11
VRA
p1114
sg13
I1
sa(dp1115
g7
I127
sg17
VC0024141
p1116
sg10
I3
sg11
VSLE
p1117
sg13
I1
sa(dp1118
g7
I159
sg17
VC1527336
p1119
sg10
I18
sg11
VSjogren's syndrome
p1120
sg13
I2
sa(dp1121
g7
I179
sg17
VC1527336
p1122
sg10
I2
sg11
VSS
p1123
sg13
I1
sa(dp1124
g7
I217
sg17
VC0026769
p1125
sg10
I18
sg11
Vmultiple sclerosis
p1126
sg13
I2
sa(dp1127
g7
I132
sg17
VC0003873
p1128
sg10
I20
sg11
Vrheumatoid arthritis
p1129
sg13
I2
sa(dp1130
g7
I20
sg17
VC0020514
p1131
sg10
I4
sg11
VHPRL
p1132
sg13
I1
sa(dp1133
g7
I72
sg17
VC0004364
p1134
sg10
I19
sg11
Vautoimmune diseases
p1135
sg13
I2
sa(dp1136
g7
I237
sg17
VC0026769
p1137
sg10
I2
sg11
VMS
p1138
sg13
I1
sa(dp1139
g7
I0
sg17
VC0020514
p1140
sg10
I18
sg11
VHyperprolactinemia
p1141
sg13
I1
sa(dp1142
g7
I184
sg17
VC0920350
p1143
sg10
I23
sg11
VHashimoto's thyroiditis
p1144
sg13
I2
sa(dp1145
g7
I209
sg17
VC0920350
p1146
sg10
I2
sg11
VHT
p1147
sg13
I1
sasa(dp1148
g2
S"We describe the role of PRL in the pathogenesis of rheumatic diseases, particularly connective tissue diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), primary Sjoegren's syndrome, systemic sclerosis, polymyalgia rheumatica, and seronegative arthritis.\n"
p1149
sg4
(lp1150
(dp1151
g7
I24
sg8
VP01236
p1152
sg10
I3
sg11
VPRL
p1153
sg13
I1
sasg14
(lp1154
(dp1155
g7
I214
sg17
VC0036421
p1156
sg10
I18
sg11
Vsystemic sclerosis
p1157
sg13
I2
sa(dp1158
g7
I158
sg17
VC0003873
p1159
sg10
I20
sg11
Vrheumatoid arthritis
p1160
sg13
I2
sa(dp1161
g7
I35
sg17
VC0699748
p1162
sg10
I12
sg11
Vpathogenesis
p1163
sg13
I1
sa(dp1164
g7
I193
sg17
VC1527336
p1165
sg10
I19
sg11
VSjoegren's syndrome
p1166
sg13
I2
sa(dp1167
g7
I122
sg17
VC0024141
p1168
sg10
I28
sg11
Vsystemic lupus erythematosus
p1169
sg13
I3
sa(dp1170
g7
I152
sg17
VC0024141
p1171
sg10
I3
sg11
VSLE
p1172
sg13
I1
sa(dp1173
g7
I262
sg17
VC0409679
p1174
sg10
I22
sg11
Vseronegative arthritis
p1175
sg13
I2
sa(dp1176
g7
I180
sg17
VC0003873
p1177
sg10
I2
sg11
VRA
p1178
sg13
I1
sa(dp1179
g7
I84
sg17
VC0009782
p1180
sg10
I26
sg11
Vconnective tissue diseases
p1181
sg13
I3
sa(dp1182
g7
I234
sg17
VC0032533
p1183
sg10
I22
sg11
Vpolymyalgia rheumatica
p1184
sg13
I2
sa(dp1185
g7
I51
sg17
VC0035435
p1186
sg10
I18
sg11
Vrheumatic diseases
p1187
sg13
I2
sasa(dp1188
g2
S'Moreover, we show that the reduction of eosinophilia and the recruitment of inflammatory monocytes to the lungs required early triggering of TLR9, IFN-Gamma and CCR2 by immunotherapy components.\n'
p1189
sg4
(lp1190
(dp1191
g7
I147
sg8
VP01579
p1192
sg10
I9
sg11
VIFN-Gamma
p1193
sg13
I1
sa(dp1194
g7
I161
sg8
VP41597
p1195
sg10
I4
sg11
VCCR2
p1196
sg13
I1
sa(dp1197
g7
I141
sg8
g9
sg10
I4
sg11
VTLR9
p1198
sg13
I1
sasg14
(lp1199
(dp1200
g7
I61
sg17
VC0271510
p1201
sg10
I11
sg11
Vrecruitment
p1202
sg13
I1
sa(dp1203
g7
I40
sg17
VC0014457
p1204
sg10
I12
sg11
Veosinophilia
p1205
sg13
I1
sasa(dp1206
g2
S'Subjects treated with TLR9 agonists were at a higher risk of anemia (risk ratio [RR] 1.04, 95% confidence interval [CI]: 1.02-1.06), neutropenia (RR 1.16, 95% CI: 1.11-1.21), leukopenia (RR 1.16, 95% CI: 1.11-1.22), lymphopenia (RR 1.17, 95% CI: 1.10-1.25), thrombocytopenia (RR 1.20, 95% CI: 1.14-1.27), flu-like symptoms (RR 10.59, 95% CI: 3.66-30.66), diarrhea (RR 1.40, 95% CI: 1.18-1.67) and headache (RR 1.61, 95% CI: 1.26-2.06).\n'
p1207
sg4
(lp1208
(dp1209
g7
I305
sg8
g9
sg10
I3
sg11
Vflu
p1210
sg13
I1
sa(dp1211
g7
I22
sg8
g9
sg10
I4
sg11
VTLR9
p1212
sg13
I1
sasg14
(lp1213
(dp1214
g7
I61
sg17
VC0002871
p1215
sg10
I6
sg11
Vanemia
p1216
sg13
I1
sa(dp1217
g7
I305
sg17
VC0392171
p1218
sg10
I17
sg11
Vflu-like symptoms
p1219
sg13
I2
sa(dp1220
g7
I355
sg17
VC0011991
p1221
sg10
I8
sg11
Vdiarrhea
p1222
sg13
I1
sa(dp1223
g7
I397
sg17
VC0018681
p1224
sg10
I8
sg11
Vheadache
p1225
sg13
I1
sa(dp1226
g7
I216
sg17
VC0024312
p1227
sg10
I11
sg11
Vlymphopenia
p1228
sg13
I1
sa(dp1229
g7
I175
sg17
VC0023530
p1230
sg10
I10
sg11
Vleukopenia
p1231
sg13
I1
sasa(dp1232
g2
S'Both the TLR7 and TLR9 agonists dose dependently reduced airway eosinophilia, while the TLR3 agonist only reduced airway eosinophilia at a dose of 1.0 mg/kg.\n'
p1233
sg4
(lp1234
(dp1235
g7
I18
sg8
g9
sg10
I4
sg11
VTLR9
p1236
sg13
I1
sa(dp1237
g7
I9
sg8
g9
sg10
I4
sg11
VTLR7
p1238
sg13
I1
sa(dp1239
g7
I88
sg8
g9
sg10
I4
sg11
VTLR3
p1240
sg13
I1
sasg14
(lp1241
(dp1242
g7
I64
sg17
VC0014457
p1243
sg10
I12
sg11
Veosinophilia
p1244
sg13
I1
sa(dp1245
g7
I64
sg17
VC0014457
p1246
sg10
I12
sg11
Veosinophilia
p1247
sg13
I1
sasa(dp1248
g2
S'&lt;p&gt;Lichen planopilaris (LPP) is a variant of lichen planus that affects the scalp causing scarring hair loss.\n'
p1249
sg4
(lp1250
sg14
(lp1251
(dp1252
g7
I51
sg17
VC0023646
p1253
sg10
I13
sg11
Vlichen planus
p1254
sg13
I2
sa(dp1255
g7
I96
sg17
VC0008767
p1256
sg10
I8
sg11
Vscarring
p1257
sg13
I1
sa(dp1258
g7
I9
sg17
VC0023645
p1259
sg10
I19
sg11
VLichen planopilaris
p1260
sg13
I2
sasa(dp1261
g2
S'This family of diseases contains 2 subgroups, largely based on clinical features: keratosis pilaris atrophicans (KPA; including keratosis pilaris atrophicans faciei/ulerythema ophryogenes, atrophoderma vermiculata, and keratosis follicularis spinulosa decalvans); and the lichen planopilaris (LPP) subgroup (including LPP, frontal fibrosing alopecia, Graham-Little-Piccardi-Lassueur Syndrome and fibrosing alopecia in a pattern distribution).\n'
p1262
sg4
(lp1263
sg14
(lp1264
(dp1265
g7
I113
sg17
VC0263428
p1266
sg10
I3
sg11
VKPA
p1267
sg13
I1
sa(dp1268
g7
I82
sg17
VC0263428
p1269
sg10
I29
sg11
Vkeratosis pilaris atrophicans
p1270
sg13
I3
sa(dp1271
g7
I323
sg17
VC1274700
p1272
sg10
I26
sg11
Vfrontal fibrosing alopecia
p1273
sg13
I3
sa(dp1274
g7
I189
sg17
VC0151514
p1275
sg10
I12
sg11
Vatrophoderma
p1276
sg13
I1
sa(dp1277
g7
I383
sg17
VC0039082
p1278
sg10
I8
sg11
VSyndrome
p1279
sg13
I1
sa(dp1280
g7
I293
sg17
VC0023645
p1281
sg10
I3
sg11
VLPP
p1282
sg13
I1
sa(dp1283
g7
I219
sg17
VC0343057
p1284
sg10
I42
sg11
Vkeratosis follicularis spinulosa decalvans
p1285
sg13
I4
sa(dp1286
g7
I165
sg17
VC0263428
p1287
sg10
I22
sg11
Vulerythema ophryogenes
p1288
sg13
I2
sa(dp1289
g7
I82
sg17
VC0263428
p1290
sg10
I29
sg11
Vkeratosis pilaris atrophicans
p1291
sg13
I3
sa(dp1292
g7
I293
sg17
VC0023645
p1293
sg10
I3
sg11
VLPP
p1294
sg13
I1
sa(dp1295
g7
I272
sg17
VC0023645
p1296
sg10
I19
sg11
Vlichen planopilaris
p1297
sg13
I2
sasa(dp1298
g2
S'An interface dermatitis with lichenoid inflammation is characteristic of the LPP group of disorders, but the literature provides scant information about the histopathology of the KPA group.\n'
p1299
sg4
(lp1300
sg14
(lp1301
(dp1302
g7
I39
sg17
VC0021368
p1303
sg10
I12
sg11
Vinflammation
p1304
sg13
I1
sa(dp1305
g7
I3
sg17
VC0262981
p1306
sg10
I20
sg11
Vinterface dermatitis
p1307
sg13
I2
sasa(dp1308
g2
S'Recently, there have been25 cases reported in the literature of lichen planuspigmentosus (LPPi) that preceded the developmentof frontal fibrosing alopecia (FFA), which is a variantof lichen planopilaris (LPP).\n'
p1309
sg4
(lp1310
sg14
(lp1311
(dp1312
g7
I64
sg17
VC0023643
p1313
sg10
I6
sg11
Vlichen
p1314
sg13
I1
sa(dp1315
g7
I90
sg17
VC0023645
p1316
sg10
I3
sg11
VLPP
p1317
sg13
I1
sa(dp1318
g7
I128
sg17
VC1274700
p1319
sg10
I26
sg11
Vfrontal fibrosing alopecia
p1320
sg13
I3
sa(dp1321
g7
I183
sg17
VC0023645
p1322
sg10
I19
sg11
Vlichen planopilaris
p1323
sg13
I2
sa(dp1324
g7
I156
sg17
VC1274700
p1325
sg10
I3
sg11
VFFA
p1326
sg13
I1
sasa(dp1327
g2
S'Lower levels of acylCer and LPP accompany skin diseases, such as atopic dermatitis, lamellar ichthyosis, and psoriasis.\n'
p1328
sg4
(lp1329
sg14
(lp1330
(dp1331
g7
I109
sg17
VC0033860
p1332
sg10
I9
sg11
Vpsoriasis
p1333
sg13
I1
sa(dp1334
g7
I84
sg17
VC0020758
p1335
sg10
I19
sg11
Vlamellar ichthyosis
p1336
sg13
I2
sa(dp1337
g7
I42
sg17
VC0037274
p1338
sg10
I13
sg11
Vskin diseases
p1339
sg13
I2
sa(dp1340
g7
I65
sg17
VC0011615
p1341
sg10
I17
sg11
Vatopic dermatitis
p1342
sg13
I2
sasa(dp1343
g2
S'A number of associations such as hepatitis C virus infection, frontal fibrosing alopecia, acrokeratosis of Bazex and nephrotic syndrome have been reported with LPP.\n'
p1344
sg4
(lp1345
sg14
(lp1346
(dp1347
g7
I62
sg17
VC1274700
p1348
sg10
I26
sg11
Vfrontal fibrosing alopecia
p1349
sg13
I3
sa(dp1350
g7
I117
sg17
VC0027726
p1351
sg10
I18
sg11
Vnephrotic syndrome
p1352
sg13
I2
sa(dp1353
g7
I90
sg17
VC0001202
p1354
sg10
I13
sg11
Vacrokeratosis
p1355
sg13
I1
sa(dp1356
g7
I33
sg17
VC0019196
p1357
sg10
I11
sg11
Vhepatitis C
p1358
sg13
I2
sa(dp1359
g7
I45
sg17
VC0042769
p1360
sg10
I15
sg11
Vvirus infection
p1361
sg13
I2
sasa(dp1362
g2
S'Lichen planopilaris (LPP) is a follicular variant of lichen planus.\n'
p1363
sg4
(lp1364
sg14
(lp1365
(dp1366
g7
I21
sg17
VC0023645
p1367
sg10
I3
sg11
VLPP
p1368
sg13
I1
sa(dp1369
g7
I0
sg17
VC0023645
p1370
sg10
I19
sg11
VLichen planopilaris
p1371
sg13
I2
sa(dp1372
g7
I53
sg17
VC0023646
p1373
sg10
I13
sg11
Vlichen planus
p1374
sg13
I2
sasa(dp1375
g2
S'However, genes like HSP90, PAK2, CD247 and others included in the first 1% of the prioritized list need to be further explored in preeclampsia pathogenesis through experimental approaches.\n'
p1376
sg4
(lp1377
(dp1378
g7
I20
sg8
VP07900
p1379
sg10
I5
sg11
VHSP90
p1380
sg13
I1
sa(dp1381
g7
I33
sg8
VP20963
p1382
sg10
I5
sg11
VCD247
p1383
sg13
I1
sa(dp1384
g7
I27
sg8
g9
sg10
I4
sg11
VPAK2
p1385
sg13
I1
sasg14
(lp1386
(dp1387
g7
I143
sg17
VC0699748
p1388
sg10
I12
sg11
Vpathogenesis
p1389
sg13
I1
sa(dp1390
g7
I130
sg17
VC0032914
p1391
sg10
I12
sg11
Vpreeclampsia
p1392
sg13
I1
sasa(dp1393
g2
S'We report a case of acute pancreatitis with diabetic ketoacidosis associated with increased serum myoglobin concentration, acute renal failure, and disseminated intravascular coagulation.\n'
p1394
sg4
(lp1395
(dp1396
g7
I92
sg8
VP02144
p1397
sg10
I15
sg11
Vserum myoglobin
p1398
sg13
I2
sasg14
(lp1399
(dp1400
g7
I148
sg17
VC0012739
p1401
sg10
I38
sg11
Vdisseminated intravascular coagulation
p1402
sg13
I3
sa(dp1403
g7
I44
sg17
VC0011880
p1404
sg10
I21
sg11
Vdiabetic ketoacidosis
p1405
sg13
I2
sa(dp1406
g7
I20
sg17
VC0001339
p1407
sg10
I18
sg11
Vacute pancreatitis
p1408
sg13
I2
sa(dp1409
g7
I123
sg17
VC0022660
p1410
sg10
I19
sg11
Vacute renal failure
p1411
sg13
I3
sasa(dp1412
g2
S'We examined the relationship among acute pancreatitis, diabetic ketoacidosis, and hypermyoglobinemia in the literature.\n'
p1413
sg4
(lp1414
sg14
(lp1415
(dp1416
g7
I35
sg17
VC0001339
p1417
sg10
I18
sg11
Vacute pancreatitis
p1418
sg13
I2
sa(dp1419
g7
I55
sg17
VC0011880
p1420
sg10
I21
sg11
Vdiabetic ketoacidosis
p1421
sg13
I2
sasa(dp1422
g2
S'The frequency of nontraumatic rhabdomyolysis in diabetic ketoacidosis was investigated by serial measurements of the serum levels of myoglobin and the serum activity of creatine kinase isoenzyme MM in 12 consecutively admitted ketoacidotic patients.\n'
p1423
sg4
(lp1424
(dp1425
g7
I133
sg8
VP02144
p1426
sg10
I9
sg11
Vmyoglobin
p1427
sg13
I1
sa(dp1428
g7
I169
sg8
VP12532
p1429
sg10
I15
sg11
Vcreatine kinase
p1430
sg13
I2
sasg14
(lp1431
(dp1432
g7
I30
sg17
VC0035410
p1433
sg10
I14
sg11
Vrhabdomyolysis
p1434
sg13
I1
sa(dp1435
g7
I48
sg17
VC0011880
p1436
sg10
I21
sg11
Vdiabetic ketoacidosis
p1437
sg13
I2
sasa(dp1438
g2
S'In conclusion, our findings suggest that nontraumatic rhabdomyolysis with hypermyoglobinaemia and elevated serum activity of creatine kinase isoenzyme MM may be a hitherto unrecognized common feature of diabetic ketoacidosis.\n'
p1439
sg4
(lp1440
(dp1441
g7
I125
sg8
VP12532
p1442
sg10
I28
sg11
Vcreatine kinase isoenzyme MM
p1443
sg13
I4
sasg14
(lp1444
(dp1445
g7
I54
sg17
VC0035410
p1446
sg10
I14
sg11
Vrhabdomyolysis
p1447
sg13
I1
sa(dp1448
g7
I203
sg17
VC0011880
p1449
sg10
I21
sg11
Vdiabetic ketoacidosis
p1450
sg13
I2
sasa(dp1451
g2
S'Numerous studies have confirmed the carcinogenic role of HMGN5 in cancer, but its function in the regulation of chemosensitivity is largely unknown and controversial.\n'
p1452
sg4
(lp1453
(dp1454
g7
I57
sg8
VP82970
p1455
sg10
I5
sg11
VHMGN5
p1456
sg13
I1
sasg14
(lp1457
(dp1458
g7
I66
sg17
VC0006826
p1459
sg10
I6
sg11
Vcancer
p1460
sg13
I1
sasa(dp1461
g2
S'A previous study by the authors of the present study demonstrated that HMGN5 contributes to the progression of urothelial bladder cancer (UBC) through regulating the expression of E-cadherin and vascular endothelial growth factor (VEGF)-C, which are associated with the sensitivity of tumor cells to cisplatin.\n'
p1462
sg4
(lp1463
(dp1464
g7
I195
sg8
g9
sg10
I34
sg11
Vvascular endothelial growth factor
p1465
sg13
I4
sa(dp1466
g7
I231
sg8
g9
sg10
I4
sg11
VVEGF
p1467
sg13
I1
sa(dp1468
g7
I71
sg8
VP82970
p1469
sg10
I5
sg11
VHMGN5
p1470
sg13
I1
sa(dp1471
g7
I180
sg8
VP12830
p1472
sg10
I10
sg11
VE-cadherin
p1473
sg13
I1
sasg14
(lp1474
(dp1475
g7
I122
sg17
VC0699885
p1476
sg10
I14
sg11
Vbladder cancer
p1477
sg13
I2
sa(dp1478
g7
I285
sg17
VC0027651
p1479
sg10
I5
sg11
Vtumor
p1480
sg13
I1
sasa(dp1481
g2
S"Bioinformatics and luciferase reporter assays demonstrated that miR-495 targets the 3'-untranslated region of high-mobility group nucleosome-binding domain 5 (HMGN5), a potential oncogene in various types of cancers.\n"
p1482
sg4
(lp1483
(dp1484
g7
I110
sg8
VP00390
p1485
sg10
I47
sg11
Vhigh-mobility group nucleosome-binding domain 5
p1486
sg13
I5
sa(dp1487
g7
I159
sg8
VP82970
p1488
sg10
I5
sg11
VHMGN5
p1489
sg13
I1
sasg14
(lp1490
(dp1491
g7
I208
sg17
VC0006826
p1492
sg10
I7
sg11
Vcancers
p1493
sg13
I1
sasa(dp1494
g2
S'High-mobility group nucleosome-binding domain 5 (HMGN5), a well-known oncogene in gliomas, was identified as a functional target of miR-409-3p using bioinformatics, dual-luciferase reporter assay, real-time quantitative polymerase chain reaction, and Western blot analysis.\n'
p1495
sg4
(lp1496
(dp1497
g7
I132
sg8
g9
sg10
I10
sg11
VmiR-409-3p
p1498
sg13
I1
sa(dp1499
g7
I49
sg8
VP82970
p1500
sg10
I5
sg11
VHMGN5
p1501
sg13
I1
sa(dp1502
g7
I0
sg8
VP00390
p1503
sg10
I47
sg11
VHigh-mobility group nucleosome-binding domain 5
p1504
sg13
I5
sasg14
(lp1505
(dp1506
g7
I82
sg17
VC0017638
p1507
sg10
I7
sg11
Vgliomas
p1508
sg13
I1
sasa(dp1509
g2
S'Restoration of HMGN5 expression significantly reversed the inhibitory effects of miR-409-3p overexpression on glioma cell invasion and proliferation.\n'
p1510
sg4
(lp1511
(dp1512
g7
I81
sg8
g9
sg10
I10
sg11
VmiR-409-3p
p1513
sg13
I1
sa(dp1514
g7
I15
sg8
VP82970
p1515
sg10
I5
sg11
VHMGN5
p1516
sg13
I1
sasg14
(lp1517
(dp1518
g7
I135
sg17
VC0334094
p1519
sg10
I13
sg11
Vproliferation
p1520
sg13
I1
sa(dp1521
g7
I110
sg17
VC0017638
p1522
sg10
I6
sg11
Vglioma
p1523
sg13
I1
sa(dp1524
g7
I117
sg17
VC2699153
p1525
sg10
I13
sg11
Vcell invasion
p1526
sg13
I2
sasa(dp1527
g2
S'Taken together, our results suggest that miR-409-3p inhibits glioma cell invasion and proliferation by targeting HMGN5, representing a potential therapeutic target for glioma.\n'
p1528
sg4
(lp1529
(dp1530
g7
I41
sg8
g9
sg10
I10
sg11
VmiR-409-3p
p1531
sg13
I1
sa(dp1532
g7
I113
sg8
VP82970
p1533
sg10
I5
sg11
VHMGN5
p1534
sg13
I1
sasg14
(lp1535
(dp1536
g7
I86
sg17
VC0334094
p1537
sg10
I13
sg11
Vproliferation
p1538
sg13
I1
sa(dp1539
g7
I61
sg17
VC0017638
p1540
sg10
I6
sg11
Vglioma
p1541
sg13
I1
sa(dp1542
g7
I68
sg17
VC2699153
p1543
sg10
I13
sg11
Vcell invasion
p1544
sg13
I2
sa(dp1545
g7
I61
sg17
VC0017638
p1546
sg10
I6
sg11
Vglioma
p1547
sg13
I1
sasa(dp1548
g2
S'It was first discovered in mouse, and recent studies found that the expressions of HMGN5 in many human cancers were also highly regulated, such as prostate, bladder, breast, and lung and clear cell renal cell carcinoma.\n'
p1549
sg4
(lp1550
(dp1551
g7
I83
sg8
VP82970
p1552
sg10
I5
sg11
VHMGN5
p1553
sg13
I1
sasg14
(lp1554
(dp1555
g7
I103
sg17
VC0006826
p1556
sg10
I7
sg11
Vcancers
p1557
sg13
I1
sa(dp1558
g7
I187
sg17
VC0279702
p1559
sg10
I31
sg11
Vclear cell renal cell carcinoma
p1560
sg13
I5
sasa(dp1561
g2
S'Importantly, deficiency of HMGN5 has been shown to be linked to cancer cell growth, cell cycle regulation, migration, invasion, and clinical outcomes, and it represents a promising therapeutic target for many malignant tumors.\n'
p1562
sg4
(lp1563
(dp1564
g7
I27
sg8
VP82970
p1565
sg10
I5
sg11
VHMGN5
p1566
sg13
I1
sasg14
(lp1567
(dp1568
g7
I64
sg17
VC1516170
p1569
sg10
I18
sg11
Vcancer cell growth
p1570
sg13
I3
sa(dp1571
g7
I209
sg17
VC0006826
p1572
sg10
I16
sg11
Vmalignant tumors
p1573
sg13
I2
sa(dp1574
g7
I118
sg17
VC2699153
p1575
sg10
I8
sg11
Vinvasion
p1576
sg13
I1
sasa(dp1577
g2
S'In the present review, we provide an overview of the current knowledge concerning the role of HMGN5 in cancer development and progression.\n'
p1578
sg4
(lp1579
(dp1580
g7
I94
sg8
VP82970
p1581
sg10
I5
sg11
VHMGN5
p1582
sg13
I1
sasg14
(lp1583
(dp1584
g7
I103
sg17
VC0006826
p1585
sg10
I6
sg11
Vcancer
p1586
sg13
I1
sasa(dp1587
g2
S'Nucleosome-binding protein 1 (NSBP1) has been suggested as an oncogene in various types of human cancers.\n'
p1588
sg4
(lp1589
(dp1590
g7
I0
sg8
VP14222
p1591
sg10
I28
sg11
VNucleosome-binding protein 1
p1592
sg13
I3
sa(dp1593
g7
I30
sg8
VP82970
p1594
sg10
I5
sg11
VNSBP1
p1595
sg13
I1
sasg14
(lp1596
(dp1597
g7
I97
sg17
VC0006826
p1598
sg10
I7
sg11
Vcancers
p1599
sg13
I1
sasa(dp1600
g2
S'We found that NSBP1 was highly expressed in non-small cell lung cancer (NSCLC) cells, and knockdown of NSBP1 by NSBP1 small interfering RNA (siRNA) significantly suppressed NSCLC cell proliferation and invasion.\n'
p1601
sg4
(lp1602
(dp1603
g7
I112
sg8
VP82970
p1604
sg10
I27
sg11
VNSBP1 small interfering RNA
p1605
sg13
I4
sa(dp1606
g7
I14
sg8
VP82970
p1607
sg10
I5
sg11
VNSBP1
p1608
sg13
I1
sa(dp1609
g7
I14
sg8
VP82970
p1610
sg10
I5
sg11
VNSBP1
p1611
sg13
I1
sasg14
(lp1612
(dp1613
g7
I72
sg17
VC0007131
p1614
sg10
I5
sg11
VNSCLC
p1615
sg13
I1
sa(dp1616
g7
I44
sg17
VC0007131
p1617
sg10
I26
sg11
Vnon-small cell lung cancer
p1618
sg13
I4
sa(dp1619
g7
I184
sg17
VC0334094
p1620
sg10
I13
sg11
Vproliferation
p1621
sg13
I1
sa(dp1622
g7
I72
sg17
VC0007131
p1623
sg10
I5
sg11
VNSCLC
p1624
sg13
I1
sa(dp1625
g7
I202
sg17
VC2699153
p1626
sg10
I8
sg11
Vinvasion
p1627
sg13
I1
sasa(dp1628
g2
S'Overexpression of miR-326 significantly inhibited NSCLC cell proliferation and invasion, which mimicked the effect of NSBP1 siRNA.\n'
p1629
sg4
(lp1630
(dp1631
g7
I118
sg8
VP82970
p1632
sg10
I11
sg11
VNSBP1 siRNA
p1633
sg13
I2
sa(dp1634
g7
I18
sg8
g9
sg10
I7
sg11
VmiR-326
p1635
sg13
I1
sasg14
(lp1636
(dp1637
g7
I50
sg17
VC0007131
p1638
sg10
I5
sg11
VNSCLC
p1639
sg13
I1
sa(dp1640
g7
I79
sg17
VC2699153
p1641
sg10
I8
sg11
Vinvasion
p1642
sg13
I1
sa(dp1643
g7
I61
sg17
VC0334094
p1644
sg10
I13
sg11
Vproliferation
p1645
sg13
I1
sasa(dp1646
g2
S'Furthermore, suppression of NSBP1 by NSBP1 siRNA or miR-326 overexpression remarkably repressed the expression of cyclin B1 and matrix metalloproteinase 9 (MMP9), which are associated with cancer cell proliferation and invasion.\n'
p1647
sg4
(lp1648
(dp1649
g7
I114
sg8
VP14635
p1650
sg10
I9
sg11
Vcyclin B1
p1651
sg13
I2
sa(dp1652
g7
I37
sg8
VP82970
p1653
sg10
I11
sg11
VNSBP1 siRNA
p1654
sg13
I2
sa(dp1655
g7
I28
sg8
VP82970
p1656
sg10
I5
sg11
VNSBP1
p1657
sg13
I1
sa(dp1658
g7
I156
sg8
VP14780
p1659
sg10
I4
sg11
VMMP9
p1660
sg13
I1
sa(dp1661
g7
I52
sg8
g9
sg10
I7
sg11
VmiR-326
p1662
sg13
I1
sa(dp1663
g7
I128
sg8
VP14780
p1664
sg10
I26
sg11
Vmatrix metalloproteinase 9
p1665
sg13
I3
sasg14
(lp1666
(dp1667
g7
I201
sg17
VC0334094
p1668
sg10
I13
sg11
Vproliferation
p1669
sg13
I1
sa(dp1670
g7
I219
sg17
VC2699153
p1671
sg10
I8
sg11
Vinvasion
p1672
sg13
I1
sa(dp1673
g7
I13
sg17
VC0221103
p1674
sg10
I11
sg11
Vsuppression
p1675
sg13
I1
sa(dp1676
g7
I189
sg17
VC0006826
p1677
sg10
I6
sg11
Vcancer
p1678
sg13
I1
sasa(dp1679
g2
S'In addition, an inverse correlation between miR-326 and NSBP1 expression levels was found in NSCLC clinical specimens.\n'
p1680
sg4
(lp1681
(dp1682
g7
I56
sg8
VP82970
p1683
sg10
I5
sg11
VNSBP1
p1684
sg13
I1
sasg14
(lp1685
(dp1686
g7
I93
sg17
VC0007131
p1687
sg10
I5
sg11
VNSCLC
p1688
sg13
I1
sasa(dp1689
g2
S'Our study demonstrated a direct target relationship between NSBP1 and miR-326 through which miR-326 inhibited cell proliferation and invasion of NSCLC cells.\n'
p1690
sg4
(lp1691
(dp1692
g7
I60
sg8
VP82970
p1693
sg10
I5
sg11
VNSBP1
p1694
sg13
I1
sa(dp1695
g7
I70
sg8
g9
sg10
I7
sg11
VmiR-326
p1696
sg13
I1
sasg14
(lp1697
(dp1698
g7
I133
sg17
VC2699153
p1699
sg10
I8
sg11
Vinvasion
p1700
sg13
I1
sa(dp1701
g7
I115
sg17
VC0334094
p1702
sg10
I13
sg11
Vproliferation
p1703
sg13
I1
sa(dp1704
g7
I145
sg17
VC0007131
p1705
sg10
I5
sg11
VNSCLC
p1706
sg13
I1
sasa(dp1707
g2
S'Thus, miR-326-NSBP1 is a promising candidate target for developing novel anticancer therapeutics for NSCLC.\n'
p1708
sg4
(lp1709
(dp1710
g7
I6
sg8
g9
sg10
I13
sg11
VmiR-326-NSBP1
p1711
sg13
I1
sasg14
(lp1712
(dp1713
g7
I101
sg17
VC0007131
p1714
sg10
I5
sg11
VNSCLC
p1715
sg13
I1
sasa(dp1716
g2
S'Correlation analysis also showed that HMGN5 expression levels were significantly inversely correlated with the miR-340 expression in prostate cancer tissues.\n'
p1717
sg4
(lp1718
(dp1719
g7
I38
sg8
VP82970
p1720
sg10
I5
sg11
VHMGN5
p1721
sg13
I1
sa(dp1722
g7
I111
sg8
g9
sg10
I7
sg11
VmiR-340
p1723
sg13
I1
sasg14
(lp1724
(dp1725
g7
I133
sg17
VC0600139
p1726
sg10
I15
sg11
Vprostate cancer
p1727
sg13
I2
sasa(dp1728
g2
S'In addition, overexpression of HMGN5 significantly reversed the inhibitory effect of miR-340 on prostate cancer cell proliferation and invasion.\n'
p1729
sg4
(lp1730
(dp1731
g7
I31
sg8
VP82970
p1732
sg10
I5
sg11
VHMGN5
p1733
sg13
I1
sa(dp1734
g7
I85
sg8
g9
sg10
I7
sg11
VmiR-340
p1735
sg13
I1
sasg14
(lp1736
(dp1737
g7
I135
sg17
VC2699153
p1738
sg10
I8
sg11
Vinvasion
p1739
sg13
I1
sa(dp1740
g7
I117
sg17
VC0334094
p1741
sg10
I13
sg11
Vproliferation
p1742
sg13
I1
sa(dp1743
g7
I96
sg17
VC0600139
p1744
sg10
I15
sg11
Vprostate cancer
p1745
sg13
I2
sasa(dp1746
g2
S'Moreover, the decreased miR-340 expression may contribute to the development and progression of prostate cancer through a mechanism that involves HMGN5.\n'
p1747
sg4
(lp1748
(dp1749
g7
I146
sg8
VP82970
p1750
sg10
I5
sg11
VHMGN5
p1751
sg13
I1
sasg14
(lp1752
(dp1753
g7
I81
sg17
VC1739135
p1754
sg10
I30
sg11
Vprogression of prostate cancer
p1755
sg13
I4
sasa(dp1756
g2
S'Thus, miR340 and its target gene HMGN5 can serve as potentially useful therapeutic candidates for prostate cancer treatment.\n'
p1757
sg4
(lp1758
(dp1759
g7
I33
sg8
VP82970
p1760
sg10
I5
sg11
VHMGN5
p1761
sg13
I1
sasg14
(lp1762
(dp1763
g7
I98
sg17
VC0600139
p1764
sg10
I15
sg11
Vprostate cancer
p1765
sg13
I2
sasa(dp1766
g2
S'The high-mobility group nucleosome-binding protein-5 (HMGN5) is frequently overexpressed in various malignant cancers.\n'
p1767
sg4
(lp1768
(dp1769
g7
I54
sg8
VP82970
p1770
sg10
I5
sg11
VHMGN5
p1771
sg13
I1
sa(dp1772
g7
I4
sg8
VP00390
p1773
sg10
I48
sg11
Vhigh-mobility group nucleosome-binding protein-5
p1774
sg13
I4
sasg14
(lp1775
(dp1776
g7
I110
sg17
VC0006826
p1777
sg10
I7
sg11
Vcancers
p1778
sg13
I1
sasa(dp1779
g2
S'However, the potential correlation between HMGN5 and prognosis in patients with meningiomas remains unknown.\n'
p1780
sg4
(lp1781
(dp1782
g7
I43
sg8
VP82970
p1783
sg10
I5
sg11
VHMGN5
p1784
sg13
I1
sasg14
(lp1785
(dp1786
g7
I80
sg17
VC0025286
p1787
sg10
I11
sg11
Vmeningiomas
p1788
sg13
I1
sasa(dp1789
g2
S'In the present study, we explored the expression of HMGN5 in meningiomas with immunohistochemistry and correlated the results to the patient outcome.\n'
p1790
sg4
(lp1791
(dp1792
g7
I52
sg8
VP82970
p1793
sg10
I5
sg11
VHMGN5
p1794
sg13
I1
sasg14
(lp1795
(dp1796
g7
I61
sg17
VC0025286
p1797
sg10
I11
sg11
Vmeningiomas
p1798
sg13
I1
sasa(dp1799
g2
S'We demonstrate that there is a positive association between HMGN5 expression and meningioma histological grade.\n'
p1800
sg4
(lp1801
(dp1802
g7
I60
sg8
VP82970
p1803
sg10
I5
sg11
VHMGN5
p1804
sg13
I1
sasg14
(lp1805
(dp1806
g7
I81
sg17
VC0025286
p1807
sg10
I10
sg11
Vmeningioma
p1808
sg13
I1
sasa(dp1809
g2
S'Statistical analysis reveals that lower HMGN5 expression predict lower meningioma recurrence.\n'
p1810
sg4
(lp1811
(dp1812
g7
I40
sg8
VP82970
p1813
sg10
I5
sg11
VHMGN5
p1814
sg13
I1
sasg14
(lp1815
(dp1816
g7
I82
sg17
VC1458156
p1817
sg10
I10
sg11
Vrecurrence
p1818
sg13
I1
sa(dp1819
g7
I71
sg17
VC0025286
p1820
sg10
I10
sg11
Vmeningioma
p1821
sg13
I1
sasa(dp1822
g2
S'Our results further revealed that HMGN5 inhibition decreased P-glycoprotein (MDR-1) expression without affecting multidrug resistance associated proteins 1 (MRP-1) expression to increase chemosensitivity to temozolomide (TMZ) of meningioma cells.\n'
p1823
sg4
(lp1824
(dp1825
g7
I113
sg8
g9
sg10
I42
sg11
Vmultidrug resistance associated proteins 1
p1826
sg13
I5
sa(dp1827
g7
I61
sg8
VP08183
p1828
sg10
I14
sg11
VP-glycoprotein
p1829
sg13
I1
sa(dp1830
g7
I34
sg8
VP82970
p1831
sg10
I5
sg11
VHMGN5
p1832
sg13
I1
sa(dp1833
g7
I77
sg8
g9
sg10
I5
sg11
VMDR-1
p1834
sg13
I1
sa(dp1835
g7
I157
sg8
VP08183
p1836
sg10
I5
sg11
VMRP-1
p1837
sg13
I1
sasg14
(lp1838
(dp1839
g7
I229
sg17
VC0025286
p1840
sg10
I10
sg11
Vmeningioma
p1841
sg13
I1
sasa(dp1842
g2
S'Collectively, this study indicates that HMGN5 is a novel target for developing effective therapeutic strategies for malignant meningiomas.\n'
p1843
sg4
(lp1844
(dp1845
g7
I40
sg8
VP82970
p1846
sg10
I5
sg11
VHMGN5
p1847
sg13
I1
sasg14
(lp1848
(dp1849
g7
I116
sg17
VC0259785
p1850
sg10
I21
sg11
Vmalignant meningiomas
p1851
sg13
I2
sasa(dp1852
g2
S"In this study, we show that TK1 is upregulated and localizes on the plasma membrane of Burkitt's lymphoma, acute promyelocytic leukemia, T cell leukemia, and acute lymphoblastic leukemia (ALL).\n"
p1853
sg4
(lp1854
(dp1855
g7
I28
sg8
VP04183
p1856
sg10
I3
sg11
VTK1
p1857
sg13
I1
sasg14
(lp1858
(dp1859
g7
I107
sg17
VC0023487
p1860
sg10
I28
sg11
Vacute promyelocytic leukemia
p1861
sg13
I3
sa(dp1862
g7
I87
sg17
VC0006413
p1863
sg10
I18
sg11
VBurkitt's lymphoma
p1864
sg13
I2
sa(dp1865
g7
I188
sg17
VC1961102
p1866
sg10
I3
sg11
VALL
p1867
sg13
I1
sa(dp1868
g7
I158
sg17
VC1961102
p1869
sg10
I28
sg11
Vacute lymphoblastic leukemia
p1870
sg13
I3
sa(dp1871
g7
I137
sg17
VC0023492
p1872
sg10
I15
sg11
VT cell leukemia
p1873
sg13
I3
sasa(dp1874
g2
S'TK1 has been reported as a reliable prognostic factor in solid tumors and chronic lymphocytic leukemia, but has not yet been tested in large populations of patients with non-Hodgkin lymphoma.\n'
p1875
sg4
(lp1876
(dp1877
g7
I0
sg8
VP04183
p1878
sg10
I3
sg11
VTK1
p1879
sg13
I1
sasg14
(lp1880
(dp1881
g7
I57
sg17
VC0280100
p1882
sg10
I12
sg11
Vsolid tumors
p1883
sg13
I2
sa(dp1884
g7
I170
sg17
VC0024305
p1885
sg10
I20
sg11
Vnon-Hodgkin lymphoma
p1886
sg13
I2
sa(dp1887
g7
I74
sg17
VC0023434
p1888
sg10
I28
sg11
Vchronic lymphocytic leukemia
p1889
sg13
I3
sasa(dp1890
g2
S'In this study, the prognostic significance of TK1 levels was assessed in 170 prospectively enrolled patients with previously untreated follicular lymphoma (FL).\n'
p1891
sg4
(lp1892
(dp1893
g7
I46
sg8
VP04183
p1894
sg10
I3
sg11
VTK1
p1895
sg13
I1
sasg14
(lp1896
(dp1897
g7
I135
sg17
VC0024301
p1898
sg10
I19
sg11
Vfollicular lymphoma
p1899
sg13
I2
sa(dp1900
g7
I156
sg17
VC0024301
p1901
sg10
I2
sg11
VFL
p1902
sg13
I1
sasa(dp1903
g2
S'The TK1 level at the time of treatment initiation was shown to correlate with the clinical stage, Follicular Lymphoma International Prognostic Index (FLIPI) score, Beta(2)-microglobulin level, lactate dehydrogenase level and B symptoms.\n'
p1904
sg4
(lp1905
(dp1906
g7
I164
sg8
VP61769
p1907
sg10
I21
sg11
VBeta(2)-microglobulin
p1908
sg13
I1
sa(dp1909
g7
I4
sg8
VP04183
p1910
sg10
I3
sg11
VTK1
p1911
sg13
I1
sa(dp1912
g7
I193
sg8
VP49366
p1913
sg10
I21
sg11
Vlactate dehydrogenase
p1914
sg13
I2
sasg14
(lp1915
(dp1916
g7
I98
sg17
VC0024301
p1917
sg10
I19
sg11
VFollicular Lymphoma
p1918
sg13
I2
sasa(dp1919
g2
S'We show that high serum TK1 levels predict poorer overall survival and correlate with unmutated immunoglobulin variable region genes, CD38 and ZAP-70 expression, and subsequent risk of developing large B-cell lymphoma (Richter syndrome).\n'
p1920
sg4
(lp1921
(dp1922
g7
I134
sg8
VP28907
p1923
sg10
I4
sg11
VCD38
p1924
sg13
I1
sa(dp1925
g7
I96
sg8
g9
sg10
I36
sg11
Vimmunoglobulin variable region genes
p1926
sg13
I4
sa(dp1927
g7
I24
sg8
VP04183
p1928
sg10
I3
sg11
VTK1
p1929
sg13
I1
sa(dp1930
g7
I143
sg8
VP43403
p1931
sg10
I6
sg11
VZAP-70
p1932
sg13
I1
sasg14
(lp1933
(dp1934
g7
I219
sg17
VC0349631
p1935
sg10
I16
sg11
VRichter syndrome
p1936
sg13
I2
sa(dp1937
g7
I202
sg17
VC0079731
p1938
sg10
I15
sg11
VB-cell lymphoma
p1939
sg13
I2
sasa(dp1940
g2
S'In the present study, we revealed that the Hippo transducer, the transcriptional coactivator with PDZ-binding motif (TAZ), acts as a downstream mediator of PODXL in colon cancer.\n'
p1941
sg4
(lp1942
(dp1943
g7
I156
sg8
g9
sg10
I5
sg11
VPODXL
p1944
sg13
I1
sa(dp1945
g7
I65
sg8
g9
sg10
I50
sg11
Vtranscriptional coactivator with PDZ-binding motif
p1946
sg13
I5
sa(dp1947
g7
I117
sg8
g9
sg10
I3
sg11
VTAZ
p1948
sg13
I1
sasg14
(lp1949
(dp1950
g7
I165
sg17
VC0699790
p1951
sg10
I12
sg11
Vcolon cancer
p1952
sg13
I2
sasa(dp1953
g2
S'Moreover, PODXL plays a critical role in cancer stemness, invasiveness, and sensitivity to chemotherapies in colon cancer HCT15 cells.\n'
p1954
sg4
(lp1955
(dp1956
g7
I10
sg8
g9
sg10
I5
sg11
VPODXL
p1957
sg13
I1
sasg14
(lp1958
(dp1959
g7
I41
sg17
VC0006826
p1960
sg10
I6
sg11
Vcancer
p1961
sg13
I1
sa(dp1962
g7
I109
sg17
VC0699790
p1963
sg10
I12
sg11
Vcolon cancer
p1964
sg13
I2
sasa(dp1965
g2
S'Notably, expression of PODXL showed a positive correlation with stem-like and epithelial-mesenchymal transition (EMT) core signatures, and was associated with poor survival outcomes in patients with colon cancer.\n'
p1966
sg4
(lp1967
(dp1968
g7
I23
sg8
g9
sg10
I5
sg11
VPODXL
p1969
sg13
I1
sasg14
(lp1970
(dp1971
g7
I199
sg17
VC0699790
p1972
sg10
I12
sg11
Vcolon cancer
p1973
sg13
I2
sa(dp1974
g7
I101
sg17
VC0599156
p1975
sg10
I10
sg11
Vtransition
p1976
sg13
I1
sasa(dp1977
g2
S'These findings provide novel insights into the molecular mechanism of PODXL-mediated tumorigenesis in colon cancer.\n'
p1978
sg4
(lp1979
(dp1980
g7
I70
sg8
g9
sg10
I5
sg11
VPODXL
p1981
sg13
I1
sasg14
(lp1982
(dp1983
g7
I102
sg17
VC0699790
p1984
sg10
I12
sg11
Vcolon cancer
p1985
sg13
I2
sa(dp1986
g7
I85
sg17
VC0007621
p1987
sg10
I13
sg11
Vtumorigenesis
p1988
sg13
I1
sasa(dp1989
g2
S'Podocalyxin (PODXL), which belongs to the CD34 family and regulates cell morphology, has been linked to EMT in lung cancer, and PODXL overexpression is associated with poor prognosis in several different classes of cancers.\n'
p1990
sg4
(lp1991
(dp1992
g7
I104
sg8
g9
sg10
I3
sg11
VEMT
p1993
sg13
I1
sa(dp1994
g7
I13
sg8
g9
sg10
I5
sg11
VPODXL
p1995
sg13
I1
sa(dp1996
g7
I42
sg8
VP28906
p1997
sg10
I11
sg11
VCD34 family
p1998
sg13
I2
sa(dp1999
g7
I13
sg8
g9
sg10
I5
sg11
VPODXL
p2000
sg13
I1
sa(dp2001
g7
I0
sg8
g9
sg10
I11
sg11
VPodocalyxin
p2002
sg13
I1
sasg14
(lp2003
(dp2004
g7
I215
sg17
VC0006826
p2005
sg10
I7
sg11
Vcancers
p2006
sg13
I1
sa(dp2007
g7
I111
sg17
VC0684249
p2008
sg10
I11
sg11
Vlung cancer
p2009
sg13
I2
sasa(dp2010
g2
S'The aim of this study was to clarify the role of PODXL overexpression in EMT in lung cancer, and to determine the prognostic value of PODXL overexpression in tumors from lung cancer patients.\n'
p2011
sg4
(lp2012
(dp2013
g7
I49
sg8
g9
sg10
I5
sg11
VPODXL
p2014
sg13
I1
sa(dp2015
g7
I73
sg8
g9
sg10
I3
sg11
VEMT
p2016
sg13
I1
sa(dp2017
g7
I49
sg8
g9
sg10
I5
sg11
VPODXL
p2018
sg13
I1
sasg14
(lp2019
(dp2020
g7
I158
sg17
VC0027651
p2021
sg10
I6
sg11
Vtumors
p2022
sg13
I1
sa(dp2023
g7
I80
sg17
VC0684249
p2024
sg10
I11
sg11
Vlung cancer
p2025
sg13
I2
sa(dp2026
g7
I80
sg17
VC0684249
p2027
sg10
I11
sg11
Vlung cancer
p2028
sg13
I2
sasa(dp2029
g2
S'The morphology, EMT marker expression, and migration and invasion abilities of engineered A549 PODXL-knockdown (KD) or PODXL-overexpression (OE) lung adenocarcinoma cells were examined.\n'
p2030
sg4
(lp2031
sg14
(lp2032
(dp2033
g7
I145
sg17
VC0152013
p2034
sg10
I19
sg11
Vlung adenocarcinoma
p2035
sg13
I2
sa(dp2036
g7
I57
sg17
VC2699153
p2037
sg10
I8
sg11
Vinvasion
p2038
sg13
I1
sasa(dp2039
g2
S'PODXL expression levels were assessed by immunohistochemistry in 114 human clinical lung adenocarcinoma specimens and correlated with clinical outcomes.\n'
p2040
sg4
(lp2041
(dp2042
g7
I0
sg8
g9
sg10
I5
sg11
VPODXL
p2043
sg13
I1
sasg14
(lp2044
(dp2045
g7
I84
sg17
VC0152013
p2046
sg10
I19
sg11
Vlung adenocarcinoma
p2047
sg13
I2
sasa(dp2048
g2
S'A highly selective inhibitor of phosphatidylinositol 3-kinase-Akt signaling attenuated EMT of PODXL-OE cells, while a transforming growth factor inhibitor did not, suggesting that PODXL induces EMT of lung adenocarcinoma cells via the phosphatidylinositol 3-kinase pathway.\n'
p2049
sg4
(lp2050
(dp2051
g7
I87
sg8
g9
sg10
I3
sg11
VEMT
p2052
sg13
I1
sa(dp2053
g7
I118
sg8
g9
sg10
I26
sg11
Vtransforming growth factor
p2054
sg13
I3
sa(dp2055
g7
I94
sg8
g9
sg10
I5
sg11
VPODXL
p2056
sg13
I1
sa(dp2057
g7
I32
sg8
VP42336
p2058
sg10
I29
sg11
Vphosphatidylinositol 3-kinase
p2059
sg13
I2
sa(dp2060
g7
I32
sg8
VP42336
p2061
sg10
I29
sg11
Vphosphatidylinositol 3-kinase
p2062
sg13
I2
sa(dp2063
g7
I94
sg8
g9
sg10
I8
sg11
VPODXL-OE
p2064
sg13
I1
sa(dp2065
g7
I62
sg8
g9
sg10
I3
sg11
VAkt
p2066
sg13
I1
sasg14
(lp2067
(dp2068
g7
I201
sg17
VC0152013
p2069
sg10
I19
sg11
Vlung adenocarcinoma
p2070
sg13
I2
sasa(dp2071
g2
S'In lung adenocarcinoma clinical specimens, PODXL expression was detected in minimally invasive and invasive adenocarcinoma, but not in non-invasive adenocarcinoma.\n'
p2072
sg4
(lp2073
(dp2074
g7
I43
sg8
g9
sg10
I5
sg11
VPODXL
p2075
sg13
I1
sasg14
(lp2076
(dp2077
g7
I3
sg17
VC0152013
p2078
sg10
I19
sg11
Vlung adenocarcinoma
p2079
sg13
I2
sa(dp2080
g7
I8
sg17
VC0001418
p2081
sg10
I14
sg11
Vadenocarcinoma
p2082
sg13
I1
sa(dp2083
g7
I8
sg17
VC0001418
p2084
sg10
I14
sg11
Vadenocarcinoma
p2085
sg13
I1
sasa(dp2086
g2
S'PODXL overexpression induces EMT in lung adenocarcinoma and contributes to tumor progression.\n'
p2087
sg4
(lp2088
(dp2089
g7
I29
sg8
g9
sg10
I3
sg11
VEMT
p2090
sg13
I1
sa(dp2091
g7
I0
sg8
g9
sg10
I5
sg11
VPODXL
p2092
sg13
I1
sasg14
(lp2093
(dp2094
g7
I75
sg17
VC0178874
p2095
sg10
I17
sg11
Vtumor progression
p2096
sg13
I2
sa(dp2097
g7
I36
sg17
VC0152013
p2098
sg10
I19
sg11
Vlung adenocarcinoma
p2099
sg13
I2
sasa(dp2100
g2
S'The aim of this study was to investigate the impact of PODXL expression on survival in esophageal and gastric adenocarcinoma.\n'
p2101
sg4
(lp2102
(dp2103
g7
I55
sg8
g9
sg10
I5
sg11
VPODXL
p2104
sg13
I1
sasg14
(lp2105
(dp2106
g7
I102
sg17
VC0278701
p2107
sg10
I22
sg11
Vgastric adenocarcinoma
p2108
sg13
I2
sasa(dp2109
g2
S'In gastric adenocarcinoma, patients with PODXL negative tumors had a superior TTR and a trend towards an improved OS.\n'
p2110
sg4
(lp2111
sg14
(lp2112
(dp2113
g7
I56
sg17
VC0027651
p2114
sg10
I6
sg11
Vtumors
p2115
sg13
I1
sa(dp2116
g7
I3
sg17
VC0278701
p2117
sg10
I22
sg11
Vgastric adenocarcinoma
p2118
sg13
I2
sasa(dp2119
g2
S'In esophageal and gastric adenocarcinoma combined, the prognostic significance of PODXL expression on TTR was confirmed in unadjusted Cox regression analysis (HR = 5.36, 95 % CI 1.68-17.06, p = 0.005) and remained significant in the adjusted model (HR = 3.39, 95 % CI 1.01-11.35, p = 0.048).\n'
p2120
sg4
(lp2121
(dp2122
g7
I82
sg8
g9
sg10
I5
sg11
VPODXL
p2123
sg13
I1
sa(dp2124
g7
I102
sg8
VP02766
p2125
sg10
I3
sg11
VTTR
p2126
sg13
I1
sasg14
(lp2127
(dp2128
g7
I18
sg17
VC0278701
p2129
sg10
I22
sg11
Vgastric adenocarcinoma
p2130
sg13
I2
sasa(dp2131
g2
S'In esophageal and gastric adenocarcinoma, PODXL expression is an independent prognostic biomarker for reduced time to recurrence and poor overall survival.\n'
p2132
sg4
(lp2133
(dp2134
g7
I42
sg8
g9
sg10
I5
sg11
VPODXL
p2135
sg13
I1
sasg14
(lp2136
(dp2137
g7
I118
sg17
VC1458156
p2138
sg10
I10
sg11
Vrecurrence
p2139
sg13
I1
sa(dp2140
g7
I18
sg17
VC0278701
p2141
sg10
I22
sg11
Vgastric adenocarcinoma
p2142
sg13
I2
sasa(dp2143
g2
S'Here, we report that high PODXL expression was an independent predictor of worse overall survival of pancreatic cancer patients, and that PODXL promoted pancreatic cancer cell motility and invasion by physically binding to the cytoskeletal protein gelsolin.\n'
p2144
sg4
(lp2145
(dp2146
g7
I26
sg8
g9
sg10
I5
sg11
VPODXL
p2147
sg13
I1
sa(dp2148
g7
I26
sg8
g9
sg10
I5
sg11
VPODXL
p2149
sg13
I1
sasg14
(lp2150
(dp2151
g7
I101
sg17
VC0235974
p2152
sg10
I17
sg11
Vpancreatic cancer
p2153
sg13
I2
sa(dp2154
g7
I101
sg17
VC0235974
p2155
sg10
I17
sg11
Vpancreatic cancer
p2156
sg13
I2
sa(dp2157
g7
I189
sg17
VC2699153
p2158
sg10
I8
sg11
Vinvasion
p2159
sg13
I1
sasa(dp2160
g2
S'Furthermore, transfection of a PODXL-rescue construct into pancreatic cancer cells in which both PODXL and gelsolin were suppressed failed to increase the formation of the protrusions.\n'
p2161
sg4
(lp2162
(dp2163
g7
I31
sg8
g9
sg10
I5
sg11
VPODXL
p2164
sg13
I1
sa(dp2165
g7
I107
sg8
VP06396
p2166
sg10
I8
sg11
Vgelsolin
p2167
sg13
I1
sa(dp2168
g7
I31
sg8
g9
sg10
I22
sg11
VPODXL-rescue construct
p2169
sg13
I2
sasg14
(lp2170
(dp2171
g7
I172
sg17
VC0333056
p2172
sg10
I11
sg11
Vprotrusions
p2173
sg13
I1
sa(dp2174
g7
I59
sg17
VC0235974
p2175
sg10
I17
sg11
Vpancreatic cancer
p2176
sg13
I2
sasa(dp2177
g2
S'Podocalyxin-like 1 (PODXL) is an anti-adhesive transmembrane protein that has been demonstrated to be an independent factor of poor prognosis in colorectal cancer (CRC).\n'
p2178
sg4
(lp2179
(dp2180
g7
I20
sg8
g9
sg10
I5
sg11
VPODXL
p2181
sg13
I1
sa(dp2182
g7
I0
sg8
g9
sg10
I18
sg11
VPodocalyxin-like 1
p2183
sg13
I2
sasg14
(lp2184
(dp2185
g7
I164
sg17
VC1527249
p2186
sg10
I3
sg11
VCRC
p2187
sg13
I1
sa(dp2188
g7
I145
sg17
VC1527249
p2189
sg10
I17
sg11
Vcolorectal cancer
p2190
sg13
I2
sasa(dp2191
g2
S"In addition, we identified a possible target of miR-5100, podocalyxin-like 1 (PODXL), and demonstrated miR-5100 directly binds to the 3' untranslated region of PODXL and post-transcriptionally regulates its expression in pancreatic cancer cells.\n"
p2192
sg4
(lp2193
(dp2194
g7
I78
sg8
g9
sg10
I5
sg11
VPODXL
p2195
sg13
I1
sa(dp2196
g7
I78
sg8
g9
sg10
I5
sg11
VPODXL
p2197
sg13
I1
sa(dp2198
g7
I58
sg8
g9
sg10
I18
sg11
Vpodocalyxin-like 1
p2199
sg13
I2
sa(dp2200
g7
I48
sg8
g9
sg10
I8
sg11
VmiR-5100
p2201
sg13
I1
sasg14
(lp2202
(dp2203
g7
I221
sg17
VC0235974
p2204
sg10
I17
sg11
Vpancreatic cancer
p2205
sg13
I2
sasa(dp2206
g2
S'We also clarified the close relationship between expression of PODXL in human pancreatic cancer specimens and liver metastasis (P=0.0003), and determined that post-operative survival was longer in the low-PODXL expression group than in the high-PODXL expression group (P&lt;0.05).\n'
p2207
sg4
(lp2208
(dp2209
g7
I63
sg8
g9
sg10
I5
sg11
VPODXL
p2210
sg13
I1
sa(dp2211
g7
I63
sg8
g9
sg10
I5
sg11
VPODXL
p2212
sg13
I1
sasg14
(lp2213
(dp2214
g7
I110
sg17
VC0494165
p2215
sg10
I16
sg11
Vliver metastasis
p2216
sg13
I2
sa(dp2217
g7
I78
sg17
VC0235974
p2218
sg10
I17
sg11
Vpancreatic cancer
p2219
sg13
I2
sasa(dp2220
g2
S'These results indicate that miR-5100 and PODXL have considerable therapeutic potential for anti-metastatic therapy and could be potential indicators for cancer metastases in patients with pancreatic cancer.\n'
p2221
sg4
(lp2222
(dp2223
g7
I28
sg8
g9
sg10
I8
sg11
VmiR-5100
p2224
sg13
I1
sa(dp2225
g7
I41
sg8
g9
sg10
I5
sg11
VPODXL
p2226
sg13
I1
sasg14
(lp2227
(dp2228
g7
I188
sg17
VC0235974
p2229
sg10
I17
sg11
Vpancreatic cancer
p2230
sg13
I2
sa(dp2231
g7
I160
sg17
VC0027627
p2232
sg10
I10
sg11
Vmetastases
p2233
sg13
I1
sa(dp2234
g7
I153
sg17
VC0006826
p2235
sg10
I6
sg11
Vcancer
p2236
sg13
I1
sasa(dp2237
g2
S'Previously we demonstrated that miR-199b was significantly downregulated in acute myeloid leukemia (AML) and targets podocalyxin and discoidin domain receptor 1.\n'
p2238
sg4
(lp2239
(dp2240
g7
I117
sg8
g9
sg10
I11
sg11
Vpodocalyxin
p2241
sg13
I1
sa(dp2242
g7
I133
sg8
g9
sg10
I27
sg11
Vdiscoidin domain receptor 1
p2243
sg13
I4
sa(dp2244
g7
I32
sg8
g9
sg10
I8
sg11
VmiR-199b
p2245
sg13
I1
sasg14
(lp2246
(dp2247
g7
I76
sg17
VC0023467
p2248
sg10
I22
sg11
Vacute myeloid leukemia
p2249
sg13
I3
sa(dp2250
g7
I100
sg17
VC0023467
p2251
sg10
I3
sg11
VAML
p2252
sg13
I1
sasa(dp2253
g2
S'Therefore, we set out to determine if podocalyxin plays a functional role in breast tumor progression.\n'
p2254
sg4
(lp2255
sg14
(lp2256
(dp2257
g7
I84
sg17
VC0178874
p2258
sg10
I17
sg11
Vtumor progression
p2259
sg13
I2
sasa(dp2260
g2
S'Forced overexpression of podocalyxin caused cohesive clusters of epithelial MCF-7 breast tumor cells to bud off from the primary tumor and collectively invade the stroma of the mouse mammary gland in vivo.\n'
p2261
sg4
(lp2262
sg14
(lp2263
(dp2264
g7
I121
sg17
VC0677930
p2265
sg10
I13
sg11
Vprimary tumor
p2266
sg13
I2
sa(dp2267
g7
I82
sg17
VC1458155
p2268
sg10
I12
sg11
Vbreast tumor
p2269
sg13
I2
sasa(dp2270
g2
S'The DEGs MAPT, DSTN, SPTBN1, ARHGEF2 and SKA1 are suggested to be candidate biomarkers for childhood obesity.\n'
p2271
sg4
(lp2272
(dp2273
g7
I4
sg8
g9
sg10
I9
sg11
VDEGs MAPT
p2274
sg13
I2
sa(dp2275
g7
I15
sg8
VP60981
p2276
sg10
I4
sg11
VDSTN
p2277
sg13
I1
sa(dp2278
g7
I29
sg8
g9
sg10
I7
sg11
VARHGEF2
p2279
sg13
I1
sa(dp2280
g7
I21
sg8
g9
sg10
I6
sg11
VSPTBN1
p2281
sg13
I1
sa(dp2282
g7
I41
sg8
g9
sg10
I4
sg11
VSKA1
p2283
sg13
I1
sasg14
(lp2284
(dp2285
g7
I91
sg17
VC2362324
p2286
sg10
I17
sg11
Vchildhood obesity
p2287
sg13
I2
sasa(dp2288
g2
S'All received support and advice by community Diabetes Specialist Nurses (DSNs) and Dieticians covering Central and Eastern Cheshire, UK.\n'
p2289
sg4
(lp2290
sg14
(lp2291
(dp2292
g7
I45
sg17
VC0011849
p2293
sg10
I8
sg11
VDiabetes
p2294
sg13
I1
sasa(dp2295
g2
S'In 2009, the PCT confirmed 3 years funding for a Paediatric Diabetes specialist nurse (PDSN) for schools.\n'
p2296
sg4
(lp2297
sg14
(lp2298
(dp2299
g7
I60
sg17
VC0011849
p2300
sg10
I8
sg11
VDiabetes
p2301
sg13
I1
sa(dp2302
g7
I13
sg17
VC0162566
p2303
sg10
I3
sg11
VPCT
p2304
sg13
I1
sasa(dp2305
g2
S'The aim of this study was to explore the interaction between diabetes specialist nurses (DSNs) and patients with type 2 diabetes (T2D) during group sessions about self-management.\n'
p2306
sg4
(lp2307
sg14
(lp2308
(dp2309
g7
I130
sg17
VC0011860
p2310
sg10
I3
sg11
VT2D
p2311
sg13
I1
sa(dp2312
g7
I113
sg17
VC0011860
p2313
sg10
I15
sg11
Vtype 2 diabetes
p2314
sg13
I3
sa(dp2315
g7
I61
sg17
VC0011849
p2316
sg10
I8
sg11
Vdiabetes
p2317
sg13
I1
sasa(dp2318
g2
S'In 8 Italian municipalities, 2,512 men and women without both diabetes and CI-DSN at baseline are examined.\n'
p2319
sg4
(lp2320
sg14
(lp2321
(dp2322
g7
I78
sg17
VC0011195
p2323
sg10
I3
sg11
VDSN
p2324
sg13
I1
sa(dp2325
g7
I62
sg17
VC0011849
p2326
sg10
I8
sg11
Vdiabetes
p2327
sg13
I1
sasa(dp2328
g2
S'The majority (72%) of PHCCs had diabetes-responsible general practitioners (GPs) and almost all (97%) had diabetes specialist nurses (DSNs) with some degree of postgraduate education in diabetes.\n'
p2329
sg4
(lp2330
sg14
(lp2331
(dp2332
g7
I32
sg17
VC0011849
p2333
sg10
I8
sg11
Vdiabetes
p2334
sg13
I1
sa(dp2335
g7
I32
sg17
VC0011849
p2336
sg10
I8
sg11
Vdiabetes
p2337
sg13
I1
sa(dp2338
g7
I53
sg17
VC0272302
p2339
sg10
I21
sg11
Vgeneral practitioners
p2340
sg13
I2
sa(dp2341
g7
I32
sg17
VC0011849
p2342
sg10
I8
sg11
Vdiabetes
p2343
sg13
I1
sa(dp2344
g7
I76
sg17
VC0272302
p2345
sg10
I3
sg11
VGPs
p2346
sg13
I1
sasa(dp2347
g2
S'The PHCCs reported that they used regional/local diabetes guidelines (93%), were engaged in call-recall diabetic reviews by GP(s) (66%) and DSN(s) (89%), checked that patients had participated in the reviews by GP(s) (69%) and DSN(s) (78%), arranged group education programmes (23%) and reported data to a National Diabetes Register (82%).\n'
p2348
sg4
(lp2349
sg14
(lp2350
(dp2351
g7
I315
sg17
VC0011849
p2352
sg10
I8
sg11
VDiabetes
p2353
sg13
I1
sa(dp2354
g7
I140
sg17
VC0011195
p2355
sg10
I3
sg11
VDSN
p2356
sg13
I1
sa(dp2357
g7
I140
sg17
VC0011195
p2358
sg10
I3
sg11
VDSN
p2359
sg13
I1
sa(dp2360
g7
I49
sg17
VC0011849
p2361
sg10
I8
sg11
Vdiabetes
p2362
sg13
I1
sasa(dp2363
g2
S'The presence of diabetes-responsible GP(s) and DSN(s) who use guidelines may contribute to good and equal quality of care.\n'
p2364
sg4
(lp2365
sg14
(lp2366
(dp2367
g7
I47
sg17
VC0011195
p2368
sg10
I3
sg11
VDSN
p2369
sg13
I1
sa(dp2370
g7
I16
sg17
VC0011849
p2371
sg10
I8
sg11
Vdiabetes
p2372
sg13
I1
sasa(dp2373
g2
S'To review the working practices of UK diabetes specialist nurses (DSNs), specific clinical roles, and to examine changes since 2000.\n'
p2374
sg4
(lp2375
sg14
(lp2376
(dp2377
g7
I38
sg17
VC0011849
p2378
sg10
I8
sg11
Vdiabetes
p2379
sg13
I1
sasa(dp2380
g2
S'Postal questionnaires were sent to lead DSNs from all identifiable UK diabetes centres (n = 361).\n'
p2381
sg4
(lp2382
sg14
(lp2383
(dp2384
g7
I70
sg17
VC0011849
p2385
sg10
I8
sg11
Vdiabetes
p2386
sg13
I1
sasa(dp2387
g2
S'Quantitative and qualitative data were collected on the specific clinical roles, employment, and continual professional development of hospital and community DSNs, Nurse Consultants and Diabetes Healthcare Assistants.\n'
p2388
sg4
(lp2389
sg14
(lp2390
(dp2391
g7
I186
sg17
VC0011849
p2392
sg10
I8
sg11
VDiabetes
p2393
sg13
I1
sasa(dp2394
g2
S'22% of DSNs have a formal role in diabetes research compared with 48% in 2000.\n'
p2395
sg4
(lp2396
sg14
(lp2397
(dp2398
g7
I34
sg17
VC0011849
p2399
sg10
I8
sg11
Vdiabetes
p2400
sg13
I1
sasa(dp2401
g2
S'Patients were recruited from 40 general practices and randomised (40:40:20 ratio) to receive routine care alone or, in addition, motivational telephone support from a peer supporter or a diabetes specialist nurse (9 peers and 12 DSNs) for a period of up to 6 months.\n'
p2402
sg4
(lp2403
sg14
(lp2404
(dp2405
g7
I187
sg17
VC0011849
p2406
sg10
I8
sg11
Vdiabetes
p2407
sg13
I1
sasa(dp2408
g2
S'We exposed the human NSCLC cell lines Calu-1, CL3, H1299, CH27, H23, and H1355 to B[a]P and assessed cell cycle progression using flow cytometry.\n'
p2409
sg4
(lp2410
sg14
(lp2411
(dp2412
g7
I21
sg17
VC0007131
p2413
sg10
I5
sg11
VNSCLC
p2414
sg13
I1
sasa(dp2415
g2
S'Moreover, DOX-loaded micelles could slowly and efficiency decrease cell viability of non-small-cell lung carcinoma CL3 cells.\n'
p2416
sg4
(lp2417
sg14
(lp2418
(dp2419
g7
I85
sg17
VC0007131
p2420
sg10
I29
sg11
Vnon-small-cell lung carcinoma
p2421
sg13
I3
sasa(dp2422
g2
S'Comet assay was used to evaluate the DNA damage induced by a relatively low dose of COF (100 g/ml) in human lung adenocarcinoma CL-3 cells.\n'
p2423
sg4
(lp2424
sg14
(lp2425
(dp2426
g7
I108
sg17
VC0152013
p2427
sg10
I19
sg11
Vlung adenocarcinoma
p2428
sg13
I2
sa(dp2429
g7
I37
sg17
VC0012860
p2430
sg10
I10
sg11
VDNA damage
p2431
sg13
I2
sasa(dp2432
g2
S'Pb(II) increased the phosphorylated ERK1/2 and phosphorylated AKT but not the phosphorylated ERK5, phosphorylated p38 and JNK activity in human non-small cell lung adenocarcinoma CL3 cells.\n'
p2433
sg4
(lp2434
(dp2435
g7
I36
sg8
VP27361
p2436
sg10
I6
sg11
VERK1/2
p2437
sg13
I1
sa(dp2438
g7
I93
sg8
VP53778
p2439
sg10
I4
sg11
VERK5
p2440
sg13
I1
sa(dp2441
g7
I114
sg8
VP46108
p2442
sg10
I3
sg11
Vp38
p2443
sg13
I1
sa(dp2444
g7
I122
sg8
VP53779
p2445
sg10
I3
sg11
VJNK
p2446
sg13
I1
sa(dp2447
g7
I62
sg8
g9
sg10
I3
sg11
VAKT
p2448
sg13
I1
sasg14
(lp2449
(dp2450
g7
I159
sg17
VC0152013
p2451
sg10
I19
sg11
Vlung adenocarcinoma
p2452
sg13
I2
sasa(dp2453
g2
S'The results from reverse-transcription polymerase chain reaction showed that the hOGG1 mRNA expression was induced by hydrogen peroxide (H2O2) and COF in human lung adenocarcinoma CL-3 cells.\n'
p2454
sg4
(lp2455
sg14
(lp2456
(dp2457
g7
I160
sg17
VC0152013
p2458
sg10
I19
sg11
Vlung adenocarcinoma
p2459
sg13
I2
sasa(dp2460
g2
S'To reveal the relationship between the high mortality rate of lung cancer in Chinese women and exposure to cooking oil fumes (COF), DNA adduct formation, induced by COF collected from frying fish under domestic conditions, was assessed in human lung adenocarcinoma CL-3 cell lines using the (32)P-postlabeling assay.\n'
p2461
sg4
(lp2462
sg14
(lp2463
(dp2464
g7
I245
sg17
VC0152013
p2465
sg10
I19
sg11
Vlung adenocarcinoma
p2466
sg13
I2
sa(dp2467
g7
I62
sg17
VC0684249
p2468
sg10
I11
sg11
Vlung cancer
p2469
sg13
I2
sa(dp2470
g7
I132
sg17
VC1511660
p2471
sg10
I20
sg11
VDNA adduct formation
p2472
sg13
I3
sasa(dp2473
g2
S'In this study we have explored the involvement of oxidative stress in Cr(VI)-induced JNK, p38 and ERK signaling pathways and their effects on Cr(VI) cytotoxicity in human non-small cell lung carcinoma CL3 cells.\n'
p2474
sg4
(lp2475
(dp2476
g7
I90
sg8
VP46108
p2477
sg10
I3
sg11
Vp38
p2478
sg13
I1
sa(dp2479
g7
I98
sg8
VP29323
p2480
sg10
I3
sg11
VERK
p2481
sg13
I1
sa(dp2482
g7
I85
sg8
VP53779
p2483
sg10
I3
sg11
VJNK
p2484
sg13
I1
sasg14
(lp2485
(dp2486
g7
I171
sg17
VC0007131
p2487
sg10
I29
sg11
Vnon-small cell lung carcinoma
p2488
sg13
I4
sa(dp2489
g7
I149
sg17
VC0596402
p2490
sg10
I12
sg11
Vcytotoxicity
p2491
sg13
I1
sa(dp2492
g7
I50
sg17
VC0242606
p2493
sg10
I16
sg11
Voxidative stress
p2494
sg13
I2
sasa(dp2495
g2
S'The expression pattern of mucin genes was studied in 7 lung adenocarcinoma cell lines (CL1, CL2, CL3, NCL2, PC9, PC13, PC14) and 12 lung adenocarcinoma tissues.\n'
p2496
sg4
(lp2497
(dp2498
g7
I102
sg8
g9
sg10
I4
sg11
VNCL2
p2499
sg13
I1
sa(dp2500
g7
I92
sg8
g9
sg10
I3
sg11
VCL2
p2501
sg13
I1
sa(dp2502
g7
I108
sg8
g9
sg10
I3
sg11
VPC9
p2503
sg13
I1
sa(dp2504
g7
I26
sg8
g9
sg10
I11
sg11
Vmucin genes
p2505
sg13
I2
sa(dp2506
g7
I87
sg8
g9
sg10
I3
sg11
VCL1
p2507
sg13
I1
sasg14
(lp2508
(dp2509
g7
I55
sg17
VC0152013
p2510
sg10
I19
sg11
Vlung adenocarcinoma
p2511
sg13
I2
sa(dp2512
g7
I55
sg17
VC0152013
p2513
sg10
I19
sg11
Vlung adenocarcinoma
p2514
sg13
I2
sasa(dp2515
g2
S'Osteogenesis imperfecta model, oim(-/-) , mice have a defect in the collagen, which leads to brittle bone; PHOSPHO1 mutants, Phospho1(-/-) , have ductile bone resulting from altered mineralization.\n'
p2516
sg4
(lp2517
(dp2518
g7
I107
sg8
g9
sg10
I16
sg11
VPHOSPHO1 mutants
p2519
sg13
I2
sasg14
(lp2520
(dp2521
g7
I0
sg17
VC0029434
p2522
sg10
I23
sg11
VOsteogenesis imperfecta
p2523
sg13
I2
sasa(dp2524
g2
S'Because two mammalian isoforms of iPLA2 (iPLA2beta and iPLA2gamma) have been cloned and characterized, the aim of this study was to identify the specific isoform(s) in macrophages that regulates the expression of iNOS in response to virus infection.\n'
p2525
sg4
(lp2526
(dp2527
g7
I34
sg8
g9
sg10
I5
sg11
ViPLA2
p2528
sg13
I1
sa(dp2529
g7
I55
sg8
g9
sg10
I10
sg11
ViPLA2gamma
p2530
sg13
I1
sa(dp2531
g7
I41
sg8
g9
sg10
I9
sg11
ViPLA2beta
p2532
sg13
I1
sasg14
(lp2533
(dp2534
g7
I233
sg17
VC0042769
p2535
sg10
I15
sg11
Vvirus infection
p2536
sg13
I2
sasa(dp2537
g2
S'cAMP response element-binding protein (CREB) is one downstream target of iPLA2 that is required for the transcriptional activation of iNOS in response to virus infection, and consistent with the effects of BEL enantiomers on iNOS expression, (S)-BEL more effectively inhibits EMCV-induced CREB phosphorylation than (R)-BEL in macrophages.\n'
p2538
sg4
(lp2539
(dp2540
g7
I73
sg8
g9
sg10
I5
sg11
ViPLA2
p2541
sg13
I1
sa(dp2542
g7
I0
sg8
g9
sg10
I37
sg11
VcAMP response element-binding protein
p2543
sg13
I4
sa(dp2544
g7
I39
sg8
VP16220
p2545
sg10
I4
sg11
VCREB
p2546
sg13
I1
sa(dp2547
g7
I39
sg8
VP16220
p2548
sg10
I4
sg11
VCREB
p2549
sg13
I1
sa(dp2550
g7
I134
sg8
g9
sg10
I4
sg11
ViNOS
p2551
sg13
I1
sasg14
(lp2552
(dp2553
g7
I154
sg17
VC0042769
p2554
sg10
I15
sg11
Vvirus infection
p2555
sg13
I2
sasa(dp2556
g2
S'Using macrophages isolated from iPLA2beta-null mice, virus infection fails to stimulate iNOS mRNA accumulation and protein expression, thus providing genetic evidence that iPLA2beta is required for EMCV-induced iNOS expression.\n'
p2557
sg4
(lp2558
(dp2559
g7
I88
sg8
g9
sg10
I9
sg11
ViNOS mRNA
p2560
sg13
I2
sa(dp2561
g7
I88
sg8
g9
sg10
I4
sg11
ViNOS
p2562
sg13
I1
sa(dp2563
g7
I32
sg8
g9
sg10
I9
sg11
ViPLA2beta
p2564
sg13
I1
sa(dp2565
g7
I32
sg8
g9
sg10
I9
sg11
ViPLA2beta
p2566
sg13
I1
sasg14
(lp2567
(dp2568
g7
I53
sg17
VC0042769
p2569
sg10
I15
sg11
Vvirus infection
p2570
sg13
I2
sasa(dp2571
g2
S'Specific attention will be placed on the ability of virus infection to activate multiple signaling cascades (such as PKR, MAPK, iPLA2, NF-kappaB) and how these pathways are integrated in the regulation of individual target gene expression.\n'
p2572
sg4
(lp2573
(dp2574
g7
I135
sg8
VP19838
p2575
sg10
I9
sg11
VNF-kappaB
p2576
sg13
I1
sa(dp2577
g7
I117
sg8
g9
sg10
I3
sg11
VPKR
p2578
sg13
I1
sa(dp2579
g7
I122
sg8
VP53779
p2580
sg10
I4
sg11
VMAPK
p2581
sg13
I1
sa(dp2582
g7
I128
sg8
g9
sg10
I5
sg11
ViPLA2
p2583
sg13
I1
sasg14
(lp2584
(dp2585
g7
I52
sg17
VC0042769
p2586
sg10
I15
sg11
Vvirus infection
p2587
sg13
I2
sasa(dp2588
g2
S'In comparison with PRCC1, PRCC2 cases showed upregulated expression of Alfa5-integrin (ITGA5) whereas the expression of Alfa6- (ITGA6) and Beta8-integrins (ITGB8) was downregulated.\n'
p2589
sg4
(lp2590
(dp2591
g7
I87
sg8
VP08648
p2592
sg10
I5
sg11
VITGA5
p2593
sg13
I1
sa(dp2594
g7
I156
sg8
VP26012
p2595
sg10
I5
sg11
VITGB8
p2596
sg13
I1
sasg14
(lp2597
sa(dp2598
g2
S'HFD-fed mice lacking Cnot7 and Tob express elevated levels of Ucp1 mRNA in iWAT and are resistant to diet-induced obesity.\n'
p2599
sg4
(lp2600
(dp2601
g7
I31
sg8
VP50616
p2602
sg10
I3
sg11
VTob
p2603
sg13
I1
sa(dp2604
g7
I21
sg8
g9
sg10
I5
sg11
VCnot7
p2605
sg13
I1
sa(dp2606
g7
I62
sg8
VP25874
p2607
sg10
I9
sg11
VUcp1 mRNA
p2608
sg13
I2
sasg14
(lp2609
(dp2610
g7
I114
sg17
VC0028754
p2611
sg10
I7
sg11
Vobesity
p2612
sg13
I1
sasa(dp2613
g2
S'Thus, the Cnot7-Tob-BRF1 axis inhibits Ucp1 expression and contributes to obesity.\n'
p2614
sg4
(lp2615
(dp2616
g7
I39
sg8
VP25874
p2617
sg10
I4
sg11
VUcp1
p2618
sg13
I1
sa(dp2619
g7
I20
sg8
g9
sg10
I4
sg11
VBRF1
p2620
sg13
I1
sa(dp2621
g7
I16
sg8
VP50616
p2622
sg10
I3
sg11
VTob
p2623
sg13
I1
sa(dp2624
g7
I10
sg8
g9
sg10
I5
sg11
VCnot7
p2625
sg13
I1
sasg14
(lp2626
(dp2627
g7
I74
sg17
VC0028754
p2628
sg10
I7
sg11
Vobesity
p2629
sg13
I1
sasa(dp2630
g2
S'Since abnormal and unbalanced JAK/STAT activation is associated with immune disorders and cancer, hCAF1 could play a major role in innate immunity and oncogenesis, contributing to tumour escape.\n'
p2631
sg4
(lp2632
(dp2633
g7
I34
sg8
g9
sg10
I4
sg11
VSTAT
p2634
sg13
I1
sa(dp2635
g7
I98
sg8
g9
sg10
I5
sg11
VhCAF1
p2636
sg13
I1
sasg14
(lp2637
(dp2638
g7
I180
sg17
VC0027651
p2639
sg10
I6
sg11
Vtumour
p2640
sg13
I1
sa(dp2641
g7
I69
sg17
VC0021053
p2642
sg10
I16
sg11
Vimmune disorders
p2643
sg13
I2
sa(dp2644
g7
I151
sg17
VC0007621
p2645
sg10
I11
sg11
Voncogenesis
p2646
sg13
I1
sa(dp2647
g7
I90
sg17
VC0006826
p2648
sg10
I6
sg11
Vcancer
p2649
sg13
I1
sasa(dp2650
g2
S'Our previous study (Nakamura et al., 2004) showed that deletion of the Cnot7 gene in mice caused almost no abnormal phenotypes except for male infertility, due to oligo-astheno-teratozoospermia.\n'
p2651
sg4
(lp2652
(dp2653
g7
I71
sg8
g9
sg10
I10
sg11
VCnot7 gene
p2654
sg13
I2
sasg14
(lp2655
(dp2656
g7
I138
sg17
VC0021364
p2657
sg10
I16
sg11
Vmale infertility
p2658
sg13
I2
sasa(dp2659
g2
S'Mutations in the gene encoding the neural cell adhesion molecule L1CAM cause several neurological disorders collectively referred to as L1 syndrome.\n'
p2660
sg4
(lp2661
(dp2662
g7
I35
sg8
g9
sg10
I35
sg11
Vneural cell adhesion molecule L1CAM
p2663
sg13
I5
sasg14
(lp2664
(dp2665
g7
I85
sg17
VC0027765
p2666
sg10
I22
sg11
Vneurological disorders
p2667
sg13
I2
sa(dp2668
g7
I139
sg17
VC0039082
p2669
sg10
I8
sg11
Vsyndrome
p2670
sg13
I1
sa(dp2671
g7
I47
sg17
VC0001511
p2672
sg10
I8
sg11
Vadhesion
p2673
sg13
I1
sasa(dp2674
g2
S'A 59-year-old woman receiving methotrexate and tacrolimus for rheumatoid arthritis (RA) was referred to our hospital following bilateral ground-glass opacity observed in her chest X-ray and elevated serum KL-6.\n'
p2675
sg4
(lp2676
(dp2677
g7
I199
sg8
g9
sg10
I10
sg11
Vserum KL-6
p2678
sg13
I2
sasg14
(lp2679
(dp2680
g7
I84
sg17
VC0003873
p2681
sg10
I2
sg11
VRA
p2682
sg13
I1
sa(dp2683
g7
I150
sg17
VC1265876
p2684
sg10
I7
sg11
Vopacity
p2685
sg13
I1
sa(dp2686
g7
I62
sg17
VC0003873
p2687
sg10
I20
sg11
Vrheumatoid arthritis
p2688
sg13
I2
sasa(dp2689
g2
S'During treatment of rheumatoid arthritis (RA)-associated interstitial lung disease (ILD) with prednisolone, chest image findings improved in association with decreased KL-6 levels.\n'
p2690
sg4
(lp2691
sg14
(lp2692
(dp2693
g7
I57
sg17
VC0206062
p2694
sg10
I25
sg11
Vinterstitial lung disease
p2695
sg13
I3
sa(dp2696
g7
I20
sg17
VC0003873
p2697
sg10
I20
sg11
Vrheumatoid arthritis
p2698
sg13
I2
sa(dp2699
g7
I42
sg17
VC0003873
p2700
sg10
I2
sg11
VRA
p2701
sg13
I1
sa(dp2702
g7
I84
sg17
VC0206062
p2703
sg10
I3
sg11
VILD
p2704
sg13
I1
sasa(dp2705
g2
S'The results showed that treatment with the MUC1-MBP/BCG anti-tumor vaccine did not cause any organ toxicity, except for arthritis or local nodules induced by BCG in several rats.\n'
p2706
sg4
(lp2707
(dp2708
g7
I48
sg8
VP13727
p2709
sg10
I3
sg11
VMBP
p2710
sg13
I1
sasg14
(lp2711
(dp2712
g7
I120
sg17
VC0003864
p2713
sg10
I9
sg11
Varthritis
p2714
sg13
I1
sa(dp2715
g7
I139
sg17
VC0028259
p2716
sg10
I7
sg11
Vnodules
p2717
sg13
I1
sa(dp2718
g7
I61
sg17
VC0027651
p2719
sg10
I5
sg11
Vtumor
p2720
sg13
I1
sasa(dp2721
g2
S'To investigate leptin, adiponectin, soluble intercellular adhesion molecule-1 (sICAM-1), soluble vascular cell adhesion molecule-1 (sVCAM-1) levels and their relationship with each other and metabolic parameters in women with polycystic ovary syndrome (PCOS).\n'
p2722
sg4
(lp2723
(dp2724
g7
I23
sg8
g9
sg10
I11
sg11
Vadiponectin
p2725
sg13
I1
sa(dp2726
g7
I97
sg8
VP19320
p2727
sg10
I33
sg11
Vvascular cell adhesion molecule-1
p2728
sg13
I4
sa(dp2729
g7
I79
sg8
VP05362
p2730
sg10
I7
sg11
VsICAM-1
p2731
sg13
I1
sa(dp2732
g7
I36
sg8
VP05362
p2733
sg10
I41
sg11
Vsoluble intercellular adhesion molecule-1
p2734
sg13
I4
sa(dp2735
g7
I15
sg8
VP41159
p2736
sg10
I6
sg11
Vleptin
p2737
sg13
I1
sasg14
(lp2738
(dp2739
g7
I253
sg17
VC0032460
p2740
sg10
I4
sg11
VPCOS
p2741
sg13
I1
sa(dp2742
g7
I58
sg17
VC0001511
p2743
sg10
I8
sg11
Vadhesion
p2744
sg13
I1
sa(dp2745
g7
I58
sg17
VC0001511
p2746
sg10
I8
sg11
Vadhesion
p2747
sg13
I1
sa(dp2748
g7
I226
sg17
VC0032460
p2749
sg10
I25
sg11
Vpolycystic ovary syndrome
p2750
sg13
I3
sasa(dp2751
g2
S'Non-insulin resistant PCOS had significantly higher adiponectin and sVCAM-1 levels.\n'
p2752
sg4
(lp2753
(dp2754
g7
I4
sg8
VP01308
p2755
sg10
I7
sg11
Vinsulin
p2756
sg13
I1
sa(dp2757
g7
I52
sg8
g9
sg10
I11
sg11
Vadiponectin
p2758
sg13
I1
sasg14
(lp2759
(dp2760
g7
I22
sg17
VC0032460
p2761
sg10
I4
sg11
VPCOS
p2762
sg13
I1
sasa(dp2763
g2
S'Increases in IL-6 and TNF-Alfa and adhesion molecules (E-selectin, ICAM-1 and VCAM-1) were also observed, particularly in the PCOS IR group, providing evidence that inflammation and oxidative stress are related in PCOS patients.\n'
p2764
sg4
(lp2765
(dp2766
g7
I22
sg8
VP01375
p2767
sg10
I31
sg11
VTNF-Alfa and adhesion molecules
p2768
sg13
I4
sa(dp2769
g7
I78
sg8
VP19320
p2770
sg10
I6
sg11
VVCAM-1
p2771
sg13
I1
sa(dp2772
g7
I67
sg8
VP05362
p2773
sg10
I6
sg11
VICAM-1
p2774
sg13
I1
sa(dp2775
g7
I13
sg8
VP05231
p2776
sg10
I4
sg11
VIL-6
p2777
sg13
I1
sa(dp2778
g7
I55
sg8
VP16581
p2779
sg10
I10
sg11
VE-selectin
p2780
sg13
I1
sasg14
(lp2781
(dp2782
g7
I182
sg17
VC0242606
p2783
sg10
I16
sg11
Voxidative stress
p2784
sg13
I2
sa(dp2785
g7
I126
sg17
VC0032460
p2786
sg10
I4
sg11
VPCOS
p2787
sg13
I1
sa(dp2788
g7
I165
sg17
VC0021368
p2789
sg10
I12
sg11
Vinflammation
p2790
sg13
I1
sa(dp2791
g7
I35
sg17
VC0001511
p2792
sg10
I8
sg11
Vadhesion
p2793
sg13
I1
sa(dp2794
g7
I126
sg17
VC0032460
p2795
sg10
I4
sg11
VPCOS
p2796
sg13
I1
sasa(dp2797
g2
S'Inflammation in PCOS induces leukocyte-endothelium interactions and a simultaneous increase in IL-6, TNF-Alfa, E-selectin, ICAM-1 and VCAM-1.\n'
p2798
sg4
(lp2799
(dp2800
g7
I123
sg8
VP05362
p2801
sg10
I6
sg11
VICAM-1
p2802
sg13
I1
sa(dp2803
g7
I95
sg8
VP05231
p2804
sg10
I4
sg11
VIL-6
p2805
sg13
I1
sa(dp2806
g7
I101
sg8
VP01375
p2807
sg10
I8
sg11
VTNF-Alfa
p2808
sg13
I1
sa(dp2809
g7
I111
sg8
VP16581
p2810
sg10
I10
sg11
VE-selectin
p2811
sg13
I1
sa(dp2812
g7
I134
sg8
VP19320
p2813
sg10
I6
sg11
VVCAM-1
p2814
sg13
I1
sasg14
(lp2815
(dp2816
g7
I0
sg17
VC0021368
p2817
sg10
I12
sg11
VInflammation
p2818
sg13
I1
sa(dp2819
g7
I16
sg17
VC0032460
p2820
sg10
I4
sg11
VPCOS
p2821
sg13
I1
sasa(dp2822
g2
S'In conclusion, we disclosed a novel mechanism that JQ1 inhibits cell proliferation, induces cell senescence and apoptosis of chondrosarcoma cells through the regulation of the YAP/p21/c-Myc/Bcl-xL signaling axis.\n'
p2823
sg4
(lp2824
(dp2825
g7
I190
sg8
g9
sg10
I6
sg11
VBcl-xL
p2826
sg13
I1
sa(dp2827
g7
I176
sg8
VP46937
p2828
sg10
I3
sg11
VYAP
p2829
sg13
I1
sa(dp2830
g7
I180
sg8
VP42857
p2831
sg10
I3
sg11
Vp21
p2832
sg13
I1
sa(dp2833
g7
I184
sg8
VP12524
p2834
sg10
I5
sg11
Vc-Myc
p2835
sg13
I1
sasg14
(lp2836
(dp2837
g7
I125
sg17
VC0008479
p2838
sg10
I14
sg11
Vchondrosarcoma
p2839
sg13
I1
sa(dp2840
g7
I69
sg17
VC0334094
p2841
sg10
I13
sg11
Vproliferation
p2842
sg13
I1
sasa(dp2843
g2
S'BH-3 mimetics ABT-737 and ABT-263 are synthetic small-molecule inhibitors of anti-apoptotic proteins B-cell lymphoma-2 (Bcl2) and Bcl-xL, which play a critical role in survival of chondrosarcoma cells.\n'
p2844
sg4
(lp2845
(dp2846
g7
I120
sg8
VP10415
p2847
sg10
I4
sg11
VBcl2
p2848
sg13
I1
sa(dp2849
g7
I77
sg8
g9
sg10
I41
sg11
Vanti-apoptotic proteins B-cell lymphoma-2
p2850
sg13
I4
sa(dp2851
g7
I130
sg8
g9
sg10
I6
sg11
VBcl-xL
p2852
sg13
I1
sasg14
(lp2853
(dp2854
g7
I180
sg17
VC0008479
p2855
sg10
I14
sg11
Vchondrosarcoma
p2856
sg13
I1
sa(dp2857
g7
I101
sg17
VC0079731
p2858
sg10
I15
sg11
VB-cell lymphoma
p2859
sg13
I2
sasa(dp2860
g2
S'Here we show that the IHh signal pathway was activated in chondrosarcoma, and knocking down the expression of Gli1 attenuated the disturbed IHh signal pathway, which not only suppressed cell proliferation and promoted G2/M cell cycle arrest but also enhanced cell apoptosis by downregulating Bcl-2 and Bcl-xl expression.\n'
p2861
sg4
(lp2862
(dp2863
g7
I292
sg8
VP10415
p2864
sg10
I5
sg11
VBcl-2
p2865
sg13
I1
sa(dp2866
g7
I22
sg8
g9
sg10
I3
sg11
VIHh
p2867
sg13
I1
sa(dp2868
g7
I110
sg8
VP08151
p2869
sg10
I4
sg11
VGli1
p2870
sg13
I1
sa(dp2871
g7
I302
sg8
g9
sg10
I6
sg11
VBcl-xl
p2872
sg13
I1
sasg14
(lp2873
(dp2874
g7
I191
sg17
VC0334094
p2875
sg10
I13
sg11
Vproliferation
p2876
sg13
I1
sa(dp2877
g7
I22
sg17
VC0342384
p2878
sg10
I3
sg11
VIHh
p2879
sg13
I1
sa(dp2880
g7
I58
sg17
VC0008479
p2881
sg10
I14
sg11
Vchondrosarcoma
p2882
sg13
I1
sa(dp2883
g7
I22
sg17
VC0342384
p2884
sg10
I3
sg11
VIHh
p2885
sg13
I1
sasa(dp2886
g2
S'As in conventional chondrosarcoma, antiapoptotic proteins (Bcl-2, and/or Bcl-xl) were highly expressed in all subtypes.\n'
p2887
sg4
(lp2888
(dp2889
g7
I73
sg8
g9
sg10
I6
sg11
VBcl-xl
p2890
sg13
I1
sa(dp2891
g7
I59
sg8
VP10415
p2892
sg10
I5
sg11
VBcl-2
p2893
sg13
I1
sasg14
(lp2894
(dp2895
g7
I6
sg17
VC1335473
p2896
sg10
I27
sg11
Vconventional chondrosarcoma
p2897
sg13
I2
sasa(dp2898
g2
S'BPB induced upregulation of Bax, Bad and Bak, downregulation of Bcl-2, Bid and Bcl-XL and dysfunction of mitochondria in chondrosarcoma.\n'
p2899
sg4
(lp2900
(dp2901
g7
I64
sg8
VP10415
p2902
sg10
I5
sg11
VBcl-2
p2903
sg13
I1
sa(dp2904
g7
I71
sg8
VP55957
p2905
sg10
I3
sg11
VBid
p2906
sg13
I1
sa(dp2907
g7
I79
sg8
g9
sg10
I6
sg11
VBcl-XL
p2908
sg13
I1
sa(dp2909
g7
I41
sg8
g9
sg10
I3
sg11
VBak
p2910
sg13
I1
sa(dp2911
g7
I33
sg8
g9
sg10
I3
sg11
VBad
p2912
sg13
I1
sasg14
(lp2913
(dp2914
g7
I121
sg17
VC0008479
p2915
sg10
I14
sg11
Vchondrosarcoma
p2916
sg13
I1
sasa(dp2917
g2
S'EGCG induced upregulation of Bax and Bak, downregulation of Bcl-2 and Bcl-XL, and dysfunction of mitochondria in chondrosarcoma.\n'
p2918
sg4
(lp2919
(dp2920
g7
I70
sg8
g9
sg10
I6
sg11
VBcl-XL
p2921
sg13
I1
sa(dp2922
g7
I37
sg8
g9
sg10
I3
sg11
VBak
p2923
sg13
I1
sa(dp2924
g7
I60
sg8
VP10415
p2925
sg10
I5
sg11
VBcl-2
p2926
sg13
I1
sasg14
(lp2927
(dp2928
g7
I113
sg17
VC0008479
p2929
sg10
I14
sg11
Vchondrosarcoma
p2930
sg13
I1
sasa(dp2931
g2
S'FPTB induced up-regulation of Bax and Bak, down-regulation of Bcl-2 and Bcl-XL and dysfunction of mitochondria in chondrosarcoma.\n'
p2932
sg4
(lp2933
(dp2934
g7
I72
sg8
g9
sg10
I6
sg11
VBcl-XL
p2935
sg13
I1
sa(dp2936
g7
I62
sg8
VP10415
p2937
sg10
I5
sg11
VBcl-2
p2938
sg13
I1
sa(dp2939
g7
I38
sg8
g9
sg10
I3
sg11
VBak
p2940
sg13
I1
sa(dp2941
g7
I0
sg8
VP49356
p2942
sg10
I4
sg11
VFPTB
p2943
sg13
I1
sasg14
(lp2944
(dp2945
g7
I114
sg17
VC0008479
p2946
sg10
I14
sg11
Vchondrosarcoma
p2947
sg13
I1
sasa(dp2948
g2
S'This study aims to investigate the expression patterns of HIF-1Alfa in chondrosarcoma, and its association with clinicopathologic features, Bcl-xL expression, apoptosis index (AI), and overall survival of patients with chondrosarcoma.\n'
p2949
sg4
(lp2950
(dp2951
g7
I140
sg8
g9
sg10
I6
sg11
VBcl-xL
p2952
sg13
I1
sasg14
(lp2953
(dp2954
g7
I71
sg17
VC0008479
p2955
sg10
I14
sg11
Vchondrosarcoma
p2956
sg13
I1
sa(dp2957
g7
I71
sg17
VC0008479
p2958
sg10
I14
sg11
Vchondrosarcoma
p2959
sg13
I1
sasa(dp2960
g2
S'In eight patients with chondrosarcoma, increased expression of HIF-1Alfa and Bcl-xL was detected in chondrosarcoma tissues compared with the paired adjacent normal tissues.\n'
p2961
sg4
(lp2962
(dp2963
g7
I77
sg8
g9
sg10
I6
sg11
VBcl-xL
p2964
sg13
I1
sasg14
(lp2965
(dp2966
g7
I23
sg17
VC0008479
p2967
sg10
I14
sg11
Vchondrosarcoma
p2968
sg13
I1
sa(dp2969
g7
I23
sg17
VC0008479
p2970
sg10
I14
sg11
Vchondrosarcoma
p2971
sg13
I1
sasa(dp2972
g2
S'These findings suggest that increased HIF-1Alfa levels mediated up-regulation of Bcl-xL play a prominent role in evasion of apoptosis and tumor progression, and can be predictive for the prognosis in human chondrosarcoma.\n'
p2973
sg4
(lp2974
(dp2975
g7
I81
sg8
g9
sg10
I6
sg11
VBcl-xL
p2976
sg13
I1
sasg14
(lp2977
(dp2978
g7
I138
sg17
VC0178874
p2979
sg10
I17
sg11
Vtumor progression
p2980
sg13
I2
sa(dp2981
g7
I206
sg17
VC0008479
p2982
sg10
I14
sg11
Vchondrosarcoma
p2983
sg13
I1
sasa(dp2984
g2
S'Three-dimensional speckle tracking echocardiography (3D-STE) was used to evaluate the improvement of continuous subcutaneous insulin infusion on the left ventricular (LV) systolic function of patients with type 2 diabetes mellitu (T2DM).\n'
p2985
sg4
(lp2986
(dp2987
g7
I125
sg8
VP01308
p2988
sg10
I7
sg11
Vinsulin
p2989
sg13
I1
sasg14
(lp2990
(dp2991
g7
I206
sg17
VC0011860
p2992
sg10
I15
sg11
Vtype 2 diabetes
p2993
sg13
I3
sasa(dp2994
g2
S'To elucidate association of renal dysfunction (RD) with unfavorable outcomes of in-hospital and long-term (1 year) treatment stages of patients with ST-elevation (STE) myocardial infarction (MI) and concomitant diabetes mellitus (DM).\n'
p2995
sg4
(lp2996
sg14
(lp2997
(dp2998
g7
I230
sg17
VC0011849
p2999
sg10
I2
sg11
VDM
p3000
sg13
I1
sa(dp3001
g7
I211
sg17
VC0011849
p3002
sg10
I17
sg11
Vdiabetes mellitus
p3003
sg13
I2
sa(dp3004
g7
I168
sg17
VC0027051
p3005
sg10
I21
sg11
Vmyocardial infarction
p3006
sg13
I2
sa(dp3007
g7
I191
sg17
VC0027051
p3008
sg10
I2
sg11
VMI
p3009
sg13
I1
sasa(dp3010
g2
S'Multivariate regression analysis showed that GPLS and diabetes mellitus were independent predictors for complex NSTE-ACS.\n'
p3011
sg4
(lp3012
(dp3013
g7
I112
sg8
g9
sg10
I8
sg11
VNSTE-ACS
p3014
sg13
I1
sasg14
(lp3015
(dp3016
g7
I54
sg17
VC0011849
p3017
sg10
I17
sg11
Vdiabetes mellitus
p3018
sg13
I2
sasa(dp3019
g2
S'No differences were observed between the two groups in baseline characteristics; except AS-STEMI group had more patients with diabetes and EA-STEMI group had more patients with family history of coronary artery disease.\n'
p3020
sg4
(lp3021
sg14
(lp3022
(dp3023
g7
I195
sg17
VC1956346
p3024
sg10
I23
sg11
Vcoronary artery disease
p3025
sg13
I3
sa(dp3026
g7
I91
sg17
VC1536220
p3027
sg10
I5
sg11
VSTEMI
p3028
sg13
I1
sa(dp3029
g7
I126
sg17
VC0011849
p3030
sg10
I8
sg11
Vdiabetes
p3031
sg13
I1
sa(dp3032
g7
I91
sg17
VC1536220
p3033
sg10
I5
sg11
VSTEMI
p3034
sg13
I1
sasa(dp3035
g2
S'To elucidate association of renal dysfunction (RD) with unfavorable outcomes of in-hospital and long-term (1 year) treatment stages of patients with ST-elevation (STE) myocardial infarction (M) and concomitant diabetes mellitus (DM).\n'
p3036
sg4
(lp3037
sg14
(lp3038
(dp3039
g7
I229
sg17
VC0011849
p3040
sg10
I2
sg11
VDM
p3041
sg13
I1
sa(dp3042
g7
I210
sg17
VC0011849
p3043
sg10
I17
sg11
Vdiabetes mellitus
p3044
sg13
I2
sa(dp3045
g7
I168
sg17
VC0027051
p3046
sg10
I21
sg11
Vmyocardial infarction
p3047
sg13
I2
sasa(dp3048
g2
S'Incidence of complicated diabetes (P &lt; 0.05), pre-PCI Killip &gt;= II (55.9% (19/34) vs. 26.8% (15/56), P &lt; 0.05) and multivessel disease (70.6% (24/34) vs. 35.7% (20/56), P &lt; 0.05) were significantly higher in group D than in group C. TIMI 3 and the opening time of IRA was similar between group A and group B and between group C and group D. The incidence of in-hospital MACE was significantly higher in group B than in group A (14.4% (13/90) vs. 3.0% (4/135), P &lt; 0.05) which was similar between group C and group D. Early (1 hour) but not late (24 hours) ST resolution post PCI is related to a favorable clinical outcome in STEMI patients.\n'
p3049
sg4
(lp3050
sg14
(lp3051
(dp3052
g7
I640
sg17
VC1536220
p3053
sg10
I5
sg11
VSTEMI
p3054
sg13
I1
sa(dp3055
g7
I312
sg17
VC0348801
p3056
sg10
I7
sg11
Vgroup B
p3057
sg13
I2
sa(dp3058
g7
I25
sg17
VC0011849
p3059
sg10
I8
sg11
Vdiabetes
p3060
sg13
I1
sa(dp3061
g7
I312
sg17
VC0348801
p3062
sg10
I7
sg11
Vgroup B
p3063
sg13
I2
sasa(dp3064
g2
S'Immunohistochemistry (IHC) and Western blotting were performed to evaluate SOX4 expression between OLP and OLP-OSCC tissues and among oral cancer cell lines and normal human oral keratinocytes (NHOKs).\n'
p3065
sg4
(lp3066
(dp3067
g7
I75
sg8
g9
sg10
I4
sg11
VSOX4
p3068
sg13
I1
sasg14
(lp3069
(dp3070
g7
I134
sg17
VC0153381
p3071
sg10
I11
sg11
Voral cancer
p3072
sg13
I2
sasa(dp3073
g2
S'LC-MS/MS analysis showed that 88 proteins including SOX4 were only identified in OLP-OSCC FFPE tissues when compared to OLP FFPE tissues.\n'
p3074
sg4
(lp3075
(dp3076
g7
I52
sg8
g9
sg10
I4
sg11
VSOX4
p3077
sg13
I1
sasg14
(lp3078
sa(dp3079
g2
S'IHC confirmed that SOX4 expression was significantly higher in OLP-OSCC than OLP and Western blot analysis indicated that SOX4 was over-expressed in UM1/UM2 cells when compared to NHOKs.\n'
p3080
sg4
(lp3081
(dp3082
g7
I19
sg8
g9
sg10
I4
sg11
VSOX4
p3083
sg13
I1
sa(dp3084
g7
I19
sg8
g9
sg10
I4
sg11
VSOX4
p3085
sg13
I1
sasg14
(lp3086
sa(dp3087
g2
S'Our study indicated that SOX4 is significantly upregulated in OLP-OSCC versus OLP tissues.\n'
p3088
sg4
(lp3089
(dp3090
g7
I25
sg8
g9
sg10
I4
sg11
VSOX4
p3091
sg13
I1
sasg14
(lp3092
sa(dp3093
g2
S'These findings suggest that SOX4 might be actively involved in the progression of OLP to OSCC.\n'
p3094
sg4
(lp3095
(dp3096
g7
I28
sg8
g9
sg10
I4
sg11
VSOX4
p3097
sg13
I1
sasg14
(lp3098
sa(dp3099
g2
S'This study evaluated whether SOX4 affects oncogenic behavior and chemoradiotherapy response in head and neck squamous cell carcinoma (HNSCC) cells, and documented the relationship between its expression and prognosis in oral squamous cell carcinoma (OSCC).\n'
p3100
sg4
(lp3101
(dp3102
g7
I29
sg8
g9
sg10
I4
sg11
VSOX4
p3103
sg13
I1
sasg14
(lp3104
(dp3105
g7
I95
sg17
VC1168401
p3106
sg10
I37
sg11
Vhead and neck squamous cell carcinoma
p3107
sg13
I6
sa(dp3108
g7
I109
sg17
VC0007137
p3109
sg10
I23
sg11
Vsquamous cell carcinoma
p3110
sg13
I3
sa(dp3111
g7
I134
sg17
VC1168401
p3112
sg10
I5
sg11
VHNSCC
p3113
sg13
I1
sasa(dp3114
g2
S'SOX4 expression in OSCC tissues was investigated by immunohistochemistry.\n'
p3115
sg4
(lp3116
(dp3117
g7
I0
sg8
g9
sg10
I4
sg11
VSOX4
p3118
sg13
I1
sasg14
(lp3119
sa(dp3120
g2
S'Immunostaining showed SOX4 protein was significantly increased in OSCC tissues compared with adjacent normal mucosa.\n'
p3121
sg4
(lp3122
(dp3123
g7
I22
sg8
g9
sg10
I12
sg11
VSOX4 protein
p3124
sg13
I2
sasg14
(lp3125
sa(dp3126
g2
S'SOX4 expression was observed in 51.8 % of 85 OSCC tissues, and was significantly correlated with treatment failure (P = 0.032) and shorter overall survival (P = 0.036) in patients with OSCC.\n'
p3127
sg4
(lp3128
(dp3129
g7
I0
sg8
g9
sg10
I4
sg11
VSOX4
p3130
sg13
I1
sasg14
(lp3131
sa(dp3132
g2
S'This study was the first to investigate correlations between SOX4 expression levels and the clinicopathologic factors of oral squamous cell carcinoma (OSCC).\n'
p3133
sg4
(lp3134
(dp3135
g7
I61
sg8
g9
sg10
I4
sg11
VSOX4
p3136
sg13
I1
sasg14
(lp3137
(dp3138
g7
I126
sg17
VC0007137
p3139
sg10
I23
sg11
Vsquamous cell carcinoma
p3140
sg13
I3
sasa(dp3141
g2
S'We analyzed SOX4 expression levels in 50 patients with OSCC using immunohistochemistry.\n'
p3142
sg4
(lp3143
(dp3144
g7
I12
sg8
g9
sg10
I4
sg11
VSOX4
p3145
sg13
I1
sasg14
(lp3146
sa(dp3147
g2
S'The expression level of SOX4 in primary foci of poorly differentiated OSCC was higher than that of well differentiated OSCC, which indicated that SOX4 expression is associated with the differentiation of OSCC.\n'
p3148
sg4
(lp3149
(dp3150
g7
I24
sg8
g9
sg10
I4
sg11
VSOX4
p3151
sg13
I1
sa(dp3152
g7
I24
sg8
g9
sg10
I4
sg11
VSOX4
p3153
sg13
I1
sasg14
(lp3154
sa(dp3155
g2
S'These results indicate that undifferentiated OSCC cells expressing SOX4 are more likely to metastasize and neoadjuvant therapy including chemoradiation therapy may have some effect in metastatic prevention.\n'
p3156
sg4
(lp3157
(dp3158
g7
I67
sg8
g9
sg10
I4
sg11
VSOX4
p3159
sg13
I1
sasg14
(lp3160
(dp3161
g7
I91
sg17
VC0027627
p3162
sg10
I11
sg11
Vmetastasize
p3163
sg13
I1
sasa(dp3164
g2
S'Cryptorchidism was significantly associated with development of MGCSCTs, SCTs, and SEMs, but not ICTs (p&lt;0.01).\n'
p3165
sg4
(lp3166
sg14
(lp3167
(dp3168
g7
I0
sg17
VC0010417
p3169
sg10
I14
sg11
VCryptorchidism
p3170
sg13
I1
sa(dp3171
g7
I67
sg17
VC0796149
p3172
sg10
I4
sg11
VSCTs
p3173
sg13
I1
sasa(dp3174
g2
S'Since nerve functions are affected by inflammatory response during the course of leprosy, changes in the production of NGF and its receptor (NGF R) may be directly associated with disability and sensory loss.\n'
p3175
sg4
(lp3176
(dp3177
g7
I119
sg8
VP01138
p3178
sg10
I3
sg11
VNGF
p3179
sg13
I1
sa(dp3180
g7
I119
sg8
VP01138
p3181
sg10
I3
sg11
VNGF
p3182
sg13
I1
sasg14
(lp3183
(dp3184
g7
I38
sg17
VC1155266
p3185
sg10
I21
sg11
Vinflammatory response
p3186
sg13
I2
sa(dp3187
g7
I195
sg17
VC0278134
p3188
sg10
I12
sg11
Vsensory loss
p3189
sg13
I2
sa(dp3190
g7
I81
sg17
VC0023343
p3191
sg10
I7
sg11
Vleprosy
p3192
sg13
I1
sasa(dp3193
g2
S'Skin biopsies were collected and submitted to immunohistochemistry using specific antibodies to IL-17, NGF and NGF R. Quantitative analysis of NGF, NGFR and IL-17 immunostaining showed a significant difference between the clinical forms, with higher expression of NGF and NGFR in lepromatous leprosy and IL-17 in tuberculoid leprosy.\n'
p3194
sg4
(lp3195
(dp3196
g7
I111
sg8
VP01138
p3197
sg10
I5
sg11
VNGF R
p3198
sg13
I2
sa(dp3199
g7
I103
sg8
VP01138
p3200
sg10
I3
sg11
VNGF
p3201
sg13
I1
sa(dp3202
g7
I103
sg8
VP01138
p3203
sg10
I3
sg11
VNGF
p3204
sg13
I1
sa(dp3205
g7
I103
sg8
VP01138
p3206
sg10
I3
sg11
VNGF
p3207
sg13
I1
sa(dp3208
g7
I148
sg8
VP08138
p3209
sg10
I4
sg11
VNGFR
p3210
sg13
I1
sa(dp3211
g7
I148
sg8
VP08138
p3212
sg10
I4
sg11
VNGFR
p3213
sg13
I1
sasg14
(lp3214
(dp3215
g7
I280
sg17
VC0023348
p3216
sg10
I19
sg11
Vlepromatous leprosy
p3217
sg13
I2
sa(dp3218
g7
I313
sg17
VC0023351
p3219
sg10
I19
sg11
Vtuberculoid leprosy
p3220
sg13
I2
sasa(dp3221
g2
S"The recovered CD271(+) BM-MSCs from post-therapy mice, when injected into healthy mice, caused active tuberculosis infection in the animal's lung.\n"
p3222
sg4
(lp3223
sg14
(lp3224
(dp3225
g7
I102
sg17
VC0041296
p3226
sg10
I22
sg11
Vtuberculosis infection
p3227
sg13
I2
sasa(dp3228
g2
S'Next, in human subjects, previously treated for pulmonary tuberculosis, the MTB-containing CD271(+) BM-MSCs exhibited high expression of hypoxia-inducible factor 1Alfa and low expression of CD146, a hypoxia down-regulated cell surface marker of human BM-MSCs.\n'
p3229
sg4
(lp3230
(dp3231
g7
I137
sg8
g9
sg10
I30
sg11
Vhypoxia-inducible factor 1Alfa
p3232
sg13
I3
sa(dp3233
g7
I190
sg8
VP43121
p3234
sg10
I5
sg11
VCD146
p3235
sg13
I1
sasg14
(lp3236
(dp3237
g7
I48
sg17
VC0041327
p3238
sg10
I22
sg11
Vpulmonary tuberculosis
p3239
sg13
I2
sa(dp3240
g7
I137
sg17
VC0242184
p3241
sg10
I7
sg11
Vhypoxia
p3242
sg13
I1
sa(dp3243
g7
I137
sg17
VC0242184
p3244
sg10
I7
sg11
Vhypoxia
p3245
sg13
I1
sasa(dp3246
g2
S'The bone marrow niche of Mycobacterium tuberculosis within CD271(+) BM-MSCs stem cells is the proposed explanation for the localized cortical resorption that is observed in bone stress markers.\n'
p3247
sg4
(lp3248
sg14
(lp3249
(dp3250
g7
I39
sg17
VC0041296
p3251
sg10
I12
sg11
Vtuberculosis
p3252
sg13
I1
sasa(dp3253
g2
S'Therefore, the objective of this study was to correlate the immunoexpression patterns of NGF and NGF-R in the different clinical forms of leprosy, and to associate the findings with the in situ expression of TGF-Beta and clinical classification of the disease.\n'
p3254
sg4
(lp3255
(dp3256
g7
I89
sg8
VP01138
p3257
sg10
I3
sg11
VNGF
p3258
sg13
I1
sa(dp3259
g7
I97
sg8
VP01138
p3260
sg10
I5
sg11
VNGF-R
p3261
sg13
I1
sa(dp3262
g7
I208
sg8
VP18075
p3263
sg10
I8
sg11
VTGF-Beta
p3264
sg13
I1
sasg14
(lp3265
(dp3266
g7
I138
sg17
VC0023343
p3267
sg10
I7
sg11
Vleprosy
p3268
sg13
I1
sasa(dp3269
g2
S'There was a significant positive correlation between NGF and NGF-R in the different clinical forms of leprosy.\n'
p3270
sg4
(lp3271
(dp3272
g7
I53
sg8
VP01138
p3273
sg10
I3
sg11
VNGF
p3274
sg13
I1
sa(dp3275
g7
I61
sg8
VP01138
p3276
sg10
I5
sg11
VNGF-R
p3277
sg13
I1
sasg14
(lp3278
(dp3279
g7
I102
sg17
VC0023343
p3280
sg10
I7
sg11
Vleprosy
p3281
sg13
I1
sasa(dp3282
g2
S'Moreover, most viable M. tuberculosis was recovered from the bone marrow CD271(+)CD45(-)-enriched cell fraction, and only few viable bacteria could be isolated from the CD271(-)CD45(+) cell fraction.\n'
p3283
sg4
(lp3284
(dp3285
g7
I81
sg8
VP08575
p3286
sg10
I4
sg11
VCD45
p3287
sg13
I1
sa(dp3288
g7
I169
sg8
VP08138
p3289
sg10
I12
sg11
VCD271(-)CD45
p3290
sg13
I1
sasg14
(lp3291
(dp3292
g7
I25
sg17
VC0041296
p3293
sg10
I12
sg11
Vtuberculosis
p3294
sg13
I1
sasa(dp3295
g2
S'Inhibition of the interaction between p53 and MDM2/MDMX has attracted significant attention in anticancer therapy development.\n'
p3296
sg4
(lp3297
(dp3298
g7
I51
sg8
g9
sg10
I4
sg11
VMDMX
p3299
sg13
I1
sa(dp3300
g7
I38
sg8
VP42771
p3301
sg10
I3
sg11
Vp53
p3302
sg13
I1
sasg14
(lp3303
sa(dp3304
g2
S'MdmX overexpression contributes to the development of cancer by inhibiting tumor suppressor p53.\n'
p3305
sg4
(lp3306
(dp3307
g7
I75
sg8
VP42771
p3308
sg10
I20
sg11
Vtumor suppressor p53
p3309
sg13
I3
sa(dp3310
g7
I0
sg8
g9
sg10
I4
sg11
VMdmX
p3311
sg13
I1
sasg14
(lp3312
(dp3313
g7
I54
sg17
VC0006826
p3314
sg10
I6
sg11
Vcancer
p3315
sg13
I1
sa(dp3316
g7
I75
sg17
VC0027651
p3317
sg10
I5
sg11
Vtumor
p3318
sg13
I1
sasa(dp3319
g2
S'A switch in the alternative splicing of MdmX transcript, leading to the inclusion of exon 6, has been identified as the primary mechanism responsible for increased MdmX protein levels in human cancers, including melanoma.\n'
p3320
sg4
(lp3321
(dp3322
g7
I164
sg8
g9
sg10
I12
sg11
VMdmX protein
p3323
sg13
I2
sa(dp3324
g7
I40
sg8
g9
sg10
I15
sg11
VMdmX transcript
p3325
sg13
I2
sasg14
(lp3326
(dp3327
g7
I193
sg17
VC0006826
p3328
sg10
I7
sg11
Vcancers
p3329
sg13
I1
sa(dp3330
g7
I212
sg17
VC0025202
p3331
sg10
I8
sg11
Vmelanoma
p3332
sg13
I1
sasa(dp3333
g2
S'Recent studies showed that interfering with cellular splicing machinery can result in MdmX downregulation in cancer cells.\n'
p3334
sg4
(lp3335
(dp3336
g7
I86
sg8
g9
sg10
I4
sg11
VMdmX
p3337
sg13
I1
sasg14
(lp3338
(dp3339
g7
I109
sg17
VC0006826
p3340
sg10
I6
sg11
Vcancer
p3341
sg13
I1
sasa(dp3342
g2
S'We, therefore, hypothesized that enoxacin could, by modulating miRNAs targeting splicing machinery, activate p53 in melanoma cells overexpressing MdmX.\n'
p3343
sg4
(lp3344
(dp3345
g7
I146
sg8
g9
sg10
I4
sg11
VMdmX
p3346
sg13
I1
sa(dp3347
g7
I109
sg8
VP42771
p3348
sg10
I3
sg11
Vp53
p3349
sg13
I1
sasg14
(lp3350
(dp3351
g7
I116
sg17
VC0025202
p3352
sg10
I8
sg11
Vmelanoma
p3353
sg13
I1
sasa(dp3354
g2
S'Not only in melanoma, but also in MCF7 breast carcinoma and A2780 ovarian carcinoma cells overexpressing MdmX.\n'
p3355
sg4
(lp3356
(dp3357
g7
I105
sg8
g9
sg10
I4
sg11
VMdmX
p3358
sg13
I1
sasg14
(lp3359
(dp3360
g7
I39
sg17
VC0678222
p3361
sg10
I16
sg11
Vbreast carcinoma
p3362
sg13
I2
sa(dp3363
g7
I12
sg17
VC0025202
p3364
sg10
I8
sg11
Vmelanoma
p3365
sg13
I1
sa(dp3366
g7
I66
sg17
VC0029925
p3367
sg10
I17
sg11
Vovarian carcinoma
p3368
sg13
I2
sasa(dp3369
g2
S'Together, our results suggest that some clinically approved fluoroquinolones could potentially be repurposed as activators of p53 tumor suppressor in cancers overexpressing MdmX oncoprotein and that p53 activation might contribute to the previously reported activity of enoxacin towards human cancer cells.\n'
p3370
sg4
(lp3371
(dp3372
g7
I126
sg8
VP42771
p3373
sg10
I20
sg11
Vp53 tumor suppressor
p3374
sg13
I3
sa(dp3375
g7
I126
sg8
VP42771
p3376
sg10
I3
sg11
Vp53
p3377
sg13
I1
sa(dp3378
g7
I173
sg8
g9
sg10
I16
sg11
VMdmX oncoprotein
p3379
sg13
I2
sasg14
(lp3380
(dp3381
g7
I130
sg17
VC0027651
p3382
sg10
I5
sg11
Vtumor
p3383
sg13
I1
sa(dp3384
g7
I150
sg17
VC0006826
p3385
sg10
I6
sg11
Vcancer
p3386
sg13
I1
sa(dp3387
g7
I150
sg17
VC0006826
p3388
sg10
I7
sg11
Vcancers
p3389
sg13
I1
sasa(dp3390
g2
S'These will be discussed as will recent findings of MDMX inhibitors: these are of special importance as it has been shown that cancers that become resistant to MDM2 inhibitors often amplify MDM4.\n'
p3391
sg4
(lp3392
(dp3393
g7
I51
sg8
g9
sg10
I4
sg11
VMDMX
p3394
sg13
I1
sa(dp3395
g7
I189
sg8
g9
sg10
I4
sg11
VMDM4
p3396
sg13
I1
sasg14
(lp3397
(dp3398
g7
I126
sg17
VC0006826
p3399
sg10
I7
sg11
Vcancers
p3400
sg13
I1
sasa(dp3401
g2
S'Our recent studies conducted in South America have shown that mycotoxin contamination of red chili peppers (RCPs) may be associated with an increased risk of gallbladder cancer (GBC).\n'
p3402
sg4
(lp3403
sg14
(lp3404
(dp3405
g7
I178
sg17
VC0153452
p3406
sg10
I3
sg11
VGBC
p3407
sg13
I1
sa(dp3408
g7
I158
sg17
VC0153452
p3409
sg10
I18
sg11
Vgallbladder cancer
p3410
sg13
I2
sasa(dp3411
g2
S'Three proteins were uniquely altered in vaginal carcinoma (DDX48, erbB3-binding protein and biliverdin reductase) and five in cervical carcinoma (peroxiredoxin 2, annexin A2, sarcomeric tropomyosin kappa, human ribonuclease inhibitor and prolyl-4-hydrolase beta).\n'
p3412
sg4
(lp3413
(dp3414
g7
I92
sg8
VP53004
p3415
sg10
I20
sg11
Vbiliverdin reductase
p3416
sg13
I2
sa(dp3417
g7
I59
sg8
VP38919
p3418
sg10
I5
sg11
VDDX48
p3419
sg13
I1
sa(dp3420
g7
I66
sg8
VP21860
p3421
sg10
I21
sg11
VerbB3-binding protein
p3422
sg13
I2
sa(dp3423
g7
I163
sg8
VP07355
p3424
sg10
I40
sg11
Vannexin A2, sarcomeric tropomyosin kappa
p3425
sg13
I5
sa(dp3426
g7
I146
sg8
VP32119
p3427
sg10
I15
sg11
Vperoxiredoxin 2
p3428
sg13
I2
sa(dp3429
g7
I205
sg8
VP13489
p3430
sg10
I28
sg11
Vhuman ribonuclease inhibitor
p3431
sg13
I3
sasg14
(lp3432
(dp3433
g7
I126
sg17
VC0302592
p3434
sg10
I18
sg11
Vcervical carcinoma
p3435
sg13
I2
sa(dp3436
g7
I40
sg17
VC0262659
p3437
sg10
I17
sg11
Vvaginal carcinoma
p3438
sg13
I2
sasa(dp3439
g2
S'Mitochondrial (mt) DNA-associated NARP (neurogenic muscle weakness, ataxia, and retinitis pigmentosa) syndrome is due to mutation in the MT-ATP6 gene.\n'
p3440
sg4
(lp3441
(dp3442
g7
I34
sg8
VP47972
p3443
sg10
I4
sg11
VNARP
p3444
sg13
I1
sa(dp3445
g7
I137
sg8
VP36543
p3446
sg10
I12
sg11
VMT-ATP6 gene
p3447
sg13
I2
sasg14
(lp3448
(dp3449
g7
I80
sg17
VC0035334
p3450
sg10
I20
sg11
Vretinitis pigmentosa
p3451
sg13
I2
sa(dp3452
g7
I51
sg17
VC0030552
p3453
sg10
I15
sg11
Vmuscle weakness
p3454
sg13
I2
sa(dp3455
g7
I68
sg17
VC0004134
p3456
sg10
I6
sg11
Vataxia
p3457
sg13
I1
sa(dp3458
g7
I102
sg17
VC0039082
p3459
sg10
I8
sg11
Vsyndrome
p3460
sg13
I1
sasa(dp3461
g2
S'Pathogenic mutations in MT-ATP6 are associated with the Leigh syndrome, the syndrome of neuropathy, ataxia, and retinitis pigmentosa (NARP), as well as with non-classical phenotypes, while MT-ATP8 is less frequently mutated in patients with mitochondrial disease.\n'
p3462
sg4
(lp3463
(dp3464
g7
I189
sg8
VP03928
p3465
sg10
I7
sg11
VMT-ATP8
p3466
sg13
I1
sa(dp3467
g7
I24
sg8
VP36543
p3468
sg10
I7
sg11
VMT-ATP6
p3469
sg13
I1
sasg14
(lp3470
(dp3471
g7
I241
sg17
VC0751651
p3472
sg10
I21
sg11
Vmitochondrial disease
p3473
sg13
I2
sa(dp3474
g7
I88
sg17
VC1328349
p3475
sg10
I44
sg11
Vneuropathy, ataxia, and retinitis pigmentosa
p3476
sg13
I5
sa(dp3477
g7
I56
sg17
VC0023264
p3478
sg10
I14
sg11
VLeigh syndrome
p3479
sg13
I2
sa(dp3480
g7
I62
sg17
VC0039082
p3481
sg10
I8
sg11
Vsyndrome
p3482
sg13
I1
sasa(dp3483
g2
S'Analysis of these populations demonstrated an altered metabolic signature in cells harbouring decreased levels of mutant m.8993T&gt;G mtDNA, associated with neuropathy, ataxia, and retinitis pigmentosa (NARP).\n'
p3484
sg4
(lp3485
sg14
(lp3486
(dp3487
g7
I157
sg17
VC1328349
p3488
sg10
I44
sg11
Vneuropathy, ataxia, and retinitis pigmentosa
p3489
sg13
I5
sa(dp3490
g7
I114
sg17
VC0596988
p3491
sg10
I6
sg11
Vmutant
p3492
sg13
I1
sasa(dp3493
g2
S'Neurogenic muscle weakness, ataxia, and retinitis pigmentosa (NARP) is caused by m.8993T&gt;G/C mutations in the mitochondrial adenosine triphosphate synthase subunit 6 gene (MT-ATP6).\n'
p3494
sg4
(lp3495
(dp3496
g7
I113
sg8
VP56381
p3497
sg10
I60
sg11
Vmitochondrial adenosine triphosphate synthase subunit 6 gene
p3498
sg13
I7
sa(dp3499
g7
I175
sg8
VP36543
p3500
sg10
I7
sg11
VMT-ATP6
p3501
sg13
I1
sasg14
(lp3502
(dp3503
g7
I28
sg17
VC0004134
p3504
sg10
I6
sg11
Vataxia
p3505
sg13
I1
sa(dp3506
g7
I40
sg17
VC0035334
p3507
sg10
I20
sg11
Vretinitis pigmentosa
p3508
sg13
I2
sa(dp3509
g7
I11
sg17
VC0030552
p3510
sg10
I15
sg11
Vmuscle weakness
p3511
sg13
I2
sasa(dp3512
g2
S"In addition, we successfully reduced human mutated mtDNA levels responsible for Leber's hereditary optic neuropathy (LHOND), and neurogenic muscle weakness, ataxia, and retinitis pigmentosa (NARP), in mammalian oocytes using mitochondria-targeted TALEN (mito-TALENs).\n"
p3513
sg4
(lp3514
sg14
(lp3515
(dp3516
g7
I140
sg17
VC0030552
p3517
sg10
I15
sg11
Vmuscle weakness
p3518
sg13
I2
sa(dp3519
g7
I80
sg17
VC0917796
p3520
sg10
I35
sg11
VLeber's hereditary optic neuropathy
p3521
sg13
I4
sa(dp3522
g7
I169
sg17
VC0035334
p3523
sg10
I20
sg11
Vretinitis pigmentosa
p3524
sg13
I2
sa(dp3525
g7
I157
sg17
VC0004134
p3526
sg10
I6
sg11
Vataxia
p3527
sg13
I1
sasa(dp3528
g2
S'Based on our previous findings that ROS level was higher in human osteosarcoma cybrids--Neuropathy, Ataxia and Retinitis Pigmentosa (NARP) and was reduced by selenite treatment, this study was designed to elucidate the effects of selenite administration on oxidative and nitrosative damage to lipids, proteins and DNA.\n'
p3529
sg4
(lp3530
sg14
(lp3531
(dp3532
g7
I100
sg17
VC0004134
p3533
sg10
I6
sg11
VAtaxia
p3534
sg13
I1
sa(dp3535
g7
I66
sg17
VC0029463
p3536
sg10
I12
sg11
Vosteosarcoma
p3537
sg13
I1
sa(dp3538
g7
I88
sg17
VC0442874
p3539
sg10
I10
sg11
VNeuropathy
p3540
sg13
I1
sa(dp3541
g7
I111
sg17
VC0035334
p3542
sg10
I20
sg11
VRetinitis Pigmentosa
p3543
sg13
I2
sasa(dp3544
g2
S'We report a patient having classical clinical feature of neurologic muscle weakness, ataxia, and retinitis pigmentosa (NARP) and a novel mutation, m.8729 G&gt;A in mitochondria DNA.\n'
p3545
sg4
(lp3546
sg14
(lp3547
(dp3548
g7
I97
sg17
VC0035334
p3549
sg10
I20
sg11
Vretinitis pigmentosa
p3550
sg13
I2
sa(dp3551
g7
I68
sg17
VC0030552
p3552
sg10
I15
sg11
Vmuscle weakness
p3553
sg13
I2
sa(dp3554
g7
I131
sg17
VC2985438
p3555
sg10
I14
sg11
Vnovel mutation
p3556
sg13
I2
sa(dp3557
g7
I85
sg17
VC0004134
p3558
sg10
I6
sg11
Vataxia
p3559
sg13
I1
sasa(dp3560
g2
S'His mother, who had previously been diagnosed with cerebral palsy, was concurrently diagnosed with neuropathy, ataxia, and retinitis pigmentosa (NARP) due to heteroplasmy of the same mutation.\n'
p3561
sg4
(lp3562
sg14
(lp3563
(dp3564
g7
I99
sg17
VC1328349
p3565
sg10
I44
sg11
Vneuropathy, ataxia, and retinitis pigmentosa
p3566
sg13
I5
sa(dp3567
g7
I51
sg17
VC0007789
p3568
sg10
I14
sg11
Vcerebral palsy
p3569
sg13
I2
sasa(dp3570
g2
S"In this issue, Gammage and colleagues successfully apply this improved technology on patients' cells with two types of genetic alterations responsible for neuropathy ataxia and retinitis pigmentosa (NARP) syndrome and Kearns Sayre syndrome and progressive external ophthalmoplegia (PEO).\n"
p3571
sg4
(lp3572
sg14
(lp3573
(dp3574
g7
I166
sg17
VC0004134
p3575
sg10
I6
sg11
Vataxia
p3576
sg13
I1
sa(dp3577
g7
I155
sg17
VC0442874
p3578
sg10
I10
sg11
Vneuropathy
p3579
sg13
I1
sa(dp3580
g7
I244
sg17
VC0162674
p3581
sg10
I36
sg11
Vprogressive external ophthalmoplegia
p3582
sg13
I3
sa(dp3583
g7
I218
sg17
VC0022541
p3584
sg10
I21
sg11
VKearns Sayre syndrome
p3585
sg13
I3
sa(dp3586
g7
I205
sg17
VC0039082
p3587
sg10
I8
sg11
Vsyndrome
p3588
sg13
I1
sa(dp3589
g7
I177
sg17
VC0035334
p3590
sg10
I20
sg11
Vretinitis pigmentosa
p3591
sg13
I2
sa(dp3592
g7
I282
sg17
VC0162674
p3593
sg10
I3
sg11
VPEO
p3594
sg13
I1
sasa(dp3595
g2
S"There are several diseases that have a mitochondrial origin such as chronic progressive external ophthalmoplegia (CPEO) and the Kearns- Sayre syndrome (KSS), myoclonic epilepsy with ragged-red fibers (MERRF), mitochondrial encephalomyopathy, lactic acidosis and strokelike episodes (MELAS), Leber's hereditary optic neuropathy (LHON), the syndrome of neurogenic muscle weakness, ataxia and retinitis pigmentosa (NARP), and Leigh's syndrome.\n"
p3596
sg4
(lp3597
sg14
(lp3598
(dp3599
g7
I158
sg17
VC0162672
p3600
sg10
I41
sg11
Vmyoclonic epilepsy with ragged-red fibers
p3601
sg13
I5
sa(dp3602
g7
I201
sg17
VC0162672
p3603
sg10
I5
sg11
VMERRF
p3604
sg13
I1
sa(dp3605
g7
I128
sg17
VC0022541
p3606
sg10
I22
sg11
VKearns- Sayre syndrome
p3607
sg13
I3
sa(dp3608
g7
I291
sg17
VC0917796
p3609
sg10
I35
sg11
VLeber's hereditary optic neuropathy
p3610
sg13
I4
sa(dp3611
g7
I114
sg17
VC0162674
p3612
sg10
I4
sg11
VCPEO
p3613
sg13
I1
sa(dp3614
g7
I142
sg17
VC0039082
p3615
sg10
I8
sg11
Vsyndrome
p3616
sg13
I1
sa(dp3617
g7
I142
sg17
VC0039082
p3618
sg10
I8
sg11
Vsyndrome
p3619
sg13
I1
sa(dp3620
g7
I242
sg17
VC0001125
p3621
sg10
I15
sg11
Vlactic acidosis
p3622
sg13
I2
sa(dp3623
g7
I209
sg17
VC0162666
p3624
sg10
I31
sg11
Vmitochondrial encephalomyopathy
p3625
sg13
I2
sa(dp3626
g7
I152
sg17
VC0022541
p3627
sg10
I3
sg11
VKSS
p3628
sg13
I1
sa(dp3629
g7
I283
sg17
VC0162671
p3630
sg10
I5
sg11
VMELAS
p3631
sg13
I1
sa(dp3632
g7
I328
sg17
VC0917796
p3633
sg10
I4
sg11
VLHON
p3634
sg13
I1
sa(dp3635
g7
I351
sg17
VC0342772
p3636
sg10
I59
sg11
Vneurogenic muscle weakness, ataxia and retinitis pigmentosa
p3637
sg13
I7
sa(dp3638
g7
I68
sg17
VC0162674
p3639
sg10
I44
sg11
Vchronic progressive external ophthalmoplegia
p3640
sg13
I4
sasa(dp3641
g2
S'Neuroblastoma cells treated with free myb-as or nontargeted CCL-myb-as showed the same level of c-myb protein expression as control cells.\n'
p3642
sg4
(lp3643
(dp3644
g7
I96
sg8
VP10243
p3645
sg10
I13
sg11
Vc-myb protein
p3646
sg13
I2
sa(dp3647
g7
I38
sg8
VP10243
p3648
sg10
I3
sg11
Vmyb
p3649
sg13
I1
sa(dp3650
g7
I38
sg8
VP10243
p3651
sg10
I3
sg11
Vmyb
p3652
sg13
I1
sa(dp3653
g7
I60
sg8
VP43320
p3654
sg10
I3
sg11
VCCL
p3655
sg13
I1
sasg14
(lp3656
(dp3657
g7
I0
sg17
VC0027819
p3658
sg10
I13
sg11
VNeuroblastoma
p3659
sg13
I1
sa(dp3660
g7
I60
sg17
VC1852438
p3661
sg10
I3
sg11
VCCL
p3662
sg13
I1
sasa(dp3663
g2
S'Immune cell activation, involving the time-dependent activation of macrophages and NK cells, contributes to the antitumor activity of targeted liposome-CpG-myb-as against neuroblastoma and could improve the effectiveness of antitumor targeted liposomes.\n'
p3664
sg4
(lp3665
sg14
(lp3666
(dp3667
g7
I171
sg17
VC0027819
p3668
sg10
I13
sg11
Vneuroblastoma
p3669
sg13
I1
sasa(dp3670
g2
S'While YY1 is known to exert both positive and negative regulatory influences on nuclear-encoded mitochondrial proteins, as well as on neurodegeneration-related genes, in all cell lines we studied (including neuroblastoma) the effect of YY1 on GDAP1 expression is activatory.\n'
p3671
sg4
(lp3672
(dp3673
g7
I6
sg8
VP25490
p3674
sg10
I3
sg11
VYY1
p3675
sg13
I1
sa(dp3676
g7
I6
sg8
VP25490
p3677
sg10
I3
sg11
VYY1
p3678
sg13
I1
sa(dp3679
g7
I243
sg8
g9
sg10
I5
sg11
VGDAP1
p3680
sg13
I1
sa(dp3681
g7
I80
sg8
VP02649
p3682
sg10
I38
sg11
Vnuclear-encoded mitochondrial proteins
p3683
sg13
I3
sasg14
(lp3684
(dp3685
g7
I207
sg17
VC0027819
p3686
sg10
I13
sg11
Vneuroblastoma
p3687
sg13
I1
sa(dp3688
g7
I134
sg17
VC0027746
p3689
sg10
I17
sg11
Vneurodegeneration
p3690
sg13
I1
sasa(dp3691
g2
S'Using the DBH-expressing human neuroblastoma SK-N-BE(2)C and DBH-negative HeLa cell lines as model systems, we report here that this CRE/YY1/AP1 area interacts with multiple nuclear proteins, including CRE-binding protein (CREB) and transcription factor YY1 in a cell-specific manner.\n'
p3692
sg4
(lp3693
(dp3694
g7
I202
sg8
g9
sg10
I19
sg11
VCRE-binding protein
p3695
sg13
I2
sa(dp3696
g7
I233
sg8
VP25490
p3697
sg10
I24
sg11
Vtranscription factor YY1
p3698
sg13
I3
sa(dp3699
g7
I10
sg8
VP09172
p3700
sg10
I3
sg11
VDBH
p3701
sg13
I1
sa(dp3702
g7
I223
sg8
VP16220
p3703
sg10
I4
sg11
VCREB
p3704
sg13
I1
sa(dp3705
g7
I137
sg8
VP25490
p3706
sg10
I3
sg11
VYY1
p3707
sg13
I1
sa(dp3708
g7
I141
sg8
VP27695
p3709
sg10
I3
sg11
VAP1
p3710
sg13
I1
sasg14
(lp3711
(dp3712
g7
I31
sg17
VC0027819
p3713
sg10
I13
sg11
Vneuroblastoma
p3714
sg13
I1
sasa(dp3715
g2
S'However, little is known about the expression of CD44v6 in Gastric Carcinoma (GC).\n'
p3716
sg4
(lp3717
sg14
(lp3718
(dp3719
g7
I59
sg17
VC0699791
p3720
sg10
I17
sg11
VGastric Carcinoma
p3721
sg13
I2
sa(dp3722
g7
I78
sg17
VC0699791
p3723
sg10
I2
sg11
VGC
p3724
sg13
I1
sasa(dp3725
g2
S'Multiple carcinomas including breast, ovarian, colon, lung and stomach cancer, overexpress the hyaluronic acid (HA) receptor, CD44.\n'
p3726
sg4
(lp3727
sg14
(lp3728
(dp3729
g7
I63
sg17
VC0024623
p3730
sg10
I14
sg11
Vstomach cancer
p3731
sg13
I2
sa(dp3732
g7
I9
sg17
VC0007097
p3733
sg10
I10
sg11
Vcarcinomas
p3734
sg13
I1
sasa(dp3735
g2
S'Here, we show that the transcription of a long non-coding RNA (lncRNA), Gastric Adenocarcinoma Associated, Positive CD44 Regulator, Long Intergenic Non-Coding RNA (GAPLINC), is directly activated by HIF-1Alfa in gastric cancer (GC).\n'
p3736
sg4
(lp3737
sg14
(lp3738
(dp3739
g7
I228
sg17
VC0024623
p3740
sg10
I2
sg11
VGC
p3741
sg13
I1
sa(dp3742
g7
I72
sg17
VC0278701
p3743
sg10
I22
sg11
VGastric Adenocarcinoma
p3744
sg13
I2
sa(dp3745
g7
I212
sg17
VC0024623
p3746
sg10
I14
sg11
Vgastric cancer
p3747
sg13
I2
sasa(dp3748
g2
S'The expressions of 10 putative cell surface markers of CSCs, as well as aldehyde dehydrogenase (ALDH) activity, were studied, and the tumorigenic properties of cells were evaluated by in vitro tumorsphere assays and in vivo xenografts by limiting dilution assays.Results: We found that a subpopulation of gastric carcinoma cells expressing EPCAM, CD133, CD166, CD44, and a high ALDH activity presented the properties to generate new heterogeneous tumorspheres in vitro and tumors in vivo CD44 and CD166 were coexpressed, representing 6.1% to 37.5% of the cells; ALDH activity was detected in 1.6% to 15.4% of the cells; and the ALDH+ cells represented a core within the CD44+/CD166+ subpopulation that contained the highest frequency of tumorigenic CSCs in vivo The ALDH+ cells possessed drug efflux properties and were more resistant to standard chemotherapy than the ALDH- cells, a process that was partially reversed by verapamil treatment.Conclusions: CD44 and ALDH are the most specific biomarkers to detect and isolate tumorigenic and chemoresistant gastric CSCs in noncardia gastric carcinomas independently of the histologic classification of the tumor.\n'
p3749
sg4
(lp3750
(dp3751
g7
I96
sg8
VP00352
p3752
sg10
I4
sg11
VALDH
p3753
sg13
I1
sa(dp3754
g7
I676
sg8
g9
sg10
I6
sg11
VCD166+
p3755
sg13
I1
sa(dp3756
g7
I354
sg8
g9
sg10
I5
sg11
VCD166
p3757
sg13
I1
sa(dp3758
g7
I340
sg8
VP16422
p3759
sg10
I5
sg11
VEPCAM
p3760
sg13
I1
sa(dp3761
g7
I96
sg8
VP49366
p3762
sg10
I4
sg11
VALDH
p3763
sg13
I1
sa(dp3764
g7
I96
sg8
VP00352
p3765
sg10
I4
sg11
VALDH
p3766
sg13
I1
sa(dp3767
g7
I96
sg8
VP00352
p3768
sg10
I4
sg11
VALDH
p3769
sg13
I1
sa(dp3770
g7
I354
sg8
g9
sg10
I5
sg11
VCD166
p3771
sg13
I1
sa(dp3772
g7
I96
sg8
VP00352
p3773
sg10
I4
sg11
VALDH
p3774
sg13
I1
sa(dp3775
g7
I347
sg8
g9
sg10
I5
sg11
VCD133
p3776
sg13
I1
sa(dp3777
g7
I72
sg8
VP49366
p3778
sg10
I22
sg11
Valdehyde dehydrogenase
p3779
sg13
I2
sasg14
(lp3780
(dp3781
g7
I193
sg17
VC0027651
p3782
sg10
I6
sg11
Vtumors
p3783
sg13
I1
sa(dp3784
g7
I778
sg17
VC0850310
p3785
sg10
I9
sg11
Vpossessed
p3786
sg13
I1
sa(dp3787
g7
I305
sg17
VC0699791
p3788
sg10
I17
sg11
Vgastric carcinoma
p3789
sg13
I2
sa(dp3790
g7
I134
sg17
VC0027651
p3791
sg10
I5
sg11
Vtumor
p3792
sg13
I1
sa(dp3793
g7
I1090
sg17
VC0007097
p3794
sg10
I10
sg11
Vcarcinomas
p3795
sg13
I1
sasa(dp3796
g2
S'Clinically, low CD10 expression was consistent with a specific set of ovarian cancer patient samples.\n'
p3797
sg4
(lp3798
(dp3799
g7
I16
sg8
VP08473
p3800
sg10
I4
sg11
VCD10
p3801
sg13
I1
sasg14
(lp3802
(dp3803
g7
I70
sg17
VC1140680
p3804
sg10
I14
sg11
Vovarian cancer
p3805
sg13
I2
sasa(dp3806
g2
S'Furthermore, our data indicate that primary stage targeting of CD10-/ALDH- CSCs in specific ovarian cancer patients in future may facilitate targeting of recurrent disease, before it ever develops.\n'
p3807
sg4
(lp3808
(dp3809
g7
I63
sg8
VP08473
p3810
sg10
I16
sg11
VCD10-/ALDH- CSCs
p3811
sg13
I2
sasg14
(lp3812
(dp3813
g7
I92
sg17
VC1140680
p3814
sg10
I14
sg11
Vovarian cancer
p3815
sg13
I2
sa(dp3816
g7
I154
sg17
VC0277556
p3817
sg10
I17
sg11
Vrecurrent disease
p3818
sg13
I2
sasa(dp3819
g2
S'All cases were negative for CD10 and WT-1 ruling out endometrial stromal tumor and were negative for HMB-45 and melan-A ruling out perivascular epithelioid cell tumor (both endometrial stromal tumor and perivascular epithelioid cell tumor have prominent vessels but have different histomorphology).\n'
p3820
sg4
(lp3821
(dp3822
g7
I112
sg8
g9
sg10
I7
sg11
Vmelan-A
p3823
sg13
I1
sa(dp3824
g7
I28
sg8
VP08473
p3825
sg10
I4
sg11
VCD10
p3826
sg13
I1
sa(dp3827
g7
I101
sg8
g9
sg10
I6
sg11
VHMB-45
p3828
sg13
I1
sasg14
(lp3829
(dp3830
g7
I53
sg17
VC0334695
p3831
sg10
I25
sg11
Vendometrial stromal tumor
p3832
sg13
I3
sa(dp3833
g7
I73
sg17
VC0027651
p3834
sg10
I5
sg11
Vtumor
p3835
sg13
I1
sa(dp3836
g7
I73
sg17
VC0027651
p3837
sg10
I5
sg11
Vtumor
p3838
sg13
I1
sa(dp3839
g7
I53
sg17
VC0334695
p3840
sg10
I25
sg11
Vendometrial stromal tumor
p3841
sg13
I3
sasa(dp3842
g2
S'Immunohistochemistry indicated a phenotypic transition from a uterine leiomyosarcoma to a vaginal epithelioid lesion; marker expression changed from the uterine tumor actin+/desmin+/caldesmon+/CD10- phenotype, through the tumor emboli, to an actin-/desmin-/caldesmon-/CD10+ phenotype in the vaginal lesion.\n'
p3843
sg4
(lp3844
(dp3845
g7
I182
sg8
g9
sg10
I10
sg11
Vcaldesmon+
p3846
sg13
I1
sa(dp3847
g7
I257
sg8
g9
sg10
I26
sg11
Vcaldesmon-/CD10+ phenotype
p3848
sg13
I2
sa(dp3849
g7
I174
sg8
VP98155
p3850
sg10
I7
sg11
Vdesmin+
p3851
sg13
I1
sa(dp3852
g7
I242
sg8
VP98155
p3853
sg10
I13
sg11
Vactin-/desmin
p3854
sg13
I1
sa(dp3855
g7
I193
sg8
VP08473
p3856
sg10
I4
sg11
VCD10
p3857
sg13
I1
sasg14
(lp3858
(dp3859
g7
I161
sg17
VC0027651
p3860
sg10
I5
sg11
Vtumor
p3861
sg13
I1
sa(dp3862
g7
I44
sg17
VC0599156
p3863
sg10
I10
sg11
Vtransition
p3864
sg13
I1
sa(dp3865
g7
I291
sg17
VC0566943
p3866
sg10
I14
sg11
Vvaginal lesion
p3867
sg13
I2
sa(dp3868
g7
I62
sg17
VC0280631
p3869
sg10
I22
sg11
Vuterine leiomyosarcoma
p3870
sg13
I2
sa(dp3871
g7
I153
sg17
VC0042138
p3872
sg10
I13
sg11
Vuterine tumor
p3873
sg13
I2
sasa(dp3874
g2
S'Immunohistochemistry for IFITM1 and CD10 was performed in 20 cases of smooth muscle neoplasms (10 cases leiomyoma, 10 cases leiomyosarcoma), 14 cases of endometrial stromal sarcoma (ESS) (12 cases of low grade and 2 cases of high grade) and 12 cases of carcinosarcoma.\n'
p3875
sg4
(lp3876
(dp3877
g7
I25
sg8
VP13164
p3878
sg10
I6
sg11
VIFITM1
p3879
sg13
I1
sa(dp3880
g7
I36
sg8
VP08473
p3881
sg10
I4
sg11
VCD10
p3882
sg13
I1
sasg14
(lp3883
(dp3884
g7
I124
sg17
VC0023269
p3885
sg10
I14
sg11
Vleiomyosarcoma
p3886
sg13
I1
sa(dp3887
g7
I182
sg17
VC0206630
p3888
sg10
I3
sg11
VESS
p3889
sg13
I1
sa(dp3890
g7
I253
sg17
VC0007140
p3891
sg10
I14
sg11
Vcarcinosarcoma
p3892
sg13
I1
sa(dp3893
g7
I77
sg17
VC0282606
p3894
sg10
I16
sg11
Vmuscle neoplasms
p3895
sg13
I2
sa(dp3896
g7
I104
sg17
VC0023267
p3897
sg10
I9
sg11
Vleiomyoma
p3898
sg13
I1
sa(dp3899
g7
I153
sg17
VC0206630
p3900
sg10
I27
sg11
Vendometrial stromal sarcoma
p3901
sg13
I3
sasa(dp3902
g2
S'While both IFITM1 (83%) and CD10 (91%) had high sensitivity in differentiating low-grade ESSs from smooth muscle neoplasms, IFITM1 (70%) had higher specificity compared with CD10 (45%).\n'
p3903
sg4
(lp3904
(dp3905
g7
I28
sg8
VP08473
p3906
sg10
I4
sg11
VCD10
p3907
sg13
I1
sa(dp3908
g7
I28
sg8
VP08473
p3909
sg10
I4
sg11
VCD10
p3910
sg13
I1
sa(dp3911
g7
I11
sg8
VP13164
p3912
sg10
I6
sg11
VIFITM1
p3913
sg13
I1
sa(dp3914
g7
I11
sg8
VP13164
p3915
sg10
I6
sg11
VIFITM1
p3916
sg13
I1
sasg14
(lp3917
(dp3918
g7
I106
sg17
VC0282606
p3919
sg10
I16
sg11
Vmuscle neoplasms
p3920
sg13
I2
sasa(dp3921
g2
S'In this study IFITM1 appears to be a more specific marker of endometrial stromal differentiation compared with CD10 in differentiating low-grade ESSs from smooth muscle neoplasms.\n'
p3922
sg4
(lp3923
(dp3924
g7
I111
sg8
VP08473
p3925
sg10
I4
sg11
VCD10
p3926
sg13
I1
sasg14
(lp3927
(dp3928
g7
I162
sg17
VC0282606
p3929
sg10
I16
sg11
Vmuscle neoplasms
p3930
sg13
I2
sasa(dp3931
g2
S'To further evaluate the nature of the HLA association with alopecia areata (AA), we investigated the HLA-DRB1 locus in 161 AA patients and 165 matched controls from Belgium and Germany.\n'
p3932
sg4
(lp3933
(dp3934
g7
I38
sg8
VP30486
p3935
sg10
I3
sg11
VHLA
p3936
sg13
I1
sa(dp3937
g7
I101
sg8
VP20039
p3938
sg10
I14
sg11
VHLA-DRB1 locus
p3939
sg13
I2
sasg14
(lp3940
(dp3941
g7
I76
sg17
VC0002171
p3942
sg10
I2
sg11
VAA
p3943
sg13
I1
sa(dp3944
g7
I76
sg17
VC0002171
p3945
sg10
I2
sg11
VAA
p3946
sg13
I1
sa(dp3947
g7
I59
sg17
VC0002171
p3948
sg10
I15
sg11
Valopecia areata
p3949
sg13
I2
sasa(dp3950
g2
S'In the present study, we found that miR-19a expression was significantly upregulated in metastatic clear cell renal carcinoma than that in adjacent and primary carcinoma tissues using qPCR and in situ hybridization experiments.\n'
p3951
sg4
(lp3952
(dp3953
g7
I36
sg8
g9
sg10
I7
sg11
VmiR-19a
p3954
sg13
I1
sasg14
(lp3955
(dp3956
g7
I152
sg17
VC1335475
p3957
sg10
I17
sg11
Vprimary carcinoma
p3958
sg13
I2
sa(dp3959
g7
I99
sg17
VC0279702
p3960
sg10
I26
sg11
Vclear cell renal carcinoma
p3961
sg13
I4
sasa(dp3962
g2
S'Thus, we provide evidence demonstrating that downregulation of miR-19a may be therapeutically beneficial for metastatic renal carcinoma.\n'
p3963
sg4
(lp3964
(dp3965
g7
I63
sg8
g9
sg10
I7
sg11
VmiR-19a
p3966
sg13
I1
sasg14
(lp3967
(dp3968
g7
I109
sg17
VC0919989
p3969
sg10
I26
sg11
Vmetastatic renal carcinoma
p3970
sg13
I3
sasa(dp3971
g2
S'Taqman probe stem-loop real-time PCR was used to accurately measure the levels of miR-19a in bladder cancer cell lines, 100 pairs of bladder cancer tissues and the adjacent non-neoplastic tissues and also the plasma collected from bladder cancer patients and normal controls.\n'
p3972
sg4
(lp3973
(dp3974
g7
I82
sg8
g9
sg10
I7
sg11
VmiR-19a
p3975
sg13
I1
sasg14
(lp3976
(dp3977
g7
I93
sg17
VC0699885
p3978
sg10
I14
sg11
Vbladder cancer
p3979
sg13
I2
sa(dp3980
g7
I93
sg17
VC0699885
p3981
sg10
I14
sg11
Vbladder cancer
p3982
sg13
I2
sa(dp3983
g7
I93
sg17
VC0699885
p3984
sg10
I14
sg11
Vbladder cancer
p3985
sg13
I2
sasa(dp3986
g2
S'miR-19a mimics and inhibitors were transfected into bladder cancer cells to investigate its role on regulating cell proliferation which was measured by CCK-8 and colony formation assay.\n'
p3987
sg4
(lp3988
(dp3989
g7
I0
sg8
g9
sg10
I7
sg11
VmiR-19a
p3990
sg13
I1
sasg14
(lp3991
(dp3992
g7
I52
sg17
VC0699885
p3993
sg10
I14
sg11
Vbladder cancer
p3994
sg13
I2
sa(dp3995
g7
I116
sg17
VC0334094
p3996
sg10
I13
sg11
Vproliferation
p3997
sg13
I1
sasa(dp3998
g2
S'miR-19a was significantly up-regulated in bladder cancer tissues and high-level of miR-19a was correlative with more aggressive phenotypes of bladder cancer.\n'
p3999
sg4
(lp4000
(dp4001
g7
I0
sg8
g9
sg10
I7
sg11
VmiR-19a
p4002
sg13
I1
sa(dp4003
g7
I0
sg8
g9
sg10
I7
sg11
VmiR-19a
p4004
sg13
I1
sasg14
(lp4005
(dp4006
g7
I42
sg17
VC0699885
p4007
sg10
I14
sg11
Vbladder cancer
p4008
sg13
I2
sa(dp4009
g7
I117
sg17
VC0001807
p4010
sg10
I10
sg11
Vaggressive
p4011
sg13
I1
sa(dp4012
g7
I42
sg17
VC0699885
p4013
sg10
I14
sg11
Vbladder cancer
p4014
sg13
I2
sasa(dp4015
g2
S'Meanwhile, gain or loss of function of miR-19a demonstrated that miR-19a can promote cell growth of bladder cancer cells and the further mechanism studies indicated that its oncogenic role was dependent on targeting PTEN.\n'
p4016
sg4
(lp4017
(dp4018
g7
I39
sg8
g9
sg10
I7
sg11
VmiR-19a
p4019
sg13
I1
sa(dp4020
g7
I216
sg8
VP60484
p4021
sg10
I4
sg11
VPTEN
p4022
sg13
I1
sa(dp4023
g7
I39
sg8
g9
sg10
I7
sg11
VmiR-19a
p4024
sg13
I1
sasg14
(lp4025
(dp4026
g7
I100
sg17
VC0699885
p4027
sg10
I14
sg11
Vbladder cancer
p4028
sg13
I2
sasa(dp4029
g2
S'Furthermore, investigation of miR-19a expression in the plasma of bladder cancer patients showed that miR-19a was also increased in plasma of bladder cancer patients which strongly supported miR-19a could be developed as potential diagnostic marker of bladder cancer.\n'
p4030
sg4
(lp4031
(dp4032
g7
I30
sg8
g9
sg10
I7
sg11
VmiR-19a
p4033
sg13
I1
sa(dp4034
g7
I30
sg8
g9
sg10
I7
sg11
VmiR-19a
p4035
sg13
I1
sa(dp4036
g7
I30
sg8
g9
sg10
I7
sg11
VmiR-19a
p4037
sg13
I1
sasg14
(lp4038
(dp4039
g7
I66
sg17
VC0699885
p4040
sg10
I14
sg11
Vbladder cancer
p4041
sg13
I2
sa(dp4042
g7
I66
sg17
VC0699885
p4043
sg10
I14
sg11
Vbladder cancer
p4044
sg13
I2
sa(dp4045
g7
I66
sg17
VC0699885
p4046
sg10
I14
sg11
Vbladder cancer
p4047
sg13
I2
sasa(dp4048
g2
S'Our data indicated that miR-19a might act as an oncogenic microRNA in bladder cancer and was significantly up-regulated in bladder cancer carcinogenesis.\n'
p4049
sg4
(lp4050
(dp4051
g7
I24
sg8
g9
sg10
I7
sg11
VmiR-19a
p4052
sg13
I1
sasg14
(lp4053
(dp4054
g7
I70
sg17
VC0699885
p4055
sg10
I14
sg11
Vbladder cancer
p4056
sg13
I2
sa(dp4057
g7
I138
sg17
VC0596263
p4058
sg10
I14
sg11
Vcarcinogenesis
p4059
sg13
I1
sa(dp4060
g7
I70
sg17
VC0699885
p4061
sg10
I14
sg11
Vbladder cancer
p4062
sg13
I2
sasa(dp4063
g2
S'The oncogenic role of miR19a in bladder cancer was dependent on targeting PTEN.\n'
p4064
sg4
(lp4065
(dp4066
g7
I74
sg8
VP60484
p4067
sg10
I4
sg11
VPTEN
p4068
sg13
I1
sasg14
(lp4069
(dp4070
g7
I32
sg17
VC0699885
p4071
sg10
I14
sg11
Vbladder cancer
p4072
sg13
I2
sasa(dp4073
g2
S'The synergy effect between miRNA-19a and arsenic trioxide that advocates targeting the mir-19a may represent a potential approach to enhance the efficacy and safety of ATO to treat bladder cancer by a decrease in dose.\n'
p4074
sg4
(lp4075
(dp4076
g7
I87
sg8
g9
sg10
I7
sg11
Vmir-19a
p4077
sg13
I1
sasg14
(lp4078
(dp4079
g7
I181
sg17
VC0699885
p4080
sg10
I14
sg11
Vbladder cancer
p4081
sg13
I2
sasa(dp4082
g2
S'There was significant decreases in serum albumin and haptoglobin and increases in alpha-1 globulin, ceruloplasmin and alpha-1 globulin, there were no significant differences between schistosomiasis patients and the controls in terms of changes in any laboratory test as a result of the treatment, thus suggesting that patients with active schistosomiasis do not incur a higher risk of hepatic dysfunction while using oral contraception.\n'
p4083
sg4
(lp4084
(dp4085
g7
I100
sg8
VP00450
p4086
sg10
I13
sg11
Vceruloplasmin
p4087
sg13
I1
sa(dp4088
g7
I82
sg8
VP25100
p4089
sg10
I16
sg11
Valpha-1 globulin
p4090
sg13
I2
sa(dp4091
g7
I82
sg8
VP25100
p4092
sg10
I16
sg11
Valpha-1 globulin
p4093
sg13
I2
sa(dp4094
g7
I35
sg8
g9
sg10
I13
sg11
Vserum albumin
p4095
sg13
I2
sa(dp4096
g7
I53
sg8
VP00738
p4097
sg10
I11
sg11
Vhaptoglobin
p4098
sg13
I1
sasg14
(lp4099
(dp4100
g7
I182
sg17
VC0036323
p4101
sg10
I15
sg11
Vschistosomiasis
p4102
sg13
I1
sa(dp4103
g7
I182
sg17
VC0036323
p4104
sg10
I15
sg11
Vschistosomiasis
p4105
sg13
I1
sa(dp4106
g7
I385
sg17
VC0086565
p4107
sg10
I19
sg11
Vhepatic dysfunction
p4108
sg13
I2
sasa(dp4109
g2
S'Aqueous flare values and the vitreous levels of VEGF, IL-6, MCP-1, sICAM-1, and sVEGFR-2 were compared between previously untreated patients with BRVO and patients with macular hole (MH).\n'
p4110
sg4
(lp4111
(dp4112
g7
I60
sg8
VP41597
p4113
sg10
I5
sg11
VMCP-1
p4114
sg13
I1
sa(dp4115
g7
I54
sg8
VP05231
p4116
sg10
I4
sg11
VIL-6
p4117
sg13
I1
sasg14
(lp4118
(dp4119
g7
I169
sg17
VC0024441
p4120
sg10
I12
sg11
Vmacular hole
p4121
sg13
I2
sa(dp4122
g7
I183
sg17
VC0024441
p4123
sg10
I2
sg11
VMH
p4124
sg13
I1
sa(dp4125
g7
I8
sg17
VC1517205
p4126
sg10
I5
sg11
Vflare
p4127
sg13
I1
sasa(dp4128
g2
S'We investigated the relations between the aqueous flare value and vitreous levels of vascular endothelial growth factor (VEGF), soluble intercellular adhesion molecule-1 (sICAM-1), and interleukin-6 (IL-6) in patients with CRVO and macular edema or patients with idiopathic macular hole (MH).\n'
p4129
sg4
(lp4130
(dp4131
g7
I200
sg8
VP05231
p4132
sg10
I4
sg11
VIL-6
p4133
sg13
I1
sa(dp4134
g7
I185
sg8
VP05231
p4135
sg10
I13
sg11
Vinterleukin-6
p4136
sg13
I1
sa(dp4137
g7
I85
sg8
g9
sg10
I34
sg11
Vvascular endothelial growth factor
p4138
sg13
I4
sa(dp4139
g7
I136
sg8
VP05362
p4140
sg10
I33
sg11
Vintercellular adhesion molecule-1
p4141
sg13
I3
sa(dp4142
g7
I121
sg8
g9
sg10
I4
sg11
VVEGF
p4143
sg13
I1
sasg14
(lp4144
(dp4145
g7
I274
sg17
VC0024441
p4146
sg10
I12
sg11
Vmacular hole
p4147
sg13
I2
sa(dp4148
g7
I232
sg17
VC0271051
p4149
sg10
I13
sg11
Vmacular edema
p4150
sg13
I2
sa(dp4151
g7
I150
sg17
VC0001511
p4152
sg10
I8
sg11
Vadhesion
p4153
sg13
I1
sa(dp4154
g7
I288
sg17
VC0024441
p4155
sg10
I2
sg11
VMH
p4156
sg13
I1
sa(dp4157
g7
I50
sg17
VC1517205
p4158
sg10
I5
sg11
Vflare
p4159
sg13
I1
sasa(dp4160
g2
S'Vitreous fluid levels of vascular endothelial growth factor (VEGF), soluble VEGF receptor 2 (sVEGFR-2), soluble intercellular adhesion molecule 1 (sICAM-1), interleukin 6 (IL-6), monocyte chemotactic protein 1 (MCP-1), and pentraxin 3 (PTX3) were significantly higher in CRVO patients than in macular hole patients.\n'
p4161
sg4
(lp4162
(dp4163
g7
I61
sg8
g9
sg10
I4
sg11
VVEGF
p4164
sg13
I1
sa(dp4165
g7
I223
sg8
VP26022
p4166
sg10
I11
sg11
Vpentraxin 3
p4167
sg13
I2
sa(dp4168
g7
I112
sg8
VP05362
p4169
sg10
I33
sg11
Vintercellular adhesion molecule 1
p4170
sg13
I4
sa(dp4171
g7
I76
sg8
g9
sg10
I15
sg11
VVEGF receptor 2
p4172
sg13
I3
sa(dp4173
g7
I236
sg8
VP26022
p4174
sg10
I4
sg11
VPTX3
p4175
sg13
I1
sa(dp4176
g7
I211
sg8
VP41597
p4177
sg10
I5
sg11
VMCP-1
p4178
sg13
I1
sa(dp4179
g7
I172
sg8
VP05231
p4180
sg10
I4
sg11
VIL-6
p4181
sg13
I1
sa(dp4182
g7
I25
sg8
g9
sg10
I34
sg11
Vvascular endothelial growth factor
p4183
sg13
I4
sa(dp4184
g7
I157
sg8
VP05231
p4185
sg10
I13
sg11
Vinterleukin 6
p4186
sg13
I2
sa(dp4187
g7
I179
sg8
VP14222
p4188
sg10
I30
sg11
Vmonocyte chemotactic protein 1
p4189
sg13
I4
sasg14
(lp4190
(dp4191
g7
I126
sg17
VC0001511
p4192
sg10
I8
sg11
Vadhesion
p4193
sg13
I1
sa(dp4194
g7
I293
sg17
VC0024441
p4195
sg10
I12
sg11
Vmacular hole
p4196
sg13
I2
sasa(dp4197
g2
S'In 39 patients with BRVO and macular edema and 21 individuals with idiopathic macular hole (MH) serving as controls, vitreous fluid samples were obtained during vitreoretinal surgery, and the levels of vascular endothelial growth factor (VEGF), soluble VEGF receptor 2 (sVEGFR-2), soluble intercellular adhesion molecule 1 (sICAM-1), interleukin 6 (IL-6), monocyte chemotactic protein 1 (MCP-1), pentraxin 3 (PTX3), and pigment epithelium-derived factor (PEDF) were measured by enzyme-linked immunosorbent assay.\n'
p4198
sg4
(lp4199
(dp4200
g7
I202
sg8
g9
sg10
I34
sg11
Vvascular endothelial growth factor
p4201
sg13
I4
sa(dp4202
g7
I238
sg8
g9
sg10
I4
sg11
VVEGF
p4203
sg13
I1
sa(dp4204
g7
I349
sg8
VP05231
p4205
sg10
I4
sg11
VIL-6
p4206
sg13
I1
sa(dp4207
g7
I334
sg8
VP05231
p4208
sg10
I13
sg11
Vinterleukin 6
p4209
sg13
I2
sa(dp4210
g7
I388
sg8
VP41597
p4211
sg10
I5
sg11
VMCP-1
p4212
sg13
I1
sa(dp4213
g7
I409
sg8
VP26022
p4214
sg10
I4
sg11
VPTX3
p4215
sg13
I1
sa(dp4216
g7
I396
sg8
VP26022
p4217
sg10
I11
sg11
Vpentraxin 3
p4218
sg13
I2
sa(dp4219
g7
I289
sg8
VP05362
p4220
sg10
I33
sg11
Vintercellular adhesion molecule 1
p4221
sg13
I4
sa(dp4222
g7
I356
sg8
VP14222
p4223
sg10
I30
sg11
Vmonocyte chemotactic protein 1
p4224
sg13
I4
sa(dp4225
g7
I253
sg8
g9
sg10
I15
sg11
VVEGF receptor 2
p4226
sg13
I3
sasg14
(lp4227
(dp4228
g7
I92
sg17
VC0024441
p4229
sg10
I2
sg11
VMH
p4230
sg13
I1
sa(dp4231
g7
I78
sg17
VC0024441
p4232
sg10
I12
sg11
Vmacular hole
p4233
sg13
I2
sa(dp4234
g7
I29
sg17
VC0271051
p4235
sg10
I13
sg11
Vmacular edema
p4236
sg13
I2
sa(dp4237
g7
I303
sg17
VC0001511
p4238
sg10
I8
sg11
Vadhesion
p4239
sg13
I1
sasa(dp4240
g2
S'To investigate relationships among vitreous fluid levels of soluble vascular endothelial growth factor receptor-2 (sVEGFR-2), vascular endothelial growth factor (VEGF), and soluble intercellular adhesion molecule 1 (sICAM-1) in patients with branch retinal vein occlusion (BRVO) and macular edema or patients with idiopathic macular hole.\n'
p4241
sg4
(lp4242
(dp4243
g7
I116
sg8
g9
sg10
I4
sg11
VVEGF
p4244
sg13
I1
sa(dp4245
g7
I68
sg8
VP35968
p4246
sg10
I45
sg11
Vvascular endothelial growth factor receptor-2
p4247
sg13
I5
sa(dp4248
g7
I181
sg8
VP05362
p4249
sg10
I33
sg11
Vintercellular adhesion molecule 1
p4250
sg13
I4
sa(dp4251
g7
I68
sg8
g9
sg10
I34
sg11
Vvascular endothelial growth factor
p4252
sg13
I4
sasg14
(lp4253
(dp4254
g7
I283
sg17
VC0271051
p4255
sg10
I13
sg11
Vmacular edema
p4256
sg13
I2
sa(dp4257
g7
I325
sg17
VC0024441
p4258
sg10
I12
sg11
Vmacular hole
p4259
sg13
I2
sa(dp4260
g7
I242
sg17
VC0339505
p4261
sg10
I29
sg11
Vbranch retinal vein occlusion
p4262
sg13
I4
sa(dp4263
g7
I195
sg17
VC0001511
p4264
sg10
I8
sg11
Vadhesion
p4265
sg13
I1
sa(dp4266
g7
I273
sg17
VC0339505
p4267
sg10
I4
sg11
VBRVO
p4268
sg13
I1
sasa(dp4269
g2
S'BRVO patients had a significantly higher vitreous fluid level of sVEGFR-2 (median, 1670 pg/mL; interquartile range [IQL], 1205 to 2225 pg/mL) than macular hole patients (median, 1265 pg/mL; IQR, 731 to 1800 pg/mL; P = .017), as was the case for VEGF (median, 237 pg/mL; IQR, 42.2 to 1305 pg/mL; vs median, 15.6 pg/mL; IQR, 15.6 to 15.6 pg/mL; P &lt; .001) and sICAM-1 (median, 10.1 ng/mL; IQR, 6.3 to 22.5 ng/mL; vs median, 4.1 ng/mL; IQR, 3.3 to 6.0 ng/mL; P &lt; .001).\n'
p4270
sg4
(lp4271
sg14
(lp4272
(dp4273
g7
I147
sg17
VC0024441
p4274
sg10
I12
sg11
Vmacular hole
p4275
sg13
I2
sasa(dp4276
g2
S'Vitreous levels of sICAM-1 were significantly increased in vitreous specimens from both PVR (median +/- SD; 12.0 +/- 76.3 ng/ml; P &lt; 0.01) and PDR (8.4 +/- 24.0 ng/ml; P &lt; 0.01) when compared to vitreous from eyes with macular holes (0.\n'
p4277
sg4
(lp4278
sg14
(lp4279
(dp4280
g7
I88
sg17
VC1860404
p4281
sg10
I3
sg11
VPVR
p4282
sg13
I1
sa(dp4283
g7
I146
sg17
VC1845050
p4284
sg10
I3
sg11
VPDR
p4285
sg13
I1
sa(dp4286
g7
I225
sg17
VC0024441
p4287
sg10
I13
sg11
Vmacular holes
p4288
sg13
I2
sasa(dp4289
g2
S'Levels of sICAM-1 in this group were compared with those in vitreous from 31 eyes with RRD without clinical risk factors for PVR, 32 eyes with established PVR and 10 eyes with macular holes.\n'
p4290
sg4
(lp4291
(dp4292
g7
I125
sg8
VP15151
p4293
sg10
I3
sg11
VPVR
p4294
sg13
I1
sasg14
(lp4295
(dp4296
g7
I125
sg17
VC1860404
p4297
sg10
I3
sg11
VPVR
p4298
sg13
I1
sa(dp4299
g7
I125
sg17
VC1860404
p4300
sg10
I3
sg11
VPVR
p4301
sg13
I1
sa(dp4302
g7
I176
sg17
VC0024441
p4303
sg10
I13
sg11
Vmacular holes
p4304
sg13
I2
sasa(dp4305
g2
S'Vitreous sICAM-1 levels in eyes with RRD at high risk of developing PVR were significantly lower than in eyes with established PVR (p=0.037), but higher than in eyes with macular holes (p &lt;0.0001).\n'
p4306
sg4
(lp4307
(dp4308
g7
I68
sg8
VP15151
p4309
sg10
I3
sg11
VPVR
p4310
sg13
I1
sasg14
(lp4311
(dp4312
g7
I68
sg17
VC1860404
p4313
sg10
I3
sg11
VPVR
p4314
sg13
I1
sa(dp4315
g7
I171
sg17
VC0024441
p4316
sg10
I13
sg11
Vmacular holes
p4317
sg13
I2
sa(dp4318
g7
I68
sg17
VC1860404
p4319
sg10
I3
sg11
VPVR
p4320
sg13
I1
sasa(dp4321
g2
S'Rare pathogenic alleles with high penetrance and associated haplotypes at 10 loci (CFTR, FAH, HBB, HEXA, LDLR, LPL, PAH, PABP2, PDDR, and SACS) are expressed in probands with cystic fibrosis, tyrosinemia, beta-thalassemia, Tay-Sachs, familial hypercholesterolemia, hyperchylomicronemia, PKU, oculopharyngeal muscular dystrophy, pseudo vitamin D deficiency rickets, and spastic ataxia of Charlevoix-Saguenay, respectively) reveal the interpopulation and intrapopulation genetic diversity of Quebec.\n'
p4322
sg4
(lp4323
(dp4324
g7
I89
sg8
VP16930
p4325
sg10
I3
sg11
VFAH
p4326
sg13
I1
sa(dp4327
g7
I94
sg8
VP02042
p4328
sg10
I3
sg11
VHBB
p4329
sg13
I1
sa(dp4330
g7
I83
sg8
VP13569
p4331
sg10
I4
sg11
VCFTR
p4332
sg13
I1
sa(dp4333
g7
I128
sg8
g9
sg10
I4
sg11
VPDDR
p4334
sg13
I1
sa(dp4335
g7
I116
sg8
VP00439
p4336
sg10
I3
sg11
VPAH
p4337
sg13
I1
sa(dp4338
g7
I99
sg8
VP06865
p4339
sg10
I4
sg11
VHEXA
p4340
sg13
I1
sa(dp4341
g7
I105
sg8
VP01130
p4342
sg10
I4
sg11
VLDLR
p4343
sg13
I1
sa(dp4344
g7
I121
sg8
g9
sg10
I5
sg11
VPABP2
p4345
sg13
I1
sa(dp4346
g7
I111
sg8
VP06858
p4347
sg10
I3
sg11
VLPL
p4348
sg13
I1
sasg14
(lp4349
(dp4350
g7
I175
sg17
VC0010674
p4351
sg10
I15
sg11
Vcystic fibrosis
p4352
sg13
I2
sa(dp4353
g7
I192
sg17
VC0268483
p4354
sg10
I11
sg11
Vtyrosinemia
p4355
sg13
I1
sa(dp4356
g7
I292
sg17
VC0270952
p4357
sg10
I34
sg11
Voculopharyngeal muscular dystrophy
p4358
sg13
I3
sa(dp4359
g7
I116
sg17
VC0152171
p4360
sg10
I3
sg11
VPAH
p4361
sg13
I1
sa(dp4362
g7
I138
sg17
VC1849140
p4363
sg10
I4
sg11
VSACS
p4364
sg13
I1
sa(dp4365
g7
I356
sg17
VC0035579
p4366
sg10
I7
sg11
Vrickets
p4367
sg13
I1
sa(dp4368
g7
I369
sg17
VC1849140
p4369
sg10
I37
sg11
Vspastic ataxia of Charlevoix-Saguenay
p4370
sg13
I4
sa(dp4371
g7
I205
sg17
VC0005283
p4372
sg10
I16
sg11
Vbeta-thalassemia
p4373
sg13
I1
sa(dp4374
g7
I265
sg17
VC0023817
p4375
sg10
I20
sg11
Vhyperchylomicronemia
p4376
sg13
I1
sa(dp4377
g7
I234
sg17
VC0020445
p4378
sg10
I29
sg11
Vfamilial hypercholesterolemia
p4379
sg13
I2
sa(dp4380
g7
I335
sg17
VC0042870
p4381
sg10
I20
sg11
Vvitamin D deficiency
p4382
sg13
I3
sa(dp4383
g7
I287
sg17
VC0031485
p4384
sg10
I3
sg11
VPKU
p4385
sg13
I1
sasa(dp4386
g2
S"Biochemical, neuropathological, and genetic evidence suggests an important role for TCERG1 in Huntington's disease (HD) pathogenesis.\n"
p4387
sg4
(lp4388
(dp4389
g7
I84
sg8
g9
sg10
I6
sg11
VTCERG1
p4390
sg13
I1
sasg14
(lp4391
(dp4392
g7
I94
sg17
VC0020179
p4393
sg10
I20
sg11
VHuntington's disease
p4394
sg13
I2
sa(dp4395
g7
I120
sg17
VC0699748
p4396
sg10
I12
sg11
Vpathogenesis
p4397
sg13
I1
sa(dp4398
g7
I116
sg17
VC0020179
p4399
sg10
I2
sg11
VHD
p4400
sg13
I1
sasa(dp4401
g2
S'Further investigations on the underlying mechanisms showed that the depletion of dG9a repressed starvation-induced autophagy by controlling the expression level of Atg8a, a critical gene for the progression of autophagy, in a different manner to that in cancer cells.\n'
p4402
sg4
(lp4403
sg14
(lp4404
(dp4405
g7
I254
sg17
VC0006826
p4406
sg10
I6
sg11
Vcancer
p4407
sg13
I1
sasa(dp4408
g2
S'Bioinformatic analysis of human tumours revealed that several core autophagy genes, including GABARAP, correlate with oncogenic KRAS mutations and poor prognosis in human pancreatic cancer, supporting a potential tumour-suppressive effect of the pathway in Ras-driven human cancers.\n'
p4409
sg4
(lp4410
(dp4411
g7
I128
sg8
VP01116
p4412
sg10
I4
sg11
VKRAS
p4413
sg13
I1
sa(dp4414
g7
I94
sg8
g9
sg10
I7
sg11
VGABARAP
p4415
sg13
I1
sa(dp4416
g7
I257
sg8
VP01116
p4417
sg10
I3
sg11
VRas
p4418
sg13
I1
sasg14
(lp4419
(dp4420
g7
I32
sg17
VC0027651
p4421
sg10
I7
sg11
Vtumours
p4422
sg13
I1
sa(dp4423
g7
I32
sg17
VC0027651
p4424
sg10
I6
sg11
Vtumour
p4425
sg13
I1
sa(dp4426
g7
I171
sg17
VC0235974
p4427
sg10
I17
sg11
Vpancreatic cancer
p4428
sg13
I2
sa(dp4429
g7
I274
sg17
VC0006826
p4430
sg10
I7
sg11
Vcancers
p4431
sg13
I1
sasa(dp4432
g2
S'Using a yeast two-hybrid screening approach, based on a thyroid cancer patients library, we showed that CDH6 directly interacts with GABARAP, BNIP3 and BNIP3L, and that through these interactions CDH6 restrains autophagy and promotes re-organization of mitochondrial network through a DRP1-mediated mechanism.\n'
p4433
sg4
(lp4434
(dp4435
g7
I152
sg8
g9
sg10
I6
sg11
VBNIP3L
p4436
sg13
I1
sa(dp4437
g7
I104
sg8
VP55285
p4438
sg10
I4
sg11
VCDH6
p4439
sg13
I1
sa(dp4440
g7
I285
sg8
VP46939
p4441
sg10
I4
sg11
VDRP1
p4442
sg13
I1
sa(dp4443
g7
I104
sg8
VP55285
p4444
sg10
I4
sg11
VCDH6
p4445
sg13
I1
sa(dp4446
g7
I133
sg8
g9
sg10
I7
sg11
VGABARAP
p4447
sg13
I1
sa(dp4448
g7
I142
sg8
g9
sg10
I5
sg11
VBNIP3
p4449
sg13
I1
sasg14
(lp4450
(dp4451
g7
I56
sg17
VC0007115
p4452
sg10
I14
sg11
Vthyroid cancer
p4453
sg13
I2
sasa(dp4454
g2
S'We previously reported that GABARAPL1 expression was frequently downregulated in cancer cells while a high GABARAPL1 expression is a good prognosis marker for patients with lymph node-positive breast cancer.\n'
p4455
sg4
(lp4456
(dp4457
g7
I28
sg8
g9
sg10
I9
sg11
VGABARAPL1
p4458
sg13
I1
sa(dp4459
g7
I28
sg8
g9
sg10
I9
sg11
VGABARAPL1
p4460
sg13
I1
sasg14
(lp4461
(dp4462
g7
I179
sg17
VC3160887
p4463
sg10
I27
sg11
Vnode-positive breast cancer
p4464
sg13
I3
sa(dp4465
g7
I81
sg17
VC0006826
p4466
sg10
I6
sg11
Vcancer
p4467
sg13
I1
sasa(dp4468
g2
S'In this study, we asked using qRT-PCR, western blotting and epigenetic quantification whether the expression of the GABARAP family was regulated in breast cancer by epigenetic modifications.\n'
p4469
sg4
(lp4470
(dp4471
g7
I116
sg8
g9
sg10
I14
sg11
VGABARAP family
p4472
sg13
I2
sasg14
(lp4473
(dp4474
g7
I148
sg17
VC0678222
p4475
sg10
I13
sg11
Vbreast cancer
p4476
sg13
I2
sasa(dp4477
g2
S'Our data demonstrated that a specific decrease of GABARAPL1 expression in breast cancers was associated with both DNA methylation and histone deacetylation and that CREB-1 recruitment on GABARAPL1 promoter was required for GABARAPL1 expression.\n'
p4478
sg4
(lp4479
(dp4480
g7
I50
sg8
g9
sg10
I9
sg11
VGABARAPL1
p4481
sg13
I1
sa(dp4482
g7
I165
sg8
VP16220
p4483
sg10
I6
sg11
VCREB-1
p4484
sg13
I1
sa(dp4485
g7
I134
sg8
VP62805
p4486
sg10
I7
sg11
Vhistone
p4487
sg13
I1
sa(dp4488
g7
I187
sg8
g9
sg10
I18
sg11
VGABARAPL1 promoter
p4489
sg13
I2
sa(dp4490
g7
I50
sg8
g9
sg10
I9
sg11
VGABARAPL1
p4491
sg13
I1
sasg14
(lp4492
(dp4493
g7
I172
sg17
VC0271510
p4494
sg10
I11
sg11
Vrecruitment
p4495
sg13
I1
sa(dp4496
g7
I74
sg17
VC0006142
p4497
sg10
I14
sg11
Vbreast cancers
p4498
sg13
I2
sasa(dp4499
g2
S'Here we demonstrate that runx1 deletion in mice induces the persistence of MYH10 in platelets, and a similar persistence was observed in platelets of patients with constitutional (familial platelet disorder/acute myeloid leukemia) or acquired (chronic myelomonocytic leukemia) RUNX1 mutations.\n'
p4500
sg4
(lp4501
(dp4502
g7
I25
sg8
VP01719
p4503
sg10
I14
sg11
Vrunx1 deletion
p4504
sg13
I2
sa(dp4505
g7
I75
sg8
VP35580
p4506
sg10
I5
sg11
VMYH10
p4507
sg13
I1
sasg14
(lp4508
(dp4509
g7
I244
sg17
VC0023480
p4510
sg10
I31
sg11
Vchronic myelomonocytic leukemia
p4511
sg13
I3
sa(dp4512
g7
I189
sg17
VC0005818
p4513
sg10
I17
sg11
Vplatelet disorder
p4514
sg13
I2
sa(dp4515
g7
I207
sg17
VC0023467
p4516
sg10
I22
sg11
Vacute myeloid leukemia
p4517
sg13
I3
sasa(dp4518
g2
S'MYH10 was also detected in platelets of patients with the Paris-Trousseau syndrome, a thrombocytopenia related to the deletion of the transcription factor FLI1 that forms a complex with RUNX1 to regulate megakaryopoiesis, whereas MYH10 persistence was not observed in other inherited forms of thrombocytopenia.\n'
p4519
sg4
(lp4520
(dp4521
g7
I155
sg8
g9
sg10
I4
sg11
VFLI1
p4522
sg13
I1
sa(dp4523
g7
I0
sg8
VP35580
p4524
sg10
I5
sg11
VMYH10
p4525
sg13
I1
sa(dp4526
g7
I0
sg8
VP35580
p4527
sg10
I5
sg11
VMYH10
p4528
sg13
I1
sasg14
(lp4529
(dp4530
g7
I58
sg17
VC0795841
p4531
sg10
I24
sg11
VParis-Trousseau syndrome
p4532
sg13
I2
sasa(dp4533
g2
S'We propose MYH10 detection as a new and simple tool to identify inherited platelet disorders and myeloid neoplasms with abnormalities in RUNX1 and its associated proteins.\n'
p4534
sg4
(lp4535
(dp4536
g7
I11
sg8
VP35580
p4537
sg10
I5
sg11
VMYH10
p4538
sg13
I1
sasg14
(lp4539
(dp4540
g7
I74
sg17
VC0005818
p4541
sg10
I18
sg11
Vplatelet disorders
p4542
sg13
I2
sa(dp4543
g7
I105
sg17
VC0027651
p4544
sg10
I9
sg11
Vneoplasms
p4545
sg13
I1
sasa(dp4546
g2
S'The existence of gynecomastia, age, detection of heterogeneous nodules on ultrasound, and preoperative alpha-fetoprotein and beta HCG are relevant data in relation to histological type of tumor.\n'
p4547
sg4
(lp4548
(dp4549
g7
I103
sg8
VP02771
p4550
sg10
I30
sg11
Valpha-fetoprotein and beta HCG
p4551
sg13
I4
sasg14
(lp4552
(dp4553
g7
I130
sg17
VC1855900
p4554
sg10
I3
sg11
VHCG
p4555
sg13
I1
sa(dp4556
g7
I63
sg17
VC0028259
p4557
sg10
I7
sg11
Vnodules
p4558
sg13
I1
sa(dp4559
g7
I17
sg17
VC0018418
p4560
sg10
I12
sg11
Vgynecomastia
p4561
sg13
I1
sa(dp4562
g7
I188
sg17
VC0027651
p4563
sg10
I5
sg11
Vtumor
p4564
sg13
I1
sasa(dp4565
g2
S'List of Abbreviations: AO: Acridine orange, AIDS: Acquired immunodeficiency syndrome, ACT: Artemisinin-based combination therapy, CM:Cerebral malaria, BCP:Benzothiocarboxypurine, DDT:Dichloro-diphenyl-trichloroethane, DNA:DeoxyriboNucleic Acid, ELAM-1: Endothelial leukocyte adhesion molecule, G6PD: Glucose-6-Phosphate Dehydrogenase, HIV: Human immuno deficiency virus, HRP 2: Histidine Rich Protein 2, ICAM -1: Inter cellular adhesion molecule1, ICER: Incremental cost effectiveness ratio, IL-1: Interleukin -1, IFN-g: Interferon-gamma, IgG: Immunoglobulin G, MP: Malaria parasite, NADP: Oxidised Nicotinamide Adenine Dinucleotide Phosphate, NADPH: Reduced Nicotinamide Adenine Dinucleotide Phosphate, PCV: Packed Cell Volume (haematocrit), P. falciparum: Plasmodium falciparum, PLDH: Plasmodium lactate dehydrogenase, PCR: Polymerase Chain Reaction, PPV: Positive predictive value, QBC: Quantitative Buffy Coat examination, TNF: Tumour necrosis factor, NPV: Negative predictive value, RDT: Rapid diagnostic test, SP: Sulphadoxine -Pyrimethamine, SMA: Severe malarial anaemia, UM: Uncomplicated malaria, USA:United States of America, VCAM-1: Vascular cell adhesion molecule, WBC: White Blood Cell, WHO: World Health Organization.\n'
p4566
sg4
(lp4567
(dp4568
g7
I1144
sg8
g9
sg10
I31
sg11
VVascular cell adhesion molecule
p4569
sg13
I4
sa(dp4570
g7
I521
sg8
VP01579
p4571
sg10
I16
sg11
VInterferon-gamma
p4572
sg13
I1
sa(dp4573
g7
I413
sg8
VP01185
p4574
sg10
I33
sg11
VInter cellular adhesion molecule1
p4575
sg13
I4
sa(dp4576
g7
I927
sg8
VP01375
p4577
sg10
I3
sg11
VTNF
p4578
sg13
I1
sa(dp4579
g7
I514
sg8
VP01579
p4580
sg10
I5
sg11
VIFN-g
p4581
sg13
I1
sa(dp4582
g7
I300
sg8
VP49366
p4583
sg10
I33
sg11
VGlucose-6-Phosphate Dehydrogenase
p4584
sg13
I2
sa(dp4585
g7
I294
sg8
VP11441
p4586
sg10
I4
sg11
VG6PD
p4587
sg13
I1
sa(dp4588
g7
I498
sg8
VP60568
p4589
sg10
I14
sg11
VInterleukin -1
p4590
sg13
I2
sa(dp4591
g7
I245
sg8
VP16581
p4592
sg10
I6
sg11
VELAM-1
p4593
sg13
I1
sa(dp4594
g7
I539
sg8
g9
sg10
I21
sg11
VIgG: Immunoglobulin G
p4595
sg13
I3
sa(dp4596
g7
I492
sg8
VP01584
p4597
sg10
I4
sg11
VIL-1
p4598
sg13
I1
sa(dp4599
g7
I1136
sg8
VP19320
p4600
sg10
I6
sg11
VVCAM-1
p4601
sg13
I1
sa(dp4602
g7
I932
sg8
VP01375
p4603
sg10
I22
sg11
VTumour necrosis factor
p4604
sg13
I3
sa(dp4605
g7
I340
sg8
g9
sg10
I62
sg11
VHuman immuno deficiency virus, HRP 2: Histidine Rich Protein 2
p4606
sg13
I10
sa(dp4607
g7
I253
sg8
g9
sg10
I39
sg11
VEndothelial leukocyte adhesion molecule
p4608
sg13
I4
sa(dp4609
g7
I787
sg8
VP49366
p4610
sg10
I32
sg11
VPlasmodium lactate dehydrogenase
p4611
sg13
I3
sasg14
(lp4612
(dp4613
g7
I133
sg17
VC0024534
p4614
sg10
I16
sg11
VCerebral malaria
p4615
sg13
I2
sa(dp4616
g7
I275
sg17
VC0001511
p4617
sg10
I8
sg11
Vadhesion
p4618
sg13
I1
sa(dp4619
g7
I988
sg17
VC0206743
p4620
sg10
I3
sg11
VRDT
p4621
sg13
I1
sa(dp4622
g7
I275
sg17
VC0001511
p4623
sg10
I8
sg11
Vadhesion
p4624
sg13
I1
sa(dp4625
g7
I1049
sg17
VC0026847
p4626
sg10
I3
sg11
VSMA
p4627
sg13
I1
sa(dp4628
g7
I275
sg17
VC0001511
p4629
sg10
I8
sg11
Vadhesion
p4630
sg13
I1
sa(dp4631
g7
I50
sg17
VC0001175
p4632
sg10
I34
sg11
VAcquired immunodeficiency syndrome
p4633
sg13
I3
sa(dp4634
g7
I142
sg17
VC0024530
p4635
sg10
I7
sg11
Vmalaria
p4636
sg13
I1
sa(dp4637
g7
I335
sg17
VC0019693
p4638
sg10
I3
sg11
VHIV
p4639
sg13
I1
sa(dp4640
g7
I566
sg17
VC0024530
p4641
sg10
I7
sg11
VMalaria
p4642
sg13
I1
sa(dp4643
g7
I1070
sg17
VC0002871
p4644
sg10
I7
sg11
Vanaemia
p4645
sg13
I1
sa(dp4646
g7
I932
sg17
VC0333516
p4647
sg10
I15
sg11
VTumour necrosis
p4648
sg13
I2
sasa(dp4649
g2
S'HS intake increased natriuresis, diuresis, and urinary DA while it decreased cortical NOS I expression (P &lt; 0.05 vs. NS), Nicotinamide adenine dinucleotide phosphate diaphorase (NADPH-d) activity in MD (P &lt; 0.001 vs. NS) and cortical nitrates+nitrites (NOx) production (NS 2.04 +/- 0.22 vs. HS 1.28 +/- 0.10 nmol mg protein-1, P &lt; 0.01).\n'
p4650
sg4
(lp4651
(dp4652
g7
I125
sg8
VP28331
p4653
sg10
I54
sg11
VNicotinamide adenine dinucleotide phosphate diaphorase
p4654
sg13
I5
sa(dp4655
g7
I181
sg8
VP30043
p4656
sg10
I7
sg11
VNADPH-d
p4657
sg13
I1
sasg14
(lp4658
sa(dp4659
g2
S'Decreased G6PD activity and, as a result, decreased NADPH level have been associated with diabetic kidney disease, altered nitric oxide production, aldosterone-mediated endothelial dysfunction, and dialysis-associated anemia.\n'
p4660
sg4
(lp4661
(dp4662
g7
I10
sg8
VP11441
p4663
sg10
I4
sg11
VG6PD
p4664
sg13
I1
sasg14
(lp4665
(dp4666
g7
I169
sg17
VC0856169
p4667
sg10
I23
sg11
Vendothelial dysfunction
p4668
sg13
I2
sa(dp4669
g7
I90
sg17
VC0011881
p4670
sg10
I23
sg11
Vdiabetic kidney disease
p4671
sg13
I3
sa(dp4672
g7
I218
sg17
VC0002871
p4673
sg10
I6
sg11
Vanemia
p4674
sg13
I1
sasa(dp4675
g2
S'Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most common enzymatic disorder of red blood cells in human subjects, causing hemolytic anemia linked to impaired nicotinamide adenine dinucleotide phosphate (NADPH) production and imbalanced redox homeostasis in erythrocytes.\n'
p4676
sg4
(lp4677
(dp4678
g7
I0
sg8
VP49366
p4679
sg10
I33
sg11
VGlucose-6-phosphate dehydrogenase
p4680
sg13
I2
sa(dp4681
g7
I35
sg8
VP11441
p4682
sg10
I4
sg11
VG6PD
p4683
sg13
I1
sasg14
(lp4684
(dp4685
g7
I163
sg17
VC0684336
p4686
sg10
I8
sg11
Vimpaired
p4687
sg13
I1
sa(dp4688
g7
I136
sg17
VC0002878
p4689
sg10
I16
sg11
Vhemolytic anemia
p4690
sg13
I2
sasa(dp4691
g2
S'Interestingly, D2 recovery was accompanied by improvements in photosynthetic parameters (Asat and Fv/Fm) and the NADPH/NADP(+) ratio.\n'
p4692
sg4
(lp4693
sg14
(lp4694
(dp4695
g7
I89
sg17
VC1845028
p4696
sg10
I4
sg11
VAsat
p4697
sg13
I1
sasa(dp4698
g2
S'HFD significantly enhanced the Asm activity, ceramide production, colocalization of Nlrp3 (Nod-like receptor protein 3) with ASC (apoptosis-associated speck-like protein) or Caspase-1, NADPH-dependent superoxide (O2(*-)) production in glomeruli of Asm(+/+) mice than in control diet-fed mice.\n'
p4699
sg4
(lp4700
(dp4701
g7
I31
sg8
VP17405
p4702
sg10
I3
sg11
VAsm
p4703
sg13
I1
sa(dp4704
g7
I91
sg8
VP54259
p4705
sg10
I27
sg11
VNod-like receptor protein 3
p4706
sg13
I4
sa(dp4707
g7
I185
sg8
VP30043
p4708
sg10
I26
sg11
VNADPH-dependent superoxide
p4709
sg13
I2
sa(dp4710
g7
I174
sg8
VP29466
p4711
sg10
I9
sg11
VCaspase-1
p4712
sg13
I1
sa(dp4713
g7
I84
sg8
VP54259
p4714
sg10
I5
sg11
VNlrp3
p4715
sg13
I1
sasg14
(lp4716
(dp4717
g7
I91
sg17
VC0751781
p4718
sg10
I3
sg11
VNod
p4719
sg13
I1
sasa(dp4720
g2
S'We have studied the effects of growth factors and cytokines on the tumorigenicity and invasion capacity of tumor cells by using regressor and progressor tumor cell lines (ER-1 and ERpP, respectively) derived from an SHR rat mammary adenocarcinoma.\n'
p4721
sg4
(lp4722
sg14
(lp4723
(dp4724
g7
I224
sg17
VC0858252
p4725
sg10
I22
sg11
Vmammary adenocarcinoma
p4726
sg13
I2
sa(dp4727
g7
I86
sg17
VC2699153
p4728
sg10
I8
sg11
Vinvasion
p4729
sg13
I1
sa(dp4730
g7
I67
sg17
VC1519697
p4731
sg10
I14
sg11
Vtumorigenicity
p4732
sg13
I1
sa(dp4733
g7
I67
sg17
VC0027651
p4734
sg10
I5
sg11
Vtumor
p4735
sg13
I1
sa(dp4736
g7
I67
sg17
VC0027651
p4737
sg10
I5
sg11
Vtumor
p4738
sg13
I1
sasa(dp4739
g2
S'We have studied the effect of growth factors and cytokine on tumorigenesis and invasive capacity of tumor cells by examining a regressor tumor cell line (ER-1) derived from SHR rat mammary adenocarcinoma.\n'
p4740
sg4
(lp4741
sg14
(lp4742
(dp4743
g7
I61
sg17
VC0027651
p4744
sg10
I5
sg11
Vtumor
p4745
sg13
I1
sa(dp4746
g7
I181
sg17
VC0858252
p4747
sg10
I22
sg11
Vmammary adenocarcinoma
p4748
sg13
I2
sa(dp4749
g7
I61
sg17
VC0007621
p4750
sg10
I13
sg11
Vtumorigenesis
p4751
sg13
I1
sa(dp4752
g7
I61
sg17
VC0027651
p4753
sg10
I5
sg11
Vtumor
p4754
sg13
I1
sasa(dp4755
g2
S'Level of several proteins including haptoglobin, transthyretin, osteopontin, vitronectin, complement factor H and different classes of immunoglobulins are found to be considerably increased in CSF of higher grades of gliomas.\n'
p4756
sg4
(lp4757
(dp4758
g7
I36
sg8
VP00738
p4759
sg10
I11
sg11
Vhaptoglobin
p4760
sg13
I1
sa(dp4761
g7
I49
sg8
VP02766
p4762
sg10
I13
sg11
Vtransthyretin
p4763
sg13
I1
sa(dp4764
g7
I64
sg8
VP10451
p4765
sg10
I11
sg11
Vosteopontin
p4766
sg13
I1
sa(dp4767
g7
I77
sg8
VP04004
p4768
sg10
I11
sg11
Vvitronectin
p4769
sg13
I1
sa(dp4770
g7
I135
sg8
g9
sg10
I15
sg11
Vimmunoglobulins
p4771
sg13
I1
sa(dp4772
g7
I90
sg8
g9
sg10
I19
sg11
Vcomplement factor H
p4773
sg13
I3
sasg14
(lp4774
(dp4775
g7
I217
sg17
VC0017638
p4776
sg10
I7
sg11
Vgliomas
p4777
sg13
I1
sasa(dp4778
g2
S'Vitronectin is an extracellular matrix protein, the synthesis of which by glioma cells correlates with tumor grade.\n'
p4779
sg4
(lp4780
(dp4781
g7
I18
sg8
VP55082
p4782
sg10
I28
sg11
Vextracellular matrix protein
p4783
sg13
I3
sa(dp4784
g7
I0
sg8
VP04004
p4785
sg10
I11
sg11
VVitronectin
p4786
sg13
I1
sasg14
(lp4787
(dp4788
g7
I103
sg17
VC0027651
p4789
sg10
I5
sg11
Vtumor
p4790
sg13
I1
sa(dp4791
g7
I74
sg17
VC0017638
p4792
sg10
I6
sg11
Vglioma
p4793
sg13
I1
sasa(dp4794
g2
S'The current study was designed to investigate the relationship between serum vitronectin levels and clinicopathological characteristics, diagnosis and prognosis in glioma patients.\n'
p4795
sg4
(lp4796
(dp4797
g7
I71
sg8
VP04004
p4798
sg10
I17
sg11
Vserum vitronectin
p4799
sg13
I2
sasg14
(lp4800
(dp4801
g7
I164
sg17
VC0017638
p4802
sg10
I6
sg11
Vglioma
p4803
sg13
I1
sasa(dp4804
g2
S'Serum vitronectin levels were significantly elevated in glioma patients as compared with other groups.\n'
p4805
sg4
(lp4806
(dp4807
g7
I0
sg8
VP04004
p4808
sg10
I17
sg11
VSerum vitronectin
p4809
sg13
I2
sasg14
(lp4810
(dp4811
g7
I56
sg17
VC0017638
p4812
sg10
I6
sg11
Vglioma
p4813
sg13
I1
sasa(dp4814
g2
S'Serum vitronectin levels could significantly distinguish glioma patients from other groups and discriminate high-grade glioma from low-grade glioma.\n'
p4815
sg4
(lp4816
(dp4817
g7
I0
sg8
VP04004
p4818
sg10
I17
sg11
VSerum vitronectin
p4819
sg13
I2
sasg14
(lp4820
(dp4821
g7
I57
sg17
VC0017638
p4822
sg10
I6
sg11
Vglioma
p4823
sg13
I1
sa(dp4824
g7
I57
sg17
VC0017638
p4825
sg10
I6
sg11
Vglioma
p4826
sg13
I1
sa(dp4827
g7
I131
sg17
VC1997217
p4828
sg10
I16
sg11
Vlow-grade glioma
p4829
sg13
I2
sasa(dp4830
g2
S'Serum vitronectin may be a promising diagnostic and prognostic biomarker that can be detected in the peripheral blood of patients with glioma.\n'
p4831
sg4
(lp4832
(dp4833
g7
I6
sg8
VP04004
p4834
sg10
I11
sg11
Vvitronectin
p4835
sg13
I1
sasg14
(lp4836
(dp4837
g7
I135
sg17
VC0017638
p4838
sg10
I6
sg11
Vglioma
p4839
sg13
I1
sasa(dp4840
g2
S'Bioinformatics analysis emphasized key roles of integrin Beta3, hypoxia and vitronectin and their strong correlations with EGFRvIII expression in malignant glioma patient samples in vivo.\n'
p4841
sg4
(lp4842
(dp4843
g7
I64
sg8
VP04004
p4844
sg10
I23
sg11
Vhypoxia and vitronectin
p4845
sg13
I3
sasg14
(lp4846
(dp4847
g7
I64
sg17
VC0242184
p4848
sg10
I7
sg11
Vhypoxia
p4849
sg13
I1
sa(dp4850
g7
I146
sg17
VC0555198
p4851
sg10
I16
sg11
Vmalignant glioma
p4852
sg13
I2
sasa(dp4853
g2
S'In conclusion, we demonstrate that EGFRvIII/integrin Beta3 complexes promote GBM progression and metastasis in the environment of hypoxia and vitronectin-enrichment, and cilengitide may serve as a promising therapeutics for EGFRvIII-positive GBMs.\n'
p4854
sg4
(lp4855
sg14
(lp4856
(dp4857
g7
I77
sg17
VC0017636
p4858
sg10
I3
sg11
VGBM
p4859
sg13
I1
sa(dp4860
g7
I130
sg17
VC0242184
p4861
sg10
I7
sg11
Vhypoxia
p4862
sg13
I1
sa(dp4863
g7
I97
sg17
VC0027627
p4864
sg10
I10
sg11
Vmetastasis
p4865
sg13
I1
sasa(dp4866
g2
S'Glioma cells derived from the brain of the (12) V-Ha-Ras transgenic mice were used to study the effect of PI-3 kinase inhibitor SF1126 on activation of AKT and ERK signaling, proliferation, vitronectin mediated migration and changes in the distribution of cortical actin on vitronectin in the glioma cells in vitro.\n'
p4867
sg4
(lp4868
(dp4869
g7
I106
sg8
g9
sg10
I11
sg11
VPI-3 kinase
p4870
sg13
I2
sa(dp4871
g7
I190
sg8
VP04004
p4872
sg10
I11
sg11
Vvitronectin
p4873
sg13
I1
sa(dp4874
g7
I190
sg8
VP04004
p4875
sg10
I11
sg11
Vvitronectin
p4876
sg13
I1
sa(dp4877
g7
I152
sg8
g9
sg10
I3
sg11
VAKT
p4878
sg13
I1
sa(dp4879
g7
I160
sg8
VP29323
p4880
sg10
I3
sg11
VERK
p4881
sg13
I1
sa(dp4882
g7
I53
sg8
VP01116
p4883
sg10
I3
sg11
VRas
p4884
sg13
I1
sasg14
(lp4885
(dp4886
g7
I293
sg17
VC0017638
p4887
sg10
I6
sg11
Vglioma
p4888
sg13
I1
sa(dp4889
g7
I175
sg17
VC0334094
p4890
sg10
I13
sg11
Vproliferation
p4891
sg13
I1
sa(dp4892
g7
I0
sg17
VC0017638
p4893
sg10
I6
sg11
VGlioma
p4894
sg13
I1
sasa(dp4895
g2
S'Most notably, treatment of SF1126 blocked integrin-dependent migration in transwell and scratch assays and caused a significant change in the organization and distribution of cortical actin on vitronectin in the glioma cells.\n'
p4896
sg4
(lp4897
(dp4898
g7
I193
sg8
VP04004
p4899
sg10
I11
sg11
Vvitronectin
p4900
sg13
I1
sasg14
(lp4901
(dp4902
g7
I212
sg17
VC0017638
p4903
sg10
I6
sg11
Vglioma
p4904
sg13
I1
sasa(dp4905
g2
S'The hit compound 5.3d inhibited invasion and migration of both GBM stem cells (Gli7 and Gli4) and GBM cancer cell lines (C6, SNB75) on fibronectin, vitronectin, and laminin.\n'
p4906
sg4
(lp4907
(dp4908
g7
I148
sg8
VP04004
p4909
sg10
I11
sg11
Vvitronectin
p4910
sg13
I1
sa(dp4911
g7
I165
sg8
g9
sg10
I7
sg11
Vlaminin
p4912
sg13
I1
sa(dp4913
g7
I88
sg8
VP10075
p4914
sg10
I4
sg11
VGli4
p4915
sg13
I1
sasg14
(lp4916
(dp4917
g7
I63
sg17
VC0017636
p4918
sg10
I3
sg11
VGBM
p4919
sg13
I1
sa(dp4920
g7
I32
sg17
VC2699153
p4921
sg10
I8
sg11
Vinvasion
p4922
sg13
I1
sa(dp4923
g7
I102
sg17
VC0006826
p4924
sg10
I6
sg11
Vcancer
p4925
sg13
I1
sa(dp4926
g7
I63
sg17
VC0017636
p4927
sg10
I3
sg11
VGBM
p4928
sg13
I1
sasa(dp4929
g2
S'In this study, efficient downregulation of cathepsin B and uPAR by siRNA treatments significantly reduced glioma cell adhesion to laminin as compared to vitronectin, fibronectin, or collagen I in U251 and 4910 glioma cell lines.\n'
p4930
sg4
(lp4931
(dp4932
g7
I130
sg8
g9
sg10
I7
sg11
Vlaminin
p4933
sg13
I1
sa(dp4934
g7
I43
sg8
VP07858
p4935
sg10
I11
sg11
Vcathepsin B
p4936
sg13
I2
sa(dp4937
g7
I153
sg8
VP04004
p4938
sg10
I11
sg11
Vvitronectin
p4939
sg13
I1
sasg14
(lp4940
(dp4941
g7
I106
sg17
VC0017638
p4942
sg10
I6
sg11
Vglioma
p4943
sg13
I1
sa(dp4944
g7
I106
sg17
VC0017638
p4945
sg10
I6
sg11
Vglioma
p4946
sg13
I1
sa(dp4947
g7
I118
sg17
VC0001511
p4948
sg10
I8
sg11
Vadhesion
p4949
sg13
I1
sasa(dp4950
g2
S'Necl-5, a cell surface receptor for vitronectin, is expressed in GBM but not normal brain.\n'
p4951
sg4
(lp4952
(dp4953
g7
I36
sg8
VP04004
p4954
sg10
I11
sg11
Vvitronectin
p4955
sg13
I1
sa(dp4956
g7
I0
sg8
VP15151
p4957
sg10
I6
sg11
VNecl-5
p4958
sg13
I1
sasg14
(lp4959
(dp4960
g7
I65
sg17
VC0017636
p4961
sg10
I3
sg11
VGBM
p4962
sg13
I1
sasa(dp4963
g2
S'These included sudden appearance of tender, erythematous nodular eruptions mimicking ENL, severe constitutional symptoms like high grade fever, malaise, vomiting, epistaxis, joint pain and tenosynovitis simulating Type 2 Lepra Reaction.\n'
p4964
sg4
(lp4965
sg14
(lp4966
(dp4967
g7
I65
sg17
VC0302295
p4968
sg10
I9
sg11
Veruptions
p4969
sg13
I1
sa(dp4970
g7
I174
sg17
VC0003862
p4971
sg10
I10
sg11
Vjoint pain
p4972
sg13
I2
sa(dp4973
g7
I144
sg17
VC0231218
p4974
sg10
I7
sg11
Vmalaise
p4975
sg13
I1
sa(dp4976
g7
I189
sg17
VC0039520
p4977
sg10
I13
sg11
Vtenosynovitis
p4978
sg13
I1
sa(dp4979
g7
I214
sg17
VC0343466
p4980
sg10
I21
sg11
VType 2 Lepra Reaction
p4981
sg13
I4
sa(dp4982
g7
I153
sg17
VC0042963
p4983
sg10
I8
sg11
Vvomiting
p4984
sg13
I1
sa(dp4985
g7
I163
sg17
VC0014591
p4986
sg10
I9
sg11
Vepistaxis
p4987
sg13
I1
sasa(dp4988
g2
S'OGR1 and TRPC4 are prominently expressed in healthy cerebellar tissue throughout postnatal development and in primary cerebellar medulloblastoma tissues.\n'
p4989
sg4
(lp4990
(dp4991
g7
I9
sg8
g9
sg10
I5
sg11
VTRPC4
p4992
sg13
I1
sa(dp4993
g7
I0
sg8
g9
sg10
I4
sg11
VOGR1
p4994
sg13
I1
sasg14
(lp4995
(dp4996
g7
I118
sg17
VC1862179
p4997
sg10
I26
sg11
Vcerebellar medulloblastoma
p4998
sg13
I2
sasa(dp4999
g2
S'Our results suggest that OGR1 enhances expression of TRPC4-containing channels that contribute to enhanced invasion and metastasis of granule precursor-derived human medulloblastoma.\n'
p5000
sg4
(lp5001
(dp5002
g7
I25
sg8
g9
sg10
I4
sg11
VOGR1
p5003
sg13
I1
sa(dp5004
g7
I53
sg8
g9
sg10
I5
sg11
VTRPC4
p5005
sg13
I1
sasg14
(lp5006
(dp5007
g7
I166
sg17
VC0025149
p5008
sg10
I15
sg11
Vmedulloblastoma
p5009
sg13
I1
sa(dp5010
g7
I120
sg17
VC0027627
p5011
sg10
I10
sg11
Vmetastasis
p5012
sg13
I1
sa(dp5013
g7
I107
sg17
VC2699153
p5014
sg10
I8
sg11
Vinvasion
p5015
sg13
I1
sasa(dp5016
g2
S'Here, we report that OGR1 and G2A are expressed in human medulloblastoma tissue and its corresponding neuronal cell line.\n'
p5017
sg4
(lp5018
(dp5019
g7
I30
sg8
g9
sg10
I3
sg11
VG2A
p5020
sg13
I1
sa(dp5021
g7
I21
sg8
g9
sg10
I4
sg11
VOGR1
p5022
sg13
I1
sasg14
(lp5023
(dp5024
g7
I57
sg17
VC0025149
p5025
sg10
I15
sg11
Vmedulloblastoma
p5026
sg13
I1
sasa(dp5027
g2
S'Two daughters of an affected mother demonstrated symptoms of stage III ADNIV, with posterior uveitis, cystoid macular edema, intraocular fibrosis, retinal neovascularization, retinal degeneration, and cataract.\n'
p5028
sg4
(lp5029
sg14
(lp5030
(dp5031
g7
I175
sg17
VC0035304
p5032
sg10
I20
sg11
Vretinal degeneration
p5033
sg13
I2
sa(dp5034
g7
I137
sg17
VC0016059
p5035
sg10
I8
sg11
Vfibrosis
p5036
sg13
I1
sa(dp5037
g7
I201
sg17
VC0086543
p5038
sg10
I8
sg11
Vcataract
p5039
sg13
I1
sa(dp5040
g7
I102
sg17
VC0024440
p5041
sg10
I21
sg11
Vcystoid macular edema
p5042
sg13
I3
sa(dp5043
g7
I83
sg17
VC0042167
p5044
sg10
I17
sg11
Vposterior uveitis
p5045
sg13
I2
sa(dp5046
g7
I155
sg17
VC0035320
p5047
sg10
I27
sg11
Vneovascularization, retinal
p5048
sg13
I2
sasa(dp5049
g2
S'Visual acuity and features of ADNIV, including inflammatory cells, neovascularization, fibrosis, and cystoid macular edema, were reviewed.\n'
p5050
sg4
(lp5051
sg14
(lp5052
(dp5053
g7
I67
sg17
VC0027686
p5054
sg10
I18
sg11
Vneovascularization
p5055
sg13
I1
sa(dp5056
g7
I101
sg17
VC0024440
p5057
sg10
I21
sg11
Vcystoid macular edema
p5058
sg13
I3
sa(dp5059
g7
I87
sg17
VC0016059
p5060
sg10
I8
sg11
Vfibrosis
p5061
sg13
I1
sasa(dp5062
g2
S'Autosomal dominant neovascular inflammatory vitreoretinopathy (ADNIV) is an inherited eye disease characterized by retinal and iris neovascularization, abnormal retinal pigmentation, anterior chamber and vitreous inflammation, cystoid macular edema, vitreous hemorrhage, and traction retinal detachment.\n'
p5063
sg4
(lp5064
sg14
(lp5065
(dp5066
g7
I127
sg17
VC0154916
p5067
sg10
I23
sg11
Viris neovascularization
p5068
sg13
I2
sa(dp5069
g7
I227
sg17
VC0024440
p5070
sg10
I21
sg11
Vcystoid macular edema
p5071
sg13
I3
sa(dp5072
g7
I250
sg17
VC0042909
p5073
sg10
I19
sg11
Vvitreous hemorrhage
p5074
sg13
I2
sa(dp5075
g7
I275
sg17
VC0154828
p5076
sg10
I27
sg11
Vtraction retinal detachment
p5077
sg13
I3
sa(dp5078
g7
I86
sg17
VC0015397
p5079
sg10
I11
sg11
Veye disease
p5080
sg13
I2
sa(dp5081
g7
I213
sg17
VC0021368
p5082
sg10
I12
sg11
Vinflammation
p5083
sg13
I1
sasa(dp5084
g2
S'Common metabolic problems in northeastern Thailand include renal stone disease, distal renal tubular acidosis, hypokalemic periodic paralysis, sudden unexplained nocturnal death and malnutrition-related diabetes mellitus.\n'
p5085
sg4
(lp5086
sg14
(lp5087
(dp5088
g7
I111
sg17
VC0238358
p5089
sg10
I30
sg11
Vhypokalemic periodic paralysis
p5090
sg13
I3
sa(dp5091
g7
I203
sg17
VC0011849
p5092
sg10
I17
sg11
Vdiabetes mellitus
p5093
sg13
I2
sa(dp5094
g7
I80
sg17
VC1704380
p5095
sg10
I29
sg11
Vdistal renal tubular acidosis
p5096
sg13
I4
sa(dp5097
g7
I59
sg17
VC0022650
p5098
sg10
I11
sg11
Vrenal stone
p5099
sg13
I2
sa(dp5100
g7
I182
sg17
VC0162429
p5101
sg10
I12
sg11
Vmalnutrition
p5102
sg13
I1
sasa(dp5103
g2
S'High prevalence of CD in presence of anemia and short stature in seropositive FDR in index study indicates need of targeted screening of this subgroup for the presence of CD.CD is unlikely in the absence of HLADQ2/DQ8.\n'
p5104
sg4
(lp5105
sg14
(lp5106
(dp5107
g7
I48
sg17
VC0013336
p5108
sg10
I13
sg11
Vshort stature
p5109
sg13
I2
sa(dp5110
g7
I37
sg17
VC0002871
p5111
sg10
I6
sg11
Vanemia
p5112
sg13
I1
sasa(dp5113
g2
S'The concurrence of the intracranial multiple primary tumors (MPTs) consisting of acoustic neuroma (AN) and pituitary adenoma is very rare.\n'
p5114
sg4
(lp5115
sg14
(lp5116
(dp5117
g7
I99
sg17
VC0027859
p5118
sg10
I2
sg11
VAN
p5119
sg13
I1
sa(dp5120
g7
I81
sg17
VC0027859
p5121
sg10
I16
sg11
Vacoustic neuroma
p5122
sg13
I2
sa(dp5123
g7
I45
sg17
VC0677930
p5124
sg10
I14
sg11
Vprimary tumors
p5125
sg13
I2
sa(dp5126
g7
I107
sg17
VC0032000
p5127
sg10
I17
sg11
Vpituitary adenoma
p5128
sg13
I2
sasa(dp5129
g2
S'Thirty five cases of MPTs were subdivided into three subtypes, i.e., 1) main duct type, 2) branch duct type and 3) peripheral type (mucinous cystadenoma/cystadenocarcinoma).\n'
p5130
sg4
(lp5131
(dp5132
g7
I21
sg8
g9
sg10
I4
sg11
VMPTs
p5133
sg13
I1
sasg14
(lp5134
(dp5135
g7
I153
sg17
VC0010631
p5136
sg10
I18
sg11
Vcystadenocarcinoma
p5137
sg13
I1
sa(dp5138
g7
I132
sg17
VC0010635
p5139
sg10
I20
sg11
Vmucinous cystadenoma
p5140
sg13
I2
sasa(dp5141
g2
S'Together, these data suggest that IL11 could trigger an ER stress response in the placenta, which may contribute to obstetric complications such as preeclampsia.\n'
p5142
sg4
(lp5143
(dp5144
g7
I34
sg8
VP20809
p5145
sg10
I4
sg11
VIL11
p5146
sg13
I1
sasg14
(lp5147
(dp5148
g7
I148
sg17
VC0032914
p5149
sg10
I12
sg11
Vpreeclampsia
p5150
sg13
I1
sasa(dp5151
g2
S'The relationship between IL-11 and CLS has rarely been reported, especially in patients with colorectal cancer.\n'
p5152
sg4
(lp5153
(dp5154
g7
I25
sg8
VP20809
p5155
sg10
I5
sg11
VIL-11
p5156
sg13
I1
sa(dp5157
g7
I35
sg8
VP51812
p5158
sg10
I3
sg11
VCLS
p5159
sg13
I1
sasg14
(lp5160
(dp5161
g7
I35
sg17
VC0265252
p5162
sg10
I3
sg11
VCLS
p5163
sg13
I1
sa(dp5164
g7
I93
sg17
VC1527249
p5165
sg10
I17
sg11
Vcolorectal cancer
p5166
sg13
I2
sasa(dp5167
g2
S'Although rare, CLS could be a severe side effect after the administration of IL-11.\n'
p5168
sg4
(lp5169
(dp5170
g7
I77
sg8
VP20809
p5171
sg10
I5
sg11
VIL-11
p5172
sg13
I1
sasg14
(lp5173
(dp5174
g7
I15
sg17
VC0265252
p5175
sg10
I3
sg11
VCLS
p5176
sg13
I1
sa(dp5177
g7
I37
sg17
VC0879626
p5178
sg10
I11
sg11
Vside effect
p5179
sg13
I2
sasa(dp5180
g2
S'We describe four cases of the patients with ST-elevation myocardial infarction (STEMI) that were treated with interleukin-11 (IL-11), a cardioprotective cytokine.\n'
p5181
sg4
(lp5182
(dp5183
g7
I110
sg8
VP20809
p5184
sg10
I14
sg11
Vinterleukin-11
p5185
sg13
I1
sa(dp5186
g7
I126
sg8
VP20809
p5187
sg10
I5
sg11
VIL-11
p5188
sg13
I1
sasg14
(lp5189
(dp5190
g7
I80
sg17
VC1536220
p5191
sg10
I5
sg11
VSTEMI
p5192
sg13
I1
sa(dp5193
g7
I44
sg17
VC1536220
p5194
sg10
I34
sg11
VST-elevation myocardial infarction
p5195
sg13
I3
sasa(dp5196
g2
S'The protective role of IL-11, an IL-6 family cytokine, has been implicated in ischemia/reperfusion injury (IRI) in the heart and kidney, but its role has not been elucidated in liver IRI.\n'
p5197
sg4
(lp5198
(dp5199
g7
I33
sg8
VP05231
p5200
sg10
I20
sg11
VIL-6 family cytokine
p5201
sg13
I3
sa(dp5202
g7
I23
sg8
VP20809
p5203
sg10
I5
sg11
VIL-11
p5204
sg13
I1
sasg14
(lp5205
(dp5206
g7
I78
sg17
VC0022116
p5207
sg10
I8
sg11
Vischemia
p5208
sg13
I1
sasa(dp5209
g2
S'Next, IL-11 was injected intraperitoneally (ip) 1 hour before ischemia.\n'
p5210
sg4
(lp5211
(dp5212
g7
I6
sg8
VP20809
p5213
sg10
I5
sg11
VIL-11
p5214
sg13
I1
sasg14
(lp5215
(dp5216
g7
I62
sg17
VC0022116
p5217
sg10
I8
sg11
Vischemia
p5218
sg13
I1
sasa(dp5219
g2
S'Pertussis toxin gene (ptxA-Pr), insertion sequence genes (IS481 and IS1001), adenylate cyclase genes and structural porin and flagellin genes were chosen as targets for PCR, in different studies.\n'
p5220
sg4
(lp5221
(dp5222
g7
I77
sg8
g9
sg10
I17
sg11
Vadenylate cyclase
p5223
sg13
I2
sa(dp5224
g7
I0
sg8
g9
sg10
I20
sg11
VPertussis toxin gene
p5225
sg13
I3
sasg14
(lp5226
(dp5227
g7
I0
sg17
VC0043167
p5228
sg10
I9
sg11
VPertussis
p5229
sg13
I1
sasa(dp5230
g2
S'PCR assays targeting insertion sequence IS481 (IS), pertussis toxin ptxA promoter region (PT), and outer membrane porin (PO), or recA (RA) were evaluated in respiratory specimens collected from 4,442 patients with suspected pertussis.\n'
p5231
sg4
(lp5232
(dp5233
g7
I52
sg8
VP0CE72
p5234
sg10
I67
sg11
Vpertussis toxin ptxA promoter region (PT), and outer membrane porin
p5235
sg13
I10
sa(dp5236
g7
I135
sg8
g9
sg10
I2
sg11
VRA
p5237
sg13
I1
sa(dp5238
g7
I129
sg8
g9
sg10
I4
sg11
VrecA
p5239
sg13
I1
sasg14
(lp5240
(dp5241
g7
I52
sg17
VC0043167
p5242
sg10
I9
sg11
Vpertussis
p5243
sg13
I1
sa(dp5244
g7
I52
sg17
VC0043167
p5245
sg10
I9
sg11
Vpertussis
p5246
sg13
I1
sasa(dp5247
g2
S'In this study, we evaluated the role of miR-135b in colorectal cancer (CRC) and its regulatory role for metastasis suppressor-1 (MTSS1) and its mechanisms.\n'
p5248
sg4
(lp5249
(dp5250
g7
I40
sg8
g9
sg10
I35
sg11
VmiR-135b in colorectal cancer (CRC)
p5251
sg13
I5
sa(dp5252
g7
I129
sg8
g9
sg10
I5
sg11
VMTSS1
p5253
sg13
I1
sa(dp5254
g7
I104
sg8
g9
sg10
I23
sg11
Vmetastasis suppressor-1
p5255
sg13
I2
sasg14
(lp5256
(dp5257
g7
I52
sg17
VC1527249
p5258
sg10
I17
sg11
Vcolorectal cancer
p5259
sg13
I2
sa(dp5260
g7
I71
sg17
VC1527249
p5261
sg10
I3
sg11
VCRC
p5262
sg13
I1
sa(dp5263
g7
I104
sg17
VC0027627
p5264
sg10
I10
sg11
Vmetastasis
p5265
sg13
I1
sasa(dp5266
g2
S'The levels of miR-135b and MTSS1 gene expression in 35 CRC and corresponding cancer-adjacent tissues, 27 colorectal adenoma, and 16 normal tissue samples were quantified using qRT-PCR and western blot analysis.\n'
p5267
sg4
(lp5268
(dp5269
g7
I14
sg8
g9
sg10
I8
sg11
VmiR-135b
p5270
sg13
I1
sa(dp5271
g7
I27
sg8
g9
sg10
I31
sg11
VMTSS1 gene expression in 35 CRC
p5272
sg13
I6
sasg14
(lp5273
(dp5274
g7
I55
sg17
VC1527249
p5275
sg10
I3
sg11
VCRC
p5276
sg13
I1
sa(dp5277
g7
I105
sg17
VC1302401
p5278
sg10
I18
sg11
Vcolorectal adenoma
p5279
sg13
I2
sa(dp5280
g7
I77
sg17
VC0006826
p5281
sg10
I6
sg11
Vcancer
p5282
sg13
I1
sasa(dp5283
g2
S'Jahid and colleagues have shown that miR-23a promotes the transition from indolent to invasive colorectal cancer through inhibition of the MTSS1 tumor suppressor.\n'
p5284
sg4
(lp5285
(dp5286
g7
I139
sg8
g9
sg10
I22
sg11
VMTSS1 tumor suppressor
p5287
sg13
I3
sa(dp5288
g7
I37
sg8
g9
sg10
I7
sg11
VmiR-23a
p5289
sg13
I1
sasg14
(lp5290
(dp5291
g7
I145
sg17
VC0027651
p5292
sg10
I5
sg11
Vtumor
p5293
sg13
I1
sa(dp5294
g7
I95
sg17
VC1527249
p5295
sg10
I17
sg11
Vcolorectal cancer
p5296
sg13
I2
sa(dp5297
g7
I58
sg17
VC0599156
p5298
sg10
I10
sg11
Vtransition
p5299
sg13
I1
sasa(dp5300
g2
S'To investigate the expression of miR-23a and metastasis suppressor 1 (MTSS1) and their clinical significance in colon carcinoma.\n'
p5301
sg4
(lp5302
(dp5303
g7
I33
sg8
g9
sg10
I35
sg11
VmiR-23a and metastasis suppressor 1
p5304
sg13
I5
sa(dp5305
g7
I70
sg8
g9
sg10
I5
sg11
VMTSS1
p5306
sg13
I1
sasg14
(lp5307
(dp5308
g7
I45
sg17
VC0027627
p5309
sg10
I10
sg11
Vmetastasis
p5310
sg13
I1
sa(dp5311
g7
I112
sg17
VC0699790
p5312
sg10
I15
sg11
Vcolon carcinoma
p5313
sg13
I2
sasa(dp5314
g2
S'The expression rates of miR-23a and MTSS1 were 87.0% (80/92) and 17.4% (16/92) in colon carcinoma cases, respectively (P &lt; 0.01).\n'
p5315
sg4
(lp5316
(dp5317
g7
I24
sg8
g9
sg10
I17
sg11
VmiR-23a and MTSS1
p5318
sg13
I3
sasg14
(lp5319
(dp5320
g7
I82
sg17
VC0699790
p5321
sg10
I15
sg11
Vcolon carcinoma
p5322
sg13
I2
sasa(dp5323
g2
S'Both the low expression of MTSS1 and high expression of miR-23a may serve as important biological markers for the malignant phenotypes of colon cancer, such as invasion and metastasis.\n'
p5324
sg4
(lp5325
(dp5326
g7
I56
sg8
g9
sg10
I7
sg11
VmiR-23a
p5327
sg13
I1
sa(dp5328
g7
I27
sg8
g9
sg10
I5
sg11
VMTSS1
p5329
sg13
I1
sasg14
(lp5330
(dp5331
g7
I160
sg17
VC2699153
p5332
sg10
I8
sg11
Vinvasion
p5333
sg13
I1
sa(dp5334
g7
I138
sg17
VC0699790
p5335
sg10
I12
sg11
Vcolon cancer
p5336
sg13
I2
sa(dp5337
g7
I173
sg17
VC0027627
p5338
sg10
I10
sg11
Vmetastasis
p5339
sg13
I1
sasa(dp5340
g2
S'The aims of this study were to investigate metastasis suppressor 1 (MTSS1) expression in benign and malignant colorectal tissues and to explore its significance in the prognosis of colorectal cancer (CRC) patients.\n'
p5341
sg4
(lp5342
sg14
(lp5343
(dp5344
g7
I200
sg17
VC1527249
p5345
sg10
I3
sg11
VCRC
p5346
sg13
I1
sa(dp5347
g7
I43
sg17
VC0027627
p5348
sg10
I10
sg11
Vmetastasis
p5349
sg13
I1
sa(dp5350
g7
I181
sg17
VC1527249
p5351
sg10
I17
sg11
Vcolorectal cancer
p5352
sg13
I2
sasa(dp5353
g2
S'MTSS1 expression was detected by immunohistochemistry in CRC, colorectal adenomatous polyp (precancerous lesion) and normal colorectal tissues.\n'
p5354
sg4
(lp5355
(dp5356
g7
I0
sg8
g9
sg10
I5
sg11
VMTSS1
p5357
sg13
I1
sasg14
(lp5358
(dp5359
g7
I57
sg17
VC1527249
p5360
sg10
I3
sg11
VCRC
p5361
sg13
I1
sa(dp5362
g7
I62
sg17
VC3272805
p5363
sg10
I28
sg11
Vcolorectal adenomatous polyp
p5364
sg13
I3
sasa(dp5365
g2
S'These genes (CACNA1C, COL2A1, CPNE8, C3F, C12ORF4, DDX11, GDF11, HOXC8, KCNA1, MDS028, TMEM106C, NR4A1, PHB2, PRICKLE1, Q6ZUQ4, SCN8A, TUBA8 and USP18) are located on porcine chromosome 5 (SSC5) and represent positional and functional candidates for arthrogryposis multiplex congenita (AMC), which maps to SSC5.\n'
p5366
sg4
(lp5367
(dp5368
g7
I128
sg8
g9
sg10
I5
sg11
VSCN8A
p5369
sg13
I1
sa(dp5370
g7
I58
sg8
g9
sg10
I5
sg11
VGDF11
p5371
sg13
I1
sa(dp5372
g7
I87
sg8
g9
sg10
I8
sg11
VTMEM106C
p5373
sg13
I1
sa(dp5374
g7
I51
sg8
g9
sg10
I5
sg11
VDDX11
p5375
sg13
I1
sa(dp5376
g7
I110
sg8
g9
sg10
I8
sg11
VPRICKLE1
p5377
sg13
I1
sa(dp5378
g7
I37
sg8
g9
sg10
I3
sg11
VC3F
p5379
sg13
I1
sa(dp5380
g7
I104
sg8
g9
sg10
I4
sg11
VPHB2
p5381
sg13
I1
sa(dp5382
g7
I97
sg8
VP22736
p5383
sg10
I5
sg11
VNR4A1
p5384
sg13
I1
sa(dp5385
g7
I65
sg8
VP31273
p5386
sg10
I5
sg11
VHOXC8
p5387
sg13
I1
sa(dp5388
g7
I42
sg8
g9
sg10
I7
sg11
VC12ORF4
p5389
sg13
I1
sa(dp5390
g7
I30
sg8
g9
sg10
I5
sg11
VCPNE8
p5391
sg13
I1
sa(dp5392
g7
I79
sg8
g9
sg10
I6
sg11
VMDS028
p5393
sg13
I1
sa(dp5394
g7
I72
sg8
g9
sg10
I5
sg11
VKCNA1
p5395
sg13
I1
sa(dp5396
g7
I135
sg8
g9
sg10
I5
sg11
VTUBA8
p5397
sg13
I1
sa(dp5398
g7
I145
sg8
g9
sg10
I5
sg11
VUSP18
p5399
sg13
I1
sasg14
(lp5400
(dp5401
g7
I250
sg17
VC2931264
p5402
sg10
I34
sg11
Varthrogryposis multiplex congenita
p5403
sg13
I3
sa(dp5404
g7
I286
sg17
VC2931264
p5405
sg10
I3
sg11
VAMC
p5406
sg13
I1
sasa(dp5407
g2
S'In this study, we tested whether this tolerance is intact in systemic lupus erythematosus-prone (New Zealand Black x SWR)F1 mice (SNF1).\n'
p5408
sg4
(lp5409
sg14
(lp5410
(dp5411
g7
I38
sg17
VC0020963
p5412
sg10
I9
sg11
Vtolerance
p5413
sg13
I1
sa(dp5414
g7
I61
sg17
VC0024141
p5415
sg10
I28
sg11
Vsystemic lupus erythematosus
p5416
sg13
I3
sasa(dp5417
g2
S'The F1 cross between SWR and NZB mice, SNF1, develops severe immune complex glomerulonephritis, in a similar manner to humans with systemic lupus erythematosus (SLE).\n'
p5418
sg4
(lp5419
sg14
(lp5420
(dp5421
g7
I131
sg17
VC0024141
p5422
sg10
I28
sg11
Vsystemic lupus erythematosus
p5423
sg13
I3
sa(dp5424
g7
I61
sg17
VC0744421
p5425
sg10
I33
sg11
Vimmune complex glomerulonephritis
p5426
sg13
I3
sa(dp5427
g7
I161
sg17
VC0024141
p5428
sg10
I3
sg11
VSLE
p5429
sg13
I1
sasa(dp5430
g2
S'Exposure to bone morphogenetic protein (BMP)-4 was found to enhance a TrkAhigh/CD15-/CD184- neuroblastoma cellular subset, accompanied by a reduction in doublecortin-positive neuroblasts and of NMYC protein expression in SH-SY5Y cells.\n'
p5431
sg4
(lp5432
(dp5433
g7
I79
sg8
VP22083
p5434
sg10
I4
sg11
VCD15
p5435
sg13
I1
sa(dp5436
g7
I194
sg8
VP04198
p5437
sg10
I12
sg11
VNMYC protein
p5438
sg13
I2
sa(dp5439
g7
I17
sg8
VP18075
p5440
sg10
I29
sg11
Vmorphogenetic protein (BMP)-4
p5441
sg13
I3
sa(dp5442
g7
I85
sg8
VP61073
p5443
sg10
I5
sg11
VCD184
p5444
sg13
I1
sasg14
(lp5445
(dp5446
g7
I92
sg17
VC0027819
p5447
sg10
I13
sg11
Vneuroblastoma
p5448
sg13
I1
sasa(dp5449
g2
S'In cell-based assays, it is demonstrated that PST3.1a alters the Beta1,6-GlcNAc N-glycans of GBM-initiating cells (GIC) by inhibiting MGAT5 enzymatic activity, resulting in the inhibition of TGFBetaR and FAK signaling associated with doublecortin (DCX) upregulation and increase oligodendrocyte lineage transcription factor 2 (OLIG2) expression.\n'
p5450
sg4
(lp5451
(dp5452
g7
I279
sg8
g9
sg10
I46
sg11
Voligodendrocyte lineage transcription factor 2
p5453
sg13
I5
sa(dp5454
g7
I234
sg8
g9
sg10
I12
sg11
Vdoublecortin
p5455
sg13
I1
sa(dp5456
g7
I327
sg8
g9
sg10
I5
sg11
VOLIG2
p5457
sg13
I1
sa(dp5458
g7
I204
sg8
g9
sg10
I3
sg11
VFAK
p5459
sg13
I1
sa(dp5460
g7
I248
sg8
g9
sg10
I3
sg11
VDCX
p5461
sg13
I1
sa(dp5462
g7
I134
sg8
g9
sg10
I5
sg11
VMGAT5
p5463
sg13
I1
sasg14
(lp5464
(dp5465
g7
I93
sg17
VC0017636
p5466
sg10
I3
sg11
VGBM
p5467
sg13
I1
sasa(dp5468
g2
S'To assess the expression of Toll-like receptor 3 (TLR-3) and TLR-7 in muscle tissue from patients with polymyositis (PM) and dermatomyositis (DM) and to investigate the function and regulation of TLR-3 in cultured muscle cells.\n'
p5469
sg4
(lp5470
(dp5471
g7
I28
sg8
g9
sg10
I20
sg11
VToll-like receptor 3
p5472
sg13
I3
sa(dp5473
g7
I50
sg8
g9
sg10
I5
sg11
VTLR-3
p5474
sg13
I1
sa(dp5475
g7
I61
sg8
g9
sg10
I5
sg11
VTLR-7
p5476
sg13
I1
sa(dp5477
g7
I50
sg8
g9
sg10
I5
sg11
VTLR-3
p5478
sg13
I1
sasg14
(lp5479
(dp5480
g7
I117
sg17
VC0085655
p5481
sg10
I2
sg11
VPM
p5482
sg13
I1
sa(dp5483
g7
I142
sg17
VC0221056
p5484
sg10
I2
sg11
VDM
p5485
sg13
I1
sa(dp5486
g7
I125
sg17
VC0221056
p5487
sg10
I15
sg11
Vdermatomyositis
p5488
sg13
I1
sa(dp5489
g7
I103
sg17
VC0085655
p5490
sg10
I12
sg11
Vpolymyositis
p5491
sg13
I1
sasa(dp5492
g2
S'We analyzed the coding sequences and exon-intron boundaries of GLIALCAM, encoding an IgG-like cell adhesion protein, in 81 individuals with Autism Spectrum Disorders, either with or without comorbid epilepsy, paroxysmal EEG and/or macrocephaly, and the PTEN gene in the subsample with macrocephaly.\n'
p5493
sg4
(lp5494
(dp5495
g7
I253
sg8
VP60484
p5496
sg10
I9
sg11
VPTEN gene
p5497
sg13
I2
sa(dp5498
g7
I63
sg8
g9
sg10
I8
sg11
VGLIALCAM
p5499
sg13
I1
sa(dp5500
g7
I85
sg8
VP01185
p5501
sg10
I30
sg11
VIgG-like cell adhesion protein
p5502
sg13
I4
sasg14
(lp5503
(dp5504
g7
I231
sg17
VC0221355
p5505
sg10
I12
sg11
Vmacrocephaly
p5506
sg13
I1
sa(dp5507
g7
I199
sg17
VC0014544
p5508
sg10
I8
sg11
Vepilepsy
p5509
sg13
I1
sa(dp5510
g7
I231
sg17
VC0221355
p5511
sg10
I12
sg11
Vmacrocephaly
p5512
sg13
I1
sa(dp5513
g7
I99
sg17
VC0001511
p5514
sg10
I8
sg11
Vadhesion
p5515
sg13
I1
sa(dp5516
g7
I140
sg17
VC1510586
p5517
sg10
I25
sg11
VAutism Spectrum Disorders
p5518
sg13
I3
sasa(dp5519
g2
S'Whilst we detected in GLIALCAM several single nucleotide variants without clear pathogenic effects, we found a novel PTEN heterozygous frameshift mutation in one case with "extreme" macrocephaly, autism, intellectual disability and seizures.\n'
p5520
sg4
(lp5521
(dp5522
g7
I117
sg8
VP60484
p5523
sg10
I4
sg11
VPTEN
p5524
sg13
I1
sasg14
(lp5525
(dp5526
g7
I232
sg17
VC0036572
p5527
sg10
I8
sg11
Vseizures
p5528
sg13
I1
sa(dp5529
g7
I182
sg17
VC0221355
p5530
sg10
I12
sg11
Vmacrocephaly
p5531
sg13
I1
sa(dp5532
g7
I135
sg17
VC0079380
p5533
sg10
I19
sg11
Vframeshift mutation
p5534
sg13
I2
sa(dp5535
g7
I196
sg17
VC0004352
p5536
sg10
I6
sg11
Vautism
p5537
sg13
I1
sa(dp5538
g7
I204
sg17
VC0025362
p5539
sg10
I23
sg11
Vintellectual disability
p5540
sg13
I2
sasa(dp5541
g2
S'In other families with dominant HEPACAM mutations, patients had macrocephaly and mental retardation with or without autism.\n'
p5542
sg4
(lp5543
sg14
(lp5544
(dp5545
g7
I64
sg17
VC0221355
p5546
sg10
I12
sg11
Vmacrocephaly
p5547
sg13
I1
sa(dp5548
g7
I81
sg17
VC0025362
p5549
sg10
I18
sg11
Vmental retardation
p5550
sg13
I2
sa(dp5551
g7
I116
sg17
VC0004352
p5552
sg10
I6
sg11
Vautism
p5553
sg13
I1
sasa(dp5554
g2
S'Dominant HEPACAM mutations can cause either macrocephaly and mental retardation with or without autism or benign familial macrocephaly.\n'
p5555
sg4
(lp5556
sg14
(lp5557
(dp5558
g7
I106
sg17
VC0220690
p5559
sg10
I28
sg11
Vbenign familial macrocephaly
p5560
sg13
I3
sa(dp5561
g7
I96
sg17
VC0004352
p5562
sg10
I6
sg11
Vautism
p5563
sg13
I1
sa(dp5564
g7
I61
sg17
VC0025362
p5565
sg10
I18
sg11
Vmental retardation
p5566
sg13
I2
sa(dp5567
g7
I44
sg17
VC0221355
p5568
sg10
I12
sg11
Vmacrocephaly
p5569
sg13
I1
sasa(dp5570
g2
S'B AaHHoe NccneAoBaHNe BownN 59 AeTeN c ANcoyHKmyNeN wyHTNpyhweN cNcTeMbl B Bo3pacTe oT 1 roAa Ao 14 neT, npoxoANBwNx ne4eHNe B OeAepanbHoM myeHTpe HeNpoxNpyprNN (HoBocNbNpcK) c 2014 no 2016 r. KpNTepNN BKnh4eHNR B NccneAoBaHNe: 1) Bo3pacT Ha MoMeHT obcneAoBaHNR cTapwe 1 roAa; 2) NMnnaHTamyNR wyHTNpyhweN cNcTeMbl B nepBble 12 Mec XN3HN.\n'
p5571
sg4
(lp5572
sg14
(lp5573
sa(dp5574
g2
S'Thus, myocyte autonomous inhibition of PKCalpha protects the adult heart from decompensation and dilated cardiomyopathy after infarction injury in association with a primary enhancement in contractility.\n'
p5575
sg4
(lp5576
(dp5577
g7
I39
sg8
VP17252
p5578
sg10
I8
sg11
VPKCalpha
p5579
sg13
I1
sasg14
(lp5580
(dp5581
g7
I97
sg17
VC0007193
p5582
sg10
I22
sg11
Vdilated cardiomyopathy
p5583
sg13
I2
sa(dp5584
g7
I126
sg17
VC0021308
p5585
sg10
I10
sg11
Vinfarction
p5586
sg13
I1
sasa(dp5587
g2
S'Hypercontractility caused by Prkca deletion protects against heart failure induced by pressure overload, and against dilated cardiomyopathy induced by deleting the gene encoding muscle LIM protein (Csrp3).\n'
p5588
sg4
(lp5589
(dp5590
g7
I198
sg8
VP50461
p5591
sg10
I5
sg11
VCsrp3
p5592
sg13
I1
sa(dp5593
g7
I164
sg8
VP50461
p5594
sg10
I32
sg11
Vgene encoding muscle LIM protein
p5595
sg13
I5
sasg14
(lp5596
(dp5597
g7
I61
sg17
VC0018802
p5598
sg10
I13
sg11
Vheart failure
p5599
sg13
I2
sa(dp5600
g7
I117
sg17
VC0007193
p5601
sg10
I22
sg11
Vdilated cardiomyopathy
p5602
sg13
I2
sasa(dp5603
g2
S'Deletion of Prkca also rescues cardiomyopathy associated with overexpression of PP-1.\n'
p5604
sg4
(lp5605
(dp5606
g7
I80
sg8
g9
sg10
I4
sg11
VPP-1
p5607
sg13
I1
sasg14
(lp5608
(dp5609
g7
I31
sg17
VC0878544
p5610
sg10
I14
sg11
Vcardiomyopathy
p5611
sg13
I1
sasa(dp5612
g2
S'PD-L1 staining was detected in 80% of anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma and follicular dendritic cell sarcoma, 75% of nodular lymphocyte predominant Hodgkin lymphoma, 53% of primary mediastinal large B-cell lymphoma, 39% of extranodal NK/T cell lymphoma, 26% of peripheral T-cell lymphoma, 10% of diffuse large B-cell lymphoma and very rare examples of mantle, marginal zone and small lymphocytic lymphomas.\n'
p5613
sg4
(lp5614
sg14
(lp5615
(dp5616
g7
I109
sg17
VC1260325
p5617
sg10
I33
sg11
Vfollicular dendritic cell sarcoma
p5618
sg13
I4
sa(dp5619
g7
I330
sg17
VC0079744
p5620
sg10
I29
sg11
Vdiffuse large B-cell lymphoma
p5621
sg13
I4
sa(dp5622
g7
I271
sg17
VC0079772
p5623
sg10
I15
sg11
VT cell lymphoma
p5624
sg13
I3
sa(dp5625
g7
I295
sg17
VC0079774
p5626
sg10
I26
sg11
Vperipheral T-cell lymphoma
p5627
sg13
I3
sa(dp5628
g7
I207
sg17
VC0855152
p5629
sg10
I41
sg11
Vprimary mediastinal large B-cell lymphoma
p5630
sg13
I5
sa(dp5631
g7
I412
sg17
VC0023434
p5632
sg10
I27
sg11
Vsmall lymphocytic lymphomas
p5633
sg13
I3
sa(dp5634
g7
I151
sg17
VC1334968
p5635
sg10
I47
sg11
Vnodular lymphocyte predominant Hodgkin lymphoma
p5636
sg13
I5
sa(dp5637
g7
I70
sg17
VC0020981
p5638
sg10
I34
sg11
Vangioimmunoblastic T-cell lymphoma
p5639
sg13
I3
sa(dp5640
g7
I38
sg17
VC0206180
p5641
sg10
I30
sg11
Vanaplastic large cell lymphoma
p5642
sg13
I4
sasa(dp5643
g2
S'PD-L1 also showed stronger expression in ALK+ ALCL compared with ALK- ALCL, suggesting an additional role of C/EBPBeta in ALK+ ALCL in generating an immunosuppressive environment.\n'
p5644
sg4
(lp5645
(dp5646
g7
I41
sg8
g9
sg10
I9
sg11
VALK+ ALCL
p5647
sg13
I2
sa(dp5648
g7
I65
sg8
g9
sg10
I9
sg11
VALK- ALCL
p5649
sg13
I2
sasg14
(lp5650
(dp5651
g7
I46
sg17
VC0206180
p5652
sg10
I4
sg11
VALCL
p5653
sg13
I1
sa(dp5654
g7
I46
sg17
VC0206180
p5655
sg10
I4
sg11
VALCL
p5656
sg13
I1
sa(dp5657
g7
I46
sg17
VC0206180
p5658
sg10
I4
sg11
VALCL
p5659
sg13
I1
sasa(dp5660
g2
S'In conclusion, surface antigen expression profiling demonstrates that C/EBPBeta plays a critical role in the activation state of ALK+ ALCL cells and reveals CD147 and PD-L1 as important downstream targets.\n'
p5661
sg4
(lp5662
(dp5663
g7
I157
sg8
VP35613
p5664
sg10
I5
sg11
VCD147
p5665
sg13
I1
sasg14
(lp5666
(dp5667
g7
I134
sg17
VC0206180
p5668
sg10
I4
sg11
VALCL
p5669
sg13
I1
sasa(dp5670
g2
S'Also, the neoplastic cells of classical Hodgkin lymphoma, anaplastic large cell lymphoma, schwannoma, thymoma, and squamous cell carcinoma of various sites frequently expressed PD-L1.\n'
p5671
sg4
(lp5672
sg14
(lp5673
(dp5674
g7
I58
sg17
VC0206180
p5675
sg10
I30
sg11
Vanaplastic large cell lymphoma
p5676
sg13
I4
sa(dp5677
g7
I102
sg17
VC0040100
p5678
sg10
I7
sg11
Vthymoma
p5679
sg13
I1
sa(dp5680
g7
I30
sg17
VC1333064
p5681
sg10
I26
sg11
Vclassical Hodgkin lymphoma
p5682
sg13
I3
sa(dp5683
g7
I115
sg17
VC0007137
p5684
sg10
I23
sg11
Vsquamous cell carcinoma
p5685
sg13
I3
sa(dp5686
g7
I90
sg17
VC0027809
p5687
sg10
I10
sg11
Vschwannoma
p5688
sg13
I1
sasa(dp5689
g2
S'These unique features, which are strictly dependent on NPM-ALK activity and expression, include perpetual cell growth, proliferation, and survival; activation of the key signal transduction pathways STAT3 and mTORC1; and expression of CD30 (the hallmark of anaplastic large-cell lymphoma) and of immunosuppressive cytokine IL-10 and cell-surface protein PD-L1/CD274.\n'
p5690
sg4
(lp5691
(dp5692
g7
I59
sg8
g9
sg10
I3
sg11
VALK
p5693
sg13
I1
sa(dp5694
g7
I360
sg8
g9
sg10
I5
sg11
VCD274
p5695
sg13
I1
sa(dp5696
g7
I55
sg8
g9
sg10
I3
sg11
VNPM
p5697
sg13
I1
sa(dp5698
g7
I235
sg8
VP28908
p5699
sg10
I4
sg11
VCD30
p5700
sg13
I1
sa(dp5701
g7
I199
sg8
VP40763
p5702
sg10
I5
sg11
VSTAT3
p5703
sg13
I1
sasg14
(lp5704
(dp5705
g7
I119
sg17
VC0334094
p5706
sg10
I13
sg11
Vproliferation
p5707
sg13
I1
sa(dp5708
g7
I257
sg17
VC0206180
p5709
sg10
I30
sg11
Vanaplastic large-cell lymphoma
p5710
sg13
I3
sasa(dp5711
g2
S'PD-L1 was expressed uniformly by anaplastic large cell lymphoma (ALCL) cell lines, but rarely in B-cell NHL, confined to a subset of diffuse large B-cell lymphomas (DLBCL) with activated B-cell features (3 of 28 cell lines and 24% of primary DLBCL).\n'
p5712
sg4
(lp5713
sg14
(lp5714
(dp5715
g7
I147
sg17
VC0079731
p5716
sg10
I16
sg11
VB-cell lymphomas
p5717
sg13
I2
sa(dp5718
g7
I104
sg17
VC0024305
p5719
sg10
I3
sg11
VNHL
p5720
sg13
I1
sa(dp5721
g7
I65
sg17
VC0206180
p5722
sg10
I4
sg11
VALCL
p5723
sg13
I1
sa(dp5724
g7
I33
sg17
VC0206180
p5725
sg10
I30
sg11
Vanaplastic large cell lymphoma
p5726
sg13
I4
sasa(dp5727
g2
S'Anti-PD-L1 blocking antibody boosted proliferation and IFN-Gamma secretion by allogeneic T cells responding to ALCL and DLBCL cells.\n'
p5728
sg4
(lp5729
(dp5730
g7
I55
sg8
VP01579
p5731
sg10
I9
sg11
VIFN-Gamma
p5732
sg13
I1
sasg14
(lp5733
(dp5734
g7
I111
sg17
VC0206180
p5735
sg10
I4
sg11
VALCL
p5736
sg13
I1
sa(dp5737
g7
I11
sg17
VC0233660
p5738
sg10
I8
sg11
Vblocking
p5739
sg13
I1
sa(dp5740
g7
I37
sg17
VC0334094
p5741
sg10
I13
sg11
Vproliferation
p5742
sg13
I1
sasa(dp5743
g2
S'In autologous cultures of primary ALCL and DLBCL, PD-L1 blockade enhanced secretion of inflammatory cytokines IFN-Gamma, granulocyte macrophage colony-stimulating factor, interleukin (IL)-1, IL-6, IL-8, IL-13, TNF-Alfa, and macrophage inflammatory protein-1Alfa.\n'
p5744
sg4
(lp5745
(dp5746
g7
I100
sg8
VP01579
p5747
sg10
I19
sg11
Vcytokines IFN-Gamma
p5748
sg13
I2
sa(dp5749
g7
I203
sg8
VP35225
p5750
sg10
I5
sg11
VIL-13
p5751
sg13
I1
sa(dp5752
g7
I210
sg8
VP01375
p5753
sg10
I8
sg11
VTNF-Alfa
p5754
sg13
I1
sa(dp5755
g7
I121
sg8
VP04141
p5756
sg10
I48
sg11
Vgranulocyte macrophage colony-stimulating factor
p5757
sg13
I4
sa(dp5758
g7
I171
sg8
VP60568
p5759
sg10
I18
sg11
Vinterleukin (IL)-1
p5760
sg13
I2
sa(dp5761
g7
I191
sg8
VP05231
p5762
sg10
I4
sg11
VIL-6
p5763
sg13
I1
sasg14
(lp5764
(dp5765
g7
I34
sg17
VC0206180
p5766
sg10
I4
sg11
VALCL
p5767
sg13
I1
sasa(dp5768
g2
S'We examined B7-H1 expression in anaplastic large cell lymphoma (ALCL) and Hodgkin lymphoma (HL) and found that it was constitutively expressed in both clinical samples and cell lines.\n'
p5769
sg4
(lp5770
(dp5771
g7
I12
sg8
g9
sg10
I5
sg11
VB7-H1
p5772
sg13
I1
sasg14
(lp5773
(dp5774
g7
I92
sg17
VC0019829
p5775
sg10
I2
sg11
VHL
p5776
sg13
I1
sa(dp5777
g7
I74
sg17
VC0019829
p5778
sg10
I16
sg11
VHodgkin lymphoma
p5779
sg13
I2
sa(dp5780
g7
I32
sg17
VC0206180
p5781
sg10
I30
sg11
Vanaplastic large cell lymphoma
p5782
sg13
I4
sa(dp5783
g7
I64
sg17
VC0206180
p5784
sg10
I4
sg11
VALCL
p5785
sg13
I1
sasa(dp5786
g2
S'In anaplastic lymphoma kinase-positive (ALK(+)) ALCL cells, B7-H1 expression was suppressed by the blocking of extracellular signal-regulated kinase (ERK) signaling and upregulated by the augmentation of ERK activity by phorbol 13-myristate 12-acetate stimulation, suggesting that B7-H1 expression is regulated by ERK signaling pathway in ALCL.\n'
p5787
sg4
(lp5788
(dp5789
g7
I150
sg8
VP29323
p5790
sg10
I3
sg11
VERK
p5791
sg13
I1
sa(dp5792
g7
I60
sg8
g9
sg10
I5
sg11
VB7-H1
p5793
sg13
I1
sa(dp5794
g7
I111
sg8
VP53779
p5795
sg10
I37
sg11
Vextracellular signal-regulated kinase
p5796
sg13
I3
sa(dp5797
g7
I150
sg8
VP29323
p5798
sg10
I3
sg11
VERK
p5799
sg13
I1
sa(dp5800
g7
I150
sg8
VP29323
p5801
sg10
I3
sg11
VERK
p5802
sg13
I1
sa(dp5803
g7
I60
sg8
g9
sg10
I5
sg11
VB7-H1
p5804
sg13
I1
sasg14
(lp5805
(dp5806
g7
I48
sg17
VC0206180
p5807
sg10
I4
sg11
VALCL
p5808
sg13
I1
sa(dp5809
g7
I99
sg17
VC0233660
p5810
sg10
I8
sg11
Vblocking
p5811
sg13
I1
sa(dp5812
g7
I48
sg17
VC0206180
p5813
sg10
I4
sg11
VALCL
p5814
sg13
I1
sa(dp5815
g7
I3
sg17
VC1321546
p5816
sg10
I19
sg11
Vanaplastic lymphoma
p5817
sg13
I2
sasa(dp5818
g2
S'ERK is one of the downstream mediators of nucleophosmin (NPM)/ALK signaling in ALK(+)ALCL, and pharmacological inhibition of ALK was shown to dephosphorylate ERK and down-regulate B7-H1.\n'
p5819
sg4
(lp5820
(dp5821
g7
I62
sg8
g9
sg10
I3
sg11
VALK
p5822
sg13
I1
sa(dp5823
g7
I62
sg8
g9
sg10
I3
sg11
VALK
p5824
sg13
I1
sa(dp5825
g7
I0
sg8
VP29323
p5826
sg10
I3
sg11
VERK
p5827
sg13
I1
sa(dp5828
g7
I180
sg8
g9
sg10
I5
sg11
VB7-H1
p5829
sg13
I1
sa(dp5830
g7
I0
sg8
VP29323
p5831
sg10
I3
sg11
VERK
p5832
sg13
I1
sasg14
(lp5833
(dp5834
g7
I85
sg17
VC0206180
p5835
sg10
I4
sg11
VALCL
p5836
sg13
I1
sasa(dp5837
g2
S'The involvement of NPM/ALK in B7-H1 expression was also demonstrated by introducing the construct into human non-ALCL lymphoid cell lines, which resulted in B7-H1 expression.\n'
p5838
sg4
(lp5839
(dp5840
g7
I30
sg8
g9
sg10
I5
sg11
VB7-H1
p5841
sg13
I1
sa(dp5842
g7
I30
sg8
g9
sg10
I5
sg11
VB7-H1
p5843
sg13
I1
sa(dp5844
g7
I19
sg8
g9
sg10
I3
sg11
VNPM
p5845
sg13
I1
sa(dp5846
g7
I23
sg8
g9
sg10
I3
sg11
VALK
p5847
sg13
I1
sasg14
(lp5848
(dp5849
g7
I113
sg17
VC0206180
p5850
sg10
I4
sg11
VALCL
p5851
sg13
I1
sasa(dp5852
g2
S'These results suggest that B7-H1 expression is controlled by common ERK signaling pathways in ALCL and HL cells.\n'
p5853
sg4
(lp5854
(dp5855
g7
I68
sg8
VP29323
p5856
sg10
I3
sg11
VERK
p5857
sg13
I1
sa(dp5858
g7
I27
sg8
g9
sg10
I5
sg11
VB7-H1
p5859
sg13
I1
sasg14
(lp5860
(dp5861
g7
I94
sg17
VC0206180
p5862
sg10
I4
sg11
VALCL
p5863
sg13
I1
sasa(dp5864
g2
S"The applicability of clinical genetics in nephrology is due to the fact that many kidney diseases are characterized by genetic mutations (e.g., von-Hippel Lindau syndrome, MYH9 related disorders, Fabry's syndrome, Liddle's and Bartter's Syndrome, and others).\n"
p5865
sg4
(lp5866
(dp5867
g7
I172
sg8
VP35579
p5868
sg10
I4
sg11
VMYH9
p5869
sg13
I1
sasg14
(lp5870
(dp5871
g7
I204
sg17
VC0221043
p5872
sg10
I16
sg11
Vsyndrome, Liddle
p5873
sg13
I2
sa(dp5874
g7
I227
sg17
VC0004775
p5875
sg10
I18
sg11
VBartter's Syndrome
p5876
sg13
I2
sa(dp5877
g7
I82
sg17
VC0022658
p5878
sg10
I15
sg11
Vkidney diseases
p5879
sg13
I2
sa(dp5880
g7
I148
sg17
VC0019562
p5881
sg10
I22
sg11
VHippel Lindau syndrome
p5882
sg13
I3
sasa(dp5883
g2
S'In this study, we tested the hypothesis that a common single nucleotide polymorphism rs16996677 in the MYH9 gene may contribute to the etiology of DN in type 2 diabetes (T2D) in a Taiwanese population with T2D.\n'
p5884
sg4
(lp5885
(dp5886
g7
I103
sg8
VP35579
p5887
sg10
I9
sg11
VMYH9 gene
p5888
sg13
I2
sasg14
(lp5889
(dp5890
g7
I170
sg17
VC0011860
p5891
sg10
I3
sg11
VT2D
p5892
sg13
I1
sa(dp5893
g7
I170
sg17
VC0011860
p5894
sg10
I3
sg11
VT2D
p5895
sg13
I1
sa(dp5896
g7
I153
sg17
VC0011860
p5897
sg10
I15
sg11
Vtype 2 diabetes
p5898
sg13
I3
sasa(dp5899
g2
S'It has been demonstrated that Wnt signaling through the secretion of Wnt inhibitors, such as DKK1, sFRP-2, and sFRP-3, plays a key role in the decreased osteoblast activity associated with multiple myeloma (MM) bone disease.\n'
p5900
sg4
(lp5901
(dp5902
g7
I111
sg8
g9
sg10
I6
sg11
VsFRP-3
p5903
sg13
I1
sa(dp5904
g7
I99
sg8
g9
sg10
I6
sg11
VsFRP-2
p5905
sg13
I1
sa(dp5906
g7
I93
sg8
g9
sg10
I4
sg11
VDKK1
p5907
sg13
I1
sasg14
(lp5908
(dp5909
g7
I211
sg17
VC0005940
p5910
sg10
I12
sg11
Vbone disease
p5911
sg13
I2
sa(dp5912
g7
I189
sg17
VC0026764
p5913
sg10
I16
sg11
Vmultiple myeloma
p5914
sg13
I2
sasa(dp5915
g2
S'The authors studied the methylation status of CDKN2A, CDKN2B, XAF1, CDH13, JUNB and a panel of soluble Wnt inhibitors including WIF1, DKK3, APC, SFRP1, SFRP2, SFRP4 and SFRP5 by methylation-specific PCR in 31 bone marrow and 21 peripheral blood samples of patients with essential thrombocythaemia.\n'
p5916
sg4
(lp5917
(dp5918
g7
I54
sg8
VP42772
p5919
sg10
I6
sg11
VCDKN2B
p5920
sg13
I1
sa(dp5921
g7
I62
sg8
g9
sg10
I4
sg11
VXAF1
p5922
sg13
I1
sa(dp5923
g7
I128
sg8
g9
sg10
I4
sg11
VWIF1
p5924
sg13
I1
sa(dp5925
g7
I134
sg8
g9
sg10
I4
sg11
VDKK3
p5926
sg13
I1
sa(dp5927
g7
I159
sg8
g9
sg10
I5
sg11
VSFRP4
p5928
sg13
I1
sa(dp5929
g7
I169
sg8
g9
sg10
I5
sg11
VSFRP5
p5930
sg13
I1
sa(dp5931
g7
I145
sg8
g9
sg10
I5
sg11
VSFRP1
p5932
sg13
I1
sa(dp5933
g7
I140
sg8
VP25054
p5934
sg10
I3
sg11
VAPC
p5935
sg13
I1
sa(dp5936
g7
I68
sg8
VP55290
p5937
sg10
I5
sg11
VCDH13
p5938
sg13
I1
sa(dp5939
g7
I46
sg8
VP42771
p5940
sg10
I6
sg11
VCDKN2A
p5941
sg13
I1
sa(dp5942
g7
I152
sg8
g9
sg10
I5
sg11
VSFRP2
p5943
sg13
I1
sa(dp5944
g7
I75
sg8
VP17275
p5945
sg10
I4
sg11
VJUNB
p5946
sg13
I1
sasg14
(lp5947
(dp5948
g7
I270
sg17
VC0040028
p5949
sg10
I26
sg11
Vessential thrombocythaemia
p5950
sg13
I2
sa(dp5951
g7
I140
sg17
VC0033036
p5952
sg10
I3
sg11
VAPC
p5953
sg13
I1
sasa(dp5954
g2
S'We studied the activity of Wnt signaling and the methylation status of WIF1, DKK3, APC, SFRP1, SFRP2, SFRP4 and SFRP5 by methylation-specific PCR in myeloma cell lines and primary myeloma samples.\n'
p5955
sg4
(lp5956
(dp5957
g7
I71
sg8
g9
sg10
I4
sg11
VWIF1
p5958
sg13
I1
sa(dp5959
g7
I88
sg8
g9
sg10
I5
sg11
VSFRP1
p5960
sg13
I1
sa(dp5961
g7
I102
sg8
g9
sg10
I5
sg11
VSFRP4
p5962
sg13
I1
sa(dp5963
g7
I77
sg8
g9
sg10
I4
sg11
VDKK3
p5964
sg13
I1
sa(dp5965
g7
I112
sg8
g9
sg10
I5
sg11
VSFRP5
p5966
sg13
I1
sa(dp5967
g7
I95
sg8
g9
sg10
I5
sg11
VSFRP2
p5968
sg13
I1
sa(dp5969
g7
I83
sg8
VP25054
p5970
sg10
I3
sg11
VAPC
p5971
sg13
I1
sasg14
(lp5972
(dp5973
g7
I149
sg17
VC0026764
p5974
sg10
I7
sg11
Vmyeloma
p5975
sg13
I1
sa(dp5976
g7
I149
sg17
VC0026764
p5977
sg10
I7
sg11
Vmyeloma
p5978
sg13
I1
sa(dp5979
g7
I83
sg17
VC0033036
p5980
sg10
I3
sg11
VAPC
p5981
sg13
I1
sasa(dp5982
g2
S'On the other hand, myeloma cells suppress osteoblast function by the secretion of osteoblast inhibiting factors, e.g., the Wnt inhibitors DKK-1 and sFRP-2.\n'
p5983
sg4
(lp5984
(dp5985
g7
I138
sg8
g9
sg10
I5
sg11
VDKK-1
p5986
sg13
I1
sa(dp5987
g7
I148
sg8
g9
sg10
I6
sg11
VsFRP-2
p5988
sg13
I1
sasg14
(lp5989
(dp5990
g7
I19
sg17
VC0026764
p5991
sg10
I7
sg11
Vmyeloma
p5992
sg13
I1
sasa(dp5993
g2
S'Hedgehog signaling is frequently activated in esophageal cancer, gastric cancer and pancreatic cancer due to transcriptional upregulation of Hedgehog ligands and epigenetic silencing of HHIP1/HHIP gene, encoding the Hedgehog inhibitor.\n'
p5994
sg4
(lp5995
(dp5996
g7
I192
sg8
g9
sg10
I9
sg11
VHHIP gene
p5997
sg13
I2
sasg14
(lp5998
(dp5999
g7
I65
sg17
VC0024623
p6000
sg10
I14
sg11
Vgastric cancer
p6001
sg13
I2
sa(dp6002
g7
I84
sg17
VC0235974
p6003
sg10
I17
sg11
Vpancreatic cancer
p6004
sg13
I2
sa(dp6005
g7
I46
sg17
VC0014859
p6006
sg10
I17
sg11
Vesophageal cancer
p6007
sg13
I2
sasa(dp6008
g2
S'Sel-1-like (SEL1L) is a putative tumor suppressor gene that is significantly downregulated in human pancreatic ductal adenocarcinoma (PDA).\n'
p6009
sg4
(lp6010
(dp6011
g7
I0
sg8
g9
sg10
I10
sg11
VSel-1-like
p6012
sg13
I1
sa(dp6013
g7
I12
sg8
g9
sg10
I5
sg11
VSEL1L
p6014
sg13
I1
sasg14
(lp6015
(dp6016
g7
I134
sg17
VC0013274
p6017
sg10
I3
sg11
VPDA
p6018
sg13
I1
sa(dp6019
g7
I33
sg17
VC0027651
p6020
sg10
I5
sg11
Vtumor
p6021
sg13
I1
sa(dp6022
g7
I100
sg17
VC1335302
p6023
sg10
I32
sg11
Vpancreatic ductal adenocarcinoma
p6024
sg13
I3
sasa(dp6025
g2
S'SEL1L is a putative tumor suppressor gene that is frequently down-regulated in pancreatic ductal adenocarcinoma (PDA).\n'
p6026
sg4
(lp6027
(dp6028
g7
I0
sg8
g9
sg10
I5
sg11
VSEL1L
p6029
sg13
I1
sasg14
(lp6030
(dp6031
g7
I20
sg17
VC0027651
p6032
sg10
I5
sg11
Vtumor
p6033
sg13
I1
sa(dp6034
g7
I79
sg17
VC1335302
p6035
sg10
I32
sg11
Vpancreatic ductal adenocarcinoma
p6036
sg13
I3
sa(dp6037
g7
I113
sg17
VC0013274
p6038
sg10
I3
sg11
VPDA
p6039
sg13
I1
sasa(dp6040
g2
S'Using a functional genomic approach, we identified a seven-gene panel (TNC, TFPI, TGFBI, SEL-1L, L1CAM, WWTR1, and CDC42BPA) that was differentially expressed across three different expression platforms, including pancreatic tumor/normal samples.\n'
p6041
sg4
(lp6042
(dp6043
g7
I76
sg8
VP10646
p6044
sg10
I4
sg11
VTFPI
p6045
sg13
I1
sa(dp6046
g7
I97
sg8
VP32004
p6047
sg10
I5
sg11
VL1CAM
p6048
sg13
I1
sa(dp6049
g7
I71
sg8
VP63316
p6050
sg10
I3
sg11
VTNC
p6051
sg13
I1
sa(dp6052
g7
I89
sg8
g9
sg10
I6
sg11
VSEL-1L
p6053
sg13
I1
sa(dp6054
g7
I104
sg8
g9
sg10
I5
sg11
VWWTR1
p6055
sg13
I1
sasg14
(lp6056
(dp6057
g7
I214
sg17
VC0030297
p6058
sg10
I16
sg11
Vpancreatic tumor
p6059
sg13
I2
sasa(dp6060
g2
S'Previously, it was reported that SEL1L is able to decrease the aggressive behavior of human pancreatic tumor cells both in vitro and in vivo.\n'
p6061
sg4
(lp6062
(dp6063
g7
I33
sg8
g9
sg10
I5
sg11
VSEL1L
p6064
sg13
I1
sasg14
(lp6065
(dp6066
g7
I63
sg17
VC0001807
p6067
sg10
I19
sg11
Vaggressive behavior
p6068
sg13
I2
sa(dp6069
g7
I92
sg17
VC0030297
p6070
sg10
I16
sg11
Vpancreatic tumor
p6071
sg13
I2
sasa(dp6072
g2
S'To gain insights into the involvement of SEL1L in tumor invasion, we performed gene expression analysis on the pancreatic cancer cell line Suit-2 subjected to two complementary strategies: upregulation and downregulation of SEL1L expression by stable transfection of the entire cDNA under an inducible promoter and by RNA-mediated interference.\n'
p6073
sg4
(lp6074
(dp6075
g7
I41
sg8
g9
sg10
I5
sg11
VSEL1L
p6076
sg13
I1
sa(dp6077
g7
I41
sg8
g9
sg10
I5
sg11
VSEL1L
p6078
sg13
I1
sasg14
(lp6079
(dp6080
g7
I50
sg17
VC0027651
p6081
sg10
I5
sg11
Vtumor
p6082
sg13
I1
sa(dp6083
g7
I56
sg17
VC2699153
p6084
sg10
I8
sg11
Vinvasion
p6085
sg13
I1
sa(dp6086
g7
I111
sg17
VC0235974
p6087
sg10
I17
sg11
Vpancreatic cancer
p6088
sg13
I2
sasa(dp6089
g2
S'The gene SEL1L is involved both in human breast and pancreatic cancer progression.\n'
p6090
sg4
(lp6091
(dp6092
g7
I4
sg8
g9
sg10
I10
sg11
Vgene SEL1L
p6093
sg13
I2
sasg14
(lp6094
(dp6095
g7
I63
sg17
VC0178874
p6096
sg10
I18
sg11
Vcancer progression
p6097
sg13
I2
sasa(dp6098
g2
S'Recent data suggest that SEL1L may play an important role in pancreatic carcinoma, similar to breast cancer, where the expression of SEL1L has been associated with a reduction in both proliferative activity in vitro and clinical tumor aggressiveness.\n'
p6099
sg4
(lp6100
(dp6101
g7
I25
sg8
g9
sg10
I5
sg11
VSEL1L
p6102
sg13
I1
sa(dp6103
g7
I25
sg8
g9
sg10
I5
sg11
VSEL1L
p6104
sg13
I1
sasg14
(lp6105
(dp6106
g7
I94
sg17
VC0678222
p6107
sg10
I13
sg11
Vbreast cancer
p6108
sg13
I2
sa(dp6109
g7
I229
sg17
VC0027651
p6110
sg10
I5
sg11
Vtumor
p6111
sg13
I1
sa(dp6112
g7
I61
sg17
VC0235974
p6113
sg10
I20
sg11
Vpancreatic carcinoma
p6114
sg13
I2
sa(dp6115
g7
I235
sg17
VC0001807
p6116
sg10
I14
sg11
Vaggressiveness
p6117
sg13
I1
sa(dp6118
g7
I184
sg17
VC0334094
p6119
sg10
I13
sg11
Vproliferative
p6120
sg13
I1
sasa(dp6121
g2
S'To investigate this possibility, we examined the expression of Sel1L in a series of primary pancreatic carcinomas by immunohistochemistry and characterized the effects of Sel1L overexpression both in vitro and in vivo.\n'
p6122
sg4
(lp6123
(dp6124
g7
I63
sg8
g9
sg10
I5
sg11
VSel1L
p6125
sg13
I1
sa(dp6126
g7
I63
sg8
g9
sg10
I5
sg11
VSel1L
p6127
sg13
I1
sasg14
(lp6128
(dp6129
g7
I103
sg17
VC0007097
p6130
sg10
I10
sg11
Vcarcinomas
p6131
sg13
I1
sasa(dp6132
g2
S'In 74 pancreatic cancers analysed, 36% lacked Sel1L expression, although there was no significant correlation between the expression of Sel1L and any clinicopathologic parameter, including survival.\n'
p6133
sg4
(lp6134
(dp6135
g7
I46
sg8
g9
sg10
I5
sg11
VSel1L
p6136
sg13
I1
sa(dp6137
g7
I46
sg8
g9
sg10
I5
sg11
VSel1L
p6138
sg13
I1
sasg14
(lp6139
(dp6140
g7
I6
sg17
VC0346647
p6141
sg10
I18
sg11
Vpancreatic cancers
p6142
sg13
I2
sasa(dp6143
g2
S'Overexpression of SEL1L in stably transfected pancreatic cancer cells caused both a decrease in clonogenicity and anchorage-independent growth as well as a significant increase in the levels of activin A and SMAD4.\n'
p6144
sg4
(lp6145
(dp6146
g7
I208
sg8
g9
sg10
I5
sg11
VSMAD4
p6147
sg13
I1
sa(dp6148
g7
I194
sg8
VP08476
p6149
sg10
I9
sg11
Vactivin A
p6150
sg13
I2
sa(dp6151
g7
I18
sg8
g9
sg10
I5
sg11
VSEL1L
p6152
sg13
I1
sasg14
(lp6153
(dp6154
g7
I46
sg17
VC0235974
p6155
sg10
I17
sg11
Vpancreatic cancer
p6156
sg13
I2
sasa(dp6157
g2
S'Thus, it can be hypothesized that Sel1L plays an important function in the growth and aggressiveness of pancreatic carcinoma.\n'
p6158
sg4
(lp6159
(dp6160
g7
I34
sg8
g9
sg10
I5
sg11
VSel1L
p6161
sg13
I1
sasg14
(lp6162
(dp6163
g7
I86
sg17
VC0001807
p6164
sg10
I14
sg11
Vaggressiveness
p6165
sg13
I1
sa(dp6166
g7
I104
sg17
VC0235974
p6167
sg10
I20
sg11
Vpancreatic carcinoma
p6168
sg13
I2
sasa(dp6169
g2
S'Levels of angiogenic markers bFGF, angiogenin and VEGF in EBC significantly discriminated between 17 individuals with newly detected NSCLC versus stable and exacerbated chronic obstructive pulmonary disease (COPD) patients as well as healthy volunteers.\n'
p6170
sg4
(lp6171
(dp6172
g7
I29
sg8
VP53370
p6173
sg10
I4
sg11
VbFGF
p6174
sg13
I1
sa(dp6175
g7
I35
sg8
VP03950
p6176
sg10
I19
sg11
Vangiogenin and VEGF
p6177
sg13
I3
sasg14
(lp6178
(dp6179
g7
I169
sg17
VC0024117
p6180
sg10
I37
sg11
Vchronic obstructive pulmonary disease
p6181
sg13
I4
sa(dp6182
g7
I208
sg17
VC0024117
p6183
sg10
I4
sg11
VCOPD
p6184
sg13
I1
sa(dp6185
g7
I133
sg17
VC0007131
p6186
sg10
I5
sg11
VNSCLC
p6187
sg13
I1
sasa(dp6188
g2
S'Hereditary amyloidosis of the Finnish type (HAF, or familial amyloid polyneuropathy type IV) is an autosomal dominant disease that has been described most commonly in the Finnish population but has also been found in some other countries.\n'
p6189
sg4
(lp6190
sg14
(lp6191
(dp6192
g7
I0
sg17
VC0206246
p6193
sg10
I22
sg11
VHereditary amyloidosis
p6194
sg13
I2
sa(dp6195
g7
I52
sg17
VC0206245
p6196
sg10
I31
sg11
Vfamilial amyloid polyneuropathy
p6197
sg13
I3
sasa(dp6198
g2
S'Plasma fibrinogen, FII, FV, FVII, FVIII, FIX, FX, FXI and FXII activity levels and C4BP concentrations were determined in 73 patients with non-metastatic colorectal cancer (48 colon and 25 rectum) and in 67 matched control subjects.\n'
p6199
sg4
(lp6200
(dp6201
g7
I34
sg8
VP00451
p6202
sg10
I5
sg11
VFVIII
p6203
sg13
I1
sa(dp6204
g7
I7
sg8
VP22087
p6205
sg10
I10
sg11
Vfibrinogen
p6206
sg13
I1
sa(dp6207
g7
I58
sg8
VP00748
p6208
sg10
I4
sg11
VFXII
p6209
sg13
I1
sa(dp6210
g7
I50
sg8
g9
sg10
I3
sg11
VFXI
p6211
sg13
I1
sa(dp6212
g7
I41
sg8
VP00740
p6213
sg10
I3
sg11
VFIX
p6214
sg13
I1
sa(dp6215
g7
I83
sg8
VP04003
p6216
sg10
I4
sg11
VC4BP
p6217
sg13
I1
sasg14
(lp6218
(dp6219
g7
I143
sg17
VC0948380
p6220
sg10
I28
sg11
Vmetastatic colorectal cancer
p6221
sg13
I3
sasa(dp6222
g2
S'Mean plasma concentrations of fibrinogen (functional and antigen), FVIII, FIX, FV and C4BP were significantly higher in colorectal cancer patients than in control subjects, while FVII and FXII levels were significantly decreased.\n'
p6223
sg4
(lp6224
(dp6225
g7
I86
sg8
VP04003
p6226
sg10
I4
sg11
VC4BP
p6227
sg13
I1
sa(dp6228
g7
I74
sg8
VP00740
p6229
sg10
I3
sg11
VFIX
p6230
sg13
I1
sa(dp6231
g7
I67
sg8
VP00451
p6232
sg10
I5
sg11
VFVIII
p6233
sg13
I1
sa(dp6234
g7
I188
sg8
VP00748
p6235
sg10
I4
sg11
VFXII
p6236
sg13
I1
sa(dp6237
g7
I30
sg8
VP22087
p6238
sg10
I10
sg11
Vfibrinogen
p6239
sg13
I1
sasg14
(lp6240
(dp6241
g7
I120
sg17
VC1527249
p6242
sg10
I17
sg11
Vcolorectal cancer
p6243
sg13
I2
sasa(dp6244
g2
S'In colorectal cancer patients high plasma fibrinogen, FVIII and FIX levels might represent further risk factors for venous thrombotic complications in the immediate post-surgery period, while decreased FVII and FXII concentrations may be an index of intravascular coagulation activation, still in a subclinical phase.\n'
p6245
sg4
(lp6246
(dp6247
g7
I42
sg8
VP00451
p6248
sg10
I25
sg11
Vfibrinogen, FVIII and FIX
p6249
sg13
I4
sa(dp6250
g7
I211
sg8
VP00748
p6251
sg10
I4
sg11
VFXII
p6252
sg13
I1
sasg14
(lp6253
(dp6254
g7
I3
sg17
VC1527249
p6255
sg10
I17
sg11
Vcolorectal cancer
p6256
sg13
I2
sasa(dp6257
g2
S'Complications of PPROM include prematurity, chorioamnionitis, neonatal sepsis, limb position defects, respiratory distress syndrome, pulmonary hypoplasia chronic lung disease, periventricular leukomalacia and intraventricular haemorrhage.A number of different sealing techniques have been employed which aim to restore a physical barrier against infection and encourage the re-accumulation of amniotic fluid.\n'
p6258
sg4
(lp6259
sg14
(lp6260
(dp6261
g7
I62
sg17
VC0456103
p6262
sg10
I15
sg11
Vneonatal sepsis
p6263
sg13
I2
sa(dp6264
g7
I102
sg17
VC0035220
p6265
sg10
I29
sg11
Vrespiratory distress syndrome
p6266
sg13
I3
sa(dp6267
g7
I133
sg17
VC0265783
p6268
sg10
I20
sg11
Vpulmonary hypoplasia
p6269
sg13
I2
sa(dp6270
g7
I209
sg17
VC0240059
p6271
sg10
I28
sg11
Vintraventricular haemorrhage
p6272
sg13
I2
sa(dp6273
g7
I44
sg17
VC0008495
p6274
sg10
I16
sg11
Vchorioamnionitis
p6275
sg13
I1
sa(dp6276
g7
I17
sg17
VC0729264
p6277
sg10
I5
sg11
VPPROM
p6278
sg13
I1
sa(dp6279
g7
I154
sg17
VC0746102
p6280
sg10
I20
sg11
Vchronic lung disease
p6281
sg13
I3
sa(dp6282
g7
I346
sg17
VC0009450
p6283
sg10
I9
sg11
Vinfection
p6284
sg13
I1
sa(dp6285
g7
I176
sg17
VC0023529
p6286
sg10
I28
sg11
Vperiventricular leukomalacia
p6287
sg13
I2
sasa(dp6288
g2
S'NL infants were unexposed to PPROM or maternal hypertension, had highest requirement for surfactant, did not develop IVH and periventricular leukomalacia (PVL) and none of them were Caucasian.\n'
p6289
sg4
(lp6290
sg14
(lp6291
(dp6292
g7
I29
sg17
VC0729264
p6293
sg10
I5
sg11
VPPROM
p6294
sg13
I1
sa(dp6295
g7
I125
sg17
VC0023529
p6296
sg10
I28
sg11
Vperiventricular leukomalacia
p6297
sg13
I2
sa(dp6298
g7
I155
sg17
VC0023529
p6299
sg10
I3
sg11
VPVL
p6300
sg13
I1
sa(dp6301
g7
I38
sg17
VC0565599
p6302
sg10
I21
sg11
Vmaternal hypertension
p6303
sg13
I2
sasa(dp6304
g2
S'Molecular analysis indicated that the livers of BDNF mutants fed HFD contained elevated levels of peroxisome proliferator-activated receptor alpha (Pparalpha or Ppara as listed in the MGI Database) and fibroblast growth factor 21 (Fgf21) transcripts compared with WTs.\n'
p6305
sg4
(lp6306
(dp6307
g7
I48
sg8
g9
sg10
I12
sg11
VBDNF mutants
p6308
sg13
I2
sa(dp6309
g7
I98
sg8
g9
sg10
I48
sg11
Vperoxisome proliferator-activated receptor alpha
p6310
sg13
I4
sa(dp6311
g7
I148
sg8
g9
sg10
I9
sg11
VPparalpha
p6312
sg13
I1
sasg14
(lp6313
(dp6314
g7
I264
sg17
VC1839736
p6315
sg10
I3
sg11
VWTs
p6316
sg13
I1
sasa(dp6317
g2
S'We measured the cerebrospinal fluid (CSF) and plasma concentrations of interleukin (IL)-1Alfa, IL-1Beta, IL-2, IL-4, IL-6, IL-10, tumor necrosis factor (TNF)-Alfa, TNF-Beta, interferon (IFN)-Gamma, the IL-1 receptor antagonist, and soluble IL-4 receptor (sIL-4r) by ELISA in 12 patients each with acute, monosymptomatic, idiopathic optic neuritis (ON), ON as part of MS, other attack forms of MS, and in neurological control subjects.\n'
p6318
sg4
(lp6319
(dp6320
g7
I105
sg8
VP60568
p6321
sg10
I4
sg11
VIL-2
p6322
sg13
I1
sa(dp6323
g7
I95
sg8
VP01584
p6324
sg10
I8
sg11
VIL-1Beta
p6325
sg13
I1
sa(dp6326
g7
I117
sg8
VP05231
p6327
sg10
I4
sg11
VIL-6
p6328
sg13
I1
sa(dp6329
g7
I164
sg8
VP01375
p6330
sg10
I8
sg11
VTNF-Beta
p6331
sg13
I1
sa(dp6332
g7
I153
sg8
VP01375
p6333
sg10
I3
sg11
VTNF
p6334
sg13
I1
sa(dp6335
g7
I111
sg8
VP05112
p6336
sg10
I4
sg11
VIL-4
p6337
sg13
I1
sa(dp6338
g7
I174
sg8
VP01563
p6339
sg10
I10
sg11
Vinterferon
p6340
sg13
I1
sa(dp6341
g7
I255
sg8
VP40967
p6342
sg10
I6
sg11
VsIL-4r
p6343
sg13
I1
sa(dp6344
g7
I232
sg8
VP40967
p6345
sg10
I21
sg11
Vsoluble IL-4 receptor
p6346
sg13
I3
sa(dp6347
g7
I71
sg8
VP60568
p6348
sg10
I22
sg11
Vinterleukin (IL)-1Alfa
p6349
sg13
I2
sa(dp6350
g7
I130
sg8
VP01375
p6351
sg10
I21
sg11
Vtumor necrosis factor
p6352
sg13
I3
sa(dp6353
g7
I186
sg8
VP01562
p6354
sg10
I3
sg11
VIFN
p6355
sg13
I1
sa(dp6356
g7
I202
sg8
g9
sg10
I13
sg11
VIL-1 receptor
p6357
sg13
I2
sasg14
(lp6358
(dp6359
g7
I348
sg17
VC0029134
p6360
sg10
I2
sg11
VON
p6361
sg13
I1
sa(dp6362
g7
I255
sg17
VC0333873
p6363
sg10
I3
sg11
VsIL
p6364
sg13
I1
sa(dp6365
g7
I348
sg17
VC0029134
p6366
sg10
I2
sg11
VON
p6367
sg13
I1
sa(dp6368
g7
I332
sg17
VC0029134
p6369
sg10
I14
sg11
Voptic neuritis
p6370
sg13
I2
sa(dp6371
g7
I130
sg17
VC0333516
p6372
sg10
I14
sg11
Vtumor necrosis
p6373
sg13
I2
sasa(dp6374
g2
S'We have reported previously that ocular infection of different strains of mice with recombinant herpes simplex virus 1 (HSV-1) constitutively expressing interleukin-2 (IL-2) provokes central nervous system (CNS) demyelination and optic neuropathy, as determined by changes in visual evoked cortical potentials and pathological changes in the optic nerve and CNS, whereas recombinant viruses expressing IL-4, gamma interferon, IL-12p35, IL-12p40, or IL-12p70 do not induce this neuropathy.\n'
p6375
sg4
(lp6376
(dp6377
g7
I168
sg8
VP60568
p6378
sg10
I4
sg11
VIL-2
p6379
sg13
I1
sa(dp6380
g7
I153
sg8
VP60568
p6381
sg10
I13
sg11
Vinterleukin-2
p6382
sg13
I1
sa(dp6383
g7
I408
sg8
VP01579
p6384
sg10
I16
sg11
Vgamma interferon
p6385
sg13
I2
sa(dp6386
g7
I402
sg8
VP05112
p6387
sg10
I4
sg11
VIL-4
p6388
sg13
I1
sasg14
(lp6389
(dp6390
g7
I33
sg17
VC0015403
p6391
sg10
I16
sg11
Vocular infection
p6392
sg13
I2
sa(dp6393
g7
I230
sg17
VC0029132
p6394
sg10
I16
sg11
Voptic neuropathy
p6395
sg13
I2
sa(dp6396
g7
I236
sg17
VC0442874
p6397
sg10
I10
sg11
Vneuropathy
p6398
sg13
I1
sa(dp6399
g7
I96
sg17
VC0019348
p6400
sg10
I14
sg11
Vherpes simplex
p6401
sg13
I2
sa(dp6402
g7
I191
sg17
VC0027769
p6403
sg10
I7
sg11
Vnervous
p6404
sg13
I1
sa(dp6405
g7
I212
sg17
VC0011304
p6406
sg10
I13
sg11
Vdemyelination
p6407
sg13
I1
sasa(dp6408
g2
S'The objective of this study was to detect interleukin-17 (IL-17), interferon-gamma (IFN-gamma), interleukin-4 (IL-4) and forkhead/winged helix transcription factor p3 (Foxp3) protein and gene expression of the optic nerve and to further explore the role of T helper cell subsets such as Th1, Th2, Th17 and Treg in the pathogenesis of optic neuritis in experimental autoimmune encephalomyelitis (EAE).\n'
p6409
sg4
(lp6410
(dp6411
g7
I42
sg8
VP60568
p6412
sg10
I14
sg11
Vinterleukin-17
p6413
sg13
I1
sa(dp6414
g7
I121
sg8
g9
sg10
I45
sg11
Vforkhead/winged helix transcription factor p3
p6415
sg13
I5
sa(dp6416
g7
I58
sg8
VP60568
p6417
sg10
I5
sg11
VIL-17
p6418
sg13
I1
sa(dp6419
g7
I168
sg8
g9
sg10
I5
sg11
VFoxp3
p6420
sg13
I1
sa(dp6421
g7
I84
sg8
VP01579
p6422
sg10
I9
sg11
VIFN-gamma
p6423
sg13
I1
sa(dp6424
g7
I96
sg8
VP05112
p6425
sg10
I13
sg11
Vinterleukin-4
p6426
sg13
I1
sa(dp6427
g7
I66
sg8
VP01579
p6428
sg10
I16
sg11
Vinterferon-gamma
p6429
sg13
I1
sa(dp6430
g7
I111
sg8
VP05112
p6431
sg10
I4
sg11
VIL-4
p6432
sg13
I1
sasg14
(lp6433
(dp6434
g7
I334
sg17
VC0029134
p6435
sg10
I14
sg11
Voptic neuritis
p6436
sg13
I2
sa(dp6437
g7
I395
sg17
VC0014070
p6438
sg10
I3
sg11
VEAE
p6439
sg13
I1
sa(dp6440
g7
I318
sg17
VC0699748
p6441
sg10
I12
sg11
Vpathogenesis
p6442
sg13
I1
sa(dp6443
g7
I365
sg17
VC0443146
p6444
sg10
I10
sg11
Vautoimmune
p6445
sg13
I1
sa(dp6446
g7
I376
sg17
VC0014070
p6447
sg10
I17
sg11
Vencephalomyelitis
p6448
sg13
I1
sasa(dp6449
g2
S'In MS and optic neuritis, IL-4 mRNA expressing cells predominated, followed by TGF-beta- and IFN-gamma-positive cells.\n'
p6450
sg4
(lp6451
(dp6452
g7
I26
sg8
VP05112
p6453
sg10
I9
sg11
VIL-4 mRNA
p6454
sg13
I2
sa(dp6455
g7
I93
sg8
VP01579
p6456
sg10
I9
sg11
VIFN-gamma
p6457
sg13
I1
sa(dp6458
g7
I79
sg8
VP18075
p6459
sg10
I8
sg11
VTGF-beta
p6460
sg13
I1
sasg14
(lp6461
(dp6462
g7
I10
sg17
VC0029134
p6463
sg10
I14
sg11
Voptic neuritis
p6464
sg13
I2
sasa(dp6465
g2
S'GKN1, GKN2, and the trefoil factors TFF1 and TFF3 were examined in tissue microarrays from 155 distal gastric adenocarcinomas.\n'
p6466
sg4
(lp6467
(dp6468
g7
I36
sg8
VP04155
p6469
sg10
I4
sg11
VTFF1
p6470
sg13
I1
sa(dp6471
g7
I6
sg8
g9
sg10
I4
sg11
VGKN2
p6472
sg13
I1
sa(dp6473
g7
I20
sg8
VP19883
p6474
sg10
I15
sg11
Vtrefoil factors
p6475
sg13
I2
sa(dp6476
g7
I45
sg8
g9
sg10
I4
sg11
VTFF3
p6477
sg13
I1
sa(dp6478
g7
I0
sg8
g9
sg10
I4
sg11
VGKN1
p6479
sg13
I1
sasg14
(lp6480
(dp6481
g7
I110
sg17
VC0001418
p6482
sg10
I15
sg11
Vadenocarcinomas
p6483
sg13
I1
sasa(dp6484
g2
S'Loss of GKN1 and GKN2 expression occurs frequently in gastric adenocarcinomas, especially in the diffuse subtype.\n'
p6485
sg4
(lp6486
(dp6487
g7
I17
sg8
g9
sg10
I4
sg11
VGKN2
p6488
sg13
I1
sa(dp6489
g7
I8
sg8
g9
sg10
I4
sg11
VGKN1
p6490
sg13
I1
sasg14
(lp6491
(dp6492
g7
I62
sg17
VC0001418
p6493
sg10
I15
sg11
Vadenocarcinomas
p6494
sg13
I1
sasa(dp6495
g2
S'Since RIs significantly correlate with renal function, they have been proposed to be independent risk factors for CKD progression, besides proteinuria, low GFR and arterial hypertension.\n'
p6496
sg4
(lp6497
sg14
(lp6498
(dp6499
g7
I164
sg17
VC0020538
p6500
sg10
I21
sg11
Varterial hypertension
p6501
sg13
I2
sasa(dp6502
g2
S'High uterine artery Doppler resistance indexes (RIs) are predictive of placental complications of pregnancy, such as preeclampsia, fetal growth restriction, and stillbirth.\n'
p6503
sg4
(lp6504
sg14
(lp6505
(dp6506
g7
I117
sg17
VC0032914
p6507
sg10
I12
sg11
Vpreeclampsia
p6508
sg13
I1
sa(dp6509
g7
I131
sg17
VC0015934
p6510
sg10
I24
sg11
Vfetal growth restriction
p6511
sg13
I3
sa(dp6512
g7
I161
sg17
VC0595939
p6513
sg10
I10
sg11
Vstillbirth
p6514
sg13
I1
sa(dp6515
g7
I81
sg17
VC0032962
p6516
sg10
I26
sg11
Vcomplications of pregnancy
p6517
sg13
I3
sasa(dp6518
g2
S'Patients with hypertension or diabetes mellitus showed higher RIs (p &lt; 0.05) than those without the ailments.\n'
p6519
sg4
(lp6520
sg14
(lp6521
(dp6522
g7
I30
sg17
VC0011849
p6523
sg10
I17
sg11
Vdiabetes mellitus
p6524
sg13
I2
sa(dp6525
g7
I14
sg17
VC0020538
p6526
sg10
I12
sg11
Vhypertension
p6527
sg13
I1
sasa(dp6528
g2
S'Myelodysplastic syndrome (MDS) and myeloproliferative disorders are rare in children; they are divided into low-grade MDS (refractory cytopenia of childhood [RCC]), advanced MDS (refractory anemia with excess blasts in transformation), and juvenile myelomonocytic leukemia (JMML), each with different characteristics and management strategies.\n'
p6529
sg4
(lp6530
sg14
(lp6531
(dp6532
g7
I274
sg17
VC0349639
p6533
sg10
I4
sg11
VJMML
p6534
sg13
I1
sa(dp6535
g7
I35
sg17
VC0027022
p6536
sg10
I28
sg11
Vmyeloproliferative disorders
p6537
sg13
I2
sa(dp6538
g7
I123
sg17
VC2826323
p6539
sg10
I33
sg11
Vrefractory cytopenia of childhood
p6540
sg13
I4
sa(dp6541
g7
I26
sg17
VC0265219
p6542
sg10
I3
sg11
VMDS
p6543
sg13
I1
sa(dp6544
g7
I240
sg17
VC0349639
p6545
sg10
I32
sg11
Vjuvenile myelomonocytic leukemia
p6546
sg13
I3
sa(dp6547
g7
I158
sg17
VC0007134
p6548
sg10
I3
sg11
VRCC
p6549
sg13
I1
sa(dp6550
g7
I179
sg17
VC0280028
p6551
sg10
I54
sg11
Vrefractory anemia with excess blasts in transformation
p6552
sg13
I7
sa(dp6553
g7
I0
sg17
VC3463824
p6554
sg10
I24
sg11
VMyelodysplastic syndrome
p6555
sg13
I2
sa(dp6556
g7
I26
sg17
VC0265219
p6557
sg10
I3
sg11
VMDS
p6558
sg13
I1
sa(dp6559
g7
I26
sg17
VC0265219
p6560
sg10
I3
sg11
VMDS
p6561
sg13
I1
sasa(dp6562
g2
S'Thus, genetic ablation or pharmacologic inhibition of Shp2 suppresses the leukemogenic effect of Pten loss, yet simultaneously induces severe anemia in mice with Pten deficiency in blood cells.\n'
p6563
sg4
(lp6564
(dp6565
g7
I97
sg8
VP60484
p6566
sg10
I4
sg11
VPten
p6567
sg13
I1
sa(dp6568
g7
I97
sg8
VP60484
p6569
sg10
I9
sg11
VPten loss
p6570
sg13
I2
sa(dp6571
g7
I54
sg8
g9
sg10
I4
sg11
VShp2
p6572
sg13
I1
sasg14
(lp6573
(dp6574
g7
I97
sg17
VC3272693
p6575
sg10
I9
sg11
VPten loss
p6576
sg13
I2
sa(dp6577
g7
I135
sg17
VC0238644
p6578
sg10
I13
sg11
Vsevere anemia
p6579
sg13
I2
sasa(dp6580
g2
S'Surprisingly, the Shp2 and Pten double-knockout mice suffered lethal anemia, a phenotype that reveals previously unappreciated cooperative roles of Pten and Shp2 in erythropoiesis.\n'
p6581
sg4
(lp6582
(dp6583
g7
I27
sg8
VP60484
p6584
sg10
I4
sg11
VPten
p6585
sg13
I1
sa(dp6586
g7
I18
sg8
g9
sg10
I4
sg11
VShp2
p6587
sg13
I1
sa(dp6588
g7
I148
sg8
VP60484
p6589
sg10
I13
sg11
VPten and Shp2
p6590
sg13
I3
sasg14
(lp6591
(dp6592
g7
I53
sg17
VC0683278
p6593
sg10
I8
sg11
Vsuffered
p6594
sg13
I1
sa(dp6595
g7
I69
sg17
VC0002871
p6596
sg10
I6
sg11
Vanemia
p6597
sg13
I1
sasa(dp6598
g2
S'Consistently, treatment of Pten-deficient mice with a specific Shp2 inhibitor suppressed myeloproliferative neoplasm while causing anemia.\n'
p6599
sg4
(lp6600
(dp6601
g7
I63
sg8
g9
sg10
I4
sg11
VShp2
p6602
sg13
I1
sasg14
(lp6603
(dp6604
g7
I89
sg17
VC1292778
p6605
sg10
I27
sg11
Vmyeloproliferative neoplasm
p6606
sg13
I2
sa(dp6607
g7
I131
sg17
VC0002871
p6608
sg10
I6
sg11
Vanemia
p6609
sg13
I1
sasa(dp6610
g2
S'Infants with non-metabolic disorders (n = 34); 10 (three neuroblastoma [NBL], three brain tumor, two acute meylogenous leukemia [AML], one rhabdomyosarcoma, and one retinoblastoma) received auto HSCT, and 24 (eight hemophagocytic lymphohistiocytosis [HLH], four juvenile meylomonocytic leukemia [JMML], four Wiscott-Aldrych Syndrome [WAS], three acute lymphoblastic leukemia [ALL], two AML, one severe aplastic anemia [SAA], one chronic granulomatous disease [CGD], and one amegakaryocytic thrombocytopenia) received allo HSCT.\n'
p6611
sg4
(lp6612
sg14
(lp6613
(dp6614
g7
I395
sg17
VC1883018
p6615
sg10
I22
sg11
Vsevere aplastic anemia
p6616
sg13
I3
sa(dp6617
g7
I474
sg17
VC0398639
p6618
sg10
I32
sg11
Vamegakaryocytic thrombocytopenia
p6619
sg13
I2
sa(dp6620
g7
I215
sg17
VC0024291
p6621
sg10
I34
sg11
Vhemophagocytic lymphohistiocytosis
p6622
sg13
I2
sa(dp6623
g7
I324
sg17
VC0039082
p6624
sg10
I8
sg11
VSyndrome
p6625
sg13
I1
sa(dp6626
g7
I460
sg17
VC0018203
p6627
sg10
I3
sg11
VCGD
p6628
sg13
I1
sa(dp6629
g7
I129
sg17
VC0023467
p6630
sg10
I3
sg11
VAML
p6631
sg13
I1
sa(dp6632
g7
I346
sg17
VC1961102
p6633
sg10
I28
sg11
Vacute lymphoblastic leukemia
p6634
sg13
I3
sa(dp6635
g7
I139
sg17
VC0035412
p6636
sg10
I16
sg11
Vrhabdomyosarcoma
p6637
sg13
I1
sa(dp6638
g7
I17
sg17
VC0025517
p6639
sg10
I19
sg11
Vmetabolic disorders
p6640
sg13
I2
sa(dp6641
g7
I119
sg17
VC0023418
p6642
sg10
I8
sg11
Vleukemia
p6643
sg13
I1
sa(dp6644
g7
I84
sg17
VC0006118
p6645
sg10
I11
sg11
Vbrain tumor
p6646
sg13
I2
sa(dp6647
g7
I119
sg17
VC0023418
p6648
sg10
I8
sg11
Vleukemia
p6649
sg13
I1
sa(dp6650
g7
I165
sg17
VC0035335
p6651
sg10
I14
sg11
Vretinoblastoma
p6652
sg13
I1
sa(dp6653
g7
I429
sg17
VC0018203
p6654
sg10
I29
sg11
Vchronic granulomatous disease
p6655
sg13
I3
sa(dp6656
g7
I129
sg17
VC0023467
p6657
sg10
I3
sg11
VAML
p6658
sg13
I1
sa(dp6659
g7
I296
sg17
VC0349639
p6660
sg10
I4
sg11
VJMML
p6661
sg13
I1
sa(dp6662
g7
I57
sg17
VC0027819
p6663
sg10
I13
sg11
Vneuroblastoma
p6664
sg13
I1
sa(dp6665
g7
I251
sg17
VC0024291
p6666
sg10
I3
sg11
VHLH
p6667
sg13
I1
sasa(dp6668
g2
S'The human choroideremia-like (CHML) gene and a locus for Usher syndrome type 2 (USH2) were recently mapped to the 1q31-qter region employing physical mapping and genetic linkage studies, respectively.\n'
p6669
sg4
(lp6670
(dp6671
g7
I57
sg8
g9
sg10
I21
sg11
VUsher syndrome type 2
p6672
sg13
I4
sa(dp6673
g7
I80
sg8
g9
sg10
I4
sg11
VUSH2
p6674
sg13
I1
sa(dp6675
g7
I30
sg8
VP26374
p6676
sg10
I4
sg11
VCHML
p6677
sg13
I1
sa(dp6678
g7
I10
sg8
VP26374
p6679
sg10
I18
sg11
Vchoroideremia-like
p6680
sg13
I1
sasg14
(lp6681
(dp6682
g7
I57
sg17
VC0339534
p6683
sg10
I21
sg11
VUsher syndrome type 2
p6684
sg13
I4
sa(dp6685
g7
I80
sg17
VC0339534
p6686
sg10
I4
sg11
VUSH2
p6687
sg13
I1
sa(dp6688
g7
I10
sg17
VC0008525
p6689
sg10
I13
sg11
Vchoroideremia
p6690
sg13
I1
sasa(dp6691
g2
S'To investigate a possible role of the CHML gene in the pathogenesis of USH2, we investigated 10 Dutch and 9 Danish USH2 patients for point mutations in the open reading frame of the CHML gene.\n'
p6692
sg4
(lp6693
(dp6694
g7
I71
sg8
g9
sg10
I4
sg11
VUSH2
p6695
sg13
I1
sa(dp6696
g7
I38
sg8
VP26374
p6697
sg10
I9
sg11
VCHML gene
p6698
sg13
I2
sa(dp6699
g7
I38
sg8
VP26374
p6700
sg10
I9
sg11
VCHML gene
p6701
sg13
I2
sasg14
(lp6702
(dp6703
g7
I55
sg17
VC0699748
p6704
sg10
I12
sg11
Vpathogenesis
p6705
sg13
I1
sasa(dp6706
g2
S'These results suggest that CHML is not involved in the pathogenesis of USH2.\n'
p6707
sg4
(lp6708
(dp6709
g7
I27
sg8
VP26374
p6710
sg10
I4
sg11
VCHML
p6711
sg13
I1
sa(dp6712
g7
I71
sg8
g9
sg10
I4
sg11
VUSH2
p6713
sg13
I1
sasg14
(lp6714
(dp6715
g7
I55
sg17
VC0699748
p6716
sg10
I12
sg11
Vpathogenesis
p6717
sg13
I1
sasa(dp6718
g2
S'We hypothesized that the Hrad17 may be expressed in thymoma, especially in invasive thymoma.\n'
p6719
sg4
(lp6720
(dp6721
g7
I25
sg8
g9
sg10
I6
sg11
VHrad17
p6722
sg13
I1
sasg14
(lp6723
(dp6724
g7
I75
sg17
VC0278846
p6725
sg10
I16
sg11
Vinvasive thymoma
p6726
sg13
I2
sa(dp6727
g7
I52
sg17
VC0040100
p6728
sg10
I7
sg11
Vthymoma
p6729
sg13
I1
sasa(dp6730
g2
S'We attempted to determine the influence of Hrad17 expression on clinicopathological features for patients with thymoma who had undergone surgery.\n'
p6731
sg4
(lp6732
(dp6733
g7
I43
sg8
g9
sg10
I6
sg11
VHrad17
p6734
sg13
I1
sasg14
(lp6735
(dp6736
g7
I111
sg17
VC0040100
p6737
sg10
I7
sg11
Vthymoma
p6738
sg13
I1
sasa(dp6739
g2
S'Expression of Hrad17 messenger ribonucleic acid (RNA) was evaluated by reverse transcription-polymerase chain reaction using a LightCycler in 38 thymomas and 10 adjacent histologically normal thymus samples from patients for whom follow-up data was available.\n'
p6740
sg4
(lp6741
(dp6742
g7
I14
sg8
g9
sg10
I16
sg11
VHrad17 messenger
p6743
sg13
I2
sasg14
(lp6744
(dp6745
g7
I145
sg17
VC0040100
p6746
sg10
I8
sg11
Vthymomas
p6747
sg13
I1
sasa(dp6748
g2
S'No relationship was seen between Hrad17 gene expression and age, gender, or pathological thymoma subtypes.\n'
p6749
sg4
(lp6750
(dp6751
g7
I33
sg8
g9
sg10
I11
sg11
VHrad17 gene
p6752
sg13
I2
sasg14
(lp6753
(dp6754
g7
I89
sg17
VC0040100
p6755
sg10
I7
sg11
Vthymoma
p6756
sg13
I1
sasa(dp6757
g2
S'Hrad17 mRNA expression in invasive thymomas (stage II-IV, 10.067 +/- 5.293) was significantly higher than that in stage I thymomas (5.193 +/- 4.485, p = 0.0168).\n'
p6758
sg4
(lp6759
(dp6760
g7
I0
sg8
g9
sg10
I11
sg11
VHrad17 mRNA
p6761
sg13
I2
sasg14
(lp6762
(dp6763
g7
I35
sg17
VC0040100
p6764
sg10
I8
sg11
Vthymomas
p6765
sg13
I1
sa(dp6766
g7
I35
sg17
VC0040100
p6767
sg10
I8
sg11
Vthymomas
p6768
sg13
I1
sasa(dp6769
g2
S'Immunohistochemistry showed that Hrad17 protein was highly expressed in invasive thymoma tumor tissue but not within the normal thymus tissue.\n'
p6770
sg4
(lp6771
(dp6772
g7
I33
sg8
g9
sg10
I14
sg11
VHrad17 protein
p6773
sg13
I2
sasg14
(lp6774
(dp6775
g7
I72
sg17
VC0278846
p6776
sg10
I16
sg11
Vinvasive thymoma
p6777
sg13
I2
sa(dp6778
g7
I89
sg17
VC0027651
p6779
sg10
I5
sg11
Vtumor
p6780
sg13
I1
sasa(dp6781
g2
S'Hrad17 was highly expressed in invasive thymoma.\n'
p6782
sg4
(lp6783
(dp6784
g7
I0
sg8
g9
sg10
I6
sg11
VHrad17
p6785
sg13
I1
sasg14
(lp6786
(dp6787
g7
I31
sg17
VC0278846
p6788
sg10
I16
sg11
Vinvasive thymoma
p6789
sg13
I2
sasa(dp6790
g2
S'In induced apical periodontitis, osteoblastic expression of SIRT6 was significantly suppressed (P = 0.001) which was associated with significantly elevated levels of LDHA (P = 0.003) and 8-OHdG (P = 0.004) and significantly enhanced recruitment of macrophages (P = 0.004).\n'
p6791
sg4
(lp6792
(dp6793
g7
I166
sg8
VP00338
p6794
sg10
I4
sg11
VLDHA
p6795
sg13
I1
sasg14
(lp6796
(dp6797
g7
I233
sg17
VC0271510
p6798
sg10
I11
sg11
Vrecruitment
p6799
sg13
I1
sa(dp6800
g7
I11
sg17
VC0031030
p6801
sg10
I20
sg11
Vapical periodontitis
p6802
sg13
I2
sasa(dp6803
g2
S'The main objective of this work was to evaluate a new therapeutic strategy against a colitis-related colorectal cancer in vivo and in vitro by targeting mTOR-signaling and lactate dehydrogenase A.\n'
p6804
sg4
(lp6805
(dp6806
g7
I85
sg8
VP31749
p6807
sg10
I33
sg11
Vcolitis-related colorectal cancer
p6808
sg13
I3
sa(dp6809
g7
I153
sg8
VP42345
p6810
sg10
I4
sg11
VmTOR
p6811
sg13
I1
sa(dp6812
g7
I172
sg8
VP49366
p6813
sg10
I23
sg11
Vlactate dehydrogenase A
p6814
sg13
I3
sasg14
(lp6815
(dp6816
g7
I85
sg17
VC0009319
p6817
sg10
I7
sg11
Vcolitis
p6818
sg13
I1
sa(dp6819
g7
I101
sg17
VC1527249
p6820
sg10
I17
sg11
Vcolorectal cancer
p6821
sg13
I2
sasa(dp6822
g2
S'There were striking laboratory abnormalities in the groups diagnosed with toxic hepatitis (mean peak values: AST 775 +/- 464 U/L, ALT 400 +/- 447 U/L, ALP 767 +/- 408 U/L, LDH 1,469 +/- 779 U/L).\n'
p6823
sg4
(lp6824
(dp6825
g7
I172
sg8
g9
sg10
I5
sg11
VLDH 1
p6826
sg13
I2
sasg14
(lp6827
(dp6828
g7
I80
sg17
VC0019159
p6829
sg10
I9
sg11
Vhepatitis
p6830
sg13
I1
sasa(dp6831
g2
S'To determine Lactate Dehydrogenase Activity (LDHA) in whole saliva in individuals with periodontal disease and the effect of ultrasonic scaling on this enzyme activity.\n'
p6832
sg4
(lp6833
(dp6834
g7
I45
sg8
VP00338
p6835
sg10
I4
sg11
VLDHA
p6836
sg13
I1
sa(dp6837
g7
I13
sg8
VP00338
p6838
sg10
I30
sg11
VLactate Dehydrogenase Activity
p6839
sg13
I3
sasg14
(lp6840
(dp6841
g7
I87
sg17
VC0031090
p6842
sg10
I19
sg11
Vperiodontal disease
p6843
sg13
I2
sasa(dp6844
g2
S'LDH-1 activity was detected to be significantly higher in the sterile cirrhotic ascites when compared with spontaneous bacterial peritonitis, malignant ascites, tuberculous ascites and congestive heart failure-related ascites.\n'
p6845
sg4
(lp6846
(dp6847
g7
I0
sg8
g9
sg10
I5
sg11
VLDH-1
p6848
sg13
I1
sasg14
(lp6849
(dp6850
g7
I107
sg17
VC0275551
p6851
sg10
I33
sg11
Vspontaneous bacterial peritonitis
p6852
sg13
I3
sa(dp6853
g7
I62
sg17
VC0678108
p6854
sg10
I7
sg11
Vsterile
p6855
sg13
I1
sa(dp6856
g7
I185
sg17
VC0018802
p6857
sg10
I24
sg11
Vcongestive heart failure
p6858
sg13
I3
sa(dp6859
g7
I142
sg17
VC0220656
p6860
sg10
I17
sg11
Vmalignant ascites
p6861
sg13
I2
sa(dp6862
g7
I161
sg17
VC0275919
p6863
sg10
I19
sg11
Vtuberculous ascites
p6864
sg13
I2
sasa(dp6865
g2
S'Hirudin variants (HV1 and HV2) were produced in infected insect cells as secreted proteins by joining their coding sequences to the leader peptide sequence of the vescicular stomatitis virus G protein.\n'
p6866
sg4
(lp6867
(dp6868
g7
I18
sg8
g9
sg10
I3
sg11
VHV1
p6869
sg13
I1
sa(dp6870
g7
I0
sg8
VP26640
p6871
sg10
I16
sg11
VHirudin variants
p6872
sg13
I2
sasg14
(lp6873
(dp6874
g7
I174
sg17
VC0038362
p6875
sg10
I10
sg11
Vstomatitis
p6876
sg13
I1
sasa(dp6877
g2
S'Macrophage migration inhibitory factor (MIF) is a proinflammatory cytokine involved in systemic, autoimmune, and inflammatory diseases, such as obesity, rheumatoid arthritis, and systemic lupus erythematosus.\n'
p6878
sg4
(lp6879
sg14
(lp6880
(dp6881
g7
I144
sg17
VC0028754
p6882
sg10
I7
sg11
Vobesity
p6883
sg13
I1
sa(dp6884
g7
I97
sg17
VC0443146
p6885
sg10
I10
sg11
Vautoimmune
p6886
sg13
I1
sa(dp6887
g7
I179
sg17
VC0024141
p6888
sg10
I28
sg11
Vsystemic lupus erythematosus
p6889
sg13
I3
sa(dp6890
g7
I153
sg17
VC0003873
p6891
sg10
I20
sg11
Vrheumatoid arthritis
p6892
sg13
I2
sasa(dp6893
g2
S'To systematically review evidence regarding the relationship between circulating macrophage migration inhibitory factor (MIF) levels and rheumatoid arthritis (RA), and the association between MIF gene polymorphisms and RA susceptibility.\n'
p6894
sg4
(lp6895
(dp6896
g7
I192
sg8
VP05109
p6897
sg10
I8
sg11
VMIF gene
p6898
sg13
I2
sasg14
(lp6899
(dp6900
g7
I159
sg17
VC0003873
p6901
sg10
I2
sg11
VRA
p6902
sg13
I1
sa(dp6903
g7
I159
sg17
VC0003873
p6904
sg10
I2
sg11
VRA
p6905
sg13
I1
sa(dp6906
g7
I137
sg17
VC0003873
p6907
sg10
I20
sg11
Vrheumatoid arthritis
p6908
sg13
I2
sasa(dp6909
g2
S'To investigate the role of macrophage migration inhibitory factor (MIF) in the pathogenesis of ankylosing spondylitis (AS).\n'
p6910
sg4
(lp6911
sg14
(lp6912
(dp6913
g7
I95
sg17
VC0038013
p6914
sg10
I22
sg11
Vankylosing spondylitis
p6915
sg13
I2
sa(dp6916
g7
I79
sg17
VC0699748
p6917
sg10
I12
sg11
Vpathogenesis
p6918
sg13
I1
sa(dp6919
g7
I119
sg17
VC0038013
p6920
sg10
I2
sg11
VAS
p6921
sg13
I1
sasa(dp6922
g2
S'Rheumatoid SAAT secreted more adiponectin and macrophage migration inhibitory factor (MIF) than respective osteoarthritis tissue.\n'
p6923
sg4
(lp6924
(dp6925
g7
I86
sg8
VP05109
p6926
sg10
I3
sg11
VMIF
p6927
sg13
I1
sa(dp6928
g7
I30
sg8
g9
sg10
I54
sg11
Vadiponectin and macrophage migration inhibitory factor
p6929
sg13
I6
sasg14
(lp6930
(dp6931
g7
I107
sg17
VC0029408
p6932
sg10
I14
sg11
Vosteoarthritis
p6933
sg13
I1
sasa(dp6934
g2
S'Macrophage migration inhibitory factor (MIF) has emerged as a promising drug target in diseases including sepsis, rheumatoid arthritis, and cancer.\n'
p6935
sg4
(lp6936
sg14
(lp6937
(dp6938
g7
I114
sg17
VC0003873
p6939
sg10
I20
sg11
Vrheumatoid arthritis
p6940
sg13
I2
sa(dp6941
g7
I140
sg17
VC0006826
p6942
sg10
I6
sg11
Vcancer
p6943
sg13
I1
sa(dp6944
g7
I106
sg17
VC0243026
p6945
sg10
I6
sg11
Vsepsis
p6946
sg13
I1
sasa(dp6947
g2
S'Macrophage migration inhibitory factor (MIF) and vascular endothelial growth factor (VEGF), as crucial parameters of angiogenesis and inflammation, were evaluated to identify the role of cyclic citrullinated peptide antibodies (anti-CCP) during angiogenesis in rheumatoid arthritis (RA) and psoriatic arthritis (PsA).\n'
p6948
sg4
(lp6949
(dp6950
g7
I49
sg8
g9
sg10
I34
sg11
Vvascular endothelial growth factor
p6951
sg13
I4
sa(dp6952
g7
I228
sg8
VP07320
p6953
sg10
I8
sg11
Vanti-CCP
p6954
sg13
I1
sa(dp6955
g7
I85
sg8
g9
sg10
I4
sg11
VVEGF
p6956
sg13
I1
sasg14
(lp6957
(dp6958
g7
I261
sg17
VC0003873
p6959
sg10
I20
sg11
Vrheumatoid arthritis
p6960
sg13
I2
sa(dp6961
g7
I134
sg17
VC0021368
p6962
sg10
I12
sg11
Vinflammation
p6963
sg13
I1
sa(dp6964
g7
I283
sg17
VC0003873
p6965
sg10
I2
sg11
VRA
p6966
sg13
I1
sa(dp6967
g7
I312
sg17
VC1519176
p6968
sg10
I3
sg11
VPsA
p6969
sg13
I1
sa(dp6970
g7
I291
sg17
VC0003872
p6971
sg10
I19
sg11
Vpsoriatic arthritis
p6972
sg13
I2
sa(dp6973
g7
I233
sg17
VC1832526
p6974
sg10
I3
sg11
VCCP
p6975
sg13
I1
sasa(dp6976
g2
S'The aim of this study was to search for any difference between the serum levels of OPG, FGF-23, and vitamin D in patients with hypogonadism and the healthy controls.\n'
p6977
sg4
(lp6978
(dp6979
g7
I83
sg8
g9
sg10
I3
sg11
VOPG
p6980
sg13
I1
sa(dp6981
g7
I88
sg8
g9
sg10
I6
sg11
VFGF-23
p6982
sg13
I1
sasg14
(lp6983
(dp6984
g7
I127
sg17
VC0020619
p6985
sg10
I12
sg11
Vhypogonadism
p6986
sg13
I1
sasa(dp6987
g2
S'These include FGF3 in Michel aplasia; FGF8 in cleft lip/palate and in hypogonadotropic hypogonadism; FGF9 in carcinoma; FGF10 in the lacrimal/salivary glands aplasia, and lacrimo-auriculo-dento-digital syndrome; FGF14 in spinocerebellar ataxia; FGF20 in Parkinson disease; and FGF23 in tumoral calcinosis and hypophosphatemic rickets.\n'
p6988
sg4
(lp6989
(dp6990
g7
I120
sg8
g9
sg10
I5
sg11
VFGF10
p6991
sg13
I1
sa(dp6992
g7
I277
sg8
g9
sg10
I5
sg11
VFGF23
p6993
sg13
I1
sa(dp6994
g7
I38
sg8
VP55075
p6995
sg10
I4
sg11
VFGF8
p6996
sg13
I1
sa(dp6997
g7
I212
sg8
g9
sg10
I5
sg11
VFGF14
p6998
sg13
I1
sa(dp6999
g7
I101
sg8
VP31371
p7000
sg10
I4
sg11
VFGF9
p7001
sg13
I1
sa(dp7002
g7
I14
sg8
VP11487
p7003
sg10
I4
sg11
VFGF3
p7004
sg13
I1
sasg14
(lp7005
(dp7006
g7
I254
sg17
VC0030567
p7007
sg10
I17
sg11
VParkinson disease
p7008
sg13
I2
sa(dp7009
g7
I29
sg17
VC0243065
p7010
sg10
I7
sg11
Vaplasia
p7011
sg13
I1
sa(dp7012
g7
I171
sg17
VC0265269
p7013
sg10
I39
sg11
Vlacrimo-auriculo-dento-digital syndrome
p7014
sg13
I2
sa(dp7015
g7
I46
sg17
VC0158646
p7016
sg10
I16
sg11
Vcleft lip/palate
p7017
sg13
I2
sa(dp7018
g7
I309
sg17
VC1704375
p7019
sg10
I24
sg11
Vhypophosphatemic rickets
p7020
sg13
I2
sa(dp7021
g7
I286
sg17
VC0263628
p7022
sg10
I18
sg11
Vtumoral calcinosis
p7023
sg13
I2
sa(dp7024
g7
I109
sg17
VC0007097
p7025
sg10
I9
sg11
Vcarcinoma
p7026
sg13
I1
sa(dp7027
g7
I29
sg17
VC0243065
p7028
sg10
I7
sg11
Vaplasia
p7029
sg13
I1
sa(dp7030
g7
I70
sg17
VC0022735
p7031
sg10
I29
sg11
Vhypogonadotropic hypogonadism
p7032
sg13
I2
sa(dp7033
g7
I221
sg17
VC0087012
p7034
sg10
I22
sg11
Vspinocerebellar ataxia
p7035
sg13
I2
sasa(dp7036
g2
S'Recent studies using genetically modified mice, such as FGF23-/- and Klotho-/- mice that exhibit altered mineral homeostasis due to a high vitamin D activity showed features of premature aging that include retarded growth, osteoporosis, atherosclerosis, ectopic calcification, immunological deficiency, skin and general organ atrophy, hypogonadism and short lifespan.\n'
p7037
sg4
(lp7038
(dp7039
g7
I56
sg8
g9
sg10
I5
sg11
VFGF23
p7040
sg13
I1
sasg14
(lp7041
(dp7042
g7
I326
sg17
VC0333641
p7043
sg10
I7
sg11
Vatrophy
p7044
sg13
I1
sa(dp7045
g7
I335
sg17
VC0020619
p7046
sg10
I12
sg11
Vhypogonadism
p7047
sg13
I1
sa(dp7048
g7
I206
sg17
VC0151686
p7049
sg10
I15
sg11
Vretarded growth
p7050
sg13
I2
sa(dp7051
g7
I223
sg17
VC0029456
p7052
sg10
I12
sg11
Vosteoporosis
p7053
sg13
I1
sa(dp7054
g7
I237
sg17
VC0004153
p7055
sg10
I15
sg11
Vatherosclerosis
p7056
sg13
I1
sa(dp7057
g7
I177
sg17
VC0231341
p7058
sg10
I15
sg11
Vpremature aging
p7059
sg13
I2
sasa(dp7060
g2
S'Moreover, Fgf23(-/-)/klotho(-/-) mice show soft tissue and vascular calcification, severe muscle wasting, hypogonadism, pulmonary emphysema, distention of intestinal wall, and skin atrophy, all of which are also seen in Fgf23(-/-) and klotho(-/-) mice.\n'
p7061
sg4
(lp7062
sg14
(lp7063
(dp7064
g7
I176
sg17
VC0151514
p7065
sg10
I12
sg11
Vskin atrophy
p7066
sg13
I2
sa(dp7067
g7
I141
sg17
VC0012359
p7068
sg10
I10
sg11
Vdistention
p7069
sg13
I1
sa(dp7070
g7
I120
sg17
VC0034067
p7071
sg10
I19
sg11
Vpulmonary emphysema
p7072
sg13
I2
sa(dp7073
g7
I59
sg17
VC0342649
p7074
sg10
I22
sg11
Vvascular calcification
p7075
sg13
I2
sa(dp7076
g7
I90
sg17
VC0026846
p7077
sg10
I14
sg11
Vmuscle wasting
p7078
sg13
I2
sa(dp7079
g7
I106
sg17
VC0020619
p7080
sg10
I12
sg11
Vhypogonadism
p7081
sg13
I1
sasa(dp7082
g2
S'Recent studies using genetically altered mouse models, such as in Fgf-23(-/-) and klotho mutant mice, that exhibit altered mineral ion metabolism due to high vitamin D activities showed features of premature aging that include atherosclerosis, emphysema, osteopenia/osteoporosis, hypogonadism, soft tissue calcifications and generalized atrophy of organs; the pathologic effects of vitamin D in these mouse models are obvious, as diminution or genetic ablation of the vitamin D pathway ameliorated most of the above-mentioned phenotypes, by reversing mineral ion metabolism, and the resultant effect being prolonged survival of the mutant mice.\n'
p7083
sg4
(lp7084
sg14
(lp7085
(dp7086
g7
I89
sg17
VC0596988
p7087
sg10
I6
sg11
Vmutant
p7088
sg13
I1
sa(dp7089
g7
I244
sg17
VC0013990
p7090
sg10
I9
sg11
Vemphysema
p7091
sg13
I1
sa(dp7092
g7
I280
sg17
VC0020619
p7093
sg10
I12
sg11
Vhypogonadism
p7094
sg13
I1
sa(dp7095
g7
I89
sg17
VC0596988
p7096
sg10
I6
sg11
Vmutant
p7097
sg13
I1
sa(dp7098
g7
I255
sg17
VC0262586
p7099
sg10
I23
sg11
Vosteopenia/osteoporosis
p7100
sg13
I1
sa(dp7101
g7
I337
sg17
VC0333641
p7102
sg10
I7
sg11
Vatrophy
p7103
sg13
I1
sa(dp7104
g7
I227
sg17
VC0004153
p7105
sg10
I15
sg11
Vatherosclerosis
p7106
sg13
I1
sa(dp7107
g7
I198
sg17
VC0231341
p7108
sg10
I15
sg11
Vpremature aging
p7109
sg13
I2
sasa(dp7110
g2
S'Clinical, cytogenetic and molecular features of acute myeloid leukemia with a MLL-SEPT5 fusion gene are reviewed.\n'
p7111
sg4
(lp7112
(dp7113
g7
I82
sg8
g9
sg10
I5
sg11
VSEPT5
p7114
sg13
I1
sa(dp7115
g7
I78
sg8
g9
sg10
I3
sg11
VMLL
p7116
sg13
I1
sasg14
(lp7117
(dp7118
g7
I48
sg17
VC0023467
p7119
sg10
I22
sg11
Vacute myeloid leukemia
p7120
sg13
I3
sasa(dp7121
g2
S'The MLL-LCX fusion protein lacked a CXXC domain of LCX, but retained an alpha-helical coiled-coil region at the COOH terminus, similar to MLL-SEPTING, MLL-CDCREL1, MLL-AF1p/Eps15, and MLL-AF6, which suggests that these fusion proteins are involved in the pathogenesis of 11q23-associated leukemia through similar mechanisms.\n'
p7122
sg4
(lp7123
(dp7124
g7
I4
sg8
g9
sg10
I22
sg11
VMLL-LCX fusion protein
p7125
sg13
I3
sa(dp7126
g7
I173
sg8
VP42566
p7127
sg10
I5
sg11
VEps15
p7128
sg13
I1
sa(dp7129
g7
I155
sg8
g9
sg10
I7
sg11
VCDCREL1
p7130
sg13
I1
sa(dp7131
g7
I4
sg8
g9
sg10
I3
sg11
VMLL
p7132
sg13
I1
sa(dp7133
g7
I4
sg8
g9
sg10
I3
sg11
VMLL
p7134
sg13
I1
sa(dp7135
g7
I188
sg8
VP55196
p7136
sg10
I3
sg11
VAF6
p7137
sg13
I1
sa(dp7138
g7
I138
sg8
g9
sg10
I11
sg11
VMLL-SEPTING
p7139
sg13
I1
sa(dp7140
g7
I168
sg8
VP42566
p7141
sg10
I4
sg11
VAF1p
p7142
sg13
I1
sa(dp7143
g7
I4
sg8
g9
sg10
I3
sg11
VMLL
p7144
sg13
I1
sasg14
(lp7145
(dp7146
g7
I255
sg17
VC0699748
p7147
sg10
I12
sg11
Vpathogenesis
p7148
sg13
I1
sa(dp7149
g7
I288
sg17
VC0023418
p7150
sg10
I8
sg11
Vleukemia
p7151
sg13
I1
sasa(dp7152
g2
S'We also investigated TG101348 activity against feeder cells and observed that STAT5 phosphorylation, granulocyte macrophage colony-stimulating factor, and interleukin 6 levels decreased, indicating reduced cytokine production in HS-5 cells treated with TG101348.\n'
p7153
sg4
(lp7154
(dp7155
g7
I155
sg8
VP05231
p7156
sg10
I13
sg11
Vinterleukin 6
p7157
sg13
I2
sa(dp7158
g7
I101
sg8
VP04141
p7159
sg10
I48
sg11
Vgranulocyte macrophage colony-stimulating factor
p7160
sg13
I4
sa(dp7161
g7
I78
sg8
VP42229
p7162
sg10
I5
sg11
VSTAT5
p7163
sg13
I1
sasg14
(lp7164
sa(dp7165
g2
S'In the present study, we examined the impact of cytoplasmic/mitochondrial localization of p33ING1b in oral squamous cell carcinoma (OSCC) patient samples and explored the therapeutic potential of adenovirally-overexpressed p33ING1b in OSCC cell lines in combination with ionizing radiation (IR) treatment.\n'
p7166
sg4
(lp7167
sg14
(lp7168
(dp7169
g7
I102
sg17
VC0007137
p7170
sg10
I28
sg11
Voral squamous cell carcinoma
p7171
sg13
I4
sa(dp7172
g7
I132
sg17
VC0007137
p7173
sg10
I4
sg11
VOSCC
p7174
sg13
I1
sa(dp7175
g7
I132
sg17
VC0007137
p7176
sg10
I4
sg11
VOSCC
p7177
sg13
I1
sasa(dp7178
g2
S'In contrast with previous reports, we found that p33ING1b protein and mRNA levels are higher in OSCC compared to normal epithelial cells.\n'
p7179
sg4
(lp7180
sg14
(lp7181
sa(dp7182
g2
S'In OSCC patient samples, higher levels of intra-tumoral cytoplasmic p33ING1b correlated with increased apoptotic markers and significantly better patient survival.\n'
p7183
sg4
(lp7184
sg14
(lp7185
sa(dp7186
g2
S'IR treatment induced p33ING1b translocation to the mitochondria and adenoviral-p33ING1b synergized with IR to kill OSCC cells.\n'
p7187
sg4
(lp7188
sg14
(lp7189
(dp7190
g7
I30
sg17
VC0040715
p7191
sg10
I13
sg11
Vtranslocation
p7192
sg13
I1
sasa(dp7193
g2
S'Our results identify a novel functional relationship between cytoplasmic p33ING1b and patient survival and highlight the potential for the use of p33ING1b as a therapeutic agent in combination with adjuvant radiotherapy in OSCC.\n'
p7194
sg4
(lp7195
sg14
(lp7196
sa(dp7197
g2
S'Since loss of heterozygosity at 13q34 has been reported in squamous cell carcinoma of head and neck, we screened for mutations in ING1 by polymerase chain reaction-single strand conformation polymorphism in 71 oral squamous cell carcinomas (OSCC) from India, 15 of which were known to harbor p53 mutations.\n'
p7198
sg4
(lp7199
(dp7200
g7
I292
sg8
VP42771
p7201
sg10
I13
sg11
Vp53 mutations
p7202
sg13
I2
sasg14
(lp7203
(dp7204
g7
I215
sg17
VC0007137
p7205
sg10
I24
sg11
Vsquamous cell carcinomas
p7206
sg13
I3
sa(dp7207
g7
I59
sg17
VC1168401
p7208
sg10
I40
sg11
Vsquamous cell carcinoma of head and neck
p7209
sg13
I7
sasa(dp7210
g2
S'These results suggest that ING1 is not a target for mutational inactivation in OSCC of Indians.\n'
p7211
sg4
(lp7212
sg14
(lp7213
(dp7214
g7
I63
sg17
VC0544461
p7215
sg10
I12
sg11
Vinactivation
p7216
sg13
I1
sasa(dp7217
g2
S'The incidence of human T cell lymphotropic virus type 1 (HLTV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) is not well defined in the literature.\n'
p7218
sg4
(lp7219
(dp7220
g7
I117
sg8
g9
sg10
I3
sg11
VHAM
p7221
sg13
I1
sa(dp7222
g7
I121
sg8
VP07996
p7223
sg10
I3
sg11
VTSP
p7224
sg13
I1
sasg14
(lp7225
(dp7226
g7
I76
sg17
VC0037928
p7227
sg10
I10
sg11
Vmyelopathy
p7228
sg13
I1
sa(dp7229
g7
I87
sg17
VC0030481
p7230
sg10
I28
sg11
Vtropical spastic paraparesis
p7231
sg13
I3
sa(dp7232
g7
I117
sg17
VC0030481
p7233
sg10
I3
sg11
VHAM
p7234
sg13
I1
sasa(dp7235
g2
S'Following adult T cell leukemia/lymphoma and HLTV-1-associated myelopathy/tropical spastic paraparesis, HTLV-1 uveitis (HU) has been established as a distinct clinical entity caused by HTLV-1 based on seroepidemiological, clinical, and virological studies.\n'
p7236
sg4
(lp7237
sg14
(lp7238
(dp7239
g7
I10
sg17
VC0023492
p7240
sg10
I21
sg11
Vadult T cell leukemia
p7241
sg13
I4
sa(dp7242
g7
I74
sg17
VC0030481
p7243
sg10
I28
sg11
Vtropical spastic paraparesis
p7244
sg13
I3
sa(dp7245
g7
I32
sg17
VC0024299
p7246
sg10
I8
sg11
Vlymphoma
p7247
sg13
I1
sa(dp7248
g7
I63
sg17
VC0037928
p7249
sg10
I10
sg11
Vmyelopathy
p7250
sg13
I1
sa(dp7251
g7
I111
sg17
VC0042164
p7252
sg10
I7
sg11
Vuveitis
p7253
sg13
I1
sasa(dp7254
g2
S'This is a study of the early identification of a new case of tropical spastic paraparesis/HLTV-1-associated myelopathy in a Spanish patient not previously reported on.\n'
p7255
sg4
(lp7256
sg14
(lp7257
(dp7258
g7
I108
sg17
VC0037928
p7259
sg10
I10
sg11
Vmyelopathy
p7260
sg13
I1
sa(dp7261
g7
I61
sg17
VC0030481
p7262
sg10
I28
sg11
Vtropical spastic paraparesis
p7263
sg13
I3
sasa(dp7264
g2
S'Myxoid liposarcoma (MLS) is a soft tissue sarcoma characterized by a recurrent t(12;16) translocation.\n'
p7265
sg4
(lp7266
sg14
(lp7267
(dp7268
g7
I88
sg17
VC0040715
p7269
sg10
I13
sg11
Vtranslocation
p7270
sg13
I1
sa(dp7271
g7
I0
sg17
VC0206634
p7272
sg10
I18
sg11
VMyxoid liposarcoma
p7273
sg13
I2
sa(dp7274
g7
I20
sg17
VC0796070
p7275
sg10
I3
sg11
VMLS
p7276
sg13
I1
sa(dp7277
g7
I30
sg17
VC1261473
p7278
sg10
I19
sg11
Vsoft tissue sarcoma
p7279
sg13
I3
sasa(dp7280
g2
S'Although myxoid liposarcomas (MLS) are the most common type of soft-tissue sarcomas in adults, their primary location in the superficial tissues is rare.\n'
p7281
sg4
(lp7282
sg14
(lp7283
(dp7284
g7
I20
sg17
VC1261473
p7285
sg10
I8
sg11
Vsarcomas
p7286
sg13
I1
sa(dp7287
g7
I30
sg17
VC0796070
p7288
sg10
I3
sg11
VMLS
p7289
sg13
I1
sa(dp7290
g7
I9
sg17
VC0206634
p7291
sg10
I19
sg11
Vmyxoid liposarcomas
p7292
sg13
I2
sasa(dp7293
g2
S'PRG4 is one of the downstream molecules of the myxoid liposarcoma (MLS)-specific fusion oncoproteins TLS-CHOP and EWS-CHOP.\n'
p7294
sg4
(lp7295
(dp7296
g7
I101
sg8
VP35637
p7297
sg10
I3
sg11
VTLS
p7298
sg13
I1
sa(dp7299
g7
I114
sg8
g9
sg10
I3
sg11
VEWS
p7300
sg13
I1
sa(dp7301
g7
I105
sg8
VP35638
p7302
sg10
I4
sg11
VCHOP
p7303
sg13
I1
sa(dp7304
g7
I0
sg8
g9
sg10
I4
sg11
VPRG4
p7305
sg13
I1
sa(dp7306
g7
I105
sg8
VP35638
p7307
sg10
I4
sg11
VCHOP
p7308
sg13
I1
sasg14
(lp7309
(dp7310
g7
I67
sg17
VC0796070
p7311
sg10
I3
sg11
VMLS
p7312
sg13
I1
sa(dp7313
g7
I47
sg17
VC0206634
p7314
sg10
I18
sg11
Vmyxoid liposarcoma
p7315
sg13
I2
sasa(dp7316
g2
S'The SUV max values of the low-grade thymomas, high-grade thymomas, TCs and MLs were 3.14 +/- 0.73, 4.34 +/- 1.49, 8.59 +/- 3.05, and 10.08 +/- 2.53, respectively, with significant differences between the low- and high-grade thymomas, and between TCs and MLs.\n'
p7317
sg4
(lp7318
sg14
(lp7319
(dp7320
g7
I75
sg17
VC0796070
p7321
sg10
I3
sg11
VMLs
p7322
sg13
I1
sa(dp7323
g7
I36
sg17
VC0040100
p7324
sg10
I8
sg11
Vthymomas
p7325
sg13
I1
sa(dp7326
g7
I75
sg17
VC0796070
p7327
sg10
I3
sg11
VMLs
p7328
sg13
I1
sa(dp7329
g7
I67
sg17
VC0242387
p7330
sg10
I3
sg11
VTCs
p7331
sg13
I1
sa(dp7332
g7
I36
sg17
VC0040100
p7333
sg10
I8
sg11
Vthymomas
p7334
sg13
I1
sa(dp7335
g7
I36
sg17
VC0040100
p7336
sg10
I8
sg11
Vthymomas
p7337
sg13
I1
sa(dp7338
g7
I67
sg17
VC0242387
p7339
sg10
I3
sg11
VTCs
p7340
sg13
I1
sasa(dp7341
g2
S'Of 24 patients with actionable mutations, five were given genotype-matched drugs corresponding to actionable mutations: everolimus to PIK3CA mutation in parotid carcinosarcoma (partial response) and tracheal squamous cell carcinoma (stable disease; 21% reduction), sorafenib to PDGFRA mutation in auditory canal adenocarcinoma (partial response), sorafenib to BRAF mutation in microcytic adnexal carcinoma (progressive disease), and afatinib to ERBB2 mutation in esophageal adenocarcinoma (progressive disease).\n'
p7342
sg4
(lp7343
(dp7344
g7
I134
sg8
VP42336
p7345
sg10
I6
sg11
VPIK3CA
p7346
sg13
I1
sa(dp7347
g7
I360
sg8
VP15056
p7348
sg10
I4
sg11
VBRAF
p7349
sg13
I1
sa(dp7350
g7
I445
sg8
VP04626
p7351
sg10
I5
sg11
VERBB2
p7352
sg13
I1
sa(dp7353
g7
I278
sg8
VP16234
p7354
sg10
I6
sg11
VPDGFRA
p7355
sg13
I1
sasg14
(lp7356
(dp7357
g7
I463
sg17
VC0279628
p7358
sg10
I25
sg11
Vesophageal adenocarcinoma
p7359
sg13
I2
sa(dp7360
g7
I199
sg17
VC0345946
p7361
sg10
I32
sg11
Vtracheal squamous cell carcinoma
p7362
sg13
I4
sa(dp7363
g7
I407
sg17
VC0677932
p7364
sg10
I19
sg11
Vprogressive disease
p7365
sg13
I2
sa(dp7366
g7
I388
sg17
VC0206697
p7367
sg10
I17
sg11
Vadnexal carcinoma
p7368
sg13
I2
sa(dp7369
g7
I407
sg17
VC0677932
p7370
sg10
I19
sg11
Vprogressive disease
p7371
sg13
I2
sa(dp7372
g7
I312
sg17
VC0001418
p7373
sg10
I14
sg11
Vadenocarcinoma
p7374
sg13
I1
sa(dp7375
g7
I161
sg17
VC0007140
p7376
sg10
I14
sg11
Vcarcinosarcoma
p7377
sg13
I1
sasa(dp7378
g2
S'The objective of this study was to determine the efficacy of neratinib in the treatment of HER2 amplified carcinosarcoma.\n'
p7379
sg4
(lp7380
(dp7381
g7
I91
sg8
VP04626
p7382
sg10
I4
sg11
VHER2
p7383
sg13
I1
sasg14
(lp7384
(dp7385
g7
I106
sg17
VC0007140
p7386
sg10
I14
sg11
Vcarcinosarcoma
p7387
sg13
I1
sasa(dp7388
g2
S'The efficacy of neratinib in the treatment of HER2 amplified carcinosarcoma was determined in vitro using seven primary carcinosarcoma cell lines with differential expression of HER2/neu.\n'
p7389
sg4
(lp7390
(dp7391
g7
I183
sg8
VP04626
p7392
sg10
I3
sg11
Vneu
p7393
sg13
I1
sa(dp7394
g7
I46
sg8
VP04626
p7395
sg10
I4
sg11
VHER2
p7396
sg13
I1
sa(dp7397
g7
I46
sg8
VP04626
p7398
sg10
I4
sg11
VHER2
p7399
sg13
I1
sasg14
(lp7400
(dp7401
g7
I61
sg17
VC0007140
p7402
sg10
I14
sg11
Vcarcinosarcoma
p7403
sg13
I1
sa(dp7404
g7
I61
sg17
VC0007140
p7405
sg10
I14
sg11
Vcarcinosarcoma
p7406
sg13
I1
sasa(dp7407
g2
S'The efficacy of neratinib was determined in treating mice harboring HER2 amplified carcinosarcoma xenografts.\n'
p7408
sg4
(lp7409
sg14
(lp7410
(dp7411
g7
I83
sg17
VC0007140
p7412
sg10
I14
sg11
Vcarcinosarcoma
p7413
sg13
I1
sasa(dp7414
g2
S'Two of seven (28.5%) carcinosarcoma cell lines were HER2/neu amplified.\n'
p7415
sg4
(lp7416
(dp7417
g7
I52
sg8
VP04626
p7418
sg10
I4
sg11
VHER2
p7419
sg13
I1
sa(dp7420
g7
I57
sg8
VP04626
p7421
sg10
I3
sg11
Vneu
p7422
sg13
I1
sasg14
(lp7423
(dp7424
g7
I21
sg17
VC0007140
p7425
sg10
I14
sg11
Vcarcinosarcoma
p7426
sg13
I1
sasa(dp7427
g2
S'HER2/neu amplified cell lines SARARK6 and SARARK9 were significantly more sensitive to neratinib than the five non-HER2/neu amplified carcinosarcoma cell lines (mean+/-SEM IC50:0.014myM+/-0.004vs.0.164myM+/-0.019 p=0.0003).\n'
p7428
sg4
(lp7429
(dp7430
g7
I5
sg8
VP04626
p7431
sg10
I3
sg11
Vneu
p7432
sg13
I1
sa(dp7433
g7
I5
sg8
VP04626
p7434
sg10
I3
sg11
Vneu
p7435
sg13
I1
sa(dp7436
g7
I0
sg8
VP04626
p7437
sg10
I4
sg11
VHER2
p7438
sg13
I1
sa(dp7439
g7
I0
sg8
VP04626
p7440
sg10
I4
sg11
VHER2
p7441
sg13
I1
sasg14
(lp7442
(dp7443
g7
I134
sg17
VC0007140
p7444
sg10
I14
sg11
Vcarcinosarcoma
p7445
sg13
I1
sa(dp7446
g7
I168
sg17
VC0432222
p7447
sg10
I3
sg11
VSEM
p7448
sg13
I1
sasa(dp7449
g2
S'Neratinib inhibited tumor growth (p=0.012) and prolonged survival in mice harboring HER2 amplified carcinosarcoma xenografts (p=0.0039).\n'
p7450
sg4
(lp7451
sg14
(lp7452
(dp7453
g7
I20
sg17
VC0598934
p7454
sg10
I12
sg11
Vtumor growth
p7455
sg13
I2
sa(dp7456
g7
I99
sg17
VC0007140
p7457
sg10
I14
sg11
Vcarcinosarcoma
p7458
sg13
I1
sasa(dp7459
g2
S'Neratinib inhibits HER2 amplified carcinosarcoma proliferation, signaling, cell cycle progression and tumor growth in vitro.\n'
p7460
sg4
(lp7461
(dp7462
g7
I19
sg8
VP04626
p7463
sg10
I4
sg11
VHER2
p7464
sg13
I1
sasg14
(lp7465
(dp7466
g7
I49
sg17
VC0334094
p7467
sg10
I13
sg11
Vproliferation
p7468
sg13
I1
sa(dp7469
g7
I34
sg17
VC0007140
p7470
sg10
I14
sg11
Vcarcinosarcoma
p7471
sg13
I1
sa(dp7472
g7
I102
sg17
VC0598934
p7473
sg10
I12
sg11
Vtumor growth
p7474
sg13
I2
sasa(dp7475
g2
S'Numerous correlative scientific investigations have demonstrated that the HER2 (ERBB2) gene is amplified in 17%-33% of carcinosarcoma, uterine serous carcinoma, and a subset of high-grade endometrioid endometrial tumors.\n'
p7476
sg4
(lp7477
(dp7478
g7
I74
sg8
VP04626
p7479
sg10
I4
sg11
VHER2
p7480
sg13
I1
sa(dp7481
g7
I80
sg8
VP04626
p7482
sg10
I5
sg11
VERBB2
p7483
sg13
I1
sasg14
(lp7484
(dp7485
g7
I143
sg17
VC0206701
p7486
sg10
I16
sg11
Vserous carcinoma
p7487
sg13
I2
sa(dp7488
g7
I213
sg17
VC0027651
p7489
sg10
I6
sg11
Vtumors
p7490
sg13
I1
sa(dp7491
g7
I119
sg17
VC0007140
p7492
sg10
I14
sg11
Vcarcinosarcoma
p7493
sg13
I1
sasa(dp7494
g2
S'The analysis of human datasets and GBM tumors revealed higher expression of p65 in GBM-associated CD68+ macrophages compared to neighboring stroma.\n'
p7495
sg4
(lp7496
(dp7497
g7
I76
sg8
VP21579
p7498
sg10
I3
sg11
Vp65
p7499
sg13
I1
sa(dp7500
g7
I83
sg8
g9
sg10
I20
sg11
VGBM-associated CD68+
p7501
sg13
I2
sasg14
(lp7502
(dp7503
g7
I39
sg17
VC0027651
p7504
sg10
I6
sg11
Vtumors
p7505
sg13
I1
sa(dp7506
g7
I35
sg17
VC0017636
p7507
sg10
I3
sg11
VGBM
p7508
sg13
I1
sa(dp7509
g7
I35
sg17
VC0017636
p7510
sg10
I3
sg11
VGBM
p7511
sg13
I1
sasa(dp7512
g2
S'Of paramount importance in the recognition of oligodendroglial and astrocytic tumor cells were the double immunostainings for ATRX/GFAP, ATRX/IDH1R132H, ATRX/Iba-1 and ATRX/CD68.\n'
p7513
sg4
(lp7514
(dp7515
g7
I173
sg8
VP34810
p7516
sg10
I4
sg11
VCD68
p7517
sg13
I1
sasg14
(lp7518
(dp7519
g7
I126
sg17
VC1845055
p7520
sg10
I4
sg11
VATRX
p7521
sg13
I1
sa(dp7522
g7
I126
sg17
VC1845055
p7523
sg10
I4
sg11
VATRX
p7524
sg13
I1
sa(dp7525
g7
I126
sg17
VC1845055
p7526
sg10
I4
sg11
VATRX
p7527
sg13
I1
sa(dp7528
g7
I67
sg17
VC0004114
p7529
sg10
I16
sg11
Vastrocytic tumor
p7530
sg13
I2
sa(dp7531
g7
I126
sg17
VC1845055
p7532
sg10
I4
sg11
VATRX
p7533
sg13
I1
sasa(dp7534
g2
S'Therefore, Dan-gua Fang might be an ideal drug for comprehensive intervention for glucose and lipid metabolism disorders in type 2 diabetes mellitus.\n'
p7535
sg4
(lp7536
(dp7537
g7
I11
sg8
VP41271
p7538
sg10
I12
sg11
VDan-gua Fang
p7539
sg13
I2
sasg14
(lp7540
(dp7541
g7
I124
sg17
VC0011860
p7542
sg10
I24
sg11
Vtype 2 diabetes mellitus
p7543
sg13
I4
sa(dp7544
g7
I94
sg17
VC0154251
p7545
sg10
I26
sg11
Vlipid metabolism disorders
p7546
sg13
I3
sasa(dp7547
g2
S'An electrochemical study of the oxidation of 8-hydroxyguanine (8-OH-Gua) at gold nanoparticles attached to single walled carbon nanotube modified edge plane pyrolytic graphite electrode (AuNP-SWCNT/EPPGE) has been carried out to develop a method for the self diagnosis of diabetes.\n'
p7548
sg4
(lp7549
sg14
(lp7550
(dp7551
g7
I272
sg17
VC0011849
p7552
sg10
I8
sg11
Vdiabetes
p7553
sg13
I1
sasa(dp7554
g2
S'Consequently, Metformin - the biguanide drug of choice orally administered for diabetes type II - is anticipated to see a spike in production.\n'
p7555
sg4
(lp7556
sg14
(lp7557
(dp7558
g7
I79
sg17
VC0011860
p7559
sg10
I16
sg11
Vdiabetes type II
p7560
sg13
I3
sasa(dp7561
g2
S'To study the toxicity features of high glucose on the endothelial cell cycle and the influence of Dan Gua-Fang, a Chinese herbal compound prescription, on the reproductive cycle of vascular endothelial cells cultivated under a high glucose condition; to reveal the partial mechanisms of Dan Gua-Fang in the prevention and treatment of endothelial injury caused by hyperglycemia in diabetes mellitus (DM); and offer a reference for dealing with the vascular complications of DM patients with long-term high blood glucose.\n'
p7562
sg4
(lp7563
(dp7564
g7
I98
sg8
VP41271
p7565
sg10
I7
sg11
VDan Gua
p7566
sg13
I2
sasg14
(lp7567
(dp7568
g7
I240
sg17
VC0012634
p7569
sg10
I9
sg11
Vcondition
p7570
sg13
I1
sa(dp7571
g7
I381
sg17
VC0011849
p7572
sg10
I17
sg11
Vdiabetes mellitus
p7573
sg13
I2
sa(dp7574
g7
I400
sg17
VC0011849
p7575
sg10
I2
sg11
VDM
p7576
sg13
I1
sa(dp7577
g7
I400
sg17
VC0011849
p7578
sg10
I2
sg11
VDM
p7579
sg13
I1
sa(dp7580
g7
I364
sg17
VC0020456
p7581
sg10
I13
sg11
Vhyperglycemia
p7582
sg13
I1
sasa(dp7583
g2
S'To study the effect of anticolchicine cytotoxicity of Dan Gua-Fang, a Chinesea Chinese), a Chinese herbal compound prescription on endothelial cells of vein (ECV304) cultivated in mediums of different glucose concentrations as well as the proliferation of those cells in the same conditions, in order to reveal the value of Dan Gua-Fang in preventing and treating endothelial damage caused by hyperglycemia in diabetes mellitus.\n'
p7584
sg4
(lp7585
(dp7586
g7
I54
sg8
VP41271
p7587
sg10
I12
sg11
VDan Gua-Fang
p7588
sg13
I2
sasg14
(lp7589
(dp7590
g7
I239
sg17
VC0334094
p7591
sg10
I13
sg11
Vproliferation
p7592
sg13
I1
sa(dp7593
g7
I410
sg17
VC0011849
p7594
sg10
I17
sg11
Vdiabetes mellitus
p7595
sg13
I2
sa(dp7596
g7
I38
sg17
VC0596402
p7597
sg10
I12
sg11
Vcytotoxicity
p7598
sg13
I1
sa(dp7599
g7
I393
sg17
VC0020456
p7600
sg10
I13
sg11
Vhyperglycemia
p7601
sg13
I1
sasa(dp7602
g2
S'(1) Dan Gua-Fang at all concentrations reduced the floating cell population of ECV304 cultivated in hyperglycemia mediums.\n'
p7603
sg4
(lp7604
sg14
(lp7605
(dp7606
g7
I100
sg17
VC0020456
p7607
sg10
I13
sg11
Vhyperglycemia
p7608
sg13
I1
sasa(dp7609
g2
S'(2) Dan Gua-Fang at all concentrations and hyperglycemia both had a function of promoting "pseudopod-like" structure formation in cultivated ECV304, but the function was not superimposed in mediums containing both hyperglycemia and Dan Gua-Fang.\n'
p7610
sg4
(lp7611
sg14
(lp7612
(dp7613
g7
I43
sg17
VC0020456
p7614
sg10
I13
sg11
Vhyperglycemia
p7615
sg13
I1
sa(dp7616
g7
I43
sg17
VC0020456
p7617
sg10
I13
sg11
Vhyperglycemia
p7618
sg13
I1
sasa(dp7619
g2
S'(3) Colchicine reduced and even vanished the "pseudopod-like" structure of the endotheliocyte apparently cultivated in mediums of hyperglycemia or with Dan Gua-Fang.\n'
p7620
sg4
(lp7621
sg14
(lp7622
(dp7623
g7
I130
sg17
VC0020456
p7624
sg10
I13
sg11
Vhyperglycemia
p7625
sg13
I1
sasa(dp7626
g2
S'The "pseudopod-like" structure of the endotheliocyte emerged quickly in Dan Gua-Fang groups after colchicine was removed, but it was not the case in hyperglycemia only without Dan Gua-Fang groups.\n'
p7627
sg4
(lp7628
sg14
(lp7629
(dp7630
g7
I149
sg17
VC0020456
p7631
sg10
I13
sg11
Vhyperglycemia
p7632
sg13
I1
sasa(dp7633
g2
S'The spinodal point concentration of statistical significance of hyperglycemia cytotoxicity is 22.2 mmol/l; 1/300 Dan Gua can reverse the endothelia cytotoxicity in different concentrations of hyperglycemia.\n'
p7634
sg4
(lp7635
sg14
(lp7636
(dp7637
g7
I78
sg17
VC0596402
p7638
sg10
I12
sg11
Vcytotoxicity
p7639
sg13
I1
sa(dp7640
g7
I64
sg17
VC0020456
p7641
sg10
I13
sg11
Vhyperglycemia
p7642
sg13
I1
sa(dp7643
g7
I78
sg17
VC0596402
p7644
sg10
I12
sg11
Vcytotoxicity
p7645
sg13
I1
sa(dp7646
g7
I64
sg17
VC0020456
p7647
sg10
I13
sg11
Vhyperglycemia
p7648
sg13
I1
sasa(dp7649
g2
S'Patients with resected stage III colon cancer who were 18 years of age or older, with an Eastern Cooperative Oncology Group performance status of 0 or 1, from four randomised controlled trials (NSABP C-08, XELOXA, X-ACT, and AVANT; 8734 patients in total) were pooled and analysed.\n'
p7650
sg4
(lp7651
sg14
(lp7652
(dp7653
g7
I23
sg17
VC3146254
p7654
sg10
I22
sg11
Vstage III colon cancer
p7655
sg13
I4
sasa(dp7656
g2
S'Based on the results of the X-ACT study, capecitabine has become one of the standard postoperative adjuvant chemotherapies for colon cancer.\n'
p7657
sg4
(lp7658
sg14
(lp7659
(dp7660
g7
I127
sg17
VC0699790
p7661
sg10
I12
sg11
Vcolon cancer
p7662
sg13
I2
sasa(dp7663
g2
S'In the adjuvant setting, the Xeloda in Adjuvant Colon Cancer Therapy (X-ACT) trial demonstrated that capecitabine as a single agent led to improvement in relapse-free survival (hazard ratio: 0.86, 95% confidence interval: 0.74-0.99, P = 0.04) and was associated with significantly fewer adverse events than 5-FU plus leucovorin (LV, folinic acid).\n'
p7664
sg4
(lp7665
sg14
(lp7666
(dp7667
g7
I48
sg17
VC0699790
p7668
sg10
I12
sg11
VColon Cancer
p7669
sg13
I2
sa(dp7670
g7
I154
sg17
VC0277556
p7671
sg10
I7
sg11
Vrelapse
p7672
sg13
I1
sasa(dp7673
g2
S'On the basis of the X-ACT trial, capecitabine was approved by the United States Food and Drug Administration, the National Institute for Clinical Excellence, and the Scottish Medicines Consortium as monotherapy for the adjuvant treatment of stage III colon cancer.\n'
p7674
sg4
(lp7675
sg14
(lp7676
(dp7677
g7
I241
sg17
VC3146254
p7678
sg10
I22
sg11
Vstage III colon cancer
p7679
sg13
I4
sasa(dp7680
g2
S'The Xeloda in Adjuvant Colon Cancer Therapy (X-ACT) study confirmed that capecitabine (Xeloda) is at least as effective and is less toxic than a bolus 5-FU and leucovorin regimen for patients with stage III colon cancer.\n'
p7681
sg4
(lp7682
sg14
(lp7683
(dp7684
g7
I23
sg17
VC0699790
p7685
sg10
I12
sg11
VColon Cancer
p7686
sg13
I2
sa(dp7687
g7
I197
sg17
VC3146254
p7688
sg10
I22
sg11
Vstage III colon cancer
p7689
sg13
I4
sasa(dp7690
g2
S"In the recent X-ACT (Xeloda in Adjuvant Colon cancer Therapy) trial, oral capecitabine (Xeloda) demonstrated superior efficacy and an improved safety profile compared with infused fluorouracil + leucovorin (folinic acid) [FU+LV] in patients with Dukes' C colorectal cancer.\n"
p7691
sg4
(lp7692
sg14
(lp7693
(dp7694
g7
I255
sg17
VC1527249
p7695
sg10
I17
sg11
Vcolorectal cancer
p7696
sg13
I2
sa(dp7697
g7
I40
sg17
VC0699790
p7698
sg10
I12
sg11
VColon cancer
p7699
sg13
I2
sasa(dp7700
g2
S'The X-ACT trial (Xeloda in Adjuvant Colon Cancer Therapy) compared traditional bolus 5-FU/LV (as per the Mayo Clinic regimen) with capecitabine, in the adjuvant treatment of 1987 stage III colon cancer patients.\n'
p7701
sg4
(lp7702
sg14
(lp7703
(dp7704
g7
I179
sg17
VC3146254
p7705
sg10
I22
sg11
Vstage III colon cancer
p7706
sg13
I4
sa(dp7707
g7
I36
sg17
VC0699790
p7708
sg10
I12
sg11
VColon Cancer
p7709
sg13
I2
sasa(dp7710
g2
S'On the basis of the X-ACT trial, capecitabine was approved by the US FDA, the National Institute for Clinical Excellence and the Scottish Medicines Consortium as monotherapy for the adjuvant treatment of stage III colon cancer.\n'
p7711
sg4
(lp7712
sg14
(lp7713
(dp7714
g7
I204
sg17
VC3146254
p7715
sg10
I22
sg11
Vstage III colon cancer
p7716
sg13
I4
sasa(dp7717
g2
S'In order to specifically target GD2 overexpressed on the surface of neuroblastoma stNB-V1 cells, anti-GD2 was conjugated to chitosan modified GNRs (CGNRs).\n'
p7718
sg4
(lp7719
sg14
(lp7720
(dp7721
g7
I68
sg17
VC0027819
p7722
sg10
I13
sg11
Vneuroblastoma
p7723
sg13
I1
sasa(dp7724
g2
S'Our results illustrated that anti-GD2-conjugated CGNRs were extensively endocytosed by GD2+ stNB-V1 neuroblastoma cells via antibody-mediated endocytosis.\n'
p7725
sg4
(lp7726
sg14
(lp7727
(dp7728
g7
I100
sg17
VC0027819
p7729
sg10
I13
sg11
Vneuroblastoma
p7730
sg13
I1
sasa(dp7731
g2
S'In order to specifically target disialoganglioside (GD2) overexpressed on the surface of neuroblastoma stNB-V1 cells, GD2 monoclonal antibody (anti-GD2) was conjugated to acidified CNTs.\n'
p7732
sg4
(lp7733
sg14
(lp7734
(dp7735
g7
I89
sg17
VC0027819
p7736
sg10
I13
sg11
Vneuroblastoma
p7737
sg13
I1
sasa(dp7738
g2
S"In addition to the well-known increase in glial fibrillary acidic protein and other proteins in reactive astrocytes, astrocytopathy is evidenced by deposition of abnormal proteins such as Beta-amyloid, hyper-phosphorylated tau, abnormal Alfa-synuclein, mutated huntingtin, phosphorylated TDP-43 and mutated SOD1, and PrPres , in Alzheimer's disease, tauopathies, Lewy body diseases, Huntington's disease, amyotrophic lateral sclerosis and Creutzfeldt-Jakob disease, respectively.\n"
p7739
sg4
(lp7740
(dp7741
g7
I299
sg8
VP00441
p7742
sg10
I12
sg11
Vmutated SOD1
p7743
sg13
I2
sa(dp7744
g7
I273
sg8
g9
sg10
I21
sg11
Vphosphorylated TDP-43
p7745
sg13
I2
sa(dp7746
g7
I237
sg8
VP37840
p7747
sg10
I14
sg11
VAlfa-synuclein
p7748
sg13
I1
sa(dp7749
g7
I253
sg8
VP42858
p7750
sg10
I18
sg11
Vmutated huntingtin
p7751
sg13
I2
sa(dp7752
g7
I42
sg8
VP05230
p7753
sg10
I31
sg11
Vglial fibrillary acidic protein
p7754
sg13
I4
sasg14
(lp7755
(dp7756
g7
I193
sg17
VC0011560
p7757
sg10
I7
sg11
Vamyloid
p7758
sg13
I1
sa(dp7759
g7
I329
sg17
VC1521724
p7760
sg10
I19
sg11
VAlzheimer's disease
p7761
sg13
I2
sa(dp7762
g7
I405
sg17
VC0002736
p7763
sg10
I29
sg11
Vamyotrophic lateral sclerosis
p7764
sg13
I3
sa(dp7765
g7
I350
sg17
VC0949664
p7766
sg10
I11
sg11
Vtauopathies
p7767
sg13
I1
sa(dp7768
g7
I383
sg17
VC0020179
p7769
sg10
I20
sg11
VHuntington's disease
p7770
sg13
I2
sa(dp7771
g7
I439
sg17
VC0022336
p7772
sg10
I25
sg11
VCreutzfeldt-Jakob disease
p7773
sg13
I2
sasa(dp7774
g2
S"Interestingly, BAG3-mediated selective macroautophagy is also involved in the clearance of aggregated proteins associated with age-related neurodegenerative disorders, like Alzheimer's disease (tau-protein), Huntington's disease (mutated huntingtin/polyQ proteins), and amyotrophic lateral sclerosis (mutated SOD1).\n"
p7775
sg4
(lp7776
(dp7777
g7
I249
sg8
VP02649
p7778
sg10
I14
sg11
VpolyQ proteins
p7779
sg13
I2
sa(dp7780
g7
I15
sg8
g9
sg10
I4
sg11
VBAG3
p7781
sg13
I1
sa(dp7782
g7
I238
sg8
VP42858
p7783
sg10
I10
sg11
Vhuntingtin
p7784
sg13
I1
sa(dp7785
g7
I309
sg8
VP00441
p7786
sg10
I4
sg11
VSOD1
p7787
sg13
I1
sasg14
(lp7788
(dp7789
g7
I173
sg17
VC1521724
p7790
sg10
I19
sg11
VAlzheimer's disease
p7791
sg13
I2
sa(dp7792
g7
I270
sg17
VC0002736
p7793
sg10
I29
sg11
Vamyotrophic lateral sclerosis
p7794
sg13
I3
sa(dp7795
g7
I208
sg17
VC0020179
p7796
sg10
I20
sg11
VHuntington's disease
p7797
sg13
I2
sa(dp7798
g7
I139
sg17
VC0524851
p7799
sg10
I27
sg11
Vneurodegenerative disorders
p7800
sg13
I2
sasa(dp7801
g2
S'This report is the first successful generation of neural cells using iPSCs from sleep bruxism patients with 5-HT2A polymorphism, which has the potential to elucidate the etiology and underlying mechanism of SB.\n'
p7802
sg4
(lp7803
(dp7804
g7
I110
sg8
g9
sg10
I4
sg11
VHT2A
p7805
sg13
I1
sasg14
(lp7806
(dp7807
g7
I80
sg17
VC0751771
p7808
sg10
I13
sg11
Vsleep bruxism
p7809
sg13
I2
sasa(dp7810
g2
S'At present, variants of the 5-hydroxytryptamine receptor 2A (5-HTR2A) and interleukin-6 (IL-6) genes may be susceptible markers to develop for obstructive sleep apnea-hypopnea syndrome (OSAHS).\n'
p7811
sg4
(lp7812
(dp7813
g7
I89
sg8
VP05231
p7814
sg10
I4
sg11
VIL-6
p7815
sg13
I1
sa(dp7816
g7
I74
sg8
VP05231
p7817
sg10
I13
sg11
Vinterleukin-6
p7818
sg13
I1
sasg14
(lp7819
(dp7820
g7
I186
sg17
VC0520679
p7821
sg10
I5
sg11
VOSAHS
p7822
sg13
I1
sa(dp7823
g7
I143
sg17
VC0520679
p7824
sg10
I41
sg11
Vobstructive sleep apnea-hypopnea syndrome
p7825
sg13
I4
sasa(dp7826
g2
S'The results of our study showed that tumor necrosis factor-Alfa (TNF-Alfa) -308 G/A (OR = 3.70, 95 % CI = 1.39-9.83), gene-linked polymorphic region (LPR) (OR = 0.57, 95 % CI = 0.41-0.79), and variable number tandem repeat (VNTR) of the 5-hydroxytryptamine transporter gene (5-HTT) (OR = 3.44, 95 % CI = 1.49-7.95) polymorphisms were associated with OSAS risk in the Chinese population, while there was no significant association between 5-hydroxytryptamine 2A receptor (5-HTR2A) 102C/T, 5-HTR2A A1438G, angiotensin-converting enzyme (ACE) insertion (I)/deletion (D), or leptin receptor (LEPR)-Gln 223Arg polymorphism and risk of OSAS in the Chinese population.\n'
p7827
sg4
(lp7828
(dp7829
g7
I237
sg8
VP31645
p7830
sg10
I36
sg11
V5-hydroxytryptamine transporter gene
p7831
sg13
I3
sa(dp7832
g7
I488
sg8
VP28223
p7833
sg10
I14
sg11
V5-HTR2A A1438G
p7834
sg13
I2
sa(dp7835
g7
I588
sg8
VP48357
p7836
sg10
I4
sg11
VLEPR
p7837
sg13
I1
sa(dp7838
g7
I535
sg8
VP12821
p7839
sg10
I3
sg11
VACE
p7840
sg13
I1
sa(dp7841
g7
I37
sg8
VP01375
p7842
sg10
I26
sg11
Vtumor necrosis factor-Alfa
p7843
sg13
I3
sa(dp7844
g7
I504
sg8
VP12821
p7845
sg10
I29
sg11
Vangiotensin-converting enzyme
p7846
sg13
I2
sa(dp7847
g7
I65
sg8
VP01375
p7848
sg10
I8
sg11
VTNF-Alfa
p7849
sg13
I1
sa(dp7850
g7
I571
sg8
VP48357
p7851
sg10
I15
sg11
Vleptin receptor
p7852
sg13
I2
sa(dp7853
g7
I438
sg8
VP34969
p7854
sg10
I31
sg11
V5-hydroxytryptamine 2A receptor
p7855
sg13
I3
sa(dp7856
g7
I275
sg8
VP31645
p7857
sg10
I5
sg11
V5-HTT
p7858
sg13
I1
sa(dp7859
g7
I471
sg8
VP28223
p7860
sg10
I7
sg11
V5-HTR2A
p7861
sg13
I1
sasg14
(lp7862
(dp7863
g7
I350
sg17
VC0520679
p7864
sg10
I4
sg11
VOSAS
p7865
sg13
I1
sa(dp7866
g7
I37
sg17
VC0333516
p7867
sg10
I14
sg11
Vtumor necrosis
p7868
sg13
I2
sa(dp7869
g7
I193
sg17
VC1710347
p7870
sg10
I29
sg11
Vvariable number tandem repeat
p7871
sg13
I4
sa(dp7872
g7
I224
sg17
VC1710347
p7873
sg10
I4
sg11
VVNTR
p7874
sg13
I1
sa(dp7875
g7
I350
sg17
VC0520679
p7876
sg10
I4
sg11
VOSAS
p7877
sg13
I1
sasa(dp7878
g2
S'Our study demonstrated that TNF-Alfa 308 G/A, 5-HTT LPR, and 5-HTT-VNTR polymorphisms were associated with OSAS risk, whereas little association was observed between 5-HTR2A 102C/T, 5-HTR2A A1438G, ACE I/D, or LEPR-Gln 223Arg polymorphism and risk of OSAS in the Chinese population.\n'
p7879
sg4
(lp7880
(dp7881
g7
I198
sg8
VP12821
p7882
sg10
I7
sg11
VACE I/D
p7883
sg13
I2
sa(dp7884
g7
I28
sg8
VP01375
p7885
sg10
I3
sg11
VTNF
p7886
sg13
I1
sa(dp7887
g7
I182
sg8
VP28223
p7888
sg10
I14
sg11
V5-HTR2A A1438G
p7889
sg13
I2
sa(dp7890
g7
I166
sg8
VP28223
p7891
sg10
I12
sg11
V5-HTR2A 102C
p7892
sg13
I2
sasg14
(lp7893
(dp7894
g7
I107
sg17
VC0520679
p7895
sg10
I4
sg11
VOSAS
p7896
sg13
I1
sa(dp7897
g7
I107
sg17
VC0520679
p7898
sg10
I4
sg11
VOSAS
p7899
sg13
I1
sasa(dp7900
g2
S'We performed a meta-analysis to better evaluate the associations between 5-HT2A, 5-HTT, and LEPR polymorphisms, and OSAS.\n'
p7901
sg4
(lp7902
(dp7903
g7
I75
sg8
g9
sg10
I4
sg11
VHT2A
p7904
sg13
I1
sa(dp7905
g7
I81
sg8
VP31645
p7906
sg10
I5
sg11
V5-HTT
p7907
sg13
I1
sasg14
(lp7908
(dp7909
g7
I116
sg17
VC0520679
p7910
sg10
I4
sg11
VOSAS
p7911
sg13
I1
sasa(dp7912
g2
S'5-HT2A, 5-HTT, and LEPR polymorphisms and OSAS were identified in PubMed and EMBASE.\n'
p7913
sg4
(lp7914
(dp7915
g7
I2
sg8
g9
sg10
I4
sg11
VHT2A
p7916
sg13
I1
sa(dp7917
g7
I8
sg8
VP31645
p7918
sg10
I5
sg11
V5-HTT
p7919
sg13
I1
sasg14
(lp7920
(dp7921
g7
I42
sg17
VC0520679
p7922
sg10
I4
sg11
VOSAS
p7923
sg13
I1
sasa(dp7924
g2
S'The -1438 "A" allele of 5-HT2A was identified as a candidate genetic risk factor for OSAS (OR: 2.33, 95%CI 1.49-3.66).\n'
p7925
sg4
(lp7926
(dp7927
g7
I26
sg8
g9
sg10
I4
sg11
VHT2A
p7928
sg13
I1
sasg14
(lp7929
(dp7930
g7
I85
sg17
VC0520679
p7931
sg10
I4
sg11
VOSAS
p7932
sg13
I1
sasa(dp7933
g2
S'There was no significant association between 5-HT2A 102C/T and OSAS risk, using any model.\n'
p7934
sg4
(lp7935
(dp7936
g7
I45
sg8
VP28223
p7937
sg10
I11
sg11
V5-HT2A 102C
p7938
sg13
I2
sasg14
(lp7939
(dp7940
g7
I63
sg17
VC0520679
p7941
sg10
I4
sg11
VOSAS
p7942
sg13
I1
sasa(dp7943
g2
S'Eight studies were finally included in the meta-analysis of the association between 5-HTR2A gene variants (including 102T/C and 1438G/A), 5-HTT gene polymorphisms (including 5-HTT gene-linked promoter region (5-HTTLRP), and serotonin transporter intron 2 variable number tandem repeat (STin2VNTR) and OSAS risk.\n'
p7944
sg4
(lp7945
(dp7946
g7
I224
sg8
VP31645
p7947
sg10
I21
sg11
Vserotonin transporter
p7948
sg13
I2
sa(dp7949
g7
I138
sg8
VP31645
p7950
sg10
I10
sg11
V5-HTT gene
p7951
sg13
I2
sa(dp7952
g7
I84
sg8
VP28223
p7953
sg10
I12
sg11
V5-HTR2A gene
p7954
sg13
I2
sasg14
(lp7955
(dp7956
g7
I301
sg17
VC0520679
p7957
sg10
I4
sg11
VOSAS
p7958
sg13
I1
sa(dp7959
g7
I255
sg17
VC1710347
p7960
sg10
I29
sg11
Vvariable number tandem repeat
p7961
sg13
I4
sasa(dp7962
g2
S'The G allele of 5-HTR2A 1438G/A, long 5-HTTLPR, and 10-tandem-repeats STin2VNTR were shown to increase OSAS susceptibility, with ORs of 2.33 (A vs. G, 95% CI 1.48-3.66), 1.24 (L vs. S, 95% CI: 1.04-1.49), and 2.87 (10 vs. 12, 95% CI: 1.38-5.97), respectively.\n'
p7963
sg4
(lp7964
(dp7965
g7
I4
sg8
VP28223
p7966
sg10
I75
sg11
VG allele of 5-HTR2A 1438G/A, long 5-HTTLPR, and 10-tandem-repeats STin2VNTR
p7967
sg13
I10
sa(dp7968
g7
I103
sg8
VP27986
p7969
sg10
I19
sg11
VOSAS susceptibility
p7970
sg13
I2
sasg14
(lp7971
(dp7972
g7
I103
sg17
VC0520679
p7973
sg10
I4
sg11
VOSAS
p7974
sg13
I1
sasa(dp7975
g2
S'Of the 5-HTR2A 1438G/A gene polymorphism, the AA genotype increased the OSAS risk, with an OR of 4.21 (95% CI: 2.83-6.25) in a recessive model in male OSAS patients, but no significant association was found in females.\n'
p7976
sg4
(lp7977
(dp7978
g7
I7
sg8
VP28223
p7979
sg10
I13
sg11
V5-HTR2A 1438G
p7980
sg13
I2
sasg14
(lp7981
(dp7982
g7
I72
sg17
VC0520679
p7983
sg10
I4
sg11
VOSAS
p7984
sg13
I1
sa(dp7985
g7
I72
sg17
VC0520679
p7986
sg10
I4
sg11
VOSAS
p7987
sg13
I1
sasa(dp7988
g2
S'Our meta-analysis demonstrated that polymorphisms in the 5-HTR2A 1438G/A and 5-HTT genes contributed to susceptibility to OSAS.\n'
p7989
sg4
(lp7990
(dp7991
g7
I77
sg8
VP31645
p7992
sg10
I11
sg11
V5-HTT genes
p7993
sg13
I2
sa(dp7994
g7
I57
sg8
VP28223
p7995
sg10
I13
sg11
V5-HTR2A 1438G
p7996
sg13
I2
sasg14
(lp7997
(dp7998
g7
I122
sg17
VC0520679
p7999
sg10
I4
sg11
VOSAS
p8000
sg13
I1
sasa(dp8001
g2
S'The serotonin 2A (5-HT2A) receptor has been implicated in obstructive sleep apnea (OSA).\n'
p8002
sg4
(lp8003
(dp8004
g7
I4
sg8
g9
sg10
I12
sg11
Vserotonin 2A
p8005
sg13
I2
sasg14
(lp8006
(dp8007
g7
I83
sg17
VC0520679
p8008
sg10
I3
sg11
VOSA
p8009
sg13
I1
sa(dp8010
g7
I58
sg17
VC0520679
p8011
sg10
I23
sg11
Vobstructive sleep apnea
p8012
sg13
I3
sasa(dp8013
g2
S'Our findings suggest that upregulated functional TRPC5 gene may be one cause of EPO-induced hypertension in patients with chronic kidney disease.\n'
p8014
sg4
(lp8015
(dp8016
g7
I49
sg8
g9
sg10
I10
sg11
VTRPC5 gene
p8017
sg13
I2
sa(dp8018
g7
I80
sg8
VP01588
p8019
sg10
I3
sg11
VEPO
p8020
sg13
I1
sasg14
(lp8021
(dp8022
g7
I92
sg17
VC0020538
p8023
sg10
I12
sg11
Vhypertension
p8024
sg13
I1
sa(dp8025
g7
I122
sg17
VC1561643
p8026
sg10
I22
sg11
Vchronic kidney disease
p8027
sg13
I3
sasa(dp8028
g2
S'TTR (transthyretin) gene could be a possible candidate for lumbosacral stenosis in Labrador retrievers based on previous human studies that have reported an association between human lumbar spinal stenosis and transthyretin protein amyloidosis.\n'
p8029
sg4
(lp8030
(dp8031
g7
I0
sg8
VP02766
p8032
sg10
I3
sg11
VTTR
p8033
sg13
I1
sa(dp8034
g7
I5
sg8
VP02766
p8035
sg10
I13
sg11
Vtransthyretin
p8036
sg13
I1
sa(dp8037
g7
I5
sg8
VP02766
p8038
sg10
I13
sg11
Vtransthyretin
p8039
sg13
I1
sasg14
(lp8040
(dp8041
g7
I59
sg17
VC1299881
p8042
sg10
I20
sg11
Vlumbosacral stenosis
p8043
sg13
I2
sa(dp8044
g7
I183
sg17
VC0158288
p8045
sg10
I22
sg11
Vlumbar spinal stenosis
p8046
sg13
I3
sa(dp8047
g7
I232
sg17
VC0002726
p8048
sg10
I11
sg11
Vamyloidosis
p8049
sg13
I1
sasa(dp8050
g2
S'Wild-type ATTR amyloidosis mainly involves the heart, although the reported occurrence of bilateral carpal tunnel syndrome, spinal stenosis and biceps tendon rupture in these patients speaks to more generalized protein deposition.\n'
p8051
sg4
(lp8052
(dp8053
g7
I0
sg8
VP02766
p8054
sg10
I14
sg11
VWild-type ATTR
p8055
sg13
I2
sasg14
(lp8056
(dp8057
g7
I100
sg17
VC0007286
p8058
sg10
I22
sg11
Vcarpal tunnel syndrome
p8059
sg13
I3
sa(dp8060
g7
I124
sg17
VC0037944
p8061
sg10
I15
sg11
Vspinal stenosis
p8062
sg13
I2
sa(dp8063
g7
I211
sg17
VC0333584
p8064
sg10
I18
sg11
Vprotein deposition
p8065
sg13
I2
sa(dp8066
g7
I15
sg17
VC0002726
p8067
sg10
I11
sg11
Vamyloidosis
p8068
sg13
I1
sasa(dp8069
g2
S'In all groups, but the HBD group, the livers were pretreated with FK506 and prostaglandin I2 analogue, and were preserved in University of Wisconsin solution after cardiac arrest.\n'
p8070
sg4
(lp8071
sg14
(lp8072
(dp8073
g7
I23
sg17
VC1840321
p8074
sg10
I3
sg11
VHBD
p8075
sg13
I1
sa(dp8076
g7
I164
sg17
VC0018790
p8077
sg10
I14
sg11
Vcardiac arrest
p8078
sg13
I2
sasa(dp8079
g2
S'We used a new vasodilator, TTC-909 (a prostaglandin I2 analog incorporated in lipid microspheres), which produced marked reduction in the pulmonary arterial pressure and resistance in an infant with primary pulmonary hypertension.\n'
p8080
sg4
(lp8081
sg14
(lp8082
(dp8083
g7
I199
sg17
VC0152171
p8084
sg10
I30
sg11
Vprimary pulmonary hypertension
p8085
sg13
I3
sasa(dp8086
g2
S'A prostaglandin I2 (PGI2) was administered before cardiac arrest by St. Thomas solution.\n'
p8087
sg4
(lp8088
sg14
(lp8089
(dp8090
g7
I50
sg17
VC0018790
p8091
sg10
I14
sg11
Vcardiac arrest
p8092
sg13
I2
sasa(dp8093
g2
S'Recently, with the introduction of prostacyclin (Prostaglandin I2, epoprostenon) as a potent vasodilator, several reports have shown a positive effect in primary pulmonary hypertension.\n'
p8094
sg4
(lp8095
sg14
(lp8096
(dp8097
g7
I154
sg17
VC0152171
p8098
sg10
I30
sg11
Vprimary pulmonary hypertension
p8099
sg13
I3
sasa(dp8100
g2
S'Furthermore, the involvement of functional GREM1 in the epithelial-mesenchymal transition (EMT) process of glioma was investigated by detecting the expression levels of glioma-associated oncogene homologue 3 (GLI3) and EMT-related molecules.\n'
p8101
sg4
(lp8102
(dp8103
g7
I219
sg8
g9
sg10
I21
sg11
VEMT-related molecules
p8104
sg13
I2
sa(dp8105
g7
I43
sg8
g9
sg10
I5
sg11
VGREM1
p8106
sg13
I1
sa(dp8107
g7
I169
sg8
VP08151
p8108
sg10
I38
sg11
Vglioma-associated oncogene homologue 3
p8109
sg13
I4
sa(dp8110
g7
I209
sg8
VP10071
p8111
sg10
I4
sg11
VGLI3
p8112
sg13
I1
sasg14
(lp8113
(dp8114
g7
I91
sg17
VC0599156
p8115
sg10
I3
sg11
VEMT
p8116
sg13
I1
sa(dp8117
g7
I91
sg17
VC0599156
p8118
sg10
I3
sg11
VEMT
p8119
sg13
I1
sa(dp8120
g7
I107
sg17
VC0017638
p8121
sg10
I6
sg11
Vglioma
p8122
sg13
I1
sa(dp8123
g7
I56
sg17
VC0599156
p8124
sg10
I33
sg11
Vepithelial-mesenchymal transition
p8125
sg13
I2
sa(dp8126
g7
I107
sg17
VC0017638
p8127
sg10
I6
sg11
Vglioma
p8128
sg13
I1
sasa(dp8129
g2
S'Suppression of GLI1/GLI2 functions by a C-terminus truncated GLI3 repressor mutant (GLI3R), or by GANT61, a pharmacological inhibitor of GLI1/GLI2, reduced hTERT protein expression in human colon cancer, prostate cancer and Glioblastoma multiforme (GBM) cell lines.\n'
p8130
sg4
(lp8131
(dp8132
g7
I20
sg8
VP10070
p8133
sg10
I4
sg11
VGLI2
p8134
sg13
I1
sa(dp8135
g7
I156
sg8
g9
sg10
I13
sg11
VhTERT protein
p8136
sg13
I2
sa(dp8137
g7
I84
sg8
VP10071
p8138
sg10
I5
sg11
VGLI3R
p8139
sg13
I1
sa(dp8140
g7
I15
sg8
VP08151
p8141
sg10
I4
sg11
VGLI1
p8142
sg13
I1
sa(dp8143
g7
I20
sg8
VP10070
p8144
sg10
I4
sg11
VGLI2
p8145
sg13
I1
sa(dp8146
g7
I15
sg8
VP08151
p8147
sg10
I4
sg11
VGLI1
p8148
sg13
I1
sa(dp8149
g7
I61
sg8
VP10071
p8150
sg10
I21
sg11
VGLI3 repressor mutant
p8151
sg13
I3
sasg14
(lp8152
(dp8153
g7
I196
sg17
VC0376358
p8154
sg10
I16
sg11
Vcancer, prostate
p8155
sg13
I2
sa(dp8156
g7
I196
sg17
VC0006826
p8157
sg10
I6
sg11
Vcancer
p8158
sg13
I1
sa(dp8159
g7
I224
sg17
VC1621958
p8160
sg10
I23
sg11
VGlioblastoma multiforme
p8161
sg13
I2
sa(dp8162
g7
I249
sg17
VC1621958
p8163
sg10
I3
sg11
VGBM
p8164
sg13
I1
sa(dp8165
g7
I76
sg17
VC0596988
p8166
sg10
I6
sg11
Vmutant
p8167
sg13
I1
sa(dp8168
g7
I0
sg17
VC0221103
p8169
sg10
I11
sg11
VSuppression
p8170
sg13
I1
sasa(dp8171
g2
S'Inhibitor of DNA binding protein-1 (ID1) has been shown to maintain the self-renewal capacity of neural stem cells and might be involved in the therapeutic resistance of GBM.\n'
p8172
sg4
(lp8173
(dp8174
g7
I36
sg8
VP29372
p8175
sg10
I3
sg11
VID1
p8176
sg13
I1
sa(dp8177
g7
I0
sg8
VP29372
p8178
sg10
I34
sg11
VInhibitor of DNA binding protein-1
p8179
sg13
I5
sasg14
(lp8180
(dp8181
g7
I170
sg17
VC0017636
p8182
sg10
I3
sg11
VGBM
p8183
sg13
I1
sasa(dp8184
g2
S'In glioblastoma neurosphere cultures that contain cancer stem cells (GBM-CSCs), the bHLH family member inhibitors of DNA binding protein 2 and 4 (Id2 and Id4) were found to be upregulated during the differentiation of GBM-CSCs in response to histone deacetylase inhibitors.\n'
p8185
sg4
(lp8186
(dp8187
g7
I84
sg8
g9
sg10
I11
sg11
VbHLH family
p8188
sg13
I2
sa(dp8189
g7
I154
sg8
VP47928
p8190
sg10
I3
sg11
VId4
p8191
sg13
I1
sa(dp8192
g7
I242
sg8
VP56524
p8193
sg10
I19
sg11
Vhistone deacetylase
p8194
sg13
I2
sa(dp8195
g7
I117
sg8
VP51523
p8196
sg10
I27
sg11
VDNA binding protein 2 and 4
p8197
sg13
I6
sa(dp8198
g7
I146
sg8
g9
sg10
I3
sg11
VId2
p8199
sg13
I1
sasg14
(lp8200
(dp8201
g7
I69
sg17
VC0017636
p8202
sg10
I3
sg11
VGBM
p8203
sg13
I1
sa(dp8204
g7
I50
sg17
VC0006826
p8205
sg10
I6
sg11
Vcancer
p8206
sg13
I1
sa(dp8207
g7
I3
sg17
VC0017636
p8208
sg10
I12
sg11
Vglioblastoma
p8209
sg13
I1
sa(dp8210
g7
I69
sg17
VC0017636
p8211
sg10
I3
sg11
VGBM
p8212
sg13
I1
sasa(dp8213
g2
S'The improvement in mitral regurgitation was greater for the mitral repair group (-2.1 +/- 0.3 vs -1.1 +/- 0.8, P &lt; .0001), and mitral regurgitation remained significantly lower on follow-up at 6 months or more (0.6 +/- 0.4 0.9 +/- 0.2, P = .002).\n'
p8214
sg4
(lp8215
sg14
(lp8216
(dp8217
g7
I19
sg17
VC0026266
p8218
sg10
I20
sg11
Vmitral regurgitation
p8219
sg13
I2
sa(dp8220
g7
I19
sg17
VC0026266
p8221
sg10
I20
sg11
Vmitral regurgitation
p8222
sg13
I2
sasa(dp8223
g2
S'This study was undertaken to examine changes in 1-cysPrx expression in human cataract samples, human lens epithelial (HLE B3) cell line, and rat organ-cultured lenses in response to oxidative insult induced by H2O2 or transforming growth factor-beta1 (TGF-beta1).\n'
p8224
sg4
(lp8225
(dp8226
g7
I252
sg8
VP01137
p8227
sg10
I9
sg11
VTGF-beta1
p8228
sg13
I1
sa(dp8229
g7
I218
sg8
VP01137
p8230
sg10
I32
sg11
Vtransforming growth factor-beta1
p8231
sg13
I3
sasg14
(lp8232
(dp8233
g7
I77
sg17
VC0086543
p8234
sg10
I8
sg11
Vcataract
p8235
sg13
I1
sasa(dp8236
g2
S'In a functional analysis, transient cotransfections in nonerythroid NIH/3T3 cells of SP1, SP3, BKLF, or EKLF and HS2 epsilony promoter-luciferase constructs, with or without coactivators (p300, CREB-binding protein [CBP], or p300/CBP-associated factor [PCAF]) and SCFAs, were performed.\n'
p8237
sg4
(lp8238
(dp8239
g7
I230
sg8
g9
sg10
I28
sg11
VCBP-associated factor [PCAF]
p8240
sg13
I3
sa(dp8241
g7
I85
sg8
VP08047
p8242
sg10
I3
sg11
VSP1
p8243
sg13
I1
sa(dp8244
g7
I113
sg8
VP11277
p8245
sg10
I43
sg11
VHS2 epsilony promoter-luciferase constructs
p8246
sg13
I4
sa(dp8247
g7
I95
sg8
VP57682
p8248
sg10
I4
sg11
VBKLF
p8249
sg13
I1
sa(dp8250
g7
I194
sg8
g9
sg10
I26
sg11
VCREB-binding protein [CBP]
p8251
sg13
I3
sa(dp8252
g7
I90
sg8
g9
sg10
I3
sg11
VSP3
p8253
sg13
I1
sa(dp8254
g7
I188
sg8
g9
sg10
I4
sg11
Vp300
p8255
sg13
I1
sa(dp8256
g7
I188
sg8
g9
sg10
I4
sg11
Vp300
p8257
sg13
I1
sa(dp8258
g7
I104
sg8
g9
sg10
I4
sg11
VEKLF
p8259
sg13
I1
sasg14
(lp8260
sa(dp8261
g2
S'Using our newly created Ngb overexpressing transgenic (Ngb-Tg) mice, we measured brain infarction on day 1 and day 14 after transient focal cerebral ischemia and performed neurobehavioral assessments in sensorimotor deficits on days 1, 3, 7, and 14.\n'
p8262
sg4
(lp8263
(dp8264
g7
I24
sg8
g9
sg10
I3
sg11
VNgb
p8265
sg13
I1
sa(dp8266
g7
I24
sg8
g9
sg10
I3
sg11
VNgb
p8267
sg13
I1
sasg14
(lp8268
(dp8269
g7
I140
sg17
VC0917798
p8270
sg10
I17
sg11
Vcerebral ischemia
p8271
sg13
I2
sa(dp8272
g7
I81
sg17
VC0751955
p8273
sg10
I16
sg11
Vbrain infarction
p8274
sg13
I2
sasa(dp8275
g2
S'Compared with wild-type controls, brain infarction volumes 1 day and 14 days after transient focal cerebral ischemia were significantly reduced in Ngb-Tg mice.\n'
p8276
sg4
(lp8277
(dp8278
g7
I147
sg8
g9
sg10
I3
sg11
VNgb
p8279
sg13
I1
sasg14
(lp8280
(dp8281
g7
I34
sg17
VC0751955
p8282
sg10
I16
sg11
Vbrain infarction
p8283
sg13
I2
sa(dp8284
g7
I99
sg17
VC0917798
p8285
sg10
I17
sg11
Vcerebral ischemia
p8286
sg13
I2
sasa(dp8287
g2
S'Evidence includes the observations that neuronal hypoxia and cerebral ischemia induce Ngb expression, that enhancing Ngb expression reduces--and knocking down Ngb expression increases--hypoxic neuronal injury in vitro and ischemic cerebral injury in vivo, and that Ngb-overexpressing transgenic mice are resistant to cerebral infarction.\n'
p8288
sg4
(lp8289
(dp8290
g7
I86
sg8
g9
sg10
I3
sg11
VNgb
p8291
sg13
I1
sa(dp8292
g7
I86
sg8
g9
sg10
I3
sg11
VNgb
p8293
sg13
I1
sa(dp8294
g7
I86
sg8
g9
sg10
I3
sg11
VNgb
p8295
sg13
I1
sa(dp8296
g7
I86
sg8
g9
sg10
I3
sg11
VNgb
p8297
sg13
I1
sasg14
(lp8298
(dp8299
g7
I61
sg17
VC0917798
p8300
sg10
I17
sg11
Vcerebral ischemia
p8301
sg13
I2
sa(dp8302
g7
I317
sg17
VC0038454
p8303
sg10
I19
sg11
Vcerebral infarction
p8304
sg13
I2
sa(dp8305
g7
I185
sg17
VC0242184
p8306
sg10
I7
sg11
Vhypoxic
p8307
sg13
I1
sa(dp8308
g7
I49
sg17
VC0242184
p8309
sg10
I7
sg11
Vhypoxia
p8310
sg13
I1
sasa(dp8311
g2
S'Sono stati presentati i casi di un effetto paradosso di aggressivita sotto la possibile influenza di acepromazina e un protocollo modificato per il trattamento di un avvelenamento da permetrina nei gatti.\n'
p8312
sg4
(lp8313
sg14
(lp8314
(dp8315
g7
I88
sg17
VC0021400
p8316
sg10
I9
sg11
Vinfluenza
p8317
sg13
I1
sasa(dp8318
g2
S'ADRP and perilipin localized to the phagosomal membrane, which contains M. leprae in skin biopsy specimens of lepromatous leprosy.\n'
p8319
sg4
(lp8320
(dp8321
g7
I9
sg8
g9
sg10
I9
sg11
Vperilipin
p8322
sg13
I1
sa(dp8323
g7
I0
sg8
g9
sg10
I4
sg11
VADRP
p8324
sg13
I1
sasg14
(lp8325
(dp8326
g7
I110
sg17
VC0023348
p8327
sg10
I19
sg11
Vlepromatous leprosy
p8328
sg13
I2
sasa(dp8329
g2
S'In this work, two novel exonic BCKDK mutations, c.520C&gt;G/p.R174G and c.1166T&gt;C/p.L389P, were identified at the homozygous state in two unrelated children with persistently reduced body fluid levels of branched-chain amino acids (BCAAs), developmental delay, microcephaly, and neurobehavioral abnormalities.\n'
p8330
sg4
(lp8331
(dp8332
g7
I31
sg8
g9
sg10
I5
sg11
VBCKDK
p8333
sg13
I1
sasg14
(lp8334
(dp8335
g7
I264
sg17
VC0025958
p8336
sg10
I12
sg11
Vmicrocephaly
p8337
sg13
I1
sa(dp8338
g7
I243
sg17
VC0424605
p8339
sg10
I19
sg11
Vdevelopmental delay
p8340
sg13
I2
sasa(dp8341
g2
S'AR-12-stimulated the co-localization of Influenza, EBV and HIV virus proteins with LC3 in autophagosomes and reduced viral protein association with the chaperones HSP90, HSP70, and GRP78.\n'
p8342
sg4
(lp8343
(dp8344
g7
I83
sg8
g9
sg10
I3
sg11
VLC3
p8345
sg13
I1
sa(dp8346
g7
I170
sg8
VP34932
p8347
sg10
I5
sg11
VHSP70
p8348
sg13
I1
sa(dp8349
g7
I181
sg8
VP11021
p8350
sg10
I5
sg11
VGRP78
p8351
sg13
I1
sa(dp8352
g7
I163
sg8
VP07900
p8353
sg10
I5
sg11
VHSP90
p8354
sg13
I1
sasg14
(lp8355
(dp8356
g7
I40
sg17
VC0021400
p8357
sg10
I9
sg11
VInfluenza
p8358
sg13
I1
sa(dp8359
g7
I59
sg17
VC0019693
p8360
sg10
I3
sg11
VHIV
p8361
sg13
I1
sasa(dp8362
g2
S'Hence, in agreement with heat shock protein 70 (HSP70) acting as Th1 cytokine-like adjuvant, an Escherichia coli-expressed r4M2e.HSP70c fusion protein comprising C-terminus of Mycobacterium tuberculosis HSP70 genetically fused to four tandem repeats of influenza A virus M2e was constructed.\n'
p8363
sg4
(lp8364
(dp8365
g7
I48
sg8
VP34932
p8366
sg10
I5
sg11
VHSP70
p8367
sg13
I1
sa(dp8368
g7
I25
sg8
VP34932
p8369
sg10
I21
sg11
Vheat shock protein 70
p8370
sg13
I4
sa(dp8371
g7
I48
sg8
VP34932
p8372
sg10
I5
sg11
VHSP70
p8373
sg13
I1
sa(dp8374
g7
I253
sg8
g9
sg10
I21
sg11
Vinfluenza A virus M2e
p8375
sg13
I4
sa(dp8376
g7
I129
sg8
VP35637
p8377
sg10
I21
sg11
VHSP70c fusion protein
p8378
sg13
I3
sasg14
(lp8379
(dp8380
g7
I190
sg17
VC0041296
p8381
sg10
I12
sg11
Vtuberculosis
p8382
sg13
I1
sa(dp8383
g7
I253
sg17
VC0021400
p8384
sg10
I9
sg11
Vinfluenza
p8385
sg13
I1
sasa(dp8386
g2
S'Furthermore, a virus challenge experiment revealed that mice vaccinated with r4M2e.HSP70c limited the severity of influenza A disease by 100% survival rate, less sever body weight loss and delaying the onset of morbidity in mice for 2days rather than other control groups.\n'
p8387
sg4
(lp8388
sg14
(lp8389
(dp8390
g7
I114
sg17
VC0021400
p8391
sg10
I9
sg11
Vinfluenza
p8392
sg13
I1
sasa(dp8393
g2
S'To prepare an effective vaccine against influenza A viruses, a chimerical DNA plasmid encoding Influenza virus M2 protein and Leishmania major HSP70 was constructed.\n'
p8394
sg4
(lp8395
(dp8396
g7
I126
sg8
VP34932
p8397
sg10
I22
sg11
VLeishmania major HSP70
p8398
sg13
I3
sasg14
(lp8399
(dp8400
g7
I40
sg17
VC0021400
p8401
sg10
I9
sg11
Vinfluenza
p8402
sg13
I1
sa(dp8403
g7
I95
sg17
VC0021400
p8404
sg10
I9
sg11
VInfluenza
p8405
sg13
I1
sasa(dp8406
g2
S'Our previous study have shown that a prime-boost administration of recombinant 4xM2e.HSP70c (r4M2e/H70c) fusion protein compared to conventional HA-based influenza vaccines provided full protection against lethal dose of influenza A viruses in mice.\n'
p8407
sg4
(lp8408
sg14
(lp8409
(dp8410
g7
I154
sg17
VC0021400
p8411
sg10
I9
sg11
Vinfluenza
p8412
sg13
I1
sa(dp8413
g7
I154
sg17
VC0021400
p8414
sg10
I9
sg11
Vinfluenza
p8415
sg13
I1
sasa(dp8416
g2
S'The data reported herein show that protection against H9N2 viral challenge was significantly increased in chickens by injection of r4M2e/H70c compared with injection of conventional HA-based influenza vaccine adjuvanted with MF59 or recombinant 4xM2e (r4M2e) without HSP70c.\n'
p8417
sg4
(lp8418
sg14
(lp8419
(dp8420
g7
I191
sg17
VC0021400
p8421
sg10
I9
sg11
Vinfluenza
p8422
sg13
I1
sasa(dp8423
g2
S'This protective immunity might be attributed to enhanced cell-mediated immunity, which is interpreted as increased lymphocytes proliferation, increased levels of Th1-type (IFN-Gamma) and Th2-type (IL-4) cytokines production and increased CD4(+) to CD8(+) ratios, resulting from the injection of four tandem repeats of the ectodomain of the conserved influenza matrix protein M2 (4xM2e) genetically fused to C-terminus of Mycobacterium tuberculosis HSP70 (mHSP70c).\n'
p8424
sg4
(lp8425
(dp8426
g7
I448
sg8
VP34932
p8427
sg10
I5
sg11
VHSP70
p8428
sg13
I1
sa(dp8429
g7
I248
sg8
VP01732
p8430
sg10
I3
sg11
VCD8
p8431
sg13
I1
sa(dp8432
g7
I238
sg8
VP01730
p8433
sg10
I3
sg11
VCD4
p8434
sg13
I1
sa(dp8435
g7
I172
sg8
VP01579
p8436
sg10
I9
sg11
VIFN-Gamma
p8437
sg13
I1
sasg14
(lp8438
(dp8439
g7
I435
sg17
VC0041296
p8440
sg10
I12
sg11
Vtuberculosis
p8441
sg13
I1
sa(dp8442
g7
I350
sg17
VC0021400
p8443
sg10
I9
sg11
Vinfluenza
p8444
sg13
I1
sa(dp8445
g7
I127
sg17
VC0334094
p8446
sg10
I13
sg11
Vproliferation
p8447
sg13
I1
sasa(dp8448
g2
S'Heat shock protein 70 (Hsp70) was identified as a cellular interaction partner of the influenza virus ribonucleoprotein (RNP) complex.\n'
p8449
sg4
(lp8450
(dp8451
g7
I0
sg8
VP34932
p8452
sg10
I21
sg11
VHeat shock protein 70
p8453
sg13
I4
sa(dp8454
g7
I23
sg8
VP34932
p8455
sg10
I5
sg11
VHsp70
p8456
sg13
I1
sasg14
(lp8457
(dp8458
g7
I86
sg17
VC0021400
p8459
sg10
I9
sg11
Vinfluenza
p8460
sg13
I1
sasa(dp8461
g2
S'Here we demonstrated that Hsp70 was involved in the regulation of influenza A viral transcription and replication.\n'
p8462
sg4
(lp8463
(dp8464
g7
I26
sg8
VP34932
p8465
sg10
I5
sg11
VHsp70
p8466
sg13
I1
sasg14
(lp8467
(dp8468
g7
I66
sg17
VC0021400
p8469
sg10
I9
sg11
Vinfluenza
p8470
sg13
I1
sasa(dp8471
g2
S'Furthermore, delivered Hsp70 could inhibit the replication of influenza A virus in mice.\n'
p8472
sg4
(lp8473
(dp8474
g7
I23
sg8
VP34932
p8475
sg10
I5
sg11
VHsp70
p8476
sg13
I1
sasg14
(lp8477
(dp8478
g7
I62
sg17
VC0021400
p8479
sg10
I9
sg11
Vinfluenza
p8480
sg13
I1
sasa(dp8481
g2
S'In this study, antigenic peptides from tetanus toxin and influenza hemagglutinin complexed to human stress-inducible Hsp70 were found to enhance the proliferation and cytokine production of human antigen-specific CD4(+) T cells.\n'
p8482
sg4
(lp8483
(dp8484
g7
I117
sg8
VP34932
p8485
sg10
I5
sg11
VHsp70
p8486
sg13
I1
sa(dp8487
g7
I190
sg8
VP14209
p8488
sg10
I26
sg11
Vhuman antigen-specific CD4
p8489
sg13
I3
sasg14
(lp8490
(dp8491
g7
I57
sg17
VC0021400
p8492
sg10
I9
sg11
Vinfluenza
p8493
sg13
I1
sa(dp8494
g7
I39
sg17
VC0039614
p8495
sg10
I7
sg11
Vtetanus
p8496
sg13
I1
sa(dp8497
g7
I149
sg17
VC0334094
p8498
sg10
I13
sg11
Vproliferation
p8499
sg13
I1
sasa(dp8500
g2
S'Herein, to construct a recombinant M2e-based vaccine candidate with the appropriate structural conformation and immunogenicity the corresponding nucleotide sequence from an H9N2 influenza strain was fused to the N-terminus of the truncated Mycobacterium tuberculosis HSP70(359-610), as a potent adjuvant, and following its cloning into the pPICZ alpha A plasmid the fusion gene was expressed in Pichia pastoris KM71H yeast.\n'
p8501
sg4
(lp8502
(dp8503
g7
I267
sg8
VP34932
p8504
sg10
I14
sg11
VHSP70(359-610)
p8505
sg13
I1
sasg14
(lp8506
(dp8507
g7
I178
sg17
VC0021400
p8508
sg10
I9
sg11
Vinfluenza
p8509
sg13
I1
sa(dp8510
g7
I254
sg17
VC0041296
p8511
sg10
I12
sg11
Vtuberculosis
p8512
sg13
I1
sasa(dp8513
g2
S'According to previous reports, this study was designed to produce a novel influenza A virus recombinant fusion protein consisted of M2e, a potent immunogenic protein from influenza A virus, fused to C-terminal domain of mycobacterium tuberculosis HSP70, HSP70(359-610), as a carrier and adjuvant.\n'
p8514
sg4
(lp8515
(dp8516
g7
I247
sg8
VP34932
p8517
sg10
I5
sg11
VHSP70
p8518
sg13
I1
sa(dp8519
g7
I254
sg8
VP34932
p8520
sg10
I14
sg11
VHSP70(359-610)
p8521
sg13
I1
sasg14
(lp8522
(dp8523
g7
I234
sg17
VC0041296
p8524
sg10
I12
sg11
Vtuberculosis
p8525
sg13
I1
sa(dp8526
g7
I74
sg17
VC0021400
p8527
sg10
I9
sg11
Vinfluenza
p8528
sg13
I1
sa(dp8529
g7
I74
sg17
VC0021400
p8530
sg10
I9
sg11
Vinfluenza
p8531
sg13
I1
sasa(dp8532
g2
S'De novo mutations in ATAD3A (ATPase family AAA-domain containing protein 3A) were recently found to cause a neurological syndrome with developmental delay, hypotonia, spasticity, optic atrophy, axonal neuropathy, and hypertrophic cardiomyopathy.\n'
p8533
sg4
(lp8534
(dp8535
g7
I21
sg8
g9
sg10
I6
sg11
VATAD3A
p8536
sg13
I1
sa(dp8537
g7
I29
sg8
VP38606
p8538
sg10
I46
sg11
VATPase family AAA-domain containing protein 3A
p8539
sg13
I6
sasg14
(lp8540
(dp8541
g7
I194
sg17
VC0270921
p8542
sg10
I17
sg11
Vaxonal neuropathy
p8543
sg13
I2
sa(dp8544
g7
I156
sg17
VC0026827
p8545
sg10
I9
sg11
Vhypotonia
p8546
sg13
I1
sa(dp8547
g7
I121
sg17
VC0039082
p8548
sg10
I8
sg11
Vsyndrome
p8549
sg13
I1
sa(dp8550
g7
I179
sg17
VC0029124
p8551
sg10
I13
sg11
Voptic atrophy
p8552
sg13
I2
sa(dp8553
g7
I167
sg17
VC0026838
p8554
sg10
I10
sg11
Vspasticity
p8555
sg13
I1
sa(dp8556
g7
I43
sg17
VC0162871
p8557
sg10
I3
sg11
VAAA
p8558
sg13
I1
sa(dp8559
g7
I217
sg17
VC0007194
p8560
sg10
I27
sg11
Vhypertrophic cardiomyopathy
p8561
sg13
I2
sa(dp8562
g7
I135
sg17
VC0424605
p8563
sg10
I19
sg11
Vdevelopmental delay
p8564
sg13
I2
sasa(dp8565
g2
S'We identified a recurrent de novo ATAD3A c.1582C&gt;T (p.Arg528Trp) variant by whole-exome sequencing (WES) in five unrelated individuals with a core phenotype of global developmental delay, hypotonia, optic atrophy, axonal neuropathy, and hypertrophic cardiomyopathy.\n'
p8566
sg4
(lp8567
(dp8568
g7
I34
sg8
g9
sg10
I14
sg11
VATAD3A c.1582C
p8569
sg13
I2
sasg14
(lp8570
(dp8571
g7
I217
sg17
VC0270921
p8572
sg10
I17
sg11
Vaxonal neuropathy
p8573
sg13
I2
sa(dp8574
g7
I240
sg17
VC0007194
p8575
sg10
I27
sg11
Vhypertrophic cardiomyopathy
p8576
sg13
I2
sa(dp8577
g7
I202
sg17
VC0029124
p8578
sg10
I13
sg11
Voptic atrophy
p8579
sg13
I2
sa(dp8580
g7
I163
sg17
VC0557874
p8581
sg10
I26
sg11
Vglobal developmental delay
p8582
sg13
I3
sa(dp8583
g7
I191
sg17
VC0026827
p8584
sg10
I9
sg11
Vhypotonia
p8585
sg13
I1
sasa(dp8586
g2
S'Immunoblot and mass spectrometry analyses revealed that the 800-kDa complex contained the OMM translocator protein (18-kDa) and VDAC along with IMM CYP11A1, ATPase family AAA domain-containing protein 3A (ATAD3A), and optic atrophy type 1 proteins, but not ANT.\n'
p8587
sg4
(lp8588
(dp8589
g7
I144
sg8
VP05108
p8590
sg10
I11
sg11
VIMM CYP11A1
p8591
sg13
I2
sa(dp8592
g7
I157
sg8
g9
sg10
I46
sg11
VATPase family AAA domain-containing protein 3A
p8593
sg13
I6
sa(dp8594
g7
I257
sg8
VP12235
p8595
sg10
I3
sg11
VANT
p8596
sg13
I1
sa(dp8597
g7
I90
sg8
VP30536
p8598
sg10
I24
sg11
VOMM translocator protein
p8599
sg13
I3
sa(dp8600
g7
I205
sg8
g9
sg10
I6
sg11
VATAD3A
p8601
sg13
I1
sasg14
(lp8602
(dp8603
g7
I218
sg17
VC0338508
p8604
sg10
I20
sg11
Voptic atrophy type 1
p8605
sg13
I4
sa(dp8606
g7
I171
sg17
VC0162871
p8607
sg10
I3
sg11
VAAA
p8608
sg13
I1
sasa(dp8609
g2
S'Knockdown of ATAD3A, but not ANT or optic atrophy type 1, in Leydig cells resulted in a significant decrease in hormone-induced, but not 22R-hydroxycholesterol-supported, steroid production.\n'
p8610
sg4
(lp8611
(dp8612
g7
I29
sg8
VP12235
p8613
sg10
I3
sg11
VANT
p8614
sg13
I1
sa(dp8615
g7
I13
sg8
g9
sg10
I6
sg11
VATAD3A
p8616
sg13
I1
sasg14
(lp8617
(dp8618
g7
I36
sg17
VC0338508
p8619
sg10
I20
sg11
Voptic atrophy type 1
p8620
sg13
I4
sasa(dp8621
g2
S'Recently, a numbers of marketed drugs for Schizophrenia are available against dopamine D2 and serotonin 5-HT2A receptors.\n'
p8622
sg4
(lp8623
(dp8624
g7
I94
sg8
VP28223
p8625
sg10
I26
sg11
Vserotonin 5-HT2A receptors
p8626
sg13
I3
sasg14
(lp8627
(dp8628
g7
I42
sg17
VC0036341
p8629
sg10
I13
sg11
VSchizophrenia
p8630
sg13
I1
sasa(dp8631
g2
S'We identified 60 miRNAs that were significantly increased in recurrent serous ovarian carcinoma compared with primary tumor tissue, including miR-630, miR-370, and miR-575.\n'
p8632
sg4
(lp8633
(dp8634
g7
I142
sg8
g9
sg10
I7
sg11
VmiR-630
p8635
sg13
I1
sa(dp8636
g7
I151
sg8
g9
sg10
I7
sg11
VmiR-370
p8637
sg13
I1
sasg14
(lp8638
(dp8639
g7
I110
sg17
VC0677930
p8640
sg10
I13
sg11
Vprimary tumor
p8641
sg13
I2
sa(dp8642
g7
I78
sg17
VC0029925
p8643
sg10
I17
sg11
Vovarian carcinoma
p8644
sg13
I2
sasa(dp8645
g2
S'Three other miRNAs, miR-19b, miR-433, and miR-370 were associated with lymph node metastasis, decreased curvature, and poorly differentiated carcinoma.\n'
p8646
sg4
(lp8647
(dp8648
g7
I29
sg8
g9
sg10
I7
sg11
VmiR-433
p8649
sg13
I1
sa(dp8650
g7
I42
sg8
g9
sg10
I7
sg11
VmiR-370
p8651
sg13
I1
sa(dp8652
g7
I20
sg8
g9
sg10
I7
sg11
VmiR-19b
p8653
sg13
I1
sasg14
(lp8654
(dp8655
g7
I71
sg17
VC0686619
p8656
sg10
I21
sg11
Vlymph node metastasis
p8657
sg13
I3
sa(dp8658
g7
I119
sg17
VC0741899
p8659
sg10
I31
sg11
Vpoorly differentiated carcinoma
p8660
sg13
I3
sasa(dp8661
g2
S'A preliminary screening study suggested that down-regulation of miR-370 occurs in oral squamous cell carcinoma (OSCC) tissue.\n'
p8662
sg4
(lp8663
(dp8664
g7
I64
sg8
g9
sg10
I7
sg11
VmiR-370
p8665
sg13
I1
sasg14
(lp8666
(dp8667
g7
I87
sg17
VC0007137
p8668
sg10
I23
sg11
Vsquamous cell carcinoma
p8669
sg13
I3
sasa(dp8670
g2
S'Squamous cell carcinoma tissues with perineural invasion had lowered miR-370 expression compared with contrasting OSCC.\n'
p8671
sg4
(lp8672
(dp8673
g7
I69
sg8
g9
sg10
I7
sg11
VmiR-370
p8674
sg13
I1
sasg14
(lp8675
(dp8676
g7
I48
sg17
VC2699153
p8677
sg10
I8
sg11
Vinvasion
p8678
sg13
I1
sa(dp8679
g7
I0
sg17
VC0007137
p8680
sg10
I23
sg11
VSquamous cell carcinoma
p8681
sg13
I3
sasa(dp8682
g2
S'Expression of four miRNAs (miR-30c, miR-30d, miR-30e-3p, miR-370) was significantly different between carcinomas and benign ovarian tissues as well as between carcinoma and borderline tissues.\n'
p8683
sg4
(lp8684
(dp8685
g7
I36
sg8
g9
sg10
I7
sg11
VmiR-30d
p8686
sg13
I1
sa(dp8687
g7
I57
sg8
g9
sg10
I7
sg11
VmiR-370
p8688
sg13
I1
sa(dp8689
g7
I27
sg8
g9
sg10
I7
sg11
VmiR-30c
p8690
sg13
I1
sa(dp8691
g7
I45
sg8
g9
sg10
I10
sg11
VmiR-30e-3p
p8692
sg13
I1
sasg14
(lp8693
(dp8694
g7
I102
sg17
VC0007097
p8695
sg10
I9
sg11
Vcarcinoma
p8696
sg13
I1
sa(dp8697
g7
I102
sg17
VC0007097
p8698
sg10
I10
sg11
Vcarcinomas
p8699
sg13
I1
sasa(dp8700
g2
S'Pruritus was assessed by the number of scratching bouts, whilst skin inflammation was evaluated by the extravascular accumulation of intravenously injected 125I-albumin (plasma extravasation) and myeloperoxidase (MPO) activity (neutrophil recruitment).\n'
p8701
sg4
(lp8702
(dp8703
g7
I196
sg8
VP05164
p8704
sg10
I15
sg11
Vmyeloperoxidase
p8705
sg13
I1
sa(dp8706
g7
I161
sg8
VP00441
p8707
sg10
I7
sg11
Valbumin
p8708
sg13
I1
sa(dp8709
g7
I213
sg8
VP05164
p8710
sg10
I3
sg11
VMPO
p8711
sg13
I1
sasg14
(lp8712
(dp8713
g7
I239
sg17
VC0271510
p8714
sg10
I11
sg11
Vrecruitment
p8715
sg13
I1
sa(dp8716
g7
I64
sg17
VC0011603
p8717
sg10
I17
sg11
Vskin inflammation
p8718
sg13
I2
sa(dp8719
g7
I0
sg17
VC0033774
p8720
sg10
I8
sg11
VPruritus
p8721
sg13
I1
sa(dp8722
g7
I177
sg17
VC0015376
p8723
sg10
I13
sg11
Vextravasation
p8724
sg13
I1
sasa(dp8725
g2
S'The neuropeptide PACAP and VPAC1 were previously found to negatively regulate megakaryopoiesis, and inhibition of their physiological pathway was found to have a thrombopoietic effect in conditions where megakaryopoiesis and thrombopoiesis were impaired, such as chemotherapy-induced thrombocytopenia and congenital thrombocytopenia.\n'
p8726
sg4
(lp8727
(dp8728
g7
I27
sg8
VP32241
p8729
sg10
I5
sg11
VVPAC1
p8730
sg13
I1
sa(dp8731
g7
I17
sg8
g9
sg10
I5
sg11
VPACAP
p8732
sg13
I1
sasg14
(lp8733
(dp8734
g7
I305
sg17
VC0272278
p8735
sg10
I27
sg11
Vcongenital thrombocytopenia
p8736
sg13
I2
sa(dp8737
g7
I245
sg17
VC0684336
p8738
sg10
I8
sg11
Vimpaired
p8739
sg13
I1
sasa(dp8740
g2
S'The present study explored the thrombopoietic effect of VPAC1 inhibition in a murine model of syngeneic bone marrow transplantation (BMT) and in passive immune thrombocytopenia.\n'
p8741
sg4
(lp8742
(dp8743
g7
I56
sg8
VP32241
p8744
sg10
I5
sg11
VVPAC1
p8745
sg13
I1
sasg14
(lp8746
(dp8747
g7
I153
sg17
VC0272286
p8748
sg10
I23
sg11
Vimmune thrombocytopenia
p8749
sg13
I2
sasa(dp8750
g2
S'Rheumatoid arthritis (RA) is an autoimmune disease which may lead to severe disabilities due to structural joint damage and extraarticular manifestations The dendritic cell marker CD83 belongs to the immunoglobulin superfamily and has previously been associated with autoimmune diseases.\n'
p8751
sg4
(lp8752
(dp8753
g7
I180
sg8
g9
sg10
I4
sg11
VCD83
p8754
sg13
I1
sa(dp8755
g7
I200
sg8
g9
sg10
I26
sg11
Vimmunoglobulin superfamily
p8756
sg13
I2
sasg14
(lp8757
(dp8758
g7
I32
sg17
VC0004364
p8759
sg10
I18
sg11
Vautoimmune disease
p8760
sg13
I2
sa(dp8761
g7
I267
sg17
VC0004364
p8762
sg10
I19
sg11
Vautoimmune diseases
p8763
sg13
I2
sa(dp8764
g7
I22
sg17
VC0003873
p8765
sg10
I2
sg11
VRA
p8766
sg13
I1
sa(dp8767
g7
I0
sg17
VC0003873
p8768
sg10
I20
sg11
VRheumatoid arthritis
p8769
sg13
I2
sasa(dp8770
g2
S'Patients with PLCH displayed a normal expression of the maturity marker CD83 on BALF myeloid DCs.\n'
p8771
sg4
(lp8772
(dp8773
g7
I72
sg8
g9
sg10
I4
sg11
VCD83
p8774
sg13
I1
sasg14
(lp8775
(dp8776
g7
I93
sg17
VC0268238
p8777
sg10
I3
sg11
VDCs
p8778
sg13
I1
sasa(dp8779
g2
S'To the differentiation-related markers, the BRAF/MAP2K1-mut LCH expressed CD14 but rarely expressed CD83 or CD86 (P &lt; .001).\n'
p8780
sg4
(lp8781
(dp8782
g7
I56
sg8
VP22033
p8783
sg10
I3
sg11
Vmut
p8784
sg13
I1
sa(dp8785
g7
I100
sg8
g9
sg10
I4
sg11
VCD83
p8786
sg13
I1
sa(dp8787
g7
I49
sg8
g9
sg10
I6
sg11
VMAP2K1
p8788
sg13
I1
sa(dp8789
g7
I74
sg8
VP08571
p8790
sg10
I4
sg11
VCD14
p8791
sg13
I1
sa(dp8792
g7
I108
sg8
VP42081
p8793
sg10
I4
sg11
VCD86
p8794
sg13
I1
sa(dp8795
g7
I44
sg8
VP15056
p8796
sg10
I4
sg11
VBRAF
p8797
sg13
I1
sasg14
(lp8798
(dp8799
g7
I60
sg17
VC0019621
p8800
sg10
I3
sg11
VLCH
p8801
sg13
I1
sasa(dp8802
g2
S'On the contrary, BRAF/MAP2K1-wt LCH cells rarely expressed CD14 but expressed CD86, and some also expressed CD83 (P &lt; .001).\n'
p8803
sg4
(lp8804
(dp8805
g7
I108
sg8
g9
sg10
I4
sg11
VCD83
p8806
sg13
I1
sa(dp8807
g7
I59
sg8
VP08571
p8808
sg10
I4
sg11
VCD14
p8809
sg13
I1
sa(dp8810
g7
I17
sg8
VP15056
p8811
sg10
I4
sg11
VBRAF
p8812
sg13
I1
sa(dp8813
g7
I22
sg8
g9
sg10
I6
sg11
VMAP2K1
p8814
sg13
I1
sa(dp8815
g7
I78
sg8
VP42081
p8816
sg10
I4
sg11
VCD86
p8817
sg13
I1
sasg14
(lp8818
(dp8819
g7
I32
sg17
VC0019621
p8820
sg10
I3
sg11
VLCH
p8821
sg13
I1
sasa(dp8822
g2
S'The protein phosphatase 1-like gene (PPM1l) was identified as causal gene for obesity and metabolic abnormalities in mice.\n'
p8823
sg4
(lp8824
(dp8825
g7
I4
sg8
g9
sg10
I31
sg11
Vprotein phosphatase 1-like gene
p8826
sg13
I4
sa(dp8827
g7
I37
sg8
g9
sg10
I5
sg11
VPPM1l
p8828
sg13
I1
sasg14
(lp8829
(dp8830
g7
I78
sg17
VC0028754
p8831
sg10
I7
sg11
Vobesity
p8832
sg13
I1
sasa(dp8833
g2
S'Three genes in this network, lipoprotein lipase (Lpl), lactamase beta (Lactb) and protein phosphatase 1-like (Ppm1l), are validated as previously unknown obesity genes, strengthening the association between this network and metabolic disease traits.\n'
p8834
sg4
(lp8835
(dp8836
g7
I110
sg8
g9
sg10
I5
sg11
VPpm1l
p8837
sg13
I1
sa(dp8838
g7
I71
sg8
VP83111
p8839
sg10
I5
sg11
VLactb
p8840
sg13
I1
sa(dp8841
g7
I49
sg8
VP06858
p8842
sg10
I3
sg11
VLpl
p8843
sg13
I1
sa(dp8844
g7
I55
sg8
VP83111
p8845
sg10
I14
sg11
Vlactamase beta
p8846
sg13
I2
sa(dp8847
g7
I29
sg8
VP06858
p8848
sg10
I18
sg11
Vlipoprotein lipase
p8849
sg13
I2
sa(dp8850
g7
I82
sg8
g9
sg10
I26
sg11
Vprotein phosphatase 1-like
p8851
sg13
I3
sasg14
(lp8852
(dp8853
g7
I154
sg17
VC0028754
p8854
sg10
I7
sg11
Vobesity
p8855
sg13
I1
sa(dp8856
g7
I224
sg17
VC0025517
p8857
sg10
I17
sg11
Vmetabolic disease
p8858
sg13
I2
sasa(dp8859
g2
S'Based on previous research, we hypothesized that RES regulates FoxO1 transcriptional activity through the phosphatidylinositol-3-kinase (PI3K)/AKT signaling pathway to achieve an antioxidative effect on osteoporosis and then we confirmed this hypothesis in the present study.\n'
p8860
sg4
(lp8861
(dp8862
g7
I137
sg8
VP42336
p8863
sg10
I4
sg11
VPI3K
p8864
sg13
I1
sa(dp8865
g7
I106
sg8
VP33981
p8866
sg10
I29
sg11
Vphosphatidylinositol-3-kinase
p8867
sg13
I1
sa(dp8868
g7
I143
sg8
g9
sg10
I3
sg11
VAKT
p8869
sg13
I1
sasg14
(lp8870
(dp8871
g7
I203
sg17
VC0029456
p8872
sg10
I12
sg11
Vosteoporosis
p8873
sg13
I1
sasa(dp8874
g2
S'FoxO1 is a major action target of RES to confer anti-osteoporosis function, and whose effect stems from its power to improve redox balance.\n'
p8875
sg4
(lp8876
(dp8877
g7
I0
sg8
g9
sg10
I5
sg11
VFoxO1
p8878
sg13
I1
sasg14
(lp8879
(dp8880
g7
I53
sg17
VC0029456
p8881
sg10
I12
sg11
Vosteoporosis
p8882
sg13
I1
sasa(dp8883
g2
S'But whether FoxO1 is involved in the oxidative damage during osteoporosis is largely unknown.\n'
p8884
sg4
(lp8885
(dp8886
g7
I12
sg8
g9
sg10
I5
sg11
VFoxO1
p8887
sg13
I1
sasg14
(lp8888
(dp8889
g7
I61
sg17
VC0029456
p8890
sg10
I12
sg11
Vosteoporosis
p8891
sg13
I1
sasa(dp8892
g2
S'In conclusion, our study revealed that the decline of FoxO1 is an important etiology factor of osteoporosis and unclosed a novel mechanism of FoxO1 regulation by TNF-Alfa.\n'
p8893
sg4
(lp8894
(dp8895
g7
I162
sg8
VP01375
p8896
sg10
I8
sg11
VTNF-Alfa
p8897
sg13
I1
sa(dp8898
g7
I54
sg8
g9
sg10
I5
sg11
VFoxO1
p8899
sg13
I1
sa(dp8900
g7
I54
sg8
g9
sg10
I5
sg11
VFoxO1
p8901
sg13
I1
sasg14
(lp8902
(dp8903
g7
I95
sg17
VC0029456
p8904
sg10
I12
sg11
Vosteoporosis
p8905
sg13
I1
sasa(dp8906
g2
S'In addition, several new PheWAS findings were identified including a cluster of association near the NDFIP1 gene for mental retardation (best SNP rs10057309, p = 4.33 x 10(-7), OR = 1.70, 95%CI = 1.38 - 2.09); association near PLCL1 gene for developmental delays and speech disorder [best SNP rs1595825, p = 1.13 x 10(-8), OR = 0.65(0.57 - 0.76)]; a cluster of associations in the IL5-IL13 region with Eosinophilic Esophagitis (EoE) [best at rs12653750, p = 3.03 x 10(-9), OR = 1.73 95%CI = (1.44 - 2.07)], previously implicated in asthma, allergy, and eosinophilia; and association of variants in GCKR and JAZF1 with allergic rhinitis in our pediatric cohorts [best SNP rs780093, p = 2.18 x 10(-5), OR = 1.39, 95%CI = (1.19 - 1.61)], previously demonstrated in metabolic disease and diabetes in adults.\n'
p8907
sg4
(lp8908
(dp8909
g7
I101
sg8
g9
sg10
I11
sg11
VNDFIP1 gene
p8910
sg13
I2
sa(dp8911
g7
I227
sg8
g9
sg10
I10
sg11
VPLCL1 gene
p8912
sg13
I2
sa(dp8913
g7
I598
sg8
g9
sg10
I4
sg11
VGCKR
p8914
sg13
I1
sa(dp8915
g7
I607
sg8
g9
sg10
I5
sg11
VJAZF1
p8916
sg13
I1
sa(dp8917
g7
I381
sg8
VP05113
p8918
sg10
I15
sg11
VIL5-IL13 region
p8919
sg13
I2
sasg14
(lp8920
(dp8921
g7
I428
sg17
VC0341106
p8922
sg10
I3
sg11
VEoE
p8923
sg13
I1
sa(dp8924
g7
I762
sg17
VC0025517
p8925
sg10
I17
sg11
Vmetabolic disease
p8926
sg13
I2
sa(dp8927
g7
I784
sg17
VC0011849
p8928
sg10
I8
sg11
Vdiabetes
p8929
sg13
I1
sa(dp8930
g7
I553
sg17
VC0014457
p8931
sg10
I12
sg11
Veosinophilia
p8932
sg13
I1
sa(dp8933
g7
I267
sg17
VC0037822
p8934
sg10
I15
sg11
Vspeech disorder
p8935
sg13
I2
sa(dp8936
g7
I540
sg17
VC0020517
p8937
sg10
I7
sg11
Vallergy
p8938
sg13
I1
sa(dp8939
g7
I117
sg17
VC0025362
p8940
sg10
I18
sg11
Vmental retardation
p8941
sg13
I2
sa(dp8942
g7
I618
sg17
VC2607914
p8943
sg10
I17
sg11
Vallergic rhinitis
p8944
sg13
I2
sa(dp8945
g7
I402
sg17
VC0341106
p8946
sg10
I24
sg11
VEosinophilic Esophagitis
p8947
sg13
I2
sa(dp8948
g7
I532
sg17
VC0004096
p8949
sg10
I6
sg11
Vasthma
p8950
sg13
I1
sasa(dp8951
g2
S'177Lu-DOTATATE = lutetium octreotate; ACO = aconitase; Ad = adenine; AD = autosomal dominant; ATRX = ATRX chromatin remodeler; ccRCC = clear cell renal cell carcinoma; c-MYC = MYC proto oncognene; CoA = coenzyme A; COMT = catechol-O-methyl transferase; CPE = carboxypeptidase E; CS = citrate synthase; CT = computed tomography; DH = pyruvate dehydrogenase; DOTATATE = DOTA-octreotate; EGLN1/2 = egl-9 family hypoxia inducible factor 1/2; EGLN2/PHD1 = egl-9 family hypoxia inducible factor 2; elF-4E = eukaryotic initiation factor 4E; EMT = epithelial-to-mesenchymal transition; EPAS1/HIF2A = endothelial PAS domain protein 2/hypoxia-inducible factor 2Alfa; ERK = extracellular signal-regulated kinase; FH = fumarate hydroxylase; GSH = glutathione; H3F3A = histone 3.3 encoding gene; HIFs = Hypoxia-inducible factors; HIF-Alfa = hypoxia-inducible factor alpha; HNPGLs = head and neck paragangliomas; HRAS = HRas protooncogene; IDH = isocitrate dehydrogenase; IGF-1R = growth factor 1 receptor; KIF1B = kinesin family member 1B; MAX = myc-associated factor X; MDH2 = malate dehydrogenase; MN = metanephrine; MRI = magnetic resonance imaging; mTORC1 = mammalian target of rapamycin complex 1; MTY = methoxytyramine; NAd = nicotinamide adenine dinucleotide; NETs = neuroendocrine tumors; NF1 = neurofibromin 1; NMN = normetanephrine; OPLS-DA = orthogonal partial least square discriminant analysis; PFS = progression free survival; PHD = prolyl hydroxylase domain protein; PPGLs = Pheochromocytoma and Paragangliomas; PRRT = peptide receptor radionuclide therapy; Pvhl = von Hippel-Lindau protein; Raptor = regulatory associated protein of mTOR; RAS = rat sarcoma oncogene; RET = rearranged during transfection proto-oncogene; ROS = reactive oxygen species; S6K = S6 kinase; SDH = succinate dehydrogenase; SDHA, -B, -C, -D, = succinate dehydrogenase subunits A, B, C, D; SDHAF2 = succinate dehydrogenase complex assembly factor 2; SDHB, C, D = succinate dehydrogenase subunits B, C, D; SDHx = succinate dehydrogenase subunits; SSTRs = somatostatin receptors; SUCLG = succinyl-CoA synthase; TERRA = Telomeric Repeat-containing RNA; TET = ten-eleven-translocation methylcytosine dioxygenase; TMEM127 = transmembrane protein 127; VEGF = vascular endothelial growth factor; VHL = von Hippel-Lindau; Alfa-KGDH = alpha-ketoglutarate dehydrogenase.\n'
p8952
sg4
(lp8953
(dp8954
g7
I1876
sg8
VP49366
p8955
sg10
I49
sg11
Vsuccinate dehydrogenase complex assembly factor 2
p8956
sg13
I6
sa(dp8957
g7
I1927
sg8
VP21912
p8958
sg10
I4
sg11
VSDHB
p8959
sg13
I1
sa(dp8960
g7
I1771
sg8
g9
sg10
I3
sg11
VSDH
p8961
sg13
I1
sa(dp8962
g7
I2023
sg8
VP61278
p8963
sg10
I30
sg11
VSSTRs = somatostatin receptors
p8964
sg13
I4
sa(dp8965
g7
I438
sg8
g9
sg10
I5
sg11
VEGLN2
p8966
sg13
I1
sa(dp8967
g7
I2266
sg8
VP40337
p8968
sg10
I3
sg11
VVHL
p8969
sg13
I1
sa(dp8970
g7
I1802
sg8
VP31040
p8971
sg10
I4
sg11
VSDHA
p8972
sg13
I1
sa(dp8973
g7
I1760
sg8
VP33981
p8974
sg10
I9
sg11
VS6 kinase
p8975
sg13
I2
sa(dp8976
g7
I578
sg8
g9
sg10
I5
sg11
VEPAS1
p8977
sg13
I1
sa(dp8978
g7
I1434
sg8
VP13674
p8979
sg10
I33
sg11
Vprolyl hydroxylase domain protein
p8980
sg13
I4
sa(dp8981
g7
I2303
sg8
VP49366
p8982
sg10
I33
sg11
Valpha-ketoglutarate dehydrogenase
p8983
sg13
I2
sa(dp8984
g7
I464
sg8
g9
sg10
I26
sg11
Vhypoxia inducible factor 2
p8985
sg13
I4
sa(dp8986
g7
I1140
sg8
VP42345
p8987
sg10
I4
sg11
VmTOR
p8988
sg13
I1
sa(dp8989
g7
I1754
sg8
VP62753
p8990
sg10
I3
sg11
VS6K
p8991
sg13
I1
sa(dp8992
g7
I592
sg8
g9
sg10
I32
sg11
Vendothelial PAS domain protein 2
p8993
sg13
I5
sa(dp8994
g7
I492
sg8
g9
sg10
I3
sg11
VelF
p8995
sg13
I1
sa(dp8996
g7
I584
sg8
g9
sg10
I5
sg11
VHIF2A
p8997
sg13
I1
sa(dp8998
g7
I2063
sg8
g9
sg10
I21
sg11
Vsuccinyl-CoA synthase
p8999
sg13
I2
sa(dp9000
g7
I231
sg8
VP31947
p9001
sg10
I20
sg11
VO-methyl transferase
p9002
sg13
I2
sa(dp9003
g7
I958
sg8
g9
sg10
I33
sg11
VIGF-1R = growth factor 1 receptor
p9004
sg13
I6
sa(dp9005
g7
I1777
sg8
VP49366
p9006
sg10
I23
sg11
Vsuccinate dehydrogenase
p9007
sg13
I2
sa(dp9008
g7
I926
sg8
VP48735
p9009
sg10
I30
sg11
VIDH = isocitrate dehydrogenase
p9010
sg13
I4
sa(dp9011
g7
I748
sg8
VP84243
p9012
sg10
I5
sg11
VH3F3A
p9013
sg13
I1
sa(dp9014
g7
I900
sg8
VP01116
p9015
sg10
I3
sg11
VRAS
p9016
sg13
I1
sa(dp9017
g7
I1058
sg8
VP49366
p9018
sg10
I27
sg11
VMDH2 = malate dehydrogenase
p9019
sg13
I4
sa(dp9020
g7
I385
sg8
g9
sg10
I7
sg11
VEGLN1/2
p9021
sg13
I1
sa(dp9022
g7
I253
sg8
VP16870
p9023
sg10
I24
sg11
VCPE = carboxypeptidase E
p9024
sg13
I4
sa(dp9025
g7
I1001
sg8
g9
sg10
I7
sg11
Vkinesin
p9026
sg13
I1
sa(dp9027
g7
I756
sg8
VP62805
p9028
sg10
I25
sg11
Vhistone 3.3 encoding gene
p9029
sg13
I4
sa(dp9030
g7
I625
sg8
g9
sg10
I30
sg11
Vhypoxia-inducible factor 2Alfa
p9031
sg13
I3
sa(dp9032
g7
I1648
sg8
VP35125
p9033
sg10
I20
sg11
Vrat sarcoma oncogene
p9034
sg13
I3
sa(dp9035
g7
I1670
sg8
VP07949
p9036
sg10
I3
sg11
VRET
p9037
sg13
I1
sa(dp9038
g7
I657
sg8
VP29323
p9039
sg10
I3
sg11
VERK
p9040
sg13
I1
sa(dp9041
g7
I1027
sg8
VP61244
p9042
sg10
I29
sg11
VMAX = myc-associated factor X
p9043
sg13
I5
sa(dp9044
g7
I408
sg8
g9
sg10
I28
sg11
Vhypoxia inducible factor 1/2
p9045
sg13
I4
sa(dp9046
g7
I2230
sg8
g9
sg10
I34
sg11
Vvascular endothelial growth factor
p9047
sg13
I4
sa(dp9048
g7
I444
sg8
g9
sg10
I4
sg11
VPHD1
p9049
sg13
I1
sasg14
(lp9050
(dp9051
g7
I1771
sg17
VC0018946
p9052
sg10
I3
sg11
VSDH
p9053
sg13
I1
sa(dp9054
g7
I1261
sg17
VC0206754
p9055
sg10
I21
sg11
Vneuroendocrine tumors
p9056
sg13
I2
sa(dp9057
g7
I1477
sg17
VC0031511
p9058
sg10
I16
sg11
VPheochromocytoma
p9059
sg13
I1
sa(dp9060
g7
I1648
sg17
VC1882848
p9061
sg10
I11
sg11
Vrat sarcoma
p9062
sg13
I2
sa(dp9063
g7
I408
sg17
VC0242184
p9064
sg10
I7
sg11
Vhypoxia
p9065
sg13
I1
sa(dp9066
g7
I790
sg17
VC0242184
p9067
sg10
I7
sg11
VHypoxia
p9068
sg13
I1
sa(dp9069
g7
I1213
sg17
VC1850380
p9070
sg10
I3
sg11
VNAd
p9071
sg13
I1
sa(dp9072
g7
I94
sg17
VC1845055
p9073
sg10
I4
sg11
VATRX
p9074
sg13
I1
sa(dp9075
g7
I197
sg17
VC2678439
p9076
sg10
I3
sg11
VCoA
p9077
sg13
I1
sa(dp9078
g7
I1498
sg17
VC0030421
p9079
sg10
I14
sg11
VParagangliomas
p9080
sg13
I1
sa(dp9081
g7
I883
sg17
VC0030421
p9082
sg10
I14
sg11
Vparagangliomas
p9083
sg13
I1
sa(dp9084
g7
I408
sg17
VC0242184
p9085
sg10
I7
sg11
Vhypoxia
p9086
sg13
I1
sa(dp9087
g7
I1284
sg17
VC0027831
p9088
sg10
I3
sg11
VNF1
p9089
sg13
I1
sa(dp9090
g7
I408
sg17
VC0242184
p9091
sg10
I7
sg11
Vhypoxia
p9092
sg13
I1
sa(dp9093
g7
I2266
sg17
VC0019562
p9094
sg10
I3
sg11
VVHL
p9095
sg13
I1
sa(dp9096
g7
I729
sg17
VC1260386
p9097
sg10
I3
sg11
VGSH
p9098
sg13
I1
sa(dp9099
g7
I135
sg17
VC0279702
p9100
sg10
I31
sg11
Vclear cell renal cell carcinoma
p9101
sg13
I5
sa(dp9102
g7
I566
sg17
VC0599156
p9103
sg10
I10
sg11
Vtransition
p9104
sg13
I1
sa(dp9105
g7
I94
sg17
VC1845055
p9106
sg10
I4
sg11
VATRX
p9107
sg13
I1
sa(dp9108
g7
I2144
sg17
VC0040715
p9109
sg10
I13
sg11
Vtranslocation
p9110
sg13
I1
sa(dp9111
g7
I197
sg17
VC2678439
p9112
sg10
I3
sg11
VCoA
p9113
sg13
I1
sa(dp9114
g7
I408
sg17
VC0242184
p9115
sg10
I7
sg11
Vhypoxia
p9116
sg13
I1
sasa(dp9117
g2
S'We report a case of MAX-associated renal cell carcinoma and confirm the role of TMEM127 mutations with renal cell carcinoma predisposition.\n'
p9118
sg4
(lp9119
sg14
(lp9120
(dp9121
g7
I35
sg17
VC0007134
p9122
sg10
I20
sg11
Vrenal cell carcinoma
p9123
sg13
I3
sa(dp9124
g7
I35
sg17
VC0007134
p9125
sg10
I20
sg11
Vrenal cell carcinoma
p9126
sg13
I3
sasa(dp9127
g2
S'Alterations of von Hippel-Lindau (VHL), succinate dehydrogenase (SDHX), and TMEM127 have been associated with the development of pheochromocytomas (PCs) and paragangliomas (PGLs) and are also associated with the development of renal neoplasms.\n'
p9128
sg4
(lp9129
(dp9130
g7
I40
sg8
VP49366
p9131
sg10
I23
sg11
Vsuccinate dehydrogenase
p9132
sg13
I2
sa(dp9133
g7
I34
sg8
VP40337
p9134
sg10
I3
sg11
VVHL
p9135
sg13
I1
sa(dp9136
g7
I76
sg8
g9
sg10
I7
sg11
VTMEM127
p9137
sg13
I1
sa(dp9138
g7
I15
sg8
VP40337
p9139
sg10
I17
sg11
Vvon Hippel-Lindau
p9140
sg13
I2
sasg14
(lp9141
(dp9142
g7
I129
sg17
VC0031511
p9143
sg10
I17
sg11
Vpheochromocytomas
p9144
sg13
I1
sa(dp9145
g7
I15
sg17
VC0019562
p9146
sg10
I17
sg11
Vvon Hippel-Lindau
p9147
sg13
I2
sa(dp9148
g7
I148
sg17
VC1864389
p9149
sg10
I3
sg11
VPCs
p9150
sg13
I1
sa(dp9151
g7
I157
sg17
VC0030421
p9152
sg10
I14
sg11
Vparagangliomas
p9153
sg13
I1
sa(dp9154
g7
I34
sg17
VC0019562
p9155
sg10
I3
sg11
VVHL
p9156
sg13
I1
sa(dp9157
g7
I227
sg17
VC0022665
p9158
sg10
I15
sg11
Vrenal neoplasms
p9159
sg13
I2
sa(dp9160
g7
I173
sg17
VC0030421
p9161
sg10
I4
sg11
VPGLs
p9162
sg13
I1
sasa(dp9163
g2
S'Immunohistochemistry for SDHB and mutation analysis for TMEM127 was performed, in addition to analysis of The Cancer Genome Atlas datasets for SDHX and TMEM127 mutated renal cell carcinomas (RCCs).\n'
p9164
sg4
(lp9165
(dp9166
g7
I25
sg8
VP21912
p9167
sg10
I4
sg11
VSDHB
p9168
sg13
I1
sa(dp9169
g7
I56
sg8
g9
sg10
I7
sg11
VTMEM127
p9170
sg13
I1
sasg14
(lp9171
(dp9172
g7
I110
sg17
VC0006826
p9173
sg10
I6
sg11
VCancer
p9174
sg13
I1
sa(dp9175
g7
I168
sg17
VC0007134
p9176
sg10
I21
sg11
Vrenal cell carcinomas
p9177
sg13
I3
sa(dp9178
g7
I191
sg17
VC0007134
p9179
sg10
I4
sg11
VRCCs
p9180
sg13
I1
sasa(dp9181
g2
S'The expanding etiology for hereditary pheochromocytomas and paragangliomas has recently included SDHA, TMEM127, MAX, and SDHAF2 as susceptibility genes.\n'
p9182
sg4
(lp9183
(dp9184
g7
I103
sg8
g9
sg10
I7
sg11
VTMEM127
p9185
sg13
I1
sa(dp9186
g7
I121
sg8
g9
sg10
I6
sg11
VSDHAF2
p9187
sg13
I1
sa(dp9188
g7
I97
sg8
VP31040
p9189
sg10
I4
sg11
VSDHA
p9190
sg13
I1
sasg14
(lp9191
(dp9192
g7
I38
sg17
VC0031511
p9193
sg10
I17
sg11
Vpheochromocytomas
p9194
sg13
I1
sa(dp9195
g7
I60
sg17
VC0030421
p9196
sg10
I14
sg11
Vparagangliomas
p9197
sg13
I1
sasa(dp9198
g2
S'This study analyzed the prospective, longitudinally followed up European-American-Asian Pheochromocytoma-Paraganglioma Registry for prevalence of SDHA, TMEM127, MAX, and SDHAF2 germline mutation carriers from 1993 to 2016.\n'
p9199
sg4
(lp9200
(dp9201
g7
I146
sg8
VP31040
p9202
sg10
I4
sg11
VSDHA
p9203
sg13
I1
sa(dp9204
g7
I170
sg8
g9
sg10
I6
sg11
VSDHAF2
p9205
sg13
I1
sa(dp9206
g7
I152
sg8
g9
sg10
I7
sg11
VTMEM127
p9207
sg13
I1
sasg14
(lp9208
(dp9209
g7
I177
sg17
VC1705427
p9210
sg10
I17
sg11
Vgermline mutation
p9211
sg13
I2
sa(dp9212
g7
I105
sg17
VC0030421
p9213
sg10
I13
sg11
VParaganglioma
p9214
sg13
I1
sa(dp9215
g7
I88
sg17
VC0031511
p9216
sg10
I16
sg11
VPheochromocytoma
p9217
sg13
I1
sasa(dp9218
g2
S'Of 972 unrelated registrants without mutations in the classic pheochromocytoma- and paraganglioma-associated genes (632 female [65.0%] and 340 male [35.0%]; age range, 8-80; mean [SD] age, 41.0 [13.3] years), 58 (6.0%) carried germline mutations of interest, including 29 SDHA, 20 TMEM127, 8 MAX, and 1 SDHAF2.\n'
p9219
sg4
(lp9220
sg14
(lp9221
(dp9222
g7
I62
sg17
VC0031511
p9223
sg10
I16
sg11
Vpheochromocytoma
p9224
sg13
I1
sa(dp9225
g7
I84
sg17
VC0030421
p9226
sg10
I13
sg11
Vparaganglioma
p9227
sg13
I1
sasa(dp9228
g2
S'Newly uncovered are 7 of 63 (11%) malignant pheochromocytomas and paragangliomas in SDHA and TMEM127 disease.\n'
p9229
sg4
(lp9230
sg14
(lp9231
(dp9232
g7
I44
sg17
VC0031511
p9233
sg10
I17
sg11
Vpheochromocytomas
p9234
sg13
I1
sa(dp9235
g7
I66
sg17
VC0030421
p9236
sg10
I14
sg11
Vparagangliomas
p9237
sg13
I1
sasa(dp9238
g2
S'The SDHA, TMEM127, MAX, and SDHAF2 genes may contribute to hereditary pheochromocytoma and paraganglioma.\n'
p9239
sg4
(lp9240
(dp9241
g7
I4
sg8
VP31040
p9242
sg10
I4
sg11
VSDHA
p9243
sg13
I1
sa(dp9244
g7
I28
sg8
g9
sg10
I12
sg11
VSDHAF2 genes
p9245
sg13
I2
sa(dp9246
g7
I10
sg8
g9
sg10
I7
sg11
VTMEM127
p9247
sg13
I1
sasg14
(lp9248
(dp9249
g7
I91
sg17
VC0030421
p9250
sg10
I13
sg11
Vparaganglioma
p9251
sg13
I1
sa(dp9252
g7
I70
sg17
VC0031511
p9253
sg10
I16
sg11
Vpheochromocytoma
p9254
sg13
I1
sasa(dp9255
g2
S'3-MT = 3-methoxytyramine; EPAS1 = endothelial pas domain protein 1; FH = fumarate hydratase; HIF2A = hypoxia inducible factor type 2A; MEN2 = multiple endocrine neoplasia type 2; NF1 = neurofibromatosis type 1; PNMT = phenylethanolamine N-methyltransferase; PPGL = pheochromocytoma and paraganglioma; RET = rearranged during transfection; SDH = succinate dehydrogenase; SDHAF2 = succinate dehydrogenase complex assembly factor 2; TCA = tricarboxylic acid; TH = tyrosine hydroxylase; TMEM127 = transmembrane protein 127; VHL = von Hippel-Lindau.\n'
p9256
sg4
(lp9257
(dp9258
g7
I370
sg8
g9
sg10
I6
sg11
VSDHAF2
p9259
sg13
I1
sa(dp9260
g7
I93
sg8
g9
sg10
I5
sg11
VHIF2A
p9261
sg13
I1
sa(dp9262
g7
I101
sg8
g9
sg10
I32
sg11
Vhypoxia inducible factor type 2A
p9263
sg13
I5
sa(dp9264
g7
I483
sg8
g9
sg10
I7
sg11
VTMEM127
p9265
sg13
I1
sa(dp9266
g7
I456
sg8
VP07101
p9267
sg10
I25
sg11
VTH = tyrosine hydroxylase
p9268
sg13
I4
sa(dp9269
g7
I339
sg8
g9
sg10
I3
sg11
VSDH
p9270
sg13
I1
sa(dp9271
g7
I345
sg8
VP49366
p9272
sg10
I23
sg11
Vsuccinate dehydrogenase
p9273
sg13
I2
sa(dp9274
g7
I345
sg8
VP49366
p9275
sg10
I23
sg11
Vsuccinate dehydrogenase
p9276
sg13
I2
sasg14
(lp9277
(dp9278
g7
I265
sg17
VC0031511
p9279
sg10
I16
sg11
Vpheochromocytoma
p9280
sg13
I1
sa(dp9281
g7
I286
sg17
VC0030421
p9282
sg10
I13
sg11
Vparaganglioma
p9283
sg13
I1
sa(dp9284
g7
I179
sg17
VC0027831
p9285
sg10
I3
sg11
VNF1
p9286
sg13
I1
sa(dp9287
g7
I520
sg17
VC0019562
p9288
sg10
I3
sg11
VVHL
p9289
sg13
I1
sa(dp9290
g7
I142
sg17
VC0025268
p9291
sg10
I35
sg11
Vmultiple endocrine neoplasia type 2
p9292
sg13
I5
sa(dp9293
g7
I101
sg17
VC0242184
p9294
sg10
I7
sg11
Vhypoxia
p9295
sg13
I1
sa(dp9296
g7
I339
sg17
VC0018946
p9297
sg10
I3
sg11
VSDH
p9298
sg13
I1
sa(dp9299
g7
I185
sg17
VC0027831
p9300
sg10
I24
sg11
Vneurofibromatosis type 1
p9301
sg13
I3
sasa(dp9302
g2
S'This study assessed the effects of leukemia-related protein 16 (LRP16) on the regulation of pancreatic functions in mouse insulinoma (MIN6) cells.\n'
p9303
sg4
(lp9304
(dp9305
g7
I35
sg8
g9
sg10
I27
sg11
Vleukemia-related protein 16
p9306
sg13
I3
sa(dp9307
g7
I64
sg8
g9
sg10
I5
sg11
VLRP16
p9308
sg13
I1
sasg14
(lp9309
(dp9310
g7
I35
sg17
VC0023418
p9311
sg10
I8
sg11
Vleukemia
p9312
sg13
I1
sa(dp9313
g7
I116
sg17
VC1522248
p9314
sg10
I16
sg11
Vmouse insulinoma
p9315
sg13
I2
sasa(dp9316
g2
S'Our recent studies have shown that a selective ABHD6 inhibitor WWL70 has anti-inflammatory and neuroprotective effects in animal models of traumatic brain injury and multiple sclerosis.\n'
p9317
sg4
(lp9318
(dp9319
g7
I47
sg8
g9
sg10
I5
sg11
VABHD6
p9320
sg13
I1
sasg14
(lp9321
(dp9322
g7
I166
sg17
VC0026769
p9323
sg10
I18
sg11
Vmultiple sclerosis
p9324
sg13
I2
sasa(dp9325
g2
S'In this study, we investigated the role of targeting ABHD6 in experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS).\n'
p9326
sg4
(lp9327
(dp9328
g7
I53
sg8
g9
sg10
I5
sg11
VABHD6
p9329
sg13
I1
sasg14
(lp9330
(dp9331
g7
I105
sg17
VC0014070
p9332
sg10
I3
sg11
VEAE
p9333
sg13
I1
sa(dp9334
g7
I86
sg17
VC0014070
p9335
sg10
I17
sg11
Vencephalomyelitis
p9336
sg13
I1
sa(dp9337
g7
I150
sg17
VC0026769
p9338
sg10
I2
sg11
VMS
p9339
sg13
I1
sa(dp9340
g7
I130
sg17
VC0026769
p9341
sg10
I18
sg11
Vmultiple sclerosis
p9342
sg13
I2
sa(dp9343
g7
I75
sg17
VC0443146
p9344
sg10
I10
sg11
Vautoimmune
p9345
sg13
I1
sasa(dp9346
g2
S'Expression of clusterin correlates with tumor progression and therapeutic response in several human malignancies, including breast cancer.\n'
p9347
sg4
(lp9348
sg14
(lp9349
(dp9350
g7
I100
sg17
VC0006826
p9351
sg10
I12
sg11
Vmalignancies
p9352
sg13
I1
sa(dp9353
g7
I40
sg17
VC0178874
p9354
sg10
I17
sg11
Vtumor progression
p9355
sg13
I2
sa(dp9356
g7
I124
sg17
VC0678222
p9357
sg10
I13
sg11
Vbreast cancer
p9358
sg13
I2
sasa(dp9359
g2
S'The objective of this explorative study was to determine whether clusterin expression in breast cancer correlated with clinical pathologic characteristics and whether its expression was predictive of response to neoadjuvant chemotherapy (NAC).\n'
p9360
sg4
(lp9361
sg14
(lp9362
(dp9363
g7
I89
sg17
VC0678222
p9364
sg10
I13
sg11
Vbreast cancer
p9365
sg13
I2
sasa(dp9366
g2
S'We determined the clusterin expression pattern in 72 triple negative breast cancers (TNBC) treated with NAC before surgery.\n'
p9367
sg4
(lp9368
(dp9369
g7
I18
sg8
VP10909
p9370
sg10
I9
sg11
Vclusterin
p9371
sg13
I1
sasg14
(lp9372
(dp9373
g7
I69
sg17
VC0006142
p9374
sg10
I14
sg11
Vbreast cancers
p9375
sg13
I2
sasa(dp9376
g2
S'Clusterin was present at higher levels in both fractions of patients with early and intermediate stages of breast cancer.\n'
p9377
sg4
(lp9378
(dp9379
g7
I0
sg8
VP10909
p9380
sg10
I9
sg11
VClusterin
p9381
sg13
I1
sasg14
(lp9382
(dp9383
g7
I107
sg17
VC0678222
p9384
sg10
I13
sg11
Vbreast cancer
p9385
sg13
I2
sasa(dp9386
g2
S'Discovery and development of a novel anticancer PEG-SMR-Clu peptide to prevent breast cancer metastasis.\n'
p9387
sg4
(lp9388
(dp9389
g7
I48
sg8
VP09466
p9390
sg10
I19
sg11
VPEG-SMR-Clu peptide
p9391
sg13
I2
sasg14
(lp9392
(dp9393
g7
I93
sg17
VC0027627
p9394
sg10
I10
sg11
Vmetastasis
p9395
sg13
I1
sa(dp9396
g7
I79
sg17
VC0678222
p9397
sg10
I13
sg11
Vbreast cancer
p9398
sg13
I2
sasa(dp9399
g2
S'PEG-SMRwt-Clu and PEG-SMRwt peptides inhibited the growth of both of MCF-7 (estrogen responsive, ER+) and MDA-MD-231 (estrogen non-responsive, ER-) human breast cancer cells in a dose and time-dependent manner, without inducing cytotoxic effects.\n'
p9400
sg4
(lp9401
(dp9402
g7
I18
sg8
VP09466
p9403
sg10
I18
sg11
VPEG-SMRwt peptides
p9404
sg13
I2
sa(dp9405
g7
I0
sg8
VP09466
p9406
sg10
I3
sg11
VPEG
p9407
sg13
I1
sa(dp9408
g7
I10
sg8
VP10909
p9409
sg10
I3
sg11
VClu
p9410
sg13
I1
sasg14
(lp9411
(dp9412
g7
I154
sg17
VC0678222
p9413
sg10
I13
sg11
Vbreast cancer
p9414
sg13
I2
sasa(dp9415
g2
S'PEG-SMRwt-CLU peptides inhibited the growth of human breast cancer cells and blocked tumor exosome release in vitro.\n'
p9416
sg4
(lp9417
(dp9418
g7
I0
sg8
VP09466
p9419
sg10
I22
sg11
VPEG-SMRwt-CLU peptides
p9420
sg13
I2
sasg14
(lp9421
(dp9422
g7
I53
sg17
VC0678222
p9423
sg10
I13
sg11
Vbreast cancer
p9424
sg13
I2
sa(dp9425
g7
I85
sg17
VC0027651
p9426
sg10
I5
sg11
Vtumor
p9427
sg13
I1
sasa(dp9428
g2
S'Clinically, breast cancer patients possess sCLU expression only in mature CD68(+) macrophages but not in immature CD33(+) immunosuppressive myeloid cells infiltrating the tumors.\n'
p9429
sg4
(lp9430
(dp9431
g7
I74
sg8
VP34810
p9432
sg10
I4
sg11
VCD68
p9433
sg13
I1
sasg14
(lp9434
(dp9435
g7
I35
sg17
VC0850310
p9436
sg10
I7
sg11
Vpossess
p9437
sg13
I1
sa(dp9438
g7
I154
sg17
VC0332448
p9439
sg10
I12
sg11
Vinfiltrating
p9440
sg13
I1
sa(dp9441
g7
I12
sg17
VC0678222
p9442
sg10
I13
sg11
Vbreast cancer
p9443
sg13
I2
sa(dp9444
g7
I171
sg17
VC0027651
p9445
sg10
I6
sg11
Vtumors
p9446
sg13
I1
sasa(dp9447
g2
S'Immunoblotting and MRM-based validation in a separate cohort testified a panel of 21 proteins such as zinc-alpha2-glycoprotein, A2GL, retinol-binding protein 4, annexin A1, SAP3, SRC8, gelsolin, kininogen 1, CO9, clusterin, ceruloplasmin, and Alfa1-antitrypsin could be a panel of candidate markers that could discriminate HE breast cancer from healthy controls.\n'
p9448
sg4
(lp9449
(dp9450
g7
I224
sg8
VP00450
p9451
sg10
I13
sg11
Vceruloplasmin
p9452
sg13
I1
sa(dp9453
g7
I208
sg8
g9
sg10
I3
sg11
VCO9
p9454
sg13
I1
sa(dp9455
g7
I173
sg8
VP17900
p9456
sg10
I4
sg11
VSAP3
p9457
sg13
I1
sa(dp9458
g7
I134
sg8
VP02753
p9459
sg10
I25
sg11
Vretinol-binding protein 4
p9460
sg13
I3
sa(dp9461
g7
I213
sg8
VP10909
p9462
sg10
I9
sg11
Vclusterin
p9463
sg13
I1
sa(dp9464
g7
I243
sg8
g9
sg10
I17
sg11
VAlfa1-antitrypsin
p9465
sg13
I1
sa(dp9466
g7
I185
sg8
VP06396
p9467
sg10
I8
sg11
Vgelsolin
p9468
sg13
I1
sa(dp9469
g7
I195
sg8
VP01042
p9470
sg10
I11
sg11
Vkininogen 1
p9471
sg13
I2
sa(dp9472
g7
I102
sg8
VP36222
p9473
sg10
I24
sg11
Vzinc-alpha2-glycoprotein
p9474
sg13
I1
sa(dp9475
g7
I161
sg8
VP04083
p9476
sg10
I10
sg11
Vannexin A1
p9477
sg13
I2
sasg14
(lp9478
(dp9479
g7
I326
sg17
VC0678222
p9480
sg10
I13
sg11
Vbreast cancer
p9481
sg13
I2
sasa(dp9482
g2
S'Exportin 4 (XPO4) is a novel identified candidate tumour-suppressor gene involved in the pathogenesis of hepatocellular carcinoma (HCC).\n'
p9483
sg4
(lp9484
(dp9485
g7
I12
sg8
g9
sg10
I4
sg11
VXPO4
p9486
sg13
I1
sa(dp9487
g7
I0
sg8
g9
sg10
I10
sg11
VExportin 4
p9488
sg13
I2
sasg14
(lp9489
(dp9490
g7
I105
sg17
VC2239176
p9491
sg10
I24
sg11
Vhepatocellular carcinoma
p9492
sg13
I2
sa(dp9493
g7
I131
sg17
VC2239176
p9494
sg10
I3
sg11
VHCC
p9495
sg13
I1
sa(dp9496
g7
I89
sg17
VC0699748
p9497
sg10
I12
sg11
Vpathogenesis
p9498
sg13
I1
sa(dp9499
g7
I50
sg17
VC0027651
p9500
sg10
I6
sg11
Vtumour
p9501
sg13
I1
sasa(dp9502
g2
S'To evaluate potential biomarkers in HCC, we employed multiple methods in this study, including qPCR, immunostaining methods and tissue microarrays (TMAs), as well as histological and pathological analysis, to assess TGFBeta, XPO4, elF5A2 and ANGPTL4 in cancerous and paracancerous liver tissues from 280 patients suffering from liver cancer.\n'
p9503
sg4
(lp9504
(dp9505
g7
I225
sg8
g9
sg10
I4
sg11
VXPO4
p9506
sg13
I1
sa(dp9507
g7
I216
sg8
VP01137
p9508
sg10
I7
sg11
VTGFBeta
p9509
sg13
I1
sa(dp9510
g7
I242
sg8
g9
sg10
I7
sg11
VANGPTL4
p9511
sg13
I1
sasg14
(lp9512
(dp9513
g7
I313
sg17
VC0683278
p9514
sg10
I9
sg11
Vsuffering
p9515
sg13
I1
sa(dp9516
g7
I328
sg17
VC0345904
p9517
sg10
I12
sg11
Vliver cancer
p9518
sg13
I2
sa(dp9519
g7
I36
sg17
VC2239176
p9520
sg10
I3
sg11
VHCC
p9521
sg13
I1
sasa(dp9522
g2
S'XPO4 in cancerous liver tissue and TGFBeta1 in paracancerous liver tissue were positively correlated with tumor differentiation.\n'
p9523
sg4
(lp9524
(dp9525
g7
I0
sg8
g9
sg10
I4
sg11
VXPO4
p9526
sg13
I1
sasg14
(lp9527
(dp9528
g7
I106
sg17
VC0027651
p9529
sg10
I5
sg11
Vtumor
p9530
sg13
I1
sasa(dp9531
g2
S'Additionally, higher levels of XPO4 in cancerous liver tissue suggested that the patient would have a better prognosis and survival rate.\n'
p9532
sg4
(lp9533
(dp9534
g7
I31
sg8
g9
sg10
I4
sg11
VXPO4
p9535
sg13
I1
sasg14
(lp9536
sa(dp9537
g2
S'However, higher production of XPO4 in paracancerous liver tissue suggested a worse prognosis.\n'
p9538
sg4
(lp9539
(dp9540
g7
I30
sg8
g9
sg10
I4
sg11
VXPO4
p9541
sg13
I1
sasg14
(lp9542
sa(dp9543
g2
S'All the results above provide new insights into better understanding biological indicators, such as XPO4, TGFBeta1, ANGPTL4 and elF5A2, in the prediction and evaluation of liver cancer, as well as signaling pathways in the control of liver cancer.\n'
p9544
sg4
(lp9545
(dp9546
g7
I106
sg8
VP01137
p9547
sg10
I8
sg11
VTGFBeta1
p9548
sg13
I1
sa(dp9549
g7
I116
sg8
g9
sg10
I7
sg11
VANGPTL4
p9550
sg13
I1
sa(dp9551
g7
I100
sg8
g9
sg10
I4
sg11
VXPO4
p9552
sg13
I1
sasg14
(lp9553
(dp9554
g7
I172
sg17
VC0345904
p9555
sg10
I12
sg11
Vliver cancer
p9556
sg13
I2
sa(dp9557
g7
I172
sg17
VC0345904
p9558
sg10
I12
sg11
Vliver cancer
p9559
sg13
I2
sasa(dp9560
g2
S'XPO4 and TGFBeta1 may serve as useful markers to evaluate the size and prognosis of liver cancer.\n'
p9561
sg4
(lp9562
(dp9563
g7
I9
sg8
VP01137
p9564
sg10
I8
sg11
VTGFBeta1
p9565
sg13
I1
sa(dp9566
g7
I0
sg8
g9
sg10
I4
sg11
VXPO4
p9567
sg13
I1
sasg14
(lp9568
(dp9569
g7
I84
sg17
VC0345904
p9570
sg10
I12
sg11
Vliver cancer
p9571
sg13
I2
sasa(dp9572
g2
S'Exportin 4 (XPO4) is a recently-discovered candidate tumor-suppressor gene identified in a liver cancer mouse model.\n'
p9573
sg4
(lp9574
(dp9575
g7
I12
sg8
g9
sg10
I4
sg11
VXPO4
p9576
sg13
I1
sa(dp9577
g7
I0
sg8
g9
sg10
I10
sg11
VExportin 4
p9578
sg13
I2
sasg14
(lp9579
(dp9580
g7
I91
sg17
VC0345904
p9581
sg10
I12
sg11
Vliver cancer
p9582
sg13
I2
sa(dp9583
g7
I53
sg17
VC0027651
p9584
sg10
I5
sg11
Vtumor
p9585
sg13
I1
sasa(dp9586
g2
S'To investigate the role of XPO4 in hepatocellular carcinoma (HCC) pathogenesis, we determined XPO4 expression and its correlation to prognosis in human primary HCC.\n'
p9587
sg4
(lp9588
(dp9589
g7
I27
sg8
g9
sg10
I4
sg11
VXPO4
p9590
sg13
I1
sa(dp9591
g7
I27
sg8
g9
sg10
I4
sg11
VXPO4
p9592
sg13
I1
sasg14
(lp9593
(dp9594
g7
I66
sg17
VC0699748
p9595
sg10
I12
sg11
Vpathogenesis
p9596
sg13
I1
sa(dp9597
g7
I61
sg17
VC2239176
p9598
sg10
I3
sg11
VHCC
p9599
sg13
I1
sa(dp9600
g7
I61
sg17
VC2239176
p9601
sg10
I3
sg11
VHCC
p9602
sg13
I1
sa(dp9603
g7
I35
sg17
VC2239176
p9604
sg10
I24
sg11
Vhepatocellular carcinoma
p9605
sg13
I2
sasa(dp9606
g2
S'One gene, XPO4, encodes a nuclear export protein whose substrate, EIF5A2, is amplified in human tumors, is required for proliferation of XPO4-deficient tumor cells, and promotes hepatocellular carcinoma in mice.\n'
p9607
sg4
(lp9608
(dp9609
g7
I10
sg8
g9
sg10
I4
sg11
VXPO4
p9610
sg13
I1
sa(dp9611
g7
I10
sg8
g9
sg10
I4
sg11
VXPO4
p9612
sg13
I1
sa(dp9613
g7
I66
sg8
g9
sg10
I6
sg11
VEIF5A2
p9614
sg13
I1
sasg14
(lp9615
(dp9616
g7
I120
sg17
VC0334094
p9617
sg10
I13
sg11
Vproliferation
p9618
sg13
I1
sa(dp9619
g7
I96
sg17
VC0027651
p9620
sg10
I5
sg11
Vtumor
p9621
sg13
I1
sa(dp9622
g7
I96
sg17
VC0027651
p9623
sg10
I6
sg11
Vtumors
p9624
sg13
I1
sa(dp9625
g7
I178
sg17
VC1512411
p9626
sg10
I24
sg11
Vhepatocellular carcinoma
p9627
sg13
I2
sasa(dp9628
g2
S'In a population of 159 patients on renal replacement therapy (RDT) we performed a 1-yr prospective observational study, with common parameters to indicate cardiovascular pathologies (PAS, LVMI), calcium-phosphorous metabolism (Ca, PO 4 , Ca x PO 4 ), dialytic adequacy (Kt/V, URR%), nutritional status (nPCR, Alb, K), and anemia (hemoglobin (Hb)).\n'
p9629
sg4
(lp9630
(dp9631
g7
I330
sg8
g9
sg10
I10
sg11
Vhemoglobin
p9632
sg13
I1
sa(dp9633
g7
I276
sg8
g9
sg10
I3
sg11
VURR
p9634
sg13
I1
sa(dp9635
g7
I309
sg8
g9
sg10
I3
sg11
VAlb
p9636
sg13
I1
sasg14
(lp9637
(dp9638
g7
I322
sg17
VC0002871
p9639
sg10
I6
sg11
Vanemia
p9640
sg13
I1
sa(dp9641
g7
I62
sg17
VC0206743
p9642
sg10
I3
sg11
VRDT
p9643
sg13
I1
sasa(dp9644
g2
S'Based on serial mortality rates for the general population of England and Wales, significantly increased mortality was shown for cancers of the pharynx (observed (Obs) 4, expected (Exp) 0.7, standardised mortality ratio (SMR) 559, p&lt;0.05), non-malignant diseases of the respiratory system (Obs 61, Exp 43.0, SMR 142, p&lt;0.05), and non-malignant diseases of the genitourinary system (Obs 10, Exp 4.1, SMR 243, p&lt;0.05).\n'
p9645
sg4
(lp9646
sg14
(lp9647
(dp9648
g7
I350
sg17
VC0080276
p9649
sg10
I36
sg11
Vdiseases of the genitourinary system
p9650
sg13
I5
sa(dp9651
g7
I129
sg17
VC0006826
p9652
sg10
I7
sg11
Vcancers
p9653
sg13
I1
sa(dp9654
g7
I257
sg17
VC0035204
p9655
sg10
I34
sg11
Vdiseases of the respiratory system
p9656
sg13
I5
sasa(dp9657
g2
S'Non-significantly increased SMRs were shown for lung cancer (Obs 45, Exp 40.7, SMR 111) and cancer of the prostate (Obs 9, Exp 7.5, SMR 116).\n'
p9658
sg4
(lp9659
(dp9660
g7
I79
sg8
g9
sg10
I7
sg11
VSMR 111
p9661
sg13
I2
sa(dp9662
g7
I116
sg8
VP41159
p9663
sg10
I5
sg11
VObs 9
p9664
sg13
I2
sa(dp9665
g7
I123
sg8
g9
sg10
I5
sg11
VExp 7
p9666
sg13
I2
sasg14
(lp9667
(dp9668
g7
I92
sg17
VC0600139
p9669
sg10
I22
sg11
Vcancer of the prostate
p9670
sg13
I4
sa(dp9671
g7
I48
sg17
VC0684249
p9672
sg10
I11
sg11
Vlung cancer
p9673
sg13
I2
sasa(dp9674
g2
S'In this largest-ever GWAS meta-analysis for nicotine dependence and the largest-ever cross-ancestry GWAS meta-analysis for any smoking phenotype, we reconfirmed the well-known CHRNA5-CHRNA3-CHRNB4 genes and further yielded a novel association in the DNA methyltransferase gene DNMT3B.\n'
p9675
sg4
(lp9676
(dp9677
g7
I250
sg8
g9
sg10
I33
sg11
VDNA methyltransferase gene DNMT3B
p9678
sg13
I4
sa(dp9679
g7
I176
sg8
VP30532
p9680
sg10
I26
sg11
VCHRNA5-CHRNA3-CHRNB4 genes
p9681
sg13
I2
sasg14
(lp9682
(dp9683
g7
I44
sg17
VC0028043
p9684
sg10
I19
sg11
Vnicotine dependence
p9685
sg13
I2
sasa(dp9686
g2
S'The relationship of HTR4 (rs3995090), HTR2A (rs6313), GRIK5 (rs8099939), GRIN2B (rs2268132), and CHRNB4 (rs1948) gene polymorphisms and COPD, as well as the contribution of these polymorphisms to the variations in quantitative characteristics that describe respiratory function, smoking behavior, and nicotine dependence was assessed in an ethnically homogeneous Tatar population.\n'
p9687
sg4
(lp9688
(dp9689
g7
I38
sg8
VP28223
p9690
sg10
I5
sg11
VHTR2A
p9691
sg13
I1
sa(dp9692
g7
I97
sg8
VP30926
p9693
sg10
I6
sg11
VCHRNB4
p9694
sg13
I1
sa(dp9695
g7
I73
sg8
g9
sg10
I6
sg11
VGRIN2B
p9696
sg13
I1
sa(dp9697
g7
I54
sg8
g9
sg10
I5
sg11
VGRIK5
p9698
sg13
I1
sasg14
(lp9699
(dp9700
g7
I136
sg17
VC0024117
p9701
sg10
I4
sg11
VCOPD
p9702
sg13
I1
sa(dp9703
g7
I301
sg17
VC0028043
p9704
sg10
I19
sg11
Vnicotine dependence
p9705
sg13
I2
sasa(dp9706
g2
S'Genome-wide association studies (GWASs) have identified associations between the CHRNA5-CHRNA3-CHRNB4 gene cluster and smoking heaviness and nicotine dependence.\n'
p9707
sg4
(lp9708
(dp9709
g7
I81
sg8
VP30532
p9710
sg10
I6
sg11
VCHRNA5
p9711
sg13
I1
sa(dp9712
g7
I95
sg8
VP30926
p9713
sg10
I6
sg11
VCHRNB4
p9714
sg13
I1
sa(dp9715
g7
I88
sg8
VP32297
p9716
sg10
I6
sg11
VCHRNA3
p9717
sg13
I1
sasg14
(lp9718
(dp9719
g7
I141
sg17
VC0028043
p9720
sg10
I19
sg11
Vnicotine dependence
p9721
sg13
I2
sasa(dp9722
g2
S'Polymorphisms in the CHRNA5-CHRNA3-CHRNB4 gene cluster (Chr15q25) have been robustly associated with nicotine dependence, including genome-wide studies, as well as with cognitive and neuropsychological measures.\n'
p9723
sg4
(lp9724
(dp9725
g7
I21
sg8
VP30532
p9726
sg10
I33
sg11
VCHRNA5-CHRNA3-CHRNB4 gene cluster
p9727
sg13
I3
sasg14
(lp9728
(dp9729
g7
I101
sg17
VC0028043
p9730
sg10
I19
sg11
Vnicotine dependence
p9731
sg13
I2
sasa(dp9732
g2
S'Here, we evaluated the effect of polymorphisms in CHRNA5-CHRNA3-CHRNB4 gene cluster and their interaction with tobacco smoking status on cognition in patients with Attention Deficit/Hyperactivity Disorder (ADHD).\n'
p9733
sg4
(lp9734
(dp9735
g7
I50
sg8
VP30532
p9736
sg10
I33
sg11
VCHRNA5-CHRNA3-CHRNB4 gene cluster
p9737
sg13
I3
sasg14
(lp9738
(dp9739
g7
I164
sg17
VC1263846
p9740
sg10
I40
sg11
VAttention Deficit/Hyperactivity Disorder
p9741
sg13
I3
sa(dp9742
g7
I206
sg17
VC1263846
p9743
sg10
I4
sg11
VADHD
p9744
sg13
I1
sasa(dp9745
g2
S'Eight SNPs from the CHRNA5-CHRNA3-CHRNB4 gene cluster were evaluated on a clinical sample of 403 adults with ADHD.\n'
p9746
sg4
(lp9747
(dp9748
g7
I34
sg8
VP30926
p9749
sg10
I6
sg11
VCHRNB4
p9750
sg13
I1
sa(dp9751
g7
I20
sg8
VP30532
p9752
sg10
I6
sg11
VCHRNA5
p9753
sg13
I1
sa(dp9754
g7
I27
sg8
VP32297
p9755
sg10
I6
sg11
VCHRNA3
p9756
sg13
I1
sasg14
(lp9757
(dp9758
g7
I109
sg17
VC1263846
p9759
sg10
I4
sg11
VADHD
p9760
sg13
I1
sasa(dp9761
g2
S'The associations between CHRNA5-CHRNA3-CHRNB4 variants and cigarettes per day (CPD), the Fagerstroem Test for Nicotine Dependence (FTND), and craving were analyzed in data from 662 lifetime smokers from an Israeli adult Jewish household sample.\n'
p9762
sg4
(lp9763
(dp9764
g7
I25
sg8
VP30532
p9765
sg10
I29
sg11
VCHRNA5-CHRNA3-CHRNB4 variants
p9766
sg13
I2
sasg14
(lp9767
(dp9768
g7
I110
sg17
VC0028043
p9769
sg10
I19
sg11
VNicotine Dependence
p9770
sg13
I2
sasa(dp9771
g2
S'We found a significant increase in levels of adhesion molecules (VCAM-1) and selectins (E-selectin) in parallel with increased severity of diabetic retinopathy, with a significant difference of inflammatory markers between stages of retinopathy.\n'
p9772
sg4
(lp9773
(dp9774
g7
I88
sg8
VP16581
p9775
sg10
I10
sg11
VE-selectin
p9776
sg13
I1
sa(dp9777
g7
I65
sg8
VP19320
p9778
sg10
I6
sg11
VVCAM-1
p9779
sg13
I1
sasg14
(lp9780
(dp9781
g7
I148
sg17
VC0035309
p9782
sg10
I11
sg11
Vretinopathy
p9783
sg13
I1
sa(dp9784
g7
I139
sg17
VC0011884
p9785
sg10
I20
sg11
Vdiabetic retinopathy
p9786
sg13
I2
sa(dp9787
g7
I45
sg17
VC0001511
p9788
sg10
I8
sg11
Vadhesion
p9789
sg13
I1
sasa(dp9790
g2
S'Our aim was to investigate the role of soluble E-selectin in the formation of diabetic retinopathy.\n'
p9791
sg4
(lp9792
(dp9793
g7
I47
sg8
VP16581
p9794
sg10
I10
sg11
VE-selectin
p9795
sg13
I1
sasg14
(lp9796
(dp9797
g7
I78
sg17
VC0011884
p9798
sg10
I20
sg11
Vdiabetic retinopathy
p9799
sg13
I2
sasa(dp9800
g2
S'An elevated E-selectin level can play a role in the development of diabetic retinopathy, but it does not seem to alter disease severity.\n'
p9801
sg4
(lp9802
(dp9803
g7
I12
sg8
VP16581
p9804
sg10
I10
sg11
VE-selectin
p9805
sg13
I1
sasg14
(lp9806
(dp9807
g7
I67
sg17
VC0011884
p9808
sg10
I20
sg11
Vdiabetic retinopathy
p9809
sg13
I2
sasa(dp9810
g2
S'However, glycemic control and the reduction of cardiovascular risk factors may also alter the level of E-selectin that might play a role in the prevention of diabetic retinopathy.\n'
p9811
sg4
(lp9812
(dp9813
g7
I103
sg8
VP16581
p9814
sg10
I10
sg11
VE-selectin
p9815
sg13
I1
sasg14
(lp9816
(dp9817
g7
I158
sg17
VC0011884
p9818
sg10
I20
sg11
Vdiabetic retinopathy
p9819
sg13
I2
sasa(dp9820
g2
S'To evaluate efficacy of the treatment, the progression of the disease (number of laser treatments, number of bevacizumab treatments, and incidence of retinal detachment) was evaluated by serial ophthalmologic examinations, and plasma soluble E-selectin levels were measured weekly.\n'
p9821
sg4
(lp9822
(dp9823
g7
I227
sg8
VP16581
p9824
sg10
I25
sg11
Vplasma soluble E-selectin
p9825
sg13
I3
sasg14
(lp9826
(dp9827
g7
I150
sg17
VC0035305
p9828
sg10
I18
sg11
Vretinal detachment
p9829
sg13
I2
sasa(dp9830
g2
S'After adjusting for age, glycemic control, and other potential confounders, baseline plasma levels of E-selectin were associated significantly with progression of DR, E-selectin and tumor necrosis factor-Alfa (TNF-Alfa) levels with incidence of proliferative DR (PDR), and soluble intercellular adhesion molecule-1 (sICAM-1) and TNF-Alfa levels with incidence of macular edema (ME).\n'
p9831
sg4
(lp9832
(dp9833
g7
I210
sg8
VP01375
p9834
sg10
I8
sg11
VTNF-Alfa
p9835
sg13
I1
sa(dp9836
g7
I210
sg8
VP01375
p9837
sg10
I8
sg11
VTNF-Alfa
p9838
sg13
I1
sa(dp9839
g7
I102
sg8
VP16581
p9840
sg10
I10
sg11
VE-selectin
p9841
sg13
I1
sa(dp9842
g7
I102
sg8
VP16581
p9843
sg10
I10
sg11
VE-selectin
p9844
sg13
I1
sa(dp9845
g7
I281
sg8
VP05362
p9846
sg10
I33
sg11
Vintercellular adhesion molecule-1
p9847
sg13
I3
sa(dp9848
g7
I182
sg8
VP01375
p9849
sg10
I26
sg11
Vtumor necrosis factor-Alfa
p9850
sg13
I3
sasg14
(lp9851
(dp9852
g7
I263
sg17
VC1845050
p9853
sg10
I3
sg11
VPDR
p9854
sg13
I1
sa(dp9855
g7
I363
sg17
VC0271051
p9856
sg10
I13
sg11
Vmacular edema
p9857
sg13
I2
sa(dp9858
g7
I182
sg17
VC0333516
p9859
sg10
I14
sg11
Vtumor necrosis
p9860
sg13
I2
sa(dp9861
g7
I295
sg17
VC0001511
p9862
sg10
I8
sg11
Vadhesion
p9863
sg13
I1
sa(dp9864
g7
I378
sg17
VC0271051
p9865
sg10
I2
sg11
VME
p9866
sg13
I1
sa(dp9867
g7
I245
sg17
VC1845050
p9868
sg10
I16
sg11
Vproliferative DR
p9869
sg13
I2
sasa(dp9870
g2
S'The 6-HT was administrated by perfusion and ejection in "brain slices" of hippocampus, inducing epileptic activity after its administration; the toxin was not able to block the epileptogenic crisis observed in the chronic model of the epilepsy, suggesting that 6-HT did not block the overactive GluRs responsible for this epileptic activity.\n'
p9871
sg4
(lp9872
sg14
(lp9873
(dp9874
g7
I96
sg17
VC0014544
p9875
sg10
I9
sg11
Vepileptic
p9876
sg13
I1
sa(dp9877
g7
I96
sg17
VC0014544
p9878
sg10
I9
sg11
Vepileptic
p9879
sg13
I1
sa(dp9880
g7
I235
sg17
VC0014544
p9881
sg10
I8
sg11
Vepilepsy
p9882
sg13
I1
sasa(dp9883
g2
S'In patients with systemic sclerosis (SSc), the relationship between innate immune activation, represented by increased expression of interferon (IFN)-regulated genes, and vascular injury/activation, manifest by increased endothelin-1 (ET-1), endothelin converting enzyme-1 (ECE1) and intercellular adhesion molecule-1, is uncertain.\n'
p9884
sg4
(lp9885
(dp9886
g7
I274
sg8
g9
sg10
I4
sg11
VECE1
p9887
sg13
I1
sa(dp9888
g7
I145
sg8
VP01562
p9889
sg10
I3
sg11
VIFN
p9890
sg13
I1
sa(dp9891
g7
I235
sg8
VP05305
p9892
sg10
I4
sg11
VET-1
p9893
sg13
I1
sa(dp9894
g7
I221
sg8
VP20800
p9895
sg10
I12
sg11
Vendothelin-1
p9896
sg13
I1
sa(dp9897
g7
I242
sg8
g9
sg10
I30
sg11
Vendothelin converting enzyme-1
p9898
sg13
I3
sa(dp9899
g7
I284
sg8
VP05362
p9900
sg10
I33
sg11
Vintercellular adhesion molecule-1
p9901
sg13
I3
sa(dp9902
g7
I133
sg8
VP01563
p9903
sg10
I10
sg11
Vinterferon
p9904
sg13
I1
sasg14
(lp9905
(dp9906
g7
I298
sg17
VC0001511
p9907
sg10
I8
sg11
Vadhesion
p9908
sg13
I1
sa(dp9909
g7
I17
sg17
VC0036421
p9910
sg10
I18
sg11
Vsystemic sclerosis
p9911
sg13
I2
sa(dp9912
g7
I37
sg17
VC0036421
p9913
sg10
I3
sg11
VSSc
p9914
sg13
I1
sasa(dp9915
g2
S'Recent findings indicate that the level of SR-BI expression correlate with aggressiveness and poor survival in breast and prostate cancer.\n'
p9916
sg4
(lp9917
(dp9918
g7
I43
sg8
g9
sg10
I5
sg11
VSR-BI
p9919
sg13
I1
sasg14
(lp9920
(dp9921
g7
I75
sg17
VC0001807
p9922
sg10
I14
sg11
Vaggressiveness
p9923
sg13
I1
sa(dp9924
g7
I122
sg17
VC0600139
p9925
sg10
I15
sg11
Vprostate cancer
p9926
sg13
I2
sasa(dp9927
g2
S'Furthermore, we performed immunohistochemistry analysis on human primary prostate cancer tissue sections derived from patients to investigate the correlation of SR-BI with clinicopathological parameters and the mTOR target pS6.\n'
p9928
sg4
(lp9929
(dp9930
g7
I211
sg8
VP42345
p9931
sg10
I4
sg11
VmTOR
p9932
sg13
I1
sa(dp9933
g7
I161
sg8
g9
sg10
I5
sg11
VSR-BI
p9934
sg13
I1
sasg14
(lp9935
(dp9936
g7
I73
sg17
VC0600139
p9937
sg10
I15
sg11
Vprostate cancer
p9938
sg13
I2
sasa(dp9939
g2
S'In contrast to LDLR, we identified SR-BI mRNA and protein expression to be induced in high Gleason grade primary prostate cancers.\n'
p9940
sg4
(lp9941
(dp9942
g7
I15
sg8
VP01130
p9943
sg10
I4
sg11
VLDLR
p9944
sg13
I1
sa(dp9945
g7
I35
sg8
g9
sg10
I10
sg11
VSR-BI mRNA
p9946
sg13
I2
sasg14
(lp9947
(dp9948
g7
I113
sg17
VC0376358
p9949
sg10
I16
sg11
Vprostate cancers
p9950
sg13
I2
sasa(dp9951
g2
S'We identified SR-BI to indicate human prostate cancer formation, suggesting that increased levels of SR-BI may be involved in the generation of a castration-resistant phenotype.\n'
p9952
sg4
(lp9953
(dp9954
g7
I14
sg8
g9
sg10
I5
sg11
VSR-BI
p9955
sg13
I1
sa(dp9956
g7
I14
sg8
g9
sg10
I5
sg11
VSR-BI
p9957
sg13
I1
sasg14
(lp9958
(dp9959
g7
I38
sg17
VC0600139
p9960
sg10
I15
sg11
Vprostate cancer
p9961
sg13
I2
sasa(dp9962
g2
S'Silencing of SR-BI may impact the ability of prostate cancer cells, particularly those of castration-resistant state, to maintain the intracellular supply of androgens by removing a supply of cholesterol.\n'
p9963
sg4
(lp9964
(dp9965
g7
I13
sg8
g9
sg10
I5
sg11
VSR-BI
p9966
sg13
I1
sasg14
(lp9967
(dp9968
g7
I45
sg17
VC0600139
p9969
sg10
I15
sg11
Vprostate cancer
p9970
sg13
I2
sasa(dp9971
g2
S'The down-regulation of SR-BI significantly impacts PSA production of prostate cancer cells, as well as the viability of C4-2 cells in the presence and absence of HDL.\n'
p9972
sg4
(lp9973
(dp9974
g7
I51
sg8
VP55786
p9975
sg10
I3
sg11
VPSA
p9976
sg13
I1
sa(dp9977
g7
I23
sg8
g9
sg10
I5
sg11
VSR-BI
p9978
sg13
I1
sa(dp9979
g7
I162
sg8
VP28845
p9980
sg10
I3
sg11
VHDL
p9981
sg13
I1
sasg14
(lp9982
(dp9983
g7
I69
sg17
VC0600139
p9984
sg10
I15
sg11
Vprostate cancer
p9985
sg13
I2
sa(dp9986
g7
I51
sg17
VC1519176
p9987
sg10
I3
sg11
VPSA
p9988
sg13
I1
sasa(dp9989
g2
S'This may indicate a deficiency in cholesterol availability to the androgen synthesis pathway or may implicate a role for SR-BI in prostate cancer signal transduction pathways.\n'
p9990
sg4
(lp9991
(dp9992
g7
I121
sg8
g9
sg10
I5
sg11
VSR-BI
p9993
sg13
I1
sasg14
(lp9994
(dp9995
g7
I130
sg17
VC0600139
p9996
sg10
I15
sg11
Vprostate cancer
p9997
sg13
I2
sasa(dp9998
g2
S'play roles in preterm labor and preterm premature rupture of membranes (pPROM); 3) integrated aspects of maternal and fetal host responses (inflammation, altered immune adaptations, endocrine and paracrine mechanisms) play increasingly understood roles in premature activation of parturition; and 4) identification and systemic treatment of common genitourinary infections, most importantly bacterial vaginosis (BV), reduce the risks of preterm delivery and PROM.\n'
p9999
sg4
(lp10000
(dp10001
g7
I72
sg8
VP50454
p10002
sg10
I5
sg11
VpPROM
p10003
sg13
I1
sasg14
(lp10004
(dp10005
g7
I391
sg17
VC0085166
p10006
sg10
I19
sg11
Vbacterial vaginosis
p10007
sg13
I2
sa(dp10008
g7
I437
sg17
VC0151526
p10009
sg10
I16
sg11
Vpreterm delivery
p10010
sg13
I2
sa(dp10011
g7
I14
sg17
VC0022876
p10012
sg10
I13
sg11
Vpreterm labor
p10013
sg13
I2
sa(dp10014
g7
I362
sg17
VC0021311
p10015
sg10
I10
sg11
Vinfections
p10016
sg13
I1
sa(dp10017
g7
I0
sg17
VC0699820
p10018
sg10
I10
sg11
Vplay roles
p10019
sg13
I2
sa(dp10020
g7
I72
sg17
VC0729264
p10021
sg10
I5
sg11
VpPROM
p10022
sg13
I1
sa(dp10023
g7
I140
sg17
VC0021368
p10024
sg10
I12
sg11
Vinflammation
p10025
sg13
I1
sa(dp10026
g7
I32
sg17
VC0729264
p10027
sg10
I38
sg11
Vpreterm premature rupture of membranes
p10028
sg13
I5
sasa(dp10029
g2
S'Univariate analysis showed the following to be significant predictors of PPROM at &lt; 35 weeks: a past history of PTD between 25 and 30 weeks (P &lt; 0.008), cerclage in the current pregnancy (P &lt; 0.0001), bacterial vaginosis (P &lt; 0.011), CL &lt; 25 mm (P &lt; 0.0001) and CF &gt; 25% (P &lt; 0.0001).\n'
p10030
sg4
(lp10031
sg14
(lp10032
(dp10033
g7
I73
sg17
VC0729264
p10034
sg10
I5
sg11
VPPROM
p10035
sg13
I1
sa(dp10036
g7
I210
sg17
VC0085166
p10037
sg10
I19
sg11
Vbacterial vaginosis
p10038
sg13
I2
sa(dp10039
g7
I115
sg17
VC0266006
p10040
sg10
I3
sg11
VPTD
p10041
sg13
I1
sasa(dp10042
g2
S'In this study, localization of gelatinase activities in six cases of glioblastoma, two cases of anaplastic astrocytoma, and six cases of low-grade astrocytomas was investigated by film in situ zymography (FIZ).\n'
p10043
sg4
(lp10044
sg14
(lp10045
(dp10046
g7
I147
sg17
VC0004114
p10047
sg10
I12
sg11
Vastrocytomas
p10048
sg13
I1
sa(dp10049
g7
I96
sg17
VC0334579
p10050
sg10
I22
sg11
Vanaplastic astrocytoma
p10051
sg13
I2
sa(dp10052
g7
I69
sg17
VC0017636
p10053
sg10
I12
sg11
Vglioblastoma
p10054
sg13
I1
sasa(dp10055
g2
S'In situ hybridization of the null cell line HLN-STL-C established from an adult T-cell leukemia patient showed that 100% of the cells contained both EBERs and LMP1 mRNA and about 0.1% of the cells contained gp350/220 mRNA, indicating that a few of the null cells which carried the EBV genome spontaneously entered the late EBV replication cycle.\n'
p10056
sg4
(lp10057
(dp10058
g7
I159
sg8
g9
sg10
I9
sg11
VLMP1 mRNA
p10059
sg13
I2
sasg14
(lp10060
(dp10061
g7
I74
sg17
VC0023492
p10062
sg10
I21
sg11
Vadult T-cell leukemia
p10063
sg13
I3
sasa(dp10064
g2
S'IQ and CELF-3 performance were highly interrelated regardless of whether subjects had autism or were controls.\n'
p10065
sg4
(lp10066
sg14
(lp10067
(dp10068
g7
I86
sg17
VC0004352
p10069
sg10
I6
sg11
Vautism
p10070
sg13
I1
sasa(dp10071
g2
S'Both IQ and CELF-3 ability were positively correlated with STG in controls, but a different pattern was observed in subjects with autism.\n'
p10072
sg4
(lp10073
sg14
(lp10074
(dp10075
g7
I130
sg17
VC0004352
p10076
sg10
I6
sg11
Vautism
p10077
sg13
I1
sasa(dp10078
g2
S'In controls, left STG gray matter was significantly (r = .42, p &lt; or = .05) related to receptive language on the CELF-3; in contrast, a zero order correlation was found with autism.\n'
p10079
sg4
(lp10080
(dp10081
g7
I116
sg8
g9
sg10
I6
sg11
VCELF-3
p10082
sg13
I1
sasg14
(lp10083
(dp10084
g7
I177
sg17
VC0004352
p10085
sg10
I6
sg11
Vautism
p10086
sg13
I1
sasa(dp10087
g2
S'Here, we showed that DUSP10 knockout (KO) mice had increased intestinal epithelial cell (IEC) proliferation and migration and developed less severe colitis than wild-type (WT) mice in response to dextran sodium sulphate (DSS) treatment, which is associated with increased ERK1/2 activation and Kruppel-like factor 5 (KLF5) expression in IEC.\n'
p10088
sg4
(lp10089
(dp10090
g7
I272
sg8
VP27361
p10091
sg10
I6
sg11
VERK1/2
p10092
sg13
I1
sa(dp10093
g7
I294
sg8
g9
sg10
I21
sg11
VKruppel-like factor 5
p10094
sg13
I3
sa(dp10095
g7
I317
sg8
g9
sg10
I4
sg11
VKLF5
p10096
sg13
I1
sa(dp10097
g7
I21
sg8
g9
sg10
I6
sg11
VDUSP10
p10098
sg13
I1
sasg14
(lp10099
(dp10100
g7
I221
sg17
VC0011195
p10101
sg10
I3
sg11
VDSS
p10102
sg13
I1
sa(dp10103
g7
I148
sg17
VC0009319
p10104
sg10
I7
sg11
Vcolitis
p10105
sg13
I1
sa(dp10106
g7
I196
sg17
VC0011195
p10107
sg10
I23
sg11
Vdextran sodium sulphate
p10108
sg13
I3
sa(dp10109
g7
I94
sg17
VC0334094
p10110
sg10
I13
sg11
Vproliferation
p10111
sg13
I1
sasa(dp10112
g2
S'Models of painful small-fiber sensory neuropathy were developed and several laboratories have progressed in the conception of TRPV1 agonists and antagonists.\n'
p10113
sg4
(lp10114
(dp10115
g7
I126
sg8
g9
sg10
I5
sg11
VTRPV1
p10116
sg13
I1
sasg14
(lp10117
(dp10118
g7
I30
sg17
VC0151313
p10119
sg10
I18
sg11
Vsensory neuropathy
p10120
sg13
I2
sa(dp10121
g7
I10
sg17
VC0030193
p10122
sg10
I7
sg11
Vpainful
p10123
sg13
I1
sasa(dp10124
g2
S'TRPV1 is involved in oxidant stress-induced pain and in neuronal injury, contributing to diabetic sensory neuropathy.\n'
p10125
sg4
(lp10126
(dp10127
g7
I0
sg8
g9
sg10
I5
sg11
VTRPV1
p10128
sg13
I1
sasg14
(lp10129
(dp10130
g7
I98
sg17
VC0151313
p10131
sg10
I18
sg11
Vsensory neuropathy
p10132
sg13
I2
sasa(dp10133
g2
S'Despite the impediments posed by phenotypic and genetic heterogeneity among women with PCOS, investigation into one locus, the DENND1A gene, is providing insight into the ovarian steroidogenesis.\n'
p10134
sg4
(lp10135
(dp10136
g7
I127
sg8
g9
sg10
I12
sg11
VDENND1A gene
p10137
sg13
I2
sasg14
(lp10138
(dp10139
g7
I87
sg17
VC0032460
p10140
sg10
I4
sg11
VPCOS
p10141
sg13
I1
sasa(dp10142
g2
S'We conducted a meta-analysis to evaluate the rs10818854, rs2479106, and rs10986105 polymorphism in DENND1A gene with PCOS susceptibility.\n'
p10143
sg4
(lp10144
(dp10145
g7
I99
sg8
g9
sg10
I12
sg11
VDENND1A gene
p10146
sg13
I2
sasg14
(lp10147
(dp10148
g7
I117
sg17
VC0032460
p10149
sg10
I4
sg11
VPCOS
p10150
sg13
I1
sasa(dp10151
g2
S'In conclusion, the DENND1A gene variant is likely to have influence on PCOS risk.\n'
p10152
sg4
(lp10153
(dp10154
g7
I19
sg8
g9
sg10
I12
sg11
VDENND1A gene
p10155
sg13
I2
sasg14
(lp10156
(dp10157
g7
I71
sg17
VC0032460
p10158
sg10
I4
sg11
VPCOS
p10159
sg13
I1
sasa(dp10160
g2
S'PCOS has a strong genetic component, and genome-wide association studies have identified several candidate genes, notably DENND1A, which encodes connecdenn 1, involved in trafficking of endosomes.\n'
p10161
sg4
(lp10162
(dp10163
g7
I145
sg8
g9
sg10
I12
sg11
Vconnecdenn 1
p10164
sg13
I2
sa(dp10165
g7
I122
sg8
g9
sg10
I7
sg11
VDENND1A
p10166
sg13
I1
sasg14
(lp10167
(dp10168
g7
I0
sg17
VC0032460
p10169
sg10
I4
sg11
VPCOS
p10170
sg13
I1
sasa(dp10171
g2
S'Furthermore, overexpression of DENND1A variant 2 in normal theca cells resulted in a PCOS phenotype with increased androgen production.\n'
p10172
sg4
(lp10173
(dp10174
g7
I31
sg8
g9
sg10
I17
sg11
VDENND1A variant 2
p10175
sg13
I3
sasg14
(lp10176
(dp10177
g7
I85
sg17
VC0032460
p10178
sg10
I4
sg11
VPCOS
p10179
sg13
I1
sasa(dp10180
g2
S'In addition, GWAS have suggested that DENND1A, epidermal growth factor signaling, and DNA repair pathways play a role in PCOS pathogenesis.\n'
p10181
sg4
(lp10182
(dp10183
g7
I47
sg8
VP01133
p10184
sg10
I23
sg11
Vepidermal growth factor
p10185
sg13
I3
sa(dp10186
g7
I38
sg8
g9
sg10
I7
sg11
VDENND1A
p10187
sg13
I1
sasg14
(lp10188
(dp10189
g7
I126
sg17
VC0699748
p10190
sg10
I12
sg11
Vpathogenesis
p10191
sg13
I1
sa(dp10192
g7
I121
sg17
VC0032460
p10193
sg10
I4
sg11
VPCOS
p10194
sg13
I1
sasa(dp10195
g2
S'The rs2479106 and rs10818854 polymorphisms in the DENND1A gene have been reported to be extensively associated with risk of polycystic ovary syndrome (PCOS).\n'
p10196
sg4
(lp10197
(dp10198
g7
I50
sg8
g9
sg10
I12
sg11
VDENND1A gene
p10199
sg13
I2
sasg14
(lp10200
(dp10201
g7
I151
sg17
VC0032460
p10202
sg10
I4
sg11
VPCOS
p10203
sg13
I1
sa(dp10204
g7
I124
sg17
VC0032460
p10205
sg10
I25
sg11
Vpolycystic ovary syndrome
p10206
sg13
I3
sasa(dp10207
g2
S'Overall, significant increase of PCOS risk was found between DENND1A-rs10818854 and PCOS susceptibility.\n'
p10208
sg4
(lp10209
(dp10210
g7
I61
sg8
g9
sg10
I7
sg11
VDENND1A
p10211
sg13
I1
sasg14
(lp10212
(dp10213
g7
I33
sg17
VC0032460
p10214
sg10
I4
sg11
VPCOS
p10215
sg13
I1
sa(dp10216
g7
I33
sg17
VC0032460
p10217
sg10
I4
sg11
VPCOS
p10218
sg13
I1
sasa(dp10219
g2
S'This meta-analysis suggested that rs2479106 and rs10818854 polymorphisms in the DENND1A gene were associated with increased risk of PCOS.\n'
p10220
sg4
(lp10221
(dp10222
g7
I80
sg8
g9
sg10
I12
sg11
VDENND1A gene
p10223
sg13
I2
sasg14
(lp10224
(dp10225
g7
I132
sg17
VC0032460
p10226
sg10
I4
sg11
VPCOS
p10227
sg13
I1
sasa(dp10228
g2
S'Variant 2 of the DENND1A gene was found overexpressed in PCOS theca cells and confirmed to enhance androgen production.\n'
p10229
sg4
(lp10230
(dp10231
g7
I17
sg8
g9
sg10
I12
sg11
VDENND1A gene
p10232
sg13
I2
sasg14
(lp10233
(dp10234
g7
I57
sg17
VC0032460
p10235
sg10
I4
sg11
VPCOS
p10236
sg13
I1
sasa(dp10237
g2
S'Our previous research had identified three susceptibility loci (rs2479106, DENND1A; rs13405728, LHCGR; rs13429458, THADA) for PCOS in Han Chinese women.\n'
p10238
sg4
(lp10239
(dp10240
g7
I75
sg8
g9
sg10
I7
sg11
VDENND1A
p10241
sg13
I1
sa(dp10242
g7
I96
sg8
VP22888
p10243
sg10
I5
sg11
VLHCGR
p10244
sg13
I1
sasg14
(lp10245
(dp10246
g7
I126
sg17
VC0032460
p10247
sg10
I4
sg11
VPCOS
p10248
sg13
I1
sasa(dp10249
g2
S'Three of the eleven variants associated with PCOS in the Han Chinese genome-wide association studies were also associated with PCOS in at least one European population when corrected for multiple testing (DENND1A, THADA and YAP1).\n'
p10250
sg4
(lp10251
(dp10252
g7
I224
sg8
VP46937
p10253
sg10
I4
sg11
VYAP1
p10254
sg13
I1
sa(dp10255
g7
I205
sg8
g9
sg10
I7
sg11
VDENND1A
p10256
sg13
I1
sasg14
(lp10257
(dp10258
g7
I45
sg17
VC0032460
p10259
sg10
I4
sg11
VPCOS
p10260
sg13
I1
sa(dp10261
g7
I45
sg17
VC0032460
p10262
sg10
I4
sg11
VPCOS
p10263
sg13
I1
sasa(dp10264
g2
S'MicroRNA-106a-5p (MiR-106a-5p), a small non-coding RNA, has been reported to be downregulated in astrocytoma, osteosarcoma and colorectal cancer.\n'
p10265
sg4
(lp10266
(dp10267
g7
I0
sg8
g9
sg10
I16
sg11
VMicroRNA-106a-5p
p10268
sg13
I1
sa(dp10269
g7
I18
sg8
g9
sg10
I11
sg11
VMiR-106a-5p
p10270
sg13
I1
sasg14
(lp10271
(dp10272
g7
I127
sg17
VC1527249
p10273
sg10
I17
sg11
Vcolorectal cancer
p10274
sg13
I2
sa(dp10275
g7
I97
sg17
VC0004114
p10276
sg10
I11
sg11
Vastrocytoma
p10277
sg13
I1
sa(dp10278
g7
I110
sg17
VC0029463
p10279
sg10
I12
sg11
Vosteosarcoma
p10280
sg13
I1
sasa(dp10281
g2
S'The study aimed to evaluate the effects of miR-106a on prostate cancer cells and the underlying molecular mechanism.\n'
p10282
sg4
(lp10283
(dp10284
g7
I43
sg8
g9
sg10
I8
sg11
VmiR-106a
p10285
sg13
I1
sasg14
(lp10286
(dp10287
g7
I55
sg17
VC0600139
p10288
sg10
I15
sg11
Vprostate cancer
p10289
sg13
I2
sasa(dp10290
g2
S'MiR-106a as an oncogene could promote proliferation and metastasis of prostate cancer cells by directly targeting PTEN in vivo and in vitro.\n'
p10291
sg4
(lp10292
(dp10293
g7
I114
sg8
VP60484
p10294
sg10
I4
sg11
VPTEN
p10295
sg13
I1
sa(dp10296
g7
I0
sg8
g9
sg10
I8
sg11
VMiR-106a
p10297
sg13
I1
sasg14
(lp10298
(dp10299
g7
I38
sg17
VC0334094
p10300
sg10
I13
sg11
Vproliferation
p10301
sg13
I1
sa(dp10302
g7
I56
sg17
VC0027627
p10303
sg10
I10
sg11
Vmetastasis
p10304
sg13
I1
sa(dp10305
g7
I70
sg17
VC0600139
p10306
sg10
I15
sg11
Vprostate cancer
p10307
sg13
I2
sasa(dp10308
g2
S'CXCL1 secreted by hAdSCs downregulated miR-106a expression in triple negative breast cancer, and resulted in ABCG2 upregulation and doxorubicin resistance.\n'
p10309
sg4
(lp10310
(dp10311
g7
I39
sg8
g9
sg10
I8
sg11
VmiR-106a
p10312
sg13
I1
sa(dp10313
g7
I0
sg8
VP09341
p10314
sg10
I5
sg11
VCXCL1
p10315
sg13
I1
sasg14
(lp10316
(dp10317
g7
I78
sg17
VC0678222
p10318
sg10
I13
sg11
Vbreast cancer
p10319
sg13
I2
sasa(dp10320
g2
S'Our findings suggest that CXCL1 secreted by hAdSCs elicits doxorubicin resistance through miR-106a-mediated ABCG2 upregulation in triple negative breast cancer.\n'
p10321
sg4
(lp10322
(dp10323
g7
I90
sg8
g9
sg10
I8
sg11
VmiR-106a
p10324
sg13
I1
sa(dp10325
g7
I26
sg8
VP09341
p10326
sg10
I5
sg11
VCXCL1
p10327
sg13
I1
sasg14
(lp10328
(dp10329
g7
I146
sg17
VC0678222
p10330
sg10
I13
sg11
Vbreast cancer
p10331
sg13
I2
sasa(dp10332
g2
S'Copy number gains in SOX2 in the region of 3q26-28 occur in 94% of SQCCs, and appear to act both early and late in disease progression by stabilizing the initial squamous injury response in stem cells and promoting growth of invasive carcinoma.\n'
p10333
sg4
(lp10334
(dp10335
g7
I21
sg8
VP48431
p10336
sg10
I4
sg11
VSOX2
p10337
sg13
I1
sasg14
(lp10338
(dp10339
g7
I225
sg17
VC1334274
p10340
sg10
I18
sg11
Vinvasive carcinoma
p10341
sg13
I2
sa(dp10342
g7
I115
sg17
VC0242656
p10343
sg10
I19
sg11
Vdisease progression
p10344
sg13
I2
sasa(dp10345
g2
S'A key feature of high-grade serous ovarian carcinoma (HGSOC) is frequent amplification of the 3q26 locus harboring PRKC-l (PRKCI).\n'
p10346
sg4
(lp10347
(dp10348
g7
I115
sg8
g9
sg10
I6
sg11
VPRKC-l
p10349
sg13
I1
sa(dp10350
g7
I123
sg8
VP41743
p10351
sg10
I5
sg11
VPRKCI
p10352
sg13
I1
sasg14
(lp10353
(dp10354
g7
I73
sg17
VC1705759
p10355
sg10
I13
sg11
Vamplification
p10356
sg13
I1
sa(dp10357
g7
I35
sg17
VC0029925
p10358
sg10
I17
sg11
Vovarian carcinoma
p10359
sg13
I2
sasa(dp10360
g2
S'Four loci, 5p15.33 (TERT), 6p21.3 (BTNL2), 3q28 (TP63) and 17q24.2 (BPTF), previously shown to be strongly associated with overall lung adenocarcinoma risk in East Asians, were re-discovered as loci associated with a higher susceptibility to EGFR mutation-positive lung adenocarcinoma.\n'
p10361
sg4
(lp10362
sg14
(lp10363
(dp10364
g7
I131
sg17
VC0152013
p10365
sg10
I19
sg11
Vlung adenocarcinoma
p10366
sg13
I2
sa(dp10367
g7
I131
sg17
VC0152013
p10368
sg10
I19
sg11
Vlung adenocarcinoma
p10369
sg13
I2
sasa(dp10370
g2
S'Chromosome 3q26-28 is a critical region of genomic amplification in non-small cell lung cancer (NSCLC), particularly lung squamous cell carcinomas (SCCs).\n'
p10371
sg4
(lp10372
sg14
(lp10373
(dp10374
g7
I96
sg17
VC0007131
p10375
sg10
I5
sg11
VNSCLC
p10376
sg13
I1
sa(dp10377
g7
I68
sg17
VC0007131
p10378
sg10
I26
sg11
Vnon-small cell lung cancer
p10379
sg13
I4
sa(dp10380
g7
I51
sg17
VC1705759
p10381
sg10
I13
sg11
Vamplification
p10382
sg13
I1
sa(dp10383
g7
I148
sg17
VC0007137
p10384
sg10
I4
sg11
VSCCs
p10385
sg13
I1
sa(dp10386
g7
I122
sg17
VC0007137
p10387
sg10
I24
sg11
Vsquamous cell carcinomas
p10388
sg13
I3
sasa(dp10389
g2
S'The PIK3CA gene at chromosome 3q26.32 was found to be amplified in up to 45% of patients with squamous cell carcinoma of the lung.\n'
p10390
sg4
(lp10391
(dp10392
g7
I4
sg8
VP42336
p10393
sg10
I11
sg11
VPIK3CA gene
p10394
sg13
I2
sasg14
(lp10395
(dp10396
g7
I94
sg17
VC0149782
p10397
sg10
I35
sg11
Vsquamous cell carcinoma of the lung
p10398
sg13
I6
sasa(dp10399
g2
S'Aspirin/NSAID interacted with MAP3K7 (colon cancer) and with MAPK14, NFAT5, and TRAF2 (rectal cancer); smoking cigarettes interacted with NFAM1 and NFAT2 (colon cancer) and MAPK8, NFAT5, and TNFRSF1A (rectal cancer); BMI interacted with NFAM1 and NFAT5 (colon cancer) and with MAPK8 and TNFRSF1A (rectal cancer).\n'
p10400
sg4
(lp10401
(dp10402
g7
I148
sg8
g9
sg10
I20
sg11
VNFAT2 (colon cancer)
p10403
sg13
I3
sa(dp10404
g7
I191
sg8
VP19438
p10405
sg10
I8
sg11
VTNFRSF1A
p10406
sg13
I1
sa(dp10407
g7
I69
sg8
g9
sg10
I5
sg11
VNFAT5
p10408
sg13
I1
sa(dp10409
g7
I138
sg8
g9
sg10
I5
sg11
VNFAM1
p10410
sg13
I1
sa(dp10411
g7
I69
sg8
g9
sg10
I5
sg11
VNFAT5
p10412
sg13
I1
sa(dp10413
g7
I30
sg8
g9
sg10
I21
sg11
VMAP3K7 (colon cancer)
p10414
sg13
I3
sa(dp10415
g7
I80
sg8
g9
sg10
I5
sg11
VTRAF2
p10416
sg13
I1
sa(dp10417
g7
I173
sg8
VP45983
p10418
sg10
I5
sg11
VMAPK8
p10419
sg13
I1
sa(dp10420
g7
I138
sg8
g9
sg10
I5
sg11
VNFAM1
p10421
sg13
I1
sa(dp10422
g7
I247
sg8
g9
sg10
I20
sg11
VNFAT5 (colon cancer)
p10423
sg13
I3
sa(dp10424
g7
I173
sg8
VP45983
p10425
sg10
I5
sg11
VMAPK8
p10426
sg13
I1
sa(dp10427
g7
I61
sg8
g9
sg10
I6
sg11
VMAPK14
p10428
sg13
I1
sa(dp10429
g7
I191
sg8
VP19438
p10430
sg10
I8
sg11
VTNFRSF1A
p10431
sg13
I1
sasg14
(lp10432
(dp10433
g7
I87
sg17
VC0007113
p10434
sg10
I13
sg11
Vrectal cancer
p10435
sg13
I2
sa(dp10436
g7
I87
sg17
VC0007113
p10437
sg10
I13
sg11
Vrectal cancer
p10438
sg13
I2
sa(dp10439
g7
I38
sg17
VC0699790
p10440
sg10
I12
sg11
Vcolon cancer
p10441
sg13
I2
sa(dp10442
g7
I38
sg17
VC0699790
p10443
sg10
I12
sg11
Vcolon cancer
p10444
sg13
I2
sa(dp10445
g7
I87
sg17
VC0007113
p10446
sg10
I13
sg11
Vrectal cancer
p10447
sg13
I2
sa(dp10448
g7
I38
sg17
VC0699790
p10449
sg10
I12
sg11
Vcolon cancer
p10450
sg13
I2
sasa(dp10451
g2
S'Previously, we have cloned the cDNAs for the meningioma expressed antigen 6 (MGEA6) and its splice variant MGEA11.\n'
p10452
sg4
(lp10453
sg14
(lp10454
(dp10455
g7
I45
sg17
VC0025286
p10456
sg10
I10
sg11
Vmeningioma
p10457
sg13
I1
sasa(dp10458
g2
S'Here, we show that antibodies against recombinantly expressed MGEA6/11 are found in 41.7% (10/24) of the sera from meningioma patients and in 2/8 sera of glioblastoma patients, whereas no response was seen in 12 sera from healthy persons.\n'
p10459
sg4
(lp10460
(dp10461
g7
I62
sg8
g9
sg10
I8
sg11
VMGEA6/11
p10462
sg13
I1
sasg14
(lp10463
(dp10464
g7
I154
sg17
VC0017636
p10465
sg10
I12
sg11
Vglioblastoma
p10466
sg13
I1
sa(dp10467
g7
I115
sg17
VC0025286
p10468
sg10
I10
sg11
Vmeningioma
p10469
sg13
I1
sasa(dp10470
g2
S'The immune response to MGEA6/11 is frequent in both meningioma and glioma patients and may likely be attributed to overexpression of the MGEA6/11 protein in the tumor cells.\n'
p10471
sg4
(lp10472
(dp10473
g7
I137
sg8
g9
sg10
I16
sg11
VMGEA6/11 protein
p10474
sg13
I2
sa(dp10475
g7
I23
sg8
g9
sg10
I8
sg11
VMGEA6/11
p10476
sg13
I1
sasg14
(lp10477
(dp10478
g7
I161
sg17
VC0027651
p10479
sg10
I5
sg11
Vtumor
p10480
sg13
I1
sa(dp10481
g7
I67
sg17
VC0017638
p10482
sg10
I6
sg11
Vglioma
p10483
sg13
I1
sa(dp10484
g7
I52
sg17
VC0025286
p10485
sg10
I10
sg11
Vmeningioma
p10486
sg13
I1
sasa(dp10487
g2
S'The meningioma expressed antigen-6 (MGEA6) was originally identified as an immunogenic antigen in meningioma patients.\n'
p10488
sg4
(lp10489
(dp10490
g7
I4
sg8
g9
sg10
I30
sg11
Vmeningioma expressed antigen-6
p10491
sg13
I3
sa(dp10492
g7
I36
sg8
g9
sg10
I5
sg11
VMGEA6
p10493
sg13
I1
sasg14
(lp10494
(dp10495
g7
I4
sg17
VC0025286
p10496
sg10
I10
sg11
Vmeningioma
p10497
sg13
I1
sa(dp10498
g7
I4
sg17
VC0025286
p10499
sg10
I10
sg11
Vmeningioma
p10500
sg13
I1
sasa(dp10501
g2
S'The clones were sequenced, and sequence comparison revealed that the seven clones represent five different genes, providing evidence that meningiomas express a spectrum of immunoreactive antigens, which were termed meningioma expressed antigens (MGEAs).\n'
p10502
sg4
(lp10503
sg14
(lp10504
(dp10505
g7
I138
sg17
VC0025286
p10506
sg10
I10
sg11
Vmeningioma
p10507
sg13
I1
sa(dp10508
g7
I138
sg17
VC0025286
p10509
sg10
I11
sg11
Vmeningiomas
p10510
sg13
I1
sasa(dp10511
g2
S'These data suggest that the newly identified MGEA genes may be useful for diagnosis and possibly therapy of meningioma.\n'
p10512
sg4
(lp10513
(dp10514
g7
I45
sg8
g9
sg10
I10
sg11
VMGEA genes
p10515
sg13
I2
sasg14
(lp10516
(dp10517
g7
I108
sg17
VC0025286
p10518
sg10
I10
sg11
Vmeningioma
p10519
sg13
I1
sasa(dp10520
g2
S'The longest open reading frame was found to be 2412 bp encoding an immunoreactive antigen termed meningioma expressed antigen 6 (MEA6).\n'
p10521
sg4
(lp10522
sg14
(lp10523
(dp10524
g7
I97
sg17
VC0025286
p10525
sg10
I10
sg11
Vmeningioma
p10526
sg13
I1
sasa(dp10527
g2
S"Using the keywords [St John's Wort OR Hypericum perforatum OR hypericin OR hyperforin OR johanniskraut OR] AND [depression OR antidepressant OR SSRI], a preliminary search (without language restriction) on the PubMed, Ovid, Clinical Trials Register of the Cochrane Collaboration Depression, Anxiety and Neurosis Group, Cochrane Field for Complementary Medicine, China National Knowledge Infrastructure and WanFang database yielded 5428 papers between 1-Jan-1960 and 1-May-2016.\n"
p10528
sg4
(lp10529
sg14
(lp10530
(dp10531
g7
I303
sg17
VC0027932
p10532
sg10
I8
sg11
VNeurosis
p10533
sg13
I1
sa(dp10534
g7
I112
sg17
VC0011581
p10535
sg10
I10
sg11
Vdepression
p10536
sg13
I1
sa(dp10537
g7
I279
sg17
VC0011581
p10538
sg10
I10
sg11
VDepression
p10539
sg13
I1
sasa(dp10540
g2
S'There is evidence to suggest that caregivers of patients with head and neck cancer (HNC) are susceptible to post-traumatic stress disorder (PTSD) symptoms.\n'
p10541
sg4
(lp10542
sg14
(lp10543
(dp10544
g7
I108
sg17
VC0038436
p10545
sg10
I30
sg11
Vpost-traumatic stress disorder
p10546
sg13
I3
sa(dp10547
g7
I140
sg17
VC0038436
p10548
sg10
I4
sg11
VPTSD
p10549
sg13
I1
sa(dp10550
g7
I62
sg17
VC0278996
p10551
sg10
I20
sg11
Vhead and neck cancer
p10552
sg13
I4
sa(dp10553
g7
I84
sg17
VC0278996
p10554
sg10
I3
sg11
VHNC
p10555
sg13
I1
sasa(dp10556
g2
S'Evidence suggests that patients with head and neck cancer (HNC) are susceptible to post-traumatic stress disorder (PTSD).\n'
p10557
sg4
(lp10558
sg14
(lp10559
(dp10560
g7
I83
sg17
VC0038436
p10561
sg10
I30
sg11
Vpost-traumatic stress disorder
p10562
sg13
I3
sa(dp10563
g7
I115
sg17
VC0038436
p10564
sg10
I4
sg11
VPTSD
p10565
sg13
I1
sa(dp10566
g7
I59
sg17
VC0278996
p10567
sg10
I3
sg11
VHNC
p10568
sg13
I1
sa(dp10569
g7
I37
sg17
VC0278996
p10570
sg10
I20
sg11
Vhead and neck cancer
p10571
sg13
I4
sasa(dp10572
g2
S'Among distressed HNC survivors, higher PTG was associated with lower tumor stage, absence of an anxiety disorder, absence of an alcohol use disorder, and better social functioning.\n'
p10573
sg4
(lp10574
sg14
(lp10575
(dp10576
g7
I69
sg17
VC0027651
p10577
sg10
I5
sg11
Vtumor
p10578
sg13
I1
sa(dp10579
g7
I96
sg17
VC0003469
p10580
sg10
I16
sg11
Vanxiety disorder
p10581
sg13
I2
sa(dp10582
g7
I6
sg17
VC0700361
p10583
sg10
I10
sg11
Vdistressed
p10584
sg13
I1
sa(dp10585
g7
I128
sg17
VC0001956
p10586
sg10
I20
sg11
Valcohol use disorder
p10587
sg13
I3
sasa(dp10588
g2
S'Although lysyl oxidase-like 1 (LOXL1) is known as the principal genetic risk factor for pseudoexfoliation (PEX) syndrome, a major cause of glaucoma and cardiovascular complications, no functional variants have been identified to date.\n'
p10589
sg4
(lp10590
(dp10591
g7
I31
sg8
g9
sg10
I5
sg11
VLOXL1
p10592
sg13
I1
sa(dp10593
g7
I9
sg8
g9
sg10
I20
sg11
Vlysyl oxidase-like 1
p10594
sg13
I3
sasg14
(lp10595
(dp10596
g7
I112
sg17
VC0039082
p10597
sg10
I8
sg11
Vsyndrome
p10598
sg13
I1
sa(dp10599
g7
I139
sg17
VC0017601
p10600
sg10
I8
sg11
Vglaucoma
p10601
sg13
I1
sasa(dp10602
g2
S'Recent studies have shed new light on the genetic factors underlying pseudoexfoliation syndrome, growing our understanding of the role of the lysyl oxidase-like 1 (LOXL1) gene and its various polymorphisms as well as identifying new genetic associations.\n'
p10603
sg4
(lp10604
(dp10605
g7
I142
sg8
g9
sg10
I20
sg11
Vlysyl oxidase-like 1
p10606
sg13
I3
sa(dp10607
g7
I164
sg8
g9
sg10
I5
sg11
VLOXL1
p10608
sg13
I1
sasg14
(lp10609
(dp10610
g7
I69
sg17
VC0206368
p10611
sg10
I26
sg11
Vpseudoexfoliation syndrome
p10612
sg13
I2
sasa(dp10613
g2
S'We found that TAPP2, syntrophin, and utrophin are coexpressed in normal human B cells and B-chronic lymphocytic leukemia (B-CLL) cells.\n'
p10614
sg4
(lp10615
(dp10616
g7
I37
sg8
VP46939
p10617
sg10
I8
sg11
Vutrophin
p10618
sg13
I1
sa(dp10619
g7
I14
sg8
g9
sg10
I5
sg11
VTAPP2
p10620
sg13
I1
sasg14
(lp10621
(dp10622
g7
I124
sg17
VC0023434
p10623
sg10
I3
sg11
VCLL
p10624
sg13
I1
sa(dp10625
g7
I92
sg17
VC0023434
p10626
sg10
I28
sg11
Vchronic lymphocytic leukemia
p10627
sg13
I3
sasa(dp10628
g2
S'CREB1 expression, which was activated by E2F, was coupled with RFC3 expression during the G1/S progression in the KG-1 acute myeloid leukemia (AML) cell line.\n'
p10629
sg4
(lp10630
(dp10631
g7
I0
sg8
VP16220
p10632
sg10
I5
sg11
VCREB1
p10633
sg13
I1
sa(dp10634
g7
I63
sg8
VP40938
p10635
sg10
I4
sg11
VRFC3
p10636
sg13
I1
sasg14
(lp10637
(dp10638
g7
I143
sg17
VC0023467
p10639
sg10
I3
sg11
VAML
p10640
sg13
I1
sa(dp10641
g7
I119
sg17
VC0023467
p10642
sg10
I22
sg11
Vacute myeloid leukemia
p10643
sg13
I3
sasa(dp10644
g2
S'The National Reference Center for equine infectious anemia (EIA) validated a commercial ELISA (Eradikit(R) EIAV Indirect ELISA, In3diagnostic(R), Turin, Italy) employing a chimeric recombinant gag and env peptide for the detection of EIA virus antibodies, following the guidelines of the World Organization for Animal Health.\n'
p10645
sg4
(lp10646
(dp10647
g7
I172
sg8
VP87889
p10648
sg10
I24
sg11
Vchimeric recombinant gag
p10649
sg13
I3
sa(dp10650
g7
I201
sg8
g9
sg10
I3
sg11
Venv
p10651
sg13
I1
sasg14
(lp10652
(dp10653
g7
I60
sg17
VC0014661
p10654
sg10
I3
sg11
VEIA
p10655
sg13
I1
sa(dp10656
g7
I60
sg17
VC0014661
p10657
sg10
I3
sg11
VEIA
p10658
sg13
I1
sa(dp10659
g7
I34
sg17
VC0014661
p10660
sg10
I24
sg11
Vequine infectious anemia
p10661
sg13
I3
sasa(dp10662
g2
S'The development of anaemia in feline leukaemia virus (FeLV)-infected cats is associated with the emergence of a novel viral subgroup, FeLV-C. FeLV-C arises from the subgroup that is transmitted, FeLV-A, through alterations in the amino acid sequence of the receptor binding domain (RBD) of the envelope glycoprotein that result in a shift in the receptor usage and the cell tropism of the virus.\n'
p10663
sg4
(lp10664
(dp10665
g7
I294
sg8
g9
sg10
I21
sg11
Venvelope glycoprotein
p10666
sg13
I2
sasg14
(lp10667
(dp10668
g7
I37
sg17
VC0023418
p10669
sg10
I9
sg11
Vleukaemia
p10670
sg13
I1
sa(dp10671
g7
I19
sg17
VC0002871
p10672
sg10
I7
sg11
Vanaemia
p10673
sg13
I1
sa(dp10674
g7
I182
sg17
VC0242781
p10675
sg10
I11
sg11
Vtransmitted
p10676
sg13
I1
sasa(dp10677
g2
S'These results suggest that the interaction between sf-Stk and the envelope proteins of the polycythemia- and anemia-inducing variants of SFFV is architecturally different.\n'
p10678
sg4
(lp10679
(dp10680
g7
I66
sg8
g9
sg10
I8
sg11
Venvelope
p10681
sg13
I1
sa(dp10682
g7
I51
sg8
VP52823
p10683
sg10
I6
sg11
Vsf-Stk
p10684
sg13
I1
sasg14
(lp10685
(dp10686
g7
I109
sg17
VC0002871
p10687
sg10
I6
sg11
Vanemia
p10688
sg13
I1
sa(dp10689
g7
I91
sg17
VC0032461
p10690
sg10
I12
sg11
Vpolycythemia
p10691
sg13
I1
sasa(dp10692
g2
S'We conclude that the common clinical features of patients with an isolated mutation of ZRSR2 are a macrocytic anemia without leukopenia, thrombocytopenia or an increase in marrow blast percentage.\n'
p10693
sg4
(lp10694
(dp10695
g7
I87
sg8
g9
sg10
I5
sg11
VZRSR2
p10696
sg13
I1
sasg14
(lp10697
(dp10698
g7
I99
sg17
VC0002886
p10699
sg10
I17
sg11
Vmacrocytic anemia
p10700
sg13
I2
sa(dp10701
g7
I125
sg17
VC0023530
p10702
sg10
I10
sg11
Vleukopenia
p10703
sg13
I1
sasa(dp10704
g2
S'Recent studies have shown that recombinant human thrombomodulin (rhTM) improves exacerbation and clinical outcome of idiopathic pulmonary fibrosis, but the mechanism remains unknown.\n'
p10705
sg4
(lp10706
(dp10707
g7
I31
sg8
VP07204
p10708
sg10
I32
sg11
Vrecombinant human thrombomodulin
p10709
sg13
I3
sa(dp10710
g7
I65
sg8
VP07204
p10711
sg10
I4
sg11
VrhTM
p10712
sg13
I1
sasg14
(lp10713
(dp10714
g7
I117
sg17
VC3161101
p10715
sg10
I29
sg11
Vidiopathic pulmonary fibrosis
p10716
sg13
I3
sasa(dp10717
g2
S'This furthers our understanding of the regulatory mechanism of cardiac sarcomere assembly in both physiologic and pathologic contexts, and uncovers a potential novel pathway to cardiomyopathy through modulating the Stk38/Rbm24 protein activity.\n'
p10718
sg4
(lp10719
(dp10720
g7
I215
sg8
g9
sg10
I5
sg11
VStk38
p10721
sg13
I1
sa(dp10722
g7
I221
sg8
g9
sg10
I13
sg11
VRbm24 protein
p10723
sg13
I2
sasg14
(lp10724
(dp10725
g7
I177
sg17
VC0878544
p10726
sg10
I14
sg11
Vcardiomyopathy
p10727
sg13
I1
sasa(dp10728
g2
S'This study uncovers a potential novel pathway to cardiomyopathy through down-regulation of the RBP Rbm24.\n'
p10729
sg4
(lp10730
(dp10731
g7
I95
sg8
g9
sg10
I9
sg11
VRBP Rbm24
p10732
sg13
I2
sasg14
(lp10733
(dp10734
g7
I49
sg17
VC0878544
p10735
sg10
I14
sg11
Vcardiomyopathy
p10736
sg13
I1
sasa(dp10737
g2
S'Nsp3 proteins of Semliki Forest (SFV), Sindbis (SINV), and Chikungunya viruses all showed avid and SH3-dependent binding to amphiphysins.\n'
p10738
sg4
(lp10739
(dp10740
g7
I0
sg8
g9
sg10
I13
sg11
VNsp3 proteins
p10741
sg13
I2
sasg14
(lp10742
(dp10743
g7
I59
sg17
VC0008055
p10744
sg10
I11
sg11
VChikungunya
p10745
sg13
I1
sasa(dp10746
g2
S'Colitis severity was assessed by body weight, colonoscopy, colon length, histological score, cytokine mRNA expression, and myeloperoxidase (MPO) activity.\n'
p10747
sg4
(lp10748
(dp10749
g7
I123
sg8
VP05164
p10750
sg10
I15
sg11
Vmyeloperoxidase
p10751
sg13
I1
sa(dp10752
g7
I140
sg8
VP05164
p10753
sg10
I3
sg11
VMPO
p10754
sg13
I1
sasg14
(lp10755
(dp10756
g7
I0
sg17
VC0009319
p10757
sg10
I7
sg11
VColitis
p10758
sg13
I1
sasa(dp10759
g2
S'Pigmentary hypertrichosis and non-autoimmune insulin-dependent diabetes mellitus (PHID) is associated with recessive mutations in SLC29A3, encoding the equilibrative nucleoside transporter hENT3 expressed in mitochondria, causing PHID and H syndromes, familial Rosai-Dorfman disease, and histiocytosis-lymphadenopathy-plus syndrome.\n'
p10760
sg4
(lp10761
(dp10762
g7
I45
sg8
VP01308
p10763
sg10
I7
sg11
Vinsulin
p10764
sg13
I1
sa(dp10765
g7
I166
sg8
g9
sg10
I28
sg11
Vnucleoside transporter hENT3
p10766
sg13
I3
sasg14
(lp10767
(dp10768
g7
I82
sg17
VC1864445
p10769
sg10
I4
sg11
VPHID
p10770
sg13
I1
sa(dp10771
g7
I241
sg17
VC0039082
p10772
sg10
I8
sg11
Vsyndrome
p10773
sg13
I1
sa(dp10774
g7
I11
sg17
VC0020555
p10775
sg10
I14
sg11
Vhypertrichosis
p10776
sg13
I1
sa(dp10777
g7
I288
sg17
VC0019618
p10778
sg10
I13
sg11
Vhistiocytosis
p10779
sg13
I1
sa(dp10780
g7
I34
sg17
VC0443146
p10781
sg10
I10
sg11
Vautoimmune
p10782
sg13
I1
sa(dp10783
g7
I241
sg17
VC0039082
p10784
sg10
I9
sg11
Vsyndromes
p10785
sg13
I1
sa(dp10786
g7
I82
sg17
VC1864445
p10787
sg10
I4
sg11
VPHID
p10788
sg13
I1
sa(dp10789
g7
I261
sg17
VC0019625
p10790
sg10
I21
sg11
VRosai-Dorfman disease
p10791
sg13
I2
sa(dp10792
g7
I45
sg17
VC0011854
p10793
sg10
I35
sg11
Vinsulin-dependent diabetes mellitus
p10794
sg13
I3
sasa(dp10795
g2
S'The patients share many of the characteristics previously reported with H syndrome, including hyperpigmentation, hypertrichosis, short stature, insulin-dependent diabetes, arthritis and systemic inflammation, as well as some novel features, including selective IgG subclass deficiency and autoimmune hepatitis.\n'
p10796
sg4
(lp10797
(dp10798
g7
I144
sg8
VP01308
p10799
sg10
I7
sg11
Vinsulin
p10800
sg13
I1
sasg14
(lp10801
(dp10802
g7
I172
sg17
VC0003864
p10803
sg10
I9
sg11
Varthritis
p10804
sg13
I1
sa(dp10805
g7
I251
sg17
VC0162539
p10806
sg10
I33
sg11
Vselective IgG subclass deficiency
p10807
sg13
I4
sa(dp10808
g7
I129
sg17
VC0013336
p10809
sg10
I13
sg11
Vshort stature
p10810
sg13
I2
sa(dp10811
g7
I195
sg17
VC0021368
p10812
sg10
I12
sg11
Vinflammation
p10813
sg13
I1
sa(dp10814
g7
I94
sg17
VC0162834
p10815
sg10
I17
sg11
Vhyperpigmentation
p10816
sg13
I1
sa(dp10817
g7
I72
sg17
VC1864445
p10818
sg10
I10
sg11
VH syndrome
p10819
sg13
I2
sa(dp10820
g7
I289
sg17
VC0241910
p10821
sg10
I20
sg11
Vautoimmune hepatitis
p10822
sg13
I2
sa(dp10823
g7
I144
sg17
VC0011854
p10824
sg10
I26
sg11
Vinsulin-dependent diabetes
p10825
sg13
I2
sa(dp10826
g7
I113
sg17
VC0020555
p10827
sg10
I14
sg11
Vhypertrichosis
p10828
sg13
I1
sasa(dp10829
g2
S'Loss of function recessive mutations in the SLC29A3 gene that encodes human equilibrative nucleoside transporter 3 (ENT3) have been identified in patients with pigmented hypertrichotic dermatosis with insulin-dependent diabetes (PHID).\n'
p10830
sg4
(lp10831
(dp10832
g7
I70
sg8
g9
sg10
I44
sg11
Vhuman equilibrative nucleoside transporter 3
p10833
sg13
I5
sa(dp10834
g7
I201
sg8
VP01308
p10835
sg10
I7
sg11
Vinsulin
p10836
sg13
I1
sasg14
(lp10837
(dp10838
g7
I160
sg17
VC1864445
p10839
sg10
I67
sg11
Vpigmented hypertrichotic dermatosis with insulin-dependent diabetes
p10840
sg13
I6
sa(dp10841
g7
I229
sg17
VC1864445
p10842
sg10
I4
sg11
VPHID
p10843
sg13
I1
sasa(dp10844
g2
S'Thus, apoptotic loss of islet Beta-cells may contribute to the occurrence of autoantibody-negative insulin-dependent diabetes in individuals with non-functional ENT3 mutations.\n'
p10845
sg4
(lp10846
(dp10847
g7
I99
sg8
VP01308
p10848
sg10
I7
sg11
Vinsulin
p10849
sg13
I1
sasg14
(lp10850
(dp10851
g7
I99
sg17
VC0011854
p10852
sg10
I26
sg11
Vinsulin-dependent diabetes
p10853
sg13
I2
sasa(dp10854
g2
S'H syndrome and pigmented hypertrichosis with insulin-dependent diabetes mellitus (PHID) had been described as two autosomal recessive disorders.\n'
p10855
sg4
(lp10856
(dp10857
g7
I45
sg8
VP01308
p10858
sg10
I7
sg11
Vinsulin
p10859
sg13
I1
sasg14
(lp10860
(dp10861
g7
I82
sg17
VC1864445
p10862
sg10
I4
sg11
VPHID
p10863
sg13
I1
sa(dp10864
g7
I0
sg17
VC1864445
p10865
sg10
I10
sg11
VH syndrome
p10866
sg13
I2
sa(dp10867
g7
I15
sg17
VC1864445
p10868
sg10
I65
sg11
Vpigmented hypertrichosis with insulin-dependent diabetes mellitus
p10869
sg13
I6
sasa(dp10870
g2
S'The term H syndrome was coined to denote the major clinical findings which include hyperpigmentation, hypertrichosis, hearing loss, hepatosplenomegaly, hypogonadism, hyperglycemia/diabetes mellitus and hallux valgus/flexion contractures.\n'
p10871
sg4
(lp10872
sg14
(lp10873
(dp10874
g7
I202
sg17
VC0018536
p10875
sg10
I13
sg11
Vhallux valgus
p10876
sg13
I2
sa(dp10877
g7
I152
sg17
VC0020619
p10878
sg10
I12
sg11
Vhypogonadism
p10879
sg13
I1
sa(dp10880
g7
I180
sg17
VC0011849
p10881
sg10
I17
sg11
Vdiabetes mellitus
p10882
sg13
I2
sa(dp10883
g7
I118
sg17
VC0011053
p10884
sg10
I12
sg11
Vhearing loss
p10885
sg13
I2
sa(dp10886
g7
I9
sg17
VC1864445
p10887
sg10
I10
sg11
VH syndrome
p10888
sg13
I2
sa(dp10889
g7
I132
sg17
VC0019214
p10890
sg10
I18
sg11
Vhepatosplenomegaly
p10891
sg13
I1
sa(dp10892
g7
I166
sg17
VC0020456
p10893
sg10
I13
sg11
Vhyperglycemia
p10894
sg13
I1
sa(dp10895
g7
I51
sg17
VC0037088
p10896
sg10
I17
sg11
Vclinical findings
p10897
sg13
I2
sa(dp10898
g7
I83
sg17
VC0162834
p10899
sg10
I17
sg11
Vhyperpigmentation
p10900
sg13
I1
sa(dp10901
g7
I216
sg17
VC0333068
p10902
sg10
I20
sg11
Vflexion contractures
p10903
sg13
I2
sa(dp10904
g7
I102
sg17
VC0020555
p10905
sg10
I14
sg11
Vhypertrichosis
p10906
sg13
I1
sasa(dp10907
g2
S'Mutations in SLC29A3 lead to pigmentary hypertrichosis and non-autoimmune insulin-dependent diabetes mellitus (PHID) and H syndromes, familial Rosai-Dorfman disease, and histiocytosis-lymphadenopathy plus syndrome.\n'
p10908
sg4
(lp10909
(dp10910
g7
I74
sg8
VP01308
p10911
sg10
I7
sg11
Vinsulin
p10912
sg13
I1
sasg14
(lp10913
(dp10914
g7
I63
sg17
VC0443146
p10915
sg10
I10
sg11
Vautoimmune
p10916
sg13
I1
sa(dp10917
g7
I74
sg17
VC0011854
p10918
sg10
I35
sg11
Vinsulin-dependent diabetes mellitus
p10919
sg13
I3
sa(dp10920
g7
I170
sg17
VC1864445
p10921
sg10
I43
sg11
Vhistiocytosis-lymphadenopathy plus syndrome
p10922
sg13
I3
sa(dp10923
g7
I123
sg17
VC0039082
p10924
sg10
I9
sg11
Vsyndromes
p10925
sg13
I1
sa(dp10926
g7
I111
sg17
VC1864445
p10927
sg10
I4
sg11
VPHID
p10928
sg13
I1
sa(dp10929
g7
I40
sg17
VC0020555
p10930
sg10
I14
sg11
Vhypertrichosis
p10931
sg13
I1
sa(dp10932
g7
I143
sg17
VC0019625
p10933
sg10
I21
sg11
VRosai-Dorfman disease
p10934
sg13
I2
sasa(dp10935
g2
S'This report describes an insulin-dependent diabetes patient with a syndromic presentation in whom a homozygous SLC29A3 mutation was identified.\n'
p10936
sg4
(lp10937
(dp10938
g7
I25
sg8
VP01308
p10939
sg10
I7
sg11
Vinsulin
p10940
sg13
I1
sasg14
(lp10941
(dp10942
g7
I25
sg17
VC0011854
p10943
sg10
I26
sg11
Vinsulin-dependent diabetes
p10944
sg13
I2
sasa(dp10945
g2
S'These clinical features overlapped with pigmented hypertrichosis with insulin-dependent diabetes (PHID), H syndrome, Faisalabad histiocytosis and sinus histiocytosis with massive lymphadenopathy (SHML), all of which are also caused by SLC29A3 mutations.\n'
p10946
sg4
(lp10947
(dp10948
g7
I70
sg8
VP01308
p10949
sg10
I7
sg11
Vinsulin
p10950
sg13
I1
sasg14
(lp10951
(dp10952
g7
I146
sg17
VC0019625
p10953
sg10
I48
sg11
Vsinus histiocytosis with massive lymphadenopathy
p10954
sg13
I5
sa(dp10955
g7
I105
sg17
VC1864445
p10956
sg10
I10
sg11
VH syndrome
p10957
sg13
I2
sa(dp10958
g7
I40
sg17
VC1864445
p10959
sg10
I56
sg11
Vpigmented hypertrichosis with insulin-dependent diabetes
p10960
sg13
I5
sa(dp10961
g7
I117
sg17
VC1864445
p10962
sg10
I24
sg11
VFaisalabad histiocytosis
p10963
sg13
I2
sa(dp10964
g7
I196
sg17
VC1864445
p10965
sg10
I4
sg11
VSHML
p10966
sg13
I1
sa(dp10967
g7
I98
sg17
VC1864445
p10968
sg10
I4
sg11
VPHID
p10969
sg13
I1
sasa(dp10970
g2
S'Germline mutations in the SLC29A3 gene result in a range of recessive, clinically related syndromes: H syndrome, pigmented hypertrichosis with insulin-dependent diabetes mellitus syndrome, Faisalabad histiocytosis, and sinus histiocytosis with massive lymphadenopathy.\n'
p10971
sg4
(lp10972
(dp10973
g7
I143
sg8
VP01308
p10974
sg10
I7
sg11
Vinsulin
p10975
sg13
I1
sasg14
(lp10976
(dp10977
g7
I101
sg17
VC1864445
p10978
sg10
I10
sg11
VH syndrome
p10979
sg13
I2
sa(dp10980
g7
I219
sg17
VC0019625
p10981
sg10
I48
sg11
Vsinus histiocytosis with massive lymphadenopathy
p10982
sg13
I5
sa(dp10983
g7
I189
sg17
VC1864445
p10984
sg10
I24
sg11
VFaisalabad histiocytosis
p10985
sg13
I2
sa(dp10986
g7
I90
sg17
VC0039082
p10987
sg10
I8
sg11
Vsyndrome
p10988
sg13
I1
sa(dp10989
g7
I113
sg17
VC1864445
p10990
sg10
I65
sg11
Vpigmented hypertrichosis with insulin-dependent diabetes mellitus
p10991
sg13
I6
sa(dp10992
g7
I90
sg17
VC0039082
p10993
sg10
I9
sg11
Vsyndromes
p10994
sg13
I1
sasa(dp10995
g2
S'Characteristic ADC map features were identified for protrusion, extrusion and sequester types of lumbar disk herniations, spondylolisthesis, reactive Modic endplate changes, Pfirrmann grades of IVD degeneration, and compromised spinal nerves.\n'
p10996
sg4
(lp10997
sg14
(lp10998
(dp10999
g7
I122
sg17
VC0038017
p11000
sg10
I17
sg11
Vspondylolisthesis
p11001
sg13
I1
sa(dp11002
g7
I52
sg17
VC0333056
p11003
sg10
I10
sg11
Vprotrusion
p11004
sg13
I1
sa(dp11005
g7
I198
sg17
VC0011164
p11006
sg10
I12
sg11
Vdegeneration
p11007
sg13
I1
sa(dp11008
g7
I109
sg17
VC0019270
p11009
sg10
I11
sg11
Vherniations
p11010
sg13
I1
sasa(dp11011
g2
S'We measured T2 relaxation time of the intervertebral discs (IVD) and facet joints (FJ) in patients with degenerative spondylolisthesis (DS) and no spondylolisthesis (NS) and investigated the characteristics of these parts in DS.\n'
p11012
sg4
(lp11013
sg14
(lp11014
(dp11015
g7
I136
sg17
VC0264184
p11016
sg10
I2
sg11
VDS
p11017
sg13
I1
sa(dp11018
g7
I117
sg17
VC0038017
p11019
sg10
I17
sg11
Vspondylolisthesis
p11020
sg13
I1
sa(dp11021
g7
I104
sg17
VC0264184
p11022
sg10
I30
sg11
Vdegenerative spondylolisthesis
p11023
sg13
I2
sa(dp11024
g7
I136
sg17
VC0264184
p11025
sg10
I2
sg11
VDS
p11026
sg13
I1
sasa(dp11027
g2
S'Early stages of scoliosis and spondylolisthesis entail changes in the intervertebral disc (IVD) structure and biochemistry.\n'
p11028
sg4
(lp11029
sg14
(lp11030
(dp11031
g7
I30
sg17
VC0038017
p11032
sg10
I17
sg11
Vspondylolisthesis
p11033
sg13
I1
sa(dp11034
g7
I16
sg17
VC0700208
p11035
sg10
I9
sg11
Vscoliosis
p11036
sg13
I1
sasa(dp11037
g2
S'Therefore, this study aims to develop the AMRSID (analysis of MR signal intensity distribution) method to analyze the 3D distribution of the MR signal intensity within the IVD and to evaluate their sensitivity to scoliosis and spondylolisthesis and their severities.\n'
p11038
sg4
(lp11039
sg14
(lp11040
(dp11041
g7
I227
sg17
VC0038017
p11042
sg10
I17
sg11
Vspondylolisthesis
p11043
sg13
I1
sa(dp11044
g7
I213
sg17
VC0700208
p11045
sg10
I9
sg11
Vscoliosis
p11046
sg13
I1
sasa(dp11047
g2
S'IVDs were collected from patients with lumbar fracture, vertebral tumor, disc herniation or spondylolisthesis.\n'
p11048
sg4
(lp11049
sg14
(lp11050
(dp11051
g7
I92
sg17
VC0038017
p11052
sg10
I17
sg11
Vspondylolisthesis
p11053
sg13
I1
sa(dp11054
g7
I66
sg17
VC0027651
p11055
sg10
I5
sg11
Vtumor
p11056
sg13
I1
sa(dp11057
g7
I78
sg17
VC0019270
p11058
sg10
I10
sg11
Vherniation
p11059
sg13
I1
sasa(dp11060
g2
S'"Pedra hume caa" is the common name of five species of Myrcia genus used as traditional medicine for the treatment of diabetes mellitus.\n'
p11061
sg4
(lp11062
sg14
(lp11063
(dp11064
g7
I12
sg17
VC1842937
p11065
sg10
I3
sg11
Vcaa
p11066
sg13
I1
sa(dp11067
g7
I118
sg17
VC0011849
p11068
sg10
I17
sg11
Vdiabetes mellitus
p11069
sg13
I2
sasa(dp11070
g2
S'Some of the species are used in folk medicine, such as a group known as "pedra-hume-caa" or "pedra-ume-caa" or "insulina vegetal" (insulin plant) that it is used for the treatment of diabetes.\n'
p11071
sg4
(lp11072
(dp11073
g7
I112
sg8
VP01308
p11074
sg10
I7
sg11
Vinsulin
p11075
sg13
I1
sasg14
(lp11076
(dp11077
g7
I84
sg17
VC1842937
p11078
sg10
I3
sg11
Vcaa
p11079
sg13
I1
sa(dp11080
g7
I84
sg17
VC1842937
p11081
sg10
I3
sg11
Vcaa
p11082
sg13
I1
sa(dp11083
g7
I183
sg17
VC0011849
p11084
sg10
I8
sg11
Vdiabetes
p11085
sg13
I1
sasa(dp11086
g2
S'Some of the species are used in folk medicine, such as a group known as "pedra-hume-caa" or "pedra-ume-caa" or "insulina vegetal" (insulin plant) that it is used for the treatment of diabetes.\n'
p11087
sg4
(lp11088
(dp11089
g7
I112
sg8
VP01308
p11090
sg10
I7
sg11
Vinsulin
p11091
sg13
I1
sasg14
(lp11092
(dp11093
g7
I84
sg17
VC1842937
p11094
sg10
I3
sg11
Vcaa
p11095
sg13
I1
sa(dp11096
g7
I84
sg17
VC1842937
p11097
sg10
I3
sg11
Vcaa
p11098
sg13
I1
sa(dp11099
g7
I183
sg17
VC0011849
p11100
sg10
I8
sg11
Vdiabetes
p11101
sg13
I1
sasa(dp11102
g2
S'Some of the species are used in folk medicine, such as a group known as "pedra-hume-caa" or "pedra-ume-caa" or "insulina vegetal" (insulin plant) that it is used for the treatment of diabetes.\n'
p11103
sg4
(lp11104
(dp11105
g7
I112
sg8
VP01308
p11106
sg10
I7
sg11
Vinsulin
p11107
sg13
I1
sasg14
(lp11108
(dp11109
g7
I84
sg17
VC1842937
p11110
sg10
I3
sg11
Vcaa
p11111
sg13
I1
sa(dp11112
g7
I84
sg17
VC1842937
p11113
sg10
I3
sg11
Vcaa
p11114
sg13
I1
sa(dp11115
g7
I183
sg17
VC0011849
p11116
sg10
I8
sg11
Vdiabetes
p11117
sg13
I1
sasa(dp11118
g2
S'Adult Tshz1(+/-) mice display glucose intolerance due to defects in glucose-stimulated insulin secretion associated with reduced Pdx1 and Clec16a expression in Tshz1(+/-) islets.\n'
p11119
sg4
(lp11120
(dp11121
g7
I138
sg8
g9
sg10
I7
sg11
VClec16a
p11122
sg13
I1
sa(dp11123
g7
I129
sg8
VP52945
p11124
sg10
I4
sg11
VPdx1
p11125
sg13
I1
sa(dp11126
g7
I6
sg8
g9
sg10
I5
sg11
VTshz1
p11127
sg13
I1
sa(dp11128
g7
I87
sg8
VP01308
p11129
sg10
I7
sg11
Vinsulin
p11130
sg13
I1
sasg14
(lp11131
(dp11132
g7
I30
sg17
VC0271650
p11133
sg10
I19
sg11
Vglucose intolerance
p11134
sg13
I2
sasa(dp11135
g2
S'Lastly, we demonstrate that TSHZ1 levels are reduced in human islets of donors with type 2 diabetes.\n'
p11136
sg4
(lp11137
(dp11138
g7
I28
sg8
g9
sg10
I5
sg11
VTSHZ1
p11139
sg13
I1
sasg14
(lp11140
(dp11141
g7
I84
sg17
VC0011860
p11142
sg10
I15
sg11
Vtype 2 diabetes
p11143
sg13
I3
sasa(dp11144
g2
S'Thus, we position Tshz1 in the transcriptional network of maturing Beta-cells and suggest that its dysregulation could contribute to the islet phenotype of human type 2 diabetes.\n'
p11145
sg4
(lp11146
(dp11147
g7
I18
sg8
g9
sg10
I5
sg11
VTshz1
p11148
sg13
I1
sasg14
(lp11149
(dp11150
g7
I162
sg17
VC0011860
p11151
sg10
I15
sg11
Vtype 2 diabetes
p11152
sg13
I3
sasa(dp11153
g2
S"Material e Metodos: Revisao bibliografica, atraves da Medline e PubMed, utilizando como palavras-chave: 'borderline personality disorder', 'cognitive-behavioral therapy', 'efficacy'.\n"
p11154
sg4
(lp11155
sg14
(lp11156
(dp11157
g7
I104
sg17
VC0006012
p11158
sg10
I32
sg11
V'borderline personality disorder
p11159
sg13
I3
sasa(dp11160
g2
S'### #################(obstructive sleep apnea hypopnea syndrome, OSAHS)########(resistant hypertension, RH)###, OSAHS############ ### 80#OSAHS##RH##[##3######(#####)##, ##################(140/90 mmHg, 1 mmHg=0.133 kPa)]############, ######6#################, ###########(apnea hypopnea index, AHI)########(SaO(2))###########, ################ ### ###, AHI#(32.9+/-10.8)#/h(x+/-s, ##)##(9.4+/-6.5)#/h, ##SaO(2)#(0.682+/-0.062)##(0.884+/-0.056), #########(t####18.863#26.614, P##&lt;0.001)#######(150.5+/-9.8) mmHg##(140.7+/-6.8) mmHg, ####(97.8+/-7.3) mmHg##(88.6+/-6.3) mmHg#######(154.3+/-8.9) mmHg##(144.8+/-5.8) mmHg, ####(100.6+/-7.4) mmHg##(91.3+/-5.5) mmHg#######(145.5+/-8.8) mmHg##(135.8+/-5.7) mmHg, ####(93.8+/-6.4) mmHg##(84.6+/-5.9) mmHg, #########(t####7.832#6.903#7.005#6.848#8.025#7.554, P##&lt;0.001)##########(11.5+/-2.2)mmHg########(10.2+/-3.1)mmHg, #########(9.0+/-2.8)mmHg########(7.9+/-3.5)mmHg, #################, #########(t####9.732#6.936, P##&lt;0.001)########&lt;10%##########75.0%######37.5%, ########(X(2)=22.857, P&lt;0.01), ###############45##############, #####(3.2+/-0.4)#######(2.6+/-0.5)#, ########(t=9.276, P&lt;0.01)# ### OSAHS##RH###, ##OSAHS###########, ########, ##########.\n'
p11161
sg4
(lp11162
sg14
(lp11163
(dp11164
g7
I22
sg17
VC0520679
p11165
sg10
I23
sg11
Vobstructive sleep apnea
p11166
sg13
I3
sa(dp11167
g7
I65
sg17
VC0520679
p11168
sg10
I5
sg11
VOSAHS
p11169
sg13
I1
sa(dp11170
g7
I65
sg17
VC0520679
p11171
sg10
I5
sg11
VOSAHS
p11172
sg13
I1
sa(dp11173
g7
I90
sg17
VC0020538
p11174
sg10
I12
sg11
Vhypertension
p11175
sg13
I1
sa(dp11176
g7
I40
sg17
VC0003578
p11177
sg10
I5
sg11
Vapnea
p11178
sg13
I1
sa(dp11179
g7
I65
sg17
VC0520679
p11180
sg10
I5
sg11
VOSAHS
p11181
sg13
I1
sa(dp11182
g7
I65
sg17
VC0520679
p11183
sg10
I5
sg11
VOSAHS
p11184
sg13
I1
sa(dp11185
g7
I65
sg17
VC0520679
p11186
sg10
I5
sg11
VOSAHS
p11187
sg13
I1
sa(dp11188
g7
I46
sg17
VC2748060
p11189
sg10
I17
sg11
Vhypopnea syndrome
p11190
sg13
I2
sasa(dp11191
g2
S'In case of coronary atherosclerosis the organism reaction to expressed CMC is manifested basically by intensified synthesis of cathodic complement-C3-similar autoprecipitin, but in case of endocarditis--by consumption of one with formation of anodic autoprecipitin and by intensified synthesis of autoprecipitating immunoglobulin G. These membranotropic autoimmune reactions are identical with the organism reactions to alien (heterologous) agents and differentially participate in development both of basic disease and perioperational complications after cardiac operations using trans- and implants, hence, they should be taken into account during membrane-stabilising and immunocorrecting therapy of recipients.\n'
p11192
sg4
(lp11193
(dp11194
g7
I315
sg8
g9
sg10
I16
sg11
Vimmunoglobulin G
p11195
sg13
I2
sa(dp11196
g7
I127
sg8
g9
sg10
I22
sg11
Vcathodic complement-C3
p11197
sg13
I2
sasg14
(lp11198
(dp11199
g7
I354
sg17
VC0443146
p11200
sg10
I20
sg11
Vautoimmune reactions
p11201
sg13
I2
sa(dp11202
g7
I11
sg17
VC2733225
p11203
sg10
I24
sg11
Vcoronary atherosclerosis
p11204
sg13
I2
sa(dp11205
g7
I189
sg17
VC0014118
p11206
sg10
I12
sg11
Vendocarditis
p11207
sg13
I1
sasa(dp11208
g2
S'In cultured rat hepatoma (H4IIE) cells, TNF-Alfa significantly increased hemopexin mRNA accumulation.\n'
p11209
sg4
(lp11210
(dp11211
g7
I73
sg8
VP02790
p11212
sg10
I14
sg11
Vhemopexin mRNA
p11213
sg13
I2
sa(dp11214
g7
I40
sg8
VP01375
p11215
sg10
I8
sg11
VTNF-Alfa
p11216
sg13
I1
sasg14
(lp11217
(dp11218
g7
I16
sg17
VC0023903
p11219
sg10
I8
sg11
Vhepatoma
p11220
sg13
I1
sasa(dp11221
g2
S'This analytical method was applied to an in vitro diagnostic multivariate index assay where a panel of hepatocellular carcinoma (HCC) biomarkers comprising alpha-fetoprotein, hemopexin, and alpha-2-macroglobulin (A2M) was examined in terms of the serum level and their fuco-fractions.\n'
p11222
sg4
(lp11223
(dp11224
g7
I175
sg8
VP02790
p11225
sg10
I9
sg11
Vhemopexin
p11226
sg13
I1
sa(dp11227
g7
I156
sg8
VP02771
p11228
sg10
I17
sg11
Valpha-fetoprotein
p11229
sg13
I1
sa(dp11230
g7
I190
sg8
VP01023
p11231
sg10
I21
sg11
Valpha-2-macroglobulin
p11232
sg13
I1
sa(dp11233
g7
I213
sg8
VP01023
p11234
sg10
I3
sg11
VA2M
p11235
sg13
I1
sasg14
(lp11236
(dp11237
g7
I129
sg17
VC2239176
p11238
sg10
I3
sg11
VHCC
p11239
sg13
I1
sa(dp11240
g7
I103
sg17
VC2239176
p11241
sg10
I24
sg11
Vhepatocellular carcinoma
p11242
sg13
I2
sasa(dp11243
g2
S'The aim of this study was to identify new target genes for microRNA polymorphisms (miR-146aC&gt;G and miR-196a2T&gt;C) in primary ovarian insufficiency (POI).\n'
p11244
sg4
(lp11245
(dp11246
g7
I-1
sg8
g9
sg10
I12
sg11
VmiR-196a2T>C
p11247
sg13
I1
sa(dp11248
g7
I83
sg8
g9
sg10
I9
sg11
VmiR-146aC
p11249
sg13
I1
sasg14
(lp11250
(dp11251
g7
I153
sg17
VC0041408
p11252
sg10
I3
sg11
VPOI
p11253
sg13
I1
sa(dp11254
g7
I122
sg17
VC0041408
p11255
sg10
I29
sg11
Vprimary ovarian insufficiency
p11256
sg13
I3
sasa(dp11257
g2
S'In addition, several specific miRNAs (miR-23a, miR-27a, miR-22-3p, miR-146a, miR-196a, miR-290-295, miR-423, and miR-608) related to POI are also examined in order to highlight the issues that deserve further investigation.\n'
p11258
sg4
(lp11259
(dp11260
g7
I67
sg8
g9
sg10
I8
sg11
VmiR-146a
p11261
sg13
I1
sa(dp11262
g7
I47
sg8
g9
sg10
I7
sg11
VmiR-27a
p11263
sg13
I1
sa(dp11264
g7
I56
sg8
g9
sg10
I9
sg11
VmiR-22-3p
p11265
sg13
I1
sa(dp11266
g7
I113
sg8
g9
sg10
I7
sg11
VmiR-608
p11267
sg13
I1
sa(dp11268
g7
I77
sg8
g9
sg10
I8
sg11
VmiR-196a
p11269
sg13
I1
sa(dp11270
g7
I38
sg8
g9
sg10
I7
sg11
VmiR-23a
p11271
sg13
I1
sasg14
(lp11272
sa(dp11273
g2
S'(2) Expand sample size to 14 cases for endometriosis group and 16 cases for control group.Reverse transcription (RT)-PCR technique was utilized to detect the expression of miR- 142- 5p, miR- 146a- 5p and miR- 543 in endometrial tissues, and verify miRNA microarray results.\n'
p11274
sg4
(lp11275
(dp11276
g7
I186
sg8
g9
sg10
I13
sg11
VmiR- 146a- 5p
p11277
sg13
I3
sa(dp11278
g7
I172
sg8
g9
sg10
I12
sg11
VmiR- 142- 5p
p11279
sg13
I3
sa(dp11280
g7
I204
sg8
g9
sg10
I8
sg11
VmiR- 543
p11281
sg13
I2
sasg14
(lp11282
(dp11283
g7
I39
sg17
VC0014175
p11284
sg10
I13
sg11
Vendometriosis
p11285
sg13
I1
sasa(dp11286
g2
S'(1) miRNA and mRNA microarray screening results showed that, among the endometrial tissues of patients with endometriosis infertility and with implantation window phase, 6 differentially expressed miRNA were indentified, among which miR-142-5p, miR-146a-5p, miR-1281, miR-940, miR-4634 showed significantly enhanced expression and miR- 543 showed significantly inhibited expression.\n'
p11287
sg4
(lp11288
(dp11289
g7
I233
sg8
g9
sg10
I10
sg11
VmiR-142-5p
p11290
sg13
I1
sa(dp11291
g7
I268
sg8
g9
sg10
I7
sg11
VmiR-940
p11292
sg13
I1
sa(dp11293
g7
I277
sg8
g9
sg10
I8
sg11
VmiR-4634
p11294
sg13
I1
sa(dp11295
g7
I245
sg8
g9
sg10
I11
sg11
VmiR-146a-5p
p11296
sg13
I1
sa(dp11297
g7
I258
sg8
g9
sg10
I8
sg11
VmiR-1281
p11298
sg13
I1
sa(dp11299
g7
I331
sg8
g9
sg10
I8
sg11
VmiR- 543
p11300
sg13
I2
sasg14
(lp11301
(dp11302
g7
I122
sg17
VC0021359
p11303
sg10
I11
sg11
Vinfertility
p11304
sg13
I1
sa(dp11305
g7
I108
sg17
VC0014175
p11306
sg10
I13
sg11
Vendometriosis
p11307
sg13
I1
sasa(dp11308
g2
S'(2) RT- PCR test showed that the average levels of expression of miR-142-5p and miR-146a-5p in implantation window phase endometrium in endometriosis group were 8.3+/-10.6 and 1.9+/-0.8 respectively; the average levels of that in control group were 1.1+/-0.6 and 0.9+/-0.4, respectively.\n'
p11309
sg4
(lp11310
(dp11311
g7
I80
sg8
g9
sg10
I11
sg11
VmiR-146a-5p
p11312
sg13
I1
sa(dp11313
g7
I65
sg8
g9
sg10
I10
sg11
VmiR-142-5p
p11314
sg13
I1
sasg14
(lp11315
(dp11316
g7
I136
sg17
VC0014175
p11317
sg10
I13
sg11
Vendometriosis
p11318
sg13
I1
sasa(dp11319
g2
S'There are multiple differential expressions of miRNA in the implantation window phase endometrium tissues of endometriosis infertility patients, among which miR-142-5p and miR-146a-5p show significantly enhanced expression and may affect embryo implantation by acting on a variety of endometrial receptivity marker molecules.\n'
p11320
sg4
(lp11321
(dp11322
g7
I172
sg8
g9
sg10
I11
sg11
VmiR-146a-5p
p11323
sg13
I1
sa(dp11324
g7
I157
sg8
g9
sg10
I10
sg11
VmiR-142-5p
p11325
sg13
I1
sasg14
(lp11326
(dp11327
g7
I123
sg17
VC0021359
p11328
sg10
I11
sg11
Vinfertility
p11329
sg13
I1
sa(dp11330
g7
I109
sg17
VC0014175
p11331
sg10
I13
sg11
Vendometriosis
p11332
sg13
I1
sasa(dp11333
g2
S'We also analyze the ezrin-meditated regulation of critical pathways associated with asthma, such as the RhoA, Rho-associated protein kinase (ROCK), and protein kinase A (cAMP/PKA) pathways.\n'
p11334
sg4
(lp11335
(dp11336
g7
I141
sg8
g9
sg10
I4
sg11
VROCK
p11337
sg13
I1
sa(dp11338
g7
I170
sg8
VP49913
p11339
sg10
I8
sg11
VcAMP/PKA
p11340
sg13
I1
sa(dp11341
g7
I110
sg8
VP08100
p11342
sg10
I29
sg11
VRho-associated protein kinase
p11343
sg13
I3
sa(dp11344
g7
I152
sg8
VP17612
p11345
sg10
I16
sg11
Vprotein kinase A
p11346
sg13
I3
sa(dp11347
g7
I104
sg8
VP61586
p11348
sg10
I4
sg11
VRhoA
p11349
sg13
I1
sasg14
(lp11350
(dp11351
g7
I84
sg17
VC0004096
p11352
sg10
I6
sg11
Vasthma
p11353
sg13
I1
sasa(dp11354
g2
S'Pneumothorax is a well-recognized complication of central venous line insertion (CVL).\n'
p11355
sg4
(lp11356
sg14
(lp11357
(dp11358
g7
I34
sg17
VC0009566
p11359
sg10
I12
sg11
Vcomplication
p11360
sg13
I1
sa(dp11361
g7
I0
sg17
VC0032326
p11362
sg10
I12
sg11
VPneumothorax
p11363
sg13
I1
sasa(dp11364
g2
S'We identify and replicate an association between the constituents of the apical plasma membrane and CF lung disease (p = 0.0099 and p = 0.0180, respectively) and highlight a role for the SLC9A3-SLC9A3R1/2-EZR complex in contributing to CF lung disease.\n'
p11365
sg4
(lp11366
(dp11367
g7
I187
sg8
VP48764
p11368
sg10
I29
sg11
VSLC9A3-SLC9A3R1/2-EZR complex
p11369
sg13
I2
sasg14
(lp11370
(dp11371
g7
I103
sg17
VC0024115
p11372
sg10
I12
sg11
Vlung disease
p11373
sg13
I2
sa(dp11374
g7
I103
sg17
VC0024115
p11375
sg10
I12
sg11
Vlung disease
p11376
sg13
I2
sasa(dp11377
g2
S'The BrGR-expressing yeast strain induced the activation of metabolic enzymes (Hxt, G6PDH, GAPDH and Ald), antioxidant systems (Gpx, Trx2, Trx3, Trr1, Tsa1 and porin) and molecular chaperones (Hsp104, Hsp90, Hsp70, Hsp42, Hsp26, Grp, Sti1 and Zpr1), which led to lower oxidative protein damage after a reduction in the level of cellular ROS in the BrGR-expressing yeast strain exposed to H(2)O(2) than in the wild-type yeast strain.\n'
p11378
sg4
(lp11379
(dp11380
g7
I100
sg8
VP33897
p11381
sg10
I3
sg11
VAld
p11382
sg13
I1
sa(dp11383
g7
I127
sg8
g9
sg10
I3
sg11
VGpx
p11384
sg13
I1
sa(dp11385
g7
I228
sg8
VP07492
p11386
sg10
I3
sg11
VGrp
p11387
sg13
I1
sa(dp11388
g7
I90
sg8
VP04406
p11389
sg10
I5
sg11
VGAPDH
p11390
sg13
I1
sa(dp11391
g7
I159
sg8
VP21796
p11392
sg10
I5
sg11
Vporin
p11393
sg13
I1
sa(dp11394
g7
I132
sg8
g9
sg10
I4
sg11
VTrx2
p11395
sg13
I1
sa(dp11396
g7
I150
sg8
g9
sg10
I4
sg11
VTsa1
p11397
sg13
I1
sa(dp11398
g7
I207
sg8
VP34932
p11399
sg10
I5
sg11
VHsp70
p11400
sg13
I1
sa(dp11401
g7
I242
sg8
g9
sg10
I4
sg11
VZpr1
p11402
sg13
I1
sa(dp11403
g7
I83
sg8
VP11413
p11404
sg10
I5
sg11
VG6PDH
p11405
sg13
I1
sa(dp11406
g7
I200
sg8
VP07900
p11407
sg10
I5
sg11
VHsp90
p11408
sg13
I1
sa(dp11409
g7
I78
sg8
g9
sg10
I3
sg11
VHxt
p11410
sg13
I1
sa(dp11411
g7
I233
sg8
VP31948
p11412
sg10
I4
sg11
VSti1
p11413
sg13
I1
sasg14
(lp11414
(dp11415
g7
I100
sg17
VC0162309
p11416
sg10
I3
sg11
VAld
p11417
sg13
I1
sasa(dp11418
g2
S'In this review, we focus on the use of these agents in children to treat inflammatory skin diseases other than psoriasis, including atopic dermatitis, hidradenitis suppurativa, pemphigus vulgaris, bullous pemphigoid, and toxic epidermal necrolysis, with an emphasis on the use of etanercept, infliximab, rituximab, omalizumab, and ustekinumab.\n'
p11419
sg4
(lp11420
sg14
(lp11421
(dp11422
g7
I177
sg17
VC0030809
p11423
sg10
I18
sg11
Vpemphigus vulgaris
p11424
sg13
I2
sa(dp11425
g7
I111
sg17
VC0033860
p11426
sg10
I9
sg11
Vpsoriasis
p11427
sg13
I1
sa(dp11428
g7
I151
sg17
VC0162836
p11429
sg10
I24
sg11
Vhidradenitis suppurativa
p11430
sg13
I2
sa(dp11431
g7
I221
sg17
VC0014518
p11432
sg10
I26
sg11
Vtoxic epidermal necrolysis
p11433
sg13
I3
sa(dp11434
g7
I197
sg17
VC0030805
p11435
sg10
I18
sg11
Vbullous pemphigoid
p11436
sg13
I2
sa(dp11437
g7
I132
sg17
VC0011615
p11438
sg10
I17
sg11
Vatopic dermatitis
p11439
sg13
I2
sa(dp11440
g7
I86
sg17
VC0037274
p11441
sg10
I13
sg11
Vskin diseases
p11442
sg13
I2
sasa(dp11443
g2
S"The addition of distamycin A enhanced the double-strand DNA cleavage at the 5'-CCT-3'/3'-GGA-5' and 5'-CCA-3'/3'-GGT-5' sequences, with a two-nucleotide 3'-stagger of the cleaved residues.\n"
p11444
sg4
(lp11445
sg14
(lp11446
(dp11447
g7
I79
sg17
VC2752078
p11448
sg10
I3
sg11
VCCT
p11449
sg13
I1
sa(dp11450
g7
I103
sg17
VC0220668
p11451
sg10
I3
sg11
VCCA
p11452
sg13
I1
sasa(dp11453
g2
S'Besides, we screened for all the known genes related to axonal autosomal recessive Charcot-Marie-Tooth disease (CMT2A2/HMSN2A2/MFN2, CMT2B1/LMNA, CMT2B2/MED25, CMT2B5/NEFL, ARCMT2F/dHMN2B/HSPB1, CMT2K/GDAP1, CMT2P/LRSAM1, CMT2R/TRIM2, CMT2S/IGHMBP2, CMT2T/HSJ1, CMTRID/COX6A1, ARAN-NM/HINT and GAN/GAN), for the genes related to autosomal recessive hereditary spastic paraplegia with thin corpus callosum and axonal peripheral neuropathy (SPG7/PGN, SPG15/ZFYVE26, SPG21/ACP33, SPG35/FA2H, SPG46/GBA2, SPG55/C12orf65 and SPG56/CYP2U1), as well as for the causative gene of peripheral neuropathy with or without agenesis of the corpus callosum (SLC12A6).\n'
p11454
sg4
(lp11455
(dp11456
g7
I133
sg8
VP02545
p11457
sg10
I6
sg11
VCMT2B1
p11458
sg13
I1
sa(dp11459
g7
I112
sg8
g9
sg10
I6
sg11
VCMT2A2
p11460
sg13
I1
sa(dp11461
g7
I140
sg8
VP02545
p11462
sg10
I4
sg11
VLMNA
p11463
sg13
I1
sa(dp11464
g7
I127
sg8
g9
sg10
I4
sg11
VMFN2
p11465
sg13
I1
sa(dp11466
g7
I214
sg8
g9
sg10
I6
sg11
VLRSAM1
p11467
sg13
I1
sa(dp11468
g7
I195
sg8
g9
sg10
I5
sg11
VCMT2K
p11469
sg13
I1
sa(dp11470
g7
I235
sg8
g9
sg10
I5
sg11
VCMT2S
p11471
sg13
I1
sa(dp11472
g7
I294
sg8
g9
sg10
I3
sg11
VGAN
p11473
sg13
I1
sa(dp11474
g7
I449
sg8
g9
sg10
I5
sg11
VSPG15
p11475
sg13
I1
sa(dp11476
g7
I439
sg8
g9
sg10
I4
sg11
VSPG7
p11477
sg13
I1
sa(dp11478
g7
I294
sg8
g9
sg10
I3
sg11
VGAN
p11479
sg13
I1
sa(dp11480
g7
I483
sg8
g9
sg10
I4
sg11
VFA2H
p11481
sg13
I1
sa(dp11482
g7
I455
sg8
g9
sg10
I7
sg11
VZFYVE26
p11483
sg13
I1
sa(dp11484
g7
I241
sg8
VP38935
p11485
sg10
I7
sg11
VIGHMBP2
p11486
sg13
I1
sa(dp11487
g7
I256
sg8
VP25686
p11488
sg10
I4
sg11
VHSJ1
p11489
sg13
I1
sa(dp11490
g7
I444
sg8
VP00747
p11491
sg10
I3
sg11
VPGN
p11492
sg13
I1
sa(dp11493
g7
I228
sg8
g9
sg10
I5
sg11
VTRIM2
p11494
sg13
I1
sa(dp11495
g7
I153
sg8
g9
sg10
I5
sg11
VMED25
p11496
sg13
I1
sa(dp11497
g7
I495
sg8
g9
sg10
I4
sg11
VGBA2
p11498
sg13
I1
sa(dp11499
g7
I167
sg8
VP07196
p11500
sg10
I4
sg11
VNEFL
p11501
sg13
I1
sa(dp11502
g7
I285
sg8
VP49773
p11503
sg10
I4
sg11
VHINT
p11504
sg13
I1
sa(dp11505
g7
I507
sg8
g9
sg10
I8
sg11
VC12orf65
p11506
sg13
I1
sa(dp11507
g7
I470
sg8
g9
sg10
I5
sg11
VACP33
p11508
sg13
I1
sa(dp11509
g7
I520
sg8
g9
sg10
I12
sg11
VSPG56/CYP2U1
p11510
sg13
I1
sa(dp11511
g7
I201
sg8
g9
sg10
I5
sg11
VGDAP1
p11512
sg13
I1
sa(dp11513
g7
I119
sg8
g9
sg10
I7
sg11
VHMSN2A2
p11514
sg13
I1
sa(dp11515
g7
I464
sg8
g9
sg10
I5
sg11
VSPG21
p11516
sg13
I1
sa(dp11517
g7
I269
sg8
VP12074
p11518
sg10
I6
sg11
VCOX6A1
p11519
sg13
I1
sasg14
(lp11520
(dp11521
g7
I208
sg17
VC3280797
p11522
sg10
I5
sg11
VCMT2P
p11523
sg13
I1
sa(dp11524
g7
I146
sg17
VC1854150
p11525
sg10
I6
sg11
VCMT2B2
p11526
sg13
I1
sa(dp11527
g7
I294
sg17
VC1850386
p11528
sg10
I3
sg11
VGAN
p11529
sg13
I1
sa(dp11530
g7
I449
sg17
VC1849128
p11531
sg10
I5
sg11
VSPG15
p11532
sg13
I1
sa(dp11533
g7
I439
sg17
VC1846564
p11534
sg10
I4
sg11
VSPG7
p11535
sg13
I1
sa(dp11536
g7
I133
sg17
VC1854154
p11537
sg10
I6
sg11
VCMT2B1
p11538
sg13
I1
sa(dp11539
g7
I294
sg17
VC1850386
p11540
sg10
I3
sg11
VGAN
p11541
sg13
I1
sa(dp11542
g7
I83
sg17
VC0007959
p11543
sg10
I27
sg11
VCharcot-Marie-Tooth disease
p11544
sg13
I2
sa(dp11545
g7
I112
sg17
VC1836485
p11546
sg10
I6
sg11
VCMT2A2
p11547
sg13
I1
sa(dp11548
g7
I119
sg17
VC1836485
p11549
sg10
I7
sg11
VHMSN2A2
p11550
sg13
I1
sa(dp11551
g7
I409
sg17
VC1263857
p11552
sg10
I28
sg11
Vaxonal peripheral neuropathy
p11553
sg13
I3
sa(dp11554
g7
I181
sg17
VC2608087
p11555
sg10
I6
sg11
VdHMN2B
p11556
sg13
I1
sa(dp11557
g7
I610
sg17
VC0175754
p11558
sg10
I31
sg11
Vagenesis of the corpus callosum
p11559
sg13
I5
sa(dp11560
g7
I464
sg17
VC1855346
p11561
sg10
I5
sg11
VSPG21
p11562
sg13
I1
sa(dp11563
g7
I329
sg17
VC0751603
p11564
sg10
I49
sg11
Vautosomal recessive hereditary spastic paraplegia
p11565
sg13
I5
sa(dp11566
g7
I416
sg17
VC0031117
p11567
sg10
I21
sg11
Vperipheral neuropathy
p11568
sg13
I2
sa(dp11569
g7
I195
sg17
VC1842983
p11570
sg10
I5
sg11
VCMT2K
p11571
sg13
I1
sasa(dp11572
g2
S'Plasmacytomas often present as a collection of findings known as POEMS-syndrome (Polyneuropathy, Organomegaly, Endocrinopathy, M-Protein spike, and Skin changes).\n'
p11573
sg4
(lp11574
sg14
(lp11575
(dp11576
g7
I71
sg17
VC0039082
p11577
sg10
I8
sg11
Vsyndrome
p11578
sg13
I1
sa(dp11579
g7
I111
sg17
VC0014130
p11580
sg10
I14
sg11
VEndocrinopathy
p11581
sg13
I1
sa(dp11582
g7
I0
sg17
VC0032131
p11583
sg10
I13
sg11
VPlasmacytomas
p11584
sg13
I1
sa(dp11585
g7
I81
sg17
VC0152025
p11586
sg10
I14
sg11
VPolyneuropathy
p11587
sg13
I1
sasa(dp11588
g2
S'POEMS (acronym for polyneuropathy, organomegaly, endocrinopathy, M protein myeloma and skin changes), is a rare disease which occurs in the setting of plasma cell dyscrasias.\n'
p11589
sg4
(lp11590
(dp11591
g7
I65
sg8
VP54296
p11592
sg10
I9
sg11
VM protein
p11593
sg13
I2
sasg14
(lp11594
(dp11595
g7
I107
sg17
VC0678236
p11596
sg10
I12
sg11
Vrare disease
p11597
sg13
I2
sa(dp11598
g7
I49
sg17
VC0014130
p11599
sg10
I14
sg11
Vendocrinopathy
p11600
sg13
I1
sa(dp11601
g7
I19
sg17
VC0152025
p11602
sg10
I14
sg11
Vpolyneuropathy
p11603
sg13
I1
sa(dp11604
g7
I151
sg17
VC1136084
p11605
sg10
I22
sg11
Vplasma cell dyscrasias
p11606
sg13
I3
sa(dp11607
g7
I75
sg17
VC0026764
p11608
sg10
I7
sg11
Vmyeloma
p11609
sg13
I1
sasa(dp11610
g2
S'Previous case reports and studies have shown that anti-myelin-associated glycoprotein (MAG) antibody can be detected in patients with polyneuropathy without any detectable M-protein.\n'
p11611
sg4
(lp11612
(dp11613
g7
I50
sg8
VP20916
p11614
sg10
I50
sg11
Vanti-myelin-associated glycoprotein (MAG) antibody
p11615
sg13
I4
sasg14
(lp11616
(dp11617
g7
I134
sg17
VC0152025
p11618
sg10
I14
sg11
Vpolyneuropathy
p11619
sg13
I1
sasa(dp11620
g2
S'Polyneuropathy, Organomegaly, Endocrinopathy, M protein and Skin changes (POEMS) syndrome is rare plasma cell dyscrasia with multisystem involvement.\n'
p11621
sg4
(lp11622
sg14
(lp11623
(dp11624
g7
I81
sg17
VC0039082
p11625
sg10
I8
sg11
Vsyndrome
p11626
sg13
I1
sa(dp11627
g7
I98
sg17
VC1136084
p11628
sg10
I21
sg11
Vplasma cell dyscrasia
p11629
sg13
I3
sa(dp11630
g7
I30
sg17
VC0014130
p11631
sg10
I14
sg11
VEndocrinopathy
p11632
sg13
I1
sa(dp11633
g7
I0
sg17
VC0152025
p11634
sg10
I14
sg11
VPolyneuropathy
p11635
sg13
I1
sasa(dp11636
g2
S'The name comes from the five characteristic features: Polyneuropathy, organomegaly, endocrinopathy, M protein and skin changes.\n'
p11637
sg4
(lp11638
sg14
(lp11639
(dp11640
g7
I84
sg17
VC0014130
p11641
sg10
I14
sg11
Vendocrinopathy
p11642
sg13
I1
sa(dp11643
g7
I54
sg17
VC0152025
p11644
sg10
I14
sg11
VPolyneuropathy
p11645
sg13
I1
sasa(dp11646
g2
S'Polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes (POEMS) syndrome and monoclonal gammopathy of undetermined significance (MGUS) are paraproteinemic disorders that can cause demyelinating polyneuropathy.\n'
p11647
sg4
(lp11648
sg14
(lp11649
(dp11650
g7
I82
sg17
VC0039082
p11651
sg10
I8
sg11
Vsyndrome
p11652
sg13
I1
sa(dp11653
g7
I95
sg17
VC0026470
p11654
sg10
I50
sg11
Vmonoclonal gammopathy of undetermined significance
p11655
sg13
I5
sa(dp11656
g7
I147
sg17
VC0026470
p11657
sg10
I4
sg11
VMGUS
p11658
sg13
I1
sa(dp11659
g7
I198
sg17
VC0270922
p11660
sg10
I28
sg11
Vdemyelinating polyneuropathy
p11661
sg13
I2
sa(dp11662
g7
I30
sg17
VC0014130
p11663
sg10
I14
sg11
Vendocrinopathy
p11664
sg13
I1
sa(dp11665
g7
I0
sg17
VC0152025
p11666
sg10
I14
sg11
VPolyneuropathy
p11667
sg13
I1
sasa(dp11668
g2
S'Polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes (POEMS) syndrome, a form of osteosclerotic myeloma, is a multisystem disease related to a monoclonal plasma cell proliferative disorder.\n'
p11669
sg4
(lp11670
sg14
(lp11671
(dp11672
g7
I82
sg17
VC0039082
p11673
sg10
I8
sg11
Vsyndrome
p11674
sg13
I1
sa(dp11675
g7
I102
sg17
VC1510415
p11676
sg10
I22
sg11
Vosteosclerotic myeloma
p11677
sg13
I2
sa(dp11678
g7
I187
sg17
VC0334094
p11679
sg10
I13
sg11
Vproliferative
p11680
sg13
I1
sa(dp11681
g7
I30
sg17
VC0014130
p11682
sg10
I14
sg11
Vendocrinopathy
p11683
sg13
I1
sa(dp11684
g7
I0
sg17
VC0152025
p11685
sg10
I14
sg11
VPolyneuropathy
p11686
sg13
I1
sasa(dp11687
g2
S'She had been treated with cyclophosphamide, melphalan, lenalidomide and corticosteroids for POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy or edema, M protein, skin changes).\n'
p11688
sg4
(lp11689
sg14
(lp11690
(dp11691
g7
I138
sg17
VC0014130
p11692
sg10
I14
sg11
Vendocrinopathy
p11693
sg13
I1
sa(dp11694
g7
I156
sg17
VC0013604
p11695
sg10
I5
sg11
Vedema
p11696
sg13
I1
sa(dp11697
g7
I108
sg17
VC0152025
p11698
sg10
I14
sg11
Vpolyneuropathy
p11699
sg13
I1
sa(dp11700
g7
I92
sg17
VC0085404
p11701
sg10
I14
sg11
VPOEMS syndrome
p11702
sg13
I2
sasa(dp11703
g2
S'Polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes (POEMS) syndrome is a rare cause of demyelinating neuropathy, with multi-organ involvement characterised by plasma cell dyscrasia and VEGF overproduction.\n'
p11704
sg4
(lp11705
sg14
(lp11706
(dp11707
g7
I110
sg17
VC0270922
p11708
sg10
I24
sg11
Vdemyelinating neuropathy
p11709
sg13
I2
sa(dp11710
g7
I82
sg17
VC0039082
p11711
sg10
I8
sg11
Vsyndrome
p11712
sg13
I1
sa(dp11713
g7
I30
sg17
VC0014130
p11714
sg10
I14
sg11
Vendocrinopathy
p11715
sg13
I1
sa(dp11716
g7
I182
sg17
VC1136084
p11717
sg10
I21
sg11
Vplasma cell dyscrasia
p11718
sg13
I3
sa(dp11719
g7
I0
sg17
VC0152025
p11720
sg10
I14
sg11
VPolyneuropathy
p11721
sg13
I1
sasa(dp11722
g2
S'As a consequence, leukemia induction and leukemia maintenance were severely impaired in Inca1-/- bone marrow cells.\n'
p11723
sg4
(lp11724
sg14
(lp11725
(dp11726
g7
I18
sg17
VC0023418
p11727
sg10
I8
sg11
Vleukemia
p11728
sg13
I1
sa(dp11729
g7
I18
sg17
VC0023418
p11730
sg10
I8
sg11
Vleukemia
p11731
sg13
I1
sa(dp11732
g7
I76
sg17
VC0684336
p11733
sg10
I8
sg11
Vimpaired
p11734
sg13
I1
sasa(dp11735
g2
S'The re-initiation of leukemia was also significantly inhibited in absence of Inca1-/- in MLL-AF9- and c-myc/BCL2-positive leukemia mouse models.\n'
p11736
sg4
(lp11737
(dp11738
g7
I102
sg8
VP12524
p11739
sg10
I5
sg11
Vc-myc
p11740
sg13
I1
sa(dp11741
g7
I93
sg8
VP42568
p11742
sg10
I3
sg11
VAF9
p11743
sg13
I1
sa(dp11744
g7
I108
sg8
VP10415
p11745
sg10
I4
sg11
VBCL2
p11746
sg13
I1
sa(dp11747
g7
I77
sg8
g9
sg10
I15
sg11
VInca1-/- in MLL
p11748
sg13
I3
sasg14
(lp11749
(dp11750
g7
I21
sg17
VC0023418
p11751
sg10
I8
sg11
Vleukemia
p11752
sg13
I1
sa(dp11753
g7
I21
sg17
VC0023418
p11754
sg10
I8
sg11
Vleukemia
p11755
sg13
I1
sasa(dp11756
g2
S'These findings indicate distinct functional properties of Inca1 in normal hematopoietic cells compared to leukemia initiating cells.\n'
p11757
sg4
(lp11758
(dp11759
g7
I58
sg8
g9
sg10
I5
sg11
VInca1
p11760
sg13
I1
sasg14
(lp11761
(dp11762
g7
I106
sg17
VC0023418
p11763
sg10
I8
sg11
Vleukemia
p11764
sg13
I1
sasa(dp11765
g2
S'This preliminary study indicated the tumor suppressing roles of miR-372 in cell cycle progression of TW01 cells, possibly via the down-regulation of CDK2 and CCNA1 as well as the up-regulation of CDKN1A and INCA1.Key Words: apoptosis, microRNA, nasopharyngeal carcinoma, miR-372, CDK2, CCNA1.\n'
p11766
sg4
(lp11767
(dp11768
g7
I158
sg8
VP78396
p11769
sg10
I5
sg11
VCCNA1
p11770
sg13
I1
sa(dp11771
g7
I196
sg8
VP38936
p11772
sg10
I6
sg11
VCDKN1A
p11773
sg13
I1
sa(dp11774
g7
I149
sg8
VP24941
p11775
sg10
I4
sg11
VCDK2
p11776
sg13
I1
sa(dp11777
g7
I149
sg8
VP24941
p11778
sg10
I4
sg11
VCDK2
p11779
sg13
I1
sa(dp11780
g7
I158
sg8
VP78396
p11781
sg10
I5
sg11
VCCNA1
p11782
sg13
I1
sa(dp11783
g7
I207
sg8
g9
sg10
I5
sg11
VINCA1
p11784
sg13
I1
sasg14
(lp11785
(dp11786
g7
I245
sg17
VC2931822
p11787
sg10
I24
sg11
Vnasopharyngeal carcinoma
p11788
sg13
I2
sa(dp11789
g7
I37
sg17
VC0027651
p11790
sg10
I5
sg11
Vtumor
p11791
sg13
I1
sasa(dp11792
g2
S'Furthermore, blasts from acute lymphoid leukemia and acute myeloid leukemia patients expressed significantly reduced INCA1 levels highlighting its relevance for growth control in vivo.\n'
p11793
sg4
(lp11794
(dp11795
g7
I117
sg8
g9
sg10
I5
sg11
VINCA1
p11796
sg13
I1
sasg14
(lp11797
(dp11798
g7
I25
sg17
VC1961102
p11799
sg10
I23
sg11
Vacute lymphoid leukemia
p11800
sg13
I3
sa(dp11801
g7
I53
sg17
VC0023467
p11802
sg10
I22
sg11
Vacute myeloid leukemia
p11803
sg13
I3
sasa(dp11804
g2
S'Our objectives were (i) to assess the current prevalence of childhood overweight (including obesity) (OWOB) in France and its relationship with comprehensive socioeconomic status (SES) indicators and (ii) to examine trends in OWOB prevalence and changes in energy intake (EI) and sedentary behavior (SED) based on the previous INCA 1 (Individuelle Nationale des Consommations Alimentaires) data (1998-1999).\n'
p11805
sg4
(lp11806
(dp11807
g7
I327
sg8
g9
sg10
I6
sg11
VINCA 1
p11808
sg13
I2
sasg14
(lp11809
(dp11810
g7
I92
sg17
VC0028754
p11811
sg10
I7
sg11
Vobesity
p11812
sg13
I1
sa(dp11813
g7
I70
sg17
VC0497406
p11814
sg10
I10
sg11
Voverweight
p11815
sg13
I1
sa(dp11816
g7
I358
sg17
VC0394006
p11817
sg10
I3
sg11
Vdes
p11818
sg13
I1
sasa(dp11819
g2
S'Both estradiol and global ischemia markedly increased ERalpha, but not ERbeta, protein in CA1.\n'
p11820
sg4
(lp11821
(dp11822
g7
I54
sg8
VP03372
p11823
sg10
I7
sg11
VERalpha
p11824
sg13
I1
sasg14
(lp11825
(dp11826
g7
I26
sg17
VC0022116
p11827
sg10
I8
sg11
Vischemia
p11828
sg13
I1
sasa(dp11829
g2
S'It has been reported that BMPR2 is associated with chondrosarcoma.\n'
p11830
sg4
(lp11831
(dp11832
g7
I26
sg8
g9
sg10
I5
sg11
VBMPR2
p11833
sg13
I1
sasg14
(lp11834
(dp11835
g7
I51
sg17
VC0008479
p11836
sg10
I14
sg11
Vchondrosarcoma
p11837
sg13
I1
sasa(dp11838
g2
S'Moreover, the detection of BMPR2 is more frequent in dedifferentiated chondrosarcomas (DDCS) than in conventional chondrosarcomas (CCS).\n'
p11839
sg4
(lp11840
(dp11841
g7
I27
sg8
g9
sg10
I5
sg11
VBMPR2
p11842
sg13
I1
sasg14
(lp11843
(dp11844
g7
I131
sg17
VC0008479
p11845
sg10
I3
sg11
VCCS
p11846
sg13
I1
sa(dp11847
g7
I70
sg17
VC0008479
p11848
sg10
I15
sg11
Vchondrosarcomas
p11849
sg13
I1
sa(dp11850
g7
I70
sg17
VC0008479
p11851
sg10
I15
sg11
Vchondrosarcomas
p11852
sg13
I1
sasa(dp11853
g2
S'BMPR2, phospho-SMAD1/5 (pSMAD1/5), and runt-related transcription factor 2 (RUNX2) expressions were found to be associated with the pathological grades of chondrosarcoma and could be a promising target of treatment outcome.\n'
p11854
sg4
(lp11855
(dp11856
g7
I76
sg8
g9
sg10
I5
sg11
VRUNX2
p11857
sg13
I1
sa(dp11858
g7
I0
sg8
g9
sg10
I5
sg11
VBMPR2
p11859
sg13
I1
sa(dp11860
g7
I7
sg8
VP41250
p11861
sg10
I15
sg11
Vphospho-SMAD1/5
p11862
sg13
I1
sa(dp11863
g7
I24
sg8
VP41250
p11864
sg10
I8
sg11
VpSMAD1/5
p11865
sg13
I1
sasg14
(lp11866
(dp11867
g7
I39
sg17
VC0013336
p11868
sg10
I4
sg11
Vrunt
p11869
sg13
I1
sa(dp11870
g7
I155
sg17
VC0008479
p11871
sg10
I14
sg11
Vchondrosarcoma
p11872
sg13
I1
sasa(dp11873
g2
S'It has been demonstrated that more prevalent expression of bone morphogenetic protein receptor 2 (BMPR2) has been detected in dedifferentiated chondrosarcomas than conventional chondrosarcomas.\n'
p11874
sg4
(lp11875
(dp11876
g7
I98
sg8
g9
sg10
I5
sg11
VBMPR2
p11877
sg13
I1
sa(dp11878
g7
I59
sg8
g9
sg10
I37
sg11
Vbone morphogenetic protein receptor 2
p11879
sg13
I5
sasg14
(lp11880
(dp11881
g7
I143
sg17
VC0008479
p11882
sg10
I15
sg11
Vchondrosarcomas
p11883
sg13
I1
sa(dp11884
g7
I143
sg17
VC0008479
p11885
sg10
I15
sg11
Vchondrosarcomas
p11886
sg13
I1
sasa(dp11887
g2
S'Here, we find that BMPR2 inhibition induces apoptosis and autophagy of chondrosarcoma.\n'
p11888
sg4
(lp11889
(dp11890
g7
I19
sg8
g9
sg10
I5
sg11
VBMPR2
p11891
sg13
I1
sasg14
(lp11892
(dp11893
g7
I71
sg17
VC0008479
p11894
sg10
I14
sg11
Vchondrosarcoma
p11895
sg13
I1
sasa(dp11896
g2
S'We found that BMPR2 expression was correlated with the clinicopathological features of chondrosarcomas, and could predict the treatment outcome.\n'
p11897
sg4
(lp11898
(dp11899
g7
I14
sg8
g9
sg10
I5
sg11
VBMPR2
p11900
sg13
I1
sasg14
(lp11901
(dp11902
g7
I87
sg17
VC0008479
p11903
sg10
I15
sg11
Vchondrosarcomas
p11904
sg13
I1
sasa(dp11905
g2
S'Knockdown of BMPR2 by small interfering RNA results in growth inhibition in chondrosarcoma cells.\n'
p11906
sg4
(lp11907
(dp11908
g7
I13
sg8
g9
sg10
I5
sg11
VBMPR2
p11909
sg13
I1
sasg14
(lp11910
(dp11911
g7
I76
sg17
VC0008479
p11912
sg10
I14
sg11
Vchondrosarcoma
p11913
sg13
I1
sasa(dp11914
g2
S'Silencing BMPR2 promoted G2/M cell cycle arrest, induced chondrosarcoma cell apoptosis through caspase-3-dependent pathway via repression of X-linked inhibitor of apoptosis protein (XIAP) and induced autophagy of chondrosarcoma cells via XIAP-Mdm2-p53 pathway.\n'
p11915
sg4
(lp11916
(dp11917
g7
I248
sg8
VP42771
p11918
sg10
I3
sg11
Vp53
p11919
sg13
I1
sa(dp11920
g7
I95
sg8
VP42574
p11921
sg10
I9
sg11
Vcaspase-3
p11922
sg13
I1
sa(dp11923
g7
I182
sg8
VP98170
p11924
sg10
I4
sg11
VXIAP
p11925
sg13
I1
sa(dp11926
g7
I10
sg8
g9
sg10
I5
sg11
VBMPR2
p11927
sg13
I1
sa(dp11928
g7
I182
sg8
VP98170
p11929
sg10
I4
sg11
VXIAP
p11930
sg13
I1
sa(dp11931
g7
I141
sg8
VP98170
p11932
sg10
I39
sg11
VX-linked inhibitor of apoptosis protein
p11933
sg13
I5
sasg14
(lp11934
(dp11935
g7
I57
sg17
VC0008479
p11936
sg10
I14
sg11
Vchondrosarcoma
p11937
sg13
I1
sa(dp11938
g7
I57
sg17
VC0008479
p11939
sg10
I14
sg11
Vchondrosarcoma
p11940
sg13
I1
sasa(dp11941
g2
S'Inhibition of autophagy induced by BMPR2 small interfering RNA (siBMPR2) sensitized chondrosarcoma cells to siBMPR2-induced apoptotic cell death, suggesting that autophagy has a protective role for chondrosarcoma cells in context of siBMPR2-induced apoptotic cell death.\n'
p11942
sg4
(lp11943
(dp11944
g7
I35
sg8
g9
sg10
I27
sg11
VBMPR2 small interfering RNA
p11945
sg13
I4
sasg14
(lp11946
(dp11947
g7
I84
sg17
VC0008479
p11948
sg10
I14
sg11
Vchondrosarcoma
p11949
sg13
I1
sa(dp11950
g7
I84
sg17
VC0008479
p11951
sg10
I14
sg11
Vchondrosarcoma
p11952
sg13
I1
sasa(dp11953
g2
S'Taken together, our results suggest that BMPR2 has a significant role in the tumorigenesis of chondrosarcoma, and could be an important prognostic marker for chondrosarcoma.\n'
p11954
sg4
(lp11955
(dp11956
g7
I41
sg8
g9
sg10
I5
sg11
VBMPR2
p11957
sg13
I1
sasg14
(lp11958
(dp11959
g7
I94
sg17
VC0008479
p11960
sg10
I14
sg11
Vchondrosarcoma
p11961
sg13
I1
sa(dp11962
g7
I77
sg17
VC0007621
p11963
sg10
I13
sg11
Vtumorigenesis
p11964
sg13
I1
sa(dp11965
g7
I94
sg17
VC0008479
p11966
sg10
I14
sg11
Vchondrosarcoma
p11967
sg13
I1
sasa(dp11968
g2
S'BMPR2 inhibition could eventually provide a promising therapy for chondrosarcoma treatment.\n'
p11969
sg4
(lp11970
(dp11971
g7
I0
sg8
g9
sg10
I5
sg11
VBMPR2
p11972
sg13
I1
sasg14
(lp11973
(dp11974
g7
I66
sg17
VC0008479
p11975
sg10
I14
sg11
Vchondrosarcoma
p11976
sg13
I1
sasa(dp11977
g2
S'The role of Beta-defensin-1 in asthma and chronic obstructive pulmonary disease (COPD) remains unclear.\n'
p11978
sg4
(lp11979
(dp11980
g7
I12
sg8
VP60022
p11981
sg10
I15
sg11
VBeta-defensin-1
p11982
sg13
I1
sasg14
(lp11983
(dp11984
g7
I81
sg17
VC0024117
p11985
sg10
I4
sg11
VCOPD
p11986
sg13
I1
sa(dp11987
g7
I42
sg17
VC0024117
p11988
sg10
I37
sg11
Vchronic obstructive pulmonary disease
p11989
sg13
I4
sa(dp11990
g7
I31
sg17
VC0004096
p11991
sg10
I6
sg11
Vasthma
p11992
sg13
I1
sasa(dp11993
g2
S'In Japanese and Chinese populations, two different beta-defensin-1 polymorphisms have been associated with chronic obstructive pulmonary disease phenotypes.\n'
p11994
sg4
(lp11995
(dp11996
g7
I51
sg8
VP60022
p11997
sg10
I15
sg11
Vbeta-defensin-1
p11998
sg13
I1
sasg14
(lp11999
(dp12000
g7
I107
sg17
VC0024117
p12001
sg10
I37
sg11
Vchronic obstructive pulmonary disease
p12002
sg13
I4
sasa(dp12003
g2
S'The autosomal recessive ataxias are separated into Friedreich ataxia, ataxia due to vitamin E deficiency, ataxia due to Abeta-lipoproteinemia, Refsum disease, late-onset Tay-Sachs disease, cerebrotendineous xanthomatosis, spinocerebellar ataxia with axonal neuropathy, ataxia telangiectasia, ataxia telangiectasia-like disorder, ataxia with oculomotor apraxia 1 and 2, spastic ataxia of Charlevoix-Saguenay, Cayman ataxia, Marinesco-Sjoegren syndrome, and autosomal recessive mitochondrial ataxias (AR-CPEO, SANDO, SCAE, AHS, IOSCA, MEMSA, LBSL CoQ-deficiency, PDC-deficiency).\n'
p12004
sg4
(lp12005
(dp12006
g7
I120
sg8
g9
sg10
I5
sg11
VAbeta
p12007
sg13
I1
sa(dp12008
g7
I526
sg8
g9
sg10
I5
sg11
VIOSCA
p12009
sg13
I1
sa(dp12010
g7
I508
sg8
VP54098
p12011
sg10
I5
sg11
VSANDO
p12012
sg13
I1
sa(dp12013
g7
I561
sg8
VP20941
p12014
sg10
I3
sg11
VPDC
p12015
sg13
I1
sa(dp12016
g7
I521
sg8
VP02765
p12017
sg10
I3
sg11
VAHS
p12018
sg13
I1
sa(dp12019
g7
I540
sg8
g9
sg10
I8
sg11
VLBSL CoQ
p12020
sg13
I2
sa(dp12021
g7
I515
sg8
VP54098
p12022
sg10
I4
sg11
VSCAE
p12023
sg13
I1
sasg14
(lp12024
(dp12025
g7
I269
sg17
VC0004135
p12026
sg10
I21
sg11
Vataxia telangiectasia
p12027
sg13
I2
sa(dp12028
g7
I508
sg17
VC1843851
p12029
sg10
I5
sg11
VSANDO
p12030
sg13
I1
sa(dp12031
g7
I369
sg17
VC1849140
p12032
sg10
I37
sg11
Vspastic ataxia of Charlevoix-Saguenay
p12033
sg13
I4
sa(dp12034
g7
I24
sg17
VC0004134
p12035
sg10
I7
sg11
Vataxias
p12036
sg13
I1
sa(dp12037
g7
I515
sg17
VC1843852
p12038
sg10
I4
sg11
VSCAE
p12039
sg13
I1
sa(dp12040
g7
I51
sg17
VC0016719
p12041
sg10
I17
sg11
VFriedreich ataxia
p12042
sg13
I2
sa(dp12043
g7
I222
sg17
VC0087012
p12044
sg10
I22
sg11
Vspinocerebellar ataxia
p12045
sg13
I2
sa(dp12046
g7
I207
sg17
VC0043325
p12047
sg10
I13
sg11
Vxanthomatosis
p12048
sg13
I1
sa(dp12049
g7
I143
sg17
VC0034960
p12050
sg10
I14
sg11
VRefsum disease
p12051
sg13
I2
sa(dp12052
g7
I526
sg17
VC1849096
p12053
sg10
I5
sg11
VIOSCA
p12054
sg13
I1
sa(dp12055
g7
I250
sg17
VC0270921
p12056
sg10
I17
sg11
Vaxonal neuropathy
p12057
sg13
I2
sa(dp12058
g7
I24
sg17
VC0004134
p12059
sg10
I6
sg11
Vataxia
p12060
sg13
I1
sa(dp12061
g7
I341
sg17
VC0271270
p12062
sg10
I18
sg11
Voculomotor apraxia
p12063
sg13
I2
sa(dp12064
g7
I84
sg17
VC0042875
p12065
sg10
I20
sg11
Vvitamin E deficiency
p12066
sg13
I3
sa(dp12067
g7
I502
sg17
VC0162674
p12068
sg10
I4
sg11
VCPEO
p12069
sg13
I1
sa(dp12070
g7
I170
sg17
VC0039373
p12071
sg10
I17
sg11
VTay-Sachs disease
p12072
sg13
I2
sa(dp12073
g7
I442
sg17
VC0039082
p12074
sg10
I8
sg11
Vsyndrome
p12075
sg13
I1
sa(dp12076
g7
I24
sg17
VC0004134
p12077
sg10
I6
sg11
Vataxia
p12078
sg13
I1
sa(dp12079
g7
I24
sg17
VC0004134
p12080
sg10
I6
sg11
Vataxia
p12081
sg13
I1
sa(dp12082
g7
I269
sg17
VC0004135
p12083
sg10
I21
sg11
Vataxia telangiectasia
p12084
sg13
I2
sa(dp12085
g7
I24
sg17
VC0004134
p12086
sg10
I6
sg11
Vataxia
p12087
sg13
I1
sa(dp12088
g7
I540
sg17
VC1970180
p12089
sg10
I4
sg11
VLBSL
p12090
sg13
I1
sa(dp12091
g7
I24
sg17
VC0004134
p12092
sg10
I7
sg11
Vataxias
p12093
sg13
I1
sa(dp12094
g7
I561
sg17
VC1869117
p12095
sg10
I3
sg11
VPDC
p12096
sg13
I1
sasa(dp12097
g2
S'Only patients presenting PEO as part of their clinical phenotype had POLG mutations, in seven of them together with myopathic signs and in one with a sensori-motor peripheral neuropathy.\n'
p12098
sg4
(lp12099
(dp12100
g7
I69
sg8
VP54098
p12101
sg10
I4
sg11
VPOLG
p12102
sg13
I1
sasg14
(lp12103
(dp12104
g7
I158
sg17
VC0235025
p12105
sg10
I27
sg11
Vmotor peripheral neuropathy
p12106
sg13
I3
sasa(dp12107
g2
S'Moreover, it is suggested that blockades of 5-HT3 and 5-HT4 receptors are not relevant to the control of motion sickness; and furthermore, it suggested that blocking 5-HT4 receptors in addition to 5-HT3 receptors does not have an additional effect on the control of cisplatin-induced emesis, but that 5-HT4 receptors are at least partly involved in the mechanism of emesis induced by copper sulfate.\n'
p12108
sg4
(lp12109
(dp12110
g7
I197
sg8
g9
sg10
I15
sg11
V5-HT3 receptors
p12111
sg13
I2
sa(dp12112
g7
I44
sg8
g9
sg10
I25
sg11
V5-HT3 and 5-HT4 receptors
p12113
sg13
I4
sa(dp12114
g7
I54
sg8
g9
sg10
I15
sg11
V5-HT4 receptors
p12115
sg13
I2
sa(dp12116
g7
I54
sg8
g9
sg10
I15
sg11
V5-HT4 receptors
p12117
sg13
I2
sasg14
(lp12118
(dp12119
g7
I105
sg17
VC0026603
p12120
sg10
I15
sg11
Vmotion sickness
p12121
sg13
I2
sa(dp12122
g7
I284
sg17
VC0042963
p12123
sg10
I6
sg11
Vemesis
p12124
sg13
I1
sa(dp12125
g7
I157
sg17
VC0233660
p12126
sg10
I8
sg11
Vblocking
p12127
sg13
I1
sa(dp12128
g7
I284
sg17
VC0042963
p12129
sg10
I6
sg11
Vemesis
p12130
sg13
I1
sasa(dp12131
g2
S'Therefore, we used Biolog GN2 microplates to analyze the ability of 103 clinical, predominantly diarrheal, isolates of Aeromonas to use various carbon sources, and we verified whether, among the substrates metabolized by these strains, there were some endogenous to the human intestine.\n'
p12132
sg4
(lp12133
sg14
(lp12134
sa(dp12135
g2
S'RP30 was one of these strains that was randomly selected and analysed by using a morphological, physiological and biochemical plate, Biolog GN2 Microplate System and API 20E system.\n'
p12136
sg4
(lp12137
(dp12138
g7
I0
sg8
g9
sg10
I4
sg11
VRP30
p12139
sg13
I1
sasg14
(lp12140
(dp12141
g7
I0
sg17
VC1842816
p12142
sg10
I4
sg11
VRP30
p12143
sg13
I1
sasa(dp12144
g2
S'Histological and clinical diagnoses of the 14 patients were as follows: IgA nephropathy 3, non-IgA GN 2, and asymptomatic significant microscopic hematuria [more than 100 red blood cells per high-power field (x400)] with or without proteinuria 9.\n'
p12145
sg4
(lp12146
(dp12147
g7
I91
sg8
g9
sg10
I12
sg11
Vnon-IgA GN 2
p12148
sg13
I3
sa(dp12149
g7
I72
sg8
VP11912
p12150
sg10
I17
sg11
VIgA nephropathy 3
p12151
sg13
I3
sasg14
(lp12152
(dp12153
g7
I134
sg17
VC0239937
p12154
sg10
I21
sg11
Vmicroscopic hematuria
p12155
sg13
I2
sa(dp12156
g7
I72
sg17
VC0017661
p12157
sg10
I15
sg11
VIgA nephropathy
p12158
sg13
I2
sasa(dp12159
g2
S'The incidence of membranous form of glomerulonephritis was high (34 out of 44 kidney biopsy cases, 77%), the rest of patients showing mesangiocapillary GN-8 (18%) and mesangial proliferative GN-2 (5%).\n'
p12160
sg4
(lp12161
sg14
(lp12162
(dp12163
g7
I36
sg17
VC0017658
p12164
sg10
I18
sg11
Vglomerulonephritis
p12165
sg13
I1
sa(dp12166
g7
I177
sg17
VC0334094
p12167
sg10
I13
sg11
Vproliferative
p12168
sg13
I1
sasa(dp12169
g2
S'In organ cultures, nephrosis-producing IBV strains (GN-2 and M-41) were slightly more ciliostatic and respiratory strains (Beaudette and Kita-1/Tokushima) less ciliostatic at 40.5 degrees C than at 37 degrees C. Mortality of chicken embryos infected with the GN-2, M-41 and Kita-1/Tokushima strains was greater at 40.5 degrees C than at 37 degrees C, while the reverse was true of the Beaudette strain which caused no embryo mortality at 40.5 degrees C. The Beaudette strain of IBV was the only one which could not be recovered from the kidneys of young chickens four days after infection.\n'
p12170
sg4
(lp12171
(dp12172
g7
I52
sg8
g9
sg10
I4
sg11
VGN-2
p12173
sg13
I1
sasg14
(lp12174
(dp12175
g7
I19
sg17
VC0027720
p12176
sg10
I9
sg11
Vnephrosis
p12177
sg13
I1
sa(dp12178
g7
I579
sg17
VC0009450
p12179
sg10
I9
sg11
Vinfection
p12180
sg13
I1
sasa(dp12181
g2
S"In addition, in Alzheimer's disease we found simple gangliosides (GN2, GM3) to be elevated in the frontal and parietal cortex, which might correlate accelerated lysosomal degradation of gangliosides and/or astrogliosis occurring during neuronal death.\n"
p12182
sg4
(lp12183
sg14
(lp12184
(dp12185
g7
I16
sg17
VC1521724
p12186
sg10
I19
sg11
VAlzheimer's disease
p12187
sg13
I2
sa(dp12188
g7
I206
sg17
VC0017639
p12189
sg10
I12
sg11
Vastrogliosis
p12190
sg13
I1
sasa(dp12191
g2
S'The aim of this study was to investigate the immunoreactivity to tryptase and to cathepsin-G of MC from human cutaneous mastocytosis and to compare their number in normal skin and cutaneous mastocytosis.\n'
p12192
sg4
(lp12193
(dp12194
g7
I81
sg8
VP25774
p12195
sg10
I11
sg11
Vcathepsin-G
p12196
sg13
I1
sasg14
(lp12197
(dp12198
g7
I110
sg17
VC1136033
p12199
sg10
I22
sg11
Vcutaneous mastocytosis
p12200
sg13
I2
sa(dp12201
g7
I110
sg17
VC1136033
p12202
sg10
I22
sg11
Vcutaneous mastocytosis
p12203
sg13
I2
sasa(dp12204
g2
S'Morphometric evaluation of MC number demostrated that the number of both tryptase- and cathepsin-G-positive MC was significantly higher in cutaneous mastocytosis as compared to normal skin and that in both conditions the number of tryptase-positive MC was significantly higher as compared to the number of cathepsin-G-positive MC.\n'
p12205
sg4
(lp12206
(dp12207
g7
I87
sg8
VP25774
p12208
sg10
I11
sg11
Vcathepsin-G
p12209
sg13
I1
sa(dp12210
g7
I87
sg8
VP25774
p12211
sg10
I11
sg11
Vcathepsin-G
p12212
sg13
I1
sasg14
(lp12213
(dp12214
g7
I139
sg17
VC1136033
p12215
sg10
I22
sg11
Vcutaneous mastocytosis
p12216
sg13
I2
sasa(dp12217
g2
S'In conclusion, in this study, for the first time we have demonstrated the presence of MC with immunoreactivity to cathepsin-G in human cutaneous mastocytosis, as well as the co-localization of tryptase and cathepsin-G in MC secretory granules.\n'
p12218
sg4
(lp12219
(dp12220
g7
I114
sg8
VP25774
p12221
sg10
I11
sg11
Vcathepsin-G
p12222
sg13
I1
sa(dp12223
g7
I114
sg8
VP25774
p12224
sg10
I11
sg11
Vcathepsin-G
p12225
sg13
I1
sasg14
(lp12226
(dp12227
g7
I135
sg17
VC1136033
p12228
sg10
I22
sg11
Vcutaneous mastocytosis
p12229
sg13
I2
sasa(dp12230
g2
S'The aim of our retrospective study was to evaluate the association of miR-126-3p, miR-126-5p and miR-664-3p tumour expression levels with outcomes of patients with metastatic colorectal cancer treated with bevacizumab.\n'
p12231
sg4
(lp12232
(dp12233
g7
I97
sg8
g9
sg10
I10
sg11
VmiR-664-3p
p12234
sg13
I1
sa(dp12235
g7
I82
sg8
g9
sg10
I10
sg11
VmiR-126-5p
p12236
sg13
I1
sa(dp12237
g7
I70
sg8
g9
sg10
I10
sg11
VmiR-126-3p
p12238
sg13
I1
sasg14
(lp12239
(dp12240
g7
I164
sg17
VC0948380
p12241
sg10
I28
sg11
Vmetastatic colorectal cancer
p12242
sg13
I3
sa(dp12243
g7
I108
sg17
VC0027651
p12244
sg10
I6
sg11
Vtumour
p12245
sg13
I1
sasa(dp12246
g2
S'In the present study, we investigated the role of miR-126-5p and Bcl2l2 in cervical cancer cells.\n'
p12247
sg4
(lp12248
(dp12249
g7
I65
sg8
g9
sg10
I6
sg11
VBcl2l2
p12250
sg13
I1
sa(dp12251
g7
I50
sg8
g9
sg10
I10
sg11
VmiR-126-5p
p12252
sg13
I1
sasg14
(lp12253
(dp12254
g7
I75
sg17
VC0302592
p12255
sg10
I15
sg11
Vcervical cancer
p12256
sg13
I2
sasa(dp12257
g2
S'First, miR-126-5p expression was aberrantly downregulated in human cervical cancer tumor tissues in comparison with normal tissues, as evaluated by RT-PCR.\n'
p12258
sg4
(lp12259
(dp12260
g7
I7
sg8
g9
sg10
I10
sg11
VmiR-126-5p
p12261
sg13
I1
sasg14
(lp12262
(dp12263
g7
I83
sg17
VC0027651
p12264
sg10
I5
sg11
Vtumor
p12265
sg13
I1
sa(dp12266
g7
I67
sg17
VC0302592
p12267
sg10
I15
sg11
Vcervical cancer
p12268
sg13
I2
sasa(dp12269
g2
S'Consistently, the levels of miR-126-5p were also significantly reduced in cervical cancer cell lines when compared to normal cervical epithelial cells.\n'
p12270
sg4
(lp12271
(dp12272
g7
I28
sg8
g9
sg10
I10
sg11
VmiR-126-5p
p12273
sg13
I1
sasg14
(lp12274
(dp12275
g7
I74
sg17
VC0302592
p12276
sg10
I15
sg11
Vcervical cancer
p12277
sg13
I2
sasa(dp12278
g2
S'Flow cytometric analysis showed that the rate of apoptosis of cervical cancer cells was significantly increased by miR-126-5p overexpression but inhibited by miR-126-5p inhibitor.\n'
p12279
sg4
(lp12280
(dp12281
g7
I115
sg8
g9
sg10
I10
sg11
VmiR-126-5p
p12282
sg13
I1
sa(dp12283
g7
I115
sg8
g9
sg10
I10
sg11
VmiR-126-5p
p12284
sg13
I1
sasg14
(lp12285
(dp12286
g7
I62
sg17
VC0302592
p12287
sg10
I15
sg11
Vcervical cancer
p12288
sg13
I2
sasa(dp12289
g2
S'A similar change pattern was observed in the expression of apoptosis-regulated protein caspase 3 in cervical cancer cells transfected with miR-126-5p mimic or inhibitor.\n'
p12290
sg4
(lp12291
(dp12292
g7
I139
sg8
g9
sg10
I10
sg11
VmiR-126-5p
p12293
sg13
I1
sa(dp12294
g7
I79
sg8
VP42574
p12295
sg10
I17
sg11
Vprotein caspase 3
p12296
sg13
I3
sasg14
(lp12297
(dp12298
g7
I100
sg17
VC0302592
p12299
sg10
I15
sg11
Vcervical cancer
p12300
sg13
I2
sasa(dp12301
g2
S'By bioinformatic prediction with online databases and verification using luciferase reporter assay, we then identified that Bcl2l2 is a direct target of miR-126-5p in cervical cancer cells.\n'
p12302
sg4
(lp12303
(dp12304
g7
I124
sg8
g9
sg10
I6
sg11
VBcl2l2
p12305
sg13
I1
sa(dp12306
g7
I153
sg8
g9
sg10
I10
sg11
VmiR-126-5p
p12307
sg13
I1
sasg14
(lp12308
(dp12309
g7
I167
sg17
VC0302592
p12310
sg10
I15
sg11
Vcervical cancer
p12311
sg13
I2
sasa(dp12312
g2
S'The expression of Bcl2l2 was strongly downregulated by the miR-126-5p mimic but upregulated by the miR-126-5p inhibitor in cervical cancer cells, and Bcl2l2 expression was significantly increased in human cervical cancer tumor tissues, which was negatively correlated with miR-126-5p levels.\n'
p12313
sg4
(lp12314
(dp12315
g7
I18
sg8
g9
sg10
I6
sg11
VBcl2l2
p12316
sg13
I1
sa(dp12317
g7
I59
sg8
g9
sg10
I10
sg11
VmiR-126-5p
p12318
sg13
I1
sa(dp12319
g7
I59
sg8
g9
sg10
I10
sg11
VmiR-126-5p
p12320
sg13
I1
sa(dp12321
g7
I18
sg8
g9
sg10
I6
sg11
VBcl2l2
p12322
sg13
I1
sasg14
(lp12323
(dp12324
g7
I123
sg17
VC0302592
p12325
sg10
I15
sg11
Vcervical cancer
p12326
sg13
I2
sa(dp12327
g7
I123
sg17
VC0302592
p12328
sg10
I15
sg11
Vcervical cancer
p12329
sg13
I2
sa(dp12330
g7
I221
sg17
VC0027651
p12331
sg10
I5
sg11
Vtumor
p12332
sg13
I1
sasa(dp12333
g2
S'Furthermore, we confirmed that the rate of apoptosis was significantly increased by Bcl2l2 silencing in cervical cancer cells, which was not affected by the miR-126-5p inhibitor.\n'
p12334
sg4
(lp12335
(dp12336
g7
I84
sg8
g9
sg10
I6
sg11
VBcl2l2
p12337
sg13
I1
sa(dp12338
g7
I157
sg8
g9
sg10
I10
sg11
VmiR-126-5p
p12339
sg13
I1
sasg14
(lp12340
(dp12341
g7
I104
sg17
VC0302592
p12342
sg10
I15
sg11
Vcervical cancer
p12343
sg13
I2
sasa(dp12344
g2
S'In summary, miR-126-5p plays an inhibitory role in human cervical cancer progression, regulating the apoptosis of cancer cells via directly targeting Bcl2l2.\n'
p12345
sg4
(lp12346
(dp12347
g7
I12
sg8
g9
sg10
I10
sg11
VmiR-126-5p
p12348
sg13
I1
sa(dp12349
g7
I150
sg8
g9
sg10
I6
sg11
VBcl2l2
p12350
sg13
I1
sasg14
(lp12351
(dp12352
g7
I66
sg17
VC0006826
p12353
sg10
I6
sg11
Vcancer
p12354
sg13
I1
sa(dp12355
g7
I66
sg17
VC0178874
p12356
sg10
I18
sg11
Vcancer progression
p12357
sg13
I2
sasa(dp12358
g2
S'Patients with miR-126*low myelodysplastic syndrome had significantly lower response rates (P = 0.04) and higher relapse rates (P = 0.03), as well as shorter progression-free (PFS; P = 0.004) and overall survival (OS; P = 0.004).\n'
p12359
sg4
(lp12360
sg14
(lp12361
(dp12362
g7
I26
sg17
VC0033027
p12363
sg10
I24
sg11
Vmyelodysplastic syndrome
p12364
sg13
I2
sa(dp12365
g7
I112
sg17
VC0277556
p12366
sg10
I7
sg11
Vrelapse
p12367
sg13
I1
sasa(dp12368
g2
S'In the present study, the relationship between miR-126-5p/3p expression levels and overall survival in 109 patients with acute myeloid leukemia (AML) who received intensive therapy were evaluated.\n'
p12369
sg4
(lp12370
(dp12371
g7
I47
sg8
g9
sg10
I13
sg11
VmiR-126-5p/3p
p12372
sg13
I1
sasg14
(lp12373
(dp12374
g7
I121
sg17
VC0023467
p12375
sg10
I22
sg11
Vacute myeloid leukemia
p12376
sg13
I3
sa(dp12377
g7
I145
sg17
VC0023467
p12378
sg10
I3
sg11
VAML
p12379
sg13
I1
sasa(dp12380
g2
S"The presence of XBP-1s, the active form of XBP-1, after administration of anti-Ig to Akata Burkitt's lymphoma cells is consistent with a role for this factor in reactivation of the EBV lytic cycle, although signalling through MEF2D was quantitatively much more significant in activation of Zp.\n"
p12381
sg4
(lp12382
(dp12383
g7
I16
sg8
g9
sg10
I6
sg11
VXBP-1s
p12384
sg13
I1
sa(dp12385
g7
I226
sg8
g9
sg10
I5
sg11
VMEF2D
p12386
sg13
I1
sa(dp12387
g7
I16
sg8
VP17861
p12388
sg10
I5
sg11
VXBP-1
p12389
sg13
I1
sasg14
(lp12390
(dp12391
g7
I185
sg17
VC0024348
p12392
sg10
I5
sg11
Vlytic
p12393
sg13
I1
sa(dp12394
g7
I91
sg17
VC0006413
p12395
sg10
I18
sg11
VBurkitt's lymphoma
p12396
sg13
I2
sasa(dp12397
g2
S'As expected, markers of neuronal differentiation such as anti-apoptotic protein B-cell lymphoma 2 (BCL2), myocyte enhancer factor-2D (MEF2D) and zipper protein kinase (MAP3K12; aka ZPK/MUK/DLK) were each up-regulated in response to differentiation.\n'
p12398
sg4
(lp12399
(dp12400
g7
I189
sg8
VP80370
p12401
sg10
I3
sg11
VDLK
p12402
sg13
I1
sa(dp12403
g7
I99
sg8
VP10415
p12404
sg10
I4
sg11
VBCL2
p12405
sg13
I1
sa(dp12406
g7
I134
sg8
g9
sg10
I5
sg11
VMEF2D
p12407
sg13
I1
sa(dp12408
g7
I168
sg8
g9
sg10
I7
sg11
VMAP3K12
p12409
sg13
I1
sa(dp12410
g7
I185
sg8
g9
sg10
I3
sg11
VMUK
p12411
sg13
I1
sa(dp12412
g7
I145
sg8
g9
sg10
I21
sg11
Vzipper protein kinase
p12413
sg13
I3
sa(dp12414
g7
I106
sg8
g9
sg10
I26
sg11
Vmyocyte enhancer factor-2D
p12415
sg13
I3
sa(dp12416
g7
I177
sg8
g9
sg10
I7
sg11
Vaka ZPK
p12417
sg13
I2
sa(dp12418
g7
I57
sg8
g9
sg10
I40
sg11
Vanti-apoptotic protein B-cell lymphoma 2
p12419
sg13
I5
sasg14
(lp12420
(dp12421
g7
I80
sg17
VC0079731
p12422
sg10
I15
sg11
VB-cell lymphoma
p12423
sg13
I2
sasa(dp12424
g2
S'The decrease in T-Shc and T1 were less obvious in mucinous adenocarcinoma and not observed in serous or endometrioid adenocarcinoma.\n'
p12425
sg4
(lp12426
sg14
(lp12427
(dp12428
g7
I104
sg17
VC1569637
p12429
sg10
I27
sg11
Vendometrioid adenocarcinoma
p12430
sg13
I2
sa(dp12431
g7
I50
sg17
VC0007130
p12432
sg10
I23
sg11
Vmucinous adenocarcinoma
p12433
sg13
I2
sasa(dp12434
g2
S'Overexpression of the signalling adaptor protein ShcD in melanoma was found to be a prerequisite for melanoma migration and invasion.\n'
p12435
sg4
(lp12436
(dp12437
g7
I49
sg8
g9
sg10
I4
sg11
VShcD
p12438
sg13
I1
sasg14
(lp12439
(dp12440
g7
I124
sg17
VC2699153
p12441
sg10
I8
sg11
Vinvasion
p12442
sg13
I1
sa(dp12443
g7
I57
sg17
VC0025202
p12444
sg10
I8
sg11
Vmelanoma
p12445
sg13
I1
sa(dp12446
g7
I57
sg17
VC0025202
p12447
sg10
I8
sg11
Vmelanoma
p12448
sg13
I1
sasa(dp12449
g2
S'We have further demonstrated that ShcD accumulates in the nucleus upon hydrogen peroxide treatment in FLAG-ShcD expressing HEK293 cells, as well as 518.A2 melanoma cells.\n'
p12450
sg4
(lp12451
(dp12452
g7
I34
sg8
g9
sg10
I4
sg11
VShcD
p12453
sg13
I1
sa(dp12454
g7
I34
sg8
g9
sg10
I4
sg11
VShcD
p12455
sg13
I1
sasg14
(lp12456
(dp12457
g7
I155
sg17
VC0025202
p12458
sg10
I8
sg11
Vmelanoma
p12459
sg13
I1
sasa(dp12460
g2
S'We suggest that ShcD nuclear translocation might provide melanoma cells with a mechanism that enables them to resist DNA damage due to oxidative stress.\n'
p12461
sg4
(lp12462
(dp12463
g7
I16
sg8
g9
sg10
I4
sg11
VShcD
p12464
sg13
I1
sasg14
(lp12465
(dp12466
g7
I135
sg17
VC0242606
p12467
sg10
I16
sg11
Voxidative stress
p12468
sg13
I2
sa(dp12469
g7
I57
sg17
VC0025202
p12470
sg10
I8
sg11
Vmelanoma
p12471
sg13
I1
sa(dp12472
g7
I117
sg17
VC0012860
p12473
sg10
I10
sg11
VDNA damage
p12474
sg13
I2
sa(dp12475
g7
I29
sg17
VC0040715
p12476
sg10
I13
sg11
Vtranslocation
p12477
sg13
I1
sasa(dp12478
g2
S'Rai like protein (RaLP) is a newly identified Src homology 2 domain containing (Shc) family member selectively expressed during the transition to metastatic melanoma and thus is a potential melanoma-specific drugable target.\n'
p12479
sg4
(lp12480
(dp12481
g7
I46
sg8
VP12931
p12482
sg10
I52
sg11
VSrc homology 2 domain containing (Shc) family member
p12483
sg13
I8
sa(dp12484
g7
I18
sg8
g9
sg10
I4
sg11
VRaLP
p12485
sg13
I1
sa(dp12486
g7
I0
sg8
VP13489
p12487
sg10
I16
sg11
VRai like protein
p12488
sg13
I3
sasg14
(lp12489
(dp12490
g7
I132
sg17
VC0599156
p12491
sg10
I10
sg11
Vtransition
p12492
sg13
I1
sa(dp12493
g7
I157
sg17
VC0025202
p12494
sg10
I8
sg11
Vmelanoma
p12495
sg13
I1
sa(dp12496
g7
I146
sg17
VC0278883
p12497
sg10
I19
sg11
Vmetastatic melanoma
p12498
sg13
I2
sasa(dp12499
g2
S'Mutations in ABHD5 gene are associated with the onset of Chanarin-Dorfman syndrome (CDS), a rare autosomal recessive lipid storage disorder, characterized by non-bullous congenital ichthyosiform erythroderma (NCIE), hepatomegaly and liver steatosis.\n'
p12500
sg4
(lp12501
(dp12502
g7
I13
sg8
g9
sg10
I10
sg11
VABHD5 gene
p12503
sg13
I2
sasg14
(lp12504
(dp12505
g7
I216
sg17
VC0019209
p12506
sg10
I12
sg11
Vhepatomegaly
p12507
sg13
I1
sa(dp12508
g7
I209
sg17
VC1855792
p12509
sg10
I4
sg11
VNCIE
p12510
sg13
I1
sa(dp12511
g7
I57
sg17
VC0268238
p12512
sg10
I25
sg11
VChanarin-Dorfman syndrome
p12513
sg13
I2
sa(dp12514
g7
I158
sg17
VC1855792
p12515
sg10
I49
sg11
Vnon-bullous congenital ichthyosiform erythroderma
p12516
sg13
I4
sa(dp12517
g7
I233
sg17
VC0015695
p12518
sg10
I15
sg11
Vliver steatosis
p12519
sg13
I2
sa(dp12520
g7
I84
sg17
VC0268238
p12521
sg10
I3
sg11
VCDS
p12522
sg13
I1
sasa(dp12523
g2
S'It is an autosomal recessive disease caused by mutations in the ABHD5 gene.\n'
p12524
sg4
(lp12525
(dp12526
g7
I64
sg8
g9
sg10
I10
sg11
VABHD5 gene
p12527
sg13
I2
sasg14
(lp12528
sa(dp12529
g2
S'Mutations of comparative gene identification 58 (CGI-58) in humans cause Chanarin-Dorfman syndrome, a rare autosomal recessive disease in which excess triacylglycerol (TAG) accumulates in multiple tissues.\n'
p12530
sg4
(lp12531
sg14
(lp12532
(dp12533
g7
I151
sg17
VC0037293
p12534
sg10
I15
sg11
Vtriacylglycerol
p12535
sg13
I1
sa(dp12536
g7
I168
sg17
VC0037293
p12537
sg10
I3
sg11
VTAG
p12538
sg13
I1
sa(dp12539
g7
I73
sg17
VC0268238
p12540
sg10
I25
sg11
VChanarin-Dorfman syndrome
p12541
sg13
I2
sasa(dp12542
g2
S'The case histories of two children (aged two months) affected by myocarditis showing an atypical band of serum creatine kinase (EC 2.7.3.2; CK) in the CK isoenzyme electrophoretic pattern are reported.\n'
p12543
sg4
(lp12544
(dp12545
g7
I105
sg8
VP12532
p12546
sg10
I21
sg11
Vserum creatine kinase
p12547
sg13
I3
sasg14
(lp12548
(dp12549
g7
I65
sg17
VC0027059
p12550
sg10
I11
sg11
Vmyocarditis
p12551
sg13
I1
sasa(dp12552
g2
S'The objective of this study was to evaluate the nephroprotective potential of resveratrol and piperine at same dose on cationic bovine serum albumin (cBSA) induced immune complex glomerulonephritis (ICGN) in BALB/c mice.\n'
p12553
sg4
(lp12554
(dp12555
g7
I128
sg8
VP49639
p12556
sg10
I20
sg11
Vbovine serum albumin
p12557
sg13
I3
sasg14
(lp12558
(dp12559
g7
I199
sg17
VC0744421
p12560
sg10
I4
sg11
VICGN
p12561
sg13
I1
sa(dp12562
g7
I164
sg17
VC0744421
p12563
sg10
I33
sg11
Vimmune complex glomerulonephritis
p12564
sg13
I3
sasa(dp12565
g2
S'The object of the present study was to investigate the effects of VA, alone and in combination with methylprednisolone (MP), on cationic bovine serum albumin (cBSA induced immune-complex glomerulonephritis in female BALB/c mice.\n'
p12566
sg4
(lp12567
(dp12568
g7
I128
sg8
VP49639
p12569
sg10
I29
sg11
Vcationic bovine serum albumin
p12570
sg13
I4
sasg14
(lp12571
(dp12572
g7
I172
sg17
VC0744421
p12573
sg10
I33
sg11
Vimmune-complex glomerulonephritis
p12574
sg13
I2
sasa(dp12575
g2
S'Bovine serum albumin (BSA) glomerulonephritis is a type of immune complex glomerulonephritis that is characterized by a large number of leukocytes infiltrating the kidney.\n'
p12576
sg4
(lp12577
(dp12578
g7
I22
sg8
VP49639
p12579
sg10
I3
sg11
VBSA
p12580
sg13
I1
sa(dp12581
g7
I0
sg8
VP49639
p12582
sg10
I20
sg11
VBovine serum albumin
p12583
sg13
I3
sasg14
(lp12584
(dp12585
g7
I27
sg17
VC0017658
p12586
sg10
I18
sg11
Vglomerulonephritis
p12587
sg13
I1
sa(dp12588
g7
I147
sg17
VC0332448
p12589
sg10
I12
sg11
Vinfiltrating
p12590
sg13
I1
sa(dp12591
g7
I59
sg17
VC0744421
p12592
sg10
I33
sg11
Vimmune complex glomerulonephritis
p12593
sg13
I3
sasa(dp12594
g2
S'The aim of this study is to show the results of the retrospective analysis (2010-2012) on hospital discharge records (HDRs) related to diseases potentially due to S. pneumoniae, using a selection of ICD9-CM codes.\n'
p12595
sg4
(lp12596
sg14
(lp12597
(dp12598
g7
I90
sg17
VC1840333
p12599
sg10
I26
sg11
Vhospital discharge records
p12600
sg13
I3
sa(dp12601
g7
I118
sg17
VC1840333
p12602
sg10
I4
sg11
VHDRs
p12603
sg13
I1
sasa(dp12604
g2
S'The aim of this study is to show the results of the retrospective analysis (2010-2012) on hospital discharge records (HDRs) related to diseases potentially due to S. pneumoniae, using a selection of ICD9-CM codes.\n'
p12605
sg4
(lp12606
sg14
(lp12607
(dp12608
g7
I90
sg17
VC1840333
p12609
sg10
I26
sg11
Vhospital discharge records
p12610
sg13
I3
sa(dp12611
g7
I118
sg17
VC1840333
p12612
sg10
I4
sg11
VHDRs
p12613
sg13
I1
sasa(dp12614
g2
S'GATA binding protein 3 (GATA3) and suppressors of cytokine signalling3 mRNA were differentially regulated in HDM and influenza-stimulated cultures+/-IFN-Beta.\n'
p12615
sg4
(lp12616
(dp12617
g7
I149
sg8
VP01574
p12618
sg10
I8
sg11
VIFN-Beta
p12619
sg13
I1
sa(dp12620
g7
I0
sg8
VP23771
p12621
sg10
I22
sg11
VGATA binding protein 3
p12622
sg13
I4
sa(dp12623
g7
I24
sg8
VP23771
p12624
sg10
I5
sg11
VGATA3
p12625
sg13
I1
sasg14
(lp12626
(dp12627
g7
I117
sg17
VC0021400
p12628
sg10
I9
sg11
Vinfluenza
p12629
sg13
I1
sasa(dp12630
g2
S'In this article we review the current available evidence describing the effects of allopurinol in hypertension, kidney disease, and coronary heart disease, highlighting unresolved issues surrounding allopurinol use for uric acid lowering in individuals without gout.\n'
p12631
sg4
(lp12632
sg14
(lp12633
(dp12634
g7
I98
sg17
VC0020538
p12635
sg10
I12
sg11
Vhypertension
p12636
sg13
I1
sa(dp12637
g7
I261
sg17
VC0018099
p12638
sg10
I4
sg11
Vgout
p12639
sg13
I1
sa(dp12640
g7
I112
sg17
VC0022658
p12641
sg10
I14
sg11
Vkidney disease
p12642
sg13
I2
sa(dp12643
g7
I132
sg17
VC0010054
p12644
sg10
I22
sg11
Vcoronary heart disease
p12645
sg13
I3
sasa(dp12646
g2
S'Many epidemiological studies have evaluated associations of platelet glycoprotein receptor alpha2beta1 integrin (ITGA2) and glycoprotein IIIa (ITGB3) gene polymorphisms with diabetic retinopathy (DR), but the published data are inconclusive.\n'
p12647
sg4
(lp12648
(dp12649
g7
I124
sg8
VP05106
p12650
sg10
I17
sg11
Vglycoprotein IIIa
p12651
sg13
I2
sa(dp12652
g7
I60
sg8
VP14770
p12653
sg10
I51
sg11
Vplatelet glycoprotein receptor alpha2beta1 integrin
p12654
sg13
I5
sa(dp12655
g7
I143
sg8
VP05106
p12656
sg10
I5
sg11
VITGB3
p12657
sg13
I1
sa(dp12658
g7
I113
sg8
VP17301
p12659
sg10
I5
sg11
VITGA2
p12660
sg13
I1
sasg14
(lp12661
(dp12662
g7
I174
sg17
VC0011884
p12663
sg10
I20
sg11
Vdiabetic retinopathy
p12664
sg13
I2
sa(dp12665
g7
I196
sg17
VC0011884
p12666
sg10
I2
sg11
VDR
p12667
sg13
I1
sasa(dp12668
g2
S'Genetic polymorphisms of the alpha2beta1 integrin and glycoprotein IIIa (GPIIIa) have been associated with myocardial infarction, stroke, and diabetic retinopathy.\n'
p12669
sg4
(lp12670
(dp12671
g7
I29
sg8
VP05106
p12672
sg10
I42
sg11
Valpha2beta1 integrin and glycoprotein IIIa
p12673
sg13
I5
sa(dp12674
g7
I73
sg8
VP05106
p12675
sg10
I6
sg11
VGPIIIa
p12676
sg13
I1
sasg14
(lp12677
(dp12678
g7
I130
sg17
VC0038454
p12679
sg10
I6
sg11
Vstroke
p12680
sg13
I1
sa(dp12681
g7
I142
sg17
VC0011884
p12682
sg10
I20
sg11
Vdiabetic retinopathy
p12683
sg13
I2
sa(dp12684
g7
I107
sg17
VC0027051
p12685
sg10
I21
sg11
Vmyocardial infarction
p12686
sg13
I2
sasa(dp12687
g2
S'Immunostaining procedures were used to seek for the expression of the following 30 membrane antigens related to the immune system, using dendriform cells obtained in conjunctival specimens from 80 normal subjects and 105 with chronic conjunctivitis: class II antigens HLADR and DQ, CD1a (T6) and CD5, which usually mark Langerhans cells, macrophage markers CD14, CD36 and CD63, various lymphocyte antigens (CD2, CD4 and CD8), receptor to interleukin 2 (CD25), adhesion molecules and integrins (CD11a, CD11b, CD11c, CD18, CD29, CD41, CD61), the selectin CD62, ICAM-1 (CD54), ICAM-3 (CD50) and ELAM-1, CD45RO, related to activation of immune cells, and its ligand CD22, receptors to immunoglobulins (CD23 and CD32) and complement (CD21), transferrin receptor CD71, tryptase and vimentin, were thus investigated.\n'
p12688
sg4
(lp12689
(dp12690
g7
I592
sg8
VP16581
p12691
sg10
I6
sg11
VELAM-1
p12692
sg13
I1
sa(dp12693
g7
I296
sg8
VP06127
p12694
sg10
I3
sg11
VCD5
p12695
sg13
I1
sa(dp12696
g7
I420
sg8
VP01732
p12697
sg10
I3
sg11
VCD8
p12698
sg13
I1
sa(dp12699
g7
I527
sg8
VP08514
p12700
sg10
I4
sg11
VCD41
p12701
sg13
I1
sa(dp12702
g7
I508
sg8
VP20702
p12703
sg10
I5
sg11
VCD11c
p12704
sg13
I1
sa(dp12705
g7
I372
sg8
VP08962
p12706
sg10
I4
sg11
VCD63
p12707
sg13
I1
sa(dp12708
g7
I494
sg8
VP20701
p12709
sg10
I5
sg11
VCD11a
p12710
sg13
I1
sa(dp12711
g7
I438
sg8
VP60568
p12712
sg10
I13
sg11
Vinterleukin 2
p12713
sg13
I2
sa(dp12714
g7
I501
sg8
VP11215
p12715
sg10
I5
sg11
VCD11b
p12716
sg13
I1
sa(dp12717
g7
I707
sg8
VP12318
p12718
sg10
I4
sg11
VCD32
p12719
sg13
I1
sa(dp12720
g7
I453
sg8
VP01589
p12721
sg10
I4
sg11
VCD25
p12722
sg13
I1
sa(dp12723
g7
I412
sg8
VP01730
p12724
sg10
I3
sg11
VCD4
p12725
sg13
I1
sa(dp12726
g7
I574
sg8
VP32942
p12727
sg10
I6
sg11
VICAM-3
p12728
sg13
I1
sa(dp12729
g7
I698
sg8
VP06734
p12730
sg10
I4
sg11
VCD23
p12731
sg13
I1
sa(dp12732
g7
I736
sg8
VP02787
p12733
sg10
I25
sg11
Vtransferrin receptor CD71
p12734
sg13
I3
sa(dp12735
g7
I567
sg8
VP05362
p12736
sg10
I4
sg11
VCD54
p12737
sg13
I1
sa(dp12738
g7
I515
sg8
VP05107
p12739
sg10
I4
sg11
VCD18
p12740
sg13
I1
sa(dp12741
g7
I533
sg8
VP05106
p12742
sg10
I4
sg11
VCD61
p12743
sg13
I1
sa(dp12744
g7
I559
sg8
VP05362
p12745
sg10
I6
sg11
VICAM-1
p12746
sg13
I1
sa(dp12747
g7
I407
sg8
VP06729
p12748
sg10
I3
sg11
VCD2
p12749
sg13
I1
sa(dp12750
g7
I282
sg8
VP15813
p12751
sg10
I4
sg11
VCD1a
p12752
sg13
I1
sa(dp12753
g7
I681
sg8
g9
sg10
I15
sg11
Vimmunoglobulins
p12754
sg13
I1
sa(dp12755
g7
I386
sg8
VP30486
p12756
sg10
I19
sg11
Vlymphocyte antigens
p12757
sg13
I2
sa(dp12758
g7
I582
sg8
VP32942
p12759
sg10
I4
sg11
VCD50
p12760
sg13
I1
sa(dp12761
g7
I729
sg8
VP20023
p12762
sg10
I4
sg11
VCD21
p12763
sg13
I1
sa(dp12764
g7
I250
sg8
g9
sg10
I8
sg11
Vclass II
p12765
sg13
I2
sa(dp12766
g7
I553
sg8
VP16109
p12767
sg10
I4
sg11
VCD62
p12768
sg13
I1
sa(dp12769
g7
I357
sg8
VP08571
p12770
sg10
I4
sg11
VCD14
p12771
sg13
I1
sasg14
(lp12772
(dp12773
g7
I226
sg17
VC0155145
p12774
sg10
I22
sg11
Vchronic conjunctivitis
p12775
sg13
I2
sa(dp12776
g7
I460
sg17
VC0001511
p12777
sg10
I8
sg11
Vadhesion
p12778
sg13
I1
sasa(dp12779
g2
S'In order to elucidate the involvement of adhesion mechanisms in the process of megakaryocyte-dependent fibroblast growth, we applied BSA-coupled polymers of glucose, galactose, fucose, mannose, and several lectins (AAA, LCA, LTA, UEA-I) to cocultures of CD61 -positive (CD61+)/MACS-enriched megakaryocytes and human bone marrow fibroblasts.\n'
p12780
sg4
(lp12781
(dp12782
g7
I254
sg8
VP05106
p12783
sg10
I14
sg11
VCD61 -positive
p12784
sg13
I2
sa(dp12785
g7
I270
sg8
VP05106
p12786
sg10
I5
sg11
VCD61+
p12787
sg13
I1
sa(dp12788
g7
I215
sg8
g9
sg10
I3
sg11
VAAA
p12789
sg13
I1
sa(dp12790
g7
I133
sg8
VP49639
p12791
sg10
I3
sg11
VBSA
p12792
sg13
I1
sa(dp12793
g7
I220
sg8
VP09496
p12794
sg10
I3
sg11
VLCA
p12795
sg13
I1
sa(dp12796
g7
I225
sg8
VP10515
p12797
sg10
I3
sg11
VLTA
p12798
sg13
I1
sasg14
(lp12799
(dp12800
g7
I41
sg17
VC0001511
p12801
sg10
I8
sg11
Vadhesion
p12802
sg13
I1
sa(dp12803
g7
I220
sg17
VC0339527
p12804
sg10
I3
sg11
VLCA
p12805
sg13
I1
sa(dp12806
g7
I215
sg17
VC0162871
p12807
sg10
I3
sg11
VAAA
p12808
sg13
I1
sasa(dp12809
g2
S'Complications included pyogenic granuloma (10 patients, 24.4%), exposure keratopathy (7 patients, 17.1%) lagophthalmos (5 patients, 12.2%), ectropion (6 patients, 14.6%), lateral canthal dystopia (2 cases, 4.9%), eyelid notch (2 cases, 4.9%) and trichiasis (4 cases, 9.8%).\n'
p12810
sg4
(lp12811
sg14
(lp12812
(dp12813
g7
I23
sg17
VC0085653
p12814
sg10
I18
sg11
Vpyogenic granuloma
p12815
sg13
I2
sa(dp12816
g7
I246
sg17
VC0221259
p12817
sg10
I10
sg11
Vtrichiasis
p12818
sg13
I1
sa(dp12819
g7
I105
sg17
VC0152226
p12820
sg10
I13
sg11
Vlagophthalmos
p12821
sg13
I1
sa(dp12822
g7
I64
sg17
VC0339295
p12823
sg10
I20
sg11
Vexposure keratopathy
p12824
sg13
I2
sa(dp12825
g7
I140
sg17
VC0013592
p12826
sg10
I9
sg11
Vectropion
p12827
sg13
I1
sasa(dp12828
g2
S'Complications included eyelid margin notch (3 cases), persistent canthal dystopia (3 cases), trichiasis (2 cases), pyogenic granuloma (2 cases), eyelid margin nodule (1 case), lower eyelid elevation of 1 mm (1 case), and mild resolving medial lagophthalmos (1 case).\n'
p12829
sg4
(lp12830
sg14
(lp12831
(dp12832
g7
I159
sg17
VC0028259
p12833
sg10
I6
sg11
Vnodule
p12834
sg13
I1
sa(dp12835
g7
I93
sg17
VC0221259
p12836
sg10
I10
sg11
Vtrichiasis
p12837
sg13
I1
sa(dp12838
g7
I115
sg17
VC0085653
p12839
sg10
I18
sg11
Vpyogenic granuloma
p12840
sg13
I2
sa(dp12841
g7
I243
sg17
VC0152226
p12842
sg10
I13
sg11
Vlagophthalmos
p12843
sg13
I1
sasa(dp12844
g2
S'After operation slight entropion occurred in 8 cases, slight ectropion in 3 cases, lagophthalmos for 2 -- 3 mm in 7 cases, notch of the palpebral margin in 5 cases and thinness of the donor tarsal plates in 4 cases, but the functional and aesthetic results were normal.\n'
p12845
sg4
(lp12846
sg14
(lp12847
(dp12848
g7
I23
sg17
VC0014390
p12849
sg10
I9
sg11
Ventropion
p12850
sg13
I1
sa(dp12851
g7
I83
sg17
VC0152226
p12852
sg10
I13
sg11
Vlagophthalmos
p12853
sg13
I1
sa(dp12854
g7
I61
sg17
VC0013592
p12855
sg10
I9
sg11
Vectropion
p12856
sg13
I1
sasa(dp12857
g2
S'We screened the exons of RAY1/ST7 and ST7OT1-3 for sequence variants in 90 unrelated autism probands and identified several rare variants, including a Ile361Val substitution.\n'
p12858
sg4
(lp12859
(dp12860
g7
I30
sg8
g9
sg10
I3
sg11
VST7
p12861
sg13
I1
sa(dp12862
g7
I25
sg8
g9
sg10
I4
sg11
VRAY1
p12863
sg13
I1
sasg14
(lp12864
(dp12865
g7
I85
sg17
VC0004352
p12866
sg10
I6
sg11
Vautism
p12867
sg13
I1
sasa(dp12868
g2
S'Several signaling systems downstream of G-CSFR have been identified that are defective or hyperactivated in myeloid cells of patients with congenital neutropenia: severely reduced expression of myeloid-specific transcription factors LEF-1 and C/EBPAlfa, severely reduced expression and functions of HCLS1 protein, severely reduced expression of neutrophil elastase protein, dramatic compensatory up-regulation of the NAMPT/NAD(+)/SIRT pathway leading to continuous activation of emergency granulopoiesis via the transcription factor C/EBPBeta, and hyperactivation of STAT5 protein by tyrosine phosphorylation.\n'
p12869
sg4
(lp12870
(dp12871
g7
I40
sg8
VP07333
p12872
sg10
I6
sg11
VG-CSFR
p12873
sg13
I1
sa(dp12874
g7
I345
sg8
VP08246
p12875
sg10
I19
sg11
Vneutrophil elastase
p12876
sg13
I2
sa(dp12877
g7
I299
sg8
VP14317
p12878
sg10
I13
sg11
VHCLS1 protein
p12879
sg13
I2
sa(dp12880
g7
I512
sg8
VP35398
p12881
sg10
I30
sg11
Vtranscription factor C/EBPBeta
p12882
sg13
I3
sa(dp12883
g7
I194
sg8
g9
sg10
I44
sg11
Vmyeloid-specific transcription factors LEF-1
p12884
sg13
I4
sa(dp12885
g7
I567
sg8
VP42229
p12886
sg10
I13
sg11
VSTAT5 protein
p12887
sg13
I2
sasg14
(lp12888
(dp12889
g7
I139
sg17
VC0340970
p12890
sg10
I22
sg11
Vcongenital neutropenia
p12891
sg13
I2
sa(dp12892
g7
I479
sg17
VC2745965
p12893
sg10
I9
sg11
Vemergency
p12894
sg13
I1
sa(dp12895
g7
I423
sg17
VC1850380
p12896
sg10
I3
sg11
VNAD
p12897
sg13
I1
sasa(dp12898
g2
S'We observed spontaneous osteoclastogenesis with a significant increase in OC formation and bone resorbing activity in late-stage CKD and HD patients when compared with early-stage CKD patients and healthy donors, likely due to an increased expression of RANKL and LIGHT (homologous to Lymphotoxins exhibiting Inducible expression and competing with herpes simplex virus Glycoprotein D for herpes virus entry mediator [HVEM], a receptor expressed by T lymphocytes) in PBMCs.\n'
p12899
sg4
(lp12900
(dp12901
g7
I264
sg8
g9
sg10
I5
sg11
VLIGHT
p12902
sg13
I1
sa(dp12903
g7
I254
sg8
g9
sg10
I5
sg11
VRANKL
p12904
sg13
I1
sasg14
(lp12905
(dp12906
g7
I349
sg17
VC0019348
p12907
sg10
I14
sg11
Vherpes simplex
p12908
sg13
I2
sa(dp12909
g7
I349
sg17
VC0019340
p12910
sg10
I6
sg11
Vherpes
p12911
sg13
I1
sasa(dp12912
g2
S'Healthy individuals of African ancestry have neutropenia that has been linked with the variant rs2814778(G) of the gene encoding atypical chemokine receptor 1 (ACKR1).\n'
p12913
sg4
(lp12914
(dp12915
g7
I115
sg8
VP61073
p12916
sg10
I43
sg11
Vgene encoding atypical chemokine receptor 1
p12917
sg13
I6
sasg14
(lp12918
sa(dp12919
g2
S'Here we describe an unexpected fundamental role for ACKR1 in hematopoiesis and provide the mechanism that links its absence with neutropenia.\n'
p12920
sg4
(lp12921
sg14
(lp12922
sa(dp12923
g2
S'The absence of erythroid ACKR1 altered mouse hematopoiesis including stem and progenitor cells, which ultimately gave rise to phenotypically distinct neutrophils that readily left the circulation, causing neutropenia.\n'
p12924
sg4
(lp12925
(dp12926
g7
I15
sg8
VP22557
p12927
sg10
I15
sg11
Verythroid ACKR1
p12928
sg13
I2
sasg14
(lp12929
sa(dp12930
g2
S'In vivo studies in Adult Dark Agouti (DA) rats with unilateral surgically-induced ocular hypertension (OHT) treated with either CoQ10/TPGS micelles or TPGS vehicle twice daily for three weeks were performed, following which retinal cell health was assessed in vivo using DARC (Detection of Apoptotic Retinal Cells) and post-mortem with Brn3a histological assessment on whole retinal mounts.\n'
p12931
sg4
(lp12932
(dp12933
g7
I271
sg8
VP55283
p12934
sg10
I4
sg11
VDARC
p12935
sg13
I1
sa(dp12936
g7
I277
sg8
VP55283
p12937
sg10
I36
sg11
VDetection of Apoptotic Retinal Cells
p12938
sg13
I5
sa(dp12939
g7
I336
sg8
g9
sg10
I5
sg11
VBrn3a
p12940
sg13
I1
sasg14
(lp12941
(dp12942
g7
I103
sg17
VC0028840
p12943
sg10
I3
sg11
VOHT
p12944
sg13
I1
sa(dp12945
g7
I82
sg17
VC0028840
p12946
sg10
I19
sg11
Vocular hypertension
p12947
sg13
I2
sasa(dp12948
g2
S"After correction for multiple testing, DARC polymorphism rs3027012 in 5'-UTR was associated with higher risk of low absolute phagocyte count (APC&lt;500 and &lt;1000 cells per microliter, P=0.001 and P&lt;0.0005, respectively) and hospitalization due to febrile neutropenia (P=0.002).\n"
p12949
sg4
(lp12950
sg14
(lp12951
(dp12952
g7
I254
sg17
VC0746883
p12953
sg10
I19
sg11
Vfebrile neutropenia
p12954
sg13
I2
sa(dp12955
g7
I142
sg17
VC0033036
p12956
sg10
I3
sg11
VAPC
p12957
sg13
I1
sasa(dp12958
g2
S'We examined the effects of PR and EZ on NPC1L1, ABCG5, and ABCG8 expression in human hepatoma HepG2 cells and the murine small intestine.\n'
p12959
sg4
(lp12960
(dp12961
g7
I40
sg8
g9
sg10
I6
sg11
VNPC1L1
p12962
sg13
I1
sa(dp12963
g7
I48
sg8
g9
sg10
I5
sg11
VABCG5
p12964
sg13
I1
sa(dp12965
g7
I59
sg8
g9
sg10
I5
sg11
VABCG8
p12966
sg13
I1
sasg14
(lp12967
(dp12968
g7
I85
sg17
VC0023903
p12969
sg10
I8
sg11
Vhepatoma
p12970
sg13
I1
sasa(dp12971
g2
S'In addition, knockdown of epigenetic regulator UHRF1 (ubiquitin-like, containing PHD and RING finger domains 1) in RIP3-null cancer cells reduces the methylation level of the Rip3 promoter.\n'
p12972
sg4
(lp12973
(dp12974
g7
I115
sg8
g9
sg10
I4
sg11
VRIP3
p12975
sg13
I1
sa(dp12976
g7
I175
sg8
g9
sg10
I13
sg11
VRip3 promoter
p12977
sg13
I2
sa(dp12978
g7
I81
sg8
VP20941
p12979
sg10
I3
sg11
VPHD
p12980
sg13
I1
sa(dp12981
g7
I54
sg8
VP62979
p12982
sg10
I9
sg11
Vubiquitin
p12983
sg13
I1
sa(dp12984
g7
I47
sg8
g9
sg10
I5
sg11
VUHRF1
p12985
sg13
I1
sasg14
(lp12986
(dp12987
g7
I125
sg17
VC0006826
p12988
sg10
I6
sg11
Vcancer
p12989
sg13
I1
sasa(dp12990
g2
S'A previous study revealed that ubiquitin-like with PHD and RING finger domains 1 (UHRF1) promoted cell proliferation and was a potential biomarker in medulloblastoma (MB).\n'
p12991
sg4
(lp12992
(dp12993
g7
I82
sg8
g9
sg10
I5
sg11
VUHRF1
p12994
sg13
I1
sa(dp12995
g7
I31
sg8
g9
sg10
I49
sg11
Vubiquitin-like with PHD and RING finger domains 1
p12996
sg13
I8
sasg14
(lp12997
(dp12998
g7
I150
sg17
VC0025149
p12999
sg10
I15
sg11
Vmedulloblastoma
p13000
sg13
I1
sa(dp13001
g7
I103
sg17
VC0334094
p13002
sg10
I13
sg11
Vproliferation
p13003
sg13
I1
sa(dp13004
g7
I167
sg17
VC0025149
p13005
sg10
I2
sg11
VMB
p13006
sg13
I1
sasa(dp13007
g2
S'Three lncRNAs, sex determining region Y-box 2 overlapping transcript (SOX2-OT), NCBP2 antisense RNA 2 (NCBP2-AS2) and ubiquitin like with PHD and ring finger domains 1 (UHRF1), were predicted to be associated with lung cancer; RT-qPCR confirmed that SOX2-OT and NCBP2-AS2 were associated with lung cancer.\n'
p13008
sg4
(lp13009
(dp13010
g7
I118
sg8
g9
sg10
I49
sg11
Vubiquitin like with PHD and ring finger domains 1
p13011
sg13
I9
sa(dp13012
g7
I169
sg8
g9
sg10
I5
sg11
VUHRF1
p13013
sg13
I1
sa(dp13014
g7
I103
sg8
VP52298
p13015
sg10
I9
sg11
VNCBP2-AS2
p13016
sg13
I1
sa(dp13017
g7
I70
sg8
VP48431
p13018
sg10
I7
sg11
VSOX2-OT
p13019
sg13
I1
sa(dp13020
g7
I103
sg8
VP52298
p13021
sg10
I9
sg11
VNCBP2-AS2
p13022
sg13
I1
sa(dp13023
g7
I80
sg8
VP52298
p13024
sg10
I21
sg11
VNCBP2 antisense RNA 2
p13025
sg13
I4
sa(dp13026
g7
I15
sg8
VP48431
p13027
sg10
I53
sg11
Vsex determining region Y-box 2 overlapping transcript
p13028
sg13
I7
sa(dp13029
g7
I70
sg8
VP48431
p13030
sg10
I7
sg11
VSOX2-OT
p13031
sg13
I1
sasg14
(lp13032
(dp13033
g7
I214
sg17
VC0684249
p13034
sg10
I11
sg11
Vlung cancer
p13035
sg13
I2
sa(dp13036
g7
I214
sg17
VC0684249
p13037
sg10
I11
sg11
Vlung cancer
p13038
sg13
I2
sasa(dp13039
g2
S'UHRF1 (ubiquitin-like, with PHD and RING finger domains 1) plays a crucial role in DNA methylation, chromatin remodeling and gene expression and is aberrantly upregulated in various types of human cancers.\n'
p13040
sg4
(lp13041
(dp13042
g7
I28
sg8
VP20941
p13043
sg10
I3
sg11
VPHD
p13044
sg13
I1
sa(dp13045
g7
I7
sg8
VP62979
p13046
sg10
I14
sg11
Vubiquitin-like
p13047
sg13
I1
sa(dp13048
g7
I0
sg8
g9
sg10
I5
sg11
VUHRF1
p13049
sg13
I1
sasg14
(lp13050
(dp13051
g7
I197
sg17
VC0006826
p13052
sg10
I7
sg11
Vcancers
p13053
sg13
I1
sasa(dp13054
g2
S'UHRF1 (ubiquitin-like with PHD and RING finger domains 1) is a critical regulator for DNA methylation, and its frequent overexpression in human cancers has been associated with tumor-promoting effects.\n'
p13055
sg4
(lp13056
(dp13057
g7
I0
sg8
g9
sg10
I5
sg11
VUHRF1
p13058
sg13
I1
sa(dp13059
g7
I7
sg8
VP20941
p13060
sg10
I49
sg11
Vubiquitin-like with PHD and RING finger domains 1
p13061
sg13
I8
sasg14
(lp13062
(dp13063
g7
I177
sg17
VC0027651
p13064
sg10
I5
sg11
Vtumor
p13065
sg13
I1
sa(dp13066
g7
I144
sg17
VC0006826
p13067
sg10
I7
sg11
Vcancers
p13068
sg13
I1
sasa(dp13069
g2
S'Recessive mutations in ORC1, ORC4, ORC6, CDT1 or CDC6 of the preRC in human cause Meier-Gorlin syndrome (MGS) that is characterized by impaired post-natal growth, short stature and microcephaly.\n'
p13070
sg4
(lp13071
(dp13072
g7
I35
sg8
g9
sg10
I4
sg11
VORC6
p13073
sg13
I1
sa(dp13074
g7
I49
sg8
g9
sg10
I4
sg11
VCDC6
p13075
sg13
I1
sa(dp13076
g7
I23
sg8
g9
sg10
I4
sg11
VORC1
p13077
sg13
I1
sa(dp13078
g7
I41
sg8
g9
sg10
I4
sg11
VCDT1
p13079
sg13
I1
sa(dp13080
g7
I29
sg8
g9
sg10
I4
sg11
VORC4
p13081
sg13
I1
sasg14
(lp13082
(dp13083
g7
I181
sg17
VC0025958
p13084
sg10
I12
sg11
Vmicrocephaly
p13085
sg13
I1
sa(dp13086
g7
I135
sg17
VC0684336
p13087
sg10
I8
sg11
Vimpaired
p13088
sg13
I1
sa(dp13089
g7
I82
sg17
VC1868684
p13090
sg10
I21
sg11
VMeier-Gorlin syndrome
p13091
sg13
I2
sa(dp13092
g7
I105
sg17
VC1969653
p13093
sg10
I3
sg11
VMGS
p13094
sg13
I1
sa(dp13095
g7
I163
sg17
VC0013336
p13096
sg10
I13
sg11
Vshort stature
p13097
sg13
I2
sasa(dp13098
g2
S'Mutations in ORC1, ORC4, ORC6, CDT1, and CDC6, which encode proteins required for DNA replication origin licensing, cause Meier-Gorlin syndrome (MGS), a disorder conferring microcephaly, primordial dwarfism, underdeveloped ears, and skeletal abnormalities.\n'
p13099
sg4
(lp13100
(dp13101
g7
I41
sg8
g9
sg10
I4
sg11
VCDC6
p13102
sg13
I1
sa(dp13103
g7
I31
sg8
g9
sg10
I4
sg11
VCDT1
p13104
sg13
I1
sa(dp13105
g7
I25
sg8
g9
sg10
I4
sg11
VORC6
p13106
sg13
I1
sa(dp13107
g7
I13
sg8
g9
sg10
I4
sg11
VORC1
p13108
sg13
I1
sa(dp13109
g7
I19
sg8
g9
sg10
I4
sg11
VORC4
p13110
sg13
I1
sasg14
(lp13111
(dp13112
g7
I145
sg17
VC1969653
p13113
sg10
I3
sg11
VMGS
p13114
sg13
I1
sa(dp13115
g7
I187
sg17
VC0013336
p13116
sg10
I19
sg11
Vprimordial dwarfism
p13117
sg13
I2
sa(dp13118
g7
I173
sg17
VC0025958
p13119
sg10
I12
sg11
Vmicrocephaly
p13120
sg13
I1
sa(dp13121
g7
I122
sg17
VC1868684
p13122
sg10
I21
sg11
VMeier-Gorlin syndrome
p13123
sg13
I2
sasa(dp13124
g2
S'Significantly higher concentrations of HMGB1 were found in nasal secretions from patients with chronic rhinosinusitis with nasal polyp or allergic rhinitis compared with the control subjects.\n'
p13125
sg4
(lp13126
(dp13127
g7
I39
sg8
VP09429
p13128
sg10
I5
sg11
VHMGB1
p13129
sg13
I1
sasg14
(lp13130
(dp13131
g7
I123
sg17
VC0027430
p13132
sg10
I11
sg11
Vnasal polyp
p13133
sg13
I2
sa(dp13134
g7
I95
sg17
VC0149516
p13135
sg10
I22
sg11
Vchronic rhinosinusitis
p13136
sg13
I2
sa(dp13137
g7
I138
sg17
VC2607914
p13138
sg10
I17
sg11
Vallergic rhinitis
p13139
sg13
I2
sasa(dp13140
g2
S'Previous studies have shown that HMGB1 is elevated in the nasal lavage fluids (NLF) of children suffering from allergic rhinitis (AR) and is associated with the severity of this disease.\n'
p13141
sg4
(lp13142
(dp13143
g7
I33
sg8
VP09429
p13144
sg10
I5
sg11
VHMGB1
p13145
sg13
I1
sasg14
(lp13146
(dp13147
g7
I96
sg17
VC0683278
p13148
sg10
I9
sg11
Vsuffering
p13149
sg13
I1
sa(dp13150
g7
I130
sg17
VC2607914
p13151
sg10
I2
sg11
VAR
p13152
sg13
I1
sa(dp13153
g7
I111
sg17
VC2607914
p13154
sg10
I17
sg11
Vallergic rhinitis
p13155
sg13
I2
sasa(dp13156
g2
S'The major cystinosis mutation is a 57 kb deletion on human chromosome 17p13 that removes the majority of CTNS and the entire adjacent gene, CARKL/SHPK.\n'
p13157
sg4
(lp13158
(dp13159
g7
I140
sg8
g9
sg10
I5
sg11
VCARKL
p13160
sg13
I1
sa(dp13161
g7
I146
sg8
g9
sg10
I4
sg11
VSHPK
p13162
sg13
I1
sasg14
(lp13163
(dp13164
g7
I105
sg17
VC0015624
p13165
sg10
I4
sg11
VCTNS
p13166
sg13
I1
sa(dp13167
g7
I10
sg17
VC0010690
p13168
sg10
I10
sg11
Vcystinosis
p13169
sg13
I1
sasa(dp13170
g2
S'The most common mutation in the nephropathic cystinosis (CTNS) gene is a homozygous 57-kb deletion that also includes an adjacent gene carbohydrate kinase-like (CARKL).\n'
p13171
sg4
(lp13172
(dp13173
g7
I161
sg8
g9
sg10
I5
sg11
VCARKL
p13174
sg13
I1
sa(dp13175
g7
I135
sg8
g9
sg10
I24
sg11
Vcarbohydrate kinase-like
p13176
sg13
I2
sasg14
(lp13177
(dp13178
g7
I57
sg17
VC0015624
p13179
sg10
I4
sg11
VCTNS
p13180
sg13
I1
sa(dp13181
g7
I32
sg17
VC0015624
p13182
sg10
I23
sg11
Vnephropathic cystinosis
p13183
sg13
I2
sasa(dp13184
g2
S'Analysis of the resulting data revealed a number of interesting features about this genomic region, including the long-range organization of CTNS, insight about the breakpoints and intervening DNA associated with the common cystinosis-causing deletion, and structural information about five genes neighboring CTNS (human ortholog of rat vanilloid receptor subtype 1 gene, CARKL, TIP-1, P2X5, and HUMINAE).\n'
p13185
sg4
(lp13186
(dp13187
g7
I141
sg8
g9
sg10
I4
sg11
VCTNS
p13188
sg13
I1
sa(dp13189
g7
I372
sg8
g9
sg10
I5
sg11
VCARKL
p13190
sg13
I1
sa(dp13191
g7
I379
sg8
g9
sg10
I5
sg11
VTIP-1
p13192
sg13
I1
sa(dp13193
g7
I386
sg8
g9
sg10
I4
sg11
VP2X5
p13194
sg13
I1
sa(dp13195
g7
I333
sg8
g9
sg10
I37
sg11
Vrat vanilloid receptor subtype 1 gene
p13196
sg13
I6
sasg14
(lp13197
(dp13198
g7
I141
sg17
VC0015624
p13199
sg10
I4
sg11
VCTNS
p13200
sg13
I1
sa(dp13201
g7
I224
sg17
VC0010690
p13202
sg10
I10
sg11
Vcystinosis
p13203
sg13
I1
sa(dp13204
g7
I141
sg17
VC0015624
p13205
sg10
I4
sg11
VCTNS
p13206
sg13
I1
sasa(dp13207
g2
S'In particular, sequence analysis detected the presence of a novel gene (CARKL) residing within the most common cystinosis-causing deletion.\n'
p13208
sg4
(lp13209
(dp13210
g7
I72
sg8
g9
sg10
I5
sg11
VCARKL
p13211
sg13
I1
sasg14
(lp13212
(dp13213
g7
I111
sg17
VC0010690
p13214
sg10
I10
sg11
Vcystinosis
p13215
sg13
I1
sasa(dp13216
g2
S'Interestingly, both CTNS and CARKL are absent in nearly half of all cystinosis patients (i.e., those homozygous for the common deletion).\n'
p13217
sg4
(lp13218
(dp13219
g7
I20
sg8
g9
sg10
I4
sg11
VCTNS
p13220
sg13
I1
sa(dp13221
g7
I29
sg8
g9
sg10
I5
sg11
VCARKL
p13222
sg13
I1
sasg14
(lp13223
(dp13224
g7
I68
sg17
VC0010690
p13225
sg10
I10
sg11
Vcystinosis
p13226
sg13
I1
sa(dp13227
g7
I20
sg17
VC0015624
p13228
sg10
I4
sg11
VCTNS
p13229
sg13
I1
sasa(dp13230
g2
S'There is limited evidence regarding interactions between pulmonary (dys)function, posture, and mobility of the upper body quadrant in patients with chronic obstructive pulmonary disease (COPD).\n'
p13231
sg4
(lp13232
sg14
(lp13233
(dp13234
g7
I187
sg17
VC0024117
p13235
sg10
I4
sg11
VCOPD
p13236
sg13
I1
sa(dp13237
g7
I68
sg17
VC0013364
p13238
sg10
I3
sg11
Vdys
p13239
sg13
I1
sa(dp13240
g7
I148
sg17
VC0024117
p13241
sg10
I37
sg11
Vchronic obstructive pulmonary disease
p13242
sg13
I4
sasa(dp13243
g2
S'Background There is limited evidence regarding interactions between pulmonary (dys)function, posture, and mobility of the upper body quadrant in patients with chronic obstructive pulmonary disease (COPD).\n'
p13244
sg4
(lp13245
sg14
(lp13246
(dp13247
g7
I79
sg17
VC0013364
p13248
sg10
I3
sg11
Vdys
p13249
sg13
I1
sa(dp13250
g7
I198
sg17
VC0024117
p13251
sg10
I4
sg11
VCOPD
p13252
sg13
I1
sa(dp13253
g7
I159
sg17
VC0024117
p13254
sg10
I37
sg11
Vchronic obstructive pulmonary disease
p13255
sg13
I4
sasa(dp13256
g2
S'Recent progress in our understanding of the developmental regulation of this tissue, the differentiation pathways, recognition of pathogens and antimicrobial responses is now exploited to help understand how epithelial cell function and dysfunction contributes to the pathogenesis of a variety of inflammatory lung diseases.\n'
p13257
sg4
(lp13258
sg14
(lp13259
(dp13260
g7
I310
sg17
VC0024115
p13261
sg10
I13
sg11
Vlung diseases
p13262
sg13
I2
sa(dp13263
g7
I268
sg17
VC0699748
p13264
sg10
I12
sg11
Vpathogenesis
p13265
sg13
I1
sasa(dp13266
g2
S'Herein, advances in our knowledge of the biology of airway epithelium, as well as its role and (dys)function in asthma, chronic obstructive pulmonary fibrosis and cystic fibrosis will be discussed.\n'
p13267
sg4
(lp13268
sg14
(lp13269
(dp13270
g7
I163
sg17
VC0010674
p13271
sg10
I15
sg11
Vcystic fibrosis
p13272
sg13
I2
sa(dp13273
g7
I96
sg17
VC0013364
p13274
sg10
I3
sg11
Vdys
p13275
sg13
I1
sa(dp13276
g7
I112
sg17
VC0004096
p13277
sg10
I6
sg11
Vasthma
p13278
sg13
I1
sa(dp13279
g7
I140
sg17
VC0034069
p13280
sg10
I18
sg11
Vpulmonary fibrosis
p13281
sg13
I2
sasa(dp13282
g2
S'Managing neurogenic dysphagia with effective protection of the airway passages and prompt treatment of aspiration pneumonias is necessary to prevent respiratory failure.\n'
p13283
sg4
(lp13284
sg14
(lp13285
(dp13286
g7
I103
sg17
VC0032290
p13287
sg10
I21
sg11
Vaspiration pneumonias
p13288
sg13
I2
sa(dp13289
g7
I9
sg17
VC1955520
p13290
sg10
I20
sg11
Vneurogenic dysphagia
p13291
sg13
I2
sa(dp13292
g7
I149
sg17
VC1145670
p13293
sg10
I19
sg11
Vrespiratory failure
p13294
sg13
I2
sasa(dp13295
g2
S'Multivariate analysis identified four independent risk factors for mortality in patients with severe sepsis and septic shock: three or more organ dysfunctions (OR, 3.212; 95% CI, 1.585-6.506; p&lt;0.001), acute respiratory failure (OR, 2.649 95% CI, 1.327-5.287; p=0.006), positive blood culture (OR, 2.708; 95% CI, 1.289-5.689; p=0.009) and chronic heart failure (OR, 2.112; 95% CI, 1.036-4.308; p=0.040).\n'
p13296
sg4
(lp13297
sg14
(lp13298
(dp13299
g7
I112
sg17
VC0036983
p13300
sg10
I12
sg11
Vseptic shock
p13301
sg13
I2
sa(dp13302
g7
I205
sg17
VC0264490
p13303
sg10
I25
sg11
Vacute respiratory failure
p13304
sg13
I3
sa(dp13305
g7
I342
sg17
VC0264716
p13306
sg10
I21
sg11
Vchronic heart failure
p13307
sg13
I3
sa(dp13308
g7
I94
sg17
VC1719672
p13309
sg10
I13
sg11
Vsevere sepsis
p13310
sg13
I2
sasa(dp13311
g2
S'Our results highlight the importance of three or more organ dys-functions, acute respiratory failure, positive blood culture and chronic heart failure as independent risk factors for mortality in the first 24 hours after admission in patients with severe sepsis and septic shock.\n'
p13312
sg4
(lp13313
sg14
(lp13314
(dp13315
g7
I248
sg17
VC1719672
p13316
sg10
I13
sg11
Vsevere sepsis
p13317
sg13
I2
sa(dp13318
g7
I266
sg17
VC0036983
p13319
sg10
I12
sg11
Vseptic shock
p13320
sg13
I2
sa(dp13321
g7
I75
sg17
VC0264490
p13322
sg10
I25
sg11
Vacute respiratory failure
p13323
sg13
I3
sa(dp13324
g7
I129
sg17
VC0264716
p13325
sg10
I21
sg11
Vchronic heart failure
p13326
sg13
I3
sa(dp13327
g7
I60
sg17
VC0013364
p13328
sg10
I3
sg11
Vdys
p13329
sg13
I1
sasa(dp13330
g2
S'This review briefly touches on CF genetics as it applies to lung disease and will focus on the current hypotheses of CFTR (dys)function and its impact on pulmonary fluid homeostasis.\n'
p13331
sg4
(lp13332
(dp13333
g7
I117
sg8
VP13569
p13334
sg10
I4
sg11
VCFTR
p13335
sg13
I1
sa(dp13336
g7
I123
sg8
VP11532
p13337
sg10
I3
sg11
Vdys
p13338
sg13
I1
sasg14
(lp13339
(dp13340
g7
I123
sg17
VC0013364
p13341
sg10
I3
sg11
Vdys
p13342
sg13
I1
sa(dp13343
g7
I60
sg17
VC0024115
p13344
sg10
I12
sg11
Vlung disease
p13345
sg13
I2
sasa(dp13346
g2
S'To investigate the expression of the CDH13 gene and BCR/ABL fusion gene in chronic myeloid leukemia(CML) patients at different stages and explore their relationship.\n'
p13347
sg4
(lp13348
(dp13349
g7
I52
sg8
VP11274
p13350
sg10
I3
sg11
VBCR
p13351
sg13
I1
sa(dp13352
g7
I37
sg8
VP55290
p13353
sg10
I10
sg11
VCDH13 gene
p13354
sg13
I2
sa(dp13355
g7
I56
sg8
VP55157
p13356
sg10
I3
sg11
VABL
p13357
sg13
I1
sasg14
(lp13358
(dp13359
g7
I100
sg17
VC0023473
p13360
sg10
I3
sg11
VCML
p13361
sg13
I1
sa(dp13362
g7
I56
sg17
VC0000744
p13363
sg10
I3
sg11
VABL
p13364
sg13
I1
sa(dp13365
g7
I75
sg17
VC0023473
p13366
sg10
I24
sg11
Vchronic myeloid leukemia
p13367
sg13
I3
sasa(dp13368
g2
S'We performed genomewide screening for methylated CpG islands and identified 8 genes frequently methylated in leukemia cell lines and in patients with acute myeloid leukemia (AML): NOR1, CDH13, p15, NPM2, OLIG2, PGR, HIN1, and SLC26A4.\n'
p13369
sg4
(lp13370
(dp13371
g7
I198
sg8
g9
sg10
I4
sg11
VNPM2
p13372
sg13
I1
sa(dp13373
g7
I204
sg8
g9
sg10
I5
sg11
VOLIG2
p13374
sg13
I1
sa(dp13375
g7
I180
sg8
g9
sg10
I4
sg11
VNOR1
p13376
sg13
I1
sa(dp13377
g7
I186
sg8
VP55290
p13378
sg10
I5
sg11
VCDH13
p13379
sg13
I1
sa(dp13380
g7
I226
sg8
g9
sg10
I7
sg11
VSLC26A4
p13381
sg13
I1
sa(dp13382
g7
I216
sg8
g9
sg10
I4
sg11
VHIN1
p13383
sg13
I1
sa(dp13384
g7
I211
sg8
VP06401
p13385
sg10
I3
sg11
VPGR
p13386
sg13
I1
sa(dp13387
g7
I193
sg8
VP53999
p13388
sg10
I3
sg11
Vp15
p13389
sg13
I1
sasg14
(lp13390
(dp13391
g7
I150
sg17
VC0023467
p13392
sg10
I22
sg11
Vacute myeloid leukemia
p13393
sg13
I3
sa(dp13394
g7
I174
sg17
VC0023467
p13395
sg10
I3
sg11
VAML
p13396
sg13
I1
sa(dp13397
g7
I109
sg17
VC0023418
p13398
sg10
I8
sg11
Vleukemia
p13399
sg13
I1
sasa(dp13400
g2
S'Although defective progenitor-stromal adhesion is a well-recognized feature of chronic myeloid leukemia (CML), the role of CDH13 abnormalities has not been evaluated in this disease.\n'
p13401
sg4
(lp13402
(dp13403
g7
I123
sg8
VP55290
p13404
sg10
I5
sg11
VCDH13
p13405
sg13
I1
sasg14
(lp13406
(dp13407
g7
I38
sg17
VC0001511
p13408
sg10
I8
sg11
Vadhesion
p13409
sg13
I1
sa(dp13410
g7
I105
sg17
VC0023473
p13411
sg10
I3
sg11
VCML
p13412
sg13
I1
sa(dp13413
g7
I79
sg17
VC0023473
p13414
sg10
I24
sg11
Vchronic myeloid leukemia
p13415
sg13
I3
sasa(dp13416
g2
S'Recent work from our laboratory suggested pIgR may be upregulated in pancreatic ductal adenocarcinoma (PDAC).\n'
p13417
sg4
(lp13418
(dp13419
g7
I42
sg8
VP01833
p13420
sg10
I4
sg11
VpIgR
p13421
sg13
I1
sasg14
(lp13422
(dp13423
g7
I103
sg17
VC1335302
p13424
sg10
I4
sg11
VPDAC
p13425
sg13
I1
sa(dp13426
g7
I69
sg17
VC1335302
p13427
sg10
I32
sg11
Vpancreatic ductal adenocarcinoma
p13428
sg13
I3
sasa(dp13429
g2
S'In this work we investigated the expression of the SERCA3-type calcium pump in choroid plexus epithelial cells grown in vitro, and in normal and hyperplastic choroid plexus tissue, in choroid plexus papillomas displaying various degrees of atypia, and in choroid plexus carcinoma by immunohistochemistry in situ.\n'
p13430
sg4
(lp13431
sg14
(lp13432
(dp13433
g7
I255
sg17
VC0431109
p13434
sg10
I24
sg11
Vchoroid plexus carcinoma
p13435
sg13
I3
sa(dp13436
g7
I145
sg17
VC0020507
p13437
sg10
I12
sg11
Vhyperplastic
p13438
sg13
I1
sa(dp13439
g7
I184
sg17
VC0205770
p13440
sg10
I25
sg11
Vchoroid plexus papillomas
p13441
sg13
I3
sasa(dp13442
g2
S'Whereas normal choroid plexus epithelial cells express SERCA3 abundantly, SERCA3 expression is strongly decreased in papillomas, and is absent in choroid plexus carcinoma, while expression in hyperplastic epithelium is high, similarly to normal epithelium.\n'
p13443
sg4
(lp13444
sg14
(lp13445
(dp13446
g7
I117
sg17
VC0030354
p13447
sg10
I10
sg11
Vpapillomas
p13448
sg13
I1
sa(dp13449
g7
I192
sg17
VC0020507
p13450
sg10
I12
sg11
Vhyperplastic
p13451
sg13
I1
sa(dp13452
g7
I146
sg17
VC0431109
p13453
sg10
I24
sg11
Vchoroid plexus carcinoma
p13454
sg13
I3
sasa(dp13455
g2
S'We hypothesized that mutations in AP2S1 and GNA11 are causative in Danish patients with suspected FHH and that these mutations are not found in patients with primary hyperparathyroidism (PHPT), which is the main differential diagnostic disorder.\n'
p13456
sg4
(lp13457
(dp13458
g7
I44
sg8
VP29992
p13459
sg10
I5
sg11
VGNA11
p13460
sg13
I1
sa(dp13461
g7
I34
sg8
VP53680
p13462
sg10
I5
sg11
VAP2S1
p13463
sg13
I1
sasg14
(lp13464
(dp13465
g7
I187
sg17
VC0221002
p13466
sg10
I4
sg11
VPHPT
p13467
sg13
I1
sa(dp13468
g7
I158
sg17
VC0221002
p13469
sg10
I27
sg11
Vprimary hyperparathyroidism
p13470
sg13
I2
sasa(dp13471
g2
S'Familial hypocalciuric hypercalcemia (FHH) is a genetically heterogeneous condition resembling primary hyperparathyroidism (PHPT) but not curable by surgery; FHH types 1, 2, and 3 are due to loss-of-function mutations of the CASR, GNA11, or AP2S1 genes, respectively.\n'
p13472
sg4
(lp13473
(dp13474
g7
I225
sg8
VP41180
p13475
sg10
I4
sg11
VCASR
p13476
sg13
I1
sa(dp13477
g7
I231
sg8
VP29992
p13478
sg10
I5
sg11
VGNA11
p13479
sg13
I1
sa(dp13480
g7
I241
sg8
VP53680
p13481
sg10
I11
sg11
VAP2S1 genes
p13482
sg13
I2
sasg14
(lp13483
(dp13484
g7
I124
sg17
VC0221002
p13485
sg10
I4
sg11
VPHPT
p13486
sg13
I1
sa(dp13487
g7
I74
sg17
VC0012634
p13488
sg10
I9
sg11
Vcondition
p13489
sg13
I1
sa(dp13490
g7
I38
sg17
VC0342637
p13491
sg10
I3
sg11
VFHH
p13492
sg13
I1
sa(dp13493
g7
I38
sg17
VC0342637
p13494
sg10
I3
sg11
VFHH
p13495
sg13
I1
sa(dp13496
g7
I95
sg17
VC0221002
p13497
sg10
I27
sg11
Vprimary hyperparathyroidism
p13498
sg13
I2
sa(dp13499
g7
I0
sg17
VC0342637
p13500
sg10
I36
sg11
VFamilial hypocalciuric hypercalcemia
p13501
sg13
I3
sasa(dp13502
g2
S'The aim of this study was to analyse prevalence and pathogenicity of CaSR, GNA11 and AP2S1 mutations in patients with an FHH phenotype and to compare them with a sample of patients with primary hyperparathyroidism (PHPT) in order to identify the most useful laboratory parameter for a differential diagnosis.\n'
p13503
sg4
(lp13504
(dp13505
g7
I85
sg8
VP53680
p13506
sg10
I5
sg11
VAP2S1
p13507
sg13
I1
sa(dp13508
g7
I69
sg8
VP41180
p13509
sg10
I4
sg11
VCaSR
p13510
sg13
I1
sa(dp13511
g7
I75
sg8
VP29992
p13512
sg10
I5
sg11
VGNA11
p13513
sg13
I1
sa(dp13514
g7
I121
sg8
VP41180
p13515
sg10
I3
sg11
VFHH
p13516
sg13
I1
sasg14
(lp13517
(dp13518
g7
I215
sg17
VC0221002
p13519
sg10
I4
sg11
VPHPT
p13520
sg13
I1
sa(dp13521
g7
I186
sg17
VC0221002
p13522
sg10
I27
sg11
Vprimary hyperparathyroidism
p13523
sg13
I2
sasa(dp13524
g2
S'Tripartite motif-containing protein 37 (TRIM37), a new member of the RING-B-box-coiled-coil (RBCC) subfamily of zinc finger proteins, was found to be involved in the development and progression of several cancers.\n'
p13525
sg4
(lp13526
(dp13527
g7
I112
sg8
g9
sg10
I20
sg11
Vzinc finger proteins
p13528
sg13
I3
sa(dp13529
g7
I40
sg8
g9
sg10
I6
sg11
VTRIM37
p13530
sg13
I1
sa(dp13531
g7
I69
sg8
VP38432
p13532
sg10
I22
sg11
VRING-B-box-coiled-coil
p13533
sg13
I1
sa(dp13534
g7
I93
sg8
g9
sg10
I4
sg11
VRBCC
p13535
sg13
I1
sa(dp13536
g7
I0
sg8
g9
sg10
I38
sg11
VTripartite motif-containing protein 37
p13537
sg13
I4
sasg14
(lp13538
(dp13539
g7
I205
sg17
VC0006826
p13540
sg10
I7
sg11
Vcancers
p13541
sg13
I1
sasa(dp13542
g2
S'In the present work, we clearly demonstrate that HMGB1 secreted by cancer cells is N-glycosylated at Asn37, which facilitates monocytic (M)-MDSC differentiation from bone marrow via the p38/NFKB/Erk1/2 pathway and also contributes to conversion of monocytes into MDSC-like cells; HMGB1 blockade by a monoclonal antibody against the HMGB1 B box obviously reduced the accumulation of M-MDSC in tumor-bearing mice, delaying tumor growth and development; additionally, MDSC expansion and HMGB1 up-regulation were also found in breast cancer patients.\n'
p13543
sg4
(lp13544
(dp13545
g7
I195
sg8
VP27361
p13546
sg10
I6
sg11
VErk1/2
p13547
sg13
I1
sa(dp13548
g7
I49
sg8
VP09429
p13549
sg10
I5
sg11
VHMGB1
p13550
sg13
I1
sa(dp13551
g7
I190
sg8
g9
sg10
I4
sg11
VNFKB
p13552
sg13
I1
sa(dp13553
g7
I49
sg8
VP09429
p13554
sg10
I5
sg11
VHMGB1
p13555
sg13
I1
sa(dp13556
g7
I186
sg8
VP46108
p13557
sg10
I3
sg11
Vp38
p13558
sg13
I1
sa(dp13559
g7
I49
sg8
VP09429
p13560
sg10
I5
sg11
VHMGB1
p13561
sg13
I1
sa(dp13562
g7
I332
sg8
VP09429
p13563
sg10
I7
sg11
VHMGB1 B
p13564
sg13
I2
sasg14
(lp13565
(dp13566
g7
I67
sg17
VC0006826
p13567
sg10
I6
sg11
Vcancer
p13568
sg13
I1
sa(dp13569
g7
I523
sg17
VC0678222
p13570
sg10
I13
sg11
Vbreast cancer
p13571
sg13
I2
sa(dp13572
g7
I421
sg17
VC0598934
p13573
sg10
I12
sg11
Vtumor growth
p13574
sg13
I2
sa(dp13575
g7
I392
sg17
VC0027651
p13576
sg10
I5
sg11
Vtumor
p13577
sg13
I1
sasa(dp13578
g2
S'We examined a possible association between the COMT Val158Met polymorphism and conversion disorder in a study of 48 patients with conversion disorder and 48 control patients.\n'
p13579
sg4
(lp13580
(dp13581
g7
I47
sg8
VP21964
p13582
sg10
I14
sg11
VCOMT Val158Met
p13583
sg13
I2
sasg14
(lp13584
(dp13585
g7
I79
sg17
VC0009946
p13586
sg10
I19
sg11
Vconversion disorder
p13587
sg13
I2
sa(dp13588
g7
I79
sg17
VC0009946
p13589
sg10
I19
sg11
Vconversion disorder
p13590
sg13
I2
sasa(dp13591
g2
S'We conclude that the COMT Val158Met genotype is quite common in Turkey and that it is not a risk factor for conversion disorder in the Turkish population.\n'
p13592
sg4
(lp13593
(dp13594
g7
I21
sg8
VP21964
p13595
sg10
I23
sg11
VCOMT Val158Met genotype
p13596
sg13
I3
sasg14
(lp13597
(dp13598
g7
I108
sg17
VC0009946
p13599
sg10
I19
sg11
Vconversion disorder
p13600
sg13
I2
sasa(dp13601
g2
S'Factor VII (FVII) activating protease (FSAP) is a circulating serine protease that is likely to be involved in a number of disease conditions such as stroke, atherosclerosis, liver fibrosis, thrombosis and cancer.\n'
p13602
sg4
(lp13603
(dp13604
g7
I0
sg8
VP08709
p13605
sg10
I37
sg11
VFactor VII (FVII) activating protease
p13606
sg13
I5
sa(dp13607
g7
I39
sg8
g9
sg10
I4
sg11
VFSAP
p13608
sg13
I1
sa(dp13609
g7
I62
sg8
VP57727
p13610
sg10
I15
sg11
Vserine protease
p13611
sg13
I2
sasg14
(lp13612
(dp13613
g7
I150
sg17
VC0038454
p13614
sg10
I6
sg11
Vstroke
p13615
sg13
I1
sa(dp13616
g7
I158
sg17
VC0004153
p13617
sg10
I15
sg11
Vatherosclerosis
p13618
sg13
I1
sa(dp13619
g7
I175
sg17
VC0239946
p13620
sg10
I14
sg11
Vliver fibrosis
p13621
sg13
I2
sa(dp13622
g7
I206
sg17
VC0006826
p13623
sg10
I6
sg11
Vcancer
p13624
sg13
I1
sa(dp13625
g7
I191
sg17
VC0040053
p13626
sg10
I10
sg11
Vthrombosis
p13627
sg13
I1
sasa(dp13628
g2
S'With purpose to study content of alpha-defensins (1-3) and synthesis and liberation of other proteins and peptides by neutrophils the concentrations of alpha-defensins, lipoprotein (alpha), C-reactive protein, precursor of cerebral natriuretic peptide, coagulation factor VII and von Willebrand factor were determined in supernatants of leukocytal cultures in patients with exertional angina pectoris and atherosclerosis of lower extremities.\n'
p13629
sg4
(lp13630
(dp13631
g7
I280
sg8
VP04275
p13632
sg10
I21
sg11
Vvon Willebrand factor
p13633
sg13
I3
sa(dp13634
g7
I190
sg8
VP02741
p13635
sg10
I18
sg11
VC-reactive protein
p13636
sg13
I2
sa(dp13637
g7
I223
sg8
VP16860
p13638
sg10
I28
sg11
Vcerebral natriuretic peptide
p13639
sg13
I3
sa(dp13640
g7
I33
sg8
VP59665
p13641
sg10
I15
sg11
Valpha-defensins
p13642
sg13
I1
sa(dp13643
g7
I253
sg8
VP08709
p13644
sg10
I22
sg11
Vcoagulation factor VII
p13645
sg13
I3
sa(dp13646
g7
I169
sg8
VP02652
p13647
sg10
I19
sg11
Vlipoprotein (alpha)
p13648
sg13
I2
sasg14
(lp13649
(dp13650
g7
I374
sg17
VC0577698
p13651
sg10
I17
sg11
Vexertional angina
p13652
sg13
I2
sa(dp13653
g7
I405
sg17
VC0004153
p13654
sg10
I15
sg11
Vatherosclerosis
p13655
sg13
I1
sasa(dp13656
g2
S'The frequency of HLA-DR4 was increased in patients with optic neuritis alone compared to controls and to patients with multiple sclerosis, but further studies are required to confirm this finding.\n'
p13657
sg4
(lp13658
(dp13659
g7
I17
sg8
VP30486
p13660
sg10
I7
sg11
VHLA-DR4
p13661
sg13
I1
sasg14
(lp13662
(dp13663
g7
I56
sg17
VC0029134
p13664
sg10
I14
sg11
Voptic neuritis
p13665
sg13
I2
sa(dp13666
g7
I119
sg17
VC0026769
p13667
sg10
I18
sg11
Vmultiple sclerosis
p13668
sg13
I2
sasa(dp13669
g2
S'The MS profiling by PGC-LC also revealed several glycan structural isomers that corresponded to LacdiNAc-type (GalNAcBeta1-4GlcNAc) motifs that were unique to the serous ovarian cancers and that correlated with elevated gene expression of B4GALNT3 and B4GALNT4 in patients with serous cancer.\n'
p13670
sg4
(lp13671
(dp13672
g7
I252
sg8
g9
sg10
I8
sg11
VB4GALNT4
p13673
sg13
I1
sa(dp13674
g7
I239
sg8
g9
sg10
I8
sg11
VB4GALNT3
p13675
sg13
I1
sasg14
(lp13676
(dp13677
g7
I178
sg17
VC0006826
p13678
sg10
I6
sg11
Vcancer
p13679
sg13
I1
sa(dp13680
g7
I170
sg17
VC1140680
p13681
sg10
I15
sg11
Vovarian cancers
p13682
sg13
I2
sasa(dp13683
g2
S'We previously showed that B4GALNT3 overexpression enhances colon cancer cell malignant phenotypes in vitro and in vivo.\n'
p13684
sg4
(lp13685
(dp13686
g7
I26
sg8
g9
sg10
I8
sg11
VB4GALNT3
p13687
sg13
I1
sasg14
(lp13688
(dp13689
g7
I59
sg17
VC0699790
p13690
sg10
I12
sg11
Vcolon cancer
p13691
sg13
I2
sasa(dp13692
g2
S'However, the role of B4GALNT3 in cancer stemness remains unclear.\n'
p13693
sg4
(lp13694
(dp13695
g7
I21
sg8
g9
sg10
I8
sg11
VB4GALNT3
p13696
sg13
I1
sasg14
(lp13697
(dp13698
g7
I33
sg17
VC0006826
p13699
sg10
I6
sg11
Vcancer
p13700
sg13
I1
sasa(dp13701
g2
S'We found that B4GALNT3 expression was positively correlated with advanced stages and poor survival in colorectal cancer patients.\n'
p13702
sg4
(lp13703
(dp13704
g7
I14
sg8
g9
sg10
I8
sg11
VB4GALNT3
p13705
sg13
I1
sasg14
(lp13706
(dp13707
g7
I102
sg17
VC1527249
p13708
sg10
I17
sg11
Vcolorectal cancer
p13709
sg13
I2
sasa(dp13710
g2
S'Knockdown of B4GALNT3 using small interfering (si) RNAs in colon cancer cell lines (HCT116, SW480, HCT15, and HT29 cells) decreased sphere formation and the expression of stem cell markers, OCT4 and NANOG.\n'
p13711
sg4
(lp13712
(dp13713
g7
I199
sg8
g9
sg10
I5
sg11
VNANOG
p13714
sg13
I1
sasg14
(lp13715
(dp13716
g7
I59
sg17
VC0699790
p13717
sg10
I12
sg11
Vcolon cancer
p13718
sg13
I2
sasa(dp13719
g2
S'Taken together, these data suggest B4GALNT3 regulates cancer stemness and the invasive properties of colon cancer cells through modifying EGFR glycosylation and signaling.\n'
p13720
sg4
(lp13721
(dp13722
g7
I35
sg8
g9
sg10
I8
sg11
VB4GALNT3
p13723
sg13
I1
sasg14
(lp13724
(dp13725
g7
I54
sg17
VC0006826
p13726
sg10
I6
sg11
Vcancer
p13727
sg13
I1
sa(dp13728
g7
I101
sg17
VC0699790
p13729
sg10
I12
sg11
Vcolon cancer
p13730
sg13
I2
sasa(dp13731
g2
S'In this study, we investigated the expression and role of B4GALNT3 in human neuroblastoma (NB).\n'
p13732
sg4
(lp13733
(dp13734
g7
I58
sg8
g9
sg10
I8
sg11
VB4GALNT3
p13735
sg13
I1
sasg14
(lp13736
(dp13737
g7
I91
sg17
VC0027819
p13738
sg10
I2
sg11
VNB
p13739
sg13
I1
sa(dp13740
g7
I76
sg17
VC0027819
p13741
sg10
I13
sg11
Vneuroblastoma
p13742
sg13
I1
sasa(dp13743
g2
S'Detection rates were as follows: IL-7: NVG higher than POAG; IL-10: POAG lower than cataract or NVG; and GM-CSF: cataract higher than POAG or NVG.\n'
p13744
sg4
(lp13745
(dp13746
g7
I105
sg8
VP04141
p13747
sg10
I6
sg11
VGM-CSF
p13748
sg13
I1
sa(dp13749
g7
I33
sg8
VP13232
p13750
sg10
I4
sg11
VIL-7
p13751
sg13
I1
sasg14
(lp13752
(dp13753
g7
I55
sg17
VC0339573
p13754
sg10
I4
sg11
VPOAG
p13755
sg13
I1
sa(dp13756
g7
I84
sg17
VC0086543
p13757
sg10
I8
sg11
Vcataract
p13758
sg13
I1
sa(dp13759
g7
I55
sg17
VC0339573
p13760
sg10
I4
sg11
VPOAG
p13761
sg13
I1
sa(dp13762
g7
I84
sg17
VC0086543
p13763
sg10
I8
sg11
Vcataract
p13764
sg13
I1
sa(dp13765
g7
I55
sg17
VC0339573
p13766
sg10
I4
sg11
VPOAG
p13767
sg13
I1
sasa(dp13768
g2
S'Sixty-four vitreous samples (40 RVO, 24 controls with idiopathic floaters) were analyzed in this retrospective case series using LC/MS for LPAs 16:0, 18:0, 18:1, 20:4, and ELISA kits or Luminex technology for ATX, angiopoetin-1 (ANG-1), interleukin-6 (IL-6), interleukin-7 (IL-7), interleukin-8 (IL-8), monocyte chemoattractant protein-1 (MCP-1), pigment epithelium-derived factor (PEDF), and vascular endothelial growth factor (VEGF).\n'
p13769
sg4
(lp13770
(dp13771
g7
I274
sg8
VP13232
p13772
sg10
I4
sg11
VIL-7
p13773
sg13
I1
sa(dp13774
g7
I393
sg8
g9
sg10
I34
sg11
Vvascular endothelial growth factor
p13775
sg13
I4
sa(dp13776
g7
I237
sg8
VP05231
p13777
sg10
I13
sg11
Vinterleukin-6
p13778
sg13
I1
sa(dp13779
g7
I259
sg8
VP13232
p13780
sg10
I13
sg11
Vinterleukin-7
p13781
sg13
I1
sa(dp13782
g7
I339
sg8
VP41597
p13783
sg10
I5
sg11
VMCP-1
p13784
sg13
I1
sa(dp13785
g7
I209
sg8
g9
sg10
I3
sg11
VATX
p13786
sg13
I1
sa(dp13787
g7
I229
sg8
VP03950
p13788
sg10
I5
sg11
VANG-1
p13789
sg13
I1
sa(dp13790
g7
I214
sg8
VP03950
p13791
sg10
I13
sg11
Vangiopoetin-1
p13792
sg13
I1
sa(dp13793
g7
I252
sg8
VP05231
p13794
sg10
I4
sg11
VIL-6
p13795
sg13
I1
sa(dp13796
g7
I429
sg8
g9
sg10
I4
sg11
VVEGF
p13797
sg13
I1
sa(dp13798
g7
I281
sg8
VP60568
p13799
sg10
I13
sg11
Vinterleukin-8
p13800
sg13
I1
sa(dp13801
g7
I303
sg8
VP41597
p13802
sg10
I34
sg11
Vmonocyte chemoattractant protein-1
p13803
sg13
I3
sa(dp13804
g7
I296
sg8
VP60568
p13805
sg10
I4
sg11
VIL-8
p13806
sg13
I1
sasg14
(lp13807
sa(dp13808
g2
S'Poly I:C induces IL-7 production, early inflammatory responses, and characteristic pathologies of SS-like dacryoadenitis in non-autoimmune-prone C57BL/6 mice.\n'
p13809
sg4
(lp13810
(dp13811
g7
I17
sg8
VP13232
p13812
sg10
I4
sg11
VIL-7
p13813
sg13
I1
sasg14
(lp13814
(dp13815
g7
I40
sg17
VC1155266
p13816
sg10
I22
sg11
Vinflammatory responses
p13817
sg13
I2
sa(dp13818
g7
I106
sg17
VC0155223
p13819
sg10
I14
sg11
Vdacryoadenitis
p13820
sg13
I1
sa(dp13821
g7
I128
sg17
VC0443146
p13822
sg10
I10
sg11
Vautoimmune
p13823
sg13
I1
sasa(dp13824
g2
S'Diagnosis of AIDS-NHL was preceded by a significantly elevated frequency of activated/germinal center-like CD19CD10CD71CD86AID B cells (P = 0.0072), elevated serum prevalence of the TLR2 ligand, and significantly elevated B-cell TLR2 expression (P = 0.0015), positively correlating with the frequency of activated/germinal center-like B cells (rho = 0.7273, P = 0.0144).\n'
p13825
sg4
(lp13826
(dp13827
g7
I222
sg8
g9
sg10
I11
sg11
VB-cell TLR2
p13828
sg13
I2
sa(dp13829
g7
I182
sg8
g9
sg10
I11
sg11
VTLR2 ligand
p13830
sg13
I2
sasg14
(lp13831
(dp13832
g7
I18
sg17
VC0024305
p13833
sg10
I3
sg11
VNHL
p13834
sg13
I1
sasa(dp13835
g2
S'TLR2-stimulated purified B cells exhibited the activated B-cell phenotype observed in HIV+ subjects before AIDS-NHL diagnosis.\n'
p13836
sg4
(lp13837
(dp13838
g7
I0
sg8
g9
sg10
I4
sg11
VTLR2
p13839
sg13
I1
sasg14
(lp13840
(dp13841
g7
I112
sg17
VC0024305
p13842
sg10
I3
sg11
VNHL
p13843
sg13
I1
sasa(dp13844
g2
S'These results indicate that an elevated fraction of B cells display an activated/germinal center phenotype in those HIV+ subjects who go on to develop AIDS-NHL and suggest that TLR2-mediated activation may play a role in HIV infection-associated B-cell activation, potentially contributing to the genesis of AIDS-NHL.\n'
p13845
sg4
(lp13846
(dp13847
g7
I177
sg8
g9
sg10
I4
sg11
VTLR2
p13848
sg13
I1
sasg14
(lp13849
(dp13850
g7
I156
sg17
VC0024305
p13851
sg10
I3
sg11
VNHL
p13852
sg13
I1
sa(dp13853
g7
I221
sg17
VC0019693
p13854
sg10
I13
sg11
VHIV infection
p13855
sg13
I2
sa(dp13856
g7
I156
sg17
VC0024305
p13857
sg10
I3
sg11
VNHL
p13858
sg13
I1
sasa(dp13859
g2
S'The regulatory role of AVP on the hypothalamic-pituitary-adrenal (HPA) axis suggests potential uses for AVP receptor modulators in various CNS indications, including depression, anxiety and post-traumatic stress disorder.\n'
p13860
sg4
(lp13861
(dp13862
g7
I104
sg8
VP01185
p13863
sg10
I12
sg11
VAVP receptor
p13864
sg13
I2
sa(dp13865
g7
I23
sg8
VP01185
p13866
sg10
I3
sg11
VAVP
p13867
sg13
I1
sasg14
(lp13868
(dp13869
g7
I190
sg17
VC0038436
p13870
sg10
I30
sg11
Vpost-traumatic stress disorder
p13871
sg13
I3
sa(dp13872
g7
I166
sg17
VC0011581
p13873
sg10
I10
sg11
Vdepression
p13874
sg13
I1
sasa(dp13875
g2
S'When POLN was ectopically overexpressed in human cells, it specifically coimmunoprecipitated with the homologous recombination factors BRCA1 and FANCJ, but not with previously suggested interaction partners (HELQ and members of the Fanconi anemia core complex).\n'
p13876
sg4
(lp13877
(dp13878
g7
I208
sg8
g9
sg10
I4
sg11
VHELQ
p13879
sg13
I1
sa(dp13880
g7
I232
sg8
VP51587
p13881
sg10
I27
sg11
VFanconi anemia core complex
p13882
sg13
I4
sa(dp13883
g7
I145
sg8
g9
sg10
I5
sg11
VFANCJ
p13884
sg13
I1
sa(dp13885
g7
I102
sg8
VP19883
p13886
sg10
I38
sg11
Vhomologous recombination factors BRCA1
p13887
sg13
I4
sasg14
(lp13888
(dp13889
g7
I232
sg17
VC3469521
p13890
sg10
I14
sg11
VFanconi anemia
p13891
sg13
I2
sa(dp13892
g7
I145
sg17
VC1836860
p13893
sg10
I5
sg11
VFANCJ
p13894
sg13
I1
sasa(dp13895
g2
S'Moreover, we obtained evidence for physical and functional interaction of POLN with factors belonging to the Fanconi anemia pathway, a master regulator of cross-link repair.\n'
p13896
sg4
(lp13897
(dp13898
g7
I74
sg8
g9
sg10
I4
sg11
VPOLN
p13899
sg13
I1
sasg14
(lp13900
(dp13901
g7
I109
sg17
VC3469521
p13902
sg10
I14
sg11
VFanconi anemia
p13903
sg13
I2
sasa(dp13904
g2
S'The results indicate that the Pol n I component MV is an allergen for human beings as well as for mice, and useful as a diagnostic tool for chironomid allergy.\n'
p13905
sg4
(lp13906
(dp13907
g7
I30
sg8
VP10266
p13908
sg10
I20
sg11
VPol n I component MV
p13909
sg13
I5
sasg14
(lp13910
(dp13911
g7
I151
sg17
VC0020517
p13912
sg10
I7
sg11
Vallergy
p13913
sg13
I1
sasa(dp13914
g2
S'Prevalence of service receipt was highest among women in the highest family income category (&gt;400% of federal poverty level [FPL]) and among women with insurance coverage for each of the following: contraceptive services among women at risk for unintended pregnancy; medical services beyond advice to help achieve pregnancy; vaccinations (hepatitis B and human papillomavirus [HPV], ever; tetanus, past 10 years; influenza, past year); discussions with a health care professional about improving health before pregnancy and taking vitamins with folic acid; blood pressure and diabetes screening; discussions with a health care professional in the past year about diet, among those with obesity; discussions with a health care professional in the past year about smoking, among current smokers; Pap tests within the past 3 years; and mammograms within the past 2 years.\n'
p13915
sg4
(lp13916
sg14
(lp13917
(dp13918
g7
I689
sg17
VC0028754
p13919
sg10
I7
sg11
Vobesity
p13920
sg13
I1
sa(dp13921
g7
I416
sg17
VC0021400
p13922
sg10
I9
sg11
Vinfluenza
p13923
sg13
I1
sa(dp13924
g7
I797
sg17
VC1863340
p13925
sg10
I3
sg11
VPap
p13926
sg13
I1
sa(dp13927
g7
I342
sg17
VC0019163
p13928
sg10
I11
sg11
Vhepatitis B
p13929
sg13
I2
sa(dp13930
g7
I579
sg17
VC0011849
p13931
sg10
I8
sg11
Vdiabetes
p13932
sg13
I1
sa(dp13933
g7
I392
sg17
VC0039614
p13934
sg10
I7
sg11
Vtetanus
p13935
sg13
I1
sasa(dp13936
g2
S'Herein we describe a new phenotype associated with a mutation in exon 11 of the LMNA gene: hypertrophic cardiomyopathy, atrioventricular block, severe dyslipidemia and diabetes.\n'
p13937
sg4
(lp13938
(dp13939
g7
I80
sg8
VP02545
p13940
sg10
I9
sg11
VLMNA gene
p13941
sg13
I2
sasg14
(lp13942
(dp13943
g7
I168
sg17
VC0011849
p13944
sg10
I8
sg11
Vdiabetes
p13945
sg13
I1
sa(dp13946
g7
I91
sg17
VC0007194
p13947
sg10
I27
sg11
Vhypertrophic cardiomyopathy
p13948
sg13
I2
sa(dp13949
g7
I120
sg17
VC0004245
p13950
sg10
I22
sg11
Vatrioventricular block
p13951
sg13
I2
sa(dp13952
g7
I151
sg17
VC0242339
p13953
sg10
I12
sg11
Vdyslipidemia
p13954
sg13
I1
sasa(dp13955
g2
S'Independent analysis of LMNA variants via the type 2 diabetes (T2D) Knowledge Portal showed that variant p.G602S associated significantly with type 2 diabetes (p = 0.02; odds ratio = 4.58), and was more frequent in African Americans (allele frequency 0.297%).\n'
p13956
sg4
(lp13957
(dp13958
g7
I24
sg8
VP02545
p13959
sg10
I13
sg11
VLMNA variants
p13960
sg13
I2
sasg14
(lp13961
(dp13962
g7
I63
sg17
VC0011860
p13963
sg10
I3
sg11
VT2D
p13964
sg13
I1
sa(dp13965
g7
I46
sg17
VC0011860
p13966
sg10
I15
sg11
Vtype 2 diabetes
p13967
sg13
I3
sa(dp13968
g7
I46
sg17
VC0011860
p13969
sg10
I15
sg11
Vtype 2 diabetes
p13970
sg13
I3
sasa(dp13971
g2
S'Lipodystrophy is a rare disorder characterized by the complete or partial loss of subcutaneous adipose tissue, insulin resistance, diabetes mellitus and hyperlipidemia.Proteinuric renal disease is a prevalent feature of generalized lipodystrophy but rare in familial partial lipodystrophy.Patients carrying the c.1045C &gt; T missense LMNA mutation (p.R349W) may present with familial partial lipodystrophy, proteinuric nephropathy, cardiomyopathy and atypical myopathy.\n'
p13972
sg4
(lp13973
(dp13974
g7
I111
sg8
VP01308
p13975
sg10
I7
sg11
Vinsulin
p13976
sg13
I1
sasg14
(lp13977
(dp13978
g7
I220
sg17
VC0221032
p13979
sg10
I25
sg11
Vgeneralized lipodystrophy
p13980
sg13
I2
sa(dp13981
g7
I131
sg17
VC0011849
p13982
sg10
I17
sg11
Vdiabetes mellitus
p13983
sg13
I2
sa(dp13984
g7
I258
sg17
VC0271694
p13985
sg10
I30
sg11
Vfamilial partial lipodystrophy
p13986
sg13
I3
sa(dp13987
g7
I439
sg17
VC0026848
p13988
sg10
I8
sg11
Vmyopathy
p13989
sg13
I1
sa(dp13990
g7
I420
sg17
VC0022658
p13991
sg10
I11
sg11
Vnephropathy
p13992
sg13
I1
sa(dp13993
g7
I433
sg17
VC0878544
p13994
sg10
I14
sg11
Vcardiomyopathy
p13995
sg13
I1
sa(dp13996
g7
I153
sg17
VC0020473
p13997
sg10
I14
sg11
Vhyperlipidemia
p13998
sg13
I1
sa(dp13999
g7
I180
sg17
VC0022658
p14000
sg10
I13
sg11
Vrenal disease
p14001
sg13
I2
sa(dp14002
g7
I111
sg17
VC0021655
p14003
sg10
I18
sg11
Vinsulin resistance
p14004
sg13
I2
sa(dp14005
g7
I19
sg17
VC0678236
p14006
sg10
I13
sg11
Vrare disorder
p14007
sg13
I2
sa(dp14008
g7
I258
sg17
VC0271694
p14009
sg10
I30
sg11
Vfamilial partial lipodystrophy
p14010
sg13
I3
sa(dp14011
g7
I0
sg17
VC0023787
p14012
sg10
I13
sg11
VLipodystrophy
p14013
sg13
I1
sasa(dp14014
g2
S"BAT 5'-deiodinase activity was unaffected by propylthiouracil (PTU) and was elevated in hypothyroid rats, whereas EPI 5'-deiodinase was totally inhibited by PTU and was depressed in hypothyroidism.\n"
p14015
sg4
(lp14016
(dp14017
g7
I114
sg8
VP10646
p14018
sg10
I17
sg11
VEPI 5'-deiodinase
p14019
sg13
I2
sa(dp14020
g7
I0
sg8
g9
sg10
I17
sg11
VBAT 5'-deiodinase
p14021
sg13
I2
sasg14
(lp14022
(dp14023
g7
I88
sg17
VC0020676
p14024
sg10
I11
sg11
Vhypothyroid
p14025
sg13
I1
sa(dp14026
g7
I114
sg17
VC0267963
p14027
sg10
I3
sg11
VEPI
p14028
sg13
I1
sa(dp14029
g7
I182
sg17
VC0020676
p14030
sg10
I14
sg11
Vhypothyroidism
p14031
sg13
I1
sasa(dp14032
g2
S'Here, we report a novel mutation in ERCC8 gene in a 16-year-old boy who suffers from poor weight gain, short stature, microcephaly, intellectual disability, and photosensitivity.\n'
p14033
sg4
(lp14034
(dp14035
g7
I36
sg8
VP01243
p14036
sg10
I10
sg11
VERCC8 gene
p14037
sg13
I2
sasg14
(lp14038
(dp14039
g7
I85
sg17
VC0231246
p14040
sg10
I16
sg11
Vpoor weight gain
p14041
sg13
I3
sa(dp14042
g7
I161
sg17
VC0393720
p14043
sg10
I16
sg11
Vphotosensitivity
p14044
sg13
I1
sa(dp14045
g7
I72
sg17
VC0683278
p14046
sg10
I7
sg11
Vsuffers
p14047
sg13
I1
sa(dp14048
g7
I118
sg17
VC0025958
p14049
sg10
I12
sg11
Vmicrocephaly
p14050
sg13
I1
sa(dp14051
g7
I132
sg17
VC0025362
p14052
sg10
I23
sg11
Vintellectual disability
p14053
sg13
I2
sa(dp14054
g7
I18
sg17
VC2985438
p14055
sg10
I14
sg11
Vnovel mutation
p14056
sg13
I2
sa(dp14057
g7
I103
sg17
VC0013336
p14058
sg10
I13
sg11
Vshort stature
p14059
sg13
I2
sasa(dp14060
g2
S'Cockayne syndrome is caused by biallelic ERCC8 (CSA) or ERCC6 (CSB) mutations and is characterized by growth restriction, microcephaly, developmental delay, and premature pathological aging.\n'
p14061
sg4
(lp14062
(dp14063
g7
I41
sg8
VP01243
p14064
sg10
I11
sg11
VERCC8 (CSA)
p14065
sg13
I2
sa(dp14066
g7
I56
sg8
g9
sg10
I5
sg11
VERCC6
p14067
sg13
I1
sa(dp14068
g7
I63
sg8
VP35548
p14069
sg10
I3
sg11
VCSB
p14070
sg13
I1
sasg14
(lp14071
(dp14072
g7
I122
sg17
VC0025958
p14073
sg10
I12
sg11
Vmicrocephaly
p14074
sg13
I1
sa(dp14075
g7
I0
sg17
VC0009207
p14076
sg10
I17
sg11
VCockayne syndrome
p14077
sg13
I2
sa(dp14078
g7
I48
sg17
VC0751039
p14079
sg10
I3
sg11
VCSA
p14080
sg13
I1
sa(dp14081
g7
I63
sg17
VC1858160
p14082
sg10
I3
sg11
VCSB
p14083
sg13
I1
sa(dp14084
g7
I21
sg17
VC0751039
p14085
sg10
I25
sg11
Vcaused by biallelic ERCC8
p14086
sg13
I4
sa(dp14087
g7
I136
sg17
VC0424605
p14088
sg10
I19
sg11
Vdevelopmental delay
p14089
sg13
I2
sasa(dp14090
g2
S'This study included 54 beta-thalassemia major patients divided into 2 groups; group A consisted of 28 patients who have thrombocytosis secondary to a previous splenectomy and group B comprised of 26 patients who did not have a splenectomy with normal platelet count, as well as a control group of 30 healthy individuals.\n'
p14091
sg4
(lp14092
sg14
(lp14093
(dp14094
g7
I28
sg17
VC0002875
p14095
sg10
I17
sg11
Vthalassemia major
p14096
sg13
I2
sa(dp14097
g7
I120
sg17
VC0836924
p14098
sg10
I14
sg11
Vthrombocytosis
p14099
sg13
I1
sa(dp14100
g7
I175
sg17
VC0348801
p14101
sg10
I7
sg11
Vgroup B
p14102
sg13
I2
sasa(dp14103
g2
S'A microarray analysis of the B-1 lymphocytes revealed that IL-10 deficiency is associated with down-regulation of the genes that code for claudin-10, a protein that is involved in cell-to-cell contact and that has been linked to lung adenocarcinoma.\n'
p14104
sg4
(lp14105
(dp14106
g7
I138
sg8
VP78369
p14107
sg10
I10
sg11
Vclaudin-10
p14108
sg13
I1
sasg14
(lp14109
(dp14110
g7
I229
sg17
VC0152013
p14111
sg10
I19
sg11
Vlung adenocarcinoma
p14112
sg13
I2
sasa(dp14113
g2
S'Thus, our findings suggest that the axis IL-10/claudin-10 is a promising target for the development of therapeutic agents against aggressive melanoma.\n'
p14114
sg4
(lp14115
(dp14116
g7
I47
sg8
VP78369
p14117
sg10
I10
sg11
Vclaudin-10
p14118
sg13
I1
sasg14
(lp14119
(dp14120
g7
I141
sg17
VC0025202
p14121
sg10
I8
sg11
Vmelanoma
p14122
sg13
I1
sa(dp14123
g7
I130
sg17
VC0001807
p14124
sg10
I10
sg11
Vaggressive
p14125
sg13
I1
sasa(dp14126
g2
S'To explore the expression distinction of the cell adhesion proteins claudin-10,-14,-17 and E-cadherin in the adjacent non-neoplastic tissues and gastric cancer tissues, 50 gastric cancer tissues and 50 samples of adjacent non-neoplastic tissues adjacent to the tumors were examined for expression of claudin-10,-14,-17 and E-cadherin by streptavidin-perosidase immunohistochemical staining method.\n'
p14127
sg4
(lp14128
(dp14129
g7
I68
sg8
VP78369
p14130
sg10
I18
sg11
Vclaudin-10,-14,-17
p14131
sg13
I1
sa(dp14132
g7
I337
sg8
g9
sg10
I23
sg11
Vstreptavidin-perosidase
p14133
sg13
I1
sa(dp14134
g7
I68
sg8
VP78369
p14135
sg10
I18
sg11
Vclaudin-10,-14,-17
p14136
sg13
I1
sa(dp14137
g7
I91
sg8
VP12830
p14138
sg10
I10
sg11
VE-cadherin
p14139
sg13
I1
sa(dp14140
g7
I91
sg8
VP12830
p14141
sg10
I10
sg11
VE-cadherin
p14142
sg13
I1
sasg14
(lp14143
(dp14144
g7
I145
sg17
VC0024623
p14145
sg10
I14
sg11
Vgastric cancer
p14146
sg13
I2
sa(dp14147
g7
I261
sg17
VC0027651
p14148
sg10
I6
sg11
Vtumors
p14149
sg13
I1
sa(dp14150
g7
I50
sg17
VC0001511
p14151
sg10
I8
sg11
Vadhesion
p14152
sg13
I1
sa(dp14153
g7
I145
sg17
VC0024623
p14154
sg10
I14
sg11
Vgastric cancer
p14155
sg13
I2
sasa(dp14156
g2
S'The positive expression rates of claudin-10 in gastric cancer tissues and adjacent non-neoplastic tissues were 24% and 72% respectively (P &lt; 0.01).\n'
p14157
sg4
(lp14158
(dp14159
g7
I33
sg8
VP78369
p14160
sg10
I10
sg11
Vclaudin-10
p14161
sg13
I1
sasg14
(lp14162
(dp14163
g7
I47
sg17
VC0024623
p14164
sg10
I14
sg11
Vgastric cancer
p14165
sg13
I2
sasa(dp14166
g2
S'In contrast, the positive expression rates of claudin-14 in gastric cancer tissues and adjacent non-neoplastic tissues were 58% and 24% respectively (P = 0.015 &lt; 0.05) Thus in our study, the expression of E-cadherin, claudin-10, and claudin-17 was down-regulated in gastric cancer tissue while the expression of claudin-14 was up-regulated.\n'
p14167
sg4
(lp14168
(dp14169
g7
I46
sg8
g9
sg10
I10
sg11
Vclaudin-14
p14170
sg13
I1
sa(dp14171
g7
I208
sg8
VP12830
p14172
sg10
I10
sg11
VE-cadherin
p14173
sg13
I1
sa(dp14174
g7
I236
sg8
VP56750
p14175
sg10
I10
sg11
Vclaudin-17
p14176
sg13
I1
sa(dp14177
g7
I220
sg8
VP78369
p14178
sg10
I10
sg11
Vclaudin-10
p14179
sg13
I1
sasg14
(lp14180
(dp14181
g7
I60
sg17
VC0024623
p14182
sg10
I14
sg11
Vgastric cancer
p14183
sg13
I2
sa(dp14184
g7
I60
sg17
VC0024623
p14185
sg10
I14
sg11
Vgastric cancer
p14186
sg13
I2
sasa(dp14187
g2
S'Our study reveals that the expression of E-cadherin, claudin-10, and claudin-17 were down-regulated in gastric cancer tissue while the expression of claudin-14 was up-regulated and correlation between claudins and E-cadherin expression with lymphatic metastasis were observed.\n'
p14188
sg4
(lp14189
(dp14190
g7
I69
sg8
VP56750
p14191
sg10
I10
sg11
Vclaudin-17
p14192
sg13
I1
sa(dp14193
g7
I41
sg8
VP12830
p14194
sg10
I10
sg11
VE-cadherin
p14195
sg13
I1
sa(dp14196
g7
I41
sg8
VP12830
p14197
sg10
I10
sg11
VE-cadherin
p14198
sg13
I1
sa(dp14199
g7
I53
sg8
VP78369
p14200
sg10
I10
sg11
Vclaudin-10
p14201
sg13
I1
sasg14
(lp14202
(dp14203
g7
I103
sg17
VC0024623
p14204
sg10
I14
sg11
Vgastric cancer
p14205
sg13
I2
sa(dp14206
g7
I241
sg17
VC0024232
p14207
sg10
I20
sg11
Vlymphatic metastasis
p14208
sg13
I2
sasa(dp14209
g2
S'Four genes (MMP-2, c-fos, claudin 1 (CLDN1) and claudin 10(CLDN10)) were correlated with the results of microarray and real time RT-PCR analyses for the gene-expression data in samples from 41 patients with lung adenocarcinoma.\n'
p14210
sg4
(lp14211
(dp14212
g7
I12
sg8
VP08253
p14213
sg10
I5
sg11
VMMP-2
p14214
sg13
I1
sa(dp14215
g7
I48
sg8
VP78369
p14216
sg10
I10
sg11
Vclaudin 10
p14217
sg13
I2
sa(dp14218
g7
I19
sg8
VP01100
p14219
sg10
I5
sg11
Vc-fos
p14220
sg13
I1
sa(dp14221
g7
I26
sg8
g9
sg10
I9
sg11
Vclaudin 1
p14222
sg13
I2
sa(dp14223
g7
I37
sg8
g9
sg10
I5
sg11
VCLDN1
p14224
sg13
I1
sa(dp14225
g7
I59
sg8
VP78369
p14226
sg10
I6
sg11
VCLDN10
p14227
sg13
I1
sasg14
(lp14228
(dp14229
g7
I207
sg17
VC0152013
p14230
sg10
I19
sg11
Vlung adenocarcinoma
p14231
sg13
I2
sasa(dp14232
g2
S'Immunohistochemical staining for these genes in samples from 81 cases of lung adenocarcinoma demonstrated the expressions of CLDN1 and CLDN10 were correlated with overall survival of patients with lung adenocarcinoma.\n'
p14233
sg4
(lp14234
(dp14235
g7
I135
sg8
VP78369
p14236
sg10
I6
sg11
VCLDN10
p14237
sg13
I1
sa(dp14238
g7
I125
sg8
g9
sg10
I5
sg11
VCLDN1
p14239
sg13
I1
sasg14
(lp14240
(dp14241
g7
I73
sg17
VC0152013
p14242
sg10
I19
sg11
Vlung adenocarcinoma
p14243
sg13
I2
sa(dp14244
g7
I73
sg17
VC0152013
p14245
sg10
I19
sg11
Vlung adenocarcinoma
p14246
sg13
I2
sasa(dp14247
g2
S'Overexpression of CLDN1 and CLDN10 indicates a favorable prognosis for overall survival in some patients with lung adenocarcinoma.\n'
p14248
sg4
(lp14249
(dp14250
g7
I18
sg8
g9
sg10
I5
sg11
VCLDN1
p14251
sg13
I1
sa(dp14252
g7
I28
sg8
VP78369
p14253
sg10
I6
sg11
VCLDN10
p14254
sg13
I1
sasg14
(lp14255
(dp14256
g7
I110
sg17
VC0152013
p14257
sg10
I19
sg11
Vlung adenocarcinoma
p14258
sg13
I2
sasa(dp14259
g2
S'Furthermore, circadian regulation of Gnaz was disturbed in the db/db mouse, a model of diabetic retinopathy.\n'
p14260
sg4
(lp14261
sg14
(lp14262
(dp14263
g7
I87
sg17
VC0011884
p14264
sg10
I20
sg11
Vdiabetic retinopathy
p14265
sg13
I2
sasa(dp14266
g2
S'The highest rates of somatic, non-synonymous mutations were found in GNG10 and GNAZ, neither of which has been previously reported to be mutated in melanoma.\n'
p14267
sg4
(lp14268
(dp14269
g7
I69
sg8
VP50151
p14270
sg10
I5
sg11
VGNG10
p14271
sg13
I1
sa(dp14272
g7
I79
sg8
VP19086
p14273
sg10
I4
sg11
VGNAZ
p14274
sg13
I1
sasg14
(lp14275
(dp14276
g7
I148
sg17
VC0025202
p14277
sg10
I8
sg11
Vmelanoma
p14278
sg13
I1
sasa(dp14279
g2
S'Various other protein products of genes associated with bipolar disorder either bind to or are affected by phosphatidyl-inositol phosphate products of this pathway (ADBRK2, HIP1R, KCNQ2, RGS4, WFS1), are associated with its constituent elements (BCR, DUSP6, FAT, GNAZ) or are downstream targets of this signalling cascade (DPYSL2, DRD3, GAD1, G6PD, GCH1, KCNQ2, NOS3, SLC6A3, SLC6A4, SST, TH, TIMELESS).\n'
p14280
sg4
(lp14281
(dp14282
g7
I343
sg8
VP11441
p14283
sg10
I4
sg11
VG6PD
p14284
sg13
I1
sa(dp14285
g7
I193
sg8
g9
sg10
I4
sg11
VWFS1
p14286
sg13
I1
sa(dp14287
g7
I384
sg8
VP61278
p14288
sg10
I3
sg11
VSST
p14289
sg13
I1
sa(dp14290
g7
I251
sg8
g9
sg10
I5
sg11
VDUSP6
p14291
sg13
I1
sa(dp14292
g7
I263
sg8
VP19086
p14293
sg10
I4
sg11
VGNAZ
p14294
sg13
I1
sa(dp14295
g7
I337
sg8
g9
sg10
I4
sg11
VGAD1
p14296
sg13
I1
sa(dp14297
g7
I258
sg8
g9
sg10
I3
sg11
VFAT
p14298
sg13
I1
sa(dp14299
g7
I323
sg8
g9
sg10
I6
sg11
VDPYSL2
p14300
sg13
I1
sa(dp14301
g7
I349
sg8
VP30793
p14302
sg10
I4
sg11
VGCH1
p14303
sg13
I1
sa(dp14304
g7
I393
sg8
VP60174
p14305
sg10
I8
sg11
VTIMELESS
p14306
sg13
I1
sa(dp14307
g7
I362
sg8
VP60323
p14308
sg10
I4
sg11
VNOS3
p14309
sg13
I1
sa(dp14310
g7
I376
sg8
VP31645
p14311
sg10
I6
sg11
VSLC6A4
p14312
sg13
I1
sa(dp14313
g7
I368
sg8
g9
sg10
I6
sg11
VSLC6A3
p14314
sg13
I1
sa(dp14315
g7
I246
sg8
VP11274
p14316
sg10
I3
sg11
VBCR
p14317
sg13
I1
sa(dp14318
g7
I180
sg8
g9
sg10
I5
sg11
VKCNQ2
p14319
sg13
I1
sa(dp14320
g7
I331
sg8
VP35462
p14321
sg10
I4
sg11
VDRD3
p14322
sg13
I1
sa(dp14323
g7
I173
sg8
g9
sg10
I5
sg11
VHIP1R
p14324
sg13
I1
sa(dp14325
g7
I187
sg8
VP49798
p14326
sg10
I4
sg11
VRGS4
p14327
sg13
I1
sa(dp14328
g7
I180
sg8
g9
sg10
I5
sg11
VKCNQ2
p14329
sg13
I1
sasg14
(lp14330
(dp14331
g7
I56
sg17
VC0005586
p14332
sg10
I16
sg11
Vbipolar disorder
p14333
sg13
I2
sa(dp14334
g7
I193
sg17
VC0043207
p14335
sg10
I4
sg11
VWFS1
p14336
sg13
I1
sasa(dp14337
g2
S'In a recent study we found that the risk for unilateral retinoblastoma in offspring is 4 fold higher in women that are homozygotes for the 19 bp deletion in the DHFR gene and took folic acid supplement during pregnancy.\n'
p14338
sg4
(lp14339
(dp14340
g7
I161
sg8
VP00374
p14341
sg10
I9
sg11
VDHFR gene
p14342
sg13
I2
sasg14
(lp14343
(dp14344
g7
I45
sg17
VC0854915
p14345
sg10
I25
sg11
Vunilateral retinoblastoma
p14346
sg13
I2
sasa(dp14347
g2
S'Retinoblastoma protein (pRb) was highly phosphorylated but p107 was upregulated, and the expression of E2f target genes was dysregulated as shown by upregulation of Cdc6 but downregulation of cyclin E, dihydrofolate reductase (dhfr), Cdc25a and B-Myb in chondrocytes of K6(H)/D1(H) mice.\n'
p14348
sg4
(lp14349
(dp14350
g7
I103
sg8
VP01893
p14351
sg10
I16
sg11
VE2f target genes
p14352
sg13
I3
sa(dp14353
g7
I192
sg8
VP24864
p14354
sg10
I8
sg11
Vcyclin E
p14355
sg13
I2
sa(dp14356
g7
I234
sg8
VP30304
p14357
sg10
I6
sg11
VCdc25a
p14358
sg13
I1
sa(dp14359
g7
I227
sg8
VP00374
p14360
sg10
I4
sg11
Vdhfr
p14361
sg13
I1
sa(dp14362
g7
I0
sg8
g9
sg10
I22
sg11
VRetinoblastoma protein
p14363
sg13
I2
sa(dp14364
g7
I245
sg8
VP10244
p14365
sg10
I5
sg11
VB-Myb
p14366
sg13
I1
sa(dp14367
g7
I24
sg8
g9
sg10
I3
sg11
VpRb
p14368
sg13
I1
sa(dp14369
g7
I165
sg8
g9
sg10
I4
sg11
VCdc6
p14370
sg13
I1
sa(dp14371
g7
I59
sg8
VP28749
p14372
sg10
I4
sg11
Vp107
p14373
sg13
I1
sa(dp14374
g7
I202
sg8
VP00374
p14375
sg10
I23
sg11
Vdihydrofolate reductase
p14376
sg13
I2
sasg14
(lp14377
(dp14378
g7
I0
sg17
VC0035335
p14379
sg10
I14
sg11
VRetinoblastoma
p14380
sg13
I1
sasa(dp14381
g2
S'The authors used a case-control study design to examine the association between retinoblastoma risk and maternal variations in the folate-metabolizing genes methylenetetrahydrofolate reductase (MTHFR) (a cytosine-to-thymine substitution at nucleotide 677 [MTHFR677C-&gt;T]; reference single nucleotide polymorphism rs1801133) and dihydrofolate reductase (DHFR) (a 19-base-pair deletion of intron 1a [DHFR19bpdel]; rs70991108).\n'
p14382
sg4
(lp14383
(dp14384
g7
I330
sg8
VP00374
p14385
sg10
I23
sg11
Vdihydrofolate reductase
p14386
sg13
I2
sa(dp14387
g7
I355
sg8
VP00374
p14388
sg10
I4
sg11
VDHFR
p14389
sg13
I1
sa(dp14390
g7
I194
sg8
VP42898
p14391
sg10
I5
sg11
VMTHFR
p14392
sg13
I1
sa(dp14393
g7
I131
sg8
VP42898
p14394
sg10
I61
sg11
Vfolate-metabolizing genes methylenetetrahydrofolate reductase
p14395
sg13
I4
sasg14
(lp14396
(dp14397
g7
I80
sg17
VC0035335
p14398
sg10
I14
sg11
Vretinoblastoma
p14399
sg13
I1
sasa(dp14400
g2
S"The risk of having a child with unilateral retinoblastoma was associated with maternal homozygosity for DHFR19bpdel (odds ratio, 3.78; 95% confidence interval, 1.89-7.55; P = .0002), even after controlling for the child's DHFR19bpdel genotype (odds ratio, 2.81; 95% confidence interval, 1.32-5.99; P = .0073).\n"
p14401
sg4
(lp14402
sg14
(lp14403
(dp14404
g7
I32
sg17
VC0854915
p14405
sg10
I25
sg11
Vunilateral retinoblastoma
p14406
sg13
I2
sasa(dp14407
g2
S'Maternal homozygosity for a polymorphism in the DHFR gene necessary for converting synthetic folic acid into biologic folate was associated with an increased risk for retinoblastoma.\n'
p14408
sg4
(lp14409
(dp14410
g7
I48
sg8
VP00374
p14411
sg10
I9
sg11
VDHFR gene
p14412
sg13
I2
sasg14
(lp14413
(dp14414
g7
I167
sg17
VC0035335
p14415
sg10
I14
sg11
Vretinoblastoma
p14416
sg13
I1
sasa(dp14417
g2
S'To explore the role of Major Vault Protein (MVP) in oral cavity squamous cell carcinoma patients.\n'
p14418
sg4
(lp14419
(dp14420
g7
I23
sg8
g9
sg10
I19
sg11
VMajor Vault Protein
p14421
sg13
I3
sa(dp14422
g7
I44
sg8
g9
sg10
I3
sg11
VMVP
p14423
sg13
I1
sasg14
(lp14424
(dp14425
g7
I23
sg17
VC0026267
p14426
sg10
I19
sg11
VMajor Vault Protein
p14427
sg13
I3
sa(dp14428
g7
I44
sg17
VC0026267
p14429
sg10
I3
sg11
VMVP
p14430
sg13
I1
sa(dp14431
g7
I52
sg17
VC0585362
p14432
sg10
I35
sg11
Voral cavity squamous cell carcinoma
p14433
sg13
I5
sasa(dp14434
g2
S'Molecular analysis of the GYS2 gene was not feasible, but this particular gene was included in the panel of hypoglycemia of whole exome sequencing (WES) which was at our disposal.\n'
p14435
sg4
(lp14436
(dp14437
g7
I26
sg8
VP54840
p14438
sg10
I9
sg11
VGYS2 gene
p14439
sg13
I2
sasg14
(lp14440
(dp14441
g7
I108
sg17
VC0020615
p14442
sg10
I12
sg11
Vhypoglycemia
p14443
sg13
I1
sasa(dp14444
g2
S'To understand the frequency of GSD0 in patients presenting with ketotic hypoglycaemia and to report a novel mutation in the GYS2 gene.\n'
p14445
sg4
(lp14446
(dp14447
g7
I124
sg8
VP54840
p14448
sg10
I9
sg11
VGYS2 gene
p14449
sg13
I2
sasg14
(lp14450
(dp14451
g7
I64
sg17
VC0271713
p14452
sg10
I21
sg11
Vketotic hypoglycaemia
p14453
sg13
I2
sa(dp14454
g7
I102
sg17
VC2985438
p14455
sg10
I14
sg11
Vnovel mutation
p14456
sg13
I2
sasa(dp14457
g2
S'The GYS2 gene was sequenced in 50 patients diagnosed with ketotic hypoglycaemia.\n'
p14458
sg4
(lp14459
(dp14460
g7
I4
sg8
VP54840
p14461
sg10
I9
sg11
VGYS2 gene
p14462
sg13
I2
sasg14
(lp14463
(dp14464
g7
I58
sg17
VC0271713
p14465
sg10
I21
sg11
Vketotic hypoglycaemia
p14466
sg13
I2
sasa(dp14467
g2
S'Sequencing of the GYS2 gene is more likely to be positive in patients with fasting ketotic hypoglycaemia and concomitant postprandial hyperglycaemia with hyperlactataemia.\n'
p14468
sg4
(lp14469
(dp14470
g7
I18
sg8
VP54840
p14471
sg10
I9
sg11
VGYS2 gene
p14472
sg13
I2
sasg14
(lp14473
(dp14474
g7
I83
sg17
VC0271713
p14475
sg10
I21
sg11
Vketotic hypoglycaemia
p14476
sg13
I2
sa(dp14477
g7
I134
sg17
VC0020456
p14478
sg10
I14
sg11
Vhyperglycaemia
p14479
sg13
I1
sasa(dp14480
g2
S'Biochemical evaluation as well as direct sequencing of exons and exon-intron boundary regions of the GYS2 gene were performed in a patient presenting fasting hypoglycemia and postprandial hyperglycemia and her parents.\n'
p14481
sg4
(lp14482
(dp14483
g7
I101
sg8
VP54840
p14484
sg10
I9
sg11
VGYS2 gene
p14485
sg13
I2
sasg14
(lp14486
(dp14487
g7
I188
sg17
VC0020456
p14488
sg10
I13
sg11
Vhyperglycemia
p14489
sg13
I1
sa(dp14490
g7
I150
sg17
VC0271708
p14491
sg10
I20
sg11
Vfasting hypoglycemia
p14492
sg13
I2
sasa(dp14493
g2
S'A 7 year-old boy presenting with growth retardation, fasting hypoglycemia and ketoacidosis was diagnosed as having both idiopathic growth hormone (GH) deficiency and hepatic glycogen synthase (GS) deficiency caused by a homozygous mutation in exon 5 of the liver glycogen synthase gene (GYS-2).\n'
p14494
sg4
(lp14495
(dp14496
g7
I120
sg8
VP01242
p14497
sg10
I25
sg11
Vidiopathic growth hormone
p14498
sg13
I3
sa(dp14499
g7
I287
sg8
VP13807
p14500
sg10
I5
sg11
VGYS-2
p14501
sg13
I1
sa(dp14502
g7
I263
sg8
VP13807
p14503
sg10
I22
sg11
Vglycogen synthase gene
p14504
sg13
I3
sa(dp14505
g7
I193
sg8
VP15104
p14506
sg10
I2
sg11
VGS
p14507
sg13
I1
sa(dp14508
g7
I166
sg8
g9
sg10
I25
sg11
Vhepatic glycogen synthase
p14509
sg13
I3
sasg14
(lp14510
(dp14511
g7
I53
sg17
VC0271708
p14512
sg10
I20
sg11
Vfasting hypoglycemia
p14513
sg13
I2
sa(dp14514
g7
I78
sg17
VC0220982
p14515
sg10
I12
sg11
Vketoacidosis
p14516
sg13
I1
sa(dp14517
g7
I33
sg17
VC0151686
p14518
sg10
I18
sg11
Vgrowth retardation
p14519
sg13
I2
sasa(dp14520
g2
S'GPB dosed at 6 mL BID lowered fasting ammonia levels in cirrhotic patients with HE as compared with baseline, was better tolerated than 9 mL BID, and is appropriate for further evaluation in patients with cirrhosis and episodic HE.\n'
p14521
sg4
(lp14522
sg14
(lp14523
(dp14524
g7
I205
sg17
VC0023890
p14525
sg10
I9
sg11
Vcirrhosis
p14526
sg13
I1
sasa(dp14527
g2
S'GPB reduced HE events as well as ammonia in patients with cirrhosis and HE and its safety profile was similar to placebo.\n'
p14528
sg4
(lp14529
sg14
(lp14530
(dp14531
g7
I58
sg17
VC0023890
p14532
sg10
I9
sg11
Vcirrhosis
p14533
sg13
I1
sasa(dp14534
g2
S'In vitro and clinical studies have been performed to assess GPB digestion, safety, and pharmacology in healthy adults and individuals with cirrhosis.\n'
p14535
sg4
(lp14536
sg14
(lp14537
(dp14538
g7
I139
sg17
VC0023890
p14539
sg10
I9
sg11
Vcirrhosis
p14540
sg13
I1
sasa(dp14541
g2
S'GPB exhibits delayed release characteristics, presumably reflecting gradual PBA release by pancreatic lipases, and is well tolerated in adults with cirrhosis, suggesting that further clinical testing for HE is warranted.\n'
p14542
sg4
(lp14543
(dp14544
g7
I0
sg8
VP06028
p14545
sg10
I3
sg11
VGPB
p14546
sg13
I1
sa(dp14547
g7
I102
sg8
VP04118
p14548
sg10
I7
sg11
Vlipases
p14549
sg13
I1
sasg14
(lp14550
(dp14551
g7
I148
sg17
VC0023890
p14552
sg10
I9
sg11
Vcirrhosis
p14553
sg13
I1
sasa(dp14554
g2
S'However, the role of S1PR1 in the progression of human acute myeloid leukemia (AML) remains to be fully elucidated.\n'
p14555
sg4
(lp14556
(dp14557
g7
I21
sg8
VP21453
p14558
sg10
I5
sg11
VS1PR1
p14559
sg13
I1
sasg14
(lp14560
(dp14561
g7
I79
sg17
VC0023467
p14562
sg10
I3
sg11
VAML
p14563
sg13
I1
sa(dp14564
g7
I55
sg17
VC0023467
p14565
sg10
I22
sg11
Vacute myeloid leukemia
p14566
sg13
I3
sasa(dp14567
g2
S'Using overexpression and RNA interference knockdown assays, it was shown that the expression of S1PR1 in several human myeloid leukemia cell lines contributed to the suppression of cell apoptosis and promotion of cell proliferation.\n'
p14568
sg4
(lp14569
(dp14570
g7
I96
sg8
VP21453
p14571
sg10
I5
sg11
VS1PR1
p14572
sg13
I1
sasg14
(lp14573
(dp14574
g7
I218
sg17
VC0334094
p14575
sg10
I13
sg11
Vproliferation
p14576
sg13
I1
sa(dp14577
g7
I166
sg17
VC0221103
p14578
sg10
I11
sg11
Vsuppression
p14579
sg13
I1
sa(dp14580
g7
I119
sg17
VC0023470
p14581
sg10
I16
sg11
Vmyeloid leukemia
p14582
sg13
I2
sasa(dp14583
g2
S'Circulating chronic lymphocytic leukemia (CLL) cells display an abnormal increase in the surface levels of the homing receptors CCR7 and CXCR4 concomitant with low S1P receptor 1 (S1P1) expression.\n'
p14584
sg4
(lp14585
(dp14586
g7
I128
sg8
VP32248
p14587
sg10
I4
sg11
VCCR7
p14588
sg13
I1
sa(dp14589
g7
I164
sg8
g9
sg10
I14
sg11
VS1P receptor 1
p14590
sg13
I3
sa(dp14591
g7
I137
sg8
VP61073
p14592
sg10
I5
sg11
VCXCR4
p14593
sg13
I1
sa(dp14594
g7
I180
sg8
g9
sg10
I4
sg11
VS1P1
p14595
sg13
I1
sasg14
(lp14596
(dp14597
g7
I12
sg17
VC0023434
p14598
sg10
I28
sg11
Vchronic lymphocytic leukemia
p14599
sg13
I3
sa(dp14600
g7
I42
sg17
VC0023434
p14601
sg10
I3
sg11
VCLL
p14602
sg13
I1
sasa(dp14603
g2
S'Previous work in our laboratory identified keratin 17 (K17) as a specific and sensitive biomarker for high-grade squamous intraepithelial lesions and cervical squamous cell carcinoma (SCC).\n'
p14604
sg4
(lp14605
(dp14606
g7
I55
sg8
VP02533
p14607
sg10
I3
sg11
VK17
p14608
sg13
I1
sa(dp14609
g7
I43
sg8
VP02533
p14610
sg10
I10
sg11
Vkeratin 17
p14611
sg13
I2
sasg14
(lp14612
(dp14613
g7
I150
sg17
VC0279671
p14614
sg10
I32
sg11
Vcervical squamous cell carcinoma
p14615
sg13
I4
sasa(dp14616
g2
S'In this study, we show that high expression of keratin-17 (K17) predicts poor outcome in patients with cervical cancer, at early or late stages of disease, surpassing in accuracy either tumor staging or loss of p27(KIP1) as a negative prognostic marker in this setting.\n'
p14617
sg4
(lp14618
(dp14619
g7
I47
sg8
VP02533
p14620
sg10
I10
sg11
Vkeratin-17
p14621
sg13
I1
sa(dp14622
g7
I211
sg8
VP40305
p14623
sg10
I3
sg11
Vp27
p14624
sg13
I1
sa(dp14625
g7
I59
sg8
VP02533
p14626
sg10
I3
sg11
VK17
p14627
sg13
I1
sa(dp14628
g7
I215
sg8
VP46527
p14629
sg10
I4
sg11
VKIP1
p14630
sg13
I1
sasg14
(lp14631
(dp14632
g7
I103
sg17
VC0302592
p14633
sg10
I15
sg11
Vcervical cancer
p14634
sg13
I2
sa(dp14635
g7
I186
sg17
VC0027651
p14636
sg10
I5
sg11
Vtumor
p14637
sg13
I1
sasa(dp14638
g2
S'In summary, both KRT4 and KRT17 expressions are related to the histopathology of the cervical squamous mucosa; KRT17 is highly overexpressed in immature squamous metaplasia, in HSIL, and in squamous cell carcinoma and the level of KRT17 in squamous cell carcinoma may help to identify patients who are at greatest risk for cervical cancer mortality.\n'
p14639
sg4
(lp14640
(dp14641
g7
I17
sg8
VP19013
p14642
sg10
I4
sg11
VKRT4
p14643
sg13
I1
sasg14
(lp14644
(dp14645
g7
I323
sg17
VC0302592
p14646
sg10
I15
sg11
Vcervical cancer
p14647
sg13
I2
sa(dp14648
g7
I153
sg17
VC0025570
p14649
sg10
I19
sg11
Vsquamous metaplasia
p14650
sg13
I2
sa(dp14651
g7
I177
sg17
VC0333875
p14652
sg10
I4
sg11
VHSIL
p14653
sg13
I1
sa(dp14654
g7
I190
sg17
VC0007137
p14655
sg10
I23
sg11
Vsquamous cell carcinoma
p14656
sg13
I3
sa(dp14657
g7
I190
sg17
VC0007137
p14658
sg10
I23
sg11
Vsquamous cell carcinoma
p14659
sg13
I3
sasa(dp14660
g2
S'P2X4 receptors in microglia are up-regulated in epilepsy and in neuropathic pain; that is to say, their total and/or PM expression levels increase.\n'
p14661
sg4
(lp14662
(dp14663
g7
I0
sg8
g9
sg10
I14
sg11
VP2X4 receptors
p14664
sg13
I2
sasg14
(lp14665
(dp14666
g7
I48
sg17
VC0014544
p14667
sg10
I8
sg11
Vepilepsy
p14668
sg13
I1
sa(dp14669
g7
I64
sg17
VC0027796
p14670
sg10
I16
sg11
Vneuropathic pain
p14671
sg13
I2
sasa(dp14672
g2
S'Expression of several members of the family including P2X2, P2X4, and P2X7 receptors has been reported to be altered in the hippocampus following status epilepticus.\n'
p14673
sg4
(lp14674
(dp14675
g7
I70
sg8
g9
sg10
I14
sg11
VP2X7 receptors
p14676
sg13
I2
sasg14
(lp14677
(dp14678
g7
I146
sg17
VC0038220
p14679
sg10
I18
sg11
Vstatus epilepticus
p14680
sg13
I2
sasa(dp14681
g2
S'Recent work also found altered neuronal injury and inflammation after status epilepticus in mice lacking the P2X4 receptor.\n'
p14682
sg4
(lp14683
(dp14684
g7
I109
sg8
g9
sg10
I13
sg11
VP2X4 receptor
p14685
sg13
I2
sasg14
(lp14686
(dp14687
g7
I70
sg17
VC0038220
p14688
sg10
I18
sg11
Vstatus epilepticus
p14689
sg13
I2
sa(dp14690
g7
I51
sg17
VC0021368
p14691
sg10
I12
sg11
Vinflammation
p14692
sg13
I1
sasa(dp14693
g2
S'In this study, we investigated the potential involvement of P2X4R in microglial functions in a model of kainate (KA)-induced status epilepticus (SE).\n'
p14694
sg4
(lp14695
(dp14696
g7
I60
sg8
g9
sg10
I5
sg11
VP2X4R
p14697
sg13
I1
sasg14
(lp14698
(dp14699
g7
I125
sg17
VC0038220
p14700
sg10
I18
sg11
Vstatus epilepticus
p14701
sg13
I2
sa(dp14702
g7
I145
sg17
VC0038220
p14703
sg10
I2
sg11
VSE
p14704
sg13
I1
sasa(dp14705
g2
S'Here we show that, in the seizure-sensitive (SS) gerbil hippocampus, a recognized genetic epilepsy model, the expressions of both P2X2 and P2X4 receptors are markedly decreased as compared with that in the seizure-resistant (SR) gerbil.\n'
p14706
sg4
(lp14707
(dp14708
g7
I139
sg8
g9
sg10
I14
sg11
VP2X4 receptors
p14709
sg13
I2
sasg14
(lp14710
(dp14711
g7
I26
sg17
VC0036572
p14712
sg10
I7
sg11
Vseizure
p14713
sg13
I1
sa(dp14714
g7
I26
sg17
VC0036572
p14715
sg10
I7
sg11
Vseizure
p14716
sg13
I1
sa(dp14717
g7
I90
sg17
VC0014544
p14718
sg10
I8
sg11
Vepilepsy
p14719
sg13
I1
sasa(dp14720
g2
S'In addition to pathogen recognition, DCIR has been shown to be pivotal in preventing autoimmune disease by controlling dendritic cell proliferation.\n'
p14721
sg4
(lp14722
(dp14723
g7
I37
sg8
g9
sg10
I4
sg11
VDCIR
p14724
sg13
I1
sasg14
(lp14725
(dp14726
g7
I134
sg17
VC0334094
p14727
sg10
I13
sg11
Vproliferation
p14728
sg13
I1
sa(dp14729
g7
I85
sg17
VC0004364
p14730
sg10
I18
sg11
Vautoimmune disease
p14731
sg13
I2
sasa(dp14732
g2
S'This study was aimed to further investigate whether DCIR polymorphisms are novel susceptibility factors for other autoimmune diseases, i.e.\n'
p14733
sg4
(lp14734
sg14
(lp14735
(dp14736
g7
I114
sg17
VC0004364
p14737
sg10
I19
sg11
Vautoimmune diseases
p14738
sg13
I2
sasa(dp14739
g2
S'Tubulointerstitial nephritis and uveitis syndrome, HLA-B27-associated uveitis, inflammatory bowel disease, and Kawasaki disease each made up fewer than 5% of diagnoses.\n'
p14740
sg4
(lp14741
(dp14742
g7
I51
sg8
VP30486
p14743
sg10
I7
sg11
VHLA-B27
p14744
sg13
I1
sasg14
(lp14745
(dp14746
g7
I0
sg17
VC1639520
p14747
sg10
I49
sg11
VTubulointerstitial nephritis and uveitis syndrome
p14748
sg13
I5
sa(dp14749
g7
I79
sg17
VC0021390
p14750
sg10
I26
sg11
Vinflammatory bowel disease
p14751
sg13
I3
sa(dp14752
g7
I33
sg17
VC0042164
p14753
sg10
I7
sg11
Vuveitis
p14754
sg13
I1
sa(dp14755
g7
I111
sg17
VC0026691
p14756
sg10
I16
sg11
VKawasaki disease
p14757
sg13
I2
sasa(dp14758
g2
S'Stromal tissue was isolated from epithelial cells with laser capture microdissection (LCMD) and analyzed by cDNA array for the expression of TGFalpha, TGF-beta1, HGF, PDGF-alpha, IGFII, bFGF, aFGF, VEGFC, and VEGF.\n'
p14759
sg4
(lp14760
(dp14761
g7
I151
sg8
VP01137
p14762
sg10
I9
sg11
VTGF-beta1
p14763
sg13
I1
sa(dp14764
g7
I192
sg8
VP05230
p14765
sg10
I4
sg11
VaFGF
p14766
sg13
I1
sa(dp14767
g7
I198
sg8
VP49767
p14768
sg10
I5
sg11
VVEGFC
p14769
sg13
I1
sa(dp14770
g7
I141
sg8
VP01135
p14771
sg10
I8
sg11
VTGFalpha
p14772
sg13
I1
sa(dp14773
g7
I167
sg8
VP04085
p14774
sg10
I10
sg11
VPDGF-alpha
p14775
sg13
I1
sa(dp14776
g7
I162
sg8
VP05231
p14777
sg10
I3
sg11
VHGF
p14778
sg13
I1
sa(dp14779
g7
I186
sg8
VP53370
p14780
sg10
I4
sg11
VbFGF
p14781
sg13
I1
sa(dp14782
g7
I179
sg8
VP01344
p14783
sg10
I5
sg11
VIGFII
p14784
sg13
I1
sasg14
(lp14785
(dp14786
g7
I162
sg17
VC0399440
p14787
sg10
I3
sg11
VHGF
p14788
sg13
I1
sasa(dp14789
g2
S'Here, we demonstrate that Inositol Polyphosphate-5-Phosphatase F (INPP5F), one of the polyphosphoinositide phosphatases, is differentially expressed in GSCs from glioma patients, and is identified as an inhibitor of STAT3 signaling via interaction with STAT3 and inhibition of its phosphorylation.\n'
p14790
sg4
(lp14791
(dp14792
g7
I66
sg8
g9
sg10
I6
sg11
VINPP5F
p14793
sg13
I1
sa(dp14794
g7
I216
sg8
VP40763
p14795
sg10
I5
sg11
VSTAT3
p14796
sg13
I1
sa(dp14797
g7
I216
sg8
VP40763
p14798
sg10
I5
sg11
VSTAT3
p14799
sg13
I1
sa(dp14800
g7
I26
sg8
g9
sg10
I38
sg11
VInositol Polyphosphate-5-Phosphatase F
p14801
sg13
I3
sasg14
(lp14802
(dp14803
g7
I162
sg17
VC0017638
p14804
sg10
I6
sg11
Vglioma
p14805
sg13
I1
sasa(dp14806
g2
S'In addition, loss of INPP5F gene in gliomas is significantly correlated with lower overall patient survivals.\n'
p14807
sg4
(lp14808
(dp14809
g7
I21
sg8
g9
sg10
I11
sg11
VINPP5F gene
p14810
sg13
I2
sasg14
(lp14811
(dp14812
g7
I36
sg17
VC0017638
p14813
sg10
I7
sg11
Vgliomas
p14814
sg13
I1
sasa(dp14815
g2
S'These findings suggest that INPP5F is a potential tumor suppressor in gliomas via inhibition of STAT3 pathway, and that deregulation of INPP5F may lead to contribution to gliomagenesis.\n'
p14816
sg4
(lp14817
(dp14818
g7
I28
sg8
g9
sg10
I6
sg11
VINPP5F
p14819
sg13
I1
sa(dp14820
g7
I96
sg8
VP40763
p14821
sg10
I5
sg11
VSTAT3
p14822
sg13
I1
sa(dp14823
g7
I28
sg8
g9
sg10
I6
sg11
VINPP5F
p14824
sg13
I1
sasg14
(lp14825
(dp14826
g7
I70
sg17
VC0017638
p14827
sg10
I7
sg11
Vgliomas
p14828
sg13
I1
sa(dp14829
g7
I50
sg17
VC0027651
p14830
sg10
I5
sg11
Vtumor
p14831
sg13
I1
sasa(dp14832
g2
S'The patient and his identical twin show a retinal dystrophy that, based on clinical appearance, visual fields, amd electrophysiology, is most likely autosomal recessive retinitis pigmentosa.\n'
p14833
sg4
(lp14834
sg14
(lp14835
(dp14836
g7
I42
sg17
VC0854723
p14837
sg10
I17
sg11
Vretinal dystrophy
p14838
sg13
I2
sa(dp14839
g7
I149
sg17
VC0339526
p14840
sg10
I40
sg11
Vautosomal recessive retinitis pigmentosa
p14841
sg13
I4
sa(dp14842
g7
I111
sg17
VC0242383
p14843
sg10
I3
sg11
Vamd
p14844
sg13
I1
sasa(dp14845
g2
S'Although Gln supplementation had no effect on the loss of the tight junction protein occludin, the increased portal endotoxin and fasting glucose concentrations found in WSD-fed mice, markers of liver damage (e.g., nonalcoholic fatty liver disease activity score and number of neutrophils in the liver) were significantly lower in the WSD+Gln group than in the WSD group (~47% and ~60% less, respectively; P &lt; 0.05).\n'
p14846
sg4
(lp14847
(dp14848
g7
I109
sg8
g9
sg10
I16
sg11
Vportal endotoxin
p14849
sg13
I2
sasg14
(lp14850
(dp14851
g7
I215
sg17
VC0400966
p14852
sg10
I32
sg11
Vnonalcoholic fatty liver disease
p14853
sg13
I4
sa(dp14854
g7
I195
sg17
VC0151763
p14855
sg10
I12
sg11
Vliver damage
p14856
sg13
I2
sasa(dp14857
g2
S'The purpose of this Evidence-Based Practice (EBP) paper is to answer PICOT questions by a review the effectiveness of chronotherapeutics interventions on depressive symptoms with depression and the depressive episode in the course of bipolar disorder.\n'
p14858
sg4
(lp14859
sg14
(lp14860
(dp14861
g7
I179
sg17
VC0011581
p14862
sg10
I10
sg11
Vdepression
p14863
sg13
I1
sa(dp14864
g7
I234
sg17
VC0005586
p14865
sg10
I16
sg11
Vbipolar disorder
p14866
sg13
I2
sa(dp14867
g7
I154
sg17
VC0086132
p14868
sg10
I19
sg11
Vdepressive symptoms
p14869
sg13
I2
sa(dp14870
g7
I198
sg17
VC0349217
p14871
sg10
I18
sg11
Vdepressive episode
p14872
sg13
I2
sasa(dp14873
g2
S'We evaluated whether post-bronchiolitis asthma was associated with polymorphisms in the TLR3 rs3775291, TLR4 rs4986790, TLR7 rs179008, TLR8 rs2407992, TLR9 rs187084, and TLR10 rs4129009 genes.\n'
p14874
sg4
(lp14875
(dp14876
g7
I151
sg8
g9
sg10
I13
sg11
VTLR9 rs187084
p14877
sg13
I2
sa(dp14878
g7
I170
sg8
g9
sg10
I21
sg11
VTLR10 rs4129009 genes
p14879
sg13
I3
sa(dp14880
g7
I135
sg8
g9
sg10
I14
sg11
VTLR8 rs2407992
p14881
sg13
I2
sa(dp14882
g7
I88
sg8
g9
sg10
I14
sg11
VTLR3 rs3775291
p14883
sg13
I2
sa(dp14884
g7
I120
sg8
g9
sg10
I13
sg11
VTLR7 rs179008
p14885
sg13
I2
sasg14
(lp14886
(dp14887
g7
I40
sg17
VC0004096
p14888
sg10
I6
sg11
Vasthma
p14889
sg13
I1
sa(dp14890
g7
I26
sg17
VC0006271
p14891
sg10
I13
sg11
Vbronchiolitis
p14892
sg13
I1
sasa(dp14893
g2
S'There were no significant associations between TLR3, TLR4, TLR8, or TLR9 polymorphisms and post-bronchiolitis asthma.\n'
p14894
sg4
(lp14895
(dp14896
g7
I68
sg8
g9
sg10
I4
sg11
VTLR9
p14897
sg13
I1
sa(dp14898
g7
I59
sg8
g9
sg10
I4
sg11
VTLR8
p14899
sg13
I1
sa(dp14900
g7
I47
sg8
g9
sg10
I4
sg11
VTLR3
p14901
sg13
I1
sasg14
(lp14902
(dp14903
g7
I110
sg17
VC0004096
p14904
sg10
I6
sg11
Vasthma
p14905
sg13
I1
sa(dp14906
g7
I96
sg17
VC0006271
p14907
sg10
I13
sg11
Vbronchiolitis
p14908
sg13
I1
sasa(dp14909
g2
S'Significant associations with SAFS compared with atopic asthma included Toll-like receptor 3 (TLR3) (p = .009), TLR9 (p = .025), C-type lectin domain family seven member A (dectin-1) (p = .043), interleukin-10 (IL-10) (p = .0010), mannose-binding lectin (MBL2) (p = .007), CC-chemokine ligand 2 (CCL2) (2 SNPs, p = .025 and .041), CCL17 (p = .002), plasminogen (p = .049) and adenosine A2a receptor (p = .024).\n'
p14910
sg4
(lp14911
(dp14912
g7
I211
sg8
VP22301
p14913
sg10
I5
sg11
VIL-10
p14914
sg13
I1
sa(dp14915
g7
I94
sg8
g9
sg10
I4
sg11
VTLR3
p14916
sg13
I1
sa(dp14917
g7
I129
sg8
g9
sg10
I42
sg11
VC-type lectin domain family seven member A
p14918
sg13
I7
sa(dp14919
g7
I195
sg8
VP22301
p14920
sg10
I14
sg11
Vinterleukin-10
p14921
sg13
I1
sa(dp14922
g7
I376
sg8
VP29274
p14923
sg10
I22
sg11
Vadenosine A2a receptor
p14924
sg13
I3
sa(dp14925
g7
I349
sg8
VP00747
p14926
sg10
I11
sg11
Vplasminogen
p14927
sg13
I1
sa(dp14928
g7
I112
sg8
g9
sg10
I4
sg11
VTLR9
p14929
sg13
I1
sa(dp14930
g7
I72
sg8
g9
sg10
I20
sg11
VToll-like receptor 3
p14931
sg13
I3
sa(dp14932
g7
I255
sg8
VP11226
p14933
sg10
I4
sg11
VMBL2
p14934
sg13
I1
sa(dp14935
g7
I331
sg8
g9
sg10
I5
sg11
VCCL17
p14936
sg13
I1
sa(dp14937
g7
I296
sg8
VP13500
p14938
sg10
I4
sg11
VCCL2
p14939
sg13
I1
sa(dp14940
g7
I231
sg8
VP11226
p14941
sg10
I22
sg11
Vmannose-binding lectin
p14942
sg13
I2
sa(dp14943
g7
I273
sg8
VP51671
p14944
sg10
I21
sg11
VCC-chemokine ligand 2
p14945
sg13
I3
sasg14
(lp14946
(dp14947
g7
I49
sg17
VC0155877
p14948
sg10
I13
sg11
Vatopic asthma
p14949
sg13
I2
sasa(dp14950
g2
S'Asthmatics had significantly lower circulating HPC expressing TLR-2 and TLR-9 with a similar trend for TLR-4.\n'
p14951
sg4
(lp14952
(dp14953
g7
I47
sg8
g9
sg10
I3
sg11
VHPC
p14954
sg13
I1
sa(dp14955
g7
I62
sg8
g9
sg10
I5
sg11
VTLR-2
p14956
sg13
I1
sa(dp14957
g7
I72
sg8
g9
sg10
I5
sg11
VTLR-9
p14958
sg13
I1
sasg14
(lp14959
(dp14960
g7
I47
sg17
VC0238339
p14961
sg10
I3
sg11
VHPC
p14962
sg13
I1
sa(dp14963
g7
I0
sg17
VC0004096
p14964
sg10
I10
sg11
VAsthmatics
p14965
sg13
I1
sasa(dp14966
g2
S'The endosomal TLRs have been shown to be associated with the induction of asthmatic inflammation (TLR3), and with disease exacerbations (TLR7, TLR8 and TLR9).\n'
p14967
sg4
(lp14968
(dp14969
g7
I137
sg8
g9
sg10
I4
sg11
VTLR7
p14970
sg13
I1
sa(dp14971
g7
I152
sg8
g9
sg10
I4
sg11
VTLR9
p14972
sg13
I1
sa(dp14973
g7
I143
sg8
g9
sg10
I4
sg11
VTLR8
p14974
sg13
I1
sa(dp14975
g7
I98
sg8
g9
sg10
I4
sg11
VTLR3
p14976
sg13
I1
sasg14
(lp14977
(dp14978
g7
I84
sg17
VC0021368
p14979
sg10
I12
sg11
Vinflammation
p14980
sg13
I1
sa(dp14981
g7
I74
sg17
VC0004096
p14982
sg10
I9
sg11
Vasthmatic
p14983
sg13
I1
sasa(dp14984
g2
S'A defect in the P-protein component of the glycine cleavage system has been the most frequent abnormality found in patients with glycine encephalopathy (NKH).\n'
p14985
sg4
(lp14986
sg14
(lp14987
(dp14988
g7
I153
sg17
VC0751748
p14989
sg10
I3
sg11
VNKH
p14990
sg13
I1
sa(dp14991
g7
I129
sg17
VC0751748
p14992
sg10
I22
sg11
Vglycine encephalopathy
p14993
sg13
I2
sasa(dp14994
g2
S'Soluble tumor necrosis factor receptor 1 (sTNF-R1), interleukin-1 receptor antagonist (IL-1Ra), von Willebrand factor (VWF), and osteoprotegerin (OPG) were measured in schizophrenia (n = 69) and affective (n = 55) spectrum patients at baseline and at one-year follow-up, and compared to healthy controls (HC) (n = 92) with analysis of covariance.\n'
p14995
sg4
(lp14996
(dp14997
g7
I96
sg8
VP04275
p14998
sg10
I21
sg11
Vvon Willebrand factor
p14999
sg13
I3
sa(dp15000
g7
I129
sg8
g9
sg10
I15
sg11
Vosteoprotegerin
p15001
sg13
I1
sa(dp15002
g7
I52
sg8
VP18510
p15003
sg10
I33
sg11
Vinterleukin-1 receptor antagonist
p15004
sg13
I3
sa(dp15005
g7
I0
sg8
g9
sg10
I40
sg11
VSoluble tumor necrosis factor receptor 1
p15006
sg13
I6
sa(dp15007
g7
I146
sg8
g9
sg10
I3
sg11
VOPG
p15008
sg13
I1
sa(dp15009
g7
I87
sg8
VP18510
p15010
sg10
I6
sg11
VIL-1Ra
p15011
sg13
I1
sa(dp15012
g7
I119
sg8
VP04275
p15013
sg10
I3
sg11
VVWF
p15014
sg13
I1
sa(dp15015
g7
I42
sg8
g9
sg10
I7
sg11
VsTNF-R1
p15016
sg13
I1
sasg14
(lp15017
(dp15018
g7
I168
sg17
VC0036341
p15019
sg10
I13
sg11
Vschizophrenia
p15020
sg13
I1
sa(dp15021
g7
I8
sg17
VC0333516
p15022
sg10
I14
sg11
Vtumor necrosis
p15023
sg13
I2
sasa(dp15024
g2
S'Serum sTNFR1 was significantly higher in patients with acute-stage schizophrenia compared to matched controls while no significant group differences were observed for the other markers.\n'
p15025
sg4
(lp15026
sg14
(lp15027
(dp15028
g7
I67
sg17
VC0036341
p15029
sg10
I13
sg11
Vschizophrenia
p15030
sg13
I1
sasa(dp15031
g2
S'Plasma levels of soluble tumor necrosis factor receptor 1 (sTNF-R1), interleukin 1 receptor antagonist (IL-1Ra), osteoprotegerin (OPG), and von Willebrand factor (vWf) were measured in patients (n=992) with schizophrenia spectrum (SCZ, n=584), schizoaffective disorder (SA, n=93), affective spectrum disorders (AFF, n=315), and healthy controls (HC, n=638).\n'
p15032
sg4
(lp15033
(dp15034
g7
I163
sg8
VP04275
p15035
sg10
I3
sg11
VvWf
p15036
sg13
I1
sa(dp15037
g7
I17
sg8
g9
sg10
I40
sg11
Vsoluble tumor necrosis factor receptor 1
p15038
sg13
I6
sa(dp15039
g7
I104
sg8
VP18510
p15040
sg10
I6
sg11
VIL-1Ra
p15041
sg13
I1
sa(dp15042
g7
I130
sg8
g9
sg10
I3
sg11
VOPG
p15043
sg13
I1
sa(dp15044
g7
I59
sg8
g9
sg10
I7
sg11
VsTNF-R1
p15045
sg13
I1
sa(dp15046
g7
I69
sg8
VP18510
p15047
sg10
I33
sg11
Vinterleukin 1 receptor antagonist
p15048
sg13
I4
sa(dp15049
g7
I140
sg8
VP04275
p15050
sg10
I21
sg11
Vvon Willebrand factor
p15051
sg13
I3
sa(dp15052
g7
I113
sg8
g9
sg10
I15
sg11
Vosteoprotegerin
p15053
sg13
I1
sasg14
(lp15054
(dp15055
g7
I244
sg17
VC0036337
p15056
sg10
I24
sg11
Vschizoaffective disorder
p15057
sg13
I2
sa(dp15058
g7
I25
sg17
VC0333516
p15059
sg10
I14
sg11
Vtumor necrosis
p15060
sg13
I2
sa(dp15061
g7
I270
sg17
VC0036337
p15062
sg10
I2
sg11
VSA
p15063
sg13
I1
sa(dp15064
g7
I207
sg17
VC0036341
p15065
sg10
I13
sg11
Vschizophrenia
p15066
sg13
I1
sasa(dp15067
g2
S'The low-molecular-weight fraction of 5% human serum albumin (LMWF-5A) is being developed to treat the signs and symptoms of severe osteoarthritis of the knee.\n'
p15068
sg4
(lp15069
(dp15070
g7
I37
sg8
g9
sg10
I22
sg11
V5% human serum albumin
p15071
sg13
I4
sasg14
(lp15072
(dp15073
g7
I131
sg17
VC0029408
p15074
sg10
I14
sg11
Vosteoarthritis
p15075
sg13
I1
sa(dp15076
g7
I102
sg17
VC0037088
p15077
sg10
I18
sg11
Vsigns and symptoms
p15078
sg13
I3
sasa(dp15079
g2
S'MIS includes 10 components: dry weight changes, dietary intake, functional capacity, comorbidity, muscle wasting and loss of subcutaneous fat as well as body mass index (BMI), serum albumin level and total iron binding capacity (TIBC).\n'
p15080
sg4
(lp15081
(dp15082
g7
I176
sg8
g9
sg10
I13
sg11
Vserum albumin
p15083
sg13
I2
sasg14
(lp15084
(dp15085
g7
I98
sg17
VC0026846
p15086
sg10
I14
sg11
Vmuscle wasting
p15087
sg13
I2
sasa(dp15088
g2
S'This study suggests that consecutive PNC contributed to the improvement of the protein intake, serum levels of albumin, cholesterol and to the delay of muscle wasting, which could also have a positive impact on the nutritional status, particularly in malnourished patients receiving HD treatment.\n'
p15089
sg4
(lp15090
(dp15091
g7
I111
sg8
VP00441
p15092
sg10
I7
sg11
Valbumin
p15093
sg13
I1
sasg14
(lp15094
(dp15095
g7
I152
sg17
VC0026846
p15096
sg10
I14
sg11
Vmuscle wasting
p15097
sg13
I2
sa(dp15098
g7
I251
sg17
VC0162429
p15099
sg10
I12
sg11
Vmalnourished
p15100
sg13
I1
sasa(dp15101
g2
S'GCs = glucocorticoids; HDG = high-dose glucocorticoids; A1C = Hemoglobin A1C; GA = Glycated Albumin; FBG = fasting blood glucose; IG = interstitial glucose; BG = blood glucose; GIH = Glucocorticoids-induced hyperglycemia; HOMA-IR = Homeostasis Model Assessment-Insulin Resistance; CGMS = continuous glucose monitoring system; AUC = the area under the curve; MODD = absolute means of daily differences; LAGE = the largest amplitude of glycemic excursions; BMI = body mass index; DM = diabetes mellitus; SLE = systemic lupus erythematosus; IQR = interquartile range; HR = hazard ratio; PUMCH = Peking Union Medical College Hospital.\n'
p15102
sg4
(lp15103
(dp15104
g7
I261
sg8
VP01308
p15105
sg10
I7
sg11
VInsulin
p15106
sg13
I1
sa(dp15107
g7
I62
sg8
g9
sg10
I10
sg11
VHemoglobin
p15108
sg13
I1
sasg14
(lp15109
(dp15110
g7
I502
sg17
VC0024141
p15111
sg10
I3
sg11
VSLE
p15112
sg13
I1
sa(dp15113
g7
I508
sg17
VC0024141
p15114
sg10
I28
sg11
Vsystemic lupus erythematosus
p15115
sg13
I3
sa(dp15116
g7
I483
sg17
VC0011849
p15117
sg10
I17
sg11
Vdiabetes mellitus
p15118
sg13
I2
sa(dp15119
g7
I261
sg17
VC0021655
p15120
sg10
I18
sg11
VInsulin Resistance
p15121
sg13
I2
sa(dp15122
g7
I207
sg17
VC0020456
p15123
sg10
I13
sg11
Vhyperglycemia
p15124
sg13
I1
sasa(dp15125
g2
S'Objective To evaluate the presence and localization of folate receptor expressing macrophages in the rat groove model of osteoarthritis and determine the suitability of a new folate conjugate with albumin-binding entity (cm09) for in vivo SPECT (single-photon emission computed tomography) analysis.\n'
p15126
sg4
(lp15127
(dp15128
g7
I55
sg8
VP15328
p15129
sg10
I15
sg11
Vfolate receptor
p15130
sg13
I2
sa(dp15131
g7
I197
sg8
VP00441
p15132
sg10
I7
sg11
Valbumin
p15133
sg13
I1
sasg14
(lp15134
(dp15135
g7
I121
sg17
VC0029408
p15136
sg10
I14
sg11
Vosteoarthritis
p15137
sg13
I1
sasa(dp15138
g2
S'Results In vivo SPECT/CT imaging of the new folate conjugate (cm09) was as useful as a folate conjugate without albumin-binding entity in the groove model of osteoarthritis with less renal accumulation.\n'
p15139
sg4
(lp15140
(dp15141
g7
I112
sg8
VP00441
p15142
sg10
I7
sg11
Valbumin
p15143
sg13
I1
sasg14
(lp15144
(dp15145
g7
I158
sg17
VC0029408
p15146
sg10
I14
sg11
Vosteoarthritis
p15147
sg13
I1
sasa(dp15148
g2
S'However, the effects of agonistic anti-4-1BB Abs have not been examined in an experimental mouse model of psoriasis.\n'
p15149
sg4
(lp15150
sg14
(lp15151
(dp15152
g7
I106
sg17
VC0033860
p15153
sg10
I9
sg11
Vpsoriasis
p15154
sg13
I1
sasa(dp15155
g2
S'Therefore, we investigated the protective effects of agonistic anti-4-1BB Abs, using imiquimod (IMQ)-induced psoriasis-like dermatitis in mice, a condition histologically and clinically similar to human psoriasis.\n'
p15156
sg4
(lp15157
sg14
(lp15158
(dp15159
g7
I109
sg17
VC0033860
p15160
sg10
I9
sg11
Vpsoriasis
p15161
sg13
I1
sa(dp15162
g7
I109
sg17
VC0033860
p15163
sg10
I9
sg11
Vpsoriasis
p15164
sg13
I1
sa(dp15165
g7
I146
sg17
VC0012634
p15166
sg10
I9
sg11
Vcondition
p15167
sg13
I1
sa(dp15168
g7
I124
sg17
VC0011603
p15169
sg10
I10
sg11
Vdermatitis
p15170
sg13
I1
sasa(dp15171
g2
S'We found that administration of agonistic anti-4-1BB Abs (10mg/kg) significantly alleviated the severity of IMQ-induced psoriasis-like skin inflammation in mice, with reduced histologic symptoms, including inflammatory infiltration, parakeratosis, and hyperkeratosis.\n'
p15172
sg4
(lp15173
sg14
(lp15174
(dp15175
g7
I252
sg17
VC0870082
p15176
sg10
I14
sg11
Vhyperkeratosis
p15177
sg13
I1
sa(dp15178
g7
I233
sg17
VC0030436
p15179
sg10
I13
sg11
Vparakeratosis
p15180
sg13
I1
sa(dp15181
g7
I206
sg17
VC0302158
p15182
sg10
I25
sg11
Vinflammatory infiltration
p15183
sg13
I2
sa(dp15184
g7
I135
sg17
VC0011603
p15185
sg10
I17
sg11
Vskin inflammation
p15186
sg13
I2
sa(dp15187
g7
I120
sg17
VC0033860
p15188
sg10
I9
sg11
Vpsoriasis
p15189
sg13
I1
sasa(dp15190
g2
S'Taken together, our data provide evidence that agonistic anti-4-1BB Abs possesses immunosuppressive properties in IMQ-induced psoriasis-like skin inflammation, providing insight into the immunomodulatory effect of agonistic anti-4-1BB Abs for psoriasis immunotherapy.\n'
p15191
sg4
(lp15192
sg14
(lp15193
(dp15194
g7
I126
sg17
VC0033860
p15195
sg10
I9
sg11
Vpsoriasis
p15196
sg13
I1
sa(dp15197
g7
I72
sg17
VC0850310
p15198
sg10
I9
sg11
Vpossesses
p15199
sg13
I1
sa(dp15200
g7
I141
sg17
VC0011603
p15201
sg10
I17
sg11
Vskin inflammation
p15202
sg13
I2
sa(dp15203
g7
I126
sg17
VC0033860
p15204
sg10
I9
sg11
Vpsoriasis
p15205
sg13
I1
sasa(dp15206
g2
S'Among identified psoriasis risk variants, three were more strongly associated with PsC than PsA (rs12189871 near HLA-C, p = 5.0 x 10(-19); rs4908742 near TNFRSF9, p = 0.00020; rs10888503 near LCE3A, p = 0.0014), and two were more strongly associated with PsA than PsC (rs12044149 near IL23R, p = 0.00018; rs9321623 near TNFAIP3, p = 0.00022).\n'
p15207
sg4
(lp15208
(dp15209
g7
I192
sg8
g9
sg10
I5
sg11
VLCE3A
p15210
sg13
I1
sa(dp15211
g7
I154
sg8
g9
sg10
I7
sg11
VTNFRSF9
p15212
sg13
I1
sa(dp15213
g7
I320
sg8
VP21580
p15214
sg10
I7
sg11
VTNFAIP3
p15215
sg13
I1
sa(dp15216
g7
I113
sg8
VP30486
p15217
sg10
I3
sg11
VHLA
p15218
sg13
I1
sasg14
(lp15219
(dp15220
g7
I83
sg17
VC0566602
p15221
sg10
I3
sg11
VPsC
p15222
sg13
I1
sa(dp15223
g7
I92
sg17
VC1519176
p15224
sg10
I3
sg11
VPsA
p15225
sg13
I1
sa(dp15226
g7
I83
sg17
VC0566602
p15227
sg10
I3
sg11
VPsC
p15228
sg13
I1
sa(dp15229
g7
I92
sg17
VC1519176
p15230
sg10
I3
sg11
VPsA
p15231
sg13
I1
sa(dp15232
g7
I17
sg17
VC0033860
p15233
sg10
I9
sg11
Vpsoriasis
p15234
sg13
I1
sasa(dp15235
g2
S'Interatrial electromechanical delay (IA-EMD) and intra-left atrial electromechanical delay (ILA-EMD) were significantly longer in the psoriasis group compared with controls.\n'
p15236
sg4
(lp15237
(dp15238
g7
I49
sg8
g9
sg10
I41
sg11
Vintra-left atrial electromechanical delay
p15239
sg13
I4
sa(dp15240
g7
I92
sg8
g9
sg10
I7
sg11
VILA-EMD
p15241
sg13
I1
sasg14
(lp15242
(dp15243
g7
I40
sg17
VC0340861
p15244
sg10
I3
sg11
VEMD
p15245
sg13
I1
sa(dp15246
g7
I134
sg17
VC0033860
p15247
sg10
I9
sg11
Vpsoriasis
p15248
sg13
I1
sa(dp15249
g7
I40
sg17
VC0340861
p15250
sg10
I3
sg11
VEMD
p15251
sg13
I1
sasa(dp15252
g2
S'To investigate the expression of the peripheral blood retinoid-related orphan receptor gamma t (RORgamma t) and 4-1BB/4-1BBL mRNA in oral lichen planus (OLP) patients.\n'
p15253
sg4
(lp15254
(dp15255
g7
I71
sg8
VP25106
p15256
sg10
I58
sg11
Vorphan receptor gamma t (RORgamma t) and 4-1BB/4-1BBL mRNA
p15257
sg13
I9
sasg14
(lp15258
(dp15259
g7
I153
sg17
VC0206139
p15260
sg10
I3
sg11
VOLP
p15261
sg13
I1
sa(dp15262
g7
I133
sg17
VC0206139
p15263
sg10
I18
sg11
Voral lichen planus
p15264
sg13
I3
sasa(dp15265
g2
S'Blood and tissue eosinophils from patients with IgE-mediated allergic responses (atopic dermatitis, extrinsic asthma) express CD137.\n'
p15266
sg4
(lp15267
(dp15268
g7
I126
sg8
g9
sg10
I5
sg11
VCD137
p15269
sg13
I1
sa(dp15270
g7
I48
sg8
VP01854
p15271
sg10
I3
sg11
VIgE
p15272
sg13
I1
sasg14
(lp15273
(dp15274
g7
I81
sg17
VC0011615
p15275
sg10
I17
sg11
Vatopic dermatitis
p15276
sg13
I2
sa(dp15277
g7
I100
sg17
VC0155877
p15278
sg10
I16
sg11
Vextrinsic asthma
p15279
sg13
I2
sa(dp15280
g7
I48
sg17
VC0270850
p15281
sg10
I3
sg11
VIgE
p15282
sg13
I1
sasa(dp15283
g2
S'Proteomic analysis revealed 14 statistically significant differentially expressed proteins, with nine showing increased expression (PDIA3, VIM/HEXA, SELENBP1, ENO1, CAPZA1, ERP29, TPI1, PARK7, and FABP3) and five showing decreased expression (EIF2S, PSMA3, RPSA, TUBB, and TUBA1B) in uveal melanomas that subsequently metastasized compared with those that did not.\n'
p15284
sg4
(lp15285
(dp15286
g7
I165
sg8
VP52907
p15287
sg10
I6
sg11
VCAPZA1
p15288
sg13
I1
sa(dp15289
g7
I149
sg8
g9
sg10
I8
sg11
VSELENBP1
p15290
sg13
I1
sa(dp15291
g7
I132
sg8
VP30101
p15292
sg10
I5
sg11
VPDIA3
p15293
sg13
I1
sa(dp15294
g7
I143
sg8
VP06865
p15295
sg10
I4
sg11
VHEXA
p15296
sg13
I1
sa(dp15297
g7
I273
sg8
VP68363
p15298
sg10
I6
sg11
VTUBA1B
p15299
sg13
I1
sa(dp15300
g7
I197
sg8
VP05413
p15301
sg10
I5
sg11
VFABP3
p15302
sg13
I1
sa(dp15303
g7
I173
sg8
VP30040
p15304
sg10
I5
sg11
VERP29
p15305
sg13
I1
sa(dp15306
g7
I250
sg8
VP25788
p15307
sg10
I5
sg11
VPSMA3
p15308
sg13
I1
sa(dp15309
g7
I263
sg8
VP04350
p15310
sg10
I4
sg11
VTUBB
p15311
sg13
I1
sa(dp15312
g7
I180
sg8
VP60174
p15313
sg10
I4
sg11
VTPI1
p15314
sg13
I1
sa(dp15315
g7
I186
sg8
g9
sg10
I5
sg11
VPARK7
p15316
sg13
I1
sasg14
(lp15317
(dp15318
g7
I318
sg17
VC0027627
p15319
sg10
I12
sg11
Vmetastasized
p15320
sg13
I1
sa(dp15321
g7
I290
sg17
VC0025202
p15322
sg10
I9
sg11
Vmelanomas
p15323
sg13
I1
sa(dp15324
g7
I186
sg17
VC1853445
p15325
sg10
I5
sg11
VPARK7
p15326
sg13
I1
sasa(dp15327
g2
S'Among these, 14 genes (FTL, K-ALPHA1, LDHA, RPL4, ENO1, ANXA2, RPL9, RPL10, RPL13A, GNB2L1, AMBP, GC, A1BG, and SERPINC1), in addition to previously well-known liver cancer related genes, were confirmed to be differentially expressed in seven liver cancer cell lines and 17 HCC tissues by semi-quantitative RT-PCR.\n'
p15328
sg4
(lp15329
(dp15330
g7
I69
sg8
VP61313
p15331
sg10
I5
sg11
VRPL10
p15332
sg13
I1
sa(dp15333
g7
I56
sg8
VP07355
p15334
sg10
I5
sg11
VANXA2
p15335
sg13
I1
sa(dp15336
g7
I28
sg8
VP25100
p15337
sg10
I8
sg11
VK-ALPHA1
p15338
sg13
I1
sa(dp15339
g7
I92
sg8
VP02760
p15340
sg10
I4
sg11
VAMBP
p15341
sg13
I1
sa(dp15342
g7
I76
sg8
VP40429
p15343
sg10
I6
sg11
VRPL13A
p15344
sg13
I1
sa(dp15345
g7
I102
sg8
VP04217
p15346
sg10
I4
sg11
VA1BG
p15347
sg13
I1
sa(dp15348
g7
I63
sg8
VP32969
p15349
sg10
I4
sg11
VRPL9
p15350
sg13
I1
sa(dp15351
g7
I44
sg8
VP36578
p15352
sg10
I4
sg11
VRPL4
p15353
sg13
I1
sa(dp15354
g7
I23
sg8
VP02792
p15355
sg10
I3
sg11
VFTL
p15356
sg13
I1
sa(dp15357
g7
I84
sg8
VP63244
p15358
sg10
I6
sg11
VGNB2L1
p15359
sg13
I1
sa(dp15360
g7
I38
sg8
VP00338
p15361
sg10
I4
sg11
VLDHA
p15362
sg13
I1
sasg14
(lp15363
(dp15364
g7
I160
sg17
VC0345904
p15365
sg10
I12
sg11
Vliver cancer
p15366
sg13
I2
sa(dp15367
g7
I274
sg17
VC2239176
p15368
sg10
I3
sg11
VHCC
p15369
sg13
I1
sa(dp15370
g7
I160
sg17
VC0345904
p15371
sg10
I12
sg11
Vliver cancer
p15372
sg13
I2
sasa(dp15373
g2
S'Expression profiles of the 9 genes ACTB, ALAS1, G6PD, GAPD, HMBS, HPRT1, K-ALPHA-1, SDHA and TBP were established in matched malignant and nonmalignant tissue specimens from 14 patients with bladder cancer.\n'
p15374
sg4
(lp15375
(dp15376
g7
I73
sg8
VP68363
p15377
sg10
I9
sg11
VK-ALPHA-1
p15378
sg13
I1
sa(dp15379
g7
I41
sg8
VP13196
p15380
sg10
I5
sg11
VALAS1
p15381
sg13
I1
sa(dp15382
g7
I66
sg8
VP55884
p15383
sg10
I5
sg11
VHPRT1
p15384
sg13
I1
sa(dp15385
g7
I93
sg8
VP20226
p15386
sg10
I3
sg11
VTBP
p15387
sg13
I1
sa(dp15388
g7
I48
sg8
VP11441
p15389
sg10
I4
sg11
VG6PD
p15390
sg13
I1
sa(dp15391
g7
I54
sg8
VP04406
p15392
sg10
I4
sg11
VGAPD
p15393
sg13
I1
sa(dp15394
g7
I35
sg8
VP63261
p15395
sg10
I4
sg11
VACTB
p15396
sg13
I1
sa(dp15397
g7
I84
sg8
VP31040
p15398
sg10
I4
sg11
VSDHA
p15399
sg13
I1
sa(dp15400
g7
I60
sg8
VP08397
p15401
sg10
I4
sg11
VHMBS
p15402
sg13
I1
sasg14
(lp15403
(dp15404
g7
I191
sg17
VC0699885
p15405
sg10
I14
sg11
Vbladder cancer
p15406
sg13
I2
sasa(dp15407
g2
S'The use of HPRT1 alone as a reference gene shown in our study was sufficient, but the normalization factors generated from two (HRPT1, ALAS1) or all three genes (HRPT1, ALAS1, K-ALPHA-1) should be considered for an improved reliability of normalization in gene profiling studies of prostate cancer.\n'
p15408
sg4
(lp15409
(dp15410
g7
I128
sg8
g9
sg10
I5
sg11
VHRPT1
p15411
sg13
I1
sa(dp15412
g7
I176
sg8
VP68363
p15413
sg10
I9
sg11
VK-ALPHA-1
p15414
sg13
I1
sa(dp15415
g7
I128
sg8
g9
sg10
I5
sg11
VHRPT1
p15416
sg13
I1
sa(dp15417
g7
I11
sg8
VP55884
p15418
sg10
I5
sg11
VHPRT1
p15419
sg13
I1
sa(dp15420
g7
I135
sg8
VP13196
p15421
sg10
I5
sg11
VALAS1
p15422
sg13
I1
sa(dp15423
g7
I135
sg8
VP13196
p15424
sg10
I5
sg11
VALAS1
p15425
sg13
I1
sasg14
(lp15426
(dp15427
g7
I128
sg17
VC1840402
p15428
sg10
I5
sg11
VHRPT1
p15429
sg13
I1
sa(dp15430
g7
I282
sg17
VC0600139
p15431
sg10
I15
sg11
Vprostate cancer
p15432
sg13
I2
sa(dp15433
g7
I128
sg17
VC1840402
p15434
sg10
I5
sg11
VHRPT1
p15435
sg13
I1
sasa(dp15436
g2
S'We show that glucose clearance rates are affected in both children with marasmus as well as kwashiorkor, which correlate with plasma albumin concentrations.\n'
p15437
sg4
(lp15438
(dp15439
g7
I126
sg8
VP00441
p15440
sg10
I14
sg11
Vplasma albumin
p15441
sg13
I2
sasg14
(lp15442
(dp15443
g7
I92
sg17
VC0022806
p15444
sg10
I11
sg11
Vkwashiorkor
p15445
sg13
I1
sa(dp15446
g7
I72
sg17
VC0086588
p15447
sg10
I8
sg11
Vmarasmus
p15448
sg13
I1
sasa(dp15449
g2
S'Although marasmus is characterized by clinical wasting, kwashiorkor is associated with peripheral edema, oxidative stress, hypoalbuminemia, and hypoglycemia.\n'
p15450
sg4
(lp15451
sg14
(lp15452
(dp15453
g7
I47
sg17
VC0235394
p15454
sg10
I7
sg11
Vwasting
p15455
sg13
I1
sa(dp15456
g7
I56
sg17
VC0022806
p15457
sg10
I11
sg11
Vkwashiorkor
p15458
sg13
I1
sa(dp15459
g7
I105
sg17
VC0242606
p15460
sg10
I16
sg11
Voxidative stress
p15461
sg13
I2
sa(dp15462
g7
I98
sg17
VC0013604
p15463
sg10
I5
sg11
Vedema
p15464
sg13
I1
sa(dp15465
g7
I9
sg17
VC0086588
p15466
sg10
I8
sg11
Vmarasmus
p15467
sg13
I1
sa(dp15468
g7
I144
sg17
VC0020615
p15469
sg10
I12
sg11
Vhypoglycemia
p15470
sg13
I1
sasa(dp15471
g2
S'Total proteins, albumin and transferrin were all significantly lower in children with edema than in those with marasmus.\n'
p15472
sg4
(lp15473
(dp15474
g7
I28
sg8
VP02787
p15475
sg10
I11
sg11
Vtransferrin
p15476
sg13
I1
sa(dp15477
g7
I16
sg8
VP00441
p15478
sg10
I7
sg11
Valbumin
p15479
sg13
I1
sasg14
(lp15480
(dp15481
g7
I86
sg17
VC0013604
p15482
sg10
I5
sg11
Vedema
p15483
sg13
I1
sa(dp15484
g7
I111
sg17
VC0086588
p15485
sg10
I8
sg11
Vmarasmus
p15486
sg13
I1
sasa(dp15487
g2
S'In this condition, 8CR inhibited edema and myonecrosis induced by the sPLA2 activity of Crotalus durissus terrificus in a dose-dependent manner by decreasing interleukin-1Beta (IL-1Beta), tumor necrosis factor Alfa (TNF-Alfa), prostaglandin E2 (PGE2), and lipid peroxidation.\n'
p15488
sg4
(lp15489
(dp15490
g7
I216
sg8
VP01375
p15491
sg10
I8
sg11
VTNF-Alfa
p15492
sg13
I1
sa(dp15493
g7
I177
sg8
VP01584
p15494
sg10
I8
sg11
VIL-1Beta
p15495
sg13
I1
sa(dp15496
g7
I158
sg8
VP01584
p15497
sg10
I17
sg11
Vinterleukin-1Beta
p15498
sg13
I1
sa(dp15499
g7
I188
sg8
VP01375
p15500
sg10
I26
sg11
Vtumor necrosis factor Alfa
p15501
sg13
I4
sa(dp15502
g7
I70
sg8
VP14555
p15503
sg10
I5
sg11
VsPLA2
p15504
sg13
I1
sasg14
(lp15505
(dp15506
g7
I8
sg17
VC0012634
p15507
sg10
I9
sg11
Vcondition
p15508
sg13
I1
sa(dp15509
g7
I43
sg17
VC0235957
p15510
sg10
I11
sg11
Vmyonecrosis
p15511
sg13
I1
sa(dp15512
g7
I33
sg17
VC0013604
p15513
sg10
I5
sg11
Vedema
p15514
sg13
I1
sa(dp15515
g7
I188
sg17
VC0333516
p15516
sg10
I14
sg11
Vtumor necrosis
p15517
sg13
I2
sasa(dp15518
g2
S'In addition, it was shown that Crotalus durissus terrificus sPLA2 increases cell oxidative stress during edema and myonecrosis, and the antioxidant properties of the polyphenolic compound may be significant in mitigating the pharmacological effect induced by sPLA2 and other snake venom toxins.\n'
p15519
sg4
(lp15520
(dp15521
g7
I60
sg8
VP14555
p15522
sg10
I5
sg11
VsPLA2
p15523
sg13
I1
sasg14
(lp15524
(dp15525
g7
I115
sg17
VC0235957
p15526
sg10
I11
sg11
Vmyonecrosis
p15527
sg13
I1
sa(dp15528
g7
I105
sg17
VC0013604
p15529
sg10
I5
sg11
Vedema
p15530
sg13
I1
sa(dp15531
g7
I81
sg17
VC0242606
p15532
sg10
I16
sg11
Voxidative stress
p15533
sg13
I2
sasa(dp15534
g2
S'Moreover, 5CQA significantly decreased the enzymatic activity and the oedema and myonecrosis induced by native sPLA2.\n'
p15535
sg4
(lp15536
sg14
(lp15537
(dp15538
g7
I70
sg17
VC0013604
p15539
sg10
I6
sg11
Voedema
p15540
sg13
I1
sa(dp15541
g7
I81
sg17
VC0235957
p15542
sg10
I11
sg11
Vmyonecrosis
p15543
sg13
I1
sasa(dp15544
g2
S'This flavonoid was able to decrease enzymatic activity and some pharmacological effects, such as myonecrosis, platelet aggregation, and neurotoxic activity caused by sPLA2, however, the inflammatory effect was not affected by naringin.\n'
p15545
sg4
(lp15546
sg14
(lp15547
(dp15548
g7
I97
sg17
VC0235957
p15549
sg10
I11
sg11
Vmyonecrosis
p15550
sg13
I1
sasa(dp15551
g2
S'Under the conditions tested, we observed that both Boc-5 and Boc-10 strongly decreased edema, myonecrosis, and neurotoxicity induced by native sPLA2.\n'
p15552
sg4
(lp15553
(dp15554
g7
I51
sg8
g9
sg10
I5
sg11
VBoc-5
p15555
sg13
I1
sa(dp15556
g7
I61
sg8
g9
sg10
I6
sg11
VBoc-10
p15557
sg13
I1
sasg14
(lp15558
(dp15559
g7
I94
sg17
VC0235957
p15560
sg10
I11
sg11
Vmyonecrosis
p15561
sg13
I1
sa(dp15562
g7
I87
sg17
VC0013604
p15563
sg10
I5
sg11
Vedema
p15564
sg13
I1
sasa(dp15565
g2
S'Incubation with pertussis toxin prior to the addition of either sPLA2 or LPA only showed abrogation of the response to LPA, thus suggesting the involvement of pertussis-sensitive Gi-proteins in the case of LPA.\n'
p15566
sg4
(lp15567
(dp15568
g7
I64
sg8
VP14555
p15569
sg10
I5
sg11
VsPLA2
p15570
sg13
I1
sa(dp15571
g7
I16
sg8
g9
sg10
I15
sg11
Vpertussis toxin
p15572
sg13
I2
sa(dp15573
g7
I179
sg8
VP63096
p15574
sg10
I11
sg11
VGi-proteins
p15575
sg13
I1
sasg14
(lp15576
(dp15577
g7
I16
sg17
VC0043167
p15578
sg10
I9
sg11
Vpertussis
p15579
sg13
I1
sa(dp15580
g7
I16
sg17
VC0043167
p15581
sg10
I9
sg11
Vpertussis
p15582
sg13
I1
sasa(dp15583
g2
S"In contrast, all of the four classical CMNs tested were negative, as were cases of Wilms' tumor and clear cell sarcoma of the kidney.\n"
p15584
sg4
(lp15585
sg14
(lp15586
(dp15587
g7
I100
sg17
VC0334488
p15588
sg10
I32
sg11
Vclear cell sarcoma of the kidney
p15589
sg13
I6
sa(dp15590
g7
I83
sg17
VC0027708
p15591
sg10
I12
sg11
VWilms' tumor
p15592
sg13
I2
sasa(dp15593
g2
S"The aspirates were from 16 cases of classical Wilms' tumor (WT), one anaplastic WT, 2 clear cell sarcomas of the kidney (CCSK), 2 malignant rhabdoid tumors of the kidney (MRTK) and 6 congenital mesoblastic nephromas (CMNs).\n"
p15594
sg4
(lp15595
sg14
(lp15596
(dp15597
g7
I60
sg17
VC0027708
p15598
sg10
I2
sg11
VWT
p15599
sg13
I1
sa(dp15600
g7
I46
sg17
VC0027708
p15601
sg10
I12
sg11
VWilms' tumor
p15602
sg13
I2
sa(dp15603
g7
I183
sg17
VC1332965
p15604
sg10
I32
sg11
Vcongenital mesoblastic nephromas
p15605
sg13
I3
sa(dp15606
g7
I60
sg17
VC0027708
p15607
sg10
I2
sg11
VWT
p15608
sg13
I1
sa(dp15609
g7
I86
sg17
VC0206651
p15610
sg10
I19
sg11
Vclear cell sarcomas
p15611
sg13
I3
sa(dp15612
g7
I140
sg17
VC0206743
p15613
sg10
I15
sg11
Vrhabdoid tumors
p15614
sg13
I2
sa(dp15615
g7
I217
sg17
VC1332965
p15616
sg10
I4
sg11
VCMNs
p15617
sg13
I1
sasa(dp15618
g2
S'Archival tissue from 38 patients with superficial smooth muscle cell and so-called fibrohistiocytic tumors (8 benign fibrous histiocytomas (BFHs), 6 dermatofibrosarcoma protuberans (DFPT), 9 malignant fibrous histiocytomas (MFHs), 9 leiomyomas (LMs) and 6 leiomyosarcomas (LMSs)) were immunostained with antibodies against SMA, HCD, CALP, PLAP and HPL.\n'
p15619
sg4
(lp15620
(dp15621
g7
I323
sg8
g9
sg10
I3
sg11
VSMA
p15622
sg13
I1
sa(dp15623
g7
I339
sg8
VP51003
p15624
sg10
I4
sg11
VPLAP
p15625
sg13
I1
sa(dp15626
g7
I348
sg8
VP09382
p15627
sg10
I3
sg11
VHPL
p15628
sg13
I1
sa(dp15629
g7
I328
sg8
VP0C7U2
p15630
sg10
I3
sg11
VHCD
p15631
sg13
I1
sa(dp15632
g7
I333
sg8
g9
sg10
I4
sg11
VCALP
p15633
sg13
I1
sasg14
(lp15634
(dp15635
g7
I110
sg17
VC0206644
p15636
sg10
I28
sg11
Vbenign fibrous histiocytomas
p15637
sg13
I3
sa(dp15638
g7
I233
sg17
VC0023267
p15639
sg10
I10
sg11
Vleiomyomas
p15640
sg13
I1
sa(dp15641
g7
I100
sg17
VC0027651
p15642
sg10
I6
sg11
Vtumors
p15643
sg13
I1
sa(dp15644
g7
I191
sg17
VC0334463
p15645
sg10
I31
sg11
Vmalignant fibrous histiocytomas
p15646
sg13
I3
sa(dp15647
g7
I256
sg17
VC0023269
p15648
sg10
I15
sg11
Vleiomyosarcomas
p15649
sg13
I1
sa(dp15650
g7
I323
sg17
VC0026847
p15651
sg10
I3
sg11
VSMA
p15652
sg13
I1
sa(dp15653
g7
I328
sg17
VC0235833
p15654
sg10
I3
sg11
VHCD
p15655
sg13
I1
sa(dp15656
g7
I245
sg17
VC1851710
p15657
sg10
I3
sg11
VLMs
p15658
sg13
I1
sa(dp15659
g7
I149
sg17
VC0392784
p15660
sg10
I31
sg11
Vdermatofibrosarcoma protuberans
p15661
sg13
I2
sa(dp15662
g7
I273
sg17
VC0023269
p15663
sg10
I4
sg11
VLMSs
p15664
sg13
I1
sa(dp15665
g7
I224
sg17
VC0334463
p15666
sg10
I4
sg11
VMFHs
p15667
sg13
I1
sasa(dp15668
g2
S'In cell culture, d12.CALP at low multiplicity of infection (0.001 plaque-forming unit/cell) selectively killed calponin-positive human synovial sarcoma, leiomyosarcoma, and osteosarcoma cells.\n'
p15669
sg4
(lp15670
(dp15671
g7
I111
sg8
VP51911
p15672
sg10
I8
sg11
Vcalponin
p15673
sg13
I1
sasg14
(lp15674
(dp15675
g7
I49
sg17
VC0009450
p15676
sg10
I9
sg11
Vinfection
p15677
sg13
I1
sa(dp15678
g7
I66
sg17
VC0011389
p15679
sg10
I6
sg11
Vplaque
p15680
sg13
I1
sa(dp15681
g7
I173
sg17
VC0029463
p15682
sg10
I12
sg11
Vosteosarcoma
p15683
sg13
I1
sa(dp15684
g7
I135
sg17
VC0039101
p15685
sg10
I16
sg11
Vsynovial sarcoma
p15686
sg13
I2
sa(dp15687
g7
I153
sg17
VC0023269
p15688
sg10
I14
sg11
Vleiomyosarcoma
p15689
sg13
I1
sasa(dp15690
g2
S'To investigate the possible role of beta-defensins in gingival health and periodontal disease, we examined the effect of several stimuli on the expression of interleukin-8 (IL-8), human beta-defensin-1, -2, -3, and -4 (hBD) in primary human diseased gingival epithelial (HGE) cell cultures from periodontitis patients by quantitative TaqMan reverse transcription polymerase chain reaction (RT-PCR).\n'
p15691
sg4
(lp15692
(dp15693
g7
I219
sg8
VP02042
p15694
sg10
I3
sg11
VhBD
p15695
sg13
I1
sa(dp15696
g7
I36
sg8
g9
sg10
I14
sg11
Vbeta-defensins
p15697
sg13
I1
sa(dp15698
g7
I173
sg8
VP60568
p15699
sg10
I4
sg11
VIL-8
p15700
sg13
I1
sa(dp15701
g7
I158
sg8
VP60568
p15702
sg10
I13
sg11
Vinterleukin-8
p15703
sg13
I1
sasg14
(lp15704
(dp15705
g7
I219
sg17
VC1840321
p15706
sg10
I3
sg11
VhBD
p15707
sg13
I1
sa(dp15708
g7
I295
sg17
VC0031099
p15709
sg10
I13
sg11
Vperiodontitis
p15710
sg13
I1
sa(dp15711
g7
I74
sg17
VC0031090
p15712
sg10
I19
sg11
Vperiodontal disease
p15713
sg13
I2
sasa(dp15714
g2
S'Human gingival epithelial cells (HGE) express two antimicrobial peptides of the beta-defensin family, human beta-defensin 1 (hBD-1) and hBD-2, as well as cytokines and chemokines that contribute to innate immunity.\n'
p15715
sg4
(lp15716
(dp15717
g7
I125
sg8
VP60022
p15718
sg10
I5
sg11
VhBD-1
p15719
sg13
I1
sa(dp15720
g7
I136
sg8
g9
sg10
I5
sg11
VhBD-2
p15721
sg13
I1
sa(dp15722
g7
I102
sg8
VP60022
p15723
sg10
I21
sg11
Vhuman beta-defensin 1
p15724
sg13
I3
sa(dp15725
g7
I80
sg8
VP59861
p15726
sg10
I20
sg11
Vbeta-defensin family
p15727
sg13
I2
sasg14
(lp15728
(dp15729
g7
I125
sg17
VC1840321
p15730
sg10
I3
sg11
VhBD
p15731
sg13
I1
sa(dp15732
g7
I125
sg17
VC1840321
p15733
sg10
I3
sg11
VhBD
p15734
sg13
I1
sasa(dp15735
g2
S'SSKcnj16-/- rats exhibited hypokalemia and reduced blood pressure, and when fed a high-salt diet (4% NaCl), experienced 100% mortality within a few days triggered by salt wasting and severe hypokalemia.\n'
p15736
sg4
(lp15737
sg14
(lp15738
(dp15739
g7
I171
sg17
VC0235394
p15740
sg10
I7
sg11
Vwasting
p15741
sg13
I1
sasa(dp15742
g2
S'Hence, patients with HNF1Beta mutations may have reduced Kir5.1 activity in the kidney, resulting in hypokalemia and hypomagnesemia.\n'
p15743
sg4
(lp15744
(dp15745
g7
I57
sg8
g9
sg10
I6
sg11
VKir5.1
p15746
sg13
I1
sa(dp15747
g7
I21
sg8
VP35680
p15748
sg10
I18
sg11
VHNF1Beta mutations
p15749
sg13
I2
sasg14
(lp15750
sa(dp15751
g2
S'The Kir5.1(-/-) mice displayed hypokalemic, hyperchloremic metabolic acidosis with hypercalciuria.\n'
p15752
sg4
(lp15753
(dp15754
g7
I4
sg8
g9
sg10
I6
sg11
VKir5.1
p15755
sg13
I1
sasg14
(lp15756
(dp15757
g7
I83
sg17
VC0020438
p15758
sg10
I14
sg11
Vhypercalciuria
p15759
sg13
I1
sa(dp15760
g7
I59
sg17
VC0220981
p15761
sg10
I18
sg11
Vmetabolic acidosis
p15762
sg13
I2
sasa(dp15763
g2
S'In conclusion, disruption of Kcnj16 induces a severe renal phenotype that, apart from hypokalemia, is the opposite of the phenotype seen in SeSAME/EAST syndrome.\n'
p15764
sg4
(lp15765
(dp15766
g7
I29
sg8
g9
sg10
I6
sg11
VKcnj16
p15767
sg13
I1
sasg14
(lp15768
(dp15769
g7
I147
sg17
VC2748572
p15770
sg10
I13
sg11
VEAST syndrome
p15771
sg13
I2
sasa(dp15772
g2
S'We found that Kir5.1(-/-) mice presented with persistent metabolic acidosis and a clear respiratory phenotype.\n'
p15773
sg4
(lp15774
(dp15775
g7
I14
sg8
g9
sg10
I6
sg11
VKir5.1
p15776
sg13
I1
sasg14
(lp15777
(dp15778
g7
I57
sg17
VC0220981
p15779
sg10
I18
sg11
Vmetabolic acidosis
p15780
sg13
I2
sasa(dp15781
g2
S'Despite metabolic acidosis, ventilation at rest and in hyperoxic hypercapnia were similar in wild-type and Kir5.1(-/-) mice.\n'
p15782
sg4
(lp15783
sg14
(lp15784
(dp15785
g7
I8
sg17
VC0220981
p15786
sg10
I18
sg11
Vmetabolic acidosis
p15787
sg13
I2
sa(dp15788
g7
I65
sg17
VC0020440
p15789
sg10
I11
sg11
Vhypercapnia
p15790
sg13
I1
sasa(dp15791
g2
S'We suggest that this compensatory modulation of the peripheral chemosensory inputs develops in Kir5.1(-/-) mice in order to counteract the effect of continuing metabolic acidosis on the activity of the peripheral chemoreceptors.\n'
p15792
sg4
(lp15793
(dp15794
g7
I95
sg8
g9
sg10
I6
sg11
VKir5.1
p15795
sg13
I1
sasg14
(lp15796
(dp15797
g7
I160
sg17
VC0220981
p15798
sg10
I18
sg11
Vmetabolic acidosis
p15799
sg13
I2
sasa(dp15800
g2
S'In this study, CYP2E1*5B, CYP2E1*6, CYP2E1*7B, GSTO1 (A140D), and TP53 (Arg72Pro) polymorphisms and response to platinum-based chemotherapy and survival in 137 advanced stage NSCLC patients were investigated.\n'
p15801
sg4
(lp15802
(dp15803
g7
I36
sg8
VP05181
p15804
sg10
I9
sg11
VCYP2E1*7B
p15805
sg13
I1
sa(dp15806
g7
I15
sg8
VP05181
p15807
sg10
I9
sg11
VCYP2E1*5B
p15808
sg13
I1
sa(dp15809
g7
I47
sg8
VP78417
p15810
sg10
I23
sg11
VGSTO1 (A140D), and TP53
p15811
sg13
I4
sa(dp15812
g7
I26
sg8
VP05181
p15813
sg10
I8
sg11
VCYP2E1*6
p15814
sg13
I1
sasg14
(lp15815
(dp15816
g7
I175
sg17
VC0007131
p15817
sg10
I5
sg11
VNSCLC
p15818
sg13
I1
sasa(dp15819
g2
S'GSTO1-1 expression pattern has not been studied in transitional cell carcinoma (TCC), as yet.\n'
p15820
sg4
(lp15821
(dp15822
g7
I0
sg8
VP78417
p15823
sg10
I7
sg11
VGSTO1-1
p15824
sg13
I1
sasg14
(lp15825
(dp15826
g7
I80
sg17
VC1861305
p15827
sg10
I3
sg11
VTCC
p15828
sg13
I1
sa(dp15829
g7
I51
sg17
VC0007138
p15830
sg10
I27
sg11
Vtransitional cell carcinoma
p15831
sg13
I3
sasa(dp15832
g2
S'Increased GSTO1-1 expression might contribute to TCC development and/or progression supporting the notion that GSTO1-1 may be a promising novel cancer target.\n'
p15833
sg4
(lp15834
(dp15835
g7
I10
sg8
VP78417
p15836
sg10
I7
sg11
VGSTO1-1
p15837
sg13
I1
sa(dp15838
g7
I10
sg8
VP78417
p15839
sg10
I7
sg11
VGSTO1-1
p15840
sg13
I1
sasg14
(lp15841
(dp15842
g7
I49
sg17
VC1861305
p15843
sg10
I3
sg11
VTCC
p15844
sg13
I1
sa(dp15845
g7
I144
sg17
VC0006826
p15846
sg10
I6
sg11
Vcancer
p15847
sg13
I1
sasa(dp15848
g2
S'Glutathione S-transferase omega 1 (GSTO1) is an atypical GST isoform that is overexpressed in several cancers and has been implicated in drug resistance.\n'
p15849
sg4
(lp15850
(dp15851
g7
I0
sg8
VP78417
p15852
sg10
I33
sg11
VGlutathione S-transferase omega 1
p15853
sg13
I4
sa(dp15854
g7
I35
sg8
g9
sg10
I3
sg11
VGST
p15855
sg13
I1
sa(dp15856
g7
I35
sg8
VP78417
p15857
sg10
I5
sg11
VGSTO1
p15858
sg13
I1
sasg14
(lp15859
(dp15860
g7
I102
sg17
VC0006826
p15861
sg10
I7
sg11
Vcancers
p15862
sg13
I1
sasa(dp15863
g2
S'Here we show that silencing of GSTO1 with siRNA significantly impairs cancer cell viability, validating GSTO1 as a potential new target in oncology.\n'
p15864
sg4
(lp15865
(dp15866
g7
I31
sg8
VP78417
p15867
sg10
I5
sg11
VGSTO1
p15868
sg13
I1
sa(dp15869
g7
I31
sg8
VP78417
p15870
sg10
I5
sg11
VGSTO1
p15871
sg13
I1
sasg14
(lp15872
(dp15873
g7
I70
sg17
VC0006826
p15874
sg10
I6
sg11
Vcancer
p15875
sg13
I1
sasa(dp15876
g2
S'These potent GSTO1 inhibitors suppress cancer cell growth, enhance the cytotoxic effects of cisplatin and inhibit tumour growth in colon cancer models as single agent.\n'
p15877
sg4
(lp15878
(dp15879
g7
I13
sg8
VP78417
p15880
sg10
I5
sg11
VGSTO1
p15881
sg13
I1
sasg14
(lp15882
(dp15883
g7
I114
sg17
VC0027651
p15884
sg10
I6
sg11
Vtumour
p15885
sg13
I1
sa(dp15886
g7
I131
sg17
VC0699790
p15887
sg10
I12
sg11
Vcolon cancer
p15888
sg13
I2
sa(dp15889
g7
I39
sg17
VC1516170
p15890
sg10
I18
sg11
Vcancer cell growth
p15891
sg13
I3
sasa(dp15892
g2
S'Our findings demonstrate the therapeutic utility of GSTO1 inhibitors as anticancer agents and identify the novel cellular pathways under GSTO1 regulation in colorectal cancer.\n'
p15893
sg4
(lp15894
(dp15895
g7
I52
sg8
VP78417
p15896
sg10
I5
sg11
VGSTO1
p15897
sg13
I1
sasg14
(lp15898
(dp15899
g7
I157
sg17
VC1527249
p15900
sg10
I17
sg11
Vcolorectal cancer
p15901
sg13
I2
sasa(dp15902
g2
S'To explore the relationship between angiogenin-1/2 (Ang-1/2) and clinical parameters of idiopathic pulmonary fibrosis (IPF), and to assess the value of Ang-1/2 in predicting the prognosis of patients with IPF.\n'
p15903
sg4
(lp15904
(dp15905
g7
I36
sg8
VP03950
p15906
sg10
I14
sg11
Vangiogenin-1/2
p15907
sg13
I1
sa(dp15908
g7
I52
sg8
VP03950
p15909
sg10
I7
sg11
VAng-1/2
p15910
sg13
I1
sa(dp15911
g7
I52
sg8
VP03950
p15912
sg10
I7
sg11
VAng-1/2
p15913
sg13
I1
sasg14
(lp15914
(dp15915
g7
I119
sg17
VC3161101
p15916
sg10
I3
sg11
VIPF
p15917
sg13
I1
sa(dp15918
g7
I88
sg17
VC3161101
p15919
sg10
I29
sg11
Vidiopathic pulmonary fibrosis
p15920
sg13
I3
sa(dp15921
g7
I119
sg17
VC3161101
p15922
sg10
I3
sg11
VIPF
p15923
sg13
I1
sasa(dp15924
g2
S'Preterm infants exposed to oxygen and mechanical ventilation are at risk for bronchopulmonary dysplasia (BPD), a multifactorial chronic lung disorder characterized by arrested alveolar development and nonsprouting, dysmorphic microvascular angiogenesis.\n'
p15925
sg4
(lp15926
sg14
(lp15927
(dp15928
g7
I77
sg17
VC0006287
p15929
sg10
I26
sg11
Vbronchopulmonary dysplasia
p15930
sg13
I2
sa(dp15931
g7
I128
sg17
VC0746102
p15932
sg10
I21
sg11
Vchronic lung disorder
p15933
sg13
I3
sa(dp15934
g7
I167
sg17
VC0018790
p15935
sg10
I8
sg11
Varrested
p15936
sg13
I1
sa(dp15937
g7
I105
sg17
VC0006012
p15938
sg10
I3
sg11
VBPD
p15939
sg13
I1
sasa(dp15940
g2
S'Many genes previously known to be affected by BPA and involved in obesity, hypertension, or heart disease were altered following these treatments, and AP-1, EGR1, and EGFR were key hubs affected by BPA and/or overfeeding.\n'
p15941
sg4
(lp15942
(dp15943
g7
I157
sg8
VP18146
p15944
sg10
I4
sg11
VEGR1
p15945
sg13
I1
sa(dp15946
g7
I151
sg8
VP01100
p15947
sg10
I4
sg11
VAP-1
p15948
sg13
I1
sasg14
(lp15949
(dp15950
g7
I66
sg17
VC0028754
p15951
sg10
I7
sg11
Vobesity
p15952
sg13
I1
sa(dp15953
g7
I75
sg17
VC0020538
p15954
sg10
I12
sg11
Vhypertension
p15955
sg13
I1
sa(dp15956
g7
I92
sg17
VC0018799
p15957
sg10
I13
sg11
Vheart disease
p15958
sg13
I2
sasa(dp15959
g2
S'Using immunohistochemistry, we studied Egr-1 expression specifically in a wide morphologic spectrum of pulmonary arteries in the lung tissue of 72 patients with different forms and stages of PAH, specifically idiopathic PAH (n = 18), advanced-stage congenital heart disease-associated PAH (PAH-CHD) (n = 21), early-stage PAH-CHD (n = 19) and non-neointimal hypoxic pulmonary hypertension (PH) (n = 4), and controls (n = 10).\n'
p15960
sg4
(lp15961
(dp15962
g7
I290
sg8
g9
sg10
I7
sg11
VPAH-CHD
p15963
sg13
I1
sa(dp15964
g7
I191
sg8
VP00439
p15965
sg10
I3
sg11
VPAH
p15966
sg13
I1
sa(dp15967
g7
I39
sg8
VP18146
p15968
sg10
I5
sg11
VEgr-1
p15969
sg13
I1
sa(dp15970
g7
I191
sg8
VP00439
p15971
sg10
I3
sg11
VPAH
p15972
sg13
I1
sasg14
(lp15973
(dp15974
g7
I389
sg17
VC0020542
p15975
sg10
I2
sg11
VPH
p15976
sg13
I1
sa(dp15977
g7
I365
sg17
VC0020542
p15978
sg10
I22
sg11
Vpulmonary hypertension
p15979
sg13
I2
sa(dp15980
g7
I191
sg17
VC0152171
p15981
sg10
I3
sg11
VPAH
p15982
sg13
I1
sa(dp15983
g7
I191
sg17
VC0152171
p15984
sg10
I3
sg11
VPAH
p15985
sg13
I1
sa(dp15986
g7
I191
sg17
VC0152171
p15987
sg10
I3
sg11
VPAH
p15988
sg13
I1
sa(dp15989
g7
I191
sg17
VC0152171
p15990
sg10
I3
sg11
VPAH
p15991
sg13
I1
sa(dp15992
g7
I357
sg17
VC0242184
p15993
sg10
I7
sg11
Vhypoxic
p15994
sg13
I1
sa(dp15995
g7
I249
sg17
VC0152021
p15996
sg10
I24
sg11
Vcongenital heart disease
p15997
sg13
I3
sa(dp15998
g7
I191
sg17
VC0152171
p15999
sg10
I3
sg11
VPAH
p16000
sg13
I1
sasa(dp16001
g2
S"Parkin substrates include two septins; SEPT4/CDCrel-2 which coaggregates with Alfa-synuclein as Lewy bodies in Parkinson's disease, and its closest homolog SEPT5/CDCrel-1/PNUTL1 whose overload with viral vector can rapidly eliminate dopamine neurons in rats.\n"
p16002
sg4
(lp16003
(dp16004
g7
I156
sg8
g9
sg10
I5
sg11
VSEPT5
p16005
sg13
I1
sa(dp16006
g7
I30
sg8
g9
sg10
I7
sg11
Vseptins
p16007
sg13
I1
sa(dp16008
g7
I171
sg8
g9
sg10
I6
sg11
VPNUTL1
p16009
sg13
I1
sa(dp16010
g7
I78
sg8
VP37840
p16011
sg10
I14
sg11
VAlfa-synuclein
p16012
sg13
I1
sa(dp16013
g7
I39
sg8
g9
sg10
I5
sg11
VSEPT4
p16014
sg13
I1
sa(dp16015
g7
I162
sg8
g9
sg10
I8
sg11
VCDCrel-1
p16016
sg13
I1
sa(dp16017
g7
I45
sg8
g9
sg10
I8
sg11
VCDCrel-2
p16018
sg13
I1
sasg14
(lp16019
(dp16020
g7
I111
sg17
VC0030567
p16021
sg10
I19
sg11
VParkinson's disease
p16022
sg13
I2
sasa(dp16023
g2
S'After validation by Western blot and quantitative real-time PCR, the expressions of three proteins related to neurodegenerative disease, septin 5, Alfa-internexin, and Alfa-synuclein, were identified to be altered by MCLR exposure.\n'
p16024
sg4
(lp16025
(dp16026
g7
I168
sg8
VP37840
p16027
sg10
I14
sg11
VAlfa-synuclein
p16028
sg13
I1
sa(dp16029
g7
I137
sg8
g9
sg10
I8
sg11
Vseptin 5
p16030
sg13
I2
sasg14
(lp16031
(dp16032
g7
I110
sg17
VC0524851
p16033
sg10
I25
sg11
Vneurodegenerative disease
p16034
sg13
I2
sasa(dp16035
g2
S"Interestingly, Septin 5, one of the genes isolated from HPAI H5N1-infected brain tissues has been reported to participate in the pathogenic process of Parkinson's disease.\n"
p16036
sg4
(lp16037
(dp16038
g7
I15
sg8
g9
sg10
I8
sg11
VSeptin 5
p16039
sg13
I2
sasg14
(lp16040
(dp16041
g7
I61
sg17
VC0016627
p16042
sg10
I4
sg11
VH5N1
p16043
sg13
I1
sa(dp16044
g7
I151
sg17
VC0030567
p16045
sg10
I19
sg11
VParkinson's disease
p16046
sg13
I2
sasa(dp16047
g2
S'A previous study successfully developed and validated a self-report BPD measure, the Minnesota Borderline Personality Disorder Scale (MBPD).\n'
p16048
sg4
(lp16049
sg14
(lp16050
(dp16051
g7
I68
sg17
VC0006012
p16052
sg10
I3
sg11
VBPD
p16053
sg13
I1
sa(dp16054
g7
I95
sg17
VC0006012
p16055
sg10
I31
sg11
VBorderline Personality Disorder
p16056
sg13
I3
sasa(dp16057
g2
S'A previous study successfully developed and validated a BPD measure embedded within a normal trait measure, the Minnesota Borderline Personality Disorder Scale (MBPD).\n'
p16058
sg4
(lp16059
sg14
(lp16060
(dp16061
g7
I122
sg17
VC0006012
p16062
sg10
I31
sg11
VBorderline Personality Disorder
p16063
sg13
I3
sa(dp16064
g7
I56
sg17
VC0006012
p16065
sg10
I3
sg11
VBPD
p16066
sg13
I1
sasa(dp16067
g2
S'This study was to investigate HSP70 expression in the peripheral lung tissues of chronic obstructive pulmonary disease (COPD) patients and in human bronchial epithelial cells (16-HBE) exposed to cigarette smoke extract (CSE).\n'
p16068
sg4
(lp16069
(dp16070
g7
I30
sg8
VP34932
p16071
sg10
I5
sg11
VHSP70
p16072
sg13
I1
sasg14
(lp16073
(dp16074
g7
I220
sg17
VC1832855
p16075
sg10
I3
sg11
VCSE
p16076
sg13
I1
sa(dp16077
g7
I81
sg17
VC0024117
p16078
sg10
I37
sg11
Vchronic obstructive pulmonary disease
p16079
sg13
I4
sa(dp16080
g7
I195
sg17
VC1832855
p16081
sg10
I23
sg11
Vcigarette smoke extract
p16082
sg13
I3
sa(dp16083
g7
I120
sg17
VC0024117
p16084
sg10
I4
sg11
VCOPD
p16085
sg13
I1
sasa(dp16086
g2
S'Sequencing analysis of the endogenous E2F4 gene in a series of colorectal cancer cell lines showed that the microsatellite-unstable cell line SW48 exhibited a serine deletion in this gene.\n'
p16087
sg4
(lp16088
(dp16089
g7
I38
sg8
g9
sg10
I9
sg11
VE2F4 gene
p16090
sg13
I2
sasg14
(lp16091
(dp16092
g7
I63
sg17
VC1527249
p16093
sg10
I17
sg11
Vcolorectal cancer
p16094
sg13
I2
sasa(dp16095
g2
S'In conclusion, our data demonstrate that cancer-associated E2F4 mutations enhance the capacity of colorectal cancer cells to grow without anchorage, thereby contributing to tumor progression.\n'
p16096
sg4
(lp16097
(dp16098
g7
I59
sg8
g9
sg10
I4
sg11
VE2F4
p16099
sg13
I1
sasg14
(lp16100
(dp16101
g7
I41
sg17
VC0006826
p16102
sg10
I6
sg11
Vcancer
p16103
sg13
I1
sa(dp16104
g7
I173
sg17
VC0178874
p16105
sg10
I17
sg11
Vtumor progression
p16106
sg13
I2
sa(dp16107
g7
I98
sg17
VC1527249
p16108
sg10
I17
sg11
Vcolorectal cancer
p16109
sg13
I2
sasa(dp16110
g2
S'The inverse immunohistochemical relationship between E2F1 and E2F4 indicates a possible mechanistic interlink in colorectal cancer.\n'
p16111
sg4
(lp16112
(dp16113
g7
I62
sg8
g9
sg10
I4
sg11
VE2F4
p16114
sg13
I1
sa(dp16115
g7
I53
sg8
g9
sg10
I4
sg11
VE2F1
p16116
sg13
I1
sasg14
(lp16117
(dp16118
g7
I113
sg17
VC1527249
p16119
sg10
I17
sg11
Vcolorectal cancer
p16120
sg13
I2
sasa(dp16121
g2
S'In an attempt to identify the role of E2F-4 as a potential mediator of cell proliferation, differentiation, tumorigenesis, and apoptosis in colorectal mucosa comparing with that of E2F-1, the authors examine 20 patients with human colon cancer and their corresponding histologically healthy mucosa by using immunohistochemical methods, computerized quantitative image analysis, and immunoblot analysis.\n'
p16122
sg4
(lp16123
(dp16124
g7
I38
sg8
g9
sg10
I5
sg11
VE2F-4
p16125
sg13
I1
sa(dp16126
g7
I181
sg8
g9
sg10
I5
sg11
VE2F-1
p16127
sg13
I1
sasg14
(lp16128
(dp16129
g7
I108
sg17
VC0007621
p16130
sg10
I13
sg11
Vtumorigenesis
p16131
sg13
I1
sa(dp16132
g7
I76
sg17
VC0334094
p16133
sg10
I13
sg11
Vproliferation
p16134
sg13
I1
sa(dp16135
g7
I231
sg17
VC0699790
p16136
sg10
I12
sg11
Vcolon cancer
p16137
sg13
I2
sasa(dp16138
g2
S'Eighteen colorectal cancer (CRC) patients from 13 kindreds meeting the Amsterdam criteria for HNPCC were analyzed and compared to sporadic CRC patients with MSI-H. We detected mutations of E2F-4 at the same repeat sequence in HNPCC.\n'
p16139
sg4
(lp16140
(dp16141
g7
I189
sg8
g9
sg10
I5
sg11
VE2F-4
p16142
sg13
I1
sasg14
(lp16143
(dp16144
g7
I28
sg17
VC1527249
p16145
sg10
I3
sg11
VCRC
p16146
sg13
I1
sa(dp16147
g7
I157
sg17
VC0920269
p16148
sg10
I3
sg11
VMSI
p16149
sg13
I1
sa(dp16150
g7
I9
sg17
VC1527249
p16151
sg10
I17
sg11
Vcolorectal cancer
p16152
sg13
I2
sa(dp16153
g7
I28
sg17
VC1527249
p16154
sg10
I3
sg11
VCRC
p16155
sg13
I1
sa(dp16156
g7
I94
sg17
VC1333990
p16157
sg10
I5
sg11
VHNPCC
p16158
sg13
I1
sa(dp16159
g7
I94
sg17
VC1333990
p16160
sg10
I5
sg11
VHNPCC
p16161
sg13
I1
sasa(dp16162
g2
S'Although the implication of vascular endothelial growth factor, angiopoietin-2, and C-X-C motif chemokine 10 has been suggested, the pathogenesis of systemic capillary leak syndrome remains unclear.\n'
p16163
sg4
(lp16164
(dp16165
g7
I64
sg8
g9
sg10
I14
sg11
Vangiopoietin-2
p16166
sg13
I1
sa(dp16167
g7
I28
sg8
g9
sg10
I34
sg11
Vvascular endothelial growth factor
p16168
sg13
I4
sasg14
(lp16169
(dp16170
g7
I149
sg17
VC0343084
p16171
sg10
I32
sg11
Vsystemic capillary leak syndrome
p16172
sg13
I4
sa(dp16173
g7
I133
sg17
VC0699748
p16174
sg10
I12
sg11
Vpathogenesis
p16175
sg13
I1
sasa(dp16176
g2
S'Microvascular dysfunction under septic shock is related to: increased capillary permeability that manifests as a breakdown of the microvascular endothelial barrier (factors which may contribute to capillary leak syndrome include endogenous proinflammatory cytokines, angiopoietin 2, vascular endothelial growth factor); arteriolar hyporesponsiveness to vasoconstrictors and vasodilators, the loss of adrenergic sensitivity and tone of smooth muscle cells lining the arterioles; loss of the anti-adhesive function of endothelial surfaces; decreased density of perfused capillaries (due to several contributing factors: decreased deformability of erythrocytes and neutrophils; activation of the clotting cascade with fibrin deposition and the formation of microthrombi; dysfunction of vascular autoregulatory mechanisms by nitric oxide; enhanced functional arteriovenous shunting of the microcirculation).\n'
p16177
sg4
(lp16178
(dp16179
g7
I283
sg8
g9
sg10
I34
sg11
Vvascular endothelial growth factor
p16180
sg13
I4
sa(dp16181
g7
I267
sg8
g9
sg10
I14
sg11
Vangiopoietin 2
p16182
sg13
I2
sa(dp16183
g7
I715
sg8
VP22087
p16184
sg10
I6
sg11
Vfibrin
p16185
sg13
I1
sasg14
(lp16186
(dp16187
g7
I113
sg17
VC1265875
p16188
sg10
I9
sg11
Vbreakdown
p16189
sg13
I1
sa(dp16190
g7
I715
sg17
VC0333565
p16191
sg10
I17
sg11
Vfibrin deposition
p16192
sg13
I2
sa(dp16193
g7
I197
sg17
VC0343084
p16194
sg10
I23
sg11
Vcapillary leak syndrome
p16195
sg13
I3
sa(dp16196
g7
I32
sg17
VC0036983
p16197
sg10
I12
sg11
Vseptic shock
p16198
sg13
I2
sasa(dp16199
g2
S'Further investigations of AL-1 as a promising new agent for treatment and/or prevention of diabetes are warranted.\n'
p16200
sg4
(lp16201
sg14
(lp16202
(dp16203
g7
I91
sg17
VC0011849
p16204
sg10
I8
sg11
Vdiabetes
p16205
sg13
I1
sasa(dp16206
g2
S'In established cardiac ATTR amyloidosis, T1 elevation was not as high as in AL amyloidosis (AL 1,130 +/- 68 ms; p = 0.01).\n'
p16207
sg4
(lp16208
sg14
(lp16209
(dp16210
g7
I28
sg17
VC0002726
p16211
sg10
I11
sg11
Vamyloidosis
p16212
sg13
I1
sa(dp16213
g7
I76
sg17
VC0268381
p16214
sg10
I14
sg11
VAL amyloidosis
p16215
sg13
I2
sasa(dp16216
g2
S'We previously reported that EphA5 receptor-ephrinA5 interactions within the ventromedial hypothalamus (VMH) influence counterregulatory hormone responses during acute hypoglycemia in nondiabetic rats.\n'
p16217
sg4
(lp16218
(dp16219
g7
I28
sg8
VP54756
p16220
sg10
I14
sg11
VEphA5 receptor
p16221
sg13
I2
sasg14
(lp16222
(dp16223
g7
I161
sg17
VC0745150
p16224
sg10
I18
sg11
Vacute hypoglycemia
p16225
sg13
I2
sasa(dp16226
g2
S'In this study, we examined whether recurrent hypoglycemia alters the capacity of the ephrinA5 ligand to activate VMH EphA5 receptors, and if so, whether these changes could contribute to pathogenesis of defective glucose counterregulation in response to a standard hypoglycemic stimulus.\n'
p16227
sg4
(lp16228
(dp16229
g7
I85
sg8
g9
sg10
I15
sg11
VephrinA5 ligand
p16230
sg13
I2
sa(dp16231
g7
I113
sg8
VP54756
p16232
sg10
I19
sg11
VVMH EphA5 receptors
p16233
sg13
I3
sasg14
(lp16234
(dp16235
g7
I187
sg17
VC0699748
p16236
sg10
I12
sg11
Vpathogenesis
p16237
sg13
I1
sa(dp16238
g7
I45
sg17
VC0020615
p16239
sg10
I12
sg11
Vhypoglycemia
p16240
sg13
I1
sasa(dp16241
g2
S'The expression of ephrinA5, but not EphA5 receptors within the VMH, was reduced by antecedent recurrent hypoglycemia.\n'
p16242
sg4
(lp16243
(dp16244
g7
I36
sg8
VP54756
p16245
sg10
I15
sg11
VEphA5 receptors
p16246
sg13
I2
sasg14
(lp16247
(dp16248
g7
I104
sg17
VC0020615
p16249
sg10
I12
sg11
Vhypoglycemia
p16250
sg13
I1
sasa(dp16251
g2
S'Activation of VMH EphA5 receptors via targeted microinjection of ephrinA5-Fc before a hyperinsulinemic hypoglycemic clamp study caused a reduction in the glucose infusion rate in nondiabetic rats exposed to recurrent hypoglycemia.\n'
p16252
sg4
(lp16253
(dp16254
g7
I14
sg8
VP54756
p16255
sg10
I19
sg11
VVMH EphA5 receptors
p16256
sg13
I3
sasg14
(lp16257
(dp16258
g7
I217
sg17
VC0020615
p16259
sg10
I12
sg11
Vhypoglycemia
p16260
sg13
I1
sasa(dp16261
g2
S'These data suggest that changes in ephrinA5/EphA5 interactions and synaptic plasticity within the VMH, a key glucose-sensing region in the brain, may contribute to the impairment in glucagon secretion and counterregulatory responses caused by recurrent hypoglycemia.\n'
p16262
sg4
(lp16263
(dp16264
g7
I44
sg8
VP54756
p16265
sg10
I5
sg11
VEphA5
p16266
sg13
I1
sa(dp16267
g7
I182
sg8
VP01275
p16268
sg10
I8
sg11
Vglucagon
p16269
sg13
I1
sasg14
(lp16270
(dp16271
g7
I253
sg17
VC0020615
p16272
sg10
I12
sg11
Vhypoglycemia
p16273
sg13
I1
sa(dp16274
g7
I168
sg17
VC0684336
p16275
sg10
I10
sg11
Vimpairment
p16276
sg13
I1
sasa(dp16277
g2
S'Activation of Beta-cell EphA5 receptors by its ligand ephrinA5 from adjacent Beta-cells has been reported to decrease insulin secretion during hypoglycemia.\n'
p16278
sg4
(lp16279
(dp16280
g7
I14
sg8
VP54756
p16281
sg10
I25
sg11
VBeta-cell EphA5 receptors
p16282
sg13
I3
sa(dp16283
g7
I118
sg8
VP01308
p16284
sg10
I7
sg11
Vinsulin
p16285
sg13
I1
sasg14
(lp16286
(dp16287
g7
I143
sg17
VC0020615
p16288
sg10
I12
sg11
Vhypoglycemia
p16289
sg13
I1
sasa(dp16290
g2
S'Given the similarities between islet and ventromedial hypothalamus (VMH) glucose sensing, we tested the hypothesis that the EphA5/ephrinA5 system might function within the VMH during hypoglycemia to stimulate counterregulatory hormone release as well.\n'
p16291
sg4
(lp16292
(dp16293
g7
I124
sg8
VP54756
p16294
sg10
I5
sg11
VEphA5
p16295
sg13
I1
sasg14
(lp16296
(dp16297
g7
I183
sg17
VC0020615
p16298
sg10
I12
sg11
Vhypoglycemia
p16299
sg13
I1
sasa(dp16300
g2
S'Local stimulation of VMH EphA5 receptors by ephrinA5-Fc or ephrinA5 overexpression increased, whereas knockdown of VMH ephrinA5 reduced counterregulatory responses during hypoglycemia.\n'
p16301
sg4
(lp16302
(dp16303
g7
I21
sg8
VP54756
p16304
sg10
I19
sg11
VVMH EphA5 receptors
p16305
sg13
I3
sasg14
(lp16306
(dp16307
g7
I171
sg17
VC0020615
p16308
sg10
I12
sg11
Vhypoglycemia
p16309
sg13
I1
sasa(dp16310
g2
S'Overexpression of VMH ephrinA5 transiently increased local glutamate concentrations, whereas ephrinA5 knockdown produced profound suppression of VMH interstitial fluid glutamine concentrations in the basal state and during hypoglycemia.\n'
p16311
sg4
(lp16312
(dp16313
g7
I93
sg8
g9
sg10
I18
sg11
VephrinA5 knockdown
p16314
sg13
I2
sasg14
(lp16315
(dp16316
g7
I223
sg17
VC0020615
p16317
sg10
I12
sg11
Vhypoglycemia
p16318
sg13
I1
sa(dp16319
g7
I130
sg17
VC0221103
p16320
sg10
I11
sg11
Vsuppression
p16321
sg13
I1
sasa(dp16322
g2
S'Changes in ephrinA5/EphA5 interactions within the VMH, a key brain glucose-sensing region, act in concert with islets to restore glucose homeostasis during acute hypoglycemia, and its effect on counterregulation may be mediated by changes in glutamate/glutamine cycling.\n'
p16323
sg4
(lp16324
(dp16325
g7
I20
sg8
VP54756
p16326
sg10
I5
sg11
VEphA5
p16327
sg13
I1
sasg14
(lp16328
(dp16329
g7
I156
sg17
VC0745150
p16330
sg10
I18
sg11
Vacute hypoglycemia
p16331
sg13
I2
sasa(dp16332
g2
S'Fractionation of dichloromethane (DCM) molecules with different chlorine isotopes by aerobic methylobacteria Methylobacterium dichloromethanicum DM4 and Albibacter nethylovorans DM10; cell-free extract of strain DM4; and transconjugant Methylobacterium evtorquens Al1/pME 8220, expressing the dcmA gene for DCM dehalogenase but unable to grow on DCM, was studied.\n'
p16333
sg4
(lp16334
(dp16335
g7
I268
sg8
VP04080
p16336
sg10
I3
sg11
VpME
p16337
sg13
I1
sa(dp16338
g7
I293
sg8
g9
sg10
I9
sg11
VdcmA gene
p16339
sg13
I2
sasg14
(lp16340
(dp16341
g7
I268
sg17
VC0751785
p16342
sg10
I3
sg11
VpME
p16343
sg13
I1
sa(dp16344
g7
I293
sg17
VC1857776
p16345
sg10
I4
sg11
VdcmA
p16346
sg13
I1
sasa(dp16347
g2
S'We also describe the first RCC with a DVL2-TFE3 gene fusion, in addition to an extrarenal pigmented PEComa with a NONO-TFE3 gene fusion.\n'
p16348
sg4
(lp16349
(dp16350
g7
I43
sg8
VP19532
p16351
sg10
I4
sg11
VTFE3
p16352
sg13
I1
sa(dp16353
g7
I114
sg8
g9
sg10
I4
sg11
VNONO
p16354
sg13
I1
sa(dp16355
g7
I38
sg8
g9
sg10
I4
sg11
VDVL2
p16356
sg13
I1
sa(dp16357
g7
I43
sg8
VP19532
p16358
sg10
I4
sg11
VTFE3
p16359
sg13
I1
sasg14
(lp16360
(dp16361
g7
I48
sg17
VC1705736
p16362
sg10
I11
sg11
Vgene fusion
p16363
sg13
I2
sa(dp16364
g7
I100
sg17
VC1300127
p16365
sg10
I6
sg11
VPEComa
p16366
sg13
I1
sa(dp16367
g7
I48
sg17
VC1705736
p16368
sg10
I11
sg11
Vgene fusion
p16369
sg13
I2
sa(dp16370
g7
I27
sg17
VC0007134
p16371
sg10
I3
sg11
VRCC
p16372
sg13
I1
sasa(dp16373
g2
S'Furthermore, among neoplasms with the SFPQ-TFE3, NONO-TFE3, DVL2-TFE3, and ASPL-TFE3 gene fusions, the RCCs are almost always PAX8 positive, cathepsin K negative by immunohistochemistry, whereas the mesenchymal counterparts (Xp11 translocation PEComas, melanotic Xp11 translocation renal cancers, and alveolar soft part sarcoma) are PAX8 negative, cathepsin K positive.\n'
p16374
sg4
(lp16375
(dp16376
g7
I225
sg8
g9
sg10
I26
sg11
VXp11 translocation PEComas
p16377
sg13
I3
sa(dp16378
g7
I49
sg8
g9
sg10
I4
sg11
VNONO
p16379
sg13
I1
sa(dp16380
g7
I38
sg8
VP23246
p16381
sg10
I4
sg11
VSFPQ
p16382
sg13
I1
sa(dp16383
g7
I43
sg8
VP19532
p16384
sg10
I4
sg11
VTFE3
p16385
sg13
I1
sa(dp16386
g7
I126
sg8
g9
sg10
I4
sg11
VPAX8
p16387
sg13
I1
sa(dp16388
g7
I43
sg8
VP19532
p16389
sg10
I4
sg11
VTFE3
p16390
sg13
I1
sa(dp16391
g7
I141
sg8
VP43235
p16392
sg10
I11
sg11
Vcathepsin K
p16393
sg13
I2
sa(dp16394
g7
I75
sg8
g9
sg10
I4
sg11
VASPL
p16395
sg13
I1
sa(dp16396
g7
I253
sg8
g9
sg10
I42
sg11
Vmelanotic Xp11 translocation renal cancers
p16397
sg13
I5
sa(dp16398
g7
I43
sg8
VP19532
p16399
sg10
I4
sg11
VTFE3
p16400
sg13
I1
sa(dp16401
g7
I126
sg8
g9
sg10
I4
sg11
VPAX8
p16402
sg13
I1
sa(dp16403
g7
I60
sg8
g9
sg10
I4
sg11
VDVL2
p16404
sg13
I1
sa(dp16405
g7
I141
sg8
VP43235
p16406
sg10
I11
sg11
Vcathepsin K
p16407
sg13
I2
sa(dp16408
g7
I43
sg8
VP19532
p16409
sg10
I4
sg11
VTFE3
p16410
sg13
I1
sasg14
(lp16411
(dp16412
g7
I244
sg17
VC1300127
p16413
sg10
I7
sg11
VPEComas
p16414
sg13
I1
sa(dp16415
g7
I19
sg17
VC0027651
p16416
sg10
I9
sg11
Vneoplasms
p16417
sg13
I1
sa(dp16418
g7
I230
sg17
VC0040715
p16419
sg10
I13
sg11
Vtranslocation
p16420
sg13
I1
sa(dp16421
g7
I230
sg17
VC0040715
p16422
sg10
I13
sg11
Vtranslocation
p16423
sg13
I1
sa(dp16424
g7
I282
sg17
VC0740457
p16425
sg10
I13
sg11
Vrenal cancers
p16426
sg13
I2
sa(dp16427
g7
I301
sg17
VC0206657
p16428
sg10
I26
sg11
Valveolar soft part sarcoma
p16429
sg13
I4
sa(dp16430
g7
I103
sg17
VC0007134
p16431
sg10
I4
sg11
VRCCs
p16432
sg13
I1
sasa(dp16433
g2
S'The compound was further tested in vitro for acetylation of histone H4 and other non-histone proteins, and in vivo in a colon carcinoma model, showing significant proapoptotic and antitumor activities.\n'
p16434
sg4
(lp16435
(dp16436
g7
I81
sg8
VP62805
p16437
sg10
I20
sg11
Vnon-histone proteins
p16438
sg13
I2
sa(dp16439
g7
I60
sg8
VP62805
p16440
sg10
I10
sg11
Vhistone H4
p16441
sg13
I2
sasg14
(lp16442
(dp16443
g7
I120
sg17
VC0699790
p16444
sg10
I15
sg11
Vcolon carcinoma
p16445
sg13
I2
sasa(dp16446
g2
S'As a proof-of-principle, we have identified cytochrome C and Histone H4 as two of the predominant protein species in the 3D colon carcinoma cultures.\n'
p16447
sg4
(lp16448
(dp16449
g7
I44
sg8
VP99999
p16450
sg10
I12
sg11
Vcytochrome C
p16451
sg13
I2
sa(dp16452
g7
I61
sg8
VP62805
p16453
sg10
I10
sg11
VHistone H4
p16454
sg13
I2
sasg14
(lp16455
(dp16456
g7
I124
sg17
VC0699790
p16457
sg10
I15
sg11
Vcolon carcinoma
p16458
sg13
I2
sasa(dp16459
g2
S'Double 2-mm core tissue microarrays were made from 261 paraffin-embedded gastric adenocarcinoma samples and examined by immunohistochemistry for histone H3 lysine 9 (H3K9) acetylation and trimethylation, histone H4 lysine 16 acetylation, and histone H4 lysine 20 trimethylation.\n'
p16460
sg4
(lp16461
(dp16462
g7
I145
sg8
g9
sg10
I19
sg11
Vhistone H3 lysine 9
p16463
sg13
I4
sa(dp16464
g7
I204
sg8
VP62805
p16465
sg10
I10
sg11
Vhistone H4
p16466
sg13
I2
sa(dp16467
g7
I204
sg8
VP62805
p16468
sg10
I20
sg11
Vhistone H4 lysine 16
p16469
sg13
I4
sasg14
(lp16470
(dp16471
g7
I73
sg17
VC0278701
p16472
sg10
I22
sg11
Vgastric adenocarcinoma
p16473
sg13
I2
sasa(dp16474
g2
S'This study aimed to investigate the expression of NOR1 in hepatocellular carcinoma (HCC) tissue and its relationship with prognosis.\n'
p16475
sg4
(lp16476
(dp16477
g7
I50
sg8
g9
sg10
I4
sg11
VNOR1
p16478
sg13
I1
sasg14
(lp16479
(dp16480
g7
I84
sg17
VC2239176
p16481
sg10
I3
sg11
VHCC
p16482
sg13
I1
sa(dp16483
g7
I58
sg17
VC2239176
p16484
sg10
I24
sg11
Vhepatocellular carcinoma
p16485
sg13
I2
sasa(dp16486
g2
S'Oxidored-nitro domain-containing protein 1 (NOR1) expression levels are greater in hepatitis, cirrhosis and hepatocellular carcinoma samples compared with from normal liver samples.\n'
p16487
sg4
(lp16488
(dp16489
g7
I44
sg8
g9
sg10
I4
sg11
VNOR1
p16490
sg13
I1
sa(dp16491
g7
I0
sg8
g9
sg10
I42
sg11
VOxidored-nitro domain-containing protein 1
p16492
sg13
I4
sasg14
(lp16493
(dp16494
g7
I94
sg17
VC0023890
p16495
sg10
I9
sg11
Vcirrhosis
p16496
sg13
I1
sa(dp16497
g7
I108
sg17
VC1512411
p16498
sg10
I24
sg11
Vhepatocellular carcinoma
p16499
sg13
I2
sa(dp16500
g7
I83
sg17
VC0019159
p16501
sg10
I9
sg11
Vhepatitis
p16502
sg13
I1
sasa(dp16503
g2
S'In conclusion, these results indicate that NOR1 may be involved in the progression of HCC and thus may be a potential target for the treatment of liver cancer.\n'
p16504
sg4
(lp16505
(dp16506
g7
I43
sg8
g9
sg10
I4
sg11
VNOR1
p16507
sg13
I1
sasg14
(lp16508
(dp16509
g7
I86
sg17
VC2239176
p16510
sg10
I3
sg11
VHCC
p16511
sg13
I1
sa(dp16512
g7
I146
sg17
VC0345904
p16513
sg10
I12
sg11
Vliver cancer
p16514
sg13
I2
sasa(dp16515
g2
S'To date, several studies have revealed that gene mutations of the transporters are likely to be associated with some diseases; however, there are no data concerning the genetic polymorphism of the hOSCP1 gene in Japanese patients with non-viral liver carcinoma (LC).\n'
p16516
sg4
(lp16517
(dp16518
g7
I197
sg8
g9
sg10
I11
sg11
VhOSCP1 gene
p16519
sg13
I2
sasg14
(lp16520
(dp16521
g7
I245
sg17
VC2239176
p16522
sg10
I15
sg11
Vliver carcinoma
p16523
sg13
I2
sa(dp16524
g7
I262
sg17
VC2239176
p16525
sg10
I2
sg11
VLC
p16526
sg13
I1
sasa(dp16527
g2
S'The nitroreductase oxidored-nitro domain containing protein 1 (NOR1) gene may be involved in the chemical carcinogenesis of hepatic cancer and nasopharyngeal carcinoma (NPC).\n'
p16528
sg4
(lp16529
(dp16530
g7
I63
sg8
g9
sg10
I4
sg11
VNOR1
p16531
sg13
I1
sa(dp16532
g7
I4
sg8
VP14222
p16533
sg10
I57
sg11
Vnitroreductase oxidored-nitro domain containing protein 1
p16534
sg13
I6
sasg14
(lp16535
(dp16536
g7
I124
sg17
VC0345904
p16537
sg10
I14
sg11
Vhepatic cancer
p16538
sg13
I2
sa(dp16539
g7
I97
sg17
VC0596321
p16540
sg10
I23
sg11
Vchemical carcinogenesis
p16541
sg13
I2
sa(dp16542
g7
I169
sg17
VC2931822
p16543
sg10
I3
sg11
VNPC
p16544
sg13
I1
sa(dp16545
g7
I143
sg17
VC2931822
p16546
sg10
I24
sg11
Vnasopharyngeal carcinoma
p16547
sg13
I2
sasa.